Unnamed: 0 stringlengths 3 8 | Date stringlengths 23 23 | Article_title stringlengths 1 250 | Stock_symbol stringlengths 1 5 | Url stringlengths 44 135 | Publisher stringclasses 1 value | Author stringclasses 1 value | Article stringlengths 1 343k | Lsa_summary stringlengths 3 53.9k | Luhn_summary stringlengths 1 53.9k | Textrank_summary stringlengths 1 53.9k | Lexrank_summary stringlengths 1 53.9k |
|---|---|---|---|---|---|---|---|---|---|---|---|
24600.0 | 2020-04-26 00:00:00 UTC | Wall St Week Ahead-Spotlight falls on 'dividend aristocrats' after market tumult | ABBV | https://www.nasdaq.com/articles/wall-st-week-ahead-spotlight-falls-on-dividend-aristocrats-after-market-tumult-2020-04-26 | nan | nan | By Lewis Krauskopf
NEW YORK, April 24 (Reuters) - Companies across a range of industries are slashing or suspending dividends to cope with the economic fallout from the coronavirus outbreak, complicating the stock selection process for money managers eager to buttress their portfolios with a steady stream of income.
The past week's plunge in oil prices has potentially accelerated that process, raising concerns about the rock-steady dividends of companies such as Exxon Mobil XOM.N and Chevron Corp CVX.N, which are set to report results on Friday, May 1.
The S&P 500 dividend aristocrats index .SPDAUDT, which tracks companies that have increased dividends annually for the past 25 years and includes Exxon and Chevron, has fallen about 19% so far in 2020 as of Thursday, greater than the 12.9% drop over that time for the S&P 500 total return index .SPXTR.
That's bad news for yield-thirsty investors at a time when payouts on U.S Treasuries stand near historic lows as the Federal Reserve keeps interest rates in check to stimulate the economy. The S&P 500's dividend yield recently exceeded the yield on the benchmark 10-year U.S. Treasury US10YT=RR by its highest margin in nearly five decades.
“In times like these, financial strength and dividends are two of the critical components in making your investment selections,” said Alan Lancz, president of investment advisory firm Alan B. Lancz & Associates Inc. “It’s not just the dividend yield, but the sustainability of that dividend.”
Lancz added to positions in stocks such as UPS UPS.N, Cisco CSCO.O and Merck MRK.N during the market's swoon, in part because of those companies' financial strength and dividends.
Investors have been particularly focused on the energy patch, where a tumble in oil to negative territory for the first time has pressured a broad range of companies.
Norway's Equinor EQNR.OL said on Thursday it was cutting its quarterly dividend by two-thirds as part of an effort to preserve cash, while oil services firm Schlumberger NV SLB.N earlier this month slashed its dividend by 75%.
Exxon's dividend yield of 8% and Chevron's of 5.9% are the second- and third-biggest in the Dow Jones Industrial Average .DJI behind only chemical company Dow Inc's DOW.N 8.6%, according to Refinitiv data.
Morningstar equity analyst Allen Good said investors are more concerned about Exxon and Chevron's dividends than in the past but payouts appeared to be safe for now. Debt levels for both companies remain relatively low while dividends "sit high in the financial priorities list" for management, he said.
AbbVie ABBV.N, 3M Co MMM.N and Aflac AFL.N, which are in the dividend aristocrats index, are also due to report first-quarter results next week.
Other companies that have recently taken action on their dividends include casino operator Las Vegas Sands LVS.N, cruise operator Carnival Corp CCL.N and apparel retailer Gap Inc GPS.N, which suspended their payouts.
“This earnings season, where companies have to basically commit to the dividend or not, will determine some potential turnover in the shareholder base,” said Margaret Reid, senior portfolio manager with The Private Bank at Union Bank.
In fact, some companies in areas of the market that have held up well recently raised dividends, including consumer staples companies Costco Wholesale Corp COST.O and Procter & Gamble PG.N and diversified healthcare company Johnson & Johnson JNJ.N.
Those companies, however, may be outliers. Goldman Sachs expects S&P 500 .SPX aggregate dividends to fall 23% to $398 billion in 2020 after rising each year over the past decade.
“For some companies to preserve cash flow to ride through the economic downturn, the smart move would be to cut or suspend the dividend now,” said Keith Lerner, chief market strategist at Truist/SunTrust Advisory Services.
Dividends dropping https://tmsnrt.rs/2ztyFBR
(Reporting by Lewis Krauskopf; Editing by Ira Iosebashvili and Nick Zieminski)
((lewis.krauskopf@thomsonreuters.com; 646-223-6082; Reuters Messaging: lewis.krauskopf.thomsonreuters.com@reuters.net, Twitter: @LKrauskopf))
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | AbbVie ABBV.N, 3M Co MMM.N and Aflac AFL.N, which are in the dividend aristocrats index, are also due to report first-quarter results next week. By Lewis Krauskopf NEW YORK, April 24 (Reuters) - Companies across a range of industries are slashing or suspending dividends to cope with the economic fallout from the coronavirus outbreak, complicating the stock selection process for money managers eager to buttress their portfolios with a steady stream of income. The past week's plunge in oil prices has potentially accelerated that process, raising concerns about the rock-steady dividends of companies such as Exxon Mobil XOM.N and Chevron Corp CVX.N, which are set to report results on Friday, May 1. | AbbVie ABBV.N, 3M Co MMM.N and Aflac AFL.N, which are in the dividend aristocrats index, are also due to report first-quarter results next week. The past week's plunge in oil prices has potentially accelerated that process, raising concerns about the rock-steady dividends of companies such as Exxon Mobil XOM.N and Chevron Corp CVX.N, which are set to report results on Friday, May 1. The S&P 500 dividend aristocrats index .SPDAUDT, which tracks companies that have increased dividends annually for the past 25 years and includes Exxon and Chevron, has fallen about 19% so far in 2020 as of Thursday, greater than the 12.9% drop over that time for the S&P 500 total return index .SPXTR. | AbbVie ABBV.N, 3M Co MMM.N and Aflac AFL.N, which are in the dividend aristocrats index, are also due to report first-quarter results next week. The S&P 500 dividend aristocrats index .SPDAUDT, which tracks companies that have increased dividends annually for the past 25 years and includes Exxon and Chevron, has fallen about 19% so far in 2020 as of Thursday, greater than the 12.9% drop over that time for the S&P 500 total return index .SPXTR. “In times like these, financial strength and dividends are two of the critical components in making your investment selections,” said Alan Lancz, president of investment advisory firm Alan B. Lancz & Associates Inc. “It’s not just the dividend yield, but the sustainability of that dividend.” Lancz added to positions in stocks such as UPS UPS.N, Cisco CSCO.O and Merck MRK.N during the market's swoon, in part because of those companies' financial strength and dividends. | AbbVie ABBV.N, 3M Co MMM.N and Aflac AFL.N, which are in the dividend aristocrats index, are also due to report first-quarter results next week. By Lewis Krauskopf NEW YORK, April 24 (Reuters) - Companies across a range of industries are slashing or suspending dividends to cope with the economic fallout from the coronavirus outbreak, complicating the stock selection process for money managers eager to buttress their portfolios with a steady stream of income. The past week's plunge in oil prices has potentially accelerated that process, raising concerns about the rock-steady dividends of companies such as Exxon Mobil XOM.N and Chevron Corp CVX.N, which are set to report results on Friday, May 1. |
24601.0 | 2020-04-24 00:00:00 UTC | Wall St Week Ahead-Spotlight falls on 'dividend aristocrats' after market tumult | ABBV | https://www.nasdaq.com/articles/wall-st-week-ahead-spotlight-falls-on-dividend-aristocrats-after-market-tumult-2020-04-24 | nan | nan | By Lewis Krauskopf
NEW YORK, April 24 (Reuters) - Companies across a range of industries are slashing or suspending dividends to cope with the economic fallout from the coronavirus outbreak, complicating the stock selection process for money managers eager to buttress their portfolios with a steady stream of income.
The past week's plunge in oil prices has potentially accelerated that process, raising concerns about the rock-steady dividends of companies such as Exxon Mobil XOM.N and Chevron Corp CVX.N, which are set to report results on Friday, May 1.
The S&P 500 dividend aristocrats index .SPDAUDT, which tracks companies that have increased dividends annually for the past 25 years and includes Exxon and Chevron, has fallen about 19% so far in 2020 as of Thursday, greater than the 12.9% drop over that time for the S&P 500 total return index .SPXTR.
That's bad news for yield-thirsty investors at a time when payouts on U.S Treasuries stand near historic lows as the Federal Reserve keeps interest rates in check to stimulate the economy. The S&P 500's dividend yield recently exceeded the yield on the benchmark 10-year U.S. Treasury US10YT=RR by its highest margin in nearly five decades.
“In times like these, financial strength and dividends are two of the critical components in making your investment selections,” said Alan Lancz, president of investment advisory firm Alan B. Lancz & Associates Inc. “It’s not just the dividend yield, but the sustainability of that dividend.”
Lancz added to positions in stocks such as UPS UPS.N, Cisco CSCO.O and Merck MRK.N during the market's swoon, in part because of those companies' financial strength and dividends.
Investors have been particularly focused on the energy patch, where a tumble in oil to negative territory for the first time has pressured a broad range of companies.
Norway's Equinor EQNR.OL said on Thursday it was cutting its quarterly dividend by two-thirds as part of an effort to preserve cash, while oil services firm Schlumberger NV SLB.N earlier this month slashed its dividend by 75%.
Exxon's dividend yield of 8% and Chevron's of 5.9% are the second- and third-biggest in the Dow Jones Industrial Average .DJI behind only chemical company Dow Inc's DOW.N 8.6%, according to Refinitiv data.
Morningstar equity analyst Allen Good said investors are more concerned about Exxon and Chevron's dividends than in the past but payouts appeared to be safe for now. Debt levels for both companies remain relatively low while dividends "sit high in the financial priorities list" for management, he said.
AbbVie ABBV.N, 3M Co MMM.N and Aflac AFL.N, which are in the dividend aristocrats index, are also due to report first-quarter results next week.
Other companies that have recently taken action on their dividends include casino operator Las Vegas Sands LVS.N, cruise operator Carnival Corp CCL.N and apparel retailer Gap Inc GPS.N, which suspended their payouts.
“This earnings season, where companies have to basically commit to the dividend or not, will determine some potential turnover in the shareholder base,” said Margaret Reid, senior portfolio manager with The Private Bank at Union Bank.
In fact, some companies in areas of the market that have held up well recently raised dividends, including consumer staples companies Costco Wholesale Corp COST.O and Procter & Gamble PG.N and diversified healthcare company Johnson & Johnson JNJ.N.
Those companies, however, may be outliers. Goldman Sachs expects S&P 500 .SPX aggregate dividends to fall 23% to $398 billion in 2020 after rising each year over the past decade.
“For some companies to preserve cash flow to ride through the economic downturn, the smart move would be to cut or suspend the dividend now,” said Keith Lerner, chief market strategist at Truist/SunTrust Advisory Services.
Dividends dropping https://tmsnrt.rs/2ztyFBR
(Reporting by Lewis Krauskopf; Editing by Ira Iosebashvili and Nick Zieminski)
((lewis.krauskopf@thomsonreuters.com; 646-223-6082; Reuters Messaging: lewis.krauskopf.thomsonreuters.com@reuters.net, Twitter: @LKrauskopf))
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | AbbVie ABBV.N, 3M Co MMM.N and Aflac AFL.N, which are in the dividend aristocrats index, are also due to report first-quarter results next week. By Lewis Krauskopf NEW YORK, April 24 (Reuters) - Companies across a range of industries are slashing or suspending dividends to cope with the economic fallout from the coronavirus outbreak, complicating the stock selection process for money managers eager to buttress their portfolios with a steady stream of income. The past week's plunge in oil prices has potentially accelerated that process, raising concerns about the rock-steady dividends of companies such as Exxon Mobil XOM.N and Chevron Corp CVX.N, which are set to report results on Friday, May 1. | AbbVie ABBV.N, 3M Co MMM.N and Aflac AFL.N, which are in the dividend aristocrats index, are also due to report first-quarter results next week. The past week's plunge in oil prices has potentially accelerated that process, raising concerns about the rock-steady dividends of companies such as Exxon Mobil XOM.N and Chevron Corp CVX.N, which are set to report results on Friday, May 1. The S&P 500 dividend aristocrats index .SPDAUDT, which tracks companies that have increased dividends annually for the past 25 years and includes Exxon and Chevron, has fallen about 19% so far in 2020 as of Thursday, greater than the 12.9% drop over that time for the S&P 500 total return index .SPXTR. | AbbVie ABBV.N, 3M Co MMM.N and Aflac AFL.N, which are in the dividend aristocrats index, are also due to report first-quarter results next week. The S&P 500 dividend aristocrats index .SPDAUDT, which tracks companies that have increased dividends annually for the past 25 years and includes Exxon and Chevron, has fallen about 19% so far in 2020 as of Thursday, greater than the 12.9% drop over that time for the S&P 500 total return index .SPXTR. “In times like these, financial strength and dividends are two of the critical components in making your investment selections,” said Alan Lancz, president of investment advisory firm Alan B. Lancz & Associates Inc. “It’s not just the dividend yield, but the sustainability of that dividend.” Lancz added to positions in stocks such as UPS UPS.N, Cisco CSCO.O and Merck MRK.N during the market's swoon, in part because of those companies' financial strength and dividends. | AbbVie ABBV.N, 3M Co MMM.N and Aflac AFL.N, which are in the dividend aristocrats index, are also due to report first-quarter results next week. By Lewis Krauskopf NEW YORK, April 24 (Reuters) - Companies across a range of industries are slashing or suspending dividends to cope with the economic fallout from the coronavirus outbreak, complicating the stock selection process for money managers eager to buttress their portfolios with a steady stream of income. The past week's plunge in oil prices has potentially accelerated that process, raising concerns about the rock-steady dividends of companies such as Exxon Mobil XOM.N and Chevron Corp CVX.N, which are set to report results on Friday, May 1. |
24602.0 | 2020-04-24 00:00:00 UTC | BUZZ-U.S. STOCKS ON THE MOVE-Medigus, Pluristem Therapeutics, Whiting Petroleum | ABBV | https://www.nasdaq.com/articles/buzz-u.s.-stocks-on-the-move-medigus-pluristem-therapeutics-whiting-petroleum-2020-04-24 | nan | nan | Eikon search string for individual stock moves: STXBZ
The Day Ahead newsletter: http://tmsnrt.rs/2ggOmBi
The Morning News Call newsletter: http://tmsnrt.rs/2fwPLTh
The Dow Jones was under pressure on Friday, hurt by declines in Boeing and Intel, with investors staying cautious about an economic recovery as some states prepared to relax coronavirus-induced lockdowns..N
At 13:08 ET, the Dow Jones Industrial Average .DJI was up 0.01% at 23,517.2. The S&P 500 .SPX was up 0.31% at 2,806.45 and the Nasdaq Composite .IXIC was up 0.61% at 8,546.346. The top three S&P 500 .PG.INX percentage gainers: ** Sysco Corp , up 7.5% ** Tractor Supply Co , up 6.1% ** Freeport-McMoRan Inc , up 5.8% The top three S&P 500 .PL.INX percentage losers: ** Helmerich & Payne Inc , down 10.6% ** Boeing Co , down 6.2% ** Simon Property Group , down 5.9% The top three NYSE .PG.N percentage gainers: ** Direxion Zacks MLP High Income Index Shares , up 748.6% ** Chesapeake Energy Corp , up 28.9% ** John Hancock Mltfactor Energy ETF , up 26.1% The top three NYSE .PL.N percentage losers: ** Amira Nature Foods Ltd , down 29% ** VictoryShares USAA MSCI USA Value Momentum ETF , down 24.7% ** Direxion Daily MSCI Brazil Bull 2X Shares , down 21.2% The top three Nasdaq .PG.O percentage gainers: ** Mesoblast Ltd , up 117.4% ** OpGen Equity Warrants , up 89% ** Medigus Ltd , up 69.4% The top three Nasdaq .PL.O percentage losers: ** Credit Suisse X Links Crude Oil Shares Covered Call Etn , down 18.3% ** National Energy Services Reunited Corp , down 14.7% ** eHealth Inc , down 13.7% ** ThermoGenesis Holdings Inc THMO.O: up 16.5%
BUZZ-ThermoGenesis Holdings: Rises on COVID-19 treatment plans ** BJ's Restaurants Inc BJRI.O: down 1.8%
BUZZ-BJ's Restaurants Inc: Falls as weekly comparable sales plunge 70% ** Tennant Co TNC.N: down 3.4%
BUZZ-Tennant Co: Dips as it withdraws 2020 forecast, CFO resigns ** Beyond Meat Inc BYND.O: up 7.7%
BUZZ-Beyond Meat on fire, tracking best week since IPO ** TRI Pointe Group Inc TPH.N: up 6.3%
BUZZ-TRI Pointe: Rise after results beat for fourth straight quarter ** Ovintiv Inc OVV.N: down 7.2%
BUZZ-Ovintiv Inc: Falls on TD Securities downgrade to "hold" ** Amazon.com Inc AMZN.O: up 0.2%
BUZZ-Amazon.com: Brokerages raise PT citing ability to outgun the pandemic ** Verizon Communications Inc VZ.N: down 0.7%
BUZZ-Verizon ticks lower after pulling 2020 revenue forecast ** BioSig Technologies Inc BSGM.O: up 12.8%
BUZZ-BioSig: Jumps after unit seeks human trial clearance for COVID-19 therapy ** Whiting Petroleum Corp WLL.N: down 26.2%
BUZZ-Whiting Petroleum: Plunges after filing chapter 11 reorganization plan ** Freeport-McMoRan Inc FCX.N: up 5.8%
BUZZ-Freeport-McMoRan: Rises on costs cuts, smaller-than-expected Q1 loss ** Terex Corp TEX.N: down 5.6%
BUZZ-Terex Corp falls as Credit Suisse downgrades to 'neutral' ** Quest Diagnostics Inc DGX.N: up 0.7%
BUZZ-Quest Diagnostics: Mizuho raises PT on COVID-19 testing potential ** XPO Logistics Inc XPO.N: up 2.8%
BUZZ-XPO Logistics: Up as Suntrust raises PT on ability to weather coronavirus storm ** Midland States Bancorp Inc MSBI.O: down 9.3%
BUZZ-Midland States Bancorp slumps after earnings ** AT&T Inc T.N: down 0.7%
BUZZ-AT&T: Rises after naming John Stankey as new CEO ** Tyson Foods Inc TSN.N: down 3.3%
BUZZ-Tyson Foods: Bernstein downgrades on disruptions to production ** Emergent BioSolutions Inc EBS.N: up 8.0%
BUZZ-Emergent BioSolutions: Up on deal to manufacture J&J's potential COVID-19 vaccine ** Eldorado Resorts Inc ERI.O: up 7.8%
BUZZ-Eldorado Resorts rises on deal to sell two properties for $155 mln ** People's United Financial Inc PBCT.O: up 4.0%
BUZZ-People's United Financial Inc: Rises on better-than-expected quarterly profit ** Tonix Pharmaceuticals Holdings Corp TNXP.O: up 1.5% BUZZ-Tonix Pharma rises on enrollment in study on muscular disorder treatment ** Gold Fields Ltd GFI.N: up 0.9% BUZZ-Gold Fields: Gains after revised 2020 guidance shows minimal COVID impact ** Host Hotels and Resorts Inc HST.N: up 0.7% ** Pebblebrook Hotel Trust PEB.N: down 0.8% BUZZ-BTIG lifts Host Hotels, Pebblebrook to 'buy' on hopes for economic recovery ** Medigus Ltd MDGS.O: up 69.4% BUZZ-Medigus: Soars on marketing partnership with Polyrizon ** PPG Industries PPG.N: down 0.5% BUZZ-PPG Industries: Downturn in aero, industrial sectors keeps CS on sidelines ** Zoom Video Communications Inc ZM.O: up 5.0% BUZZ-Zoom: Set for record high; to join Nasdaq 100 index ** Verizon Communications Inc VZ.N: down 0.7% BUZZ-PREVIEW: Verizon dips up ahead of earnings ** Eli Lilly and Co LLY.N: up 0.8% BUZZ-Street View: Eli Lilly's fundamentals remains strong amid coronavirus rout ** Intel Corp INTC.O: down 1.5% BUZZ-Street View: Coronavirus clouds Intel's H2 visibility ** J.C. Penney Company Inc JCP.N: down 12.7% BUZZ-J.C. Penney: Drops on report co in advanced talks for bankruptcy financing ** AbbVie Inc ABBV.N: up 1.1% BUZZ-AbbVie: Allergan deal to boost visibility; growth dilution to be of focus - RBC ** Workday Inc WDAY.O: up 0.9% BUZZ-Workday Inc: Cowen downgrades citing heightened challenges from the virus ** Pluristem Therapeutics Inc PSTI.O: up 22.4% BUZZ-Pluristem: Surges after securing 50 mln euros to develop COVID-19 treatment ** Snap Inc SNAP.N: down 1.1% BUZZ-Snap edges higher after pricing upsized $850 mln convertible debt deal ** American Express Co AXP.N: down 1.2% BUZZ-American Express: Rises as cost controls drive profit beat
The 11 major S&P 500 sectors:
Communication Services
.SPLRCL
down 0.42%
Consumer Discretionary
.SPLRCD
up 0.65%
Consumer Staples
.SPLRCS
up 0.45%
Energy
.SPNY
down 0.47%
Financial
.SPSY
down 0.13%
Health
.SPXHC
up 0.48%
Industrial
.SPLRCI
down 0.47%
Information Technology
.SPLRCT
up 1.09%
Materials
.SPLRCM
up 0.35%
Real Estate
.SPLRCR
down 0.73%
Utilities
.SPLRCU
down 0.54%
(Compiled by Amal S in Bengaluru)
((Amal.S@thomsonreuters.com; within U.S.+1 646 223 8780; outside U.S. +91 80 6749 3677;))
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | The top three S&P 500 .PG.INX percentage gainers: ** Sysco Corp , up 7.5% ** Tractor Supply Co , up 6.1% ** Freeport-McMoRan Inc , up 5.8% The top three S&P 500 .PL.INX percentage losers: ** Helmerich & Payne Inc , down 10.6% ** Boeing Co , down 6.2% ** Simon Property Group , down 5.9% The top three NYSE .PG.N percentage gainers: ** Direxion Zacks MLP High Income Index Shares , up 748.6% ** Chesapeake Energy Corp , up 28.9% ** John Hancock Mltfactor Energy ETF , up 26.1% The top three NYSE .PL.N percentage losers: ** Amira Nature Foods Ltd , down 29% ** VictoryShares USAA MSCI USA Value Momentum ETF , down 24.7% ** Direxion Daily MSCI Brazil Bull 2X Shares , down 21.2% The top three Nasdaq .PG.O percentage gainers: ** Mesoblast Ltd , up 117.4% ** OpGen Equity Warrants , up 89% ** Medigus Ltd , up 69.4% The top three Nasdaq .PL.O percentage losers: ** Credit Suisse X Links Crude Oil Shares Covered Call Etn , down 18.3% ** National Energy Services Reunited Corp , down 14.7% ** eHealth Inc , down 13.7% ** ThermoGenesis Holdings Inc THMO.O: up 16.5% BUZZ-ThermoGenesis Holdings: Rises on COVID-19 treatment plans ** BJ's Restaurants Inc BJRI.O: down 1.8% BUZZ-BJ's Restaurants Inc: Falls as weekly comparable sales plunge 70% ** Tennant Co TNC.N: down 3.4% BUZZ-Tennant Co: Dips as it withdraws 2020 forecast, CFO resigns ** Beyond Meat Inc BYND.O: up 7.7% BUZZ-Beyond Meat on fire, tracking best week since IPO ** TRI Pointe Group Inc TPH.N: up 6.3% BUZZ-TRI Pointe: Rise after results beat for fourth straight quarter ** Ovintiv Inc OVV.N: down 7.2% BUZZ-Ovintiv Inc: Falls on TD Securities downgrade to "hold" ** Amazon.com Inc AMZN.O: up 0.2% BUZZ-Amazon.com: Brokerages raise PT citing ability to outgun the pandemic ** Verizon Communications Inc VZ.N: down 0.7% BUZZ-Verizon ticks lower after pulling 2020 revenue forecast ** BioSig Technologies Inc BSGM.O: up 12.8% BUZZ-BioSig: Jumps after unit seeks human trial clearance for COVID-19 therapy ** Whiting Petroleum Corp WLL.N: down 26.2% BUZZ-Whiting Petroleum: Plunges after filing chapter 11 reorganization plan ** Freeport-McMoRan Inc FCX.N: up 5.8% BUZZ-Freeport-McMoRan: Rises on costs cuts, smaller-than-expected Q1 loss ** Terex Corp TEX.N: down 5.6% BUZZ-Terex Corp falls as Credit Suisse downgrades to 'neutral' ** Quest Diagnostics Inc DGX.N: up 0.7% BUZZ-Quest Diagnostics: Mizuho raises PT on COVID-19 testing potential ** XPO Logistics Inc XPO.N: up 2.8% BUZZ-XPO Logistics: Up as Suntrust raises PT on ability to weather coronavirus storm ** Midland States Bancorp Inc MSBI.O: down 9.3% BUZZ-Midland States Bancorp slumps after earnings ** AT&T Inc T.N: down 0.7% BUZZ-AT&T: Rises after naming John Stankey as new CEO ** Tyson Foods Inc TSN.N: down 3.3% BUZZ-Tyson Foods: Bernstein downgrades on disruptions to production ** Emergent BioSolutions Inc EBS.N: up 8.0% BUZZ-Emergent BioSolutions: Up on deal to manufacture J&J's potential COVID-19 vaccine ** Eldorado Resorts Inc ERI.O: up 7.8% BUZZ-Eldorado Resorts rises on deal to sell two properties for $155 mln ** People's United Financial Inc PBCT.O: up 4.0% BUZZ-People's United Financial Inc: Rises on better-than-expected quarterly profit ** Tonix Pharmaceuticals Holdings Corp TNXP.O: up 1.5% BUZZ-Tonix Pharma rises on enrollment in study on muscular disorder treatment ** Gold Fields Ltd GFI.N: up 0.9% BUZZ-Gold Fields: Gains after revised 2020 guidance shows minimal COVID impact ** Host Hotels and Resorts Inc HST.N: up 0.7% ** Pebblebrook Hotel Trust PEB.N: down 0.8% BUZZ-BTIG lifts Host Hotels, Pebblebrook to 'buy' on hopes for economic recovery ** Medigus Ltd MDGS.O: up 69.4% BUZZ-Medigus: Soars on marketing partnership with Polyrizon ** PPG Industries PPG.N: down 0.5% BUZZ-PPG Industries: Downturn in aero, industrial sectors keeps CS on sidelines ** Zoom Video Communications Inc ZM.O: up 5.0% BUZZ-Zoom: Set for record high; to join Nasdaq 100 index ** Verizon Communications Inc VZ.N: down 0.7% BUZZ-PREVIEW: Verizon dips up ahead of earnings ** Eli Lilly and Co LLY.N: up 0.8% BUZZ-Street View: Eli Lilly's fundamentals remains strong amid coronavirus rout ** Intel Corp INTC.O: down 1.5% BUZZ-Street View: Coronavirus clouds Intel's H2 visibility ** J.C. Penney Company Inc JCP.N: down 12.7% BUZZ-J.C. Penney: Drops on report co in advanced talks for bankruptcy financing ** AbbVie Inc ABBV.N: up 1.1% BUZZ-AbbVie: Allergan deal to boost visibility; growth dilution to be of focus - RBC ** Workday Inc WDAY.O: up 0.9% BUZZ-Workday Inc: Cowen downgrades citing heightened challenges from the virus ** Pluristem Therapeutics Inc PSTI.O: up 22.4% BUZZ-Pluristem: Surges after securing 50 mln euros to develop COVID-19 treatment ** Snap Inc SNAP.N: down 1.1% BUZZ-Snap edges higher after pricing upsized $850 mln convertible debt deal ** American Express Co AXP.N: down 1.2% BUZZ-American Express: Rises as cost controls drive profit beat The 11 major S&P 500 sectors: Communication Services Eikon search string for individual stock moves: STXBZ The Day Ahead newsletter: http://tmsnrt.rs/2ggOmBi The Morning News Call newsletter: http://tmsnrt.rs/2fwPLTh The Dow Jones was under pressure on Friday, hurt by declines in Boeing and Intel, with investors staying cautious about an economic recovery as some states prepared to relax coronavirus-induced lockdowns..N At 13:08 ET, the Dow Jones Industrial Average .DJI was up 0.01% at 23,517.2. down 0.54% (Compiled by Amal S in Bengaluru) ((Amal.S@thomsonreuters.com; within U.S.+1 646 223 8780; outside U.S. +91 80 6749 3677;)) The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | The top three S&P 500 .PG.INX percentage gainers: ** Sysco Corp , up 7.5% ** Tractor Supply Co , up 6.1% ** Freeport-McMoRan Inc , up 5.8% The top three S&P 500 .PL.INX percentage losers: ** Helmerich & Payne Inc , down 10.6% ** Boeing Co , down 6.2% ** Simon Property Group , down 5.9% The top three NYSE .PG.N percentage gainers: ** Direxion Zacks MLP High Income Index Shares , up 748.6% ** Chesapeake Energy Corp , up 28.9% ** John Hancock Mltfactor Energy ETF , up 26.1% The top three NYSE .PL.N percentage losers: ** Amira Nature Foods Ltd , down 29% ** VictoryShares USAA MSCI USA Value Momentum ETF , down 24.7% ** Direxion Daily MSCI Brazil Bull 2X Shares , down 21.2% The top three Nasdaq .PG.O percentage gainers: ** Mesoblast Ltd , up 117.4% ** OpGen Equity Warrants , up 89% ** Medigus Ltd , up 69.4% The top three Nasdaq .PL.O percentage losers: ** Credit Suisse X Links Crude Oil Shares Covered Call Etn , down 18.3% ** National Energy Services Reunited Corp , down 14.7% ** eHealth Inc , down 13.7% ** ThermoGenesis Holdings Inc THMO.O: up 16.5% BUZZ-ThermoGenesis Holdings: Rises on COVID-19 treatment plans ** BJ's Restaurants Inc BJRI.O: down 1.8% BUZZ-BJ's Restaurants Inc: Falls as weekly comparable sales plunge 70% ** Tennant Co TNC.N: down 3.4% BUZZ-Tennant Co: Dips as it withdraws 2020 forecast, CFO resigns ** Beyond Meat Inc BYND.O: up 7.7% BUZZ-Beyond Meat on fire, tracking best week since IPO ** TRI Pointe Group Inc TPH.N: up 6.3% BUZZ-TRI Pointe: Rise after results beat for fourth straight quarter ** Ovintiv Inc OVV.N: down 7.2% BUZZ-Ovintiv Inc: Falls on TD Securities downgrade to "hold" ** Amazon.com Inc AMZN.O: up 0.2% BUZZ-Amazon.com: Brokerages raise PT citing ability to outgun the pandemic ** Verizon Communications Inc VZ.N: down 0.7% BUZZ-Verizon ticks lower after pulling 2020 revenue forecast ** BioSig Technologies Inc BSGM.O: up 12.8% BUZZ-BioSig: Jumps after unit seeks human trial clearance for COVID-19 therapy ** Whiting Petroleum Corp WLL.N: down 26.2% BUZZ-Whiting Petroleum: Plunges after filing chapter 11 reorganization plan ** Freeport-McMoRan Inc FCX.N: up 5.8% BUZZ-Freeport-McMoRan: Rises on costs cuts, smaller-than-expected Q1 loss ** Terex Corp TEX.N: down 5.6% BUZZ-Terex Corp falls as Credit Suisse downgrades to 'neutral' ** Quest Diagnostics Inc DGX.N: up 0.7% BUZZ-Quest Diagnostics: Mizuho raises PT on COVID-19 testing potential ** XPO Logistics Inc XPO.N: up 2.8% BUZZ-XPO Logistics: Up as Suntrust raises PT on ability to weather coronavirus storm ** Midland States Bancorp Inc MSBI.O: down 9.3% BUZZ-Midland States Bancorp slumps after earnings ** AT&T Inc T.N: down 0.7% BUZZ-AT&T: Rises after naming John Stankey as new CEO ** Tyson Foods Inc TSN.N: down 3.3% BUZZ-Tyson Foods: Bernstein downgrades on disruptions to production ** Emergent BioSolutions Inc EBS.N: up 8.0% BUZZ-Emergent BioSolutions: Up on deal to manufacture J&J's potential COVID-19 vaccine ** Eldorado Resorts Inc ERI.O: up 7.8% BUZZ-Eldorado Resorts rises on deal to sell two properties for $155 mln ** People's United Financial Inc PBCT.O: up 4.0% BUZZ-People's United Financial Inc: Rises on better-than-expected quarterly profit ** Tonix Pharmaceuticals Holdings Corp TNXP.O: up 1.5% BUZZ-Tonix Pharma rises on enrollment in study on muscular disorder treatment ** Gold Fields Ltd GFI.N: up 0.9% BUZZ-Gold Fields: Gains after revised 2020 guidance shows minimal COVID impact ** Host Hotels and Resorts Inc HST.N: up 0.7% ** Pebblebrook Hotel Trust PEB.N: down 0.8% BUZZ-BTIG lifts Host Hotels, Pebblebrook to 'buy' on hopes for economic recovery ** Medigus Ltd MDGS.O: up 69.4% BUZZ-Medigus: Soars on marketing partnership with Polyrizon ** PPG Industries PPG.N: down 0.5% BUZZ-PPG Industries: Downturn in aero, industrial sectors keeps CS on sidelines ** Zoom Video Communications Inc ZM.O: up 5.0% BUZZ-Zoom: Set for record high; to join Nasdaq 100 index ** Verizon Communications Inc VZ.N: down 0.7% BUZZ-PREVIEW: Verizon dips up ahead of earnings ** Eli Lilly and Co LLY.N: up 0.8% BUZZ-Street View: Eli Lilly's fundamentals remains strong amid coronavirus rout ** Intel Corp INTC.O: down 1.5% BUZZ-Street View: Coronavirus clouds Intel's H2 visibility ** J.C. Penney Company Inc JCP.N: down 12.7% BUZZ-J.C. Penney: Drops on report co in advanced talks for bankruptcy financing ** AbbVie Inc ABBV.N: up 1.1% BUZZ-AbbVie: Allergan deal to boost visibility; growth dilution to be of focus - RBC ** Workday Inc WDAY.O: up 0.9% BUZZ-Workday Inc: Cowen downgrades citing heightened challenges from the virus ** Pluristem Therapeutics Inc PSTI.O: up 22.4% BUZZ-Pluristem: Surges after securing 50 mln euros to develop COVID-19 treatment ** Snap Inc SNAP.N: down 1.1% BUZZ-Snap edges higher after pricing upsized $850 mln convertible debt deal ** American Express Co AXP.N: down 1.2% BUZZ-American Express: Rises as cost controls drive profit beat The 11 major S&P 500 sectors: Communication Services Eikon search string for individual stock moves: STXBZ The Day Ahead newsletter: http://tmsnrt.rs/2ggOmBi The Morning News Call newsletter: http://tmsnrt.rs/2fwPLTh The Dow Jones was under pressure on Friday, hurt by declines in Boeing and Intel, with investors staying cautious about an economic recovery as some states prepared to relax coronavirus-induced lockdowns..N At 13:08 ET, the Dow Jones Industrial Average .DJI was up 0.01% at 23,517.2. down 0.54% (Compiled by Amal S in Bengaluru) ((Amal.S@thomsonreuters.com; within U.S.+1 646 223 8780; outside U.S. +91 80 6749 3677;)) The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | The top three S&P 500 .PG.INX percentage gainers: ** Sysco Corp , up 7.5% ** Tractor Supply Co , up 6.1% ** Freeport-McMoRan Inc , up 5.8% The top three S&P 500 .PL.INX percentage losers: ** Helmerich & Payne Inc , down 10.6% ** Boeing Co , down 6.2% ** Simon Property Group , down 5.9% The top three NYSE .PG.N percentage gainers: ** Direxion Zacks MLP High Income Index Shares , up 748.6% ** Chesapeake Energy Corp , up 28.9% ** John Hancock Mltfactor Energy ETF , up 26.1% The top three NYSE .PL.N percentage losers: ** Amira Nature Foods Ltd , down 29% ** VictoryShares USAA MSCI USA Value Momentum ETF , down 24.7% ** Direxion Daily MSCI Brazil Bull 2X Shares , down 21.2% The top three Nasdaq .PG.O percentage gainers: ** Mesoblast Ltd , up 117.4% ** OpGen Equity Warrants , up 89% ** Medigus Ltd , up 69.4% The top three Nasdaq .PL.O percentage losers: ** Credit Suisse X Links Crude Oil Shares Covered Call Etn , down 18.3% ** National Energy Services Reunited Corp , down 14.7% ** eHealth Inc , down 13.7% ** ThermoGenesis Holdings Inc THMO.O: up 16.5% BUZZ-ThermoGenesis Holdings: Rises on COVID-19 treatment plans ** BJ's Restaurants Inc BJRI.O: down 1.8% BUZZ-BJ's Restaurants Inc: Falls as weekly comparable sales plunge 70% ** Tennant Co TNC.N: down 3.4% BUZZ-Tennant Co: Dips as it withdraws 2020 forecast, CFO resigns ** Beyond Meat Inc BYND.O: up 7.7% BUZZ-Beyond Meat on fire, tracking best week since IPO ** TRI Pointe Group Inc TPH.N: up 6.3% BUZZ-TRI Pointe: Rise after results beat for fourth straight quarter ** Ovintiv Inc OVV.N: down 7.2% BUZZ-Ovintiv Inc: Falls on TD Securities downgrade to "hold" ** Amazon.com Inc AMZN.O: up 0.2% BUZZ-Amazon.com: Brokerages raise PT citing ability to outgun the pandemic ** Verizon Communications Inc VZ.N: down 0.7% BUZZ-Verizon ticks lower after pulling 2020 revenue forecast ** BioSig Technologies Inc BSGM.O: up 12.8% BUZZ-BioSig: Jumps after unit seeks human trial clearance for COVID-19 therapy ** Whiting Petroleum Corp WLL.N: down 26.2% BUZZ-Whiting Petroleum: Plunges after filing chapter 11 reorganization plan ** Freeport-McMoRan Inc FCX.N: up 5.8% BUZZ-Freeport-McMoRan: Rises on costs cuts, smaller-than-expected Q1 loss ** Terex Corp TEX.N: down 5.6% BUZZ-Terex Corp falls as Credit Suisse downgrades to 'neutral' ** Quest Diagnostics Inc DGX.N: up 0.7% BUZZ-Quest Diagnostics: Mizuho raises PT on COVID-19 testing potential ** XPO Logistics Inc XPO.N: up 2.8% BUZZ-XPO Logistics: Up as Suntrust raises PT on ability to weather coronavirus storm ** Midland States Bancorp Inc MSBI.O: down 9.3% BUZZ-Midland States Bancorp slumps after earnings ** AT&T Inc T.N: down 0.7% BUZZ-AT&T: Rises after naming John Stankey as new CEO ** Tyson Foods Inc TSN.N: down 3.3% BUZZ-Tyson Foods: Bernstein downgrades on disruptions to production ** Emergent BioSolutions Inc EBS.N: up 8.0% BUZZ-Emergent BioSolutions: Up on deal to manufacture J&J's potential COVID-19 vaccine ** Eldorado Resorts Inc ERI.O: up 7.8% BUZZ-Eldorado Resorts rises on deal to sell two properties for $155 mln ** People's United Financial Inc PBCT.O: up 4.0% BUZZ-People's United Financial Inc: Rises on better-than-expected quarterly profit ** Tonix Pharmaceuticals Holdings Corp TNXP.O: up 1.5% BUZZ-Tonix Pharma rises on enrollment in study on muscular disorder treatment ** Gold Fields Ltd GFI.N: up 0.9% BUZZ-Gold Fields: Gains after revised 2020 guidance shows minimal COVID impact ** Host Hotels and Resorts Inc HST.N: up 0.7% ** Pebblebrook Hotel Trust PEB.N: down 0.8% BUZZ-BTIG lifts Host Hotels, Pebblebrook to 'buy' on hopes for economic recovery ** Medigus Ltd MDGS.O: up 69.4% BUZZ-Medigus: Soars on marketing partnership with Polyrizon ** PPG Industries PPG.N: down 0.5% BUZZ-PPG Industries: Downturn in aero, industrial sectors keeps CS on sidelines ** Zoom Video Communications Inc ZM.O: up 5.0% BUZZ-Zoom: Set for record high; to join Nasdaq 100 index ** Verizon Communications Inc VZ.N: down 0.7% BUZZ-PREVIEW: Verizon dips up ahead of earnings ** Eli Lilly and Co LLY.N: up 0.8% BUZZ-Street View: Eli Lilly's fundamentals remains strong amid coronavirus rout ** Intel Corp INTC.O: down 1.5% BUZZ-Street View: Coronavirus clouds Intel's H2 visibility ** J.C. Penney Company Inc JCP.N: down 12.7% BUZZ-J.C. Penney: Drops on report co in advanced talks for bankruptcy financing ** AbbVie Inc ABBV.N: up 1.1% BUZZ-AbbVie: Allergan deal to boost visibility; growth dilution to be of focus - RBC ** Workday Inc WDAY.O: up 0.9% BUZZ-Workday Inc: Cowen downgrades citing heightened challenges from the virus ** Pluristem Therapeutics Inc PSTI.O: up 22.4% BUZZ-Pluristem: Surges after securing 50 mln euros to develop COVID-19 treatment ** Snap Inc SNAP.N: down 1.1% BUZZ-Snap edges higher after pricing upsized $850 mln convertible debt deal ** American Express Co AXP.N: down 1.2% BUZZ-American Express: Rises as cost controls drive profit beat The 11 major S&P 500 sectors: Communication Services down 0.42% Consumer Discretionary up 0.65% Consumer Staples | The top three S&P 500 .PG.INX percentage gainers: ** Sysco Corp , up 7.5% ** Tractor Supply Co , up 6.1% ** Freeport-McMoRan Inc , up 5.8% The top three S&P 500 .PL.INX percentage losers: ** Helmerich & Payne Inc , down 10.6% ** Boeing Co , down 6.2% ** Simon Property Group , down 5.9% The top three NYSE .PG.N percentage gainers: ** Direxion Zacks MLP High Income Index Shares , up 748.6% ** Chesapeake Energy Corp , up 28.9% ** John Hancock Mltfactor Energy ETF , up 26.1% The top three NYSE .PL.N percentage losers: ** Amira Nature Foods Ltd , down 29% ** VictoryShares USAA MSCI USA Value Momentum ETF , down 24.7% ** Direxion Daily MSCI Brazil Bull 2X Shares , down 21.2% The top three Nasdaq .PG.O percentage gainers: ** Mesoblast Ltd , up 117.4% ** OpGen Equity Warrants , up 89% ** Medigus Ltd , up 69.4% The top three Nasdaq .PL.O percentage losers: ** Credit Suisse X Links Crude Oil Shares Covered Call Etn , down 18.3% ** National Energy Services Reunited Corp , down 14.7% ** eHealth Inc , down 13.7% ** ThermoGenesis Holdings Inc THMO.O: up 16.5% BUZZ-ThermoGenesis Holdings: Rises on COVID-19 treatment plans ** BJ's Restaurants Inc BJRI.O: down 1.8% BUZZ-BJ's Restaurants Inc: Falls as weekly comparable sales plunge 70% ** Tennant Co TNC.N: down 3.4% BUZZ-Tennant Co: Dips as it withdraws 2020 forecast, CFO resigns ** Beyond Meat Inc BYND.O: up 7.7% BUZZ-Beyond Meat on fire, tracking best week since IPO ** TRI Pointe Group Inc TPH.N: up 6.3% BUZZ-TRI Pointe: Rise after results beat for fourth straight quarter ** Ovintiv Inc OVV.N: down 7.2% BUZZ-Ovintiv Inc: Falls on TD Securities downgrade to "hold" ** Amazon.com Inc AMZN.O: up 0.2% BUZZ-Amazon.com: Brokerages raise PT citing ability to outgun the pandemic ** Verizon Communications Inc VZ.N: down 0.7% BUZZ-Verizon ticks lower after pulling 2020 revenue forecast ** BioSig Technologies Inc BSGM.O: up 12.8% BUZZ-BioSig: Jumps after unit seeks human trial clearance for COVID-19 therapy ** Whiting Petroleum Corp WLL.N: down 26.2% BUZZ-Whiting Petroleum: Plunges after filing chapter 11 reorganization plan ** Freeport-McMoRan Inc FCX.N: up 5.8% BUZZ-Freeport-McMoRan: Rises on costs cuts, smaller-than-expected Q1 loss ** Terex Corp TEX.N: down 5.6% BUZZ-Terex Corp falls as Credit Suisse downgrades to 'neutral' ** Quest Diagnostics Inc DGX.N: up 0.7% BUZZ-Quest Diagnostics: Mizuho raises PT on COVID-19 testing potential ** XPO Logistics Inc XPO.N: up 2.8% BUZZ-XPO Logistics: Up as Suntrust raises PT on ability to weather coronavirus storm ** Midland States Bancorp Inc MSBI.O: down 9.3% BUZZ-Midland States Bancorp slumps after earnings ** AT&T Inc T.N: down 0.7% BUZZ-AT&T: Rises after naming John Stankey as new CEO ** Tyson Foods Inc TSN.N: down 3.3% BUZZ-Tyson Foods: Bernstein downgrades on disruptions to production ** Emergent BioSolutions Inc EBS.N: up 8.0% BUZZ-Emergent BioSolutions: Up on deal to manufacture J&J's potential COVID-19 vaccine ** Eldorado Resorts Inc ERI.O: up 7.8% BUZZ-Eldorado Resorts rises on deal to sell two properties for $155 mln ** People's United Financial Inc PBCT.O: up 4.0% BUZZ-People's United Financial Inc: Rises on better-than-expected quarterly profit ** Tonix Pharmaceuticals Holdings Corp TNXP.O: up 1.5% BUZZ-Tonix Pharma rises on enrollment in study on muscular disorder treatment ** Gold Fields Ltd GFI.N: up 0.9% BUZZ-Gold Fields: Gains after revised 2020 guidance shows minimal COVID impact ** Host Hotels and Resorts Inc HST.N: up 0.7% ** Pebblebrook Hotel Trust PEB.N: down 0.8% BUZZ-BTIG lifts Host Hotels, Pebblebrook to 'buy' on hopes for economic recovery ** Medigus Ltd MDGS.O: up 69.4% BUZZ-Medigus: Soars on marketing partnership with Polyrizon ** PPG Industries PPG.N: down 0.5% BUZZ-PPG Industries: Downturn in aero, industrial sectors keeps CS on sidelines ** Zoom Video Communications Inc ZM.O: up 5.0% BUZZ-Zoom: Set for record high; to join Nasdaq 100 index ** Verizon Communications Inc VZ.N: down 0.7% BUZZ-PREVIEW: Verizon dips up ahead of earnings ** Eli Lilly and Co LLY.N: up 0.8% BUZZ-Street View: Eli Lilly's fundamentals remains strong amid coronavirus rout ** Intel Corp INTC.O: down 1.5% BUZZ-Street View: Coronavirus clouds Intel's H2 visibility ** J.C. Penney Company Inc JCP.N: down 12.7% BUZZ-J.C. Penney: Drops on report co in advanced talks for bankruptcy financing ** AbbVie Inc ABBV.N: up 1.1% BUZZ-AbbVie: Allergan deal to boost visibility; growth dilution to be of focus - RBC ** Workday Inc WDAY.O: up 0.9% BUZZ-Workday Inc: Cowen downgrades citing heightened challenges from the virus ** Pluristem Therapeutics Inc PSTI.O: up 22.4% BUZZ-Pluristem: Surges after securing 50 mln euros to develop COVID-19 treatment ** Snap Inc SNAP.N: down 1.1% BUZZ-Snap edges higher after pricing upsized $850 mln convertible debt deal ** American Express Co AXP.N: down 1.2% BUZZ-American Express: Rises as cost controls drive profit beat The 11 major S&P 500 sectors: Communication Services Eikon search string for individual stock moves: STXBZ The Day Ahead newsletter: http://tmsnrt.rs/2ggOmBi The Morning News Call newsletter: http://tmsnrt.rs/2fwPLTh The Dow Jones was under pressure on Friday, hurt by declines in Boeing and Intel, with investors staying cautious about an economic recovery as some states prepared to relax coronavirus-induced lockdowns..N At 13:08 ET, the Dow Jones Industrial Average .DJI was up 0.01% at 23,517.2. The S&P 500 .SPX was up 0.31% at 2,806.45 and the Nasdaq Composite .IXIC was up 0.61% at 8,546.346. |
24603.0 | 2020-04-24 00:00:00 UTC | BUZZ-U.S. STOCKS ON THE MOVE-Whiting Petroleum, Medigus, Pluristem Therapeutics | ABBV | https://www.nasdaq.com/articles/buzz-u.s.-stocks-on-the-move-whiting-petroleum-medigus-pluristem-therapeutics-2020-04-24 | nan | nan | Eikon search string for individual stock moves: STXBZ
The Day Ahead newsletter: http://tmsnrt.rs/2ggOmBi
The Morning News Call newsletter: http://tmsnrt.rs/2fwPLTh
The S&P 500 edged higher in choppy trading on Friday as some states prepared to relax curbs imposed to contain the coronavirus outbreak, but declines in Intel and Boeing weighed on the blue-chip Dow Jones..N
At 11:06 a.m. ET, the Dow Jones Industrial Average .DJI was down 0.13% at 23,484.44. The S&P 500 .SPX was up 0.03% at 2,798.72 and the Nasdaq Composite .IXIC was up 0.03% at 8,497.058. The top three S&P 500 .PG.INX percentage gainers: ** Freeport-McMoRan Inc , up 8.8% ** Invesco Ltd , up 6.2% ** Sysco Corp , up 5.3% The top three S&P 500 .PL.INX percentage losers: ** Helmerich & Payne Inc , down 5.3% ** Simon Property Group Inc , down 5.3% ** Boeing Co , down 4.9% The top NYSE .PG.N percentage gainers: ** Curo Group Holdings Corp CURO.N, up 18%
** Twin River Worldwide Holdings, Inc TRWH.N, up 15.8%
** Wayfair Inc W.N, up 12% The top three NYSE .PL.N percentage losers: ** Moog Inc MOGB.N, down 16.6%
** Hertz Global
** Taubman Centers Inc TCO.N, down 9.7% The top Nasdaq .PG.O percentage gainers: ** Mesoblast Limted , up 130.9% ** Medigus Ltd , up 68.1% The top Nasdaq .PL.O percentage losers: ** National Energy Services Reunited Corp NESR.O, down 15.5% ** Limelight Networks Inc , down 13.7% ** BiondVax Pharmaceuticals Equity Warrants BVXVW.O, down 13.4% ** Verizon Communications Inc VZ.N: down 0.6%
BUZZ-Verizon ticks lower after pulling 2020 revenue forecast ** BioSig Technologies Inc BSGM.O: up 9.3%
BUZZ-BioSig: Jumps after unit seeks human trial clearance for COVID-19 therapy ** Whiting Petroleum Corp WLL.N: down 32.7%
BUZZ-Whiting Petroleum: Plunges after filing chapter 11 reorganization plan ** Freeport-McMoRan Inc FCX.N: up 8.8%
BUZZ-Freeport-McMoRan: Rises on costs cuts, smaller-than-expected Q1 loss ** Terex Corp TEX.N: down 5.2%
BUZZ-Terex Corp falls as Credit Suisse downgrades to 'neutral' ** Quest Diagnostics Inc DGX.N: up 0.1%
BUZZ-Quest Diagnostics: Mizuho raises PT on COVID-19 testing potential ** XPO Logistics Inc XPO.N: up 0.8%
BUZZ-XPO Logistics: Up as Suntrust raises PT on ability to weather coronavirus storm ** Midland States Bancorp Inc MSBI.O: down 7.5%
BUZZ-Midland States Bancorp slumps after earnings ** AT&T Inc T.N: down 0.2%
BUZZ-AT&T: Rises after naming John Stankey as new CEO ** Tyson Foods Inc TSN.N: down 3%
BUZZ-Tyson Foods: Bernstein downgrades on disruptions to production ** Emergent BioSolutions Inc EBS.N: up 7.8%
BUZZ-Emergent BioSolutions: Up on deal to manufacture J&J's potential COVID-19 vaccine ** Eldorado Resorts Inc ERI.O: up 5.7%
BUZZ-Eldorado Resorts rises on deal to sell two properties for $155 mln ** People's United Financial Inc PBCT.O: up 3.3%
BUZZ-People's United Financial Inc: Rises on better-than-expected quarterly profit ** Tonix Pharmaceuticals Holdings Corp TNXP.O: up 3.8% BUZZ-Tonix Pharma rises on enrollment in study on muscular disorder treatment ** Gold Fields Ltd GFI.N: up 2.4% BUZZ-Gold Fields: Gains after revised 2020 guidance shows minimal COVID impact ** Host Hotels and Resorts Inc HST.N: up 1.3% ** Pebblebrook Hotel Trust PEB.N: up 1.0% BUZZ-BTIG lifts Host Hotels, Pebblebrook to 'buy' on hopes for economic recovery ** Medigus Ltd MDGS.O: up 68.1% BUZZ-Medigus: Soars on marketing partnership with Polyrizon ** PPG Industries PPG.N: down 0.6% BUZZ-PPG Industries: Downturn in aero, industrial sectors keeps CS on sidelines ** Zoom Video Communications Inc ZM.O: up 4.5% BUZZ-Zoom: Set for record high; to join Nasdaq 100 index ** Verizon Communications Inc VZ.N: down 0.6% BUZZ-PREVIEW: Verizon dips up ahead of earnings ** Eli Lilly and Co LLY.N: up 1.6% BUZZ-Street View: Eli Lilly's fundamentals remains strong amid coronavirus rout ** Intel Corp INTC.O: down 2.3% BUZZ-Street View: Coronavirus clouds Intel's H2 visibility ** J.C. Penney Company Inc JCP.N: down 11.2% BUZZ-J.C. Penney: Drops on report co in advanced talks for bankruptcy financing ** AbbVie Inc ABBV.N: up 1.1% BUZZ-AbbVie: Allergan deal to boost visibility; growth dilution to be of focus - RBC ** Workday Inc WDAY.O: down 0.7% BUZZ-Workday Inc: Cowen downgrades citing heightened challenges from the virus ** Pluristem Therapeutics Inc PSTI.O: up 21.0% BUZZ-Pluristem: Surges after securing 50 mln euros to develop COVID-19 treatment ** Snap Inc SNAP.N: down 0.4% BUZZ-Snap edges higher after pricing upsized $850 mln convertible debt deal ** American Express Co AXP.N: down 0.1% BUZZ-American Express: Rises as cost controls drive profit beat
The 11 major S&P 500 sectors:
Communication Services
.SPLRCL
down 0.74%
Consumer Discretionary
.SPLRCD
up 0.33%
Consumer Staples
.SPLRCS
up 0.43%
Energy
.SPNY
up 0.23%
Financial
.SPSY
up 0.06%
Health
.SPXHC
up 0.29%
Industrial
.SPLRCI
down 0.52%
Information Technology
.SPLRCT
up 0.25%
Materials
.SPLRCM
up 0.31%
Real Estate
.SPLRCR
down 0.29%
Utilities
.SPLRCU
down 0.87%
(Compiled by Amal S in Bengaluru)
((Amal.S@thomsonreuters.com; within U.S.+1 646 223 8780; outside U.S. +91 80 6749 3677;))
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | The top three S&P 500 .PG.INX percentage gainers: ** Freeport-McMoRan Inc , up 8.8% ** Invesco Ltd , up 6.2% ** Sysco Corp , up 5.3% The top three S&P 500 .PL.INX percentage losers: ** Helmerich & Payne Inc , down 5.3% ** Simon Property Group Inc , down 5.3% ** Boeing Co , down 4.9% The top NYSE .PG.N percentage gainers: ** Curo Group Holdings Corp CURO.N, up 18% ** Twin River Worldwide Holdings, Inc TRWH.N, up 15.8% ** Wayfair Inc W.N, up 12% The top three NYSE .PL.N percentage losers: ** Moog Inc MOGB.N, down 16.6% ** Hertz Global ** Taubman Centers Inc TCO.N, down 9.7% The top Nasdaq .PG.O percentage gainers: ** Mesoblast Limted , up 130.9% ** Medigus Ltd , up 68.1% The top Nasdaq .PL.O percentage losers: ** National Energy Services Reunited Corp NESR.O, down 15.5% ** Limelight Networks Inc , down 13.7% ** BiondVax Pharmaceuticals Equity Warrants BVXVW.O, down 13.4% ** Verizon Communications Inc VZ.N: down 0.6% BUZZ-Verizon ticks lower after pulling 2020 revenue forecast ** BioSig Technologies Inc BSGM.O: up 9.3% BUZZ-BioSig: Jumps after unit seeks human trial clearance for COVID-19 therapy ** Whiting Petroleum Corp WLL.N: down 32.7% BUZZ-Whiting Petroleum: Plunges after filing chapter 11 reorganization plan ** Freeport-McMoRan Inc FCX.N: up 8.8% BUZZ-Freeport-McMoRan: Rises on costs cuts, smaller-than-expected Q1 loss ** Terex Corp TEX.N: down 5.2% BUZZ-Terex Corp falls as Credit Suisse downgrades to 'neutral' ** Quest Diagnostics Inc DGX.N: up 0.1% BUZZ-Quest Diagnostics: Mizuho raises PT on COVID-19 testing potential ** XPO Logistics Inc XPO.N: up 0.8% BUZZ-XPO Logistics: Up as Suntrust raises PT on ability to weather coronavirus storm ** Midland States Bancorp Inc MSBI.O: down 7.5% BUZZ-Midland States Bancorp slumps after earnings ** AT&T Inc T.N: down 0.2% BUZZ-AT&T: Rises after naming John Stankey as new CEO ** Tyson Foods Inc TSN.N: down 3% BUZZ-Tyson Foods: Bernstein downgrades on disruptions to production ** Emergent BioSolutions Inc EBS.N: up 7.8% BUZZ-Emergent BioSolutions: Up on deal to manufacture J&J's potential COVID-19 vaccine ** Eldorado Resorts Inc ERI.O: up 5.7% BUZZ-Eldorado Resorts rises on deal to sell two properties for $155 mln ** People's United Financial Inc PBCT.O: up 3.3% BUZZ-People's United Financial Inc: Rises on better-than-expected quarterly profit ** Tonix Pharmaceuticals Holdings Corp TNXP.O: up 3.8% BUZZ-Tonix Pharma rises on enrollment in study on muscular disorder treatment ** Gold Fields Ltd GFI.N: up 2.4% BUZZ-Gold Fields: Gains after revised 2020 guidance shows minimal COVID impact ** Host Hotels and Resorts Inc HST.N: up 1.3% ** Pebblebrook Hotel Trust PEB.N: up 1.0% BUZZ-BTIG lifts Host Hotels, Pebblebrook to 'buy' on hopes for economic recovery ** Medigus Ltd MDGS.O: up 68.1% BUZZ-Medigus: Soars on marketing partnership with Polyrizon ** PPG Industries PPG.N: down 0.6% BUZZ-PPG Industries: Downturn in aero, industrial sectors keeps CS on sidelines ** Zoom Video Communications Inc ZM.O: up 4.5% BUZZ-Zoom: Set for record high; to join Nasdaq 100 index ** Verizon Communications Inc VZ.N: down 0.6% BUZZ-PREVIEW: Verizon dips up ahead of earnings ** Eli Lilly and Co LLY.N: up 1.6% BUZZ-Street View: Eli Lilly's fundamentals remains strong amid coronavirus rout ** Intel Corp INTC.O: down 2.3% BUZZ-Street View: Coronavirus clouds Intel's H2 visibility ** J.C. Penney Company Inc JCP.N: down 11.2% BUZZ-J.C. Penney: Drops on report co in advanced talks for bankruptcy financing ** AbbVie Inc ABBV.N: up 1.1% BUZZ-AbbVie: Allergan deal to boost visibility; growth dilution to be of focus - RBC ** Workday Inc WDAY.O: down 0.7% BUZZ-Workday Inc: Cowen downgrades citing heightened challenges from the virus ** Pluristem Therapeutics Inc PSTI.O: up 21.0% BUZZ-Pluristem: Surges after securing 50 mln euros to develop COVID-19 treatment ** Snap Inc SNAP.N: down 0.4% BUZZ-Snap edges higher after pricing upsized $850 mln convertible debt deal ** American Express Co AXP.N: down 0.1% BUZZ-American Express: Rises as cost controls drive profit beat The 11 major S&P 500 sectors: Communication Services Eikon search string for individual stock moves: STXBZ The Day Ahead newsletter: http://tmsnrt.rs/2ggOmBi The Morning News Call newsletter: http://tmsnrt.rs/2fwPLTh The S&P 500 edged higher in choppy trading on Friday as some states prepared to relax curbs imposed to contain the coronavirus outbreak, but declines in Intel and Boeing weighed on the blue-chip Dow Jones..N At 11:06 a.m. down 0.87% (Compiled by Amal S in Bengaluru) ((Amal.S@thomsonreuters.com; within U.S.+1 646 223 8780; outside U.S. +91 80 6749 3677;)) The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | The top three S&P 500 .PG.INX percentage gainers: ** Freeport-McMoRan Inc , up 8.8% ** Invesco Ltd , up 6.2% ** Sysco Corp , up 5.3% The top three S&P 500 .PL.INX percentage losers: ** Helmerich & Payne Inc , down 5.3% ** Simon Property Group Inc , down 5.3% ** Boeing Co , down 4.9% The top NYSE .PG.N percentage gainers: ** Curo Group Holdings Corp CURO.N, up 18% ** Twin River Worldwide Holdings, Inc TRWH.N, up 15.8% ** Wayfair Inc W.N, up 12% The top three NYSE .PL.N percentage losers: ** Moog Inc MOGB.N, down 16.6% ** Hertz Global ** Taubman Centers Inc TCO.N, down 9.7% The top Nasdaq .PG.O percentage gainers: ** Mesoblast Limted , up 130.9% ** Medigus Ltd , up 68.1% The top Nasdaq .PL.O percentage losers: ** National Energy Services Reunited Corp NESR.O, down 15.5% ** Limelight Networks Inc , down 13.7% ** BiondVax Pharmaceuticals Equity Warrants BVXVW.O, down 13.4% ** Verizon Communications Inc VZ.N: down 0.6% BUZZ-Verizon ticks lower after pulling 2020 revenue forecast ** BioSig Technologies Inc BSGM.O: up 9.3% BUZZ-BioSig: Jumps after unit seeks human trial clearance for COVID-19 therapy ** Whiting Petroleum Corp WLL.N: down 32.7% BUZZ-Whiting Petroleum: Plunges after filing chapter 11 reorganization plan ** Freeport-McMoRan Inc FCX.N: up 8.8% BUZZ-Freeport-McMoRan: Rises on costs cuts, smaller-than-expected Q1 loss ** Terex Corp TEX.N: down 5.2% BUZZ-Terex Corp falls as Credit Suisse downgrades to 'neutral' ** Quest Diagnostics Inc DGX.N: up 0.1% BUZZ-Quest Diagnostics: Mizuho raises PT on COVID-19 testing potential ** XPO Logistics Inc XPO.N: up 0.8% BUZZ-XPO Logistics: Up as Suntrust raises PT on ability to weather coronavirus storm ** Midland States Bancorp Inc MSBI.O: down 7.5% BUZZ-Midland States Bancorp slumps after earnings ** AT&T Inc T.N: down 0.2% BUZZ-AT&T: Rises after naming John Stankey as new CEO ** Tyson Foods Inc TSN.N: down 3% BUZZ-Tyson Foods: Bernstein downgrades on disruptions to production ** Emergent BioSolutions Inc EBS.N: up 7.8% BUZZ-Emergent BioSolutions: Up on deal to manufacture J&J's potential COVID-19 vaccine ** Eldorado Resorts Inc ERI.O: up 5.7% BUZZ-Eldorado Resorts rises on deal to sell two properties for $155 mln ** People's United Financial Inc PBCT.O: up 3.3% BUZZ-People's United Financial Inc: Rises on better-than-expected quarterly profit ** Tonix Pharmaceuticals Holdings Corp TNXP.O: up 3.8% BUZZ-Tonix Pharma rises on enrollment in study on muscular disorder treatment ** Gold Fields Ltd GFI.N: up 2.4% BUZZ-Gold Fields: Gains after revised 2020 guidance shows minimal COVID impact ** Host Hotels and Resorts Inc HST.N: up 1.3% ** Pebblebrook Hotel Trust PEB.N: up 1.0% BUZZ-BTIG lifts Host Hotels, Pebblebrook to 'buy' on hopes for economic recovery ** Medigus Ltd MDGS.O: up 68.1% BUZZ-Medigus: Soars on marketing partnership with Polyrizon ** PPG Industries PPG.N: down 0.6% BUZZ-PPG Industries: Downturn in aero, industrial sectors keeps CS on sidelines ** Zoom Video Communications Inc ZM.O: up 4.5% BUZZ-Zoom: Set for record high; to join Nasdaq 100 index ** Verizon Communications Inc VZ.N: down 0.6% BUZZ-PREVIEW: Verizon dips up ahead of earnings ** Eli Lilly and Co LLY.N: up 1.6% BUZZ-Street View: Eli Lilly's fundamentals remains strong amid coronavirus rout ** Intel Corp INTC.O: down 2.3% BUZZ-Street View: Coronavirus clouds Intel's H2 visibility ** J.C. Penney Company Inc JCP.N: down 11.2% BUZZ-J.C. Penney: Drops on report co in advanced talks for bankruptcy financing ** AbbVie Inc ABBV.N: up 1.1% BUZZ-AbbVie: Allergan deal to boost visibility; growth dilution to be of focus - RBC ** Workday Inc WDAY.O: down 0.7% BUZZ-Workday Inc: Cowen downgrades citing heightened challenges from the virus ** Pluristem Therapeutics Inc PSTI.O: up 21.0% BUZZ-Pluristem: Surges after securing 50 mln euros to develop COVID-19 treatment ** Snap Inc SNAP.N: down 0.4% BUZZ-Snap edges higher after pricing upsized $850 mln convertible debt deal ** American Express Co AXP.N: down 0.1% BUZZ-American Express: Rises as cost controls drive profit beat The 11 major S&P 500 sectors: Communication Services Eikon search string for individual stock moves: STXBZ The Day Ahead newsletter: http://tmsnrt.rs/2ggOmBi The Morning News Call newsletter: http://tmsnrt.rs/2fwPLTh The S&P 500 edged higher in choppy trading on Friday as some states prepared to relax curbs imposed to contain the coronavirus outbreak, but declines in Intel and Boeing weighed on the blue-chip Dow Jones..N At 11:06 a.m. ET, the Dow Jones Industrial Average .DJI was down 0.13% at 23,484.44. | The top three S&P 500 .PG.INX percentage gainers: ** Freeport-McMoRan Inc , up 8.8% ** Invesco Ltd , up 6.2% ** Sysco Corp , up 5.3% The top three S&P 500 .PL.INX percentage losers: ** Helmerich & Payne Inc , down 5.3% ** Simon Property Group Inc , down 5.3% ** Boeing Co , down 4.9% The top NYSE .PG.N percentage gainers: ** Curo Group Holdings Corp CURO.N, up 18% ** Twin River Worldwide Holdings, Inc TRWH.N, up 15.8% ** Wayfair Inc W.N, up 12% The top three NYSE .PL.N percentage losers: ** Moog Inc MOGB.N, down 16.6% ** Hertz Global ** Taubman Centers Inc TCO.N, down 9.7% The top Nasdaq .PG.O percentage gainers: ** Mesoblast Limted , up 130.9% ** Medigus Ltd , up 68.1% The top Nasdaq .PL.O percentage losers: ** National Energy Services Reunited Corp NESR.O, down 15.5% ** Limelight Networks Inc , down 13.7% ** BiondVax Pharmaceuticals Equity Warrants BVXVW.O, down 13.4% ** Verizon Communications Inc VZ.N: down 0.6% BUZZ-Verizon ticks lower after pulling 2020 revenue forecast ** BioSig Technologies Inc BSGM.O: up 9.3% BUZZ-BioSig: Jumps after unit seeks human trial clearance for COVID-19 therapy ** Whiting Petroleum Corp WLL.N: down 32.7% BUZZ-Whiting Petroleum: Plunges after filing chapter 11 reorganization plan ** Freeport-McMoRan Inc FCX.N: up 8.8% BUZZ-Freeport-McMoRan: Rises on costs cuts, smaller-than-expected Q1 loss ** Terex Corp TEX.N: down 5.2% BUZZ-Terex Corp falls as Credit Suisse downgrades to 'neutral' ** Quest Diagnostics Inc DGX.N: up 0.1% BUZZ-Quest Diagnostics: Mizuho raises PT on COVID-19 testing potential ** XPO Logistics Inc XPO.N: up 0.8% BUZZ-XPO Logistics: Up as Suntrust raises PT on ability to weather coronavirus storm ** Midland States Bancorp Inc MSBI.O: down 7.5% BUZZ-Midland States Bancorp slumps after earnings ** AT&T Inc T.N: down 0.2% BUZZ-AT&T: Rises after naming John Stankey as new CEO ** Tyson Foods Inc TSN.N: down 3% BUZZ-Tyson Foods: Bernstein downgrades on disruptions to production ** Emergent BioSolutions Inc EBS.N: up 7.8% BUZZ-Emergent BioSolutions: Up on deal to manufacture J&J's potential COVID-19 vaccine ** Eldorado Resorts Inc ERI.O: up 5.7% BUZZ-Eldorado Resorts rises on deal to sell two properties for $155 mln ** People's United Financial Inc PBCT.O: up 3.3% BUZZ-People's United Financial Inc: Rises on better-than-expected quarterly profit ** Tonix Pharmaceuticals Holdings Corp TNXP.O: up 3.8% BUZZ-Tonix Pharma rises on enrollment in study on muscular disorder treatment ** Gold Fields Ltd GFI.N: up 2.4% BUZZ-Gold Fields: Gains after revised 2020 guidance shows minimal COVID impact ** Host Hotels and Resorts Inc HST.N: up 1.3% ** Pebblebrook Hotel Trust PEB.N: up 1.0% BUZZ-BTIG lifts Host Hotels, Pebblebrook to 'buy' on hopes for economic recovery ** Medigus Ltd MDGS.O: up 68.1% BUZZ-Medigus: Soars on marketing partnership with Polyrizon ** PPG Industries PPG.N: down 0.6% BUZZ-PPG Industries: Downturn in aero, industrial sectors keeps CS on sidelines ** Zoom Video Communications Inc ZM.O: up 4.5% BUZZ-Zoom: Set for record high; to join Nasdaq 100 index ** Verizon Communications Inc VZ.N: down 0.6% BUZZ-PREVIEW: Verizon dips up ahead of earnings ** Eli Lilly and Co LLY.N: up 1.6% BUZZ-Street View: Eli Lilly's fundamentals remains strong amid coronavirus rout ** Intel Corp INTC.O: down 2.3% BUZZ-Street View: Coronavirus clouds Intel's H2 visibility ** J.C. Penney Company Inc JCP.N: down 11.2% BUZZ-J.C. Penney: Drops on report co in advanced talks for bankruptcy financing ** AbbVie Inc ABBV.N: up 1.1% BUZZ-AbbVie: Allergan deal to boost visibility; growth dilution to be of focus - RBC ** Workday Inc WDAY.O: down 0.7% BUZZ-Workday Inc: Cowen downgrades citing heightened challenges from the virus ** Pluristem Therapeutics Inc PSTI.O: up 21.0% BUZZ-Pluristem: Surges after securing 50 mln euros to develop COVID-19 treatment ** Snap Inc SNAP.N: down 0.4% BUZZ-Snap edges higher after pricing upsized $850 mln convertible debt deal ** American Express Co AXP.N: down 0.1% BUZZ-American Express: Rises as cost controls drive profit beat The 11 major S&P 500 sectors: Communication Services down 0.74% Consumer Discretionary up 0.33% Consumer Staples | The top three S&P 500 .PG.INX percentage gainers: ** Freeport-McMoRan Inc , up 8.8% ** Invesco Ltd , up 6.2% ** Sysco Corp , up 5.3% The top three S&P 500 .PL.INX percentage losers: ** Helmerich & Payne Inc , down 5.3% ** Simon Property Group Inc , down 5.3% ** Boeing Co , down 4.9% The top NYSE .PG.N percentage gainers: ** Curo Group Holdings Corp CURO.N, up 18% ** Twin River Worldwide Holdings, Inc TRWH.N, up 15.8% ** Wayfair Inc W.N, up 12% The top three NYSE .PL.N percentage losers: ** Moog Inc MOGB.N, down 16.6% ** Hertz Global ** Taubman Centers Inc TCO.N, down 9.7% The top Nasdaq .PG.O percentage gainers: ** Mesoblast Limted , up 130.9% ** Medigus Ltd , up 68.1% The top Nasdaq .PL.O percentage losers: ** National Energy Services Reunited Corp NESR.O, down 15.5% ** Limelight Networks Inc , down 13.7% ** BiondVax Pharmaceuticals Equity Warrants BVXVW.O, down 13.4% ** Verizon Communications Inc VZ.N: down 0.6% BUZZ-Verizon ticks lower after pulling 2020 revenue forecast ** BioSig Technologies Inc BSGM.O: up 9.3% BUZZ-BioSig: Jumps after unit seeks human trial clearance for COVID-19 therapy ** Whiting Petroleum Corp WLL.N: down 32.7% BUZZ-Whiting Petroleum: Plunges after filing chapter 11 reorganization plan ** Freeport-McMoRan Inc FCX.N: up 8.8% BUZZ-Freeport-McMoRan: Rises on costs cuts, smaller-than-expected Q1 loss ** Terex Corp TEX.N: down 5.2% BUZZ-Terex Corp falls as Credit Suisse downgrades to 'neutral' ** Quest Diagnostics Inc DGX.N: up 0.1% BUZZ-Quest Diagnostics: Mizuho raises PT on COVID-19 testing potential ** XPO Logistics Inc XPO.N: up 0.8% BUZZ-XPO Logistics: Up as Suntrust raises PT on ability to weather coronavirus storm ** Midland States Bancorp Inc MSBI.O: down 7.5% BUZZ-Midland States Bancorp slumps after earnings ** AT&T Inc T.N: down 0.2% BUZZ-AT&T: Rises after naming John Stankey as new CEO ** Tyson Foods Inc TSN.N: down 3% BUZZ-Tyson Foods: Bernstein downgrades on disruptions to production ** Emergent BioSolutions Inc EBS.N: up 7.8% BUZZ-Emergent BioSolutions: Up on deal to manufacture J&J's potential COVID-19 vaccine ** Eldorado Resorts Inc ERI.O: up 5.7% BUZZ-Eldorado Resorts rises on deal to sell two properties for $155 mln ** People's United Financial Inc PBCT.O: up 3.3% BUZZ-People's United Financial Inc: Rises on better-than-expected quarterly profit ** Tonix Pharmaceuticals Holdings Corp TNXP.O: up 3.8% BUZZ-Tonix Pharma rises on enrollment in study on muscular disorder treatment ** Gold Fields Ltd GFI.N: up 2.4% BUZZ-Gold Fields: Gains after revised 2020 guidance shows minimal COVID impact ** Host Hotels and Resorts Inc HST.N: up 1.3% ** Pebblebrook Hotel Trust PEB.N: up 1.0% BUZZ-BTIG lifts Host Hotels, Pebblebrook to 'buy' on hopes for economic recovery ** Medigus Ltd MDGS.O: up 68.1% BUZZ-Medigus: Soars on marketing partnership with Polyrizon ** PPG Industries PPG.N: down 0.6% BUZZ-PPG Industries: Downturn in aero, industrial sectors keeps CS on sidelines ** Zoom Video Communications Inc ZM.O: up 4.5% BUZZ-Zoom: Set for record high; to join Nasdaq 100 index ** Verizon Communications Inc VZ.N: down 0.6% BUZZ-PREVIEW: Verizon dips up ahead of earnings ** Eli Lilly and Co LLY.N: up 1.6% BUZZ-Street View: Eli Lilly's fundamentals remains strong amid coronavirus rout ** Intel Corp INTC.O: down 2.3% BUZZ-Street View: Coronavirus clouds Intel's H2 visibility ** J.C. Penney Company Inc JCP.N: down 11.2% BUZZ-J.C. Penney: Drops on report co in advanced talks for bankruptcy financing ** AbbVie Inc ABBV.N: up 1.1% BUZZ-AbbVie: Allergan deal to boost visibility; growth dilution to be of focus - RBC ** Workday Inc WDAY.O: down 0.7% BUZZ-Workday Inc: Cowen downgrades citing heightened challenges from the virus ** Pluristem Therapeutics Inc PSTI.O: up 21.0% BUZZ-Pluristem: Surges after securing 50 mln euros to develop COVID-19 treatment ** Snap Inc SNAP.N: down 0.4% BUZZ-Snap edges higher after pricing upsized $850 mln convertible debt deal ** American Express Co AXP.N: down 0.1% BUZZ-American Express: Rises as cost controls drive profit beat The 11 major S&P 500 sectors: Communication Services ET, the Dow Jones Industrial Average .DJI was down 0.13% at 23,484.44. The S&P 500 .SPX was up 0.03% at 2,798.72 and the Nasdaq Composite .IXIC was up 0.03% at 8,497.058. |
24604.0 | 2020-04-24 00:00:00 UTC | BUZZ-U.S. STOCKS ON THE MOVE-Pluristem Therapeutics, J.C. Penney, Medigus | ABBV | https://www.nasdaq.com/articles/buzz-u.s.-stocks-on-the-move-pluristem-therapeutics-j.c.-penney-medigus-2020-04-24 | nan | nan | Eikon search string for individual stock moves: STXBZ
The Day Ahead newsletter: http://tmsnrt.rs/2ggOmBi
The Morning News Call newsletter: http://tmsnrt.rs/2fwPLTh
U.S. stock markets were set to gain at the open on Friday as some states prepared to relax curbs imposed to contain the coronavirus outbreak, with a surprise rise in orders for U.S.-made capital goods also lifting sentiment..N
At 8:57 a.m. ET, Dow e-minis 1YMc1 were up 0.78% at 23,520. S&P 500 e-minis ESc1 were up 0.86% at 2,804.75, while Nasdaq 100 e-minis NQc1 were up 0.66% at 8,655.75. The top three NYSE percentage gainers premarket .PRPG.NQ: ** FTS International Inc , up 58.3% ** Denbury Resources Inc , up 51.8% ** Valaris Plc , up 43.5% The top three NYSE percentage losers premarket .PRPL.NQ: ** Brightsphere Investment Group Inc , down 38% ** KT Corp , down 20% ** J.C. Penney Company Inc , down 14.9% The top three Nasdaq percentage gainers premarket .PRPG.O: ** Mesoblast Limited , up 118.9% ** Medigus Equity Warrants , up 110.5% ** Abraxas Petroleum Corp , up 87.9% The top three Nasdaq percentage losers premarket .PRPL.O: ** Synthesis Energy Systems Inc , down 13.8% ** Peck Company Holdings Inc , down 13.2% ** Heat Biologics Inc , down 8.1% ** Tonix Pharmaceuticals Holdings Corp TNXP.O: up 1% premarket BUZZ-Tonix Pharma rises on enrollment in study on muscular disorder treatment ** Gold Fields Ltd GFI.N: up 3.1% premarket BUZZ-Gold Fields: Gains after revised 2020 guidance shows minimal COVID impact ** Host Hotels and Resorts Inc HST.N: up 4.4% premarket ** Pebblebrook Hotel Trust PEB.N: up 5.8% premarket BUZZ-BTIG lifts Host Hotels, Pebblebrook to 'buy' on hopes for economic recovery ** Medigus Ltd MDGS.O: up 69.5% premarket BUZZ-Medigus: Soars on marketing partnership with Polyrizon ** Zoom Video Communications Inc ZM.O: up 4.0% premarket BUZZ-Zoom: Set for record high; to join Nasdaq 100 index ** Verizon Communications Inc VZ.N: down 0.3% premarket BUZZ-PREVIEW: Verizon dips up ahead of earnings ** Eli Lilly and Co LLY.N: up 1.3% premarket BUZZ-Street View: Eli Lilly's fundamentals remains strong amid coronavirus rout ** Intel Corp INTC.O: down 4.6% premarket BUZZ-Street View: Coronavirus clouds Intel's H2 visibility ** J.C. Penney Company Inc JCP.N: down 14.9% premarket BUZZ-J.C. Penney: Drops on report co in advanced talks for bankruptcy financing ** AbbVie Inc ABBV.N: up 0.4% premarket BUZZ-AbbVie: Allergan deal to boost visibility; growth dilution to be of focus - RBC ** Workday Inc WDAY.O: down 1.7% premarket BUZZ-Workday Inc: Cowen downgrades citing heightened challenges from the virus ** Pluristem Therapeutics Inc PSTI.O: up 20.2% premarket BUZZ-Pluristem: Surges after securing 50 mln euros to develop COVID-19 treatment ** Snap Inc SNAP.N: down 1% premarket BUZZ-Snap edges higher after pricing upsized $850 mln convertible debt deal ** American Express Co AXP.N: up 1.7% premarket BUZZ-American Express: Rises as cost controls drive profit beat
(Compiled by Amal S in Bengaluru)
((Amal.S@thomsonreuters.com; within U.S.+1 646 223 8780; outside U.S. +91 80 6749 3677;))
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | The top three NYSE percentage gainers premarket .PRPG.NQ: ** FTS International Inc , up 58.3% ** Denbury Resources Inc , up 51.8% ** Valaris Plc , up 43.5% The top three NYSE percentage losers premarket .PRPL.NQ: ** Brightsphere Investment Group Inc , down 38% ** KT Corp , down 20% ** J.C. Penney Company Inc , down 14.9% The top three Nasdaq percentage gainers premarket .PRPG.O: ** Mesoblast Limited , up 118.9% ** Medigus Equity Warrants , up 110.5% ** Abraxas Petroleum Corp , up 87.9% The top three Nasdaq percentage losers premarket .PRPL.O: ** Synthesis Energy Systems Inc , down 13.8% ** Peck Company Holdings Inc , down 13.2% ** Heat Biologics Inc , down 8.1% ** Tonix Pharmaceuticals Holdings Corp TNXP.O: up 1% premarket BUZZ-Tonix Pharma rises on enrollment in study on muscular disorder treatment ** Gold Fields Ltd GFI.N: up 3.1% premarket BUZZ-Gold Fields: Gains after revised 2020 guidance shows minimal COVID impact ** Host Hotels and Resorts Inc HST.N: up 4.4% premarket ** Pebblebrook Hotel Trust PEB.N: up 5.8% premarket BUZZ-BTIG lifts Host Hotels, Pebblebrook to 'buy' on hopes for economic recovery ** Medigus Ltd MDGS.O: up 69.5% premarket BUZZ-Medigus: Soars on marketing partnership with Polyrizon ** Zoom Video Communications Inc ZM.O: up 4.0% premarket BUZZ-Zoom: Set for record high; to join Nasdaq 100 index ** Verizon Communications Inc VZ.N: down 0.3% premarket BUZZ-PREVIEW: Verizon dips up ahead of earnings ** Eli Lilly and Co LLY.N: up 1.3% premarket BUZZ-Street View: Eli Lilly's fundamentals remains strong amid coronavirus rout ** Intel Corp INTC.O: down 4.6% premarket BUZZ-Street View: Coronavirus clouds Intel's H2 visibility ** J.C. Penney Company Inc JCP.N: down 14.9% premarket BUZZ-J.C. Penney: Drops on report co in advanced talks for bankruptcy financing ** AbbVie Inc ABBV.N: up 0.4% premarket BUZZ-AbbVie: Allergan deal to boost visibility; growth dilution to be of focus - RBC ** Workday Inc WDAY.O: down 1.7% premarket BUZZ-Workday Inc: Cowen downgrades citing heightened challenges from the virus ** Pluristem Therapeutics Inc PSTI.O: up 20.2% premarket BUZZ-Pluristem: Surges after securing 50 mln euros to develop COVID-19 treatment ** Snap Inc SNAP.N: down 1% premarket BUZZ-Snap edges higher after pricing upsized $850 mln convertible debt deal ** American Express Co AXP.N: up 1.7% premarket BUZZ-American Express: Rises as cost controls drive profit beat (Compiled by Amal S in Bengaluru) ((Amal.S@thomsonreuters.com; within U.S.+1 646 223 8780; outside U.S. +91 80 6749 3677;)) The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. Eikon search string for individual stock moves: STXBZ The Day Ahead newsletter: http://tmsnrt.rs/2ggOmBi The Morning News Call newsletter: http://tmsnrt.rs/2fwPLTh U.S. stock markets were set to gain at the open on Friday as some states prepared to relax curbs imposed to contain the coronavirus outbreak, with a surprise rise in orders for U.S.-made capital goods also lifting sentiment..N At 8:57 a.m. ET, Dow e-minis 1YMc1 were up 0.78% at 23,520. | The top three NYSE percentage gainers premarket .PRPG.NQ: ** FTS International Inc , up 58.3% ** Denbury Resources Inc , up 51.8% ** Valaris Plc , up 43.5% The top three NYSE percentage losers premarket .PRPL.NQ: ** Brightsphere Investment Group Inc , down 38% ** KT Corp , down 20% ** J.C. Penney Company Inc , down 14.9% The top three Nasdaq percentage gainers premarket .PRPG.O: ** Mesoblast Limited , up 118.9% ** Medigus Equity Warrants , up 110.5% ** Abraxas Petroleum Corp , up 87.9% The top three Nasdaq percentage losers premarket .PRPL.O: ** Synthesis Energy Systems Inc , down 13.8% ** Peck Company Holdings Inc , down 13.2% ** Heat Biologics Inc , down 8.1% ** Tonix Pharmaceuticals Holdings Corp TNXP.O: up 1% premarket BUZZ-Tonix Pharma rises on enrollment in study on muscular disorder treatment ** Gold Fields Ltd GFI.N: up 3.1% premarket BUZZ-Gold Fields: Gains after revised 2020 guidance shows minimal COVID impact ** Host Hotels and Resorts Inc HST.N: up 4.4% premarket ** Pebblebrook Hotel Trust PEB.N: up 5.8% premarket BUZZ-BTIG lifts Host Hotels, Pebblebrook to 'buy' on hopes for economic recovery ** Medigus Ltd MDGS.O: up 69.5% premarket BUZZ-Medigus: Soars on marketing partnership with Polyrizon ** Zoom Video Communications Inc ZM.O: up 4.0% premarket BUZZ-Zoom: Set for record high; to join Nasdaq 100 index ** Verizon Communications Inc VZ.N: down 0.3% premarket BUZZ-PREVIEW: Verizon dips up ahead of earnings ** Eli Lilly and Co LLY.N: up 1.3% premarket BUZZ-Street View: Eli Lilly's fundamentals remains strong amid coronavirus rout ** Intel Corp INTC.O: down 4.6% premarket BUZZ-Street View: Coronavirus clouds Intel's H2 visibility ** J.C. Penney Company Inc JCP.N: down 14.9% premarket BUZZ-J.C. Penney: Drops on report co in advanced talks for bankruptcy financing ** AbbVie Inc ABBV.N: up 0.4% premarket BUZZ-AbbVie: Allergan deal to boost visibility; growth dilution to be of focus - RBC ** Workday Inc WDAY.O: down 1.7% premarket BUZZ-Workday Inc: Cowen downgrades citing heightened challenges from the virus ** Pluristem Therapeutics Inc PSTI.O: up 20.2% premarket BUZZ-Pluristem: Surges after securing 50 mln euros to develop COVID-19 treatment ** Snap Inc SNAP.N: down 1% premarket BUZZ-Snap edges higher after pricing upsized $850 mln convertible debt deal ** American Express Co AXP.N: up 1.7% premarket BUZZ-American Express: Rises as cost controls drive profit beat (Compiled by Amal S in Bengaluru) ((Amal.S@thomsonreuters.com; within U.S.+1 646 223 8780; outside U.S. +91 80 6749 3677;)) The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. Eikon search string for individual stock moves: STXBZ The Day Ahead newsletter: http://tmsnrt.rs/2ggOmBi The Morning News Call newsletter: http://tmsnrt.rs/2fwPLTh U.S. stock markets were set to gain at the open on Friday as some states prepared to relax curbs imposed to contain the coronavirus outbreak, with a surprise rise in orders for U.S.-made capital goods also lifting sentiment..N At 8:57 a.m. S&P 500 e-minis ESc1 were up 0.86% at 2,804.75, while Nasdaq 100 e-minis NQc1 were up 0.66% at 8,655.75. | The top three NYSE percentage gainers premarket .PRPG.NQ: ** FTS International Inc , up 58.3% ** Denbury Resources Inc , up 51.8% ** Valaris Plc , up 43.5% The top three NYSE percentage losers premarket .PRPL.NQ: ** Brightsphere Investment Group Inc , down 38% ** KT Corp , down 20% ** J.C. Penney Company Inc , down 14.9% The top three Nasdaq percentage gainers premarket .PRPG.O: ** Mesoblast Limited , up 118.9% ** Medigus Equity Warrants , up 110.5% ** Abraxas Petroleum Corp , up 87.9% The top three Nasdaq percentage losers premarket .PRPL.O: ** Synthesis Energy Systems Inc , down 13.8% ** Peck Company Holdings Inc , down 13.2% ** Heat Biologics Inc , down 8.1% ** Tonix Pharmaceuticals Holdings Corp TNXP.O: up 1% premarket BUZZ-Tonix Pharma rises on enrollment in study on muscular disorder treatment ** Gold Fields Ltd GFI.N: up 3.1% premarket BUZZ-Gold Fields: Gains after revised 2020 guidance shows minimal COVID impact ** Host Hotels and Resorts Inc HST.N: up 4.4% premarket ** Pebblebrook Hotel Trust PEB.N: up 5.8% premarket BUZZ-BTIG lifts Host Hotels, Pebblebrook to 'buy' on hopes for economic recovery ** Medigus Ltd MDGS.O: up 69.5% premarket BUZZ-Medigus: Soars on marketing partnership with Polyrizon ** Zoom Video Communications Inc ZM.O: up 4.0% premarket BUZZ-Zoom: Set for record high; to join Nasdaq 100 index ** Verizon Communications Inc VZ.N: down 0.3% premarket BUZZ-PREVIEW: Verizon dips up ahead of earnings ** Eli Lilly and Co LLY.N: up 1.3% premarket BUZZ-Street View: Eli Lilly's fundamentals remains strong amid coronavirus rout ** Intel Corp INTC.O: down 4.6% premarket BUZZ-Street View: Coronavirus clouds Intel's H2 visibility ** J.C. Penney Company Inc JCP.N: down 14.9% premarket BUZZ-J.C. Penney: Drops on report co in advanced talks for bankruptcy financing ** AbbVie Inc ABBV.N: up 0.4% premarket BUZZ-AbbVie: Allergan deal to boost visibility; growth dilution to be of focus - RBC ** Workday Inc WDAY.O: down 1.7% premarket BUZZ-Workday Inc: Cowen downgrades citing heightened challenges from the virus ** Pluristem Therapeutics Inc PSTI.O: up 20.2% premarket BUZZ-Pluristem: Surges after securing 50 mln euros to develop COVID-19 treatment ** Snap Inc SNAP.N: down 1% premarket BUZZ-Snap edges higher after pricing upsized $850 mln convertible debt deal ** American Express Co AXP.N: up 1.7% premarket BUZZ-American Express: Rises as cost controls drive profit beat (Compiled by Amal S in Bengaluru) ((Amal.S@thomsonreuters.com; within U.S.+1 646 223 8780; outside U.S. +91 80 6749 3677;)) The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. ET, Dow e-minis 1YMc1 were up 0.78% at 23,520. S&P 500 e-minis ESc1 were up 0.86% at 2,804.75, while Nasdaq 100 e-minis NQc1 were up 0.66% at 8,655.75. | The top three NYSE percentage gainers premarket .PRPG.NQ: ** FTS International Inc , up 58.3% ** Denbury Resources Inc , up 51.8% ** Valaris Plc , up 43.5% The top three NYSE percentage losers premarket .PRPL.NQ: ** Brightsphere Investment Group Inc , down 38% ** KT Corp , down 20% ** J.C. Penney Company Inc , down 14.9% The top three Nasdaq percentage gainers premarket .PRPG.O: ** Mesoblast Limited , up 118.9% ** Medigus Equity Warrants , up 110.5% ** Abraxas Petroleum Corp , up 87.9% The top three Nasdaq percentage losers premarket .PRPL.O: ** Synthesis Energy Systems Inc , down 13.8% ** Peck Company Holdings Inc , down 13.2% ** Heat Biologics Inc , down 8.1% ** Tonix Pharmaceuticals Holdings Corp TNXP.O: up 1% premarket BUZZ-Tonix Pharma rises on enrollment in study on muscular disorder treatment ** Gold Fields Ltd GFI.N: up 3.1% premarket BUZZ-Gold Fields: Gains after revised 2020 guidance shows minimal COVID impact ** Host Hotels and Resorts Inc HST.N: up 4.4% premarket ** Pebblebrook Hotel Trust PEB.N: up 5.8% premarket BUZZ-BTIG lifts Host Hotels, Pebblebrook to 'buy' on hopes for economic recovery ** Medigus Ltd MDGS.O: up 69.5% premarket BUZZ-Medigus: Soars on marketing partnership with Polyrizon ** Zoom Video Communications Inc ZM.O: up 4.0% premarket BUZZ-Zoom: Set for record high; to join Nasdaq 100 index ** Verizon Communications Inc VZ.N: down 0.3% premarket BUZZ-PREVIEW: Verizon dips up ahead of earnings ** Eli Lilly and Co LLY.N: up 1.3% premarket BUZZ-Street View: Eli Lilly's fundamentals remains strong amid coronavirus rout ** Intel Corp INTC.O: down 4.6% premarket BUZZ-Street View: Coronavirus clouds Intel's H2 visibility ** J.C. Penney Company Inc JCP.N: down 14.9% premarket BUZZ-J.C. Penney: Drops on report co in advanced talks for bankruptcy financing ** AbbVie Inc ABBV.N: up 0.4% premarket BUZZ-AbbVie: Allergan deal to boost visibility; growth dilution to be of focus - RBC ** Workday Inc WDAY.O: down 1.7% premarket BUZZ-Workday Inc: Cowen downgrades citing heightened challenges from the virus ** Pluristem Therapeutics Inc PSTI.O: up 20.2% premarket BUZZ-Pluristem: Surges after securing 50 mln euros to develop COVID-19 treatment ** Snap Inc SNAP.N: down 1% premarket BUZZ-Snap edges higher after pricing upsized $850 mln convertible debt deal ** American Express Co AXP.N: up 1.7% premarket BUZZ-American Express: Rises as cost controls drive profit beat (Compiled by Amal S in Bengaluru) ((Amal.S@thomsonreuters.com; within U.S.+1 646 223 8780; outside U.S. +91 80 6749 3677;)) The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. Eikon search string for individual stock moves: STXBZ The Day Ahead newsletter: http://tmsnrt.rs/2ggOmBi The Morning News Call newsletter: http://tmsnrt.rs/2fwPLTh U.S. stock markets were set to gain at the open on Friday as some states prepared to relax curbs imposed to contain the coronavirus outbreak, with a surprise rise in orders for U.S.-made capital goods also lifting sentiment..N At 8:57 a.m. ET, Dow e-minis 1YMc1 were up 0.78% at 23,520. |
24605.0 | 2020-04-23 00:00:00 UTC | These 3 Biotechs Had Successful IPOs During the Coronavirus Crisis. Are They Buys? | ABBV | https://www.nasdaq.com/articles/these-3-biotechs-had-successful-ipos-during-the-coronavirus-crisis.-are-they-buys-2020-04 | nan | nan | An initial public offering (IPO) has a special allure: It draws in speculative investors eager to see stocks soar in the initial days of trading. In weak markets, only the strongest candidates pull off an IPO. Lesser-quality companies delay or withdraw the offering, typically citing market conditions.
Since the beginning of March, these three biotechs successfully raised money and began trading. Let's take a look at them now.
Image Source: Getty Images.
1. Imara
Completing its IPO on March 11 -- right before the first shelter-in-place orders related to the coronavirus emerged -- Imara (NASDAQ: IMRA) raised $75.2 million to advance its drug IMR-687 for rare, genetic disorders involving hemoglobin, the iron-containing protein in red blood cells. The stock is essentially flat, trading right around the $16 IPO price.
Imara plans to start a Phase 2b clinical trial of IMR-687 in the first half of 2020 for sickle cell disease, a genetic condition that causes red blood cells to become misshapen, leading to aggregation of those cells and blockage of arteries. IMR-687 provides an oral treatment for the 100,000 U.S. patients and 134,000 European patients living with the disease. The company expects interim results in the first half of 2021.
In addition, Imara believes IMR-687's mechanism can also positively affect patients with beta-thalassemia. Roughly 19,000 patients in the U.S. and Europe live with this disease, which impairs red blood cells' ability to transport oxygen to vital organs.
Backed by prominent healthcare investors including New Enterprise Associates, Orbimed, the venture arm of Pfizer, and RA Capital, Imara faces competition from Global Blood Therapeutics (NASDAQ: GBT), which gained approval this year for its oral sickle cell disease drug, Oxbryta. IMR-687 works by a different mechanism, but it's too early to tell if one is superior to the other. The U.S. Food and Drug Administration (FDA) may require a head-to-head clinical trial between IMR-687 and Oxbryta.
On the competitive front, CRISPR Therapeutics (NASDAQ: CRSP) and Vertex Pharmaceuticals (NASDAQ: VRTX) teamed up to develop a gene therapy approach that, while still in very early stages, could effectively cure both sickle cell disease and beta-thalassemia.
There's unlikely to be a ton of news this year as Imara ramps up its phase 2 trials, and I'm not expecting any big binary events. Next year's results will be critical to allow the company to raise additional financing to support future clinical trials.
Investors should note Imara's risk as a single-drug company. All its eggs are in the IMR-687 basket, meaning an unexpected safety issue could kill the drug and take the company down with it.
2. Zentalis Pharmaceuticals
Zentalis Pharmaceuticals (NASDAQ: ZNTL) raised $190 million in its IPO on April 3. The stock trades at about $25.50 per share, a gain of more than 40% from its $18 IPO price. The company's platform technology has generated four anti-cancer drug candidates, all of which are in or soon to begin early-stage human testing.
Rather than reinventing the wheel, Zentalis set out to design drugs with greater efficacy, fewer side effects, and better pharmaceutical properties than currently used cancer drugs. Its Zn-c5 takes aim at Faslodex, a hormone therapy that generated over $1 billion annually for AstraZeneca before it went generic. A phase 1/2 trial in combination with Pfizer's Ibrance could produce results in the second half of this year.
Another drug from Zentalis, Zn-d5 ,has Abbvie and Roche's leukemia treatment, Venclexta, in its crosshairs. Venclexta generated $792 million in global sales in 2019. Zentalis thinks Zn-d5's improved potency and selectivity could prove superior. Clinical trials will not start until 2021, so results are a ways off.
A third drug, Zn-e4, hopes to be an improved version of Tagrisso, AstraZeneca's cancer drug that achieved $3.2 billion in revenue in 2019. Again, Zentalis thinks its drug's better selectivity and improved solubility make it a potential next-generation Tagrisso. An initial phase 1/2 clinical trial in patients with non-small cell lung cancer, the most common form of lung cancer, is underway. Zentalis licensed the rights to the drug in China, South Korea, Taiwan, and Vietnam to SciClone Pharmaceuticals in 2014.
Potential investors need to consider the potential for COVID-19-related delays to Zentalis' clinical programs. Biotech stocks like this jump or drop on clinical results, which are expected later this year and next. However, Zentalis' prospectus mentions COVID-19 55 times and warns it could impact the timelines.
3. Keros Therapeutics
Keros Therapeutics (NASDAQ: KROS) debuted a few days after Zentalis on April 7. Raising $110.4 million at $16 per share, the stock now trades just below $28. That's a hefty 75% gain in its first two weeks.
Keros focuses on a family of proteins called "transforming growth factor betas," which function as master regulators of red blood cell and platelet production, as well as growth and repair of muscle and bone. Later this year, KER-050, the most advanced drug in the pipeline, will begin a phase 2 clinical trial to treat patients with a blood malignancy called myelodysplastic syndrome (MDS) with cytopenia (a medical term for low blood cell counts). Approximately 90% of patients with MDS will have cytopenia.
Next year, Keros plans to initiate a phase 2 trial in myelofibrosis (MF)-associated cytopenias (blood cell shortages associated with bone marrow cancer). MF is rare, with fewer than 18,500 patients in the U.S., but 38% of patients are dependent on red blood cell transfusions within one year of diagnosis, according to Keros.
Keros' second drug, KER-047, is currently in phase 1 testing in healthy volunteers. If all goes well, phase 2 trials will begin next year in patients with iron-refractory iron-deficient anemia (IRIDA) and fibrodysplasia ossificans progressiva (FOP, a disease of the connective tissues). The rare nature of these diseases makes it challenging to determine how many patients exist. For example, an estimated 3,500 patients worldwide have FOP, but only 800 have been diagnosed.
Patience required
The success if these IPOs during one of the most volatile markets in history clearly demonstrates significant investor interest in Imara, Zentalis, and Keros -- likely from specialist healthcare funds. While clinical results, a key driver of stock movement, will likely be limited in the coming months, next year should bring more activity. These high-risk, high-reward opportunities could take a few years to generate significant returns for patient biotech investors.
10 stocks we like better than IMARA Inc.
When investing geniuses David and Tom Gardner have a stock tip, it can pay to listen. After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor, has tripled the market.*
David and Tom just revealed what they believe are the ten best stocks for investors to buy right now… and IMARA Inc. wasn't one of them! That's right -- they think these 10 stocks are even better buys.
See the 10 stocks
*Stock Advisor returns as of April 16, 2020
David Haen owns shares of Global Blood Therapeutics and Pfizer. The Motley Fool owns shares of and recommends CRISPR Therapeutics. The Motley Fool recommends Vertex Pharmaceuticals. The Motley Fool has a disclosure policy.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Another drug from Zentalis, Zn-d5 ,has Abbvie and Roche's leukemia treatment, Venclexta, in its crosshairs. Backed by prominent healthcare investors including New Enterprise Associates, Orbimed, the venture arm of Pfizer, and RA Capital, Imara faces competition from Global Blood Therapeutics (NASDAQ: GBT), which gained approval this year for its oral sickle cell disease drug, Oxbryta. Next year, Keros plans to initiate a phase 2 trial in myelofibrosis (MF)-associated cytopenias (blood cell shortages associated with bone marrow cancer). | Another drug from Zentalis, Zn-d5 ,has Abbvie and Roche's leukemia treatment, Venclexta, in its crosshairs. Backed by prominent healthcare investors including New Enterprise Associates, Orbimed, the venture arm of Pfizer, and RA Capital, Imara faces competition from Global Blood Therapeutics (NASDAQ: GBT), which gained approval this year for its oral sickle cell disease drug, Oxbryta. Next year, Keros plans to initiate a phase 2 trial in myelofibrosis (MF)-associated cytopenias (blood cell shortages associated with bone marrow cancer). | Another drug from Zentalis, Zn-d5 ,has Abbvie and Roche's leukemia treatment, Venclexta, in its crosshairs. Imara plans to start a Phase 2b clinical trial of IMR-687 in the first half of 2020 for sickle cell disease, a genetic condition that causes red blood cells to become misshapen, leading to aggregation of those cells and blockage of arteries. Backed by prominent healthcare investors including New Enterprise Associates, Orbimed, the venture arm of Pfizer, and RA Capital, Imara faces competition from Global Blood Therapeutics (NASDAQ: GBT), which gained approval this year for its oral sickle cell disease drug, Oxbryta. | Another drug from Zentalis, Zn-d5 ,has Abbvie and Roche's leukemia treatment, Venclexta, in its crosshairs. IMR-687 provides an oral treatment for the 100,000 U.S. patients and 134,000 European patients living with the disease. MF is rare, with fewer than 18,500 patients in the U.S., but 38% of patients are dependent on red blood cell transfusions within one year of diagnosis, according to Keros. |
24606.0 | 2020-04-23 00:00:00 UTC | Better Buy: AbbVie vs. Gilead Sciences | ABBV | https://www.nasdaq.com/articles/better-buy%3A-abbvie-vs.-gilead-sciences-2020-04-23 | nan | nan | AbbVie (NYSE: ABBV) and Gilead Sciences (NASDAQ: GILD) are names you might be hearing a lot these days. AbbVie is in the process of acquiring Botox maker Allergan (NYSE: AGN) to boost its growth potential and reduce its reliance on the world's current top-selling drug, Humira. Meanwhile, Gilead's investigational coronavirus treatment, remdesivir, is in clinical studies, putting that company in the spotlight.
So far this year, optimism about finding a coronavirus treatment has been the wind in Gilead's sails, lifting the stock 24%. Over the same time, AbbVie shares fell by 7%. I like these stocks and would be happy to add both of them to my portfolio. But if I had to choose just one ... well, let's have a closer look and see which offers the best buying opportunity right now.
Image source: Getty Images.
The case for AbbVie
Blockbuster anti-inflammatory drug Humira, with $19 billion in annual sales, accounts for 60% of AbbVie's annual revenue. The drug's sales are still growing in the U.S., but they have slowed in Europe after biosimilars entered the market. Humira, used to treat nine autoimmune conditions, may face biosimilar competition in the U.S. as of 2023, when patents expire.
That's exactly why AbbVie's acquisition of Allergan is great news. Humira will represent less than 40% of sales at the new AbbVie. And the addition of Allergan's portfolio lifts AbbVie's plans for annual growth, with sales of more than $30 billion in 2020 -- excluding Humira -- and expectations for a high single-digit annual growth rate.
The deal includes antipsychotic drug Vraylar as part of a $1.2 billion neuroscience program. The potential blockbuster posted a 76% gain in net revenue last year to reach $857.5 million. AbbVie also gains gastrointestinal, women's health, eye care, and Botox therapeutics platforms. Medical aesthetics such as Botox and Juvederm are part of the agreement as well, representing $4.3 billion. Those assets will become part of a new business, Allergan Aesthetics, to be operated under the AbbVie umbrella.
AbbVie and Allergan have met conditions required for the transaction to move forward in Europe and are now awaiting approval from the Federal Trade Commission in the United States. AbbVie expects a decision early in the second quarter. Once the deal has closed, we can be optimistic about good days ahead. AbbVie has said the combination will add 10% growth to adjusted earnings per share in the first full year.
The case for Gilead
Gilead is the star of the moment, with hopes of remdesivir winning the coronavirus treatment race driving the shares higher. That trend may continue if positive news emerges from the trials. But there is more to this company than its work to treat COVID-19, the illness caused by the novel coronavirus.
Gilead offers a growing HIV program in a global market that is forecast to reach $40.7 billion by the end of 2026, according to Fortune Business Insights. All of Gilead's HIV drugs together posted a 12% gain in sales to reach $16.4 billion last year. Sales of Gilead's blockbuster HIV drug, Biktarvy, quadrupled to $4.7 billion last year from the prior year's level, and EvaluatePharma predicts that number may reach almost $7 billion in 2024.
On the horizon, Gilead may have another growth driver. The company submitted filgotinib, its rheumatoid arthritis drug, to the U.S. Food and Drug Administration in December. With the drug under priority review, a decision may come as soon as June. Gilead said during its fourth-quarter earnings call that the drug has the potential to launch in five new indications over the coming four years.
Also on the earnings call, the company pledged to bring 10 "transformative" treatments to patients over the next decade. That is more good news, especially considering the decline in revenue from Gilead's chronic hepatitis C program.
Which stock to choose?
Though Gilead shares are up so far this year, there's likely more to come through the revenue drivers mentioned above. As for AbbVie, the Allergan purchase offers reason to be optimistic about future share performance.
When it comes to revenue, AbbVie may be a few steps ahead of Gilead. The acquisition of Allergan offers an exciting boost in growth for a company where revenue has already seen steady gains since the spinoff from Abbott Laboratories (NYSE: ABT) in 2013. At Gilead, sales only picked up last year after declining from 2016 through 2018. Through the Allergan acquisition, AbbVie clearly has a quicker path to growth.
AbbVie also beats Gilead when it comes to valuation. AbbVie stock trades at close to 16 times earnings, its cheapest by that measure since 2016. Gilead is down from past highs, but its price-to-earnings ratio has climbed from less than 15 earlier in the year to reach 20 now.
I think AbbVie and Gilead are both good investments, but if I had to choose just one to buy right now, I would go with AbbVie.
10 stocks we like better than Gilead Sciences
When investing geniuses David and Tom Gardner have a stock tip, it can pay to listen. After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor, has tripled the market.*
David and Tom just revealed what they believe are the ten best stocks for investors to buy right now... and Gilead Sciences wasn't one of them! That's right -- they think these 10 stocks are even better buys.
See the 10 stocks
*Stock Advisor returns as of April 16, 2020
Adria Cimino has no position in any of the stocks mentioned. The Motley Fool owns shares of and recommends Gilead Sciences. The Motley Fool has a disclosure policy.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | AbbVie is in the process of acquiring Botox maker Allergan (NYSE: AGN) to boost its growth potential and reduce its reliance on the world's current top-selling drug, Humira. AbbVie and Allergan have met conditions required for the transaction to move forward in Europe and are now awaiting approval from the Federal Trade Commission in the United States. AbbVie (NYSE: ABBV) and Gilead Sciences (NASDAQ: GILD) are names you might be hearing a lot these days. | The case for AbbVie Blockbuster anti-inflammatory drug Humira, with $19 billion in annual sales, accounts for 60% of AbbVie's annual revenue. And the addition of Allergan's portfolio lifts AbbVie's plans for annual growth, with sales of more than $30 billion in 2020 -- excluding Humira -- and expectations for a high single-digit annual growth rate. AbbVie (NYSE: ABBV) and Gilead Sciences (NASDAQ: GILD) are names you might be hearing a lot these days. | The case for AbbVie Blockbuster anti-inflammatory drug Humira, with $19 billion in annual sales, accounts for 60% of AbbVie's annual revenue. I think AbbVie and Gilead are both good investments, but if I had to choose just one to buy right now, I would go with AbbVie. AbbVie (NYSE: ABBV) and Gilead Sciences (NASDAQ: GILD) are names you might be hearing a lot these days. | I think AbbVie and Gilead are both good investments, but if I had to choose just one to buy right now, I would go with AbbVie. AbbVie (NYSE: ABBV) and Gilead Sciences (NASDAQ: GILD) are names you might be hearing a lot these days. AbbVie is in the process of acquiring Botox maker Allergan (NYSE: AGN) to boost its growth potential and reduce its reliance on the world's current top-selling drug, Humira. |
24607.0 | 2020-04-22 00:00:00 UTC | Johnson & Johnson and AbbVie Earn a New FDA Approval for Imbruvica | ABBV | https://www.nasdaq.com/articles/johnson-johnson-and-abbvie-earn-a-new-fda-approval-for-imbruvica-2020-04-22 | nan | nan | Imbruvica, a blockbuster cancer drug marketed by Johnson & Johnson (NYSE: JNJ) and AbbVie (NYSE: ABBV), recently secured its 11th approval. On Tuesday, the Food and Drug Administration approved the combination of Imbruvica and Rituximab as a treatment for patients with previously untreated chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL); Rituximab is a cancer drug marketed by Biogen (NASDAQ: BIIB).
This approval was based on positive results from a phase 3 clinical trial. During the trial, CLL patients under age 70 who were treated with a combination of Imbruvica and Rituximab achieved a progression-free survival (PFS) rate -- the amount of time during and after treatment the patient lives with cancer without experiencing worsening symptoms -- of 88% after 37 months. By contrast, patients on chemotherapy drugs and Rituximab achieved a PFS rate of 75%.
Image Source: Getty Images.
Johnson & Johnson originally co-developed Imbruvica with Pharmacyclics, an oncology-focused biotech company that was acquired by AbbVie back in 2015 in a cash and stock transaction valued at $21 billion. Johnson & Johnson and AbbVie equally share the profits (and losses) from the sale of Imbruvica.
With sales of Humira -- by far AbbVie's biggest moneymaker -- losing steam in Europe due to competition from biosimilars, the pharma giant has high hopes for Imbruvica. As CEO Richard A. Gonzalez said: "Imbruvica remains the clear market-share leader across all lines of therapy in CLL. With the largest body of clinical evidence, a robust survival benefit, and the highest category rating in treatment guidelines today, we remain confident that Imbruvica will be a significant growth contributor for many years to come."
During its latest reported quarter -- Q4 2019 -- AbbVie reported net revenue of $1.3 billion from Inbruvica, representing a 28.9% year-over-year increase.
10 stocks we like better than Johnson & Johnson
When investing geniuses David and Tom Gardner have a stock tip, it can pay to listen. After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor, has tripled the market.*
David and Tom just revealed what they believe are the ten best stocks for investors to buy right now... and Johnson & Johnson wasn't one of them! That's right -- they think these 10 stocks are even better buys.
See the 10 stocks
*Stock Advisor returns as of April 16, 2020
Prosper Junior Bakiny has no position in any of the stocks mentioned. The Motley Fool owns shares of and recommends Biogen. The Motley Fool recommends Johnson & Johnson. The Motley Fool has a disclosure policy.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | With sales of Humira -- by far AbbVie's biggest moneymaker -- losing steam in Europe due to competition from biosimilars, the pharma giant has high hopes for Imbruvica. Imbruvica, a blockbuster cancer drug marketed by Johnson & Johnson (NYSE: JNJ) and AbbVie (NYSE: ABBV), recently secured its 11th approval. Johnson & Johnson originally co-developed Imbruvica with Pharmacyclics, an oncology-focused biotech company that was acquired by AbbVie back in 2015 in a cash and stock transaction valued at $21 billion. | Imbruvica, a blockbuster cancer drug marketed by Johnson & Johnson (NYSE: JNJ) and AbbVie (NYSE: ABBV), recently secured its 11th approval. Johnson & Johnson originally co-developed Imbruvica with Pharmacyclics, an oncology-focused biotech company that was acquired by AbbVie back in 2015 in a cash and stock transaction valued at $21 billion. Johnson & Johnson and AbbVie equally share the profits (and losses) from the sale of Imbruvica. | Imbruvica, a blockbuster cancer drug marketed by Johnson & Johnson (NYSE: JNJ) and AbbVie (NYSE: ABBV), recently secured its 11th approval. Johnson & Johnson originally co-developed Imbruvica with Pharmacyclics, an oncology-focused biotech company that was acquired by AbbVie back in 2015 in a cash and stock transaction valued at $21 billion. Johnson & Johnson and AbbVie equally share the profits (and losses) from the sale of Imbruvica. | Johnson & Johnson and AbbVie equally share the profits (and losses) from the sale of Imbruvica. Imbruvica, a blockbuster cancer drug marketed by Johnson & Johnson (NYSE: JNJ) and AbbVie (NYSE: ABBV), recently secured its 11th approval. Johnson & Johnson originally co-developed Imbruvica with Pharmacyclics, an oncology-focused biotech company that was acquired by AbbVie back in 2015 in a cash and stock transaction valued at $21 billion. |
24608.0 | 2020-04-22 00:00:00 UTC | 3 Great Reasons to Buy Gilead Sciences Stock | ABBV | https://www.nasdaq.com/articles/3-great-reasons-to-buy-gilead-sciences-stock-2020-04-22 | nan | nan | Like many people, I'm rooting for Gilead Sciences' (NASDAQ: GILD) experimental drug remdesivir to be successful in clinical studies targeting COVID-19. There have been some early hints at positive results, but it's too soon to know for sure how safe and effective remdesivir will actually be in treating the novel coronavirus disease.
In the meantime, I think that Gilead Sciences is a great stock to buy regardless of what happens with its coronavirus program. Here are three reasons why.
Image source: Getty Images.
1. A big new market opportunity
Quite a few big drugmakers have made fortunes in the immunology market. EvaluatePharma ranks three immunology drugs in the top six best-selling drugs over the next four years. Gilead Sciences hasn't been a player in the immunology market yet. But that should soon change.
Gilead currently awaits U.S. and European regulatory approvals for filgotinib in treating rheumatoid arthritis. The big biotech is also evaluating the drug in clinical studies targeting several other immunology indications, including Crohn's disease, psoriatic arthritis, and ulcerative colitis. Filgotinib holds the potential to generate peak annual sales of $4 billion to $6 billion if approved for all of these indications, with around half of its total sales stemming from treating rheumatoid arthritis.
And filgotinib is just the start of Gilead's immunology hopes. Gilead paid $5.1 billion to gain access to Galapagos' entire pipeline and an increased stake in the smaller biotech. Two of Galapagos' immunology candidates that Gilead has already expressed interest in are in phase 2 clinical studies. It also has a late-stage experimental drug targeting idiopathic pulmonary fibrosis.
2. A continuing juggernaut
While Gilead should soon make its mark in immunology, the biotech remains a juggernaut in HIV. The company's first approved product treated an eye disease in patients with HIV. Gilead rose to success on the back of HIV drugs such as Atripla, Truvada, and Viread.
Today, Gilead's HIV franchise boasts five blockbuster drugs. Biktarvy ranks as the leader in the group, generating sales topping $4.7 billion last year. It's a virtual shoo-in to soon become of the best-selling HIV drug of all time.
More winners are likely on the way. Gilead is evaluating long-acting HIV capsid GS-6207 in a couple of phase 2 clinical studies. GS-6207 could be the future of Gilead's HIV franchise and potentially even top Biktarvy if it's successful in clinical testing. Gilead also could have an HIV cure or two waiting in the wings. The biotech is testing two experimental drugs, vesatolimod and elipovimab, in early stage clinical trials that just might be able to cure HIV.
3. A fantastic dividend
Most biotech stocks don't pay dividends. But Gilead isn't like most biotech stocks.
Gilead Sciences initiated its dividend program in 2015. The company was making so much money that returning some of its profits to shareholders made sense. Over the past five years, Gilead boosted its dividend payout by 58%.
Its dividend yield now stands at 3.2%. That level was much higher, but Gilead's shares have jumped nearly 30% this year, causing the dividend yield to decline significantly.
There's no reason to worry about Gilead's dividend shrinking anytime soon. The company's payout ratio is below 60%. With the potential for improved earnings growth in the future from filgotinib and other new drugs, Gilead should be able to keep the dividends flowing and growing.
Lagniappe
I think that these three reasons are enough to justify buying Gilead Sciences stock all on their own. However, I worked for several years in New Orleans where there's a tradition of lagniappe -- giving a little something extra.
Another good reason to like the stock is the duopoly that it shares with AbbVie in the hepatitis C virus (HCV) market. Although its HCV franchise isn't a growth driver for Gilead, it does still make the company a lot of money.
Gilead is also a leader in oncology. Yescarta is the top cancer cell therapy and could pick up regulatory approvals for additional indications in the not-too-distant future. Gilead's acquisition earlier this year of Forty Seven should boost its position in the oncology market as well.
There's still a chance that Gilead could make a big splash in treating nonalcoholic steatohepatitis (NASH), an indication that some think could be a $35 billion market. The biotech has had some pipeline setbacks with its NASH program but has three drugs targeting the disease in phase 2 clinical testing.
And, yes, Gilead could be successful with remdesivir in treating COVID-19. While that would be great news for people across the world, the great news for investors considering Gilead is that the coronavirus drug truly is lagniappe for an already-promising stock.
10 stocks we like better than Gilead Sciences
When investing geniuses David and Tom Gardner have a stock tip, it can pay to listen. After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor, has tripled the market.*
David and Tom just revealed what they believe are the ten best stocks for investors to buy right now... and Gilead Sciences wasn't one of them! That's right -- they think these 10 stocks are even better buys.
See the 10 stocks
*Stock Advisor returns as of April 16, 2020
Keith Speights owns shares of AbbVie and Gilead Sciences. The Motley Fool owns shares of and recommends Gilead Sciences. The Motley Fool has a disclosure policy.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Another good reason to like the stock is the duopoly that it shares with AbbVie in the hepatitis C virus (HCV) market. See the 10 stocks *Stock Advisor returns as of April 16, 2020 Keith Speights owns shares of AbbVie and Gilead Sciences. Like many people, I'm rooting for Gilead Sciences' (NASDAQ: GILD) experimental drug remdesivir to be successful in clinical studies targeting COVID-19. | Another good reason to like the stock is the duopoly that it shares with AbbVie in the hepatitis C virus (HCV) market. See the 10 stocks *Stock Advisor returns as of April 16, 2020 Keith Speights owns shares of AbbVie and Gilead Sciences. Like many people, I'm rooting for Gilead Sciences' (NASDAQ: GILD) experimental drug remdesivir to be successful in clinical studies targeting COVID-19. | See the 10 stocks *Stock Advisor returns as of April 16, 2020 Keith Speights owns shares of AbbVie and Gilead Sciences. Another good reason to like the stock is the duopoly that it shares with AbbVie in the hepatitis C virus (HCV) market. Like many people, I'm rooting for Gilead Sciences' (NASDAQ: GILD) experimental drug remdesivir to be successful in clinical studies targeting COVID-19. | Another good reason to like the stock is the duopoly that it shares with AbbVie in the hepatitis C virus (HCV) market. See the 10 stocks *Stock Advisor returns as of April 16, 2020 Keith Speights owns shares of AbbVie and Gilead Sciences. GS-6207 could be the future of Gilead's HIV franchise and potentially even top Biktarvy if it's successful in clinical testing. |
24609.0 | 2020-04-22 00:00:00 UTC | 2 Best Dividend Stocks to Buy Now | ABBV | https://www.nasdaq.com/articles/2-best-dividend-stocks-to-buy-now-2020-04-22 | nan | nan | What will happen after the COVID-19 pandemic from an economic standpoint is anyone's guess. The oil and gas industry, airlines, cruise ships, sit-in restaurants, and even the financial services space are all facing an uphill battle at the moment.
Numerous household names may, in fact, vanish when everything is said and done. Put simply, this isn't the time to take on undue amounts of risk with your portfolio. What's more, investors would be wise to avoid trying to time the bottom by bargain hunting in this rather unpredictable market.
Which stocks are the best safe havens for investors in this rocky market? Blue chip pharmaceutical companies that pay a reliable dividend definitely qualify as a port in the storm, so to speak. Most of the top pharmaceutical companies should actually grow their top lines over the next 12 months -- not just hang on for dear life as the broader economy deals with the impacts of social distancing.
Armed with this insight, investors should take a look at AbbVie (NYSE: ABBV) and Pfizer (NYSE: PFE) -- both are perhaps the two best dividend-paying pharma stocks to buy right now. Here's why.
Image Source: Getty Images.
AbbVie: A dirt cheap Dividend Aristocrat
AbbVie is a Dividend Aristocrat, meaning that it belongs to a select group of companies that have increased their dividends for 25 consecutive years or more. The company didn't earn this honor by itself -- the Chicago-based biopharma was bestowed this highly coveted title through its parent company, Abbott Laboratories.
Even so, AbbVie has done an admirable job of rewarding loyal shareholders since becoming an independent company. AbbVie, in fact, has boosted its dividend by a whopping 195% since its debut in 2013. That's one of the fastest dividend growth rates within the large-cap pharmaceutical space over the last seven years.
Despite AbbVie's proven commitment to paying a top-notch dividend, investors haven't exactly flocked to this name as of late. Keeping with this theme, AbbVie's shares are trading at less than nine times projected earnings and are down by almost 18% at the time of this writing from their 52-week high. The net result is that AbbVie's dividend yield has ballooned to an eye-popping 5.62% at current levels.
The drugmaker's shares are trading at bargain-bin levels because investors are worried about the impact of biosimilar competition on the company's flagship arthritis medication Humira, combined with the upcoming merger with Botox-maker Allergan. This merger with Allergan will immediately dilute Humira's overall importance as a growth driver, but there are some significant drawbacks. Specifically, Allergan's medical-aesthetics franchise may take a big hit from the COVID-19 pandemic, and the combined company will sport a highly leveraged balance sheet.
The good news is that the revamped AbbVie should have no trouble paying off debt while continuing to service its dividend program. The core reason is that the company recently brought several new growth products to market, such as the soon-to-be-blockbuster immunology meds Rinvoq and Skyrizi. As such, there's a solid case to be made that AbbVie's main risk factors are being blown way out of proportion right now. Savvy investors, in turn, may want to take advantage of this fundamental disconnect while it still exists.
Pfizer: A top income-and-growth vehicle
Pfizer is one of the world's largest pharmaceutical companies in terms of both annual sales and market capitalization. The company's stock has long been a favorite among conservative-minded income investors, thanks to its top-notch yield of 4.12%, strong balance sheet, and enormous product portfolio.
Nonetheless, Pfizer's shares have still lost over 9% of their value this year and are currently trading near their two-year lows as a result. Investors have backed away from this pharmaceutical titan largely because of management's decision to spin off its lucrative generic-drug business. This strategic move is designed to tranform Pfizer into a "pure-bred biopharmaceutical driven by research and development," according to recent comments by the company's Senior VP of Investor Relations Charles Triano.
Investors, in turn, are arguably making a mountain out of a molehill. Pfizer has emerged as a top player in the high-growth field of oncology, yet this budding franchise has been overshadowed from a revenue-growth standpoint by a litany of patent expirations in recent years.
Driving this point home, Pfizer is calling for its top line to rise by no less than 6% per year for the next five years following this split. Therefore, this business separation should ultimately turn out to be a huge boon for current shareholders.
All told, Pfizer's stock is poised to become a top growth-and-income vehicle in the years ahead.
10 stocks we like better than Pfizer
When investing geniuses David and Tom Gardner have a stock tip, it can pay to listen. After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor, has tripled the market.*
David and Tom just revealed what they believe are the ten best stocks for investors to buy right now... and Pfizer wasn't one of them! That's right -- they think these 10 stocks are even better buys.
See the 10 stocks
*Stock Advisor returns as of April 16, 2020
George Budwell owns shares of AbbVie and Pfizer. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Armed with this insight, investors should take a look at AbbVie (NYSE: ABBV) and Pfizer (NYSE: PFE) -- both are perhaps the two best dividend-paying pharma stocks to buy right now. AbbVie: A dirt cheap Dividend Aristocrat AbbVie is a Dividend Aristocrat, meaning that it belongs to a select group of companies that have increased their dividends for 25 consecutive years or more. Even so, AbbVie has done an admirable job of rewarding loyal shareholders since becoming an independent company. | AbbVie: A dirt cheap Dividend Aristocrat AbbVie is a Dividend Aristocrat, meaning that it belongs to a select group of companies that have increased their dividends for 25 consecutive years or more. Despite AbbVie's proven commitment to paying a top-notch dividend, investors haven't exactly flocked to this name as of late. Armed with this insight, investors should take a look at AbbVie (NYSE: ABBV) and Pfizer (NYSE: PFE) -- both are perhaps the two best dividend-paying pharma stocks to buy right now. | Armed with this insight, investors should take a look at AbbVie (NYSE: ABBV) and Pfizer (NYSE: PFE) -- both are perhaps the two best dividend-paying pharma stocks to buy right now. AbbVie: A dirt cheap Dividend Aristocrat AbbVie is a Dividend Aristocrat, meaning that it belongs to a select group of companies that have increased their dividends for 25 consecutive years or more. See the 10 stocks *Stock Advisor returns as of April 16, 2020 George Budwell owns shares of AbbVie and Pfizer. | Despite AbbVie's proven commitment to paying a top-notch dividend, investors haven't exactly flocked to this name as of late. Keeping with this theme, AbbVie's shares are trading at less than nine times projected earnings and are down by almost 18% at the time of this writing from their 52-week high. Armed with this insight, investors should take a look at AbbVie (NYSE: ABBV) and Pfizer (NYSE: PFE) -- both are perhaps the two best dividend-paying pharma stocks to buy right now. |
24610.0 | 2020-04-21 00:00:00 UTC | 3 Dividend Stocks I'd Buy Right Now | ABBV | https://www.nasdaq.com/articles/3-dividend-stocks-id-buy-right-now-2020-04-21 | nan | nan | Dividend stocks can be a great source of income, especially during challenging times like these. They can help provide stability for your portfolio and minimize your losses during a market crash as well. Stable dividend stocks are in short supply lately, but the three stocks listed below offer investors a good mix of value and dividends, and they all look like solid long-term buys.
1. AbbVie
AbbVie (NYSE: ABBV) is a top drug manufacturer, and its Humira drug is critical for patients with various types of arthritis as well as people who have Crohn's disease. The drug made up 58% of the company's revenue in 2019. And while the drug did well with $19.2 billion in sales last year, that was less than the $19.9 billion it generated in 2018. AbbVie as a whole saw its top line rise by just 1.6% last year. It's an underwhelming result, but that's why the company's $63 billion purchase of Allergan (NYSE: AGN) could prove to be pivotal for its future. The move will add some high-profile drugs into AbbVie's portfolio that could help pad its growth, including Botox. The companies expect the deal to close as early as next month.
AbbVie's stock currently pays its shareholders a quarterly dividend of $1.18. That yields around 5.6% on an annual basis, and it's well above the 2% that investors can expect from the average S&P 500 stock. What makes the stock a great buy is that AbbVie is a Dividend Aristocrat and its payouts have increased by 195% since it separated from Abbott Laboratories in 2013. The acquisition of Allergan should strengthen AbbVie over the long term, and it could pave the way for more dividend increases in the future, making it an even better buy for income investors today.
Image source: Getty Images.
2. UPS
United Parcel Service (NYSE: UPS) is an attractive stock to hold for a number of reasons. The first is that as long as Amazon continues pumping out strong numbers and online sales, that's a sign that online shopping remains strong, and so does demand for logistics and delivery companies like UPS. The coronavirus pandemic is the exclamation point on that right now. Consumers are more dependent than ever on online orders as shopping options are limited, since many stores are closed down or have reduced their operations significantly.
But whether there's a pandemic or not, online shopping is still likely to soar. Data from Amazon's most recent annual results show that in two years, sales from its online stores have risen by more than 30%. Amazon's certainly not the only place where consumers can buy products online, but its sales numbers can help gauge the strength of e-commerce in general.
It's no surprise then that UPS has continued to grow as well. Its sales are up by more than 12% in two years. And if we look at over the past five years, UPS's top line has grown by 27%. They aren't earth-shattering growth numbers, but there's nothing wrong with steady, consistent increases over the years. And with UPS recording a profit in each of the past 10 years, the business model is a strong one. That's what dividend investors look for, as the last thing you want with a dividend stock is instability.
UPS raised its payouts in February, and investors will now receive $1.01 every quarter for each share that they own. With a price of around $100, that means the stock's dividend yield is around 4% per year. While UPS doesn't have the impressive track record for dividend growth that AbbVie has, it's been increasing its payouts on a regular basis since 2010.
3. Wells Fargo
Wells Fargo (NYSE: WFC) could face some challenges ahead, as the coronavirus pandemic has already hit the economy hard, and that's going to have a trickle-down effect onto the big banks as well. The company released its first-quarter results on April 14, and they weren't pretty -- the bank reported a per-share profit of just $0.01. But that's after the bank set aside a "reserve build" of $3.1 billion in anticipation of some tougher economic times, which weighed down its results.
A recession is all but official, and things aren't going to be pretty for Wells Fargo in the months ahead. So you may be wondering why, then, Wells Fargo would be on a list of dividend stocks to buy today. There are a few very good reasons for that.
The first is that while Wells Fargo was building up its war chest in anticipation of a significant slowdown in the economy, it didn't announce a suspension or a cut to its dividend. That's a good sign because the company cut its dividend in 2009 during the financial crisis. This could indicate that as concerned as Wells Fargo is about the future, it may not be anticipating that things will be as bad as they were in 2009, or that it's in better shape today than it was back then. However, a dividend cut or suspension is always in the cards, especially if the coronavirus pandemic lasts longer than people expect it to. But for now, the bank stock anticipates that it should be in good enough shape to continue on with the payouts as they are today.
Another reason why it's an opportune time to buy the stock? It's trading near its 52-week low and the dividend yield is now up to over 7%. That's a monstrous payout for a top bank stock like Wells Fargo. Lastly, holding shares of Wells Fargo is a long-term play. For all the adversity faced by the bank, perhaps most notably the fake accounts scandal which resulted in a $3 billion payment, Wells Fargo's been able to preserve payments. Even if the bank does need to cut or suspend dividend payments, once the economy recovers it'll go back to increasing its payouts and investors could be right back to earning a dividend. And buying near the stock's low could set up investors for stronger future returns and dividend yields in the years ahead.
Which stock is the best buy?
Let's have a quick look at how these three stocks have done this year compared to the S&P 500:
ABBV data by YCharts
AbbVie has performed the best thus far, and if you're a risk-averse investor, then the healthcare stock is likely your best bet going forward as well. With a strong track record for increasing dividends, it's going to be one of the more stable dividend stocks that you can hold in your portfolio today. But if you want a bit more than just recurring cash flow, then UPS could offer the best mix of dividends and growth. And if you're willing to take on some short-term risk, Wells Fargo could provide the best total returns on this list. With a high dividend and the stock coming off a disappointing quarter, it could be an opportune time to buy the stock at a low.
However, if you're a long-term investor, then any one of the three stocks listed above could be great additions to your portfolio.
10 stocks we like better than Wells Fargo
When investing geniuses David and Tom Gardner have a stock tip, it can pay to listen. After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor, has tripled the market.*
David and Tom just revealed what they believe are the ten best stocks for investors to buy right now... and Wells Fargo wasn't one of them! That's right -- they think these 10 stocks are even better buys.
See the 10 stocks
*Stock Advisor returns as of April 16, 2020
John Mackey, CEO of Whole Foods Market, an Amazon subsidiary, is a member of The Motley Fool's board of directors. David Jagielski has no position in any of the stocks mentioned. The Motley Fool owns shares of and recommends Amazon and recommends the following options: short January 2022 $1940 calls on Amazon and long January 2022 $1920 calls on Amazon. The Motley Fool has a disclosure policy.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | The acquisition of Allergan should strengthen AbbVie over the long term, and it could pave the way for more dividend increases in the future, making it an even better buy for income investors today. AbbVie AbbVie (NYSE: ABBV) is a top drug manufacturer, and its Humira drug is critical for patients with various types of arthritis as well as people who have Crohn's disease. AbbVie as a whole saw its top line rise by just 1.6% last year. | AbbVie AbbVie (NYSE: ABBV) is a top drug manufacturer, and its Humira drug is critical for patients with various types of arthritis as well as people who have Crohn's disease. AbbVie as a whole saw its top line rise by just 1.6% last year. The move will add some high-profile drugs into AbbVie's portfolio that could help pad its growth, including Botox. | AbbVie AbbVie (NYSE: ABBV) is a top drug manufacturer, and its Humira drug is critical for patients with various types of arthritis as well as people who have Crohn's disease. AbbVie as a whole saw its top line rise by just 1.6% last year. The move will add some high-profile drugs into AbbVie's portfolio that could help pad its growth, including Botox. | While UPS doesn't have the impressive track record for dividend growth that AbbVie has, it's been increasing its payouts on a regular basis since 2010. AbbVie AbbVie (NYSE: ABBV) is a top drug manufacturer, and its Humira drug is critical for patients with various types of arthritis as well as people who have Crohn's disease. AbbVie as a whole saw its top line rise by just 1.6% last year. |
24611.0 | 2020-04-21 00:00:00 UTC | 8 Safe High-Yield Dividend Stocks Offering 5% or More | ABBV | https://www.nasdaq.com/articles/8-safe-high-yield-dividend-stocks-offering-5-or-more-2020-04-21 | nan | nan | Steep market declines in 2020 have not only been brutal on returns; they've also presented income investors with a conundrum. The market is suddenly flooded with a glut of high-yield dividend stocks, but dividends in general are less safe than they've been in more than a decade.
The S&P 500 has quickly risen from a yield of 1.8% at the end of December to a yield of about 2.1% today. That's still not an exciting number, of course. But both inside and outside the index, a number of stocks have seen their yields double, triple or more. That has made it easier than it has been in a long time to find high-yield dividend stocks offering up sizable income of greater than 5%.
At the same time, however, the market has been flooded with a run of dividend cuts. Some companies are watching their profits plunge as people are confined to their homes, creating short-term cash crunches that are forcing them to conserve as much capital as possible simply to survive.
The trick, then, lies in identifying great-yielding names that will be able to maintain their dividends even if this shutdown triggers a prolonged recession.
Here are eight of the safest high-yield dividend stocks right now. These stocks boast several traits that speak to dividend safety, from conservative balance sheets and durable cash flows to histories of maintaining dividends through previous economic downturns.
SEE ALSO: 20 Best Stocks to Buy Now for the Next Bull Market
AbbVie
Market value: $124.0 billion
Dividend yield: 5.6%
Pharmaceutical powerhouse AbbVie (ABBV, $83.99) develops treatments for autoimmune disorders, cancers, viruses and neurological conditions. The company derives roughly 60% of sales from its blockbuster drug Humira, a treatment for rheumatoid arthritis, plaque psoriasis and other conditions. Other important AbbVie drugs include Imbruvica and Venclexta (for cancer) and new therapeutics Skyrizi (arthritis) and Rinvoq (psoriasis).
Humira sales are slowing, so AbbVie plans to re-energize its business by merging with Allergan (AGN). The combined business is expected to generate more than $30 billion in annual sales. Allergan adds blockbuster drugs Botox (wrinkles and migraines) and Restasis (dry-eye treatment) to AbbVie's portfolio.
The Allergan deal is expected to close in May, leaving AbbVie with $95 billion of post-acquisition debt. However, ABBV expects to leverage $19 billion of annualized cash flow from the combined business to trim $15 billion to $18 billion of debt by year-end 2021. AbbVie also expects to benefit from $3 billion of pre-tax cost synergies.
AbbVie is a Dividend Aristocrat on the merits of its 48-year streak of uninterrupted dividend growth, much of which is attributed to its time joined with Abbott Laboratories (ABT). As a standalone entity, AbbVie has generated seven years of dividend hikes - including a 35% boost announced in February - and an 18% annual dividend growth rate over the past half-decade
ABBV has long been among the market's safest high-yield dividend stocks. Indeed, the stock has only declined about 10% since the bull market's peak on Feb. 19, so its yield hasn't gotten much of a boost from share-price declines. Meanwhile, its payout look safe given that it represents just less than half of AbbVie's profits, and given that Aristocrats often go to greater-than-usual lengths to keep up their payouts in hard times.
SEE ALSO: 64 Dividend Stocks You Can Count On in 2020
Bunge
Market value: $5.5 billion
Dividend yield: 5.1%
Bunge (BG, $40.09) is a leading global agricultural company with operations in commodity grain products such as corn and wheat; cooking oil and fats that it packages for food manufacturers; milled flour and cornmeal; sugar; ethanol; and various fertilizers. Bunge deals in products necessary for food production, which will naturally be impacted by a business downturn, but it won't erode completely. Bunge also recently improved its competitive positioning by trimming more than $250 million of annual expenses.
A 28% decline since Feb. 19 has launched Bunge among safe high-yield dividend stocks with a payout above 5%. But its quarterly dole appears safe for now. Adjusted operating cash flow of $1.06 billion last year provided triple the coverage of Bunge's $317 million annual dividend. That's no one-time thing: Cash flow has exceeded $1 billion in four of the past five years. And the company, which has increased its dividend for 18 consecutive years, announced in early March a 50-cent-per-share quarterly payout in line with its most recent dividend.
At the end of March, Baird analyst Ben Kallo added BG to his "Fresh Picks" list of stocks well-positioned to weather economic uncertainty. He likes Bunge's healthy balance sheet and robust cash flows and thinks the company will benefit from China restarting agricultural purchases this year.
Insiders also appear bullish on Bunge's prospects; CEO Greg Heckman purchased of a whopping $4.8 million worth of BG stock during March.
SEE ALSO: 25 Blue Chips With Brawny Balance Sheets
Chevron
Market value: $156.0 billion
Dividend yield: 6.2%
In response to crude oil prices nearing 20-year lows, integrated energy giant Chevron (CVX, $87.17) has already taken aggressive action to protect its dividend, which the company calls its No. 1 priority. Chevron is cutting 2020 exploratory spending by roughly 30% and suspending share repurchases.
Chevron is the second largest U.S. integrated energy company - behind Exxon Mobil (XOM) - and has production and refinery operations worldwide. The company has a major drilling presence in the Permian Basin and Gulf of Mexico. It also operates refineries representing throughput capacity of 1.7 million barrels per day, as well as a network of more than 7,800 Chevron and Texaco service stations.
Thanks to a cash flow breakeven point the company estimates at roughly $51 a barrel (much lower than peers), Chevron is better positioned than most to cover expenses and its dividend even in the currently weak drilling environment.
Annual energy production exceeded 3 million barrels per day last year and the company added 494 million barrels to its proved reserves. Excluding asset sales, Chevron expects overall 2020 production to be flat and Permian Basin production to be 20% below prior guidance. Chevron also is committed to reducing run rate operating costs by more than $1 billion this year.
Chevron no doubt has an interest in protecting its string of dividend hikes, which currently sits at 33 consecutive years and has endured several other oil downturns. Dividend payments totaling just under $9 billion last year were easily covered by $12.5 billion of free cash flow.
SEE ALSO: 7 Oil and Gas Stocks That Have Entered Dangerous Waters
DXC Technology
Market value: $3.8 billion
Dividend yield: 5.6%
DXC Technology (DXC, $15.07) provides information technology services in North America, Europe, Asia and Australia. The company, formerly known as Computer Sciences Corporation, changed its name following its 2017 merger with Hewlett Packard Enterprise's (HPE) Enterprise Services business.
Today DXC specializes in IT outsourcing, cloud capabilities with embedded security, software applications, analytics and advisory services. The company serves more than 6,000 customers across 70 countries, including more than 200 of the Fortune 500 companies. DXC generated revenues exceeding $20 billion last year and ranked No. 122 on the 2019 Fortune 500 list.
The company is relying on digital segment growth to offset declines in more traditional businesses and is using acquisitions to expand its digital footprint. Last year DXC produced 80% growth in its digital pipeline, 50% growth in digital bookings and 16% growth in digital revenues. EPS declined in the first nine months of fiscal 2020 due mainly to integration-related costs, but operating cash flow doubled to $2.06 billion.
DXC also generated $1.2 billion of adjusted free cash flow, which covered nine-month dividend payments more than six times over. Long-term growth in free cash flow has been impressive at 11% annually over the past decade.
DXC has modest debt that's three times free cash flow, and less than three times the company's current cash on hand, and its dividend is an ultra-low 16% of this year's estimated profits. The firm left its dividend intact in early March, when it announced a 21-cent-per-share quarterly payout in line with its previous payments. Nonetheless, a massive 49% decline has put DXC into a class of high-yield dividend stocks offering up more than 5% at current prices.
DXC Technology recently divested its State and Local Health and Human Services business and plans to use the $5 billion of sale proceeds to further reduce debt. Cowen analyst Jared Levin and Citi analyst Ashwin Shirvaikar both applauded the sale, which came at a higher price than expected. Both analysts maintain Buy-equivalent ratings on the stock despite acknowledging that COVID-19 could impact the business.
SEE ALSO: 20 Top Stocks to Invest In During a Recession
HNI
Market value: $1.0 billion
Dividend yield: 5.2%
HNI (HNI, $23.49) designs and builds office furniture and fireplace products for residential homes. The company sells office furniture under the HON, Allsteel, Maxon and other brands and distributes through independent dealers. HNI is a market leader in fireplace products, which are marketed under the Heatilator, Heat & Glo, Majestic and other brands and sold through distribution centers and showrooms across North America, Asia, Mexico and the Middle East.
Its sales are a mix of 76% office furniture and 24% hearth products.
HNI is among a number of high-yield dividend stocks whose businesses are sure to feel the effects of both the coronavirus and a recession. However, HNI is better positioned than most furniture-makers to weather a downturn due to a recent restructuring that cut expenses and bolstered margins. Despite lower sales, adjusted EPS grew 7% last year. The company's longer-term performance has been solid, with yearly EPS increases of 13% over five years and free cash flow growth of nearly 38%.
HNI has grown its dividend continuously since 1989, with the exception of 2008-09, when it held dividends steady. Dividend growth has averaged a modest 4% over the past five years. Its cash flow covered its payout by roughly three times last year.
The company has a terrific balance sheet showing long-term debt at 28% of capitalization and only 1.3 times free cash flow. It only has $53 million in cash on hand, but that could help float the dividend for a few quarters if the company were pressed.
SEE ALSO: Every Warren Buffett Stock Ranked: The Berkshire Hathaway Portfolio
International Business Machines
Market value: $107.0 billion
Dividend yield: 5.4%
IT solutions provider International Business Machines (IBM, $120.12) greatly expanded its presence in the hybrid cloud market last year through the $34 billion acquisition of Red Hat. Thanks to Red Hat, the company now has the ability to offer open-source software to IT managers. This software is needed to modernize older applications to run in data centers and across different cloud services.
IBM was an early leader in the transition to the cloud but fell behind industry leaders Amazon.com (AMZN) and Microsoft (MSFT). Red Hat should help IBM close that gap. Cloud revenues are IBM's fastest growing business and currently represent over 25% of sales. Managers anticipate Red Hat could contribute more than two percentage points to IBM's annual sales growth over the next five years.
Management looks for free cash flow of $12.5 billion in 2020, which leaves plenty of room to cover $5.7 billion of dividend payments even if that forecast is cut due to coronavirus impact. In addition, IBM has nearly $12 billion in cash available to help pay the dividend in the short term if it came to that and management were willing.
IBM, while not a Dividend Aristocrat, does have an incentive to keep up its payout. Namely, at 24 years of dividend increases, it's one year away from membership in the elite payout club. Meanwhile, a 20% decline has driven IBM into this group of safe high-yield dividend stocks with a current yield of 5.4%.
SEE ALSO: 11 Best Tech Stocks for the New Coronavirus Norm
Nu Skin Enterprises
Market value: $1.3 billion
Dividend yield: 6.3%
Nu Skin Enterprises (NUS, $23.91) develops and sells skin care and wellness products in approximately 50 countries worldwide. Its three main brands are Nu Skin (beauty and personal care products), Pharmanex (nutritional products) and ageLOC (anti-aging products).
NuSkin sells direct to approximately 1.16 million consumers worldwide via a network of more than 800,000 independent distributors. Roughly 87% of the company's sales are made outside the U.S. China is its largest market, accounting for approximately 30% of sales.
Nu Skin's near-term growth strategy focuses on completing the transition of its business to the cloud (with more than 80% of sales and 90% of global transactions already taking place online), launching an innovative new skincare device system in 2020 and fine-tuning sales compensation to better incentivize and retain sales agents.
Due to its strong footprint in China, Nu Skin was earlier than most in recognizing the impact of COVID-19 and has already baked coronavirus impact into its 2020 guidance. The company anticipates a 5% to 10% sales decline and a 29% drop in earnings per share.
Nonetheless, Nu Skin should have no trouble covering its dividend. In February, the company increased its dividend to 37.5 cents per share - its 19th consecutive improvement. That comes out to $1.50 per share in annual dividends, versus analysts' expectations for $2.01 per share, followed by a rebound to $2.49 in 2021. Moreover, the company has $345 million in cash, about $10 million more than its debt), that it can use to cover its payout in the short term if necessary.
SEE ALSO: 15 Dividend Kings for Decades of Dividend Growth
Patterson Companies
Market value: $1.5 billion
Dividend yield: 6.7%
Last on this list of safe high-yield dividend stocks is Patterson Companies (PDCO, $15.52), a leading U.S. distributor of dental and animal health products. The company supplies consumables, equipment, software and services to approximately 100,000 dentists and dental offices across the U.S. and Canada.
Patterson entered the animal health market through its 2015 acquisition of Animal Health International and became the largest distributor of animal health products in North America, serving approximately 50,000 veterinary clinics and hospitals and livestock producers. Its sales are a mix of 57% animal health and 43% dental products.
The markets Patterson serves were chosen in part for their recession-resistant characteristics. Surveys indicate 95% of Americans value healthy teeth and more than 67% visit the dentist at least annually. In addition, 68% of U.S. households own a pet and 73% of pet-owning households visit the veterinarian at least annually.
During the first nine months of fiscal 2020, reported at the end of February, Patterson generated $128 million of free cash flow that easily covered $76 million of dividend payments. The company's EPS gains has been inconsistent, but annual growth in free cash flow has been reliable, averaging 16% over three years and 19% over five years.
Patterson has a decent though not unimpeachable dividend history. It has delivered cash distributions for a decade, though its last improvement was an 8% hike in 2017. That said, the company in mid-March felt confident enough to declare a quarterly dividend in line with its previous payouts.
Patterson withdrew its fiscal 2020 guidance in early April but said it was still on track to achieve its goals through the first two months of its fiscal fourth quarter ending in April.
SEE ALSO: 15 Super-Safe Dividend Stocks to Buy Now
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | SEE ALSO: 20 Best Stocks to Buy Now for the Next Bull Market AbbVie Market value: $124.0 billion Dividend yield: 5.6% Pharmaceutical powerhouse AbbVie (ABBV, $83.99) develops treatments for autoimmune disorders, cancers, viruses and neurological conditions. Other important AbbVie drugs include Imbruvica and Venclexta (for cancer) and new therapeutics Skyrizi (arthritis) and Rinvoq (psoriasis). Humira sales are slowing, so AbbVie plans to re-energize its business by merging with Allergan (AGN). | SEE ALSO: 20 Best Stocks to Buy Now for the Next Bull Market AbbVie Market value: $124.0 billion Dividend yield: 5.6% Pharmaceutical powerhouse AbbVie (ABBV, $83.99) develops treatments for autoimmune disorders, cancers, viruses and neurological conditions. Other important AbbVie drugs include Imbruvica and Venclexta (for cancer) and new therapeutics Skyrizi (arthritis) and Rinvoq (psoriasis). Humira sales are slowing, so AbbVie plans to re-energize its business by merging with Allergan (AGN). | As a standalone entity, AbbVie has generated seven years of dividend hikes - including a 35% boost announced in February - and an 18% annual dividend growth rate over the past half-decade ABBV has long been among the market's safest high-yield dividend stocks. SEE ALSO: 20 Best Stocks to Buy Now for the Next Bull Market AbbVie Market value: $124.0 billion Dividend yield: 5.6% Pharmaceutical powerhouse AbbVie (ABBV, $83.99) develops treatments for autoimmune disorders, cancers, viruses and neurological conditions. Other important AbbVie drugs include Imbruvica and Venclexta (for cancer) and new therapeutics Skyrizi (arthritis) and Rinvoq (psoriasis). | SEE ALSO: 20 Best Stocks to Buy Now for the Next Bull Market AbbVie Market value: $124.0 billion Dividend yield: 5.6% Pharmaceutical powerhouse AbbVie (ABBV, $83.99) develops treatments for autoimmune disorders, cancers, viruses and neurological conditions. Other important AbbVie drugs include Imbruvica and Venclexta (for cancer) and new therapeutics Skyrizi (arthritis) and Rinvoq (psoriasis). Humira sales are slowing, so AbbVie plans to re-energize its business by merging with Allergan (AGN). |
24612.0 | 2020-04-20 00:00:00 UTC | BUZZ-U.S. STOCKS ON THE MOVE-Co-Diagnostics, Xeris Pharma, Cyclacel Pharma | ABBV | https://www.nasdaq.com/articles/buzz-u.s.-stocks-on-the-move-co-diagnostics-xeris-pharma-cyclacel-pharma-2020-04-20 | nan | nan | Eikon search string for individual stock moves: STXBZ
The Day Ahead newsletter: http://tmsnrt.rs/2ggOmBi
The Morning News Call newsletter: http://tmsnrt.rs/2fwPLTh
The S&P 500 and the Dow Jones headed lower on Monday following a strong two-week rally as oil prices crashed and investors grew cautious at the start of a week that is likely to bring more dismal quarterly earnings reports and economic data..N
At 17:55 ET, the Dow Jones Industrial Average .DJI was down 0.92% at 24,020.4. The S&P 500 .SPX was down 0.33% at 2,865.2 and the Nasdaq Composite .IXIC was up 0.30% at 8,676.165. The top three S&P 500 .PG.INX percentage gainers: ** FLIR Systems Inc , up 14.7% ** Carrier Global Corp , up 6.6% ** Howmet Aerospace Inc , up 6.4% The top three S&P 500 .PL.INX percentage losers: ** L Brands Inc , down 7.5% ** Vornado Realty Trust , down 6.3% ** Occidental Petroleum Corp , down 6% The top three NYSE .PG.N percentage gainers: ** Regional Health Properties Inc , up 36.5% ** Pacer Developed Markets International Cash CWS , up 23.2% ** Montage Resources Corp , up 23% The top three NYSE .PL.N percentage losers: ** Invesco Mortgage Capital Inc , down 22.5% ** Direxion Daily S&P Biotech Bear 3X Shares , down 16.5% ** Independence Contract Drilling Inc , down 11.9% The top three Nasdaq .PG.O percentage gainers: ** Benitec Biopharma Limited , up 107.4% ** Cyclacel Pharmaceuticals Inc , up 103.8% ** Novavax Inc , up 32.9% The top three Nasdaq .PL.O percentage losers: ** Vericity Inc , down 19.5% ** Akazoo SA , down 19% ** Liberty TripAdvisor Holdings Inc , down 17.9% ** Aytu BioScience Inc AYTU.O: up 3.6%
BUZZ-Aytu: Rises on gaining exclusive license to potential COVID-19 treatment ** Redhill Biopharma RDHL.O: up 12.5%
BUZZ-Redhill Biopharma: Rises on agreement with NIAID to test cancer drug for COVID-19 ** Atossa Therapeutics Inc ATOS.O: up 5.6%
BUZZ-Atossa Therapeutics up as co seeks FDA nod to begin COVID-19 study ** Gilead Sciences Inc GILD.O: down 1.3%
BUZZ-Gilead: Brokerages downgrade on uncertainty over commercial value of COVID-19 drug ** Seattle Genetics Inc SGEN.O: up 5.1%
BUZZ-Street View: Seattle Genetics' breast cancer therapy approval brings some cheer ** Campbell Soup Co CPB.N: up 3.4%
BUZZ-Campbell Soup: Rises on strong retail demand ** Incyte Corp INCY.O: up 1.4%
BUZZ-Incyte: Touches fresh 2-yr high after FDA approval of cancer therapy ** ViaSat Inc VSAT.O: up 2.5%
BUZZ-ViaSat Inc: Rises as brokerage upgrades on higher residential internet demand ** 2U Inc TWOU.O: down 7.4%
BUZZ-2U drops ahead of $300 mln convertible debt deal ** Masimo Corp MASI.O: down 0.4%
BUZZ-Masimo Corp: Needham downgrades on likely slow 2H20 growth ** Avalon GloboCare Corp AVCO.O: up 7.9%
BUZZ-Avalon GloboCare: Rises as therapy shows promise in combating cytokine storm - Reuters News ** Shake Shack Inc SHAK.N: up 5.9%
BUZZ-Shake Shack beefs up capital, gives back government loan; shares dip ** Exelixis Inc EXEL.O: up 23.5%
BUZZ-Exelixis jumps as cancer drug combo shows promise in study ** AGNC Investment Corp AGNC.O: down 0.5% ** Annaly Capital Management Inc NLY.N: down 1.8% ** Apollo CRE Finance ARI.N: down 4.9% ** Blackstone Mortgage Trust Inc BXMT.N: down 3.1% ** Ladder Capital Corp LADR.N: down 3.4% ** Starwood Property Trust Inc STWD.N: down 3.9% ** TPG RE Finance Trust Inc TRTX.N: down 3.8%
BUZZ-U.S. mortgage REITs: DB cuts PT citing "stressed scenarios" ** INmune Bio Inc INMB.O: up 9.3%
BUZZ-INmune Bio Inc: Rises on plans to begin COVID-19 trial ** Mustang Bio Inc MBIO.O: up 1.4%
BUZZ-Mustang Bio: Rises after EMA's favorable classification of "bubble boy" therapy ** Meredith Corp MDP.N: down 6.5%
BUZZ-Meredith Corp: Falls on withdrawing 2020 outlook as ad sales get hit ** Lennox International LII.N: up 2.0%
BUZZ-Lennox International: Falls on weak Q1, warns of 20% hit from coronavirus ** Ducommun Inc DCO.N: up 3.6%
BUZZ-Ducommun: Jumps as Q1 revenue forecast higher than Wall Street estimates ** Alexion Pharmaceuticals Inc ALXN.O: up 4.9%
BUZZ-Alexion rises on study to test blood disorder drug for COVID-19 ** Clorox Co CLX.N: up 1.8%
BUZZ-Clorox: Up as Deutsche Bank expects strong Q3 helped by coronavirus ** Peloton Interative Inc PTON.O: down 3.2%
BUZZ-Peloton skids as BMO slaps with first "sell" rating since IPO ** Terex Corp TEX.N: down 4.2% ** Manitowoc Company Inc MTW.N: down 3.4%
BUZZ-GS removes Terex and Manitowoc from "buy list", downgrades to "neutral" ** Anixa Biosciences Inc ANIX.O: up 10.6% BUZZ-Anixa Biosciences: Rises on partnership for potential treatment of COVID-19 ** Cyclacel Pharmaceutical Inc CYCC.O: up 103.8% BUZZ-Cyclacel: Jumps on deal to study drugs to treat COVID-19 patients ** Boeing Co BA.N: down 4.9% BUZZ-Benchmark sees Boeing cut 787 production by 30%; lowers PT ** Eros International EROS.N: down 0.2% BUZZ-Eros International: Soars after deal to merge with STX Entertainment ** Medpace Holdings Inc MEDP.O: down 0.8% ** ICON Plc ICLR.O: down 0.4% BUZZ-Baird downgrades two contract research organizations on COVID-19 impact ** Xeris Pharmaceutical Inc XERS.O: up 15.1% BUZZ-Xeris Pharma: Rises on positive results from seizure medication study ** United Airlines Holdings Inc UAL.O: down 3.4% BUZZ-United Airlines drops on estimated quarterly loss, dour outlook ** Walt Disney Co DIS.N: down 2.3% BUZZ-Disney: Falls as brokerages move to sidelines citing hit to theme parks ** Cheesecake Factory Inc CAKE.O: up 5.9% BUZZ-Cheesecake Factory: Rises on $200 mln investment from Roark Capital ** Exxon Mobil Corp XOM.N: down 3.0% ** Chevron Corp CVX.N: down 1.8% ** Devon Energy Corp DVN.N: down 0.4% ** Callon Petroleum Co CPE.N: down 3.4% ** Chesapeake Energy Corp CHK.N: down 1.5% ** Occidental Petroleum Corp OXY.N: down 6.1% ** Schlumberger NV SLB.N: flat ** Halliburton Co HAL.N: up 0.1% ** TechnipFMC Plc FTI.N: down 1.4% BUZZ-Oil stocks drop as concerns over rising crude storage weigh on prices BUZZ-Street View: Schlumberger's dividend cut the first step on road to recovery BUZZ-Halliburton: Falls on $1.1 bln impairment charges ** Safe-T Group SFET.O: up 18.2% BUZZ-Safe-T Group: Jumps on upbeat Q1 revenue forecast ** AbbVie Inc ABBV.N: up 1.8% BUZZ-AbbVie Inc: RBC expects rebound in 2021, upgrades to "outperform" ** Facebook Inc FB.O: flat BUZZ-Facebook: Credit Suisse cuts PT as coronavirus impacts ad revenue ** Biogen Inc BIIB.O: up 1.3% BUZZ-Biogen Inc: Alzheimer's drug in focus ahead of Q1, not earnings ** Abbott Laboratories ABT.N: up 3.9% BUZZ-Abbott, Roche to benefit from surging demand for COVID-19 antibody tests - analyst ** DuPont de Nemours Inc DD.N: up 5.5% BUZZ-DuPont: Rises on expectations of stronger Q1 from coronavirus-driven demand ** Co-Diagnostics Inc CODX.O: up 17.4% BUZZ-Co-Diagnostics: Rises on increased U.S. sales of COVID-19 testing kits ** Acadia Healthcare Co Inc ACHC.O: down 0.1% ** Brookdale Senior Living Inc BKD.N: down 3.2% ** Ensign Group Inc ENSG.O: down 0.4% ** Select Medical Holdings Corp SEM.N: down 4.1% BUZZ-Strong headwinds imminent for facility-based health care providers - Analyst ** General Motors Co GM.N: flat ** Ford Motor Co F.N: down 1.7% BUZZ-CS cuts PT on Ford, GM on heavy cash burn in H1 2020 ** Royal Caribbean Cruises Ltd RCL.N: down 3.4% ** Norwegian Cruise Line Holdings Ltd NCLH.N: down 4.9% ** Carnival Corp CCL.N: down 1.4% BUZZ-J.P. Morgan slashes cruise operators' PT on virus impact
The 11 major S&P 500 sectors:
Communication Services
.SPLRCL
flat
Consumer Discretionary
.SPLRCD
up 0.09%
Consumer Staples
.SPLRCS
down 0.41%
Energy
.SPNY
down 1.63%
Financial
.SPSY
down 0.99%
Health
.SPXHC
up 0.49%
Industrial
.SPLRCI
down 1.01%
Information Technology
.SPLRCT
down 0.40%
Materials
.SPLRCM
down 0.52%
Real Estate
.SPLRCR
down 1.92%
Utilities
.SPLRCU
down 1.79%
(Compiled by Amal S in Bengaluru)
((Amal.S@thomsonreuters.com; within U.S.+1 646 223 8780; outside U.S. +91 80 6749 3677;))
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | The top three S&P 500 .PG.INX percentage gainers: ** FLIR Systems Inc , up 14.7% ** Carrier Global Corp , up 6.6% ** Howmet Aerospace Inc , up 6.4% The top three S&P 500 .PL.INX percentage losers: ** L Brands Inc , down 7.5% ** Vornado Realty Trust , down 6.3% ** Occidental Petroleum Corp , down 6% The top three NYSE .PG.N percentage gainers: ** Regional Health Properties Inc , up 36.5% ** Pacer Developed Markets International Cash CWS , up 23.2% ** Montage Resources Corp , up 23% The top three NYSE .PL.N percentage losers: ** Invesco Mortgage Capital Inc , down 22.5% ** Direxion Daily S&P Biotech Bear 3X Shares , down 16.5% ** Independence Contract Drilling Inc , down 11.9% The top three Nasdaq .PG.O percentage gainers: ** Benitec Biopharma Limited , up 107.4% ** Cyclacel Pharmaceuticals Inc , up 103.8% ** Novavax Inc , up 32.9% The top three Nasdaq .PL.O percentage losers: ** Vericity Inc , down 19.5% ** Akazoo SA , down 19% ** Liberty TripAdvisor Holdings Inc , down 17.9% ** Aytu BioScience Inc AYTU.O: up 3.6% BUZZ-Aytu: Rises on gaining exclusive license to potential COVID-19 treatment ** Redhill Biopharma RDHL.O: up 12.5% BUZZ-Redhill Biopharma: Rises on agreement with NIAID to test cancer drug for COVID-19 ** Atossa Therapeutics Inc ATOS.O: up 5.6% BUZZ-Atossa Therapeutics up as co seeks FDA nod to begin COVID-19 study ** Gilead Sciences Inc GILD.O: down 1.3% BUZZ-Gilead: Brokerages downgrade on uncertainty over commercial value of COVID-19 drug ** Seattle Genetics Inc SGEN.O: up 5.1% BUZZ-Street View: Seattle Genetics' breast cancer therapy approval brings some cheer ** Campbell Soup Co CPB.N: up 3.4% BUZZ-Campbell Soup: Rises on strong retail demand ** Incyte Corp INCY.O: up 1.4% BUZZ-Incyte: Touches fresh 2-yr high after FDA approval of cancer therapy ** ViaSat Inc VSAT.O: up 2.5% BUZZ-ViaSat Inc: Rises as brokerage upgrades on higher residential internet demand ** 2U Inc TWOU.O: down 7.4% BUZZ-2U drops ahead of $300 mln convertible debt deal ** Masimo Corp MASI.O: down 0.4% BUZZ-Masimo Corp: Needham downgrades on likely slow 2H20 growth ** Avalon GloboCare Corp AVCO.O: up 7.9% BUZZ-Avalon GloboCare: Rises as therapy shows promise in combating cytokine storm - Reuters News ** Shake Shack Inc SHAK.N: up 5.9% BUZZ-Shake Shack beefs up capital, gives back government loan; shares dip ** Exelixis Inc EXEL.O: up 23.5% BUZZ-Exelixis jumps as cancer drug combo shows promise in study ** AGNC Investment Corp AGNC.O: down 0.5% ** Annaly Capital Management Inc NLY.N: down 1.8% ** Apollo CRE Finance ARI.N: down 4.9% ** Blackstone Mortgage Trust Inc BXMT.N: down 3.1% ** Ladder Capital Corp LADR.N: down 3.4% ** Starwood Property Trust Inc STWD.N: down 3.9% ** TPG RE Finance Trust Inc TRTX.N: down 3.8% BUZZ-U.S. mortgage REITs: DB cuts PT citing "stressed scenarios" ** INmune Bio Inc INMB.O: up 9.3% BUZZ-INmune Bio Inc: Rises on plans to begin COVID-19 trial ** Mustang Bio Inc MBIO.O: up 1.4% BUZZ-Mustang Bio: Rises after EMA's favorable classification of "bubble boy" therapy ** Meredith Corp MDP.N: down 6.5% BUZZ-Meredith Corp: Falls on withdrawing 2020 outlook as ad sales get hit ** Lennox International LII.N: up 2.0% BUZZ-Lennox International: Falls on weak Q1, warns of 20% hit from coronavirus ** Ducommun Inc DCO.N: up 3.6% BUZZ-Ducommun: Jumps as Q1 revenue forecast higher than Wall Street estimates ** Alexion Pharmaceuticals Inc ALXN.O: up 4.9% BUZZ-Alexion rises on study to test blood disorder drug for COVID-19 ** Clorox Co CLX.N: up 1.8% BUZZ-Clorox: Up as Deutsche Bank expects strong Q3 helped by coronavirus ** Peloton Interative Inc PTON.O: down 3.2% BUZZ-Peloton skids as BMO slaps with first "sell" rating since IPO ** Terex Corp TEX.N: down 4.2% ** Manitowoc Company Inc MTW.N: down 3.4% BUZZ-GS removes Terex and Manitowoc from "buy list", downgrades to "neutral" ** Anixa Biosciences Inc ANIX.O: up 10.6% BUZZ-Anixa Biosciences: Rises on partnership for potential treatment of COVID-19 ** Cyclacel Pharmaceutical Inc CYCC.O: up 103.8% BUZZ-Cyclacel: Jumps on deal to study drugs to treat COVID-19 patients ** Boeing Co BA.N: down 4.9% BUZZ-Benchmark sees Boeing cut 787 production by 30%; lowers PT ** Eros International EROS.N: down 0.2% BUZZ-Eros International: Soars after deal to merge with STX Entertainment ** Medpace Holdings Inc MEDP.O: down 0.8% ** ICON Plc ICLR.O: down 0.4% BUZZ-Baird downgrades two contract research organizations on COVID-19 impact ** Xeris Pharmaceutical Inc XERS.O: up 15.1% BUZZ-Xeris Pharma: Rises on positive results from seizure medication study ** United Airlines Holdings Inc UAL.O: down 3.4% BUZZ-United Airlines drops on estimated quarterly loss, dour outlook ** Walt Disney Co DIS.N: down 2.3% BUZZ-Disney: Falls as brokerages move to sidelines citing hit to theme parks ** Cheesecake Factory Inc CAKE.O: up 5.9% BUZZ-Cheesecake Factory: Rises on $200 mln investment from Roark Capital ** Exxon Mobil Corp XOM.N: down 3.0% ** Chevron Corp CVX.N: down 1.8% ** Devon Energy Corp DVN.N: down 0.4% ** Callon Petroleum Co CPE.N: down 3.4% ** Chesapeake Energy Corp CHK.N: down 1.5% ** Occidental Petroleum Corp OXY.N: down 6.1% ** Schlumberger NV SLB.N: flat ** Halliburton Co HAL.N: up 0.1% ** TechnipFMC Plc FTI.N: down 1.4% BUZZ-Oil stocks drop as concerns over rising crude storage weigh on prices BUZZ-Street View: Schlumberger's dividend cut the first step on road to recovery BUZZ-Halliburton: Falls on $1.1 bln impairment charges ** Safe-T Group SFET.O: up 18.2% BUZZ-Safe-T Group: Jumps on upbeat Q1 revenue forecast ** AbbVie Inc ABBV.N: up 1.8% BUZZ-AbbVie Inc: RBC expects rebound in 2021, upgrades to "outperform" ** Facebook Inc FB.O: flat BUZZ-Facebook: Credit Suisse cuts PT as coronavirus impacts ad revenue ** Biogen Inc BIIB.O: up 1.3% BUZZ-Biogen Inc: Alzheimer's drug in focus ahead of Q1, not earnings ** Abbott Laboratories ABT.N: up 3.9% BUZZ-Abbott, Roche to benefit from surging demand for COVID-19 antibody tests - analyst ** DuPont de Nemours Inc DD.N: up 5.5% BUZZ-DuPont: Rises on expectations of stronger Q1 from coronavirus-driven demand ** Co-Diagnostics Inc CODX.O: up 17.4% BUZZ-Co-Diagnostics: Rises on increased U.S. sales of COVID-19 testing kits ** Acadia Healthcare Co Inc ACHC.O: down 0.1% ** Brookdale Senior Living Inc BKD.N: down 3.2% ** Ensign Group Inc ENSG.O: down 0.4% ** Select Medical Holdings Corp SEM.N: down 4.1% BUZZ-Strong headwinds imminent for facility-based health care providers - Analyst ** General Motors Co GM.N: flat ** Ford Motor Co F.N: down 1.7% BUZZ-CS cuts PT on Ford, GM on heavy cash burn in H1 2020 ** Royal Caribbean Cruises Ltd RCL.N: down 3.4% ** Norwegian Cruise Line Holdings Ltd NCLH.N: down 4.9% ** Carnival Corp CCL.N: down 1.4% BUZZ-J.P. Morgan slashes cruise operators' PT on virus impact The 11 major S&P 500 sectors: Communication Services Eikon search string for individual stock moves: STXBZ The Day Ahead newsletter: http://tmsnrt.rs/2ggOmBi The Morning News Call newsletter: http://tmsnrt.rs/2fwPLTh The S&P 500 and the Dow Jones headed lower on Monday following a strong two-week rally as oil prices crashed and investors grew cautious at the start of a week that is likely to bring more dismal quarterly earnings reports and economic data..N At 17:55 ET, the Dow Jones Industrial Average .DJI was down 0.92% at 24,020.4. down 1.79% (Compiled by Amal S in Bengaluru) ((Amal.S@thomsonreuters.com; within U.S.+1 646 223 8780; outside U.S. +91 80 6749 3677;)) The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | The top three S&P 500 .PG.INX percentage gainers: ** FLIR Systems Inc , up 14.7% ** Carrier Global Corp , up 6.6% ** Howmet Aerospace Inc , up 6.4% The top three S&P 500 .PL.INX percentage losers: ** L Brands Inc , down 7.5% ** Vornado Realty Trust , down 6.3% ** Occidental Petroleum Corp , down 6% The top three NYSE .PG.N percentage gainers: ** Regional Health Properties Inc , up 36.5% ** Pacer Developed Markets International Cash CWS , up 23.2% ** Montage Resources Corp , up 23% The top three NYSE .PL.N percentage losers: ** Invesco Mortgage Capital Inc , down 22.5% ** Direxion Daily S&P Biotech Bear 3X Shares , down 16.5% ** Independence Contract Drilling Inc , down 11.9% The top three Nasdaq .PG.O percentage gainers: ** Benitec Biopharma Limited , up 107.4% ** Cyclacel Pharmaceuticals Inc , up 103.8% ** Novavax Inc , up 32.9% The top three Nasdaq .PL.O percentage losers: ** Vericity Inc , down 19.5% ** Akazoo SA , down 19% ** Liberty TripAdvisor Holdings Inc , down 17.9% ** Aytu BioScience Inc AYTU.O: up 3.6% BUZZ-Aytu: Rises on gaining exclusive license to potential COVID-19 treatment ** Redhill Biopharma RDHL.O: up 12.5% BUZZ-Redhill Biopharma: Rises on agreement with NIAID to test cancer drug for COVID-19 ** Atossa Therapeutics Inc ATOS.O: up 5.6% BUZZ-Atossa Therapeutics up as co seeks FDA nod to begin COVID-19 study ** Gilead Sciences Inc GILD.O: down 1.3% BUZZ-Gilead: Brokerages downgrade on uncertainty over commercial value of COVID-19 drug ** Seattle Genetics Inc SGEN.O: up 5.1% BUZZ-Street View: Seattle Genetics' breast cancer therapy approval brings some cheer ** Campbell Soup Co CPB.N: up 3.4% BUZZ-Campbell Soup: Rises on strong retail demand ** Incyte Corp INCY.O: up 1.4% BUZZ-Incyte: Touches fresh 2-yr high after FDA approval of cancer therapy ** ViaSat Inc VSAT.O: up 2.5% BUZZ-ViaSat Inc: Rises as brokerage upgrades on higher residential internet demand ** 2U Inc TWOU.O: down 7.4% BUZZ-2U drops ahead of $300 mln convertible debt deal ** Masimo Corp MASI.O: down 0.4% BUZZ-Masimo Corp: Needham downgrades on likely slow 2H20 growth ** Avalon GloboCare Corp AVCO.O: up 7.9% BUZZ-Avalon GloboCare: Rises as therapy shows promise in combating cytokine storm - Reuters News ** Shake Shack Inc SHAK.N: up 5.9% BUZZ-Shake Shack beefs up capital, gives back government loan; shares dip ** Exelixis Inc EXEL.O: up 23.5% BUZZ-Exelixis jumps as cancer drug combo shows promise in study ** AGNC Investment Corp AGNC.O: down 0.5% ** Annaly Capital Management Inc NLY.N: down 1.8% ** Apollo CRE Finance ARI.N: down 4.9% ** Blackstone Mortgage Trust Inc BXMT.N: down 3.1% ** Ladder Capital Corp LADR.N: down 3.4% ** Starwood Property Trust Inc STWD.N: down 3.9% ** TPG RE Finance Trust Inc TRTX.N: down 3.8% BUZZ-U.S. mortgage REITs: DB cuts PT citing "stressed scenarios" ** INmune Bio Inc INMB.O: up 9.3% BUZZ-INmune Bio Inc: Rises on plans to begin COVID-19 trial ** Mustang Bio Inc MBIO.O: up 1.4% BUZZ-Mustang Bio: Rises after EMA's favorable classification of "bubble boy" therapy ** Meredith Corp MDP.N: down 6.5% BUZZ-Meredith Corp: Falls on withdrawing 2020 outlook as ad sales get hit ** Lennox International LII.N: up 2.0% BUZZ-Lennox International: Falls on weak Q1, warns of 20% hit from coronavirus ** Ducommun Inc DCO.N: up 3.6% BUZZ-Ducommun: Jumps as Q1 revenue forecast higher than Wall Street estimates ** Alexion Pharmaceuticals Inc ALXN.O: up 4.9% BUZZ-Alexion rises on study to test blood disorder drug for COVID-19 ** Clorox Co CLX.N: up 1.8% BUZZ-Clorox: Up as Deutsche Bank expects strong Q3 helped by coronavirus ** Peloton Interative Inc PTON.O: down 3.2% BUZZ-Peloton skids as BMO slaps with first "sell" rating since IPO ** Terex Corp TEX.N: down 4.2% ** Manitowoc Company Inc MTW.N: down 3.4% BUZZ-GS removes Terex and Manitowoc from "buy list", downgrades to "neutral" ** Anixa Biosciences Inc ANIX.O: up 10.6% BUZZ-Anixa Biosciences: Rises on partnership for potential treatment of COVID-19 ** Cyclacel Pharmaceutical Inc CYCC.O: up 103.8% BUZZ-Cyclacel: Jumps on deal to study drugs to treat COVID-19 patients ** Boeing Co BA.N: down 4.9% BUZZ-Benchmark sees Boeing cut 787 production by 30%; lowers PT ** Eros International EROS.N: down 0.2% BUZZ-Eros International: Soars after deal to merge with STX Entertainment ** Medpace Holdings Inc MEDP.O: down 0.8% ** ICON Plc ICLR.O: down 0.4% BUZZ-Baird downgrades two contract research organizations on COVID-19 impact ** Xeris Pharmaceutical Inc XERS.O: up 15.1% BUZZ-Xeris Pharma: Rises on positive results from seizure medication study ** United Airlines Holdings Inc UAL.O: down 3.4% BUZZ-United Airlines drops on estimated quarterly loss, dour outlook ** Walt Disney Co DIS.N: down 2.3% BUZZ-Disney: Falls as brokerages move to sidelines citing hit to theme parks ** Cheesecake Factory Inc CAKE.O: up 5.9% BUZZ-Cheesecake Factory: Rises on $200 mln investment from Roark Capital ** Exxon Mobil Corp XOM.N: down 3.0% ** Chevron Corp CVX.N: down 1.8% ** Devon Energy Corp DVN.N: down 0.4% ** Callon Petroleum Co CPE.N: down 3.4% ** Chesapeake Energy Corp CHK.N: down 1.5% ** Occidental Petroleum Corp OXY.N: down 6.1% ** Schlumberger NV SLB.N: flat ** Halliburton Co HAL.N: up 0.1% ** TechnipFMC Plc FTI.N: down 1.4% BUZZ-Oil stocks drop as concerns over rising crude storage weigh on prices BUZZ-Street View: Schlumberger's dividend cut the first step on road to recovery BUZZ-Halliburton: Falls on $1.1 bln impairment charges ** Safe-T Group SFET.O: up 18.2% BUZZ-Safe-T Group: Jumps on upbeat Q1 revenue forecast ** AbbVie Inc ABBV.N: up 1.8% BUZZ-AbbVie Inc: RBC expects rebound in 2021, upgrades to "outperform" ** Facebook Inc FB.O: flat BUZZ-Facebook: Credit Suisse cuts PT as coronavirus impacts ad revenue ** Biogen Inc BIIB.O: up 1.3% BUZZ-Biogen Inc: Alzheimer's drug in focus ahead of Q1, not earnings ** Abbott Laboratories ABT.N: up 3.9% BUZZ-Abbott, Roche to benefit from surging demand for COVID-19 antibody tests - analyst ** DuPont de Nemours Inc DD.N: up 5.5% BUZZ-DuPont: Rises on expectations of stronger Q1 from coronavirus-driven demand ** Co-Diagnostics Inc CODX.O: up 17.4% BUZZ-Co-Diagnostics: Rises on increased U.S. sales of COVID-19 testing kits ** Acadia Healthcare Co Inc ACHC.O: down 0.1% ** Brookdale Senior Living Inc BKD.N: down 3.2% ** Ensign Group Inc ENSG.O: down 0.4% ** Select Medical Holdings Corp SEM.N: down 4.1% BUZZ-Strong headwinds imminent for facility-based health care providers - Analyst ** General Motors Co GM.N: flat ** Ford Motor Co F.N: down 1.7% BUZZ-CS cuts PT on Ford, GM on heavy cash burn in H1 2020 ** Royal Caribbean Cruises Ltd RCL.N: down 3.4% ** Norwegian Cruise Line Holdings Ltd NCLH.N: down 4.9% ** Carnival Corp CCL.N: down 1.4% BUZZ-J.P. Morgan slashes cruise operators' PT on virus impact The 11 major S&P 500 sectors: Communication Services Eikon search string for individual stock moves: STXBZ The Day Ahead newsletter: http://tmsnrt.rs/2ggOmBi The Morning News Call newsletter: http://tmsnrt.rs/2fwPLTh The S&P 500 and the Dow Jones headed lower on Monday following a strong two-week rally as oil prices crashed and investors grew cautious at the start of a week that is likely to bring more dismal quarterly earnings reports and economic data..N At 17:55 ET, the Dow Jones Industrial Average .DJI was down 0.92% at 24,020.4. flat Consumer Discretionary | The top three S&P 500 .PG.INX percentage gainers: ** FLIR Systems Inc , up 14.7% ** Carrier Global Corp , up 6.6% ** Howmet Aerospace Inc , up 6.4% The top three S&P 500 .PL.INX percentage losers: ** L Brands Inc , down 7.5% ** Vornado Realty Trust , down 6.3% ** Occidental Petroleum Corp , down 6% The top three NYSE .PG.N percentage gainers: ** Regional Health Properties Inc , up 36.5% ** Pacer Developed Markets International Cash CWS , up 23.2% ** Montage Resources Corp , up 23% The top three NYSE .PL.N percentage losers: ** Invesco Mortgage Capital Inc , down 22.5% ** Direxion Daily S&P Biotech Bear 3X Shares , down 16.5% ** Independence Contract Drilling Inc , down 11.9% The top three Nasdaq .PG.O percentage gainers: ** Benitec Biopharma Limited , up 107.4% ** Cyclacel Pharmaceuticals Inc , up 103.8% ** Novavax Inc , up 32.9% The top three Nasdaq .PL.O percentage losers: ** Vericity Inc , down 19.5% ** Akazoo SA , down 19% ** Liberty TripAdvisor Holdings Inc , down 17.9% ** Aytu BioScience Inc AYTU.O: up 3.6% BUZZ-Aytu: Rises on gaining exclusive license to potential COVID-19 treatment ** Redhill Biopharma RDHL.O: up 12.5% BUZZ-Redhill Biopharma: Rises on agreement with NIAID to test cancer drug for COVID-19 ** Atossa Therapeutics Inc ATOS.O: up 5.6% BUZZ-Atossa Therapeutics up as co seeks FDA nod to begin COVID-19 study ** Gilead Sciences Inc GILD.O: down 1.3% BUZZ-Gilead: Brokerages downgrade on uncertainty over commercial value of COVID-19 drug ** Seattle Genetics Inc SGEN.O: up 5.1% BUZZ-Street View: Seattle Genetics' breast cancer therapy approval brings some cheer ** Campbell Soup Co CPB.N: up 3.4% BUZZ-Campbell Soup: Rises on strong retail demand ** Incyte Corp INCY.O: up 1.4% BUZZ-Incyte: Touches fresh 2-yr high after FDA approval of cancer therapy ** ViaSat Inc VSAT.O: up 2.5% BUZZ-ViaSat Inc: Rises as brokerage upgrades on higher residential internet demand ** 2U Inc TWOU.O: down 7.4% BUZZ-2U drops ahead of $300 mln convertible debt deal ** Masimo Corp MASI.O: down 0.4% BUZZ-Masimo Corp: Needham downgrades on likely slow 2H20 growth ** Avalon GloboCare Corp AVCO.O: up 7.9% BUZZ-Avalon GloboCare: Rises as therapy shows promise in combating cytokine storm - Reuters News ** Shake Shack Inc SHAK.N: up 5.9% BUZZ-Shake Shack beefs up capital, gives back government loan; shares dip ** Exelixis Inc EXEL.O: up 23.5% BUZZ-Exelixis jumps as cancer drug combo shows promise in study ** AGNC Investment Corp AGNC.O: down 0.5% ** Annaly Capital Management Inc NLY.N: down 1.8% ** Apollo CRE Finance ARI.N: down 4.9% ** Blackstone Mortgage Trust Inc BXMT.N: down 3.1% ** Ladder Capital Corp LADR.N: down 3.4% ** Starwood Property Trust Inc STWD.N: down 3.9% ** TPG RE Finance Trust Inc TRTX.N: down 3.8% BUZZ-U.S. mortgage REITs: DB cuts PT citing "stressed scenarios" ** INmune Bio Inc INMB.O: up 9.3% BUZZ-INmune Bio Inc: Rises on plans to begin COVID-19 trial ** Mustang Bio Inc MBIO.O: up 1.4% BUZZ-Mustang Bio: Rises after EMA's favorable classification of "bubble boy" therapy ** Meredith Corp MDP.N: down 6.5% BUZZ-Meredith Corp: Falls on withdrawing 2020 outlook as ad sales get hit ** Lennox International LII.N: up 2.0% BUZZ-Lennox International: Falls on weak Q1, warns of 20% hit from coronavirus ** Ducommun Inc DCO.N: up 3.6% BUZZ-Ducommun: Jumps as Q1 revenue forecast higher than Wall Street estimates ** Alexion Pharmaceuticals Inc ALXN.O: up 4.9% BUZZ-Alexion rises on study to test blood disorder drug for COVID-19 ** Clorox Co CLX.N: up 1.8% BUZZ-Clorox: Up as Deutsche Bank expects strong Q3 helped by coronavirus ** Peloton Interative Inc PTON.O: down 3.2% BUZZ-Peloton skids as BMO slaps with first "sell" rating since IPO ** Terex Corp TEX.N: down 4.2% ** Manitowoc Company Inc MTW.N: down 3.4% BUZZ-GS removes Terex and Manitowoc from "buy list", downgrades to "neutral" ** Anixa Biosciences Inc ANIX.O: up 10.6% BUZZ-Anixa Biosciences: Rises on partnership for potential treatment of COVID-19 ** Cyclacel Pharmaceutical Inc CYCC.O: up 103.8% BUZZ-Cyclacel: Jumps on deal to study drugs to treat COVID-19 patients ** Boeing Co BA.N: down 4.9% BUZZ-Benchmark sees Boeing cut 787 production by 30%; lowers PT ** Eros International EROS.N: down 0.2% BUZZ-Eros International: Soars after deal to merge with STX Entertainment ** Medpace Holdings Inc MEDP.O: down 0.8% ** ICON Plc ICLR.O: down 0.4% BUZZ-Baird downgrades two contract research organizations on COVID-19 impact ** Xeris Pharmaceutical Inc XERS.O: up 15.1% BUZZ-Xeris Pharma: Rises on positive results from seizure medication study ** United Airlines Holdings Inc UAL.O: down 3.4% BUZZ-United Airlines drops on estimated quarterly loss, dour outlook ** Walt Disney Co DIS.N: down 2.3% BUZZ-Disney: Falls as brokerages move to sidelines citing hit to theme parks ** Cheesecake Factory Inc CAKE.O: up 5.9% BUZZ-Cheesecake Factory: Rises on $200 mln investment from Roark Capital ** Exxon Mobil Corp XOM.N: down 3.0% ** Chevron Corp CVX.N: down 1.8% ** Devon Energy Corp DVN.N: down 0.4% ** Callon Petroleum Co CPE.N: down 3.4% ** Chesapeake Energy Corp CHK.N: down 1.5% ** Occidental Petroleum Corp OXY.N: down 6.1% ** Schlumberger NV SLB.N: flat ** Halliburton Co HAL.N: up 0.1% ** TechnipFMC Plc FTI.N: down 1.4% BUZZ-Oil stocks drop as concerns over rising crude storage weigh on prices BUZZ-Street View: Schlumberger's dividend cut the first step on road to recovery BUZZ-Halliburton: Falls on $1.1 bln impairment charges ** Safe-T Group SFET.O: up 18.2% BUZZ-Safe-T Group: Jumps on upbeat Q1 revenue forecast ** AbbVie Inc ABBV.N: up 1.8% BUZZ-AbbVie Inc: RBC expects rebound in 2021, upgrades to "outperform" ** Facebook Inc FB.O: flat BUZZ-Facebook: Credit Suisse cuts PT as coronavirus impacts ad revenue ** Biogen Inc BIIB.O: up 1.3% BUZZ-Biogen Inc: Alzheimer's drug in focus ahead of Q1, not earnings ** Abbott Laboratories ABT.N: up 3.9% BUZZ-Abbott, Roche to benefit from surging demand for COVID-19 antibody tests - analyst ** DuPont de Nemours Inc DD.N: up 5.5% BUZZ-DuPont: Rises on expectations of stronger Q1 from coronavirus-driven demand ** Co-Diagnostics Inc CODX.O: up 17.4% BUZZ-Co-Diagnostics: Rises on increased U.S. sales of COVID-19 testing kits ** Acadia Healthcare Co Inc ACHC.O: down 0.1% ** Brookdale Senior Living Inc BKD.N: down 3.2% ** Ensign Group Inc ENSG.O: down 0.4% ** Select Medical Holdings Corp SEM.N: down 4.1% BUZZ-Strong headwinds imminent for facility-based health care providers - Analyst ** General Motors Co GM.N: flat ** Ford Motor Co F.N: down 1.7% BUZZ-CS cuts PT on Ford, GM on heavy cash burn in H1 2020 ** Royal Caribbean Cruises Ltd RCL.N: down 3.4% ** Norwegian Cruise Line Holdings Ltd NCLH.N: down 4.9% ** Carnival Corp CCL.N: down 1.4% BUZZ-J.P. Morgan slashes cruise operators' PT on virus impact The 11 major S&P 500 sectors: Communication Services down 1.01% Information Technology down 0.52% Real Estate | The top three S&P 500 .PG.INX percentage gainers: ** FLIR Systems Inc , up 14.7% ** Carrier Global Corp , up 6.6% ** Howmet Aerospace Inc , up 6.4% The top three S&P 500 .PL.INX percentage losers: ** L Brands Inc , down 7.5% ** Vornado Realty Trust , down 6.3% ** Occidental Petroleum Corp , down 6% The top three NYSE .PG.N percentage gainers: ** Regional Health Properties Inc , up 36.5% ** Pacer Developed Markets International Cash CWS , up 23.2% ** Montage Resources Corp , up 23% The top three NYSE .PL.N percentage losers: ** Invesco Mortgage Capital Inc , down 22.5% ** Direxion Daily S&P Biotech Bear 3X Shares , down 16.5% ** Independence Contract Drilling Inc , down 11.9% The top three Nasdaq .PG.O percentage gainers: ** Benitec Biopharma Limited , up 107.4% ** Cyclacel Pharmaceuticals Inc , up 103.8% ** Novavax Inc , up 32.9% The top three Nasdaq .PL.O percentage losers: ** Vericity Inc , down 19.5% ** Akazoo SA , down 19% ** Liberty TripAdvisor Holdings Inc , down 17.9% ** Aytu BioScience Inc AYTU.O: up 3.6% BUZZ-Aytu: Rises on gaining exclusive license to potential COVID-19 treatment ** Redhill Biopharma RDHL.O: up 12.5% BUZZ-Redhill Biopharma: Rises on agreement with NIAID to test cancer drug for COVID-19 ** Atossa Therapeutics Inc ATOS.O: up 5.6% BUZZ-Atossa Therapeutics up as co seeks FDA nod to begin COVID-19 study ** Gilead Sciences Inc GILD.O: down 1.3% BUZZ-Gilead: Brokerages downgrade on uncertainty over commercial value of COVID-19 drug ** Seattle Genetics Inc SGEN.O: up 5.1% BUZZ-Street View: Seattle Genetics' breast cancer therapy approval brings some cheer ** Campbell Soup Co CPB.N: up 3.4% BUZZ-Campbell Soup: Rises on strong retail demand ** Incyte Corp INCY.O: up 1.4% BUZZ-Incyte: Touches fresh 2-yr high after FDA approval of cancer therapy ** ViaSat Inc VSAT.O: up 2.5% BUZZ-ViaSat Inc: Rises as brokerage upgrades on higher residential internet demand ** 2U Inc TWOU.O: down 7.4% BUZZ-2U drops ahead of $300 mln convertible debt deal ** Masimo Corp MASI.O: down 0.4% BUZZ-Masimo Corp: Needham downgrades on likely slow 2H20 growth ** Avalon GloboCare Corp AVCO.O: up 7.9% BUZZ-Avalon GloboCare: Rises as therapy shows promise in combating cytokine storm - Reuters News ** Shake Shack Inc SHAK.N: up 5.9% BUZZ-Shake Shack beefs up capital, gives back government loan; shares dip ** Exelixis Inc EXEL.O: up 23.5% BUZZ-Exelixis jumps as cancer drug combo shows promise in study ** AGNC Investment Corp AGNC.O: down 0.5% ** Annaly Capital Management Inc NLY.N: down 1.8% ** Apollo CRE Finance ARI.N: down 4.9% ** Blackstone Mortgage Trust Inc BXMT.N: down 3.1% ** Ladder Capital Corp LADR.N: down 3.4% ** Starwood Property Trust Inc STWD.N: down 3.9% ** TPG RE Finance Trust Inc TRTX.N: down 3.8% BUZZ-U.S. mortgage REITs: DB cuts PT citing "stressed scenarios" ** INmune Bio Inc INMB.O: up 9.3% BUZZ-INmune Bio Inc: Rises on plans to begin COVID-19 trial ** Mustang Bio Inc MBIO.O: up 1.4% BUZZ-Mustang Bio: Rises after EMA's favorable classification of "bubble boy" therapy ** Meredith Corp MDP.N: down 6.5% BUZZ-Meredith Corp: Falls on withdrawing 2020 outlook as ad sales get hit ** Lennox International LII.N: up 2.0% BUZZ-Lennox International: Falls on weak Q1, warns of 20% hit from coronavirus ** Ducommun Inc DCO.N: up 3.6% BUZZ-Ducommun: Jumps as Q1 revenue forecast higher than Wall Street estimates ** Alexion Pharmaceuticals Inc ALXN.O: up 4.9% BUZZ-Alexion rises on study to test blood disorder drug for COVID-19 ** Clorox Co CLX.N: up 1.8% BUZZ-Clorox: Up as Deutsche Bank expects strong Q3 helped by coronavirus ** Peloton Interative Inc PTON.O: down 3.2% BUZZ-Peloton skids as BMO slaps with first "sell" rating since IPO ** Terex Corp TEX.N: down 4.2% ** Manitowoc Company Inc MTW.N: down 3.4% BUZZ-GS removes Terex and Manitowoc from "buy list", downgrades to "neutral" ** Anixa Biosciences Inc ANIX.O: up 10.6% BUZZ-Anixa Biosciences: Rises on partnership for potential treatment of COVID-19 ** Cyclacel Pharmaceutical Inc CYCC.O: up 103.8% BUZZ-Cyclacel: Jumps on deal to study drugs to treat COVID-19 patients ** Boeing Co BA.N: down 4.9% BUZZ-Benchmark sees Boeing cut 787 production by 30%; lowers PT ** Eros International EROS.N: down 0.2% BUZZ-Eros International: Soars after deal to merge with STX Entertainment ** Medpace Holdings Inc MEDP.O: down 0.8% ** ICON Plc ICLR.O: down 0.4% BUZZ-Baird downgrades two contract research organizations on COVID-19 impact ** Xeris Pharmaceutical Inc XERS.O: up 15.1% BUZZ-Xeris Pharma: Rises on positive results from seizure medication study ** United Airlines Holdings Inc UAL.O: down 3.4% BUZZ-United Airlines drops on estimated quarterly loss, dour outlook ** Walt Disney Co DIS.N: down 2.3% BUZZ-Disney: Falls as brokerages move to sidelines citing hit to theme parks ** Cheesecake Factory Inc CAKE.O: up 5.9% BUZZ-Cheesecake Factory: Rises on $200 mln investment from Roark Capital ** Exxon Mobil Corp XOM.N: down 3.0% ** Chevron Corp CVX.N: down 1.8% ** Devon Energy Corp DVN.N: down 0.4% ** Callon Petroleum Co CPE.N: down 3.4% ** Chesapeake Energy Corp CHK.N: down 1.5% ** Occidental Petroleum Corp OXY.N: down 6.1% ** Schlumberger NV SLB.N: flat ** Halliburton Co HAL.N: up 0.1% ** TechnipFMC Plc FTI.N: down 1.4% BUZZ-Oil stocks drop as concerns over rising crude storage weigh on prices BUZZ-Street View: Schlumberger's dividend cut the first step on road to recovery BUZZ-Halliburton: Falls on $1.1 bln impairment charges ** Safe-T Group SFET.O: up 18.2% BUZZ-Safe-T Group: Jumps on upbeat Q1 revenue forecast ** AbbVie Inc ABBV.N: up 1.8% BUZZ-AbbVie Inc: RBC expects rebound in 2021, upgrades to "outperform" ** Facebook Inc FB.O: flat BUZZ-Facebook: Credit Suisse cuts PT as coronavirus impacts ad revenue ** Biogen Inc BIIB.O: up 1.3% BUZZ-Biogen Inc: Alzheimer's drug in focus ahead of Q1, not earnings ** Abbott Laboratories ABT.N: up 3.9% BUZZ-Abbott, Roche to benefit from surging demand for COVID-19 antibody tests - analyst ** DuPont de Nemours Inc DD.N: up 5.5% BUZZ-DuPont: Rises on expectations of stronger Q1 from coronavirus-driven demand ** Co-Diagnostics Inc CODX.O: up 17.4% BUZZ-Co-Diagnostics: Rises on increased U.S. sales of COVID-19 testing kits ** Acadia Healthcare Co Inc ACHC.O: down 0.1% ** Brookdale Senior Living Inc BKD.N: down 3.2% ** Ensign Group Inc ENSG.O: down 0.4% ** Select Medical Holdings Corp SEM.N: down 4.1% BUZZ-Strong headwinds imminent for facility-based health care providers - Analyst ** General Motors Co GM.N: flat ** Ford Motor Co F.N: down 1.7% BUZZ-CS cuts PT on Ford, GM on heavy cash burn in H1 2020 ** Royal Caribbean Cruises Ltd RCL.N: down 3.4% ** Norwegian Cruise Line Holdings Ltd NCLH.N: down 4.9% ** Carnival Corp CCL.N: down 1.4% BUZZ-J.P. Morgan slashes cruise operators' PT on virus impact The 11 major S&P 500 sectors: Communication Services Eikon search string for individual stock moves: STXBZ The Day Ahead newsletter: http://tmsnrt.rs/2ggOmBi The Morning News Call newsletter: http://tmsnrt.rs/2fwPLTh The S&P 500 and the Dow Jones headed lower on Monday following a strong two-week rally as oil prices crashed and investors grew cautious at the start of a week that is likely to bring more dismal quarterly earnings reports and economic data..N At 17:55 ET, the Dow Jones Industrial Average .DJI was down 0.92% at 24,020.4. The S&P 500 .SPX was down 0.33% at 2,865.2 and the Nasdaq Composite .IXIC was up 0.30% at 8,676.165. |
24613.0 | 2020-04-20 00:00:00 UTC | BUZZ-U.S. STOCKS ON THE MOVE-DuPont, Occidental Petroleum, Safe-T Group | ABBV | https://www.nasdaq.com/articles/buzz-u.s.-stocks-on-the-move-dupont-occidental-petroleum-safe-t-group-2020-04-20 | nan | nan | Eikon search string for individual stock moves: STXBZ
The Day Ahead newsletter: http://tmsnrt.rs/2ggOmBi
The Morning News Call newsletter: http://tmsnrt.rs/2fwPLTh
A slide in energy stocks weighed on Wall Street on Monday as crude prices crashed at the start of a week packed with quarterly earnings reports and economic data likely to underline the damage from the coronavirus outbreak..N
At 16:05 ET, the Dow Jones Industrial Average .DJI was down 0.94% at 24,014.95. The S&P 500 .SPX was down 0.65% at 2,855.74 and the Nasdaq Composite .IXIC was up 0.13% at 8,661.651. The top three S&P 500 .PG.INX percentage gainers: ** FLIR Systems Inc , up 14.1% ** Carrier Global Corp , up 6.6% ** DuPont de Nemours Inc, up 5% The top three S&P 500 .PL.INX percentage losers: ** Vornado Realty Trust , down 4.9% ** Lennar Corporation , down 4.7% ** Occidental Petroleum Corp , down 4.7% The top three NYSE .PG.N percentage gainers: ** Regional Health Properties Inc , up 41.6% ** Montage Resources Corp , up 26.8% ** Build-A-Bear Workshop Inc , up 26.2% The top three NYSE .PL.N percentage losers: ** Invesco Mortgage Capital Inc , down 19.5% ** Direxion Daily S&P Biotech Bear 3X Shares , down 13% ** Manning & Napier Inc , down 12.7% The top three Nasdaq .PG.O percentage gainers: ** Cyclacel Pharmaceuticals Inc , up 89.5% ** American Virtual Cloud Technologies Inc , up 43.8% ** Benitec Biopharma Limited , up 42.9% The top three Nasdaq .PL.O percentage losers: ** Liberty TripAdvisor Holdings Inc , down 18.4% ** BiondVax Pharmaceuticals Equity Warrants , down 15% ** Green Plains Partners LP , down 14% ** Avalon GloboCare Corp AVCO.O: up 12.9%
BUZZ-Avalon GloboCare: Rises as therapy shows promise in combating cytokine storm ** Shake Shack Inc SHAK.N: up 6.3%
BUZZ-Shake Shack beefs up capital, gives back government loan ** Exelixis Inc EXEL.O: up 25.5%
BUZZ-Exelixis jumps as cancer drug combo shows promise in study ** AGNC Investment Corp AGNC.O: up 0.1% ** Annaly Capital Management Inc NLY.N: up 0.2% ** Apollo CRE Finance ARI.N: down 3.7% ** Blackstone Mortgage Trust Inc BXMT.N: down 3.0% ** Ladder Capital Corp LADR.N: flat ** Starwood Property Trust Inc STWD.N: down 2.1% ** TPG RE Finance Trust Inc TRTX.N: down 3.0%
BUZZ-U.S. mortgage REITs: DB cuts PT citing "stressed scenarios" ** INmune Bio Inc INMB.O: up 7.1%
BUZZ-INmune Bio Inc: Rises on plans to begin COVID-19 trial ** Mustang Bio Inc MBIO.O: up 2.4%
BUZZ-Mustang Bio: Rises after EMA's favorable classification of "bubble boy" therapy ** Meredith Corp MDP.N: down 9.7%
BUZZ-Meredith Corp: Falls on withdrawing 2020 outlook as ad sales get hit ** Ducommun Inc DCO.N: up 4.6%
BUZZ-Ducommun: Jumps as Q1 revenue forecast higher than Wall Street estimates ** Alexion Pharmaceuticals Inc ALXN.O: up 4.4%
BUZZ-Alexion rises on study to test blood disorder drug for COVID-19 ** Clorox Co CLX.N: up 1.9%
BUZZ-Clorox: Up as Deutsche Bank expects strong Q3 helped by coronavirus ** Peloton Interative Inc PTON.O: down 4.5%
BUZZ-Peloton skids as BMO slaps first "sell" rating since IPO ** Terex Corp TEX.N: down 4.7% ** Manitowoc Company Inc MTW.N: down 2.5%
BUZZ-GS removes Terex and Manitowoc from "buy list", downgrades to "neutral" ** Anixa Biosciences Inc ANIX.O: up 11.6% BUZZ-Anixa Biosciences: Rises on partnership for potential treatment of COVID-19 ** Cyclacel Pharmaceutical Inc CYCC.O: up 89.5% BUZZ-Cyclacel: Jumps on deal to study drugs to treat COVID-19 patients ** Boeing Co BA.N: down 3.1% BUZZ-Benchmark sees Boeing cut 787 production by 30%; lowers PT ** Eros International EROS.N: up 9.0% BUZZ-Eros International: Soars after deal to merge with STX Entertainment ** Medpace Holdings Inc MEDP.O: down 1.9% ** ICON Plc ICLR.O: up 0.1% BUZZ-Baird downgrades two contract research organizations on COVID-19 impact ** Xeris Pharmaceutical Inc XERS.O: up 10.2% BUZZ-Xeris Pharma: Rises on positive results from seizure medication study ** United Airlines Holdings Inc UAL.O: down 3.2% BUZZ-United Airlines drops on estimated quarterly loss, dour outlook ** Walt Disney Co DIS.N: down 2.8% BUZZ-Disney: Falls as brokerages move to sidelines citing hit to theme parks ** Cheesecake Factory Inc CAKE.O: up 7.6% BUZZ-Cheesecake Factory: Rises on $200 mln investment from Roark Capital ** Exxon Mobil Corp XOM.N: down 2.2% ** Chevron Corp CVX.N: down 1.0% ** Devon Energy Corp DVN.N: up 1.1% ** Callon Petroleum Co CPE.N: down 2.5% ** Chesapeake Energy Corp CHK.N: down 1.0% ** Occidental Petroleum Corp OXY.N: down 4.8% ** Schlumberger NV SLB.N: up 0.4% ** Halliburton Co HAL.N: up 3.5% ** TechnipFMC Plc FTI.N: down 0.5% BUZZ-Oil stocks drop as concerns over rising crude storage weigh on prices BUZZ-Street View: Schlumberger's dividend cut the first step on road to recovery BUZZ-Halliburton: Falls on $1.1 bln impairment charges ** Safe-T Group SFET.O: up 17.6% BUZZ-Safe-T Group: Jumps on upbeat Q1 revenue forecast ** AbbVie Inc ABBV.N: up 0.3% BUZZ-AbbVie Inc: RBC expects rebound in 2021, upgrades to "outperform" ** Facebook Inc FB.O: up 0.3% BUZZ-Facebook: Credit Suisse cuts PT as coronavirus impacts ad revenue ** Biogen Inc BIIB.O: up 1.5% BUZZ-Biogen Inc: Alzheimer's drug in focus ahead of Q1, not earnings ** Abbott Laboratories ABT.N: up 1.0% BUZZ-Abbott, Roche to benefit from surging demand for COVID-19 antibody tests - analyst ** DuPont de Nemours Inc DD.N: up 5.0% BUZZ-DuPont: Rises on expectations of stronger Q1 from coronavirus-driven demand ** Co-Diagnostics Inc CODX.O: up 13.8% BUZZ-Co-Diagnostics: Rises on increased U.S. sales of COVID-19 testing kits ** Acadia Healthcare Co Inc ACHC.O: up 0.4% ** Brookdale Senior Living Inc BKD.N: down 1.8% ** Ensign Group Inc ENSG.O: down 1.2% ** Select Medical Holdings Corp SEM.N: down 3.6% BUZZ-Strong headwinds imminent for facility-based health care providers - Analyst ** General Motors Co GM.N: down 0.3% ** Ford Motor Co F.N: down 1.2% BUZZ-CS cuts PT on Ford, GM on heavy cash burn in H1 2020 ** Royal Caribbean Cruises Ltd RCL.N: down 1.6% ** Norwegian Cruise Line Holdings Ltd NCLH.N: down 2.7% ** Carnival Corp CCL.N: down 1.4% BUZZ-J.P. Morgan slashes cruise operators' PT on virus impact
The 11 major S&P 500 sectors:
Communication Services
.SPLRCL
down 0.15%
Consumer Discretionary
.SPLRCD
up 0.32%
Consumer Staples
.SPLRCS
down 0.63%
Energy
.SPNY
down 0.82%
Financial
.SPSY
down 0.67%
Health
.SPXHC
down 0.29%
Industrial
.SPLRCI
down 1.05%
Information Technology
.SPLRCT
down 0.55%
Materials
.SPLRCM
down 0.60%
Real Estate
.SPLRCR
down 2.25%
Utilities
.SPLRCU
down 1.98%
(Compiled by Amal S in Bengaluru)
((Amal.S@thomsonreuters.com; within U.S.+1 646 223 8780; outside U.S. +91 80 6749 3677;))
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | The top three S&P 500 .PG.INX percentage gainers: ** FLIR Systems Inc , up 14.1% ** Carrier Global Corp , up 6.6% ** DuPont de Nemours Inc, up 5% The top three S&P 500 .PL.INX percentage losers: ** Vornado Realty Trust , down 4.9% ** Lennar Corporation , down 4.7% ** Occidental Petroleum Corp , down 4.7% The top three NYSE .PG.N percentage gainers: ** Regional Health Properties Inc , up 41.6% ** Montage Resources Corp , up 26.8% ** Build-A-Bear Workshop Inc , up 26.2% The top three NYSE .PL.N percentage losers: ** Invesco Mortgage Capital Inc , down 19.5% ** Direxion Daily S&P Biotech Bear 3X Shares , down 13% ** Manning & Napier Inc , down 12.7% The top three Nasdaq .PG.O percentage gainers: ** Cyclacel Pharmaceuticals Inc , up 89.5% ** American Virtual Cloud Technologies Inc , up 43.8% ** Benitec Biopharma Limited , up 42.9% The top three Nasdaq .PL.O percentage losers: ** Liberty TripAdvisor Holdings Inc , down 18.4% ** BiondVax Pharmaceuticals Equity Warrants , down 15% ** Green Plains Partners LP , down 14% ** Avalon GloboCare Corp AVCO.O: up 12.9% BUZZ-Avalon GloboCare: Rises as therapy shows promise in combating cytokine storm ** Shake Shack Inc SHAK.N: up 6.3% BUZZ-Shake Shack beefs up capital, gives back government loan ** Exelixis Inc EXEL.O: up 25.5% BUZZ-Exelixis jumps as cancer drug combo shows promise in study ** AGNC Investment Corp AGNC.O: up 0.1% ** Annaly Capital Management Inc NLY.N: up 0.2% ** Apollo CRE Finance ARI.N: down 3.7% ** Blackstone Mortgage Trust Inc BXMT.N: down 3.0% ** Ladder Capital Corp LADR.N: flat ** Starwood Property Trust Inc STWD.N: down 2.1% ** TPG RE Finance Trust Inc TRTX.N: down 3.0% BUZZ-U.S. mortgage REITs: DB cuts PT citing "stressed scenarios" ** INmune Bio Inc INMB.O: up 7.1% BUZZ-INmune Bio Inc: Rises on plans to begin COVID-19 trial ** Mustang Bio Inc MBIO.O: up 2.4% BUZZ-Mustang Bio: Rises after EMA's favorable classification of "bubble boy" therapy ** Meredith Corp MDP.N: down 9.7% BUZZ-Meredith Corp: Falls on withdrawing 2020 outlook as ad sales get hit ** Ducommun Inc DCO.N: up 4.6% BUZZ-Ducommun: Jumps as Q1 revenue forecast higher than Wall Street estimates ** Alexion Pharmaceuticals Inc ALXN.O: up 4.4% BUZZ-Alexion rises on study to test blood disorder drug for COVID-19 ** Clorox Co CLX.N: up 1.9% BUZZ-Clorox: Up as Deutsche Bank expects strong Q3 helped by coronavirus ** Peloton Interative Inc PTON.O: down 4.5% BUZZ-Peloton skids as BMO slaps first "sell" rating since IPO ** Terex Corp TEX.N: down 4.7% ** Manitowoc Company Inc MTW.N: down 2.5% BUZZ-GS removes Terex and Manitowoc from "buy list", downgrades to "neutral" ** Anixa Biosciences Inc ANIX.O: up 11.6% BUZZ-Anixa Biosciences: Rises on partnership for potential treatment of COVID-19 ** Cyclacel Pharmaceutical Inc CYCC.O: up 89.5% BUZZ-Cyclacel: Jumps on deal to study drugs to treat COVID-19 patients ** Boeing Co BA.N: down 3.1% BUZZ-Benchmark sees Boeing cut 787 production by 30%; lowers PT ** Eros International EROS.N: up 9.0% BUZZ-Eros International: Soars after deal to merge with STX Entertainment ** Medpace Holdings Inc MEDP.O: down 1.9% ** ICON Plc ICLR.O: up 0.1% BUZZ-Baird downgrades two contract research organizations on COVID-19 impact ** Xeris Pharmaceutical Inc XERS.O: up 10.2% BUZZ-Xeris Pharma: Rises on positive results from seizure medication study ** United Airlines Holdings Inc UAL.O: down 3.2% BUZZ-United Airlines drops on estimated quarterly loss, dour outlook ** Walt Disney Co DIS.N: down 2.8% BUZZ-Disney: Falls as brokerages move to sidelines citing hit to theme parks ** Cheesecake Factory Inc CAKE.O: up 7.6% BUZZ-Cheesecake Factory: Rises on $200 mln investment from Roark Capital ** Exxon Mobil Corp XOM.N: down 2.2% ** Chevron Corp CVX.N: down 1.0% ** Devon Energy Corp DVN.N: up 1.1% ** Callon Petroleum Co CPE.N: down 2.5% ** Chesapeake Energy Corp CHK.N: down 1.0% ** Occidental Petroleum Corp OXY.N: down 4.8% ** Schlumberger NV SLB.N: up 0.4% ** Halliburton Co HAL.N: up 3.5% ** TechnipFMC Plc FTI.N: down 0.5% BUZZ-Oil stocks drop as concerns over rising crude storage weigh on prices BUZZ-Street View: Schlumberger's dividend cut the first step on road to recovery BUZZ-Halliburton: Falls on $1.1 bln impairment charges ** Safe-T Group SFET.O: up 17.6% BUZZ-Safe-T Group: Jumps on upbeat Q1 revenue forecast ** AbbVie Inc ABBV.N: up 0.3% BUZZ-AbbVie Inc: RBC expects rebound in 2021, upgrades to "outperform" ** Facebook Inc FB.O: up 0.3% BUZZ-Facebook: Credit Suisse cuts PT as coronavirus impacts ad revenue ** Biogen Inc BIIB.O: up 1.5% BUZZ-Biogen Inc: Alzheimer's drug in focus ahead of Q1, not earnings ** Abbott Laboratories ABT.N: up 1.0% BUZZ-Abbott, Roche to benefit from surging demand for COVID-19 antibody tests - analyst ** DuPont de Nemours Inc DD.N: up 5.0% BUZZ-DuPont: Rises on expectations of stronger Q1 from coronavirus-driven demand ** Co-Diagnostics Inc CODX.O: up 13.8% BUZZ-Co-Diagnostics: Rises on increased U.S. sales of COVID-19 testing kits ** Acadia Healthcare Co Inc ACHC.O: up 0.4% ** Brookdale Senior Living Inc BKD.N: down 1.8% ** Ensign Group Inc ENSG.O: down 1.2% ** Select Medical Holdings Corp SEM.N: down 3.6% BUZZ-Strong headwinds imminent for facility-based health care providers - Analyst ** General Motors Co GM.N: down 0.3% ** Ford Motor Co F.N: down 1.2% BUZZ-CS cuts PT on Ford, GM on heavy cash burn in H1 2020 ** Royal Caribbean Cruises Ltd RCL.N: down 1.6% ** Norwegian Cruise Line Holdings Ltd NCLH.N: down 2.7% ** Carnival Corp CCL.N: down 1.4% BUZZ-J.P. Morgan slashes cruise operators' PT on virus impact The 11 major S&P 500 sectors: Communication Services Eikon search string for individual stock moves: STXBZ The Day Ahead newsletter: http://tmsnrt.rs/2ggOmBi The Morning News Call newsletter: http://tmsnrt.rs/2fwPLTh A slide in energy stocks weighed on Wall Street on Monday as crude prices crashed at the start of a week packed with quarterly earnings reports and economic data likely to underline the damage from the coronavirus outbreak..N At 16:05 ET, the Dow Jones Industrial Average .DJI was down 0.94% at 24,014.95. down 1.98% (Compiled by Amal S in Bengaluru) ((Amal.S@thomsonreuters.com; within U.S.+1 646 223 8780; outside U.S. +91 80 6749 3677;)) The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | The top three S&P 500 .PG.INX percentage gainers: ** FLIR Systems Inc , up 14.1% ** Carrier Global Corp , up 6.6% ** DuPont de Nemours Inc, up 5% The top three S&P 500 .PL.INX percentage losers: ** Vornado Realty Trust , down 4.9% ** Lennar Corporation , down 4.7% ** Occidental Petroleum Corp , down 4.7% The top three NYSE .PG.N percentage gainers: ** Regional Health Properties Inc , up 41.6% ** Montage Resources Corp , up 26.8% ** Build-A-Bear Workshop Inc , up 26.2% The top three NYSE .PL.N percentage losers: ** Invesco Mortgage Capital Inc , down 19.5% ** Direxion Daily S&P Biotech Bear 3X Shares , down 13% ** Manning & Napier Inc , down 12.7% The top three Nasdaq .PG.O percentage gainers: ** Cyclacel Pharmaceuticals Inc , up 89.5% ** American Virtual Cloud Technologies Inc , up 43.8% ** Benitec Biopharma Limited , up 42.9% The top three Nasdaq .PL.O percentage losers: ** Liberty TripAdvisor Holdings Inc , down 18.4% ** BiondVax Pharmaceuticals Equity Warrants , down 15% ** Green Plains Partners LP , down 14% ** Avalon GloboCare Corp AVCO.O: up 12.9% BUZZ-Avalon GloboCare: Rises as therapy shows promise in combating cytokine storm ** Shake Shack Inc SHAK.N: up 6.3% BUZZ-Shake Shack beefs up capital, gives back government loan ** Exelixis Inc EXEL.O: up 25.5% BUZZ-Exelixis jumps as cancer drug combo shows promise in study ** AGNC Investment Corp AGNC.O: up 0.1% ** Annaly Capital Management Inc NLY.N: up 0.2% ** Apollo CRE Finance ARI.N: down 3.7% ** Blackstone Mortgage Trust Inc BXMT.N: down 3.0% ** Ladder Capital Corp LADR.N: flat ** Starwood Property Trust Inc STWD.N: down 2.1% ** TPG RE Finance Trust Inc TRTX.N: down 3.0% BUZZ-U.S. mortgage REITs: DB cuts PT citing "stressed scenarios" ** INmune Bio Inc INMB.O: up 7.1% BUZZ-INmune Bio Inc: Rises on plans to begin COVID-19 trial ** Mustang Bio Inc MBIO.O: up 2.4% BUZZ-Mustang Bio: Rises after EMA's favorable classification of "bubble boy" therapy ** Meredith Corp MDP.N: down 9.7% BUZZ-Meredith Corp: Falls on withdrawing 2020 outlook as ad sales get hit ** Ducommun Inc DCO.N: up 4.6% BUZZ-Ducommun: Jumps as Q1 revenue forecast higher than Wall Street estimates ** Alexion Pharmaceuticals Inc ALXN.O: up 4.4% BUZZ-Alexion rises on study to test blood disorder drug for COVID-19 ** Clorox Co CLX.N: up 1.9% BUZZ-Clorox: Up as Deutsche Bank expects strong Q3 helped by coronavirus ** Peloton Interative Inc PTON.O: down 4.5% BUZZ-Peloton skids as BMO slaps first "sell" rating since IPO ** Terex Corp TEX.N: down 4.7% ** Manitowoc Company Inc MTW.N: down 2.5% BUZZ-GS removes Terex and Manitowoc from "buy list", downgrades to "neutral" ** Anixa Biosciences Inc ANIX.O: up 11.6% BUZZ-Anixa Biosciences: Rises on partnership for potential treatment of COVID-19 ** Cyclacel Pharmaceutical Inc CYCC.O: up 89.5% BUZZ-Cyclacel: Jumps on deal to study drugs to treat COVID-19 patients ** Boeing Co BA.N: down 3.1% BUZZ-Benchmark sees Boeing cut 787 production by 30%; lowers PT ** Eros International EROS.N: up 9.0% BUZZ-Eros International: Soars after deal to merge with STX Entertainment ** Medpace Holdings Inc MEDP.O: down 1.9% ** ICON Plc ICLR.O: up 0.1% BUZZ-Baird downgrades two contract research organizations on COVID-19 impact ** Xeris Pharmaceutical Inc XERS.O: up 10.2% BUZZ-Xeris Pharma: Rises on positive results from seizure medication study ** United Airlines Holdings Inc UAL.O: down 3.2% BUZZ-United Airlines drops on estimated quarterly loss, dour outlook ** Walt Disney Co DIS.N: down 2.8% BUZZ-Disney: Falls as brokerages move to sidelines citing hit to theme parks ** Cheesecake Factory Inc CAKE.O: up 7.6% BUZZ-Cheesecake Factory: Rises on $200 mln investment from Roark Capital ** Exxon Mobil Corp XOM.N: down 2.2% ** Chevron Corp CVX.N: down 1.0% ** Devon Energy Corp DVN.N: up 1.1% ** Callon Petroleum Co CPE.N: down 2.5% ** Chesapeake Energy Corp CHK.N: down 1.0% ** Occidental Petroleum Corp OXY.N: down 4.8% ** Schlumberger NV SLB.N: up 0.4% ** Halliburton Co HAL.N: up 3.5% ** TechnipFMC Plc FTI.N: down 0.5% BUZZ-Oil stocks drop as concerns over rising crude storage weigh on prices BUZZ-Street View: Schlumberger's dividend cut the first step on road to recovery BUZZ-Halliburton: Falls on $1.1 bln impairment charges ** Safe-T Group SFET.O: up 17.6% BUZZ-Safe-T Group: Jumps on upbeat Q1 revenue forecast ** AbbVie Inc ABBV.N: up 0.3% BUZZ-AbbVie Inc: RBC expects rebound in 2021, upgrades to "outperform" ** Facebook Inc FB.O: up 0.3% BUZZ-Facebook: Credit Suisse cuts PT as coronavirus impacts ad revenue ** Biogen Inc BIIB.O: up 1.5% BUZZ-Biogen Inc: Alzheimer's drug in focus ahead of Q1, not earnings ** Abbott Laboratories ABT.N: up 1.0% BUZZ-Abbott, Roche to benefit from surging demand for COVID-19 antibody tests - analyst ** DuPont de Nemours Inc DD.N: up 5.0% BUZZ-DuPont: Rises on expectations of stronger Q1 from coronavirus-driven demand ** Co-Diagnostics Inc CODX.O: up 13.8% BUZZ-Co-Diagnostics: Rises on increased U.S. sales of COVID-19 testing kits ** Acadia Healthcare Co Inc ACHC.O: up 0.4% ** Brookdale Senior Living Inc BKD.N: down 1.8% ** Ensign Group Inc ENSG.O: down 1.2% ** Select Medical Holdings Corp SEM.N: down 3.6% BUZZ-Strong headwinds imminent for facility-based health care providers - Analyst ** General Motors Co GM.N: down 0.3% ** Ford Motor Co F.N: down 1.2% BUZZ-CS cuts PT on Ford, GM on heavy cash burn in H1 2020 ** Royal Caribbean Cruises Ltd RCL.N: down 1.6% ** Norwegian Cruise Line Holdings Ltd NCLH.N: down 2.7% ** Carnival Corp CCL.N: down 1.4% BUZZ-J.P. Morgan slashes cruise operators' PT on virus impact The 11 major S&P 500 sectors: Communication Services Eikon search string for individual stock moves: STXBZ The Day Ahead newsletter: http://tmsnrt.rs/2ggOmBi The Morning News Call newsletter: http://tmsnrt.rs/2fwPLTh A slide in energy stocks weighed on Wall Street on Monday as crude prices crashed at the start of a week packed with quarterly earnings reports and economic data likely to underline the damage from the coronavirus outbreak..N At 16:05 ET, the Dow Jones Industrial Average .DJI was down 0.94% at 24,014.95. down 1.98% (Compiled by Amal S in Bengaluru) ((Amal.S@thomsonreuters.com; within U.S.+1 646 223 8780; outside U.S. +91 80 6749 3677;)) The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | The top three S&P 500 .PG.INX percentage gainers: ** FLIR Systems Inc , up 14.1% ** Carrier Global Corp , up 6.6% ** DuPont de Nemours Inc, up 5% The top three S&P 500 .PL.INX percentage losers: ** Vornado Realty Trust , down 4.9% ** Lennar Corporation , down 4.7% ** Occidental Petroleum Corp , down 4.7% The top three NYSE .PG.N percentage gainers: ** Regional Health Properties Inc , up 41.6% ** Montage Resources Corp , up 26.8% ** Build-A-Bear Workshop Inc , up 26.2% The top three NYSE .PL.N percentage losers: ** Invesco Mortgage Capital Inc , down 19.5% ** Direxion Daily S&P Biotech Bear 3X Shares , down 13% ** Manning & Napier Inc , down 12.7% The top three Nasdaq .PG.O percentage gainers: ** Cyclacel Pharmaceuticals Inc , up 89.5% ** American Virtual Cloud Technologies Inc , up 43.8% ** Benitec Biopharma Limited , up 42.9% The top three Nasdaq .PL.O percentage losers: ** Liberty TripAdvisor Holdings Inc , down 18.4% ** BiondVax Pharmaceuticals Equity Warrants , down 15% ** Green Plains Partners LP , down 14% ** Avalon GloboCare Corp AVCO.O: up 12.9% BUZZ-Avalon GloboCare: Rises as therapy shows promise in combating cytokine storm ** Shake Shack Inc SHAK.N: up 6.3% BUZZ-Shake Shack beefs up capital, gives back government loan ** Exelixis Inc EXEL.O: up 25.5% BUZZ-Exelixis jumps as cancer drug combo shows promise in study ** AGNC Investment Corp AGNC.O: up 0.1% ** Annaly Capital Management Inc NLY.N: up 0.2% ** Apollo CRE Finance ARI.N: down 3.7% ** Blackstone Mortgage Trust Inc BXMT.N: down 3.0% ** Ladder Capital Corp LADR.N: flat ** Starwood Property Trust Inc STWD.N: down 2.1% ** TPG RE Finance Trust Inc TRTX.N: down 3.0% BUZZ-U.S. mortgage REITs: DB cuts PT citing "stressed scenarios" ** INmune Bio Inc INMB.O: up 7.1% BUZZ-INmune Bio Inc: Rises on plans to begin COVID-19 trial ** Mustang Bio Inc MBIO.O: up 2.4% BUZZ-Mustang Bio: Rises after EMA's favorable classification of "bubble boy" therapy ** Meredith Corp MDP.N: down 9.7% BUZZ-Meredith Corp: Falls on withdrawing 2020 outlook as ad sales get hit ** Ducommun Inc DCO.N: up 4.6% BUZZ-Ducommun: Jumps as Q1 revenue forecast higher than Wall Street estimates ** Alexion Pharmaceuticals Inc ALXN.O: up 4.4% BUZZ-Alexion rises on study to test blood disorder drug for COVID-19 ** Clorox Co CLX.N: up 1.9% BUZZ-Clorox: Up as Deutsche Bank expects strong Q3 helped by coronavirus ** Peloton Interative Inc PTON.O: down 4.5% BUZZ-Peloton skids as BMO slaps first "sell" rating since IPO ** Terex Corp TEX.N: down 4.7% ** Manitowoc Company Inc MTW.N: down 2.5% BUZZ-GS removes Terex and Manitowoc from "buy list", downgrades to "neutral" ** Anixa Biosciences Inc ANIX.O: up 11.6% BUZZ-Anixa Biosciences: Rises on partnership for potential treatment of COVID-19 ** Cyclacel Pharmaceutical Inc CYCC.O: up 89.5% BUZZ-Cyclacel: Jumps on deal to study drugs to treat COVID-19 patients ** Boeing Co BA.N: down 3.1% BUZZ-Benchmark sees Boeing cut 787 production by 30%; lowers PT ** Eros International EROS.N: up 9.0% BUZZ-Eros International: Soars after deal to merge with STX Entertainment ** Medpace Holdings Inc MEDP.O: down 1.9% ** ICON Plc ICLR.O: up 0.1% BUZZ-Baird downgrades two contract research organizations on COVID-19 impact ** Xeris Pharmaceutical Inc XERS.O: up 10.2% BUZZ-Xeris Pharma: Rises on positive results from seizure medication study ** United Airlines Holdings Inc UAL.O: down 3.2% BUZZ-United Airlines drops on estimated quarterly loss, dour outlook ** Walt Disney Co DIS.N: down 2.8% BUZZ-Disney: Falls as brokerages move to sidelines citing hit to theme parks ** Cheesecake Factory Inc CAKE.O: up 7.6% BUZZ-Cheesecake Factory: Rises on $200 mln investment from Roark Capital ** Exxon Mobil Corp XOM.N: down 2.2% ** Chevron Corp CVX.N: down 1.0% ** Devon Energy Corp DVN.N: up 1.1% ** Callon Petroleum Co CPE.N: down 2.5% ** Chesapeake Energy Corp CHK.N: down 1.0% ** Occidental Petroleum Corp OXY.N: down 4.8% ** Schlumberger NV SLB.N: up 0.4% ** Halliburton Co HAL.N: up 3.5% ** TechnipFMC Plc FTI.N: down 0.5% BUZZ-Oil stocks drop as concerns over rising crude storage weigh on prices BUZZ-Street View: Schlumberger's dividend cut the first step on road to recovery BUZZ-Halliburton: Falls on $1.1 bln impairment charges ** Safe-T Group SFET.O: up 17.6% BUZZ-Safe-T Group: Jumps on upbeat Q1 revenue forecast ** AbbVie Inc ABBV.N: up 0.3% BUZZ-AbbVie Inc: RBC expects rebound in 2021, upgrades to "outperform" ** Facebook Inc FB.O: up 0.3% BUZZ-Facebook: Credit Suisse cuts PT as coronavirus impacts ad revenue ** Biogen Inc BIIB.O: up 1.5% BUZZ-Biogen Inc: Alzheimer's drug in focus ahead of Q1, not earnings ** Abbott Laboratories ABT.N: up 1.0% BUZZ-Abbott, Roche to benefit from surging demand for COVID-19 antibody tests - analyst ** DuPont de Nemours Inc DD.N: up 5.0% BUZZ-DuPont: Rises on expectations of stronger Q1 from coronavirus-driven demand ** Co-Diagnostics Inc CODX.O: up 13.8% BUZZ-Co-Diagnostics: Rises on increased U.S. sales of COVID-19 testing kits ** Acadia Healthcare Co Inc ACHC.O: up 0.4% ** Brookdale Senior Living Inc BKD.N: down 1.8% ** Ensign Group Inc ENSG.O: down 1.2% ** Select Medical Holdings Corp SEM.N: down 3.6% BUZZ-Strong headwinds imminent for facility-based health care providers - Analyst ** General Motors Co GM.N: down 0.3% ** Ford Motor Co F.N: down 1.2% BUZZ-CS cuts PT on Ford, GM on heavy cash burn in H1 2020 ** Royal Caribbean Cruises Ltd RCL.N: down 1.6% ** Norwegian Cruise Line Holdings Ltd NCLH.N: down 2.7% ** Carnival Corp CCL.N: down 1.4% BUZZ-J.P. Morgan slashes cruise operators' PT on virus impact The 11 major S&P 500 sectors: Communication Services down 0.15% Consumer Discretionary up 0.32% Consumer Staples | The top three S&P 500 .PG.INX percentage gainers: ** FLIR Systems Inc , up 14.1% ** Carrier Global Corp , up 6.6% ** DuPont de Nemours Inc, up 5% The top three S&P 500 .PL.INX percentage losers: ** Vornado Realty Trust , down 4.9% ** Lennar Corporation , down 4.7% ** Occidental Petroleum Corp , down 4.7% The top three NYSE .PG.N percentage gainers: ** Regional Health Properties Inc , up 41.6% ** Montage Resources Corp , up 26.8% ** Build-A-Bear Workshop Inc , up 26.2% The top three NYSE .PL.N percentage losers: ** Invesco Mortgage Capital Inc , down 19.5% ** Direxion Daily S&P Biotech Bear 3X Shares , down 13% ** Manning & Napier Inc , down 12.7% The top three Nasdaq .PG.O percentage gainers: ** Cyclacel Pharmaceuticals Inc , up 89.5% ** American Virtual Cloud Technologies Inc , up 43.8% ** Benitec Biopharma Limited , up 42.9% The top three Nasdaq .PL.O percentage losers: ** Liberty TripAdvisor Holdings Inc , down 18.4% ** BiondVax Pharmaceuticals Equity Warrants , down 15% ** Green Plains Partners LP , down 14% ** Avalon GloboCare Corp AVCO.O: up 12.9% BUZZ-Avalon GloboCare: Rises as therapy shows promise in combating cytokine storm ** Shake Shack Inc SHAK.N: up 6.3% BUZZ-Shake Shack beefs up capital, gives back government loan ** Exelixis Inc EXEL.O: up 25.5% BUZZ-Exelixis jumps as cancer drug combo shows promise in study ** AGNC Investment Corp AGNC.O: up 0.1% ** Annaly Capital Management Inc NLY.N: up 0.2% ** Apollo CRE Finance ARI.N: down 3.7% ** Blackstone Mortgage Trust Inc BXMT.N: down 3.0% ** Ladder Capital Corp LADR.N: flat ** Starwood Property Trust Inc STWD.N: down 2.1% ** TPG RE Finance Trust Inc TRTX.N: down 3.0% BUZZ-U.S. mortgage REITs: DB cuts PT citing "stressed scenarios" ** INmune Bio Inc INMB.O: up 7.1% BUZZ-INmune Bio Inc: Rises on plans to begin COVID-19 trial ** Mustang Bio Inc MBIO.O: up 2.4% BUZZ-Mustang Bio: Rises after EMA's favorable classification of "bubble boy" therapy ** Meredith Corp MDP.N: down 9.7% BUZZ-Meredith Corp: Falls on withdrawing 2020 outlook as ad sales get hit ** Ducommun Inc DCO.N: up 4.6% BUZZ-Ducommun: Jumps as Q1 revenue forecast higher than Wall Street estimates ** Alexion Pharmaceuticals Inc ALXN.O: up 4.4% BUZZ-Alexion rises on study to test blood disorder drug for COVID-19 ** Clorox Co CLX.N: up 1.9% BUZZ-Clorox: Up as Deutsche Bank expects strong Q3 helped by coronavirus ** Peloton Interative Inc PTON.O: down 4.5% BUZZ-Peloton skids as BMO slaps first "sell" rating since IPO ** Terex Corp TEX.N: down 4.7% ** Manitowoc Company Inc MTW.N: down 2.5% BUZZ-GS removes Terex and Manitowoc from "buy list", downgrades to "neutral" ** Anixa Biosciences Inc ANIX.O: up 11.6% BUZZ-Anixa Biosciences: Rises on partnership for potential treatment of COVID-19 ** Cyclacel Pharmaceutical Inc CYCC.O: up 89.5% BUZZ-Cyclacel: Jumps on deal to study drugs to treat COVID-19 patients ** Boeing Co BA.N: down 3.1% BUZZ-Benchmark sees Boeing cut 787 production by 30%; lowers PT ** Eros International EROS.N: up 9.0% BUZZ-Eros International: Soars after deal to merge with STX Entertainment ** Medpace Holdings Inc MEDP.O: down 1.9% ** ICON Plc ICLR.O: up 0.1% BUZZ-Baird downgrades two contract research organizations on COVID-19 impact ** Xeris Pharmaceutical Inc XERS.O: up 10.2% BUZZ-Xeris Pharma: Rises on positive results from seizure medication study ** United Airlines Holdings Inc UAL.O: down 3.2% BUZZ-United Airlines drops on estimated quarterly loss, dour outlook ** Walt Disney Co DIS.N: down 2.8% BUZZ-Disney: Falls as brokerages move to sidelines citing hit to theme parks ** Cheesecake Factory Inc CAKE.O: up 7.6% BUZZ-Cheesecake Factory: Rises on $200 mln investment from Roark Capital ** Exxon Mobil Corp XOM.N: down 2.2% ** Chevron Corp CVX.N: down 1.0% ** Devon Energy Corp DVN.N: up 1.1% ** Callon Petroleum Co CPE.N: down 2.5% ** Chesapeake Energy Corp CHK.N: down 1.0% ** Occidental Petroleum Corp OXY.N: down 4.8% ** Schlumberger NV SLB.N: up 0.4% ** Halliburton Co HAL.N: up 3.5% ** TechnipFMC Plc FTI.N: down 0.5% BUZZ-Oil stocks drop as concerns over rising crude storage weigh on prices BUZZ-Street View: Schlumberger's dividend cut the first step on road to recovery BUZZ-Halliburton: Falls on $1.1 bln impairment charges ** Safe-T Group SFET.O: up 17.6% BUZZ-Safe-T Group: Jumps on upbeat Q1 revenue forecast ** AbbVie Inc ABBV.N: up 0.3% BUZZ-AbbVie Inc: RBC expects rebound in 2021, upgrades to "outperform" ** Facebook Inc FB.O: up 0.3% BUZZ-Facebook: Credit Suisse cuts PT as coronavirus impacts ad revenue ** Biogen Inc BIIB.O: up 1.5% BUZZ-Biogen Inc: Alzheimer's drug in focus ahead of Q1, not earnings ** Abbott Laboratories ABT.N: up 1.0% BUZZ-Abbott, Roche to benefit from surging demand for COVID-19 antibody tests - analyst ** DuPont de Nemours Inc DD.N: up 5.0% BUZZ-DuPont: Rises on expectations of stronger Q1 from coronavirus-driven demand ** Co-Diagnostics Inc CODX.O: up 13.8% BUZZ-Co-Diagnostics: Rises on increased U.S. sales of COVID-19 testing kits ** Acadia Healthcare Co Inc ACHC.O: up 0.4% ** Brookdale Senior Living Inc BKD.N: down 1.8% ** Ensign Group Inc ENSG.O: down 1.2% ** Select Medical Holdings Corp SEM.N: down 3.6% BUZZ-Strong headwinds imminent for facility-based health care providers - Analyst ** General Motors Co GM.N: down 0.3% ** Ford Motor Co F.N: down 1.2% BUZZ-CS cuts PT on Ford, GM on heavy cash burn in H1 2020 ** Royal Caribbean Cruises Ltd RCL.N: down 1.6% ** Norwegian Cruise Line Holdings Ltd NCLH.N: down 2.7% ** Carnival Corp CCL.N: down 1.4% BUZZ-J.P. Morgan slashes cruise operators' PT on virus impact The 11 major S&P 500 sectors: Communication Services Eikon search string for individual stock moves: STXBZ The Day Ahead newsletter: http://tmsnrt.rs/2ggOmBi The Morning News Call newsletter: http://tmsnrt.rs/2fwPLTh A slide in energy stocks weighed on Wall Street on Monday as crude prices crashed at the start of a week packed with quarterly earnings reports and economic data likely to underline the damage from the coronavirus outbreak..N At 16:05 ET, the Dow Jones Industrial Average .DJI was down 0.94% at 24,014.95. The S&P 500 .SPX was down 0.65% at 2,855.74 and the Nasdaq Composite .IXIC was up 0.13% at 8,661.651. |
24614.0 | 2020-04-20 00:00:00 UTC | Noteworthy ETF Inflows: VTV, HON, ABBV, GE | ABBV | https://www.nasdaq.com/articles/noteworthy-etf-inflows%3A-vtv-hon-abbv-ge-2020-04-20 | nan | nan | Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel, one standout is the Vanguard Value ETF (Symbol: VTV) where we have detected an approximate $1.2 billion dollar inflow -- that's a 2.5% increase week over week in outstanding units (from 471,419,044 to 483,182,745). Among the largest underlying components of VTV, in trading today Honeywell International Inc (Symbol: HON) is off about 1.7%, AbbVie Inc (Symbol: ABBV) is off about 0.4%, and General Electric Co (Symbol: GE) is lower by about 4%. For a complete list of holdings, visit the VTV Holdings page » The chart below shows the one year price performance of VTV, versus its 200 day moving average:
Looking at the chart above, VTV's low point in its 52 week range is $75.5507 per share, with $121.71 as the 52 week high point — that compares with a last trade of $96.97. Comparing the most recent share price to the 200 day moving average can also be a useful technical analysis technique -- learn more about the 200 day moving average ».
Exchange traded funds (ETFs) trade just like stocks, but instead of ''shares'' investors are actually buying and selling ''units''. These ''units'' can be traded back and forth just like stocks, but can also be created or destroyed to accommodate investor demand. Each week we monitor the week-over-week change in shares outstanding data, to keep a lookout for those ETFs experiencing notable inflows (many new units created) or outflows (many old units destroyed). Creation of new units will mean the underlying holdings of the ETF need to be purchased, while destruction of units involves selling underlying holdings, so large flows can also impact the individual components held within ETFs.
Click here to find out which 9 other ETFs had notable inflows »
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Among the largest underlying components of VTV, in trading today Honeywell International Inc (Symbol: HON) is off about 1.7%, AbbVie Inc (Symbol: ABBV) is off about 0.4%, and General Electric Co (Symbol: GE) is lower by about 4%. For a complete list of holdings, visit the VTV Holdings page » The chart below shows the one year price performance of VTV, versus its 200 day moving average: Looking at the chart above, VTV's low point in its 52 week range is $75.5507 per share, with $121.71 as the 52 week high point — that compares with a last trade of $96.97. These ''units'' can be traded back and forth just like stocks, but can also be created or destroyed to accommodate investor demand. | Among the largest underlying components of VTV, in trading today Honeywell International Inc (Symbol: HON) is off about 1.7%, AbbVie Inc (Symbol: ABBV) is off about 0.4%, and General Electric Co (Symbol: GE) is lower by about 4%. For a complete list of holdings, visit the VTV Holdings page » The chart below shows the one year price performance of VTV, versus its 200 day moving average: Looking at the chart above, VTV's low point in its 52 week range is $75.5507 per share, with $121.71 as the 52 week high point — that compares with a last trade of $96.97. Comparing the most recent share price to the 200 day moving average can also be a useful technical analysis technique -- learn more about the 200 day moving average ». | Among the largest underlying components of VTV, in trading today Honeywell International Inc (Symbol: HON) is off about 1.7%, AbbVie Inc (Symbol: ABBV) is off about 0.4%, and General Electric Co (Symbol: GE) is lower by about 4%. Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel, one standout is the Vanguard Value ETF (Symbol: VTV) where we have detected an approximate $1.2 billion dollar inflow -- that's a 2.5% increase week over week in outstanding units (from 471,419,044 to 483,182,745). For a complete list of holdings, visit the VTV Holdings page » The chart below shows the one year price performance of VTV, versus its 200 day moving average: Looking at the chart above, VTV's low point in its 52 week range is $75.5507 per share, with $121.71 as the 52 week high point — that compares with a last trade of $96.97. | Among the largest underlying components of VTV, in trading today Honeywell International Inc (Symbol: HON) is off about 1.7%, AbbVie Inc (Symbol: ABBV) is off about 0.4%, and General Electric Co (Symbol: GE) is lower by about 4%. Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel, one standout is the Vanguard Value ETF (Symbol: VTV) where we have detected an approximate $1.2 billion dollar inflow -- that's a 2.5% increase week over week in outstanding units (from 471,419,044 to 483,182,745). For a complete list of holdings, visit the VTV Holdings page » The chart below shows the one year price performance of VTV, versus its 200 day moving average: Looking at the chart above, VTV's low point in its 52 week range is $75.5507 per share, with $121.71 as the 52 week high point — that compares with a last trade of $96.97. |
24615.0 | 2020-04-20 00:00:00 UTC | EXCLUSIVE-In Russia, a black market for HIV drug to try on coronavirus | ABBV | https://www.nasdaq.com/articles/exclusive-in-russia-a-black-market-for-hiv-drug-to-try-on-coronavirus-2020-04-20 | nan | nan | By Polina Ivanova
MOSCOW, April 20 (Reuters) - A black market has developed in Russia for an antiviral HIV drug explored as a possible treatment for COVID-19, the respiratory disease caused by the new coronavirus, according to sellers, HIV activists and the head of the drug's main Russian producer.
More than 20 trials around the world are testing Kaletra as a COVID-19 treatment or post-exposure prophylaxis.
Russia's Health Ministry recommended it as a possible treatment for COVID-19 at the end of January after reports from China that it was beneficial, but later added that its efficacy was uncertain.
That did not deter speculators who bet that shortages of the drug, also produced as a generic in Russia under the name Kalidavir, might arise as the coronavirus spread.
"Three months ago, people were buying Kaletra from us without much enthusiasm for 900 roubles ($12) a box," one online trader of HIV drugs said.
"Now, anticipating (supply) interruptions, people are buying between 100 and 700 boxes from us, at 3,800 roubles a box. Mainly, people are buying (Kaletra) with the aim of reselling it for a very high price."
Resellers can get 7,000-8,000 roubles per box, the trader said - and that frenzy is worrying some HIV-positive people.
The number of new coronavirus cases in Russia began rising sharply this month, and on Monday it reported a daily rise of 4,268 cases, bringing the nationwide tally to 47,121.
Kaletra, as with many other prescription-only HIV treatments in Russia, is purchased in bulk by the government and distributed to registered HIV patients for free.
But interruptions in supplies of these drugs are not uncommon, so many top up their stocks privately, from pharmacies. People who do not have a Russian passport and others who prefer to stay out of the official system for various reasons also rely on private supplies.
'120 CALLS A DAY'
The director of H-Clinic in St. Petersburg, which specialises in infectious diseases and keeps a stock to cover those needs, said his pharmacy had been flooded with calls in recent weeks from worried HIV patients.
"We have a van coming from the pharmaceutical company, and everything in it has already been claimed in orders," Andrei Skvortsov said. "There were up to 120 calls a day."
The pharmacy's supplies of the generic, Kalidavir, were stable, he said, but the distributor of Kaletra had told him the delivery would be the pharmacy's last because of the need to redirect it for state tenders.
The Health Ministry did not respond to questions about the drug's resale online or possible shortages.
It first instructed doctors to use Kaletra's combined components, lopinavir and ritonavir, to treat COVID-19 on Jan. 29, based on studies of the treatment of other coronaviruses, such as Severe Acute Respiratory Syndrome (SARS).
Produced in Russia by R-Pharm under a deal with the U.S. drug maker and patent-holder AbbVie Inc ABBV.N, Kaletra is supplied in smaller quantities to some pharmacies and AIDS clinics.
Just 34 packs were sold by such pharmacies in March last year, compared to over 1,500 in March 2020, market research firm Alpharm said.
One HIV activist in central Russia said speculators were trying to buy Kaletra from HIV patients, for 3,000 roubles a box.
The activist, who asked to share only his first name, Alexei, runs a 'back-up medicine cabinet' together with a network of patients across 20 cities, stockpiling leftover drugs to distribute them to those in need when shortages appear.
BLACK MARKET
"Messages and calls started coming in from people saying they were ready to purchase these medicines," Alexei said.
"They are resellers and middlemen ... They are ready to buy everything, down to the last box. We tell them to shove off."
R-Pharm chief executive Alexei Repik said for the first time instances were being seen of Kaletra being sold illegally in pharmacies without a prescription.
"It used not to feature at all, because ... the medicine was previously only needed by HIV patients," he said.
Repik said police had notified R-Pharm at least twice of seizures of illegally obtained Kaletra.
R-Pharm assists police in tracing the provenance of drugs being sold illegally, he said, because black market sales of any drug meant patients who truly needed it were losing out.
Kaletra's side-effects most commonly include stomach upset and nausea, but it can also lead to liver and heart rhythm problems, meaning it could be dangerous to self-prescribe, he said.
But Repik did not expect shortages, because R-Pharm was boosting production to cope with expected demand from doctors prescribing Kaletra for coronavirus as well as HIV.
"But of course no one can predict the full scale of the epidemic," he added.
Chinese doctors in Wuhan, where the new coronavirus originated, described the drug as beneficial last week although another study questioned its effectiveness.
Kaletra stops the HIV virus growing and replicating. Repik said it had been recommended for the new coronavirus based on past experience with other coronaviruses and preliminary data.
"(But) it is important to understand that, for now, 100% proven antiviral medicines - medicines that directly attack the (new) coronavirus specifically - they don't exist, because studies are still ongoing."
(Additional reporting by Polina Nikolskaya; Writing by Polina Ivanova; Editing by Andrew Osborn and Kevin Liffey)
((p.ivanova@thomsonreuters.com;))
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Produced in Russia by R-Pharm under a deal with the U.S. drug maker and patent-holder AbbVie Inc ABBV.N, Kaletra is supplied in smaller quantities to some pharmacies and AIDS clinics. The director of H-Clinic in St. Petersburg, which specialises in infectious diseases and keeps a stock to cover those needs, said his pharmacy had been flooded with calls in recent weeks from worried HIV patients. It first instructed doctors to use Kaletra's combined components, lopinavir and ritonavir, to treat COVID-19 on Jan. 29, based on studies of the treatment of other coronaviruses, such as Severe Acute Respiratory Syndrome (SARS). | Produced in Russia by R-Pharm under a deal with the U.S. drug maker and patent-holder AbbVie Inc ABBV.N, Kaletra is supplied in smaller quantities to some pharmacies and AIDS clinics. Russia's Health Ministry recommended it as a possible treatment for COVID-19 at the end of January after reports from China that it was beneficial, but later added that its efficacy was uncertain. One HIV activist in central Russia said speculators were trying to buy Kaletra from HIV patients, for 3,000 roubles a box. | Produced in Russia by R-Pharm under a deal with the U.S. drug maker and patent-holder AbbVie Inc ABBV.N, Kaletra is supplied in smaller quantities to some pharmacies and AIDS clinics. By Polina Ivanova MOSCOW, April 20 (Reuters) - A black market has developed in Russia for an antiviral HIV drug explored as a possible treatment for COVID-19, the respiratory disease caused by the new coronavirus, according to sellers, HIV activists and the head of the drug's main Russian producer. "Three months ago, people were buying Kaletra from us without much enthusiasm for 900 roubles ($12) a box," one online trader of HIV drugs said. | Produced in Russia by R-Pharm under a deal with the U.S. drug maker and patent-holder AbbVie Inc ABBV.N, Kaletra is supplied in smaller quantities to some pharmacies and AIDS clinics. One HIV activist in central Russia said speculators were trying to buy Kaletra from HIV patients, for 3,000 roubles a box. "Messages and calls started coming in from people saying they were ready to purchase these medicines," Alexei said. |
24616.0 | 2020-04-19 00:00:00 UTC | 3 Stocks to Supplement Your Social Security Income | ABBV | https://www.nasdaq.com/articles/3-stocks-to-supplement-your-social-security-income-2020-04-19 | nan | nan | Don't expect Social Security will be enough to fund your retirement. The federal program was intended to provide only around 40% of retirees' income. You'll need to make up the rest on your own.
One of the best alternatives to help you accomplish this goal is to invest in dividend stocks. In particular, you'll want to find the stocks of solid, well-run companies that should be able to keep paying dividends over the long run. Here are three great stocks that could help you supplement your Social Security income.
Image source: Getty Images.
1. AbbVie
AbbVie (NYSE: ABBV) offers a dividend yield of close to 5.8%. The big drugmaker's track record looks very impressive, with 47 consecutive years of dividend increases including the time that AbbVie was part of Abbott Labs (NYSE: ABT). And since being spun off from Abbott in 2013, AbbVie has nearly tripled its dividend payout.
Last year, AbbVie raked in $33.3 billion in revenue with profits of nearly $7.9 billion. The company will soon become much larger after its pending acquisition of Allergan closes.
The primary risk with AbbVie is that it's heavily dependent on sales of one drug, Humira, which generated nearly 58% of the company's total revenue in 2019. Humira has already lost patent exclusivity in Europe and will do so in the U.S. in 2023. The drug's sales will almost certainly plunge within the next few years.
However, growth for AbbVie's other products will help offset much of the decline in Humira's sales. In particular, new immunology drugs Rinvoq and Skyrizi are expected to become major blockbuster successes. The acquisition of Allergan, with its Botox franchise and rising star in antipsychotic drug Vraylar, will also reduce AbbVie's reliance on Humira significantly. I think that AbbVie should be able to continue paying attractive dividends over the long run thanks to its post-Humira strategy.
2. Brookfield Infrastructure Partners
Brookfield Infrastructure Partners' (NYSE: BIP) dividend yields 5.7%. The company increased its dividend payment in each of the last 10 years with dividend hikes between 7% and 9% in most years.
As its name indicates, Brookfield Infrastructure focuses on infrastructure assets. It owns and operates a wide range of assets across the world, including cell towers, data centers, electricity distribution systems, natural gas pipelines, railroads, ports, and toll roads. The company generated revenue of $6.6 billion last year with $650 million in profits.
Close to 95% of Brookfield Infrastructure's cash flows are regulated or contracted. This means the company can count on a steady stream of cash coming in. That's good news for retired investors depending on dividends to supplement their income.
It's also reassuring that Brookfield Infrastructure is highly diversified across sectors and geographically. The utility sector generates the highest cash flow but still accounts for only 32% of the company's total cash flow. No geographical region generates more than 30% of total cash flow. Even if one sector or region encounters headwinds, Brookfield Infrastructure should be in good shape to keep the dividends coming.
3. Brookfield Renewable Partners
Brookfield Renewable Partners (NYSE: BEP) is a sister company to Brookfield Infrastructure Partners. Like its sibling, Brookfield Renewables offers an attractive dividend, with its yield currently at 4.8%.
As you might expect based on its name, Brookfield Renewables Partners focuses on renewable energy assets. It owns more than $50 billion in energy assets across 15 countries, including hydroelectric, wind, and solar electricity generation facilities. In 2019, the company made nearly $3 billion in revenue.
Like AbbVie, Brookfield Renewable is about to get even bigger due to an acquisition. It already owns 62% of TerraForm Power but recently struck a deal to buy the rest of the renewable energy company. This acquisition will diversify Brookfield Renewable even further into wind and solar assets.
At the end of 2019, around 73% of Brookfield Renewable's power generation was contracted under long-term contracts. The company expects to grow significantly in the future as countries and U.S. states seek to reduce their dependence on fossil fuels. This combination of stability and growth potential makes Brookfield Renewable a great pick for retirees looking to add to their Social Security income.
10 stocks we like better than Brookfield Infrastructure Partners
When investing geniuses David and Tom Gardner have a stock tip, it can pay to listen. After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor, has tripled the market.*
David and Tom just revealed what they believe are the ten best stocks for investors to buy right now... and Brookfield Infrastructure Partners wasn't one of them! That's right -- they think these 10 stocks are even better buys.
See the 10 stocks
*Stock Advisor returns as of March 18, 2020
Keith Speights owns shares of AbbVie, Brookfield Infrastructure Partners, and Brookfield Renewable Partners L.P. The Motley Fool recommends Brookfield Infrastructure Partners. The Motley Fool has a disclosure policy.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | The big drugmaker's track record looks very impressive, with 47 consecutive years of dividend increases including the time that AbbVie was part of Abbott Labs (NYSE: ABT). AbbVie AbbVie (NYSE: ABBV) offers a dividend yield of close to 5.8%. And since being spun off from Abbott in 2013, AbbVie has nearly tripled its dividend payout. | AbbVie AbbVie (NYSE: ABBV) offers a dividend yield of close to 5.8%. The big drugmaker's track record looks very impressive, with 47 consecutive years of dividend increases including the time that AbbVie was part of Abbott Labs (NYSE: ABT). And since being spun off from Abbott in 2013, AbbVie has nearly tripled its dividend payout. | See the 10 stocks *Stock Advisor returns as of March 18, 2020 Keith Speights owns shares of AbbVie, Brookfield Infrastructure Partners, and Brookfield Renewable Partners L.P. AbbVie AbbVie (NYSE: ABBV) offers a dividend yield of close to 5.8%. The big drugmaker's track record looks very impressive, with 47 consecutive years of dividend increases including the time that AbbVie was part of Abbott Labs (NYSE: ABT). | The primary risk with AbbVie is that it's heavily dependent on sales of one drug, Humira, which generated nearly 58% of the company's total revenue in 2019. AbbVie AbbVie (NYSE: ABBV) offers a dividend yield of close to 5.8%. The big drugmaker's track record looks very impressive, with 47 consecutive years of dividend increases including the time that AbbVie was part of Abbott Labs (NYSE: ABT). |
24617.0 | 2020-04-17 00:00:00 UTC | Don't Waste Your Money on Penny Stocks, These 2 Stocks Are Better Buys | ABBV | https://www.nasdaq.com/articles/dont-waste-your-money-on-penny-stocks-these-2-stocks-are-better-buys-2020-04-17 | nan | nan | The uncertainty that has gripped stock markets around the world makes at least one thing clear: This is no time to buy penny stocks. There never was a good time, really. Most companies that trade as penny stocks are outright scams, with many having no actual operations at all. More importantly, owning those types of assets is no way to build wealth over the long haul.
That doesn't mean you have to shun high-risk, high-reward stocks. Assuming your portfolio is well structured for your financial situation, there's nothing wrong with examining a riskier asset or two (even in the midst of a global pandemic). Here's why investors might want to take a closer look at Coherus BioSciences (NASDAQ: CHRS) and Precision BioSciences (NASDAQ: DTIL).
Image source: Getty Images.
A winning strategy in biosimilars
To be fair, Coherus BioSciences isn't all that risky. The company is focused on developing biosimilars, which are copycat versions of biologic drugs. They're not technically generic drugs; that term is reserved for small-molecule drugs in which the chemistry of the active pharmaceutical ingredient can be exactly recreated. It's simply too difficult to create exact copies of complex proteins, antibodies, and other biologic drugs.
For that reason, the Food and Drug Administration requires clinical trials of biosimilar candidates and strict manufacturing oversight as conditions of granting marketing approval. While that erects barriers to entry, biosimilars still represent a solid market opportunity.
Coherus BioSciences provides a great example of success. The company earned FDA approval for Udenyca, a biosimilar of Neulasta, in November 2018. Both drugs are used to boost white blood cell counts in chemotherapy patients. The biosimilar was launched in January 2019 and racked up $356 million in full-year 2019 revenue. The quick start helped the business generate full-year 2019 operating income of $107 million, which represented an encouraging turnaround from a cumulative operating loss of $771 million total over the previous four years.
Udenyca's success can be attributed to the drug actually having a brand name (uncommon among generic drugs, but something that creates familiarity with doctors), the fact that Coherus had robust manufacturing capabilities in place, and a relatively smooth uptake among major insurers.
Coherus is hoping to recreate that success with other pipeline assets. The company is developing biosimilars for both Lucentis and Eylea, each of which is used to treat wet age-related macular degeneration (wet AMD), as well as a biosimilar to AbbVie's blockbuster Humira for treating autoimmune disorders. It will take years for the biosimilar candidates to hit the market and ramp up sales, but Udenyca has significantly de-risked the development of the pipeline.
The commercial-stage company recently estimated it generated at least $115 million in product revenue and at least $33.5 million in net income during the first quarter of 2020. Coherus BioSciences said it's reasonable to expect the coronavirus pandemic to have a negative effect on operations beginning in the second quarter of this year, but added that its manufacturing assets and supply chain are based in the United States, which insulates it from potential supply disruptions.
Investors should also consider that Coherus BioSciences began 2020 with $177 million in cash and added another $200 million from a debt offering in mid-April. In other words, the business is well positioned to endure a prolonged period of uncertainty, which makes this pharma stock worth a closer look.
Image source: Getty Images.
A novel gene-editing platform
Precision BioSciences wields an early-stage drug pipeline with limited clinical data supporting it, but its intriguing potential might still attract investors. The company is developing a novel gene-editing platform that has inherent advantages over CRISPR gene editing. Among them is the fact that the business owns all of the underlying intellectual property, which allows it to pursue any and all disease indications, industrial applications, and agricultural markets.
Most of the company's current market valuation is tied to its healthcare portfolio. Precision BioSciences has leveraged its gene-editing platform to engineer cell therapies taking aim at cancer. Its lead drug candidate, PBCAR0191, has generated initial data in a handful of patients with non-Hodgkin's lymphoma (NHL) and B-cell acute lymphoblastic leukemia (B-ALL). Early results showed promise, although it's too early to draw conclusions.
What's important is that the development-stage biopharma shouldn't become too dependent on any single pipeline asset. The company has received the green light from the FDA to advance its next two oncology assets into clinical trials. Precision BioSciences also counts five discovery and pre-clinical programs outside of oncology, led by one for chronic hepatitis B for which it's partnered with Gilead Sciences.
Beyond healthcare, Precision BioSciences is exploring agricultural applications for its gene-editing platform through its wholly owned subsidiary, Elo Life Systems. The early-stage pipeline includes a partnership with Cargill to make canola oil with very low saturated fat and an intriguing program to engineer high-protein chickpeas. If the latter is successful, it could create a new supply of plant-based proteins for the likes of Beyond Meat.
Aside from the usual risks of investing in an early-stage biopharma, investors today must navigate the unique risks presented by the coronavirus pandemic. Orders to stay home have disrupted many aspects of daily life, including the ability to safely and efficiently conduct clinical trials.
Despite the industrywide uncertainty, Precision BioSciences initiated a study for its second drug candidate, PBCAR20A, in early April. Whether the company can plow ahead with its pipeline in light of the pandemic remains to be seen, but the gene-editing pioneer offers interesting possibilities to investors with a long-term mindset.
10 stocks we like better than Coherus BioSciences
When investing geniuses David and Tom Gardner have a stock tip, it can pay to listen. After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor, has tripled the market.*
David and Tom just revealed what they believe are the ten best stocks for investors to buy right now... and Coherus BioSciences wasn't one of them! That's right -- they think these 10 stocks are even better buys.
See the 10 stocks
*Stock Advisor returns as of March 18, 2020
Maxx Chatsko has no position in any of the stocks mentioned. The Motley Fool owns shares of and recommends Gilead Sciences. The Motley Fool has a disclosure policy.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | The company is developing biosimilars for both Lucentis and Eylea, each of which is used to treat wet age-related macular degeneration (wet AMD), as well as a biosimilar to AbbVie's blockbuster Humira for treating autoimmune disorders. For that reason, the Food and Drug Administration requires clinical trials of biosimilar candidates and strict manufacturing oversight as conditions of granting marketing approval. Its lead drug candidate, PBCAR0191, has generated initial data in a handful of patients with non-Hodgkin's lymphoma (NHL) and B-cell acute lymphoblastic leukemia (B-ALL). | The company is developing biosimilars for both Lucentis and Eylea, each of which is used to treat wet age-related macular degeneration (wet AMD), as well as a biosimilar to AbbVie's blockbuster Humira for treating autoimmune disorders. The quick start helped the business generate full-year 2019 operating income of $107 million, which represented an encouraging turnaround from a cumulative operating loss of $771 million total over the previous four years. A novel gene-editing platform Precision BioSciences wields an early-stage drug pipeline with limited clinical data supporting it, but its intriguing potential might still attract investors. | The company is developing biosimilars for both Lucentis and Eylea, each of which is used to treat wet age-related macular degeneration (wet AMD), as well as a biosimilar to AbbVie's blockbuster Humira for treating autoimmune disorders. Here's why investors might want to take a closer look at Coherus BioSciences (NASDAQ: CHRS) and Precision BioSciences (NASDAQ: DTIL). A novel gene-editing platform Precision BioSciences wields an early-stage drug pipeline with limited clinical data supporting it, but its intriguing potential might still attract investors. | The company is developing biosimilars for both Lucentis and Eylea, each of which is used to treat wet age-related macular degeneration (wet AMD), as well as a biosimilar to AbbVie's blockbuster Humira for treating autoimmune disorders. The uncertainty that has gripped stock markets around the world makes at least one thing clear: This is no time to buy penny stocks. The company is focused on developing biosimilars, which are copycat versions of biologic drugs. |
24618.0 | 2020-04-16 00:00:00 UTC | Gilead Sciences’ Remdesivir Data Release Brings Much Needed Relief for Patients and Investors | ABBV | https://www.nasdaq.com/articles/gilead-sciences-remdesivir-data-release-brings-much-needed-relief-for-patients-and | nan | nan | For years, Gilead Sciences' (NASDAQ: GILD) stock price has been rather disappointing for investors hoping for long-term capital appreciation. While shares do boast an impressive 3.63% dividend yield, the company's revenues have experienced an enormous decline from 2015 onwards, falling over $10 billion in the past four years as patients cured of hepatitis C no longer needed drugs from Gilead.
In a twist of fate, however, a once little-known drug manufactured by the company during the Ebola virus pandemic may hold the cure to the current coronavirus outbreak, and thereby significantly improve the company's bottom line.
Image Source: Getty Images
A potential treatment for COVID-19
The drug in the spotlight is remdesivir, a nucleotide analog (which are antiviral agents that can stop viral DNA synthesis) hypothesized to block a specific enzyme required during the replication process of the coronavirus. In a compassionate use clinical trial published last week in The New England Journal of Medicine, 36 out of 53, or 68%, of COVID-19 patients witnessed an improvement in oxygen support after three weeks of treatment with remdesivir. Since the study was conducted without the use of a placebo cohort (or control arm), it cannot definitively be concluded the drug has a positive effect on patients. For example, the 68% improvement in oxygen intake could simply be attributed to patients' own immune system fighting off the pathogens.
There is, however, one detail in the trial which may support remdesivir's efficacy. Within a subgroup of patients requiring invasive ventilation, the mortality rate was found to be 18% after treatment. In other words, 28 out of 34 patients in this subgroup recovered. In context, one report from China showed a 86% mortality rate for COVID-19 patients requiring invasive ventilation. Another report, published by the UK's Intensive Care National Audit Center, showed coronavirus patients who needed ventilators (both invasive and non invasive) had a mortality rate of 50%. The study involved at least 690 patients, making it highly statistically significant in terms of representing the overall population. Moreover, a recent report from New York City revealed the mortality rate in this category of patients to be 80%.
While the high fatality rate in these studies may be attributed to constraints in hospital space and resources in different test centers, the sheer discrepancy between mortality rates of patients requiring ventilation who are treated with remdesivir and those who were not, points to potential efficacy of the former.
The next steps
To combat the shortcomings of the compassionate use trial, the company is currently investigating the drug in at least five multicenter, randomized, placebo-controlled phase 3 trials around the world. Recently, Gilead suspended a clinical trial in China. This was neither related to the safety nor efficacy of remedesivir, but rather due to lack of enrollment, which is actually a positive sign. The suspension is sound because China has seen its new COVID-19 case count drop to double digits nationally, with less than 2,000 patients currently in treatment. Recruitment has undoubtedly become a problem there, but not for the rest of the world, where the outbreak is still growing day by day.
At least one of the clinical trials mentioned will release its results this month. If successful, the drug will likely see a quick path to approval as a part of the Food and Drug Administration's new Coronavirus Treatment Acceleration Program.
Considering other potential therapies such as AbbVie's (NYSE: ABBV) Kaletra stumbled in one investigation and how hydroxychloroquine was revealed to possess serious adverse events such as sudden death, remdesivir has become the leading candidate in potentially combating the coronavirus. If approved, the drug can reach hundreds of millions of dollars in sales thanks to a first-mover advantage, and the high volume of patients diagnosed with COVID-19.
Is Gilead a buy today?
In essence, potential investors will inherit Gilead's renowned HIV, hepatitis C, hematology, and oncology portfolios. Together, these assets boast more than 24% in net margins but are growing less than 2% per year. As a result, remdesivir represents a major catalyst for the healthcare stock's price.
The company recently announced plans to buy Forty Seven (NASDAQ: FTSV) for $4.9 billion in cash, so investors should also keep an eye on synergies from this deal once it closes. The acquisition builds on the immuno-oncology portfolio that began when Gilead bought Kite Pharma in 2017.
Since 2016, Gilead's stock has been trading at a discount compared to other biotech companies due to its suboptimal revenue growth. Now, with just 4x price-to-sales, 12x price-to-earnings, a hefty dividend payout, and a growth catalyst, Gilead is prime for a significant rebound. Investors should consider adding shares to their portfolio today.
{%sfr%}
10 stocks we like better than Gilead Sciences
When investing geniuses David and Tom Gardner have a stock tip, it can pay to listen. After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor, has tripled the market.*
David and Tom just revealed what they believe are the ten best stocks for investors to buy right now... and Gilead Sciences wasn't one of them! That's right -- they think these 10 stocks are even better buys.
See the 10 stocks
*Stock Advisor returns as of March 18, 2020
Zhiyuan Sun has no position in any of the stocks mentioned. The Motley Fool owns shares of and recommends Gilead Sciences. The Motley Fool has a disclosure policy.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Considering other potential therapies such as AbbVie's (NYSE: ABBV) Kaletra stumbled in one investigation and how hydroxychloroquine was revealed to possess serious adverse events such as sudden death, remdesivir has become the leading candidate in potentially combating the coronavirus. For years, Gilead Sciences' (NASDAQ: GILD) stock price has been rather disappointing for investors hoping for long-term capital appreciation. While shares do boast an impressive 3.63% dividend yield, the company's revenues have experienced an enormous decline from 2015 onwards, falling over $10 billion in the past four years as patients cured of hepatitis C no longer needed drugs from Gilead. | Considering other potential therapies such as AbbVie's (NYSE: ABBV) Kaletra stumbled in one investigation and how hydroxychloroquine was revealed to possess serious adverse events such as sudden death, remdesivir has become the leading candidate in potentially combating the coronavirus. Within a subgroup of patients requiring invasive ventilation, the mortality rate was found to be 18% after treatment. In context, one report from China showed a 86% mortality rate for COVID-19 patients requiring invasive ventilation. | Considering other potential therapies such as AbbVie's (NYSE: ABBV) Kaletra stumbled in one investigation and how hydroxychloroquine was revealed to possess serious adverse events such as sudden death, remdesivir has become the leading candidate in potentially combating the coronavirus. While shares do boast an impressive 3.63% dividend yield, the company's revenues have experienced an enormous decline from 2015 onwards, falling over $10 billion in the past four years as patients cured of hepatitis C no longer needed drugs from Gilead. While the high fatality rate in these studies may be attributed to constraints in hospital space and resources in different test centers, the sheer discrepancy between mortality rates of patients requiring ventilation who are treated with remdesivir and those who were not, points to potential efficacy of the former. | Considering other potential therapies such as AbbVie's (NYSE: ABBV) Kaletra stumbled in one investigation and how hydroxychloroquine was revealed to possess serious adverse events such as sudden death, remdesivir has become the leading candidate in potentially combating the coronavirus. Investors should consider adding shares to their portfolio today. * David and Tom just revealed what they believe are the ten best stocks for investors to buy right now... and Gilead Sciences wasn't one of them! |
24619.0 | 2020-04-16 00:00:00 UTC | How Safe Are AbbVie Stock and Its Dividend? | ABBV | https://www.nasdaq.com/articles/how-safe-are-abbvie-stock-and-its-dividend-2020-04-16 | nan | nan | Recent market volatility has unfairly whipsawed many stocks that are usually considered steady eddies, and the effects have been even stronger for specific sectors and speculative stocks. That said, some stocks were wildly overvalued when the market was hitting new highs not so long ago, and were ready for a correction.
Pharmaceutical maker AbbVie (NYSE: ABBV) has been caught in the downdraft, down 7% since the beginning of the year. The company pays a juicy 5.9% dividend. Which category does AbbVie fall into, and is the dividend safe?
When Humira and Botox got married
Spun off from Abbott Laboratories (NYSE: ABT) in 2013, AbbVie has grown annual revenue from $18.8 billion that year to $33.3 billion in 2019. The multipurpose drug Humira has been the main engine behind this growth; in fact, it's now the top-selling drug in the world.
Humira is a pretty big blockbuster, and the reason is its ability to block the body's inflammatory process. Like mutinous pirates, autoimmune disease causes your body's immune system to attack your own healthy cells by mistake. Any part of your body can be mistakenly attacked, resulting in conditions like lupus, Crohn's disease, rheumatoid arthritis, chronic plaque psoriasis, and other illnesses. Humira's versatility comes from its ability to block that inflammatory process, a central mechanism in autoimmune disease.
Image source: Getty Images.
But AbbVie has more going for it. In 2019, a deal was struck for AbbVie to acquire Allergan (NYSE: AGN), expanding the reach and scope of the company. The new AbbVie is expected to generate 40% of revenue from Humira and 60% from growth opportunities made possible by the integration of the two companies. The deal is expected to close in May.
Regarding the acquisition, AbbVie CEO Richard Gonzalez said:
You look at [the drugs] Skyrizi, Rinvoq, Venclexta, Imbruvica. Those all have significant growth opportunities ahead of them on the AbbVie side. And then you look at the Allergan side, you have Vraylar. This is a product that is about an $850 million product. I think the last numbers I saw showed it was growing about 70%.
Allergan also has a big presence in the growing aesthetics sector thanks to its ownership of Botox and CoolSculpting. Such elective procedures are being canceled or postponed during the coronavirus crisis, but the aesthetics sector should bounce back after the pandemic has passed.
AbbVie reported strong 2019 year-end results on Feb. 7. Net revenue of $33.3 billion increased 9.9% operationally year over year. Strong growth came from Imbruvica, which grossed sales of $4.7 billion, up 30% from the previous year.
AbbVie also reported adjusted earnings per share of $8.94, reflecting 13% year-over-year growth and beating the company's initial guidance midpoint by $0.24.
Guidance for 2020 reflects growth of 8.1% at the midpoint, with an EPS forecast between $9.61 and $9.71. Management expects to see revenue growth for 2020 approaching 8% on an operational basis. AbbVie will issue 2020 pro forma guidance following the close of the planned Allergan acquisition.
What this means for investors
The Allergan deal will help AbbVie diversify away from Humira, its major moneymaker. It already faces biosimilar competition in Europe, and will lose U.S. patent protection in 2023. In the U.S., Humira is still growing, but in Europe, sales are dropping as cheaper options become available.
AbbVie's management expects several financial benefits from the merger, including an immediate 10% increase to earnings per share over the first full year of the combination, cost reductions of at least $2 billion by year three, and operating cash flow estimated at $19 billion.
Regarding dividend safety, AbbVie said in a company announcement regarding the Allergan acquisition: "The combined company will produce robust cash flow which will support continued growth of our dividend, further investment in our pipeline, and reduction of debt. We intend to reduce debt levels by [$15 billion to] $18 billion by the end of 2021, with further deleveraging through 2023."
AbbVie has done well to position itself for the future, and the stock price should remain relatively strong through the coronavirus crisis, especially considering its price-to-earnings ratio of 15.1 versus the industry average P/E of 29.7. AbbVie looks like a safe stock to own.
A lot is riding on the finalization of the Allergan deal, but the likelihood of its going through is high at this point because all requirements have been met.
I think the dividend is safe for the short term even without the Allergan deal, but its conclusion will secure the payout for the long run. In fact, I think AbbVie is a buy at these levels, with an upside expected shortly after the Allergan deal closes. This is a very synergistic combination. I think Abbvie will deliver very nice returns for investors.
10 stocks we like better than Allergan
When investing geniuses David and Tom Gardner have a stock tip, it can pay to listen. After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor, has tripled the market.*
David and Tom just revealed what they believe are the ten best stocks for investors to buy right now... and Allergan wasn't one of them! That's right -- they think these 10 stocks are even better buys.
See the 10 stocks
*Stock Advisor returns as of March 18, 2020
Anne Burdakin owns shares of AbbVie. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | AbbVie also reported adjusted earnings per share of $8.94, reflecting 13% year-over-year growth and beating the company's initial guidance midpoint by $0.24. AbbVie has done well to position itself for the future, and the stock price should remain relatively strong through the coronavirus crisis, especially considering its price-to-earnings ratio of 15.1 versus the industry average P/E of 29.7. Pharmaceutical maker AbbVie (NYSE: ABBV) has been caught in the downdraft, down 7% since the beginning of the year. | AbbVie also reported adjusted earnings per share of $8.94, reflecting 13% year-over-year growth and beating the company's initial guidance midpoint by $0.24. AbbVie's management expects several financial benefits from the merger, including an immediate 10% increase to earnings per share over the first full year of the combination, cost reductions of at least $2 billion by year three, and operating cash flow estimated at $19 billion. Pharmaceutical maker AbbVie (NYSE: ABBV) has been caught in the downdraft, down 7% since the beginning of the year. | When Humira and Botox got married Spun off from Abbott Laboratories (NYSE: ABT) in 2013, AbbVie has grown annual revenue from $18.8 billion that year to $33.3 billion in 2019. AbbVie's management expects several financial benefits from the merger, including an immediate 10% increase to earnings per share over the first full year of the combination, cost reductions of at least $2 billion by year three, and operating cash flow estimated at $19 billion. Regarding dividend safety, AbbVie said in a company announcement regarding the Allergan acquisition: "The combined company will produce robust cash flow which will support continued growth of our dividend, further investment in our pipeline, and reduction of debt. | But AbbVie has more going for it. In fact, I think AbbVie is a buy at these levels, with an upside expected shortly after the Allergan deal closes. Pharmaceutical maker AbbVie (NYSE: ABBV) has been caught in the downdraft, down 7% since the beginning of the year. |
24620.0 | 2020-04-15 00:00:00 UTC | 4 Dirt-Cheap Dividend Stocks to Buy as the Coronavirus Pandemic Continues | ABBV | https://www.nasdaq.com/articles/4-dirt-cheap-dividend-stocks-to-buy-as-the-coronavirus-pandemic-continues-2020-04-15 | nan | nan | If you're looking for safe, steady investments in these turbulent times, there's a surprising number of good choices. With many companies now trading at steep discounts due to the downturn fueled by the COVID-19 pandemic, now's an excellent time to grow your portfolio with high-quality, dividend-paying stocks.
One of the best places for dividend investors to check out is the healthcare sector. While other businesses are struggling amid this pandemic, people will still need to take their medications regardless of what's going on in the world. As such, healthcare companies are considered to be among the safest investments right now in this market. Here are four solid companies in this industry that are boasting impressive dividends while still trading at shockingly low valuations.
Image Source: Getty Images
1. GlaxoSmithKline
GlaxoSmithKline (NYSE: GSK) tumbled down to a more than 10-year-low in March. While this decline seems like an overreaction, the fact that the stock is trading cheaply is good news for value and dividend investors alike. GlaxoSmithKline's dividend yield sits at a lucrative 5.8%, with the stock trading at bargain-bin valuations. The company's price-to-sales (P/S) ratio is just 2.3, the lowest on this list, while its trailing price-to-earnings ratio (P/E) comes in at 16.9.
GlaxoSmithKline has a fairly diversified business compared to other pharmaceutical giants on the market. The company's largest revenue driver is its pharmaceuticals business, which brought in 17.6 billion British pounds in revenue for 2019. However, revenue growth in this area remains quite slow, notching only a 2% increase from 2018.
Vaccines and consumer healthcare are both smaller segments, bringing in around 7.2 billion and 9 billion pounds in revenue for 2019, respectively. However, they are growing much faster than GlaxoSmithKline's pharmaceuticals business. The two segments reported revenue growth of 21% and 17%, respectively.
GlaxoSmithKline also announced a number of recent partnerships related to combating COVID-19, including a deal with a Chinese biotech, Xiamen Innovax Biotech, to develop a COVID-19 vaccine. While it's easy to get caught up in this excitement, there's already a fair amount of competition in this space, with a number of companies starting clinical trials. Additionally, GlaxoSmithKline emphasized that it doesn't expect to see any profit from this potential COVID-19 vaccine should it turn out to be a success.
Overall, GlaxoSmithKline's impressive dividend alongside its diversified business is enough to make it a compelling addition to most investors' portfolios.
2. AbbVie
When it comes to pharmaceutical companies boasting sky-high dividends, look no further than AbbVie (NYSE: ABBV). The stock currently offers a 5.9% dividend yield for investors, with a P/S ratio of 3.6 and trailing P/E multiple of 15..
AbbVie holds the distinction of owning one of the top-selling drugs in the world, an inflammatory treatment called Humira. While there is some concern surrounding the drug's patent expiration and the subsequent competition from new generics that would emerge, AbbVie's patent protection for Humira will still last until 2023. Until then, AbbVie's free to enjoy continued revenue growth from this mega-blockbuster drug. In the U.S. market, Humira experienced 8.6% growth in Q4 2019 year over year.
The company has other promising treatments with impressive growth as well. AbbVie's second-best-selling drug is Imbruvica, a type of specific cancer medication used in conditions such as leukemia and lymphoma (both are blood cancers). The drug saw fourth-quarter global revenue of $1.3 billion, a 28.9% increase from Q4 2018.
Although AbbVie's overall revenue growth is slower than that of some of the other companies on this list (full-year net revenue was up just 1.6% for 2019), AbbVie makes up for it by offering one of the best dividend yields you can find in the healthcare market right now.
3. Bristol Myers Squibb
With a 3.05% yield, Bristol Myers Squibb's (NYSE: BMY) dividend is on the smaller side compared to the other names on this list. However, what makes this healthcare stock a buy right now is its remarkably cheap valuation given its growth potential. The company currently has a P/S ratio of just 3.9 and its trailing P/E ratio is 29.3. While shares aren't trading as cheaply as they were in late March, this value stock still is a steal.
Bristol's lineup of blockbuster drugs was already impressive on its own, but following its $74 billion acquisition of Celgene last year, the company's growth prospects look better than ever. In the most recent quarter, Bristol's current top-selling drugs -- Opdivo, Eliquis, and Revlimid -- brought in $1.8 billion, $2 billion, and $1.3 billion in revenue, respectively.
Revlimid, Bristol's newest addition acquired from the Celgene deal, treats a type of bone marrow cancer called multiple myeloma. Eliquis is Bristol's leading blood clot (deep vein thrombosis) treatment, while Eliquis is a well-known non-small-cell lung cancer treatment for patients who have already tried chemotherapy. By 2024, these three drugs are all expected to be among the top 10 best-selling drugs in the world.
All things considered, it's not surprising that the company has seen stellar growth figures. Bristol Myers reported a 33% increase in fourth-quarter revenue between 2019 and 2018, to $7.9 billion. As to be expected after such a massive acquisition, Bristol's has quite a bit of debt on its balance sheet. The company reported $46.7 billion in debt in Q4 2019, while its cash reserves came in at around $16.2 billion.
It's hard to find a company boasting an impressive dividend, excellent growth prospects, and a cheap valuation. Bristol Myers Squibb is one of the rare stocks out there that tick off all three of these boxes.
4. Pfizer
Last but not least: Pfizer (NYSE: PFE). The company offers a respectable 4.3% dividend yield, with a P/S ratio of 3.9 and a trailing P/E ratio of 12.2. Unlike some of the other companies on this list, Pfizer has been struggling with revenue growth.
Full-year 2019 revenue came in at $51.8 billion, a slight 1% decline from 2018. However, the picture is a bit more nuanced than it first appears. While Pfizer's biopharma division has been doing well, reporting an 8% growth rate for 2019, the Upjohn unit has been weighing down the company. Although this unit includes some well-known drugs, such as Viagra and cholesterol-lowering Lipitor, sales have fallen by 16% over the past year.
The good news is that Pfizer is planning to spin off its Upjohn unit, which will combine with Mylan. With this weight off its shoulders, many investors expect Pfizer to do much better financially in the years to come as it will be able to focus on what it does best: developing new drug candidates.
On that subject, Pfizer has one of the most impressive portfolios of drug candidates out there. This includes 23 phase 3 trials underway, alongside nine clinical programs currently awaiting regulatory approval. Among Pfizer's more promising candidates on the verge of approval are an acute myeloid leukemia drug, Daurismo, as well as a second- or third-line colorectal cancer drug combo, Braftovi and Erbitux.
Betting on Pfizer during the initial stages of this transformation is likely to pay off for income investors down the road.
10 stocks we like better than Pfizer
When investing geniuses David and Tom Gardner have a stock tip, it can pay to listen. After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor, has tripled the market.*
David and Tom just revealed what they believe are the ten best stocks for investors to buy right now... and Pfizer wasn't one of them! That's right -- they think these 10 stocks are even better buys.
See the 10 stocks
*Stock Advisor returns as of March 18, 2020
Mark Prvulovic has no position in any of the stocks mentioned. The Motley Fool owns shares of and recommends Bristol Myers Squibb. The Motley Fool recommends Mylan. The Motley Fool has a disclosure policy.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | The stock currently offers a 5.9% dividend yield for investors, with a P/S ratio of 3.6 and trailing P/E multiple of 15.. AbbVie holds the distinction of owning one of the top-selling drugs in the world, an inflammatory treatment called Humira. AbbVie When it comes to pharmaceutical companies boasting sky-high dividends, look no further than AbbVie (NYSE: ABBV). While there is some concern surrounding the drug's patent expiration and the subsequent competition from new generics that would emerge, AbbVie's patent protection for Humira will still last until 2023. | AbbVie When it comes to pharmaceutical companies boasting sky-high dividends, look no further than AbbVie (NYSE: ABBV). The stock currently offers a 5.9% dividend yield for investors, with a P/S ratio of 3.6 and trailing P/E multiple of 15.. AbbVie holds the distinction of owning one of the top-selling drugs in the world, an inflammatory treatment called Humira. While there is some concern surrounding the drug's patent expiration and the subsequent competition from new generics that would emerge, AbbVie's patent protection for Humira will still last until 2023. | The stock currently offers a 5.9% dividend yield for investors, with a P/S ratio of 3.6 and trailing P/E multiple of 15.. AbbVie holds the distinction of owning one of the top-selling drugs in the world, an inflammatory treatment called Humira. Although AbbVie's overall revenue growth is slower than that of some of the other companies on this list (full-year net revenue was up just 1.6% for 2019), AbbVie makes up for it by offering one of the best dividend yields you can find in the healthcare market right now. AbbVie When it comes to pharmaceutical companies boasting sky-high dividends, look no further than AbbVie (NYSE: ABBV). | The stock currently offers a 5.9% dividend yield for investors, with a P/S ratio of 3.6 and trailing P/E multiple of 15.. AbbVie holds the distinction of owning one of the top-selling drugs in the world, an inflammatory treatment called Humira. Although AbbVie's overall revenue growth is slower than that of some of the other companies on this list (full-year net revenue was up just 1.6% for 2019), AbbVie makes up for it by offering one of the best dividend yields you can find in the healthcare market right now. AbbVie When it comes to pharmaceutical companies boasting sky-high dividends, look no further than AbbVie (NYSE: ABBV). |
24621.0 | 2020-04-13 00:00:00 UTC | Ex-Dividend Reminder: AbbVie, Allergan and Abbott Laboratories | ABBV | https://www.nasdaq.com/articles/ex-dividend-reminder%3A-abbvie-allergan-and-abbott-laboratories-2020-04-13 | nan | nan | Looking at the universe of stocks we cover at Dividend Channel, on 4/14/20, AbbVie Inc (Symbol: ABBV), Allergan PLC (Symbol: AGN), and Abbott Laboratories (Symbol: ABT) will all trade ex-dividend for their respective upcoming dividends. AbbVie Inc will pay its quarterly dividend of $1.18 on 5/15/20, Allergan PLC will pay its quarterly dividend of $0.74 on 6/15/20, and Abbott Laboratories will pay its quarterly dividend of $0.36 on 5/15/20. As a percentage of ABBV's recent stock price of $81.08, this dividend works out to approximately 1.46%, so look for shares of AbbVie Inc to trade 1.46% lower — all else being equal — when ABBV shares open for trading on 4/14/20. Similarly, investors should look for AGN to open 0.40% lower in price and for ABT to open 0.42% lower, all else being equal.
Below are dividend history charts for ABBV, AGN, and ABT, showing historical dividends prior to the most recent ones declared.
AbbVie Inc (Symbol: ABBV):
Allergan PLC (Symbol: AGN):
Abbott Laboratories (Symbol: ABT):
In general, dividends are not always predictable, following the ups and downs of company profits over time. Therefore, a good first due diligence step in forming an expectation of annual yield going forward, is looking at the history above, for a sense of stability over time. This can help in judging whether the most recent dividends from these companies are likely to continue. If they do continue, the current estimated yields on annualized basis would be 5.82% for AbbVie Inc, 1.61% for Allergan PLC, and 1.67% for Abbott Laboratories.
In Monday trading, AbbVie Inc shares are currently up about 1.7%, Allergan PLC shares are up about 0.8%, and Abbott Laboratories shares are up about 0.3% on the day.
Click here to learn which 25 S.A.F.E. dividend stocks should be on your radar screen »
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | As a percentage of ABBV's recent stock price of $81.08, this dividend works out to approximately 1.46%, so look for shares of AbbVie Inc to trade 1.46% lower — all else being equal — when ABBV shares open for trading on 4/14/20. If they do continue, the current estimated yields on annualized basis would be 5.82% for AbbVie Inc, 1.61% for Allergan PLC, and 1.67% for Abbott Laboratories. Looking at the universe of stocks we cover at Dividend Channel, on 4/14/20, AbbVie Inc (Symbol: ABBV), Allergan PLC (Symbol: AGN), and Abbott Laboratories (Symbol: ABT) will all trade ex-dividend for their respective upcoming dividends. | Looking at the universe of stocks we cover at Dividend Channel, on 4/14/20, AbbVie Inc (Symbol: ABBV), Allergan PLC (Symbol: AGN), and Abbott Laboratories (Symbol: ABT) will all trade ex-dividend for their respective upcoming dividends. AbbVie Inc will pay its quarterly dividend of $1.18 on 5/15/20, Allergan PLC will pay its quarterly dividend of $0.74 on 6/15/20, and Abbott Laboratories will pay its quarterly dividend of $0.36 on 5/15/20. AbbVie Inc (Symbol: ABBV): Allergan PLC (Symbol: AGN): Abbott Laboratories (Symbol: ABT): In general, dividends are not always predictable, following the ups and downs of company profits over time. | Looking at the universe of stocks we cover at Dividend Channel, on 4/14/20, AbbVie Inc (Symbol: ABBV), Allergan PLC (Symbol: AGN), and Abbott Laboratories (Symbol: ABT) will all trade ex-dividend for their respective upcoming dividends. AbbVie Inc will pay its quarterly dividend of $1.18 on 5/15/20, Allergan PLC will pay its quarterly dividend of $0.74 on 6/15/20, and Abbott Laboratories will pay its quarterly dividend of $0.36 on 5/15/20. AbbVie Inc (Symbol: ABBV): Allergan PLC (Symbol: AGN): Abbott Laboratories (Symbol: ABT): In general, dividends are not always predictable, following the ups and downs of company profits over time. | As a percentage of ABBV's recent stock price of $81.08, this dividend works out to approximately 1.46%, so look for shares of AbbVie Inc to trade 1.46% lower — all else being equal — when ABBV shares open for trading on 4/14/20. If they do continue, the current estimated yields on annualized basis would be 5.82% for AbbVie Inc, 1.61% for Allergan PLC, and 1.67% for Abbott Laboratories. Looking at the universe of stocks we cover at Dividend Channel, on 4/14/20, AbbVie Inc (Symbol: ABBV), Allergan PLC (Symbol: AGN), and Abbott Laboratories (Symbol: ABT) will all trade ex-dividend for their respective upcoming dividends. |
24622.0 | 2020-04-13 00:00:00 UTC | Reasons for hope: the drugs, tests and tactics that may conquer coronavirus | ABBV | https://www.nasdaq.com/articles/reasons-for-hope%3A-the-drugs-tests-and-tactics-that-may-conquer-coronavirus-2020-04-13 | nan | nan | By Christine Soares
April 13 (Reuters) - With much of the world living in lockdown, the spread of the new coronavirus, SARS-CoV-2, that was first detected in China late last year is beginning to slow in some places. As of April 12, 1.8 million had been infected and 115,000 killed by COVID-19, the disease caused by the virus.
While a safe, effective vaccine is still more than a year away, researchers are rushing to repurpose existing drugs and non-drug therapies as well as testing promising experimental drugs that were already in clinical trials.
Even moderately effective therapies or combinations could dramatically reduce the crushing demand on hospitals and intensive care units, changing the nature of the risk the new pathogen represents to populations and healthcare systems. New drugs, together with new diagnostics, antibody tests, patient- and contact-tracing technologies, disease surveillance and other early-warning tools, mean the anticipated next "wave" of the global pandemic does not have to be nearly as bad the first.
More than 70 vaccine candidates are also in development around the world, with at least five in preliminary testing in people. Here are some of the drugs, vaccines and other therapies in development:
*DRUGS*
REMDESIVIR - GILEAD SCIENCESGILD.O
Antiviral drug, originally developed to combat RNA viruses including respiratory syncytial virus. At least 13 trials underway in China, Europe and the U.S. with preliminary results from two Chinese trials expected as soon as April 2020. A February assessment by the WHO flagged this candidate as the most promising for battling COVID-19.
CAVEATS: Initial data are expected to come from studies of patients with relatively severe COVID-19. Because antivirals work best when patients are healthier, those results may show limited effectiveness.
STATUS: Repurposed Experimental
EARLY RESULTS: 0-3 months
FURTHER READING:
Gilead starts two late-stage studies to test drug for coronavirus
Link: https://www.reuters.com/article/us-health-china-gilead-sciences/gilead-starts-two-late-stage-studies-to-test-drug-for-coronavirus-idUSKCN20K38J
Investors await data on coronavirus drugs as market rally builds
Link: https://www.reuters.com/article/us-health-coronavirus-treatments-stocks/investors-await-data-on-coronavirus-drugs-as-market-rally-builds-idUSKBN21P34G
Gilead asks FDA to revoke orphan drug status for potential coronavirus drug
Link: https://www.reuters.com/article/health-coronavirus-gilead-sciences/gilead-asks-fda-to-revoke-orphan-drug-status-for-potential-coronavirus-drug-idUSL4N2BI4NV
Clinical Trials
Link: https://clinicaltrials.gov/ct2/results?cond=COVID&term=Remdesivir&cntry=&state=&city=&dist=
New England Journal of Medicine, April 2020
Link: https://www.nejm.org/doi/full/10.1056/NEJMoa2007016
HYDROXYCHLOROQUINE/CHLOROQUINE
Malaria drug also believed to have antiviral activity. Blocked SARS-CoV-2 entry into cells in an in-vitro experiment. In one small French study, some COVID-19 patients showed improvements but there was no way to know if the drug was the reason. Results published in April from another study in France and one in China found no benefit in patients treated with the drug. Dozens more clinical studies are underway around the world.
STATUS: Repurposed
EARLY RESULTS: 0-3 months
FURTHER READING:
Special Report: Doctors embrace drug touted by Trump for COVID-19, without hard evidence it works
Link: https://www.reuters.com/article/us-health-coronavirus-usa-hydroxychloroq/special-report-doctors-embrace-drug-touted-by-trump-for-covid-19-without-hard-evidence-it-works-idUSKBN21O2VO
Coronavirus drug hopefuls are cheap to make but may be in short supply
Link: https://www.reuters.com/article/us-health-coronavirus-production-costs/coronavirus-drug-hopefuls-are-cheap-to-make-but-may-be-in-short-supply-idUSKCN21S0WM
Clinical Trials
Link: https://clinicaltrials.gov/ct2/results?cond=COVID&term=hydroxychloroquine&cntry=&state=&city=&dist=
Journal of Zhejiang Univ (Med Sci), March 2020
Link: http://www.zjujournals.com/med/EN/10.3785/j.issn.1008-9292.2020.03.03
Médecine et Maladies Infectieuses, March 2020
Link: https://www.sciencedirect.com/science/article/pii/S0399077X20300858
Nature, February 2020
Link: https://www.nature.com/articles/s41422-020-0282-0
ACTEMRA (TOCILIZUMAB) - ROCHEROG.S
Monoclonal antibody approved for rheumatoid arthritis and also for treating the "cytokine storm" immune overresponse in cancer patients. Fifteen registered trials in China, Europe and the U.S. are testing it on COVID-19 patients, alone or in comparison to other therapies. One French trial is looking at 28-day effects on COVID-19 in patients with advanced or metastatic cancer.
STATUS: Repurposed
EARLY RESULTS: 0-3 months
FURTHER READING:
Coronavirus drug hopefuls are cheap to make but may be in short supply
Link: https://www.reuters.com/article/us-health-coronavirus-production-costs/coronavirus-drug-hopefuls-are-cheap-to-make-but-may-be-in-short-supply-idUSKCN21S0WM
Clinical Trials
Link: https://clinicaltrials.gov/ct2/show/NCT04333914
KEVZARA (SARILUMAB) - SANOFISASY.PA, REGENERON PHARMACEUTICALSREGN.O
Monoclonal antibody approved for inflammatory arthritis, and in trials targeting the "cytokine storm" immune response in severely ill COVID-19 patients. Regeneron's chief scientific officer has said initial data on effectiveness could come by late April.
STATUS: Repurposed
EARLY RESULTS: 0-3 months
FURTHER READING:
Data on arthritis drug to treat coronavirus could come within weeks, according to Regeneron executive
Link: https://www.reuters.com/article/us-health-coronavirus-regeneron-pharms/data-on-arthritis-drug-to-treat-coronavirus-could-come-within-weeks-regeneron-executive-idUSKCN21R2WN
Exclusive: Sanofi can produce millions of doses of potential coronavirus drug - CEO
Link: https://www.reuters.com/article/us-health-coronavirus-sanofi-exclusive/exclusive-sanofi-can-produce-millions-of-doses-of-potential-coronavirus-drug-ceo-idUSKBN21K3AD
Sanofi, Regeneron expand testing of potential coronavirus treatment
Link: https://www.reuters.com/article/us-health-coronavirus-sanofi-fr-regenero/sanofi-regeneron-expand-testing-of-potential-coronavirus-treatment-idUSKBN21H0E8
Clinical Trials
Link: https://clinicaltrials.gov/ct2/results?cond=Covid&term=sarilumab&cntry=&state=&city=&dist=
JAKAVI (RUXOLITINIB) - NOVARTISNOVN.S, INCYTEINCY.O
Developed to treat inflammatory and autoimmune diseases, and in late-stage development as a cream for atopic dermatitis. One trial each in Canada and Mexico will test the drug in COVID-19 patients with severe respiratory symptoms associated with the "cytokine storm" immune response, with preliminary results expected by June 2020. In the United States, Novartis established a managed access program for use in severe/very severe COVID-19 illness on April 7.
STATUS: Repurposed
EARLY RESULTS: 0-3 months
FURTHER READING:
Novartis, Incyte join repurposing wave to give Jakavi a trial run in COVID-19
Link: https://www.reuters.com/article/health-coronavirus-novartis/novartis-incyte-join-repurposing-wave-to-give-jakavi-a-trial-run-in-covid-19-idUSL8N2BR13T
Clinical Trials
Link: https://clinicaltrials.gov/ct2/show/NCT04337359
KALETRA (LOPINAVIR/RITONAVIR) - ABBVIEABBV.N
Antiviral combination used to treat and prevent HIV infections. More than twenty trials around the world are testing the drug as a COVID-19 treatment or post-exposure prophylaxis for people with high-risk close contact with a confirmed case. Initial results expected as soon as May 2020.
CAVEATS: One randomized controlled trial in China published results in March showing no differences in viral load or 28-day mortality among 199 patients. Median time to clinical improvement was one day shorter in patients taking the drug. However the same investigators, doctors at Jinyintan Hospital in Wuhan, said in April that they believe Kaletra, as well as a second drug, bismuth potassium citrate, helped some of the COVID-19 patients they treated.
STATUS: Repurposed
EARLY RESULTS: 0-3 months
FURTHER READING:
Key China coronavirus hospital says HIV drug beneficial to patients
Link: https://www.reuters.com/article/us-health-coronavirus-china-wuhan-hospit/key-china-coronavirus-hospital-says-hiv-drug-beneficial-to-patients-idUSKCN21R1LX
Mylan waives exclusive U.S. distribution rights for potential COVID-19 therapy
Link: https://www.reuters.com/article/us-health-coronavirus-mylan-nl/mylan-waives-exclusive-u-s-distribution-rights-for-potential-covid-19-therapy-idUSKBN21C34X
Clinical Trials
Link: https://clinicaltrials.gov/ct2/results?cond=Covid&term=Kaletra&cntry=&state=&city=&dist=
New England Journal of Medicine, March 2020
Link: https://www.nejm.org/doi/full/10.1056/NEJMoa2001282
RHACE2 APN01 - APEIRON BIOLOGICS
A recombinant human angiotensin converting enzyme 2 (rhACE2) under Phase-2 clinical development in ALI (Acute Lung Injury) and PAH (Pulmonal arterial hypertension). This synthetic version of the human protein that the novel coronavirus uses to enter cells is being tested in Austria to see if it can block viral entry and decrease viral replication in COVID-19 patients, reducing deaths or need for mechanical ventilation. Preliminary results from the trial that was announced on April 2 are expected in September 2020.
STATUS: Experimental
EARLY RESULTS: 3-6 months
FURTHER READING:
Clinical Trial
Link: https://clinicaltrials.gov/ct2/show/NCT04335136?term=APN01&cond=COVID&draw=2&rank=1
CAMOSTAT MESYLATE - UNIVERSITY OF AARHUS, DENMARK
Protease inhibitor licensed in Japan and South Korea to treat chronic pancreatitis. In vitro experiments found it blocks a mechanism SARS-Cov-2 uses to enter human cells. As of early April, an estimated 180 COVID-19 patients aged 18-110 were being recruited at nine locations in Denmark for a phase 2a trial that will examine 30-day changes in disease severity and mortality, with results expected by December 2020. The University of Tokyo also announced plans for a trial of camostat mesylate and a related drug, nafamostat mesylate, starting as early as April 2020.
STATUS: Repurposed
EARLY RESULTS: 6-12 months
IFX-1 - INFLARXIF0G.DE
Monoclonal antibody targeting complement activation product C5a. Designed to block a mechanism of inflammation, the drug is also in clinical trials for Hidradenitis Suppurativa, ANCA-associated vasculitis and Pyoderma Gangraenosum. In early April, a trial in the Netherlands launched to test IFX-1 in patients with severe COVID-19 pneumonia, with preliminary results expected in late October 2020.
STATUS: Experimental
EARLY RESULTS: 6-12 months
ASPIRIN, CLOPIDOGREL, RIVAROXABAN, ATORVASTATIN, OMEPRAZOLE - IMPERIAL COLLEGE LONDON
Trial of cardioprotective drugs to prevent direct damage to the heart muscle that appears to drive the severity of COVID-19 in certain patients as well as their likelihood of needing invasive critical care. The trial will include more than 3,000 patients in the UK, with a completion date of March 30, 2021.
EARLY RESULTS: 9-12 months
------
*VACCINES*
MRNA 1273 - MODERNA/NIAIDMRNA.O
RNA vaccine made with messenger-RNA (mRNA) encoding the spike protein of SARS-CoV-2 encapsulated in a lipid nanoparticle. The phase 1 trial with 45 subjects aged 18-55 at three locations in the U.S. will evaluate the vaccine's safety and provide early data on the immune response it induces. Trial completion is anticipated to be June 1, 2020.
STATUS: Experimental
EARLY RESULTS: 0-3 months
FURTHER READING:
J&J, Moderna sign deals with U.S. to produce huge quantity of possible coronavirus vaccines
Link: https://www.reuters.com/article/us-health-coronavirus-johnson-johnson/jj-moderna-sign-deals-with-u-s-to-produce-huge-quantity-of-possible-coronavirus-vaccines-idUSKBN21H1OY
Clinical Trial
Link: https://clinicaltrials.gov/ct2/show/NCT04283461
NVX-COV2373 - NOVAVAXNVAX.O
Novavax said its Matrix-M adjuvant would be used with the vaccine candidate - NVX-CoV2373 - to enhance immune responses. Trial in 130 adults is expected to begin in mid-May with with preliminary immunogenicity and safety results in July, according to the company.
CAVEATS: Strong immunogenicity in animal tests, but might require two doses in humans, which would limit supply.
STATUS: Experimental
EARLY RESULTS: 0-3 months
FURTHER READING:
Novavax to start human trial for novel coronavirus vaccine
Link: https://www.reuters.com/article/us-health-coronavirus-novavax/novavax-to-start-human-trial-for-novel-coronavirus-vaccine-idUSKBN21Q1BC
LENTIVIRAL MINIGENE VACCINES (LV-SMENP) - SHENZHEN GENO-IMMUNE MEDICAL INSTITUTE
Engineered minigenes encoding viral antigens; lentiviral vector designed to infect dendritic and T cells to induce immunity. The trial in 100 adults in Shenzen, China, is expected to be complete by July 31, 2020.
STATUS: Experimental
EARLY RESULTS: 3-6 months
BCG TUBERCULOSIS VACCINE - MURDOCH CHILDREN'S RESEARCH INSTITUTE; UMC UTRECHT
Bacillus Calmette-Guérin tuberculosis vaccine that induces a broad innate immune-system response, which has been shown to protect against infection or severe illness with other respiratory pathogens. Large trials in Australia and the Netherlands are testing whether using BCG to rev-up immune defenses in health workers and the elderly reduces unplanned absenteeism, respiratory illnesses including COVID-19, severe illnesses and deaths. Two additional trials by the Max Planck Institute in Germany of a TB vaccine candidate, VPM1002, are in the works.
STATUS: Repurposed
EARLY RESULTS: 3-6 months
FURTHER READING:
Explainer: How an old tuberculosis vaccine might help fight the new coronavirus
Link: https://www.reuters.com/article/us-health-coronavirus-tbvaccine-explaine/explainer-how-an-old-tuberculosis-vaccine-might-help-fight-the-new-coronavirus-idUSKBN21K372
Clinical Trials
Link: https://clinicaltrials.gov/ct2/results?cond=Covid&term=BCG&cntry=&state=&city=&dist=
INO-4800 - INOVIO PHARMACEUTICALSINO.O, COALITION FOR EPIDEMIC PREPAREDNESS INNOVATIONS (CEPI)
DNA plasmid vaccine delivered into the skin via a patch-style electroporation device. A clinical trial launched on April 3 could yield preliminary data by late summer, according to the company, which has said it can manufacture 1 million doses by year-end for additional trials and emergency use.
STATUS: Experimental
EARLY RESULTS: 3-6 months
FURTHER READING:
Potential COVID-19 vaccine shows promise in mouse study
Link: https://www.reuters.com/article/us-health-coronavirus-vaccine-candidate/potential-covid-19-vaccine-shows-promise-in-mouse-study-idUSKBN21K2BW
Clinical Trial
Link: https://clinicaltrials.gov/ct2/show/NCT04336410
AD5-NCOV - CANSINO BIOLOGICAL INC./BEIJING INSTITUTE OF BIOTECHNOLOGY
Non-replicating viral vector. A single-center phase 1 trial with 108 subjects aged 18-60 in Wuhan, Hubei, China, started in March to test the safety and immune responses generated by a recombinant vaccine that uses another respiratory virus, adenovirus, as a vector. On April 12, a randomized controlled phase 2 trial with 500 participants launched to test varying doses against placebo. Phase 1 completion is in late December 2020, and phase 2 results are expected in January 2021.
STATUS: Experimental
EARLY RESULTS: 6-12 months
CHADOX1 - UNIVERSITY OF OXFORD
Non-replicating chimpanzee adenovirus vector. Phase 1/2 trial with 510 subjects aged 18-55 at four centers in the United Kingdom. The trial will test safety and immunogenicity of one or two doses of the vaccine, and is expected to be completed in May 2021.
STATUS: Experimental
EARLY RESULTS: 12-18 months
FURTHER READING:
Epidemic response group ups coronavirus vaccine funding to $23.7 million
Link: https://www.reuters.com/article/us-health-coronavirus-vaccines-cepi/epidemic-response-group-ups-coronavirus-vaccine-funding-to-23-7-million-idUSKBN20X1PO
Epidemic response group ups coronavirus vaccine funding to $23.7 million
Link: https://www.reuters.com/article/us-health-coronavirus-vaccines-cepi/epidemic-response-group-ups-coronavirus-vaccine-funding-to-23-7-million-idUSKBN20X1PO
Clinical Trial
Link: https://clinicaltrials.gov/ct2/show/NCT04324606
------
*NON-DRUG THERAPIES*
CONVALESCENT PLASMA
Blood plasma from recovered COVID-19 patients is transfused into patients who are currently ill, in the hope the freshly-made antibodies it contains will help fight the virus. The method has been used for more than 100 years and carries little risk of harm or side effects. Small case studies suggest it may help reduce virus levels, and controlled trials are in progress in China, Europe and the United States to gather stronger evidence for a benefit. Results published in April from a study in 10 patients with severe illness in China found significant improvement compared to similar patients who did not receive the treatment.
CAVEATS: Immediately available and already in limited use, but supply of plasma from recovered patients may not be sufficient to meet all needs. Further studies of recovered patients must also determine if everyone produces a full immune response to the infection, including "neutralizing antibodies," at sufficiently high levels to become donors.
EARLY RESULTS: 0-3 months
FURTHER READING:
Why U.S. hospitals see promise in plasma from new coronavirus patients
Link: https://www.reuters.com/article/us-health-coronavirus-usa-plasma-explain/why-u-s-hospitals-see-promise-in-plasma-from-new-coronavirus-patients-idUSKBN21M0E3
Clinical Trials
Link: https://clinicaltrials.gov/ct2/results?cond=Covid&term=convalescent+plasma&cntry=&state=&city=&dist=&Search=Search
NKG2D-ACE2 CAR-NK CELLS - CHONGQING PUBLIC HEALTH MEDICAL CENTER, CHONGQING SIDEMU BIOTECHNOLOGY TECHNOLOGY
NKG2D receptor for the immune system's natural killer (NK) cells paired with the ACE-2 receptor that the coronavirus uses to enter human cells. A multicenter Phase 1/2 trial in 90 patients is testing whether this cell therapy can prevent the SARS-CoV-2 virus from entering cells and multiplying, and will look at efficacy over 28 days in patients with severe or critical COVID-19 pneumonia.
STATUS: Experimental
EARLY RESULTS: 0-3 months
------
*TESTING*
SEROLOGY/ANTIBODY TESTING
Governments and academic groups have started to test blood for antibodies indicating that a person has been exposed to the new virus, with or without showing symptoms. The presence of antibodies indicates past infection, but separate, ongoing research is needed to know what type and concentration of virus-neutralizing antibodies protect against a new infection, whether all infections produce a full antibody response, and how long protection might last.
Wide serology testing for antibodies will soon provide a broader understanding of the scope and dynamics of the pandemic, help identify which recovered patients may have some immunity to reinfection and for how long, and also help identify the neutralizing antibodies that could become templates for monoclonal antibody therapies as well as models for desired responses from a vaccine candidate. Data from serology testing are expected to begin appearing within weeks.
CAVEATS: Early data on COVID-19 patients in China suggests that they develop varying amounts of antibodies in response to infection. One pre-publication report analyzed plasma from 175 patients and found that a sign of inflammation correlated with higher antibody titers and that younger patients were less likely to produce large amounts of antibodies. Experts think instances of "reinfection" in recovered patients are more likely relapses in patients whose bodies had not cleared the virus. Data is still lacking on whether mild or symptomless infections generate meaningful antibody responses or protection.
STATUS: Experimental
EARLY RESULTS: 0-12 months
FURTHER READING:
The Lancet Infectious Diseases, March 2020
Link: https://doi.org/10.1016/S1473-3099(20)30196-1
Preprint, March 2020
Link: https://www.medrxiv.org/content/10.1101/2020.03.17.20036640v1
Preprint, April 2020
Link: https://www.medrxiv.org/content/10.1101/2020.03.30.20047365v1
Clinical Trial, U.S.
Link: https://clinicaltrials.gov/ct2/show/NCT04334954
Clinical Trial, France
Link: https://clinicaltrials.gov/ct2/show/NCT04325646
Clinical Trial, France
Link: https://clinicaltrials.gov/ct2/show/NCT04322279
Clinical Trial, France
Link: https://clinicaltrials.gov/ct2/show/NCT04325646
Clinical Trial, UK
Link: https://clinicaltrials.gov/ct2/show/NCT04334876
Clinical Trial, Italy
Link: https://clinicaltrials.gov/ct2/show/NCT04334876
Clinical Trial, Belgium
Link: https://clinicaltrials.gov/ct2/show/NCT04327570
(Reporting by Christine Soares, editing by Nancy Lapid)
((tiffany.wu@thomsonreuters.com; +1 646 223 6000;))
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Even moderately effective therapies or combinations could dramatically reduce the crushing demand on hospitals and intensive care units, changing the nature of the risk the new pathogen represents to populations and healthcare systems. A single-center phase 1 trial with 108 subjects aged 18-60 in Wuhan, Hubei, China, started in March to test the safety and immune responses generated by a recombinant vaccine that uses another respiratory virus, adenovirus, as a vector. Small case studies suggest it may help reduce virus levels, and controlled trials are in progress in China, Europe and the United States to gather stronger evidence for a benefit. | Data on arthritis drug to treat coronavirus could come within weeks, according to Regeneron executive Link: https://www.reuters.com/article/us-health-coronavirus-regeneron-pharms/data-on-arthritis-drug-to-treat-coronavirus-could-come-within-weeks-regeneron-executive-idUSKCN21R2WN Exclusive: Sanofi can produce millions of doses of potential coronavirus drug - CEO Link: https://www.reuters.com/article/us-health-coronavirus-sanofi-exclusive/exclusive-sanofi-can-produce-millions-of-doses-of-potential-coronavirus-drug-ceo-idUSKBN21K3AD Sanofi, Regeneron expand testing of potential coronavirus treatment Link: https://www.reuters.com/article/us-health-coronavirus-sanofi-fr-regenero/sanofi-regeneron-expand-testing-of-potential-coronavirus-treatment-idUSKBN21H0E8 Clinical Trials Link: https://clinicaltrials.gov/ct2/results?cond=Covid&term=sarilumab&cntry=&state=&city=&dist= Epidemic response group ups coronavirus vaccine funding to $23.7 million Link: https://www.reuters.com/article/us-health-coronavirus-vaccines-cepi/epidemic-response-group-ups-coronavirus-vaccine-funding-to-23-7-million-idUSKBN20X1PO Epidemic response group ups coronavirus vaccine funding to $23.7 million Link: https://www.reuters.com/article/us-health-coronavirus-vaccines-cepi/epidemic-response-group-ups-coronavirus-vaccine-funding-to-23-7-million-idUSKBN20X1PO Clinical Trial Link: https://clinicaltrials.gov/ct2/show/NCT04324606 ------ The Lancet Infectious Diseases, March 2020 Link: https://doi.org/10.1016/S1473-3099(20)30196-1 Preprint, March 2020 Link: https://www.medrxiv.org/content/10.1101/2020.03.17.20036640v1 Preprint, April 2020 Link: https://www.medrxiv.org/content/10.1101/2020.03.30.20047365v1 Clinical Trial, U.S. Link: https://clinicaltrials.gov/ct2/show/NCT04334954 Clinical Trial, France Link: https://clinicaltrials.gov/ct2/show/NCT04325646 Clinical Trial, France Link: https://clinicaltrials.gov/ct2/show/NCT04322279 Clinical Trial, France Link: https://clinicaltrials.gov/ct2/show/NCT04325646 Clinical Trial, UK Link: https://clinicaltrials.gov/ct2/show/NCT04334876 Clinical Trial, Italy Link: https://clinicaltrials.gov/ct2/show/NCT04334876 Clinical Trial, Belgium Link: https://clinicaltrials.gov/ct2/show/NCT04327570 (Reporting by Christine Soares, editing by Nancy Lapid) ((tiffany.wu@thomsonreuters.com; +1 646 223 6000;)) The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Gilead starts two late-stage studies to test drug for coronavirus Link: https://www.reuters.com/article/us-health-china-gilead-sciences/gilead-starts-two-late-stage-studies-to-test-drug-for-coronavirus-idUSKCN20K38J Investors await data on coronavirus drugs as market rally builds Link: https://www.reuters.com/article/us-health-coronavirus-treatments-stocks/investors-await-data-on-coronavirus-drugs-as-market-rally-builds-idUSKBN21P34G Gilead asks FDA to revoke orphan drug status for potential coronavirus drug Link: https://www.reuters.com/article/health-coronavirus-gilead-sciences/gilead-asks-fda-to-revoke-orphan-drug-status-for-potential-coronavirus-drug-idUSL4N2BI4NV Clinical Trials Link: https://clinicaltrials.gov/ct2/results?cond=COVID&term=Remdesivir&cntry=&state=&city=&dist= New England Journal of Medicine, April 2020 Link: https://www.nejm.org/doi/full/10.1056/NEJMoa2007016 Special Report: Doctors embrace drug touted by Trump for COVID-19, without hard evidence it works Link: https://www.reuters.com/article/us-health-coronavirus-usa-hydroxychloroq/special-report-doctors-embrace-drug-touted-by-trump-for-covid-19-without-hard-evidence-it-works-idUSKBN21O2VO Coronavirus drug hopefuls are cheap to make but may be in short supply Link: https://www.reuters.com/article/us-health-coronavirus-production-costs/coronavirus-drug-hopefuls-are-cheap-to-make-but-may-be-in-short-supply-idUSKCN21S0WM Clinical Trials Link: https://clinicaltrials.gov/ct2/results?cond=COVID&term=hydroxychloroquine&cntry=&state=&city=&dist= Journal of Zhejiang Univ (Med Sci), March 2020 Link: http://www.zjujournals.com/med/EN/10.3785/j.issn.1008-9292.2020.03.03 Médecine et Maladies Infectieuses, March 2020 Link: https://www.sciencedirect.com/science/article/pii/S0399077X20300858 Nature, February 2020 Link: https://www.nature.com/articles/s41422-020-0282-0 The Lancet Infectious Diseases, March 2020 Link: https://doi.org/10.1016/S1473-3099(20)30196-1 Preprint, March 2020 Link: https://www.medrxiv.org/content/10.1101/2020.03.17.20036640v1 Preprint, April 2020 Link: https://www.medrxiv.org/content/10.1101/2020.03.30.20047365v1 Clinical Trial, U.S. Link: https://clinicaltrials.gov/ct2/show/NCT04334954 Clinical Trial, France Link: https://clinicaltrials.gov/ct2/show/NCT04325646 Clinical Trial, France Link: https://clinicaltrials.gov/ct2/show/NCT04322279 Clinical Trial, France Link: https://clinicaltrials.gov/ct2/show/NCT04325646 Clinical Trial, UK Link: https://clinicaltrials.gov/ct2/show/NCT04334876 Clinical Trial, Italy Link: https://clinicaltrials.gov/ct2/show/NCT04334876 Clinical Trial, Belgium Link: https://clinicaltrials.gov/ct2/show/NCT04327570 (Reporting by Christine Soares, editing by Nancy Lapid) ((tiffany.wu@thomsonreuters.com; +1 646 223 6000;)) The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | In early April, a trial in the Netherlands launched to test IFX-1 in patients with severe COVID-19 pneumonia, with preliminary results expected in late October 2020. Novavax to start human trial for novel coronavirus vaccine Link: https://www.reuters.com/article/us-health-coronavirus-novavax/novavax-to-start-human-trial-for-novel-coronavirus-vaccine-idUSKBN21Q1BC Wide serology testing for antibodies will soon provide a broader understanding of the scope and dynamics of the pandemic, help identify which recovered patients may have some immunity to reinfection and for how long, and also help identify the neutralizing antibodies that could become templates for monoclonal antibody therapies as well as models for desired responses from a vaccine candidate. |
24623.0 | 2020-04-12 00:00:00 UTC | Is Galapagos Stock a Buy? | ABBV | https://www.nasdaq.com/articles/is-galapagos-stock-a-buy-2020-04-12 | nan | nan | After its stock reached all-time highs in February, Galapagos (NASDAQ: GLPG) saw those gains disappear. Don't fret, though. The stock price is down less than 1% year to date -- a decrease many investors, and companies, can only dream of in the current environment.
Is Galapagos's lack of price decline a signal of quality, and should investors look to acquire shares now despite the company's healthy valuation? Let's dig in.
Image Source: Getty Images
2020 will be a significant year for Galapagos. The company's lead drug, filgotinib, awaits regulatory approval in the U.S., Europe, and Japan as a treatment for moderate to severe rheumatoid arthritis (RA). Galapagos also expects to report top-line data this quarter from a phase 3 clinical trial of filgotinib in patients with ulcerative colitis. Beyond filgotinib, three additional pipeline drugs should report results from mid-stage clinical trials. Finally, Galapagos expects to see early clinical data from its novel "Toledo" program for inflammation.
Financial strength
Galapagos boasts a huge war chest, in excess of 1.86 billion euros, to fund its research and development. The company can thank its strategic partner Gilead (NASDAQ: GILD) for that; last August, the two companies entered into a 10-year global research and development collaboration for multiple products. Gilead paid $3.95 billion and made a $1.1 billion equity investment into Galapagos. This built upon a previous 2015 arrangement to co-develop and commercialize filgotinib. In that deal, Gilead paid $300 million and made a $425 million equity investment up front, and it will continue to pay milestones and royalties.
In short, investors should take comfort in Galapagos's healthy cash position and its alignment with one of the world's leading biopharma companies.
Filgotinib approval decision
The biggest catalyst for Galapagos will be the potential approval of filgotinib. Interestingly, filgotinib was submitted to European and Japanese regulators before the U.S. Food and Drug Administration (FDA). Last August, the European Medicines Agency validated filgotinib's marketing application, meaning the agency acknowledged receipt of the submission and an intent to review it. In October, a submission for approval of filgotinib as a treatment for RA was submitted to the Japanese Ministry of Health, Labor and Welfare.
Gilead announced on Dec. 19 that it had submitted a New Drug Application (NDA) to the FDA for filgotinib as a treatment for moderate to severe RA. Gilead used a priority review voucher, which commits the FDA to reviewing the NDA within a six-month timeframe instead of the standard 10 months. This means the decision deadline will fall in June.
According to a January 2020 report to Congress from the U.S. Government Accountability Office, Gilead bought the priority review voucher from Ultragenyx Pharmaceutical (NASDAQ: RARE) for $80.6 million. This means that Gilead perceives getting to market four months earlier as being of greater value than the price of the voucher. This is a potential signal of management's confidence in the drug, and it could also indicate a competitive field in which a head start to establish market share could prove to have long-term benefit.
Competition looms
Gilead faces stiff competition in RA, which affects more than 1 million people in the United States. There are currently three FDA-approved drugs for RA that inhibit enzymes called Janus kinases (JAK) to reduce inflammation, the same mechanism used by filgotinib. AbbVie (NYSE: ABBV) received FDA approval last August for Rinvoq, its once-daily oral treatment for patients with moderate to severely active RA who have an inadequate or intolerant response to an existing RA treatment called methotrexate. Beyond Rinvoq, there's also Olumiant from Eli Lilly (NYSE: LLY) and Xeljanz from Pfizer (NYSE: PFE). However, not all of these drugs are equal, and each has its drawbacks. For example, last year the FDA added a boxed warning label to Xeljanz stating the drug increased the risk of blood clots and death. Galapagos and Gilead will need to differentiate filgotinib from the others to be successful.
Galapagos will take the commercial lead in certain European countries (France, Germany, Italy, Spain, the UK, Belgium, the Netherlands, and Luxembourg), leaving the rest of the world to Gilead. In Japan, Gilead teamed up with Japanese pharma Eisai to distribute and co-promote filgotinib to the 600,000 to 1 million Japanese people suffering from RA.
The takeaway
Biotech investors will be focused on the potential approval and subsequent launch of filgotinib this year. This article has not even touched on the other indications for filgotinib, several of which are in late-stage clinical testing, or the pipeline candidates which hold promise. The current valuation, in excess of $13 billion, makes me think the potential is already priced in. I want to see how the launch of filgotinib in RA goes. In the meantime, other drug stocks offer better chances for outsized returns.
10 stocks we like better than Galapagos
When investing geniuses David and Tom Gardner have a stock tip, it can pay to listen. After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor, has tripled the market.*
David and Tom just revealed what they believe are the ten best stocks for investors to buy right now… and Galapagos wasn't one of them! That's right -- they think these 10 stocks are even better buys.
See the 10 stocks
*Stock Advisor returns as of March 18, 2020
David Haen owns shares of Pfizer. The Motley Fool owns shares of and recommends Gilead Sciences. The Motley Fool has a disclosure policy.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | AbbVie (NYSE: ABBV) received FDA approval last August for Rinvoq, its once-daily oral treatment for patients with moderate to severely active RA who have an inadequate or intolerant response to an existing RA treatment called methotrexate. According to a January 2020 report to Congress from the U.S. Government Accountability Office, Gilead bought the priority review voucher from Ultragenyx Pharmaceutical (NASDAQ: RARE) for $80.6 million. This is a potential signal of management's confidence in the drug, and it could also indicate a competitive field in which a head start to establish market share could prove to have long-term benefit. | AbbVie (NYSE: ABBV) received FDA approval last August for Rinvoq, its once-daily oral treatment for patients with moderate to severely active RA who have an inadequate or intolerant response to an existing RA treatment called methotrexate. Gilead paid $3.95 billion and made a $1.1 billion equity investment into Galapagos. In that deal, Gilead paid $300 million and made a $425 million equity investment up front, and it will continue to pay milestones and royalties. | AbbVie (NYSE: ABBV) received FDA approval last August for Rinvoq, its once-daily oral treatment for patients with moderate to severely active RA who have an inadequate or intolerant response to an existing RA treatment called methotrexate. The company's lead drug, filgotinib, awaits regulatory approval in the U.S., Europe, and Japan as a treatment for moderate to severe rheumatoid arthritis (RA). Filgotinib approval decision The biggest catalyst for Galapagos will be the potential approval of filgotinib. | AbbVie (NYSE: ABBV) received FDA approval last August for Rinvoq, its once-daily oral treatment for patients with moderate to severely active RA who have an inadequate or intolerant response to an existing RA treatment called methotrexate. Filgotinib approval decision The biggest catalyst for Galapagos will be the potential approval of filgotinib. I want to see how the launch of filgotinib in RA goes. |
24624.0 | 2020-04-11 00:00:00 UTC | 3 Top Pharma Stocks to Buy in April | ABBV | https://www.nasdaq.com/articles/3-top-pharma-stocks-to-buy-in-april-2020-04-11 | nan | nan | In most years, April isn't a special month to buy stocks. It's not a bad time to invest, but there's nothing that makes April better than other months. But this April is different.
Because of the coronavirus pandemic and the subsequent stock market plunge, this month is a very good time to invest in stocks. I'd argue that it's an especially great time to invest in shares of big drugmakers. Many pharma stocks have been hammered much harder than is warranted. My view is that three pharma stocks stand out as the top picks to buy in April.
Image source: Getty Images.
1. AbbVie
There's one overwhelmingly compelling argument for buying shares of AbbVie (NYSE: ABBV). The drugmaker's dividend yields 6%. Investors who buy AbbVie now will lock in a juicy yield that should only get better in the future.
Including the time that it was part of Abbott Labs, AbbVie has paid out a dividend in every year since 1924. It's increased the dividend payout for a remarkable 47 consecutive years. And since being spun off from Abbott in 2013, AbbVie's dividend has nearly tripled.
Can AbbVie keep the dividends flowing and growing? I think so. Sales continue to soar for the company's cancer drugs Imbruvica and Venclexta. AbbVie's new immunology drugs Rinvoq and Skyrizi are expected to become megablockbusters over the next few years. The drugmaker's pending acquisition of Allergan will bring successful products including Botox and antipsychotic drug Vraylar into its lineup.
The primary headwind for AbbVie is the loss of exclusivity for its top-selling drug Humira in Europe, with the prospects of biosimilar competition in the U.S. only three years away. However, AbbVie should be able to offset the sales declines for Humira with its current products, promising pipeline candidates, and the addition of Allergan. The company might not deliver awe-inspiring earnings growth, but with its tremendous dividend, it doesn't need to in order for investors to still enjoy solid total returns.
2. Bristol Myers Squibb
If you're looking for great growth prospects in addition to a nice dividend, check out Bristol Myers Squibb (NYSE: BMY). The big drugmaker's dividend yield stands at more than 3%, which isn't too shabby at all. But I think that BMS is poised to generate impressive growth over the next few years.
It certainly helps that BMS claims two of the drugs that market researcher EvaluatePharma projects will rank in the top five best-selling blockbusters in the world by 2024 -- blood thinner Eliquis and cancer immunotherapy Opdivo. BMS also has a couple of rising stars with arthritis drug Orencia and multiple myeloma drug Empliciti.
But the acquisition of Celgene in November 2019 was a game changer for Bristol Myers Squibb. The company's lineup now includes blockbuster blood cancer drugs Revlimid and Pomalyst, along with solid tumor drug Abraxane. And thanks to the Celgene deal, BMS also now has recently approved drugs Reblozyl and Zeposia that have blockbuster-sales potential.
More winners should be on the way. Celgene's pipeline was loaded with great candidates that BMS now has. The most promising of these include cell therapies ide-cel and liso-cel. Wall Street analysts project that BMS will grow its earnings by an average of more than 18% annually over the next five years. With this kind of growth plus its attractive valuation and strong dividend, Bristol Myers Squibb appears to be a no-brainer big pharma stock to buy in April.
3. Pfizer
Pfizer (NYSE: PFE) is a good pick to buy right now for investors who want to get ahead of what's on the way. I'm referring to Pfizer's plan to spin off its Upjohn unit and merge it with Mylan (NASDAQ: MYL) to form a new company that will be named Viatris. Although the COVID-19 pandemic has caused Pfizer to delay the transaction, it's still set to wrap up later this year.
My view is that Pfizer will be set to deliver growth that's better than most big pharma companies once the Upjohn-Mylan deal finalizes. The "new" Pfizer" will have a strong lineup including breast cancer drug Ibrance, Eliquis (which it co-markets with Bristol Myers Squibb), prostate cancer drug Xtandi, and rare-disease drug Vyndaquel.
The company's pipeline also includes eight programs awaiting regulatory approvals and over 20 programs in late-stage clinical studies. I'm especially optimistic about the prospects for pneumococcal vaccine PF-06482077.
Pfizer's dividend currently yields close to 4.4%. Although the dividend will be reduced after the Upjohn-Mylan transaction is completed, the combination of the dividend that Viatris is expected to pay out and the "new" Pfizer's dividend should be close to the level of Pfizer's current dividend.
10 stocks we like better than Pfizer
When investing geniuses David and Tom Gardner have a stock tip, it can pay to listen. After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor, has tripled the market.*
David and Tom just revealed what they believe are the ten best stocks for investors to buy right now... and Pfizer wasn't one of them! That's right -- they think these 10 stocks are even better buys.
See the 10 stocks
*Stock Advisor returns as of March 18, 2020
Keith Speights owns shares of AbbVie, Bristol Myers Squibb, and Pfizer. The Motley Fool owns shares of and recommends Bristol Myers Squibb. The Motley Fool recommends Mylan. The Motley Fool has a disclosure policy.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | AbbVie There's one overwhelmingly compelling argument for buying shares of AbbVie (NYSE: ABBV). Investors who buy AbbVie now will lock in a juicy yield that should only get better in the future. Including the time that it was part of Abbott Labs, AbbVie has paid out a dividend in every year since 1924. | See the 10 stocks *Stock Advisor returns as of March 18, 2020 Keith Speights owns shares of AbbVie, Bristol Myers Squibb, and Pfizer. AbbVie There's one overwhelmingly compelling argument for buying shares of AbbVie (NYSE: ABBV). Investors who buy AbbVie now will lock in a juicy yield that should only get better in the future. | See the 10 stocks *Stock Advisor returns as of March 18, 2020 Keith Speights owns shares of AbbVie, Bristol Myers Squibb, and Pfizer. AbbVie There's one overwhelmingly compelling argument for buying shares of AbbVie (NYSE: ABBV). Investors who buy AbbVie now will lock in a juicy yield that should only get better in the future. | AbbVie There's one overwhelmingly compelling argument for buying shares of AbbVie (NYSE: ABBV). Investors who buy AbbVie now will lock in a juicy yield that should only get better in the future. Including the time that it was part of Abbott Labs, AbbVie has paid out a dividend in every year since 1924. |
24625.0 | 2020-04-11 00:00:00 UTC | 3 Top Pharma Stocks to Buy in April | ABBV | https://www.nasdaq.com/articles/3-top-pharma-stocks-to-buy-in-april-2020-04-11-0 | nan | nan | In most years, April isn't a special month to buy stocks. It's not a bad time to invest, but there's nothing that makes April better than other months. But this April is different.
Because of the coronavirus pandemic and the subsequent stock market plunge, this month is a very good time to invest in stocks. I'd argue that it's an especially great time to invest in shares of big drugmakers. Many pharma stocks have been hammered much harder than is warranted. My view is that three pharma stocks stand out as the top picks to buy in April.
Image source: Getty Images.
1. AbbVie
There's one overwhelmingly compelling argument for buying shares of AbbVie (NYSE: ABBV). The drugmaker's dividend yields 6%. Investors who buy AbbVie now will lock in a juicy yield that should only get better in the future.
Including the time that it was part of Abbott Labs, AbbVie has paid out a dividend in every year since 1924. It's increased the dividend payout for a remarkable 47 consecutive years. And since being spun off from Abbott in 2013, AbbVie's dividend has nearly tripled.
Can AbbVie keep the dividends flowing and growing? I think so. Sales continue to soar for the company's cancer drugs Imbruvica and Venclexta. AbbVie's new immunology drugs Rinvoq and Skyrizi are expected to become megablockbusters over the next few years. The drugmaker's pending acquisition of Allergan will bring successful products including Botox and antipsychotic drug Vraylar into its lineup.
The primary headwind for AbbVie is the loss of exclusivity for its top-selling drug Humira in Europe, with the prospects of biosimilar competition in the U.S. only three years away. However, AbbVie should be able to offset the sales declines for Humira with its current products, promising pipeline candidates, and the addition of Allergan. The company might not deliver awe-inspiring earnings growth, but with its tremendous dividend, it doesn't need to in order for investors to still enjoy solid total returns.
2. Bristol Myers Squibb
If you're looking for great growth prospects in addition to a nice dividend, check out Bristol Myers Squibb (NYSE: BMY). The big drugmaker's dividend yield stands at more than 3%, which isn't too shabby at all. But I think that BMS is poised to generate impressive growth over the next few years.
It certainly helps that BMS claims two of the drugs that market researcher EvaluatePharma projects will rank in the top five best-selling blockbusters in the world by 2024 -- blood thinner Eliquis and cancer immunotherapy Opdivo. BMS also has a couple of rising stars with arthritis drug Orencia and multiple myeloma drug Empliciti.
But the acquisition of Celgene in November 2019 was a game changer for Bristol Myers Squibb. The company's lineup now includes blockbuster blood cancer drugs Revlimid and Pomalyst, along with solid tumor drug Abraxane. And thanks to the Celgene deal, BMS also now has recently approved drugs Reblozyl and Zeposia that have blockbuster-sales potential.
More winners should be on the way. Celgene's pipeline was loaded with great candidates that BMS now has. The most promising of these include cell therapies ide-cel and liso-cel. Wall Street analysts project that BMS will grow its earnings by an average of more than 18% annually over the next five years. With this kind of growth plus its attractive valuation and strong dividend, Bristol Myers Squibb appears to be a no-brainer big pharma stock to buy in April.
3. Pfizer
Pfizer (NYSE: PFE) is a good pick to buy right now for investors who want to get ahead of what's on the way. I'm referring to Pfizer's plan to spin off its Upjohn unit and merge it with Mylan (NASDAQ: MYL) to form a new company that will be named Viatris. Although the COVID-19 pandemic has caused Pfizer to delay the transaction, it's still set to wrap up later this year.
My view is that Pfizer will be set to deliver growth that's better than most big pharma companies once the Upjohn-Mylan deal finalizes. The "new" Pfizer" will have a strong lineup including breast cancer drug Ibrance, Eliquis (which it co-markets with Bristol Myers Squibb), prostate cancer drug Xtandi, and rare-disease drug Vyndaquel.
The company's pipeline also includes eight programs awaiting regulatory approvals and over 20 programs in late-stage clinical studies. I'm especially optimistic about the prospects for pneumococcal vaccine PF-06482077.
Pfizer's dividend currently yields close to 4.4%. Although the dividend will be reduced after the Upjohn-Mylan transaction is completed, the combination of the dividend that Viatris is expected to pay out and the "new" Pfizer's dividend should be close to the level of Pfizer's current dividend.
10 stocks we like better than Pfizer
When investing geniuses David and Tom Gardner have a stock tip, it can pay to listen. After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor, has tripled the market.*
David and Tom just revealed what they believe are the ten best stocks for investors to buy right now... and Pfizer wasn't one of them! That's right -- they think these 10 stocks are even better buys.
See the 10 stocks
*Stock Advisor returns as of March 18, 2020
Keith Speights owns shares of AbbVie, Bristol Myers Squibb, and Pfizer. The Motley Fool owns shares of and recommends Bristol Myers Squibb. The Motley Fool recommends Mylan. The Motley Fool has a disclosure policy.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | AbbVie There's one overwhelmingly compelling argument for buying shares of AbbVie (NYSE: ABBV). Investors who buy AbbVie now will lock in a juicy yield that should only get better in the future. Including the time that it was part of Abbott Labs, AbbVie has paid out a dividend in every year since 1924. | See the 10 stocks *Stock Advisor returns as of March 18, 2020 Keith Speights owns shares of AbbVie, Bristol Myers Squibb, and Pfizer. AbbVie There's one overwhelmingly compelling argument for buying shares of AbbVie (NYSE: ABBV). Investors who buy AbbVie now will lock in a juicy yield that should only get better in the future. | See the 10 stocks *Stock Advisor returns as of March 18, 2020 Keith Speights owns shares of AbbVie, Bristol Myers Squibb, and Pfizer. AbbVie There's one overwhelmingly compelling argument for buying shares of AbbVie (NYSE: ABBV). Investors who buy AbbVie now will lock in a juicy yield that should only get better in the future. | AbbVie There's one overwhelmingly compelling argument for buying shares of AbbVie (NYSE: ABBV). Investors who buy AbbVie now will lock in a juicy yield that should only get better in the future. Including the time that it was part of Abbott Labs, AbbVie has paid out a dividend in every year since 1924. |
24626.0 | 2020-04-08 00:00:00 UTC | Better Coronavirus Stock: Emergent BioSolutions vs. Gilead Sciences | ABBV | https://www.nasdaq.com/articles/better-coronavirus-stock%3A-emergent-biosolutions-vs.-gilead-sciences-2020-04-08 | nan | nan | To be sure, no drug has yet been proven to be effective in treating novel coronavirus disease COVID-19. Any claims that you might read online about one drug or another being a silver bullet for the disease are premature at best. However, what is true right now is that several companies are developing therapies that hold the potential to be effective at treating COVID-19.
Two of the players at the forefront of these efforts are Emergent BioSolutions (NYSE: EBS) and Gilead Sciences (NASDAQ: GILD). Both biotech stocks have been winners so far in 2020 while most stocks have plunged. Which is the better pick for long-term investors?
Image source: Getty Images.
The case for Emergent BioSolutions
If there's any company that is built for crises like the coronavirus pandemic, it's Emergent BioSolutions. The company's primary focus is developing products that address public health threats. Its biggest customer, by far, is the U.S. government.
Emergent BioSolutions' current lineup includes 10 products. Four of them are vaccines for protection against anthrax, cholera, smallpox, and typhoid. Another four are drugs that are used to treat patients with anthrax, botulism, and smallpox. The company also markets devices for emergency treatment of opioid overdoses and for removing or neutralizing several chemical warfare agents from the skin.
The company also has several products in its pipeline that could be available in the not-too-distant future. These include a pediatric cholera vaccine that's currently in late-stage testing and the Trobiguard auto-injector for potential use as a nerve agent countermeasure. Emergent BioSolutions is also developing experimental anthrax, Chikungunya virus, flu, and Zika vaccines.
There are two ways that Emergent BioSolutions is working to fight COVID-19. It's developing a plasma-derived hyperimmune therapy targeting COVID-19 in partnership with the U.S. government. The company also teamed up with Novavax on the small biotech's COVID-19 vaccine development.
Emergent BioSolutions' revenue soared 41% year over year in 2019. The consensus among Wall Street analysts is that the biotech will increase its earnings by more than 9% on average annually over the next five years.
The case for Gilead Sciences
Gilead Sciences just might have the most promising COVID-19 drug in development. A top World Health Organization (WHO) official stated in late February that Gilead's remdesivir was the "one drug right now that we think may have efficacy." More than 1,700 patients with COVID-19 have been treated so far with remdesivir under compassionate-use and expanded-access programs.
While Gilead awaits the results from ongoing late-stage clinical trials evaluating remdesivir, it's already shifting into high gear to produce the drug. The big biotech has ramped up its production capacity and expects to be able to make more than 500,000 treatment courses of the antiviral drug by October and more than 1 million by the end of the year.
In the meantime, Gilead is a leader in other arenas. The company has dominated the HIV market for years. Its latest HIV drug, Biktarvy, appears to be on track to be Gilead's biggest winner yet. Thanks to the 2017 acquisition of Kite Pharma, Gilead is a leader in cancer cell therapies. And the company's hepatitis C virus (HCV) franchise enjoys a virtual duopoly with AbbVie (NYSE: ABBV), although sales have fallen in large part because there are fewer new patients now that so many patients with HCV have been cured.
Perhaps the most exciting thing about Gilead is its pipeline. The crown jewel right now is filgotinib. Gilead awaits regulatory approvals for the drug in treating rheumatoid arthritis. Its pipeline also features several other promising candidates, notably including long-acting HIV capsid GS-6207 and cancer cell therapy KTE-X19.
Gilead's revenue increased only 1.5% year over year in 2019. However, its growth should pick up assuming filgotinib wins U.S. and European approvals. Gilead also offers a strong dividend which currently yields close to 3.5%.
Better pick
I think that both of these stocks should be on investors' radar screens. My favorite, though, is Gilead Sciences.
I like Gilead's prospects with filgotinib. I like its dividend. And with shares trading at only 11.4 times expected earnings, the stock is priced attractively. Gilead may or may not be successful with its coronavirus drug, but I expect the stock to be a winner over the long run either way.
10 stocks we like better than Gilead Sciences
When investing geniuses David and Tom Gardner have a stock tip, it can pay to listen. After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor, has tripled the market.*
David and Tom just revealed what they believe are the ten best stocks for investors to buy right now... and Gilead Sciences wasn't one of them! That's right -- they think these 10 stocks are even better buys.
See the 10 stocks
*Stock Advisor returns as of March 18, 2020
Keith Speights owns shares of Gilead Sciences. The Motley Fool owns shares of and recommends Emergent BioSolutions and Gilead Sciences. The Motley Fool has a disclosure policy.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | And the company's hepatitis C virus (HCV) franchise enjoys a virtual duopoly with AbbVie (NYSE: ABBV), although sales have fallen in large part because there are fewer new patients now that so many patients with HCV have been cured. These include a pediatric cholera vaccine that's currently in late-stage testing and the Trobiguard auto-injector for potential use as a nerve agent countermeasure. While Gilead awaits the results from ongoing late-stage clinical trials evaluating remdesivir, it's already shifting into high gear to produce the drug. | And the company's hepatitis C virus (HCV) franchise enjoys a virtual duopoly with AbbVie (NYSE: ABBV), although sales have fallen in large part because there are fewer new patients now that so many patients with HCV have been cured. Two of the players at the forefront of these efforts are Emergent BioSolutions (NYSE: EBS) and Gilead Sciences (NASDAQ: GILD). The case for Gilead Sciences Gilead Sciences just might have the most promising COVID-19 drug in development. | And the company's hepatitis C virus (HCV) franchise enjoys a virtual duopoly with AbbVie (NYSE: ABBV), although sales have fallen in large part because there are fewer new patients now that so many patients with HCV have been cured. The case for Gilead Sciences Gilead Sciences just might have the most promising COVID-19 drug in development. See the 10 stocks *Stock Advisor returns as of March 18, 2020 Keith Speights owns shares of Gilead Sciences. | And the company's hepatitis C virus (HCV) franchise enjoys a virtual duopoly with AbbVie (NYSE: ABBV), although sales have fallen in large part because there are fewer new patients now that so many patients with HCV have been cured. To be sure, no drug has yet been proven to be effective in treating novel coronavirus disease COVID-19. Emergent BioSolutions' revenue soared 41% year over year in 2019. |
24627.0 | 2020-04-07 00:00:00 UTC | In a first, China knocks U.S. from top spot in global patent race | ABBV | https://www.nasdaq.com/articles/in-a-first-china-knocks-u.s.-from-top-spot-in-global-patent-race-2020-04-07 | nan | nan | By Stephanie Nebehay
GENEVA, April 7 (Reuters) - China was the biggest source of applications for international patents in the world last year, pushing the United States out of the top spot it has held since the global system was set up more than 40 years ago, the U.N. patent agency said on Tuesday.
The World Intellectual Property Organization, which oversees a system for countries to share recognition of patents, said 58,990 applications were filed from China last year, beating out the United States which filed 57,840.
China's figure was a 200-fold increase in just 20 years, it said. The United States had filed the most applications in the world every year since the Patent Cooperation Treaty system was set up in 1978.
More than half of patent applications - 52.4 % - now come from Asia, with Japan ranking third, followed by Germany and South Korea.
Ownership of patents is widely seen as an important sign of a country's economic strength and industrial know-how.
WIPO's head, Francis Gurry, told a news conference China's success was "down to a very deliberate strategy on the part of Chinese leadership to advance innovation and to make the country a country whose economy operates at a higher level of value.
"It is working, and intellectual property is certainly part of that strategy. I would put it down to that broad movement towards becoming a higher-value economy," he said.
According to the WIPO data, China's Huawei Technologies HWT.UL, the world's biggest maker of telecoms equipment, was the top corporate patent filer for the third consecutive year.
The United States has called on countries to ban Huawei equipment from new mobile phone networks, arguing that its technology could be used by China for spying. Huawei denies that its technology poses a security risk.
Asked to what extent China's lead was due to state subsidies, Gurry said: "It's a model which does use state subsidies to a greater extent perhaps than Western economies might typically use state subsidies. So yes it certainly plays role.
"But I think it is very interesting to compare the United States of America as one example of the high performing economy, that has been top of innovation for a long time, a completely different model than what is happening in China.
"The jury is still out...perhaps both are successful."
(Reporting by Stephanie Nebehay Editing by Peter Graff)
((Stephanie.Nebehay@thomsonreuters.com; +41 58 306 2161; Reuters Messaging: stephanie.nebehay.thomsonreuters.com@reuters.net; twitter @StephNebehay))
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | According to the WIPO data, China's Huawei Technologies HWT.UL, the world's biggest maker of telecoms equipment, was the top corporate patent filer for the third consecutive year. The United States has called on countries to ban Huawei equipment from new mobile phone networks, arguing that its technology could be used by China for spying. "But I think it is very interesting to compare the United States of America as one example of the high performing economy, that has been top of innovation for a long time, a completely different model than what is happening in China. | By Stephanie Nebehay GENEVA, April 7 (Reuters) - China was the biggest source of applications for international patents in the world last year, pushing the United States out of the top spot it has held since the global system was set up more than 40 years ago, the U.N. patent agency said on Tuesday. The United States had filed the most applications in the world every year since the Patent Cooperation Treaty system was set up in 1978. According to the WIPO data, China's Huawei Technologies HWT.UL, the world's biggest maker of telecoms equipment, was the top corporate patent filer for the third consecutive year. | By Stephanie Nebehay GENEVA, April 7 (Reuters) - China was the biggest source of applications for international patents in the world last year, pushing the United States out of the top spot it has held since the global system was set up more than 40 years ago, the U.N. patent agency said on Tuesday. The World Intellectual Property Organization, which oversees a system for countries to share recognition of patents, said 58,990 applications were filed from China last year, beating out the United States which filed 57,840. Asked to what extent China's lead was due to state subsidies, Gurry said: "It's a model which does use state subsidies to a greater extent perhaps than Western economies might typically use state subsidies. | The World Intellectual Property Organization, which oversees a system for countries to share recognition of patents, said 58,990 applications were filed from China last year, beating out the United States which filed 57,840. WIPO's head, Francis Gurry, told a news conference China's success was "down to a very deliberate strategy on the part of Chinese leadership to advance innovation and to make the country a country whose economy operates at a higher level of value. According to the WIPO data, China's Huawei Technologies HWT.UL, the world's biggest maker of telecoms equipment, was the top corporate patent filer for the third consecutive year. |
24628.0 | 2020-04-07 00:00:00 UTC | U.N. agency says coronavirus emergency could trump some patent rights | ABBV | https://www.nasdaq.com/articles/u.n.-agency-says-coronavirus-emergency-could-trump-some-patent-rights-2020-04-07 | nan | nan | By Stephanie Nebehay
GENEVA, April 7 (Reuters) - Discussions are under way on enabling wider access to some patented drugs and medical supplies during the coronavirus pandemic, the head of the U.N.'s intellectual property agency said on Tuesday.
Francis Gurry, director-general of the World Intellectual Property Organization (WIPO), said that during an emergency, health and safety "trumps everything".
World Health Organization (WHO) director-general Tedros Adhanom Ghebreyesus said on Monday that he backed a proposal by Costa Rica's President Carlos Alvarado to "create a pool of rights to tests, medicines and vaccines, with free access or licensing on reasonable and affordable terms for all countries".
"We are working with Costa Rica to finalise the details," Tedros told reporters.
WIPO's Gurry, asked about demands for access to drugs and compulsory licensing, told a separate news conference: "This is a hot issue, and it's a very sensitive issue as well."
But extraordinary situations call for "extraordinary measures", he said, adding: "The international legal framework does foresee a certain number of flexibilities for countries to be able to deal with health in particular and health emergencies.
"If they are targeted, such as the compulsory license situation, a very specific compulsory license on a very specific product to ensure the supply of product in the market, that's arguably the sort of action that we need," he said.
A "non-legislative mechanism" would be a "great way forward", Gurry said, adding: "Let's look at the practical measures that can make a difference here. And of course we are involved discussions with various parties to see what might be done in this regard."
The World Trade Organization's so-called TRIPS agreement (Trade-Related Intellectual Property Rights) essentially allows countries during an emergency to grant "compulsory licenses" to companies to produce a patented product.
Canada’s emergency legislation on the coronavirus crisis adopted last month gives the health minister powers to circumvent patent law and ensure medical supplies, medication or vaccines can be produced locally.
Israel last month invoked an emergency patent-suspension clause, allowing it to import a generic version of anti-viral drug Kaletra produced by AbbVie Inc ABBV.N
Gurry said tech start-ups and creative industries including musicians and actors should be covered in compensation packages for the crisis which has hit jobs and venture capital.
"The impact on innovation is going to be extremely significant," he said. "We would like to see governments paying attention in their remediation packages also to the plight of our creators."
(Reporting by Stephanie Nebehay Editing by Peter Graff)
((Stephanie.Nebehay@thomsonreuters.com; +41 58 306 2161; Reuters Messaging: stephanie.nebehay.thomsonreuters.com@reuters.net; twitter @StephNebehay))
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Israel last month invoked an emergency patent-suspension clause, allowing it to import a generic version of anti-viral drug Kaletra produced by AbbVie Inc ABBV.N Gurry said tech start-ups and creative industries including musicians and actors should be covered in compensation packages for the crisis which has hit jobs and venture capital. World Health Organization (WHO) director-general Tedros Adhanom Ghebreyesus said on Monday that he backed a proposal by Costa Rica's President Carlos Alvarado to "create a pool of rights to tests, medicines and vaccines, with free access or licensing on reasonable and affordable terms for all countries". The World Trade Organization's so-called TRIPS agreement (Trade-Related Intellectual Property Rights) essentially allows countries during an emergency to grant "compulsory licenses" to companies to produce a patented product. | Israel last month invoked an emergency patent-suspension clause, allowing it to import a generic version of anti-viral drug Kaletra produced by AbbVie Inc ABBV.N Gurry said tech start-ups and creative industries including musicians and actors should be covered in compensation packages for the crisis which has hit jobs and venture capital. Francis Gurry, director-general of the World Intellectual Property Organization (WIPO), said that during an emergency, health and safety "trumps everything". "If they are targeted, such as the compulsory license situation, a very specific compulsory license on a very specific product to ensure the supply of product in the market, that's arguably the sort of action that we need," he said. | Israel last month invoked an emergency patent-suspension clause, allowing it to import a generic version of anti-viral drug Kaletra produced by AbbVie Inc ABBV.N Gurry said tech start-ups and creative industries including musicians and actors should be covered in compensation packages for the crisis which has hit jobs and venture capital. World Health Organization (WHO) director-general Tedros Adhanom Ghebreyesus said on Monday that he backed a proposal by Costa Rica's President Carlos Alvarado to "create a pool of rights to tests, medicines and vaccines, with free access or licensing on reasonable and affordable terms for all countries". The World Trade Organization's so-called TRIPS agreement (Trade-Related Intellectual Property Rights) essentially allows countries during an emergency to grant "compulsory licenses" to companies to produce a patented product. | Israel last month invoked an emergency patent-suspension clause, allowing it to import a generic version of anti-viral drug Kaletra produced by AbbVie Inc ABBV.N Gurry said tech start-ups and creative industries including musicians and actors should be covered in compensation packages for the crisis which has hit jobs and venture capital. By Stephanie Nebehay GENEVA, April 7 (Reuters) - Discussions are under way on enabling wider access to some patented drugs and medical supplies during the coronavirus pandemic, the head of the U.N.'s intellectual property agency said on Tuesday. World Health Organization (WHO) director-general Tedros Adhanom Ghebreyesus said on Monday that he backed a proposal by Costa Rica's President Carlos Alvarado to "create a pool of rights to tests, medicines and vaccines, with free access or licensing on reasonable and affordable terms for all countries". |
24629.0 | 2020-04-07 00:00:00 UTC | Here Are All the Companies Working on COVID-19 Vaccines, Treatments, and Testing | ABBV | https://www.nasdaq.com/articles/here-are-all-the-companies-working-on-covid-19-vaccines-treatments-and-testing-2020-04-07 | nan | nan | Help is on the way.
In the midst of a societal upheaval resulting from the novel coronavirus and the disease that it causes, COVID-19, there are many efforts in progress to find solutions to slow the spread of the disease and treat those who already have it. These efforts include those from governments, nonprofit organizations, and companies both privately held and publicly traded.
To help investors who desire to keep tabs on the publicly traded companies with COVID-19 programs, here are lists of all the companies with market caps of at least $200 million that are developing or have developed COVID-19 vaccines, treatments, and tests.
Image source: Getty Images.
Vaccines
Several companies already had vaccine platforms targeting other coronaviruses such as MERS and SARS. This enabled them to rapidly prototype experimental vaccines for immunizing against the novel coronavirus that causes COVID-19. Following are all of the companies that are actively developing COVID-19 vaccines either on their own or in partnership with another drugmaker.
COMPANY
MARKET CAP
Arcturus Therapeutics (NASDAQ:ARCT) $249.1 million
BioNTech (NASDAQ: BNTX) $12.2 billion
CSL Behring (OTC: CSLLY) $89.8 billion
Dynavax (NASDAQ: DVAX) $293.9 million
GlaxoSmithKline (NYSE: GSK) $93.7 billion
Inovio Pharmaceuticals (NASDAQ: INO) $1.2 billion
Johnson & Johnson (NYSE: JNJ) $357.9 billion
Moderna (NASDAQ: MRNA) $11.4 billion
Novavax (NASDAQ: NVAX) $821.8 million
Pfizer (NYSE: PFE) $190.2 billion
Sanofi (NASDAQ: SNY) $112.9 billion
TranslateBio (NASDAQ: TBIO) $614.1 million
Data sources: Biotechnology Innovation Organization, company press releases, Yahoo! Finance.
Two of these companies appear to be in the lead right now. In March, Moderna initiated the first clinical testing in humans of an experimental COVID-19 vaccine. The biotech's messenger RNA (mRNA) vaccine was developed in collaboration with the National Institute of Allergy and Infectious Diseases (NIAID). Inovio announced on April 6 that it had begun a phase 1 clinical study of experimental COVID-19 DNA vaccine INO-4800.
Treatments
Several companies already have approved products on the market that could hold potential in treating patients with COVID-19. Others have experimental drugs that have been included in testing for other viruses that could be effective in targeting novel coronavirus infection. Some are scrambling to develop new therapies for COVID-19. Following are the companies that are developing or testing potential COVID-19 therapies.
COMPANY
MARKET CAP
AbbVie (NYSE: ABBV) $113.7 billion
Adaptive Biotechnologies (NASDAQ: ADPT) $3.4 billion
Alnylam Pharmaceuticals (NASDAQ: ALNY) $12.6 billion
Amgen (NASDAQ: AMGN) $122.9 billion
Bayer (OTC: BAYRY) $60.2 billion
Biogen (NASDAQ: BIIB) $54.1 billion
CSL Behring $89.8 billion
CytoDyn (NASDAQOTH:CYDY) $1.3 billion
Gilead Sciences (NASDAQ: GILD) $96.6 billion
Grifols (NASDAQ: GRFS) $19.5 billion
Incyte (NASDAQ: INCY) $18 billion
Eli Lilly (NYSE: LLY) $135.8 billion
Novartis (NYSE: NVS) $193.1 billion
Regeneron Pharmaceuticals (NASDAQ: REGN) $55.5 billion
Roche Holding (OTC: RHHBY) $286.7 billion
Sanofi $112.9 billion
Takeda Pharmaceutical (NYSE: TAK) $47.6 billion
Vanda Pharmaceuticals (NASDAQ: VNDA) $568.7 million
Vir Biotechnology (NASDAQ: VIR) $3.9 billion
Data sources: Biotechnology Innovation Organization, company press releases, Yahoo! Finance.
Three drugs with the potential to treat COVID-19 have received the most public attention. Gilead's remdesivir, which was originally developed to treat the Ebola virus, is in late-stage clinical studies and could be the most promising treatment, according to World Health Organization Assistant Director-General Bruce Aylward. President Trump has spoken frequently about his view that anti-malaria drugs chloroquine and hydroxychloroquine, which are marketed by companies including Sanofi, could be effective in treating COVID-19, although health officials have stressed that the efficacy of the drugs in treating COVID-19 remains unproven at this point.
Testing
The most pressing immediate need in the battle against COVID-19 is for diagnostic tests to determine if individuals are infected by the novel coronavirus. Companies both large and small quickly developed such tests, with several receiving emergency use authorization (EUA) from the U.S. Food and Drug Administration (FDA) to be marketed commercially. Other companies have helped by providing COVID-19 testing services. Here are the companies engaged in activities related to testing for COVID-19.
COMPANY
MARKET CAP
Abbott Labs (NYSE: ABT) $142 billion
Bayer $60.2 billion
Becton Dickinson (NYSE: BDX) $63.2 billion
bioMerieux (OTC: BMXMF) $13.2 billion
Co-Diagnostics (NASDAQ: CODX) $273 million
Danaher (NYSE: DHR) $98.5 billion
Eli Lilly $135.8 billion
Grifols $19.5 billion
LabCorp (NYSE: LH) $11.9 billion
OPKO Health (NASDAQ: OPK) $817.2 million
Quest Diagnostics (NYSE: DGX) $10.4 billion
Roche Holdings $286.7 billion
Thermo Fisher Scientific (NYSE: TMO) $117.7 billion
Data sources: Biotechnology Innovation Organization, EvaluateMedTech, company press releases, Yahoo! Finance.
Roche and Thermo Fisher Scientific have committed to producing millions of COVID-19 tests. Abbott Labs recently launched the fastest COVID-19 test so far. Its test, which runs on the company's widely used ID NOW molecular diagnostics platform, can deliver positive results within five minutes and negative results within 13 minutes.
Investing considerations
Investors looking to buy shares of companies with COVID-19 programs should first determine how much risk they're willing to take. Several of the companies are relatively small. The odds of failure, especially with experimental COVID-19 vaccines and treatments, are relatively high.
It's also important to evaluate each stock's prospects beyond the companies' COVID-19 efforts. If you would be interested in buying a given stock even if it wasn't developing a COVID-19 vaccine, treatment, or test, that should put the stock much higher on your list.
10 stocks we like better than Abbott Laboratories
When investing geniuses David and Tom Gardner have a stock tip, it can pay to listen. After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor, has tripled the market.*
David and Tom just revealed what they believe are the ten best stocks for investors to buy right now... and Abbott Laboratories wasn't one of them! That's right -- they think these 10 stocks are even better buys.
See the 10 stocks
*Stock Advisor returns as of March 18, 2020
Keith Speights owns shares of AbbVie, Gilead Sciences, and Pfizer. The Motley Fool owns shares of and recommends Alnylam Pharmaceuticals, Biogen, and Gilead Sciences. The Motley Fool recommends Amgen, Becton Dickinson, Incyte, and Johnson & Johnson. The Motley Fool has a disclosure policy.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | AbbVie (NYSE: ABBV) $113.7 billion Adaptive Biotechnologies (NASDAQ: ADPT) $3.4 billion Alnylam Pharmaceuticals (NASDAQ: ALNY) $12.6 billion Amgen (NASDAQ: AMGN) $122.9 billion Bayer (OTC: BAYRY) $60.2 billion Biogen (NASDAQ: BIIB) $54.1 billion CSL Behring $89.8 billion CytoDyn (NASDAQOTH:CYDY) $1.3 billion Gilead Sciences (NASDAQ: GILD) $96.6 billion Grifols (NASDAQ: GRFS) $19.5 billion Incyte (NASDAQ: INCY) $18 billion Eli Lilly (NYSE: LLY) $135.8 billion Novartis (NYSE: NVS) $193.1 billion Regeneron Pharmaceuticals (NASDAQ: REGN) $55.5 billion Roche Holding (OTC: RHHBY) $286.7 billion Sanofi $112.9 billion Takeda Pharmaceutical (NYSE: TAK) $47.6 billion Vanda Pharmaceuticals (NASDAQ: VNDA) $568.7 million Vir Biotechnology (NASDAQ: VIR) $3.9 billion Data sources: Biotechnology Innovation Organization, company press releases, Yahoo! See the 10 stocks *Stock Advisor returns as of March 18, 2020 Keith Speights owns shares of AbbVie, Gilead Sciences, and Pfizer. The biotech's messenger RNA (mRNA) vaccine was developed in collaboration with the National Institute of Allergy and Infectious Diseases (NIAID). | AbbVie (NYSE: ABBV) $113.7 billion Adaptive Biotechnologies (NASDAQ: ADPT) $3.4 billion Alnylam Pharmaceuticals (NASDAQ: ALNY) $12.6 billion Amgen (NASDAQ: AMGN) $122.9 billion Bayer (OTC: BAYRY) $60.2 billion Biogen (NASDAQ: BIIB) $54.1 billion CSL Behring $89.8 billion CytoDyn (NASDAQOTH:CYDY) $1.3 billion Gilead Sciences (NASDAQ: GILD) $96.6 billion Grifols (NASDAQ: GRFS) $19.5 billion Incyte (NASDAQ: INCY) $18 billion Eli Lilly (NYSE: LLY) $135.8 billion Novartis (NYSE: NVS) $193.1 billion Regeneron Pharmaceuticals (NASDAQ: REGN) $55.5 billion Roche Holding (OTC: RHHBY) $286.7 billion Sanofi $112.9 billion Takeda Pharmaceutical (NYSE: TAK) $47.6 billion Vanda Pharmaceuticals (NASDAQ: VNDA) $568.7 million Vir Biotechnology (NASDAQ: VIR) $3.9 billion Data sources: Biotechnology Innovation Organization, company press releases, Yahoo! See the 10 stocks *Stock Advisor returns as of March 18, 2020 Keith Speights owns shares of AbbVie, Gilead Sciences, and Pfizer. Arcturus Therapeutics (NASDAQ:ARCT) $249.1 million BioNTech (NASDAQ: BNTX) $12.2 billion CSL Behring (OTC: CSLLY) $89.8 billion Dynavax (NASDAQ: DVAX) $293.9 million GlaxoSmithKline (NYSE: GSK) $93.7 billion Inovio Pharmaceuticals (NASDAQ: INO) $1.2 billion Johnson & Johnson (NYSE: JNJ) $357.9 billion Moderna (NASDAQ: MRNA) $11.4 billion Novavax (NASDAQ: NVAX) $821.8 million Pfizer (NYSE: PFE) $190.2 billion Sanofi (NASDAQ: SNY) $112.9 billion TranslateBio (NASDAQ: TBIO) $614.1 million Data sources: Biotechnology Innovation Organization, company press releases, Yahoo! | AbbVie (NYSE: ABBV) $113.7 billion Adaptive Biotechnologies (NASDAQ: ADPT) $3.4 billion Alnylam Pharmaceuticals (NASDAQ: ALNY) $12.6 billion Amgen (NASDAQ: AMGN) $122.9 billion Bayer (OTC: BAYRY) $60.2 billion Biogen (NASDAQ: BIIB) $54.1 billion CSL Behring $89.8 billion CytoDyn (NASDAQOTH:CYDY) $1.3 billion Gilead Sciences (NASDAQ: GILD) $96.6 billion Grifols (NASDAQ: GRFS) $19.5 billion Incyte (NASDAQ: INCY) $18 billion Eli Lilly (NYSE: LLY) $135.8 billion Novartis (NYSE: NVS) $193.1 billion Regeneron Pharmaceuticals (NASDAQ: REGN) $55.5 billion Roche Holding (OTC: RHHBY) $286.7 billion Sanofi $112.9 billion Takeda Pharmaceutical (NYSE: TAK) $47.6 billion Vanda Pharmaceuticals (NASDAQ: VNDA) $568.7 million Vir Biotechnology (NASDAQ: VIR) $3.9 billion Data sources: Biotechnology Innovation Organization, company press releases, Yahoo! See the 10 stocks *Stock Advisor returns as of March 18, 2020 Keith Speights owns shares of AbbVie, Gilead Sciences, and Pfizer. Arcturus Therapeutics (NASDAQ:ARCT) $249.1 million BioNTech (NASDAQ: BNTX) $12.2 billion CSL Behring (OTC: CSLLY) $89.8 billion Dynavax (NASDAQ: DVAX) $293.9 million GlaxoSmithKline (NYSE: GSK) $93.7 billion Inovio Pharmaceuticals (NASDAQ: INO) $1.2 billion Johnson & Johnson (NYSE: JNJ) $357.9 billion Moderna (NASDAQ: MRNA) $11.4 billion Novavax (NASDAQ: NVAX) $821.8 million Pfizer (NYSE: PFE) $190.2 billion Sanofi (NASDAQ: SNY) $112.9 billion TranslateBio (NASDAQ: TBIO) $614.1 million Data sources: Biotechnology Innovation Organization, company press releases, Yahoo! | AbbVie (NYSE: ABBV) $113.7 billion Adaptive Biotechnologies (NASDAQ: ADPT) $3.4 billion Alnylam Pharmaceuticals (NASDAQ: ALNY) $12.6 billion Amgen (NASDAQ: AMGN) $122.9 billion Bayer (OTC: BAYRY) $60.2 billion Biogen (NASDAQ: BIIB) $54.1 billion CSL Behring $89.8 billion CytoDyn (NASDAQOTH:CYDY) $1.3 billion Gilead Sciences (NASDAQ: GILD) $96.6 billion Grifols (NASDAQ: GRFS) $19.5 billion Incyte (NASDAQ: INCY) $18 billion Eli Lilly (NYSE: LLY) $135.8 billion Novartis (NYSE: NVS) $193.1 billion Regeneron Pharmaceuticals (NASDAQ: REGN) $55.5 billion Roche Holding (OTC: RHHBY) $286.7 billion Sanofi $112.9 billion Takeda Pharmaceutical (NYSE: TAK) $47.6 billion Vanda Pharmaceuticals (NASDAQ: VNDA) $568.7 million Vir Biotechnology (NASDAQ: VIR) $3.9 billion Data sources: Biotechnology Innovation Organization, company press releases, Yahoo! See the 10 stocks *Stock Advisor returns as of March 18, 2020 Keith Speights owns shares of AbbVie, Gilead Sciences, and Pfizer. To help investors who desire to keep tabs on the publicly traded companies with COVID-19 programs, here are lists of all the companies with market caps of at least $200 million that are developing or have developed COVID-19 vaccines, treatments, and tests. |
24630.0 | 2020-04-06 00:00:00 UTC | New Drugs Approved In The Month Of March | ABBV | https://www.nasdaq.com/articles/new-drugs-approved-in-the-month-of-march-2020-04-06 | nan | nan | (RTTNews) - The novel coronavirus that originated in the city of Wuhan in China last December, has spread to almost all the countries, affecting millions. As of this writing, the number of confirmed cases is 1,274,346 and the death toll is 69,480.
Almost all international airports have been closed around the world and many countries are enforcing lock downs among its nationals to reduce the spread of the virus. The situation is impacting almost all fields with pharmaceutical industry facing its own share of problems. Clinical trial enrollments are staggering due to lock down and regulatory approvals are getting delayed.
In March, only four drugs were approved by the FDA. Let us take a look at the new drugs that were approved.
Sarclisa
The FDA approved Sarclisa (isatuximab-irfc),developed by Sanofi (SNY) on March 2, 2020.
Sarclisa, a monoclonal antibody that binds to the CD38 receptor on multiple myeloma cells, is approved to be used in combination with Bristol-Myers Squibb's pomalidomide and steroid dexamethasone (pom-dex) for the treatment of adults with relapsed refractory multiple myeloma (RRMM) who have received at least two prior therapies including lenalidomide and a proteasome inhibitor.
The wholesale acquisition cost for Sarclisa is $650 per 100 mg vial and $3,250 per 500 mg vial.
Rival drug, Johnson and Johnson's Darzalex (daratumumab) had sales of $830 million in the fourth quarter of 2019.
Last week, Sanofi received positive opinion from the European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) for Sarclisa.
Durysta
The FDA approved Durysta (bimatoprost), developed by Allergan plc (AGN) on March 3, 2020 to reduce intraocular pressure (IOP) in patients with open-angle glaucoma (OAG) or ocular hypertension (OHT).
Durysta is an ophthalmic drug delivery system that is implanted into the anterior chamber of the eye. It is the first intracameral, biodegradable sustained-release implant for the indication.
Allergan, in June, had announced that it was being acquired by AbbVie Inc.(ABBV) for approximately $63 billion, cash and stock. The deal is expected to close early this year.
Isturisa The FDA approved Isturisa (osilodrostat), developed by Novartis AG (NVS), on March 6, 2020 for the treatment of patients with Cushing's disease who either cannot undergo pituitary gland surgery or have undergone the surgery but still have the disease.
Cushing disease is caused by a pituitary tumor that releases too much of a hormone called adrenocorticotropin, which stimulates the adrenal gland to produce an excessive amount of cortisol. This disease can cause significant health issues, such as high blood pressure, obesity, type 2 diabetes, blood clots in the legs and lungs, bone loss and fractures, a weakened immune system and depression.
Isturisa is the first FDA-approved drug to directly address this cortisol overproduction by blocking the enzyme known as 11-beta-hydroxylase and preventing cortisol synthesis.
The most common side effects included adrenal insufficiency, nausea, fatigue and oedema.
The drug is expected to be launched in the second or third quarter.
Zeposia
The FDA approved Zeposia (ozanimod), developed by Bristol-Myers Squibb Company (BMY), on March 25, 2020 for the treatment of adults with relapsing forms of multiple sclerosis, including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease.
Multiple sclerosis (MS) is an autoimmune disease in which the immune system attacks the protective myelin sheath that covers the nerves, creating damaging lesions that make it harder for signals to travel between each nerve cell causing a wide range of symptoms throughout the body.
Analysts expect the drug to bring in sales of $1.6 billion in 2024. Zeposia will have to compete with Novartis' Gilenya, which had $3.22 billion in sales in 2019.
Last week, Zeposia had received positive recommendation from the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency.
Bristol-Myers plans to delay the launch of the drug due to COVID-19 pandemic.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Allergan, in June, had announced that it was being acquired by AbbVie Inc.(ABBV) for approximately $63 billion, cash and stock. Almost all international airports have been closed around the world and many countries are enforcing lock downs among its nationals to reduce the spread of the virus. Sarclisa, a monoclonal antibody that binds to the CD38 receptor on multiple myeloma cells, is approved to be used in combination with Bristol-Myers Squibb's pomalidomide and steroid dexamethasone (pom-dex) for the treatment of adults with relapsed refractory multiple myeloma (RRMM) who have received at least two prior therapies including lenalidomide and a proteasome inhibitor. | Allergan, in June, had announced that it was being acquired by AbbVie Inc.(ABBV) for approximately $63 billion, cash and stock. Last week, Sanofi received positive opinion from the European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) for Sarclisa. Zeposia The FDA approved Zeposia (ozanimod), developed by Bristol-Myers Squibb Company (BMY), on March 25, 2020 for the treatment of adults with relapsing forms of multiple sclerosis, including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease. | Allergan, in June, had announced that it was being acquired by AbbVie Inc.(ABBV) for approximately $63 billion, cash and stock. Sarclisa, a monoclonal antibody that binds to the CD38 receptor on multiple myeloma cells, is approved to be used in combination with Bristol-Myers Squibb's pomalidomide and steroid dexamethasone (pom-dex) for the treatment of adults with relapsed refractory multiple myeloma (RRMM) who have received at least two prior therapies including lenalidomide and a proteasome inhibitor. Isturisa The FDA approved Isturisa (osilodrostat), developed by Novartis AG (NVS), on March 6, 2020 for the treatment of patients with Cushing's disease who either cannot undergo pituitary gland surgery or have undergone the surgery but still have the disease. | Allergan, in June, had announced that it was being acquired by AbbVie Inc.(ABBV) for approximately $63 billion, cash and stock. Let us take a look at the new drugs that were approved. Sarclisa The FDA approved Sarclisa (isatuximab-irfc),developed by Sanofi (SNY) on March 2, 2020. |
24631.0 | 2020-04-06 00:00:00 UTC | Why AbbVie Stock Tanked in March | ABBV | https://www.nasdaq.com/articles/why-abbvie-stock-tanked-in-march-2020-04-06 | nan | nan | What happened
Shares of AbbVie (NYSE: ABBV), a blue-chip biopharma, fell by a staggering 11.1% in March, according to data from S&P Global Market Intelligence. This large-cap biopharma thus lost approximately $20 billion in market capitalization last month.
On the bright side, AbbVie's stock did perform modestly better than both the Dow Jones Industrial Average and the S&P 500 in March. What's more, AbbVie's shares have also lost less ground through the entirety of the first quarter of 2020 than all of the major U.S. stock indices.
Image source: Getty Images.
So what
What went wrong for AbbVie in March? Late last year, AbbVie took on a boatload of debt to acquire Allergan (NYSE: AGN). The company's balance sheet, in turn, isn't in the greatest of shape at the moment. The reason that matters is that investors are clearly favoring companies with strong balance sheets during this marketwide meltdown. AbbVie, with its highly leveraged sheet, doesn't exactly fit that description.
Another important issue to bear in mind is that Allergan's medical aesthetics business is likely to take a big hit from the COVID-19 public health crisis. Elective procedures like Botox injections are sure to decline with stringent social distancing measures in place. That's unwelcome news for AbbVie and its shareholders as the biopharma gears up to close on this $63 billion megamerger.
Now what
The silver lining is that this top biotech stock is now stupid cheap, especially with its dividend yield sitting at a monstrous 6.28% at current levels. Specifically, AbbVie's shares are presently valued at a paltry 7.4 times expected earnings. That's an absurd valuation for a company with a proven track record of generating top-notch levels of revenue growth. As such, bargain hunters many want to pounce on this beaten-down biopharma stock soon.
10 stocks we like better than AbbVie
When investing geniuses David and Tom Gardner have a stock tip, it can pay to listen. After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor, has tripled the market.*
David and Tom just revealed what they believe are the ten best stocks for investors to buy right now... and AbbVie wasn't one of them! That's right -- they think these 10 stocks are even better buys.
See the 10 stocks
*Stock Advisor returns as of March 18, 2020
George Budwell owns shares of AbbVie. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | What happened Shares of AbbVie (NYSE: ABBV), a blue-chip biopharma, fell by a staggering 11.1% in March, according to data from S&P Global Market Intelligence. On the bright side, AbbVie's stock did perform modestly better than both the Dow Jones Industrial Average and the S&P 500 in March. What's more, AbbVie's shares have also lost less ground through the entirety of the first quarter of 2020 than all of the major U.S. stock indices. | See the 10 stocks *Stock Advisor returns as of March 18, 2020 George Budwell owns shares of AbbVie. What happened Shares of AbbVie (NYSE: ABBV), a blue-chip biopharma, fell by a staggering 11.1% in March, according to data from S&P Global Market Intelligence. On the bright side, AbbVie's stock did perform modestly better than both the Dow Jones Industrial Average and the S&P 500 in March. | 10 stocks we like better than AbbVie When investing geniuses David and Tom Gardner have a stock tip, it can pay to listen. * David and Tom just revealed what they believe are the ten best stocks for investors to buy right now... and AbbVie wasn't one of them! See the 10 stocks *Stock Advisor returns as of March 18, 2020 George Budwell owns shares of AbbVie. | * David and Tom just revealed what they believe are the ten best stocks for investors to buy right now... and AbbVie wasn't one of them! See the 10 stocks *Stock Advisor returns as of March 18, 2020 George Budwell owns shares of AbbVie. What happened Shares of AbbVie (NYSE: ABBV), a blue-chip biopharma, fell by a staggering 11.1% in March, according to data from S&P Global Market Intelligence. |
24632.0 | 2020-04-05 00:00:00 UTC | Why AbbVie Is a Fantastic Dividend Stock to Buy During the Coronavirus Market Crash | ABBV | https://www.nasdaq.com/articles/why-abbvie-is-a-fantastic-dividend-stock-to-buy-during-the-coronavirus-market-crash-2020 | nan | nan | It's hard to be optimistic when there seems to be nothing but bad news. The numbers of individuals infected with novel coronavirus disease COVID-19 continue to climb. Hospitals are overwhelmed. People are losing their jobs as their employers shut down. And stocks are in a bear market for the first time in over a decade.
But the U.S. has always overcome adversity and bounced back. It will do so again.
In the meantime, for those fortunate enough to have some cash available to invest, the coronavirus-fueled bear market presents some opportunities to make your financial future more secure. In particular, buying strong dividend stocks right now could allow you to lock in really attractive dividend yields.
I think that AbbVie (NYSE: ABBV) is a fantastic dividend stock to buy in the midst of the coronavirus market crash. Here are three reasons why.
Image source: Getty Images.
1. An impressive dividend track record
AbbVie's dividend yield of close to 6.3% will probably make your mouth water. I think, though, that the drugmaker's track record with its dividend program is what really makes it stand out.
Including the time when it was a part of Abbott Labs, AbbVie has increased its dividend for 47 consecutive years. The company isn't too far away from joining the elite group of stocks known as Dividend Kings -- members of the S&P 500 that have raised their dividends for 50 years in a row.
Since being spun off from Abbott in 2013, AbbVie has boosted its dividend payout by a total of 195%. That translates to a compound annual growth rate (CAGR) of nearly 17% for the big pharma company's dividend.
Some companies might consider cutting their dividends during tough economic times. But AbbVie has increased its dividend throughout the malaise of the 1970s, the stock market crash of 1987, the terrorist attack on 9/11, and the Great Recession. The company's steadfast commitment to raising its dividend makes me confident that AbbVie will keep its impressive dividend track record going.
2. A compelling valuation
AbbVie's share price has declined quite a bit during the coronavirus market crash. Could it fall even more? Sure. However, I think the stock has more of a cushion than many other stocks do.
Thanks to the recent sell-off, AbbVie's shares now trade at around 7.4 times expected earnings. That compelling valuation gives AbbVie a cushion, in my view.
If the stock price of a profitable, well-respected company like AbbVie falls to a certain point where its valuation is simply too attractive to pass up, investors will rush in to buy shares. I don't think that AbbVie's shares can sink a lot more than they already have before it reaches the level where that scenario occurs.
3. A steady revenue stream
You could throw the first two points out the window if AbbVie was in danger of having its revenue dry up. That's exactly what could happen for some companies during the COVID-19 crisis, for example, cruise lines and some retailers. However, this isn't a problem for AbbVie.
AbbVie's revenue stream should be nice and steady for the most part even with the measures being taken to stop the spread of the novel coronavirus. Patients can't go for very long without their prescription drugs, especially for the kinds of diseases that AbbVie's top drugs treat.
Sure, AbbVie's blockbuster drug Humira faces challenges with biosimilar rivals already on the market in Europe and on the way in the U.S. beginning in 2023. However, the company has planned for the eventual sales decline for Humira for years. It has two new immunology drugs, Rinvoq and Skyrizi, that should take up a lot of the slack.
Also, AbbVie shouldn't be as dependent on Humira in the near future. The company's pending acquisition of Allergan should close within the next couple of months. This deal will add several new drugs that are generating strong sales growth to AbbVie's lineup, notably including Botox and antipsychotic drug Vraylar.
Some good news
Even with the headwinds for Humira, Wall Street analysts project that AbbVie will be able to grow its earnings by close to 5% annually over the next five years. This level of earnings growth combined with a juicy dividend yield north of 6% should enable AbbVie to deliver solid returns for long-term investors.
10 stocks we like better than AbbVie
When investing geniuses David and Tom Gardner have a stock tip, it can pay to listen. After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor, has tripled the market.*
David and Tom just revealed what they believe are the ten best stocks for investors to buy right now... and AbbVie wasn't one of them! That's right -- they think these 10 stocks are even better buys.
See the 10 stocks
*Stock Advisor returns as of March 18, 2020
Keith Speights owns shares of AbbVie. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | If the stock price of a profitable, well-respected company like AbbVie falls to a certain point where its valuation is simply too attractive to pass up, investors will rush in to buy shares. Some good news Even with the headwinds for Humira, Wall Street analysts project that AbbVie will be able to grow its earnings by close to 5% annually over the next five years. This level of earnings growth combined with a juicy dividend yield north of 6% should enable AbbVie to deliver solid returns for long-term investors. | An impressive dividend track record AbbVie's dividend yield of close to 6.3% will probably make your mouth water. The company's steadfast commitment to raising its dividend makes me confident that AbbVie will keep its impressive dividend track record going. A compelling valuation AbbVie's share price has declined quite a bit during the coronavirus market crash. | I think that AbbVie (NYSE: ABBV) is a fantastic dividend stock to buy in the midst of the coronavirus market crash. The company's steadfast commitment to raising its dividend makes me confident that AbbVie will keep its impressive dividend track record going. If the stock price of a profitable, well-respected company like AbbVie falls to a certain point where its valuation is simply too attractive to pass up, investors will rush in to buy shares. | I think that AbbVie (NYSE: ABBV) is a fantastic dividend stock to buy in the midst of the coronavirus market crash. An impressive dividend track record AbbVie's dividend yield of close to 6.3% will probably make your mouth water. Including the time when it was a part of Abbott Labs, AbbVie has increased its dividend for 47 consecutive years. |
24633.0 | 2020-03-31 00:00:00 UTC | 19 Dividend Aristocrats That Have Gone on Deep Discount | ABBV | https://www.nasdaq.com/articles/19-dividend-aristocrats-that-have-gone-on-deep-discount-2020-03-31 | nan | nan | In times of market turmoil, one group of stocks that investors can count on to deliver reliable income growth is the Dividend Aristocrats: an elite group of companies that have produced at least 25 consecutive years of dividend hikes.
During the 2010s, these high-quality stocks returned an average of 14.75% per year, besting the S&P 500 by 1.2 percentage points. A big reason for the Dividend Aristocrats' outperformance, especially over the long term, is the high dividend component of their returns.
Studies by Standard & Poor's have shown that more than one-third of the long-term total return of stocks comes from dividends. In the case of the Aristocrats, many of them traditionally don't boast attractive yields for new money. But investors that stick with them over the long haul are rewarded with growing "yields on cost" over time.
Reliable payouts also help make this group less risky than most other stocks. For instance, volatility of the Dividend Aristocrats' returns during the 2010s, as measured by standard deviation - a measure of how widely or narrowly prices are dispersed compared to an average - was more than 9% lower than the S&P 500.
That doesn't make them invulnerable from market downturns. A number of Dividend Aristocrats have gone on discount, losing 10%, 20%, even 30% of their value since the start of the bear market. But they offer more than cheap prices - they offer real value, both in higher-than-usual yields as well as snap-back potential once the market rebounds.
Here are 19 Dividend Aristocrats that should appeal to investors who want safety and reliably rising dividends at discounted prices.
SEE ALSO: 64 Dividend Stocks You Can Count On in 2020
AbbVie
Market value: $111.1 billion
Dividend yield: 6.3%
Performance since 2/19/20: -20.1% (vs. -22.4% for the S&P 500)
AbbVie (ABBV, $75.24) expects that its pending $63 billion merger with Allergan (AGN) will offset slowing growth of its blockbuster drug Humira. AbbVie initially said the merger, which is experiencing coronavirus-related delays in closing, would create a combined business that would generate more than $30 billion in sales this year, then high-single-digit growth into the foreseeable future. (The current economic turmoil likely will dampen those expectations somewhat.)
AbbVie develops drugs for autoimmune diseases, cancer, virology (including HIV and Hepatitis C) and neurological disorders. And in fact, one of the company's HIV drugs (Kaletra) is being tested as a treatment for coronavirus. Meanwhile, Allergan is best-known for its cosmetic drug Botox and its dry-eye treatment Restasis. Wall Street firms like Allergan's strong Botox-related cash flows, which they think will bolster ABBV's growth opportunities.
The post-acquisition-related debt load will be high at $95 billion, but AbbVie expects to trim $15 billion to $18 billion of debt by the end of 2021 while also realizing $3 billion of pre-tax cost synergies. The combined business generated $19 billion in operating cash flow last year.
ABBV shares look cheap at just 7.5 times forward-looking earnings estimates, which is modest compared to the company's historical average forward P/E of 12. Dividend growth investors will like AbbVie's 48 consecutive years of payout hikes; a conservative payout ratio of 48% that provides flexibility for dividend growth and debt reduction; and a five-year annual dividend growth rate of 18.3%. ABBV also is among the highest-yielding Dividend Aristocrats at north of 6%.
SEE ALSO: Where Is the Stock Market Headed? 14 Wall Street Pros Sound Off
Aflac
Market value: $26.2 billion
Dividend yield: 3.1%
Performance since 2/19/20: -29.7%
Aflac (AFL, $36.26) offers supplemental health insurance and life insurance to more than 50 million customers worldwide. While many people are well aware of the Aflac brand (and its duck) in the U.S., the company is a market leader in Japan, where it provides supplemental medical and/or cancer insurance to one of every four households. AFL recently expanded its product lines to include accident, disability and long-term care insurance and launched vision and dental insurance products this year.
Demand for Aflac's products is rising due to steadily increasing health care costs here and in Japan. The expanding self-employed workforce in the U.S. was creating a growth opportunity, too, though the coronavirus outbreak and its effect on employment is likely to blunt that in the short term.
Aflac has delivered 11% annual EPS growth over the past three years while keeping debt extremely low at just 17% of capitalization. That has helped the company keep up a streak of 38 consecutive dividend hikes, including a 3.7% increase in early February to 28 cents per share that keeps it in the ranks of the Dividend Aristocrats.
AFL shares trade at 8 times forward earnings estimates, with 2020 profits expected to stay flat with 2019 before improving by about 4% next year. It's also trading at 0.9 times book value, compared to a historical ratio of 1.4 times book.
Piper Sandler analyst Stephen Scouten rated Aflac as one of his top 2020 financial service industry picks in January. Naturally, the stock has seen a few price-target downgrades to reflect its losses as it dropped with the rest of the market, but analysts have otherwise been standing firm on their stances. One exception: RBC Capital analyst Mark Dwelle upgraded AFL from Underperform (equivalent of Sell) to Sector Perform (equivalent of Hold).
SEE ALSO: 15 Dividend Cuts and Suspensions Chalked Up to the Coronavirus
Walgreens Boots Alliance
Market value: $40.0 billion
Dividend yield: 4.1%
Performance since 2/19/20: -13.3%
Walgreens Boots Alliance (WBA, $45.16) was challenged by falling generic drug prices and reimbursement pressures from third-party payers last year, but the company expects to boost 2020 performance by trimming $1.5 billion from expenses, strengthening its digital partnership with Microsoft (MSFT) and partnering with Kroger (KR) and LabCorp (LH) to drive traffic to stores.
Credit Suisse analyst AJ Rice earlier this year wrote that the company's prescription growth was likely to re-accelerate in 2020 as a result of its expanded relationship with UnitedHealth Group (UNH) in the Medicare Part D space.
But Walgreens suddenly finds itself positioned well for a different reason: It's one of the few retailers still allowed to conduct business during many states' stay-at-home orders and other partial closures amid the coronavirus outbreak. That's because Walgreens deals in prescriptions, health care products and basic staples that people are increasingly loading up on as they prepare to quarantine themselves. No surprise, then, that WBA has held up very well in this bear market.
However, Walgreens' stock still trades on the cheap, at just 11 times forward-looking earnings estimates (versus a historic 15 forward P/E) and 0.3 times sales. Meanwhile, WBA has improved its payout for 44 consecutive years, firmly entrenching it among the S&P Dividend Aristocrats. Better still, its dividend accounts for just 44% of its profits, giving Walgreens plenty of room to expand it once the world is in better economic straits.
SEE ALSO: 25 Dividend Stocks the Analysts Love the Most
Nucor
Market value: $10.5 billion
Dividend yield: 4.6%
Performance since 2/19/20: -26.8%
Nucor (NUE, $34.92) is North America's largest and most diversified steelmaker; the company operates 25 steel mills representing 27 million tons of annual production capacity. Thanks to its largely variable cost structure, Nucor is nimble and a low-cost producer capable of generating profits even during industry downturns - not a bad quality to boast at the moment. Nucor plans to boost profits by moving up the value chain with more value-added products and expanding its sales channels.
While Wall Street's pros are writing bearish notes left and right in this environment, Nucor is actually enjoying a few analyst upgrades.
On March 30, Goldman Sachs' Matthew Korn upgraded Nucor from Neutral (equivalent of Hold) to Buy, touting the company's "strong" balance sheet, diverse portfolio of facilities and products, and flexibility in capital expenditures. Deutsche Bank's Chris Terry upgraded NUE the same day, from Sell to Hold.
NUE shares are valued at less than four times its cash flows, which is less than its historic multiple of more than 10. It also trades at just 11 times forward-looking earnings estimates. Dividend growth is glacial, at just 1.6% annually over the past five years. But a modest payout ratio helps de-risk this Dividend Aristocrat's quarterly dole, which has been improving for 47 consecutive years.
SEE ALSO: The 12 Best Low-Volatility Stocks of the Market Crash
A.O. Smith
Market value: $6.3 billion
Dividend yield: 2.5%
Performance since 2/19/20: -12.5%
A.O. Smith (AOS, $38.60) is the market leader in residential and commercial water heaters, boilers and water treatment products. The company has benefitted from a stable North American replacement market, with replacement units representing 85% of demand, but in 2019 it faced setbacks in China, which accounts for 34% of sales.
The company expected to rebound in 2020 as a result of recent acquisitions that have strengthened its North American water treatment portfolio, reduced trade tensions and new higher-end products for affluent customers in the China market. But the coronavirus outbreak has likely set back progress at least a little in both regions.
Nonetheless, there's plenty to like about how A.O. Smith operates, given what it means for the company once the world economy rebounds. Over the past decade, AOS has generated 10% annual revenue gains, 19% yearly growth in adjusted EBITDA (earnings before interest, taxes, depreciation and amortization) and 25% annual adjusted EPS expansion.
AOS shares have fared very well compared to the broader market, and as a result, its current discount isn't quite as steep as the other Dividend Aristocrats. Nonetheless, its 16 forward P/E and 13 price-to-cash flow are both well below the company's historic valuations.
The yield on AOS shares isn't huge, either, but dividend growth has been impressive at more than 20% annually over the past five years. Moreover, A.O. Smith has a strong balance sheet, modest 40% payout ratio and plenty of cash to cover the quarterly cash distribution.
SEE ALSO: 24 Major U.S. Companies Hiring Now to Meet Coronavirus Demand
General Dynamics
Market value: $38.7 billion
Dividend yield: 3.3%
Performance since 2/19/20: -28.4%
Defense contractor General Dynamics (GD, $133.60) grew all five of its businesses last year and ended 2019 with a record $86.9 billion backlog. Aerospace orders were the highest in nearly a decade.
General Dynamics produces Gulfstream aircraft, Stryker combat vehicles, nuclear-powered submarines and combat systems for Abrams tanks. GD also supplies IT products and services to the U.S. military. Indeed, the company derives two-thirds of its revenues from the U.S. government.
Defense spending was already allocated for 2020, so in theory, General Dynamics should have avoided some of the economic headwinds associated with the coronavirus. The company's recent contract wins include $465 million from the U.S. Army for Abrams tanks, $800 million for IT support of state health insurance programs, $730 million for U.S. Navy satellite communications systems and $22.2 billion for the construction of nine new Navy submarines.
Nonetheless, General Dynamics' shares are off 28% in the current bear market, underperforming the index. But that has trimmed the stock's valuation to an attractive 10 times forward earnings - much less than its historic 17 multiple. Those losses also have juiced GD's yield to 3.3%, on a dividend that has improved for 28 consecutive years and accounts for just 33% of earnings.
SEE ALSO: The Best and Worst Presidents (According to the Stock Market)
Johnson & Johnson
Market value: $350.7 billion
Dividend yield: 2.9%
Performance since 2/19/20: -10.7%
Johnson & Johnson (JNJ, $133.01) is a household name in consumer health products with over-the-counter brands including Tylenol, Zyrtec, Motrin, Band-Aid and a full line of baby care products.
The company's pharmaceutical division is in focus right now, as it recently said it could have a COVID-19 coronavirus vaccine ready for human testing by September and possible emergency use by early 2021. Better still, it secured a $456 million U.S. government contract that will help it manufacture up to 1 billion doses.
Johnson & Johnson's positioning in health care broadly, as well as its connection to fighting the coronavirus, has made it quite the safe haven stock indeed, with losses of just more than 10% since the start of the bear market. Nonetheless, it's trading at 15 times forward-looking earnings and 15 times cash flows, both of which are a little cheaper than their historic multiples.
JNJ's also well-positioned given a liquid balance sheet with little debt and robust cash flows. Again, that's key to its 57-year dividend growth streak - one that's expected to continue with a payout hike in April, keeping it among the longest-tenured Dividend Aristocrats. And the analyst community has been reiterating their support for the stock; nine pros have weighed in on Johnson & Johnson over the past three months, all of them with Buys.
SEE ALSO: 10 Health and Pharmaceutical Companies Fighting the Coronavirus
Chubb
Market value: $51.5 billion
Dividend yield: 2.6%
Performance since 2/19/20: -30.6%
Chubb (CB, $114.04) is the world's largest property and casualty insurance company, with operations in 54 countries. The company offers commercial and personal property and casualty insurance, accident and supplemental health insurance, reinsurance and life insurance. Chubb's competitive advantages include its extensive product offerings, exceptional financial strength and global network of branch offices.
Chubb was well-positioned before the coronavirus struck. Last quarter, the company recorded its strongest organic growth in five years. Property and casualty underwriting income increased 18.5% in 2019 due to improving pricing, a better underwriting environment and falling interest rates.
However, like most of the rest of the insurance industry, Chubb has taken a spill. That's in large part because the market's decline has sent investors into Treasuries, which has sent yields on those into the ground. Insurers, however, typically invest in Treasuries and other highly rated fixed-income products to generate returns.
The good news is that CB shares are trading at 10 times forward-looking earnings, which is a nice discount from its historical average near 13. Its dividend yield, while modest, is on the high end of its range from the past 10 years. And that dividend has grown for 26 consecutive years, with No. 27 on the way. The board of directors announced in late February that it planned to recommend a 4% increase at Chubb's annual meeting later this year.
At only 27% of earnings, Chubb has a very conservative payout, even for a Dividend Aristocrat. This low ratio and the company's excellent balance sheet, with debt at less than 20% of capitalization, support an exceptionally safe dividend.
SEE ALSO: 11 Defensive Dividend Stocks for Riding Out the Storm
Genuine Parts
Market value: $9.6 billion
Dividend yield: 4.8%
Performance since 2/19/20: -33.5%
Genuine Parts (GPC, $66.08) is a leading distributor of replacement automotive parts through its 5,900 NAPA auto parts stores across 44 states. In addition, the company has automotive replacement parts businesses in Canada, Mexico, Europe, Australia and New Zealand, which grew last year via acquisitions.
Genuine Parts has posted three straight years of record sales and recently began an operational streamlining expected to trim $100 million from annual expenses and help 2020 EPS. Its chances at a fourth consecutive year of record revenues is in doubt, however, thanks to the coronavirus.
That said, vehicles require repairs even during recessions, and thus auto-parts retailers are often considered "recession-proof." But while GPC's operations might get some help during and for some time following the potential recession ahead, investors still have turned tail on Genuine Parts, selling the Dividend Aristocrat off by more than a third since the bear market started.
But don't sleep on GPC. It's a solid cash generator whose payout represents less than 60% of this year's expected profits. Indeed, the company raised its payout in mid-February, by 3.6% to 79 cents per share, marking its 64th consecutive payout hike. Meanwhile, you can buy GPC shares for nearly 11 times earnings, which is considerably less than its historic 17.6 forward P/E. And its yield, at almost 5%, is at heights last seen during 2000 and 2009.
SEE ALSO: 13 Stock Picks Getting Hit by Coronavirus Fears
Cardinal Health
Market value: $14.1 billion
Dividend yield: 4.0%
Performance since 2/19/20: -18.4%
Cardinal Health (CAH, $47.96) is a global integrated health care business with operations in 45 countries and more than $146 billion in annual sales. Cardinal supplies products to nearly 90% of American hospitals, more than 29,000 pharmacies, 6,500 labs and 3 million patients who receive its home healthcare products.
Broad trends including an aging population, increased demand for health services and improving market dynamics in generic drug programs bode well for Cardinal's future sales in a normal market. Opioid litigation weighed on the stock in 2019, but payouts now look to be much less than initially anticipated.
CAH also is expanding its specialty and nuclear health solutions to grow its pharmaceutical business. In medical products, Cardinal is adding more at-home solutions and services. A cost reduction program targeting $500 million of savings over five years should also help profits.
Like many health care stocks, Cardinal hasn't been immune to the bear market but has held up better than the index. It also looks like a solid bargain by many metrics: its forward P/E is less than 9, price-to-cash flow is 27% cheaper than it has been historically, and CAH's 4% yield is near all-time highs.
Total debt is considerable, at roughly $8 billion versus just $1.7 billion in cash, but the company generates about $1.7 billion in free cash flow annually. Moreover, its modest dividend payout ratio of 36% makes it all the likelier that Cardinal is able to extend its 34-year streak of payout hikes and remain among the Dividend Aristocrats.
SEE ALSO: The 11 Best (And 11 Worst) Stocks From the 11-Year Bull Market
Colgate-Palmolive
Market value: $55.1 billion
Dividend yield: 2.6%
Performance since 2/19/20: -11.9%
Consumer products giant Colgate-Palmolive (CL, $66.58) provided investors with a breath of fresh air in early March, when it raised its dividend by 2.3% to 44 cents per share - the company's 58th consecutive annual payout hike.
Colgate, which sells products in more than 200 countries, is a global consumer staples leader with its Colgate line of toothpastes, whiteners and toothbrushes; liquid hand soap, which it sells under the Softsoap, Palmolive and Protex brands; and in high-end pet foods, which are sold under its Hill's Science Diet and Hill's Prescription Diet brands.
CL planned on delivering organic growth by advancing its core toothpaste portfolio in 2020 via improved packaging and pricing and relaunching Science Diet pet foods with enhanced ingredients, assortment and branding.
However, Colgate finds itself outperforming the market not on hopes of better packaging driving sales. Instead, the company's shares have been sought out as a store of stability, given that it's churning out consumer staples at a time in which people across the globe are stuck at home waiting out this pandemic. That, as well as a reasonable 62% payout ratio, keeps risk to the dividend low. So does robust free cash flow that exceeds $2 billion annually.
CL is hardly cheap, at 22 times forward earnings estimates and 18 times cash flows, but it's cheaper than it has been on average over the past five years. And it's a great place to find defense. Colgate is among UBS's Buy-rated picks in the consumer staples space, with the analyst outfit expecting CL to benefit from more spending on grocery shopping and other at-home consumption.
SEE ALSO: 10 Low-Volatility ETFs for This Roller-Coaster Market
McCormick & Company
Market value: $19.0 billion
Dividend yield: 1.7%
Performance since 2/19/20: -12.7%
McCormick (MKC, $143.15) is theglobal marketleader in spices, seasonings and food flavoring, with sales in over 150 countries. The company's McCormick, French's, Frank's Red Hot and Lawry's brands are found in practically every American grocery store. shoppers. McCormick also operates a flavoring solutions business that supplies seasoning blends, herbs, coatings and flavorings to multinational food manufacturers and foodservice suppliers.
The markets for flavorings and seasonings has been increasing 5% a year due to demand from millennials and Generation Z shoppers for bolder flavors and ethnic-focused food choices. McCormick is capitalizing on this trend by launching product line extensions, leveraging its established brands and expanding operations in emerging markets and organic food channels.
McCormick reported earnings results on March 31 for the quarter ended Feb. 29, giving investors a small window into COVID-19's effects. Quarterly sales declined by 2% year-over-year, as did operating income, with the company citing coronavirus-related weakness in China. MKC, like many other firms, has withdrawn its full-year guidance but said it plans to resume guidance when it reports Q2 earnings in June 2020. McCormick also said it will "moderate the pace of its business transformation investments and has delayed its ERP system replacement program" to maximize its financial flexibility.
This Dividend Aristocrat, which boasts 34 consecutive years of dividend hikes, has a reasonable 43% payout ratio that should ensure continued income growth. Downgrades to its earnings estimates have the stock trading at a forward P/E roughly on par with its five-year average, but interesting is the decline in its price/earnings-to-growth ratio, or PEG, which measures value in relation to growth. McCormick now trades at a PEG of 1.66, where any figure above 1 is considered expensive - but that figure is roughly half its five-year average PEG of 3.2.
McDonald's
Market value: $125.3 billion
Dividend yield: 3.0%
Performance since 2/19/20: -22.0%
Fast-food icon McDonald's (MCD, $168.13) is the world's leading global foodservice retailer and operates more than 38,000 locations in more than 100 countries and serves more than 70 million customers per day. Approximately 93% of the company's restaurants are independently owned and operated.
Last year, McDonald's surpassed $100 billion in system-wide sales and achieved 5.9% worldwide comparable-sales growth (stores open 12 or more months) - its highest such gain in more than a decade. The company's Velocity Growth plan, designed to retain existing customers, regain former customers via enhanced food quality, convenience and value and encourage more frequent visits with coffee and snacks has fueled three straight years of rising customer count.
McDonald's also delivered on its pledge to return $25 billion to investors, over a three-year span, via dividends and share repurchases. MCD's payout has risen 43 years in a row, and its excellent free cash flow (which exceeded $5.7 billion last year) provides secure coverage of the company's dividend and debt service. That said, the company is putting a $15 billion share buyback plan on hold and making its dividend a priority in response to the coronavirus outbreak.
The Dividend Aristocrat, which is off more than 20% through this bear market, trades at less than 20 times forward earnings estimates and 16 times cash flow - that's cheaper than its historical averages on both counts.
SEE ALSO: The 12 Best ETFs to Battle a Bear Market
Becton Dickinson
Market value: $60.4 billion
Dividend yield: 1.4%
Performance since 2/19/20: -13.0%
Becton Dickinson (BDX, $222.87) supplies medical products and devices, laboratory equipment and diagnostic tests worldwide. The company operates in three segments - medical, life sciences and interventional, and grew its interventional business significantly through the 2017 acquisition of fellow Aristocrat CR Bard. Becton Dickinson's customers include hospitals, laboratories, the pharmaceutical industry and the general public.
The recall of its popular Alaris infusion pump caused results to fall short of expectations last quarter, but Becton Dickinson continues to guide for rising 2020 sales and EPS, which it expected to be fueled by the launch of approximately 250 new products for the interventional market.
BDX also is a player in the battle against the coronavirus. It recently secured European Union approval for a COVID-19 test that can test 24 samples simultaneously and generate results in under three hours. It is also seeking emergency FDA approval for its molecular diagnostic coronavirus test.
Earnings growth has been inconsistent due to acquisition costs, but Becton Dickinson has delivered 19% yearly growth in EBITDA (a measure of operational profits) over the past five years. That, and a low 27% payout ratio enhance the safety of its dividend.
Becton Dickinson's shares are trading at a slight discount to their historical forward P/E and price-to-cash flow metrics, but then, they haven't really declined much. BDX is off just 13% given that the pandemic isn't hampering demand for many of its products.
Dover
Market value: $12.4 billion
Dividend yield: 2.3%
Performance since 2/19/20: -27.0%
Dover (DOV, $85.64) is a diversified industrial manufacturer of engineered products for aftermarket vehicle servicing, solid waste handling, specialty pumps and refrigeration and food equipment.
Most of Dover's products are components of a larger system, where value-in-use and switching costs far exceed the cost of the product itself. The repair and replacement nature of its product lines, along with high recurring demand (30% of sales), in theory should make Dover more recession-resistant than other industrial manufacturers. But its shares are slightly underperforming the market through the current bear run.
That said, DOV stock has earned upgrades from Goldman Sachs, Morgan Stanley and JPMorgan over the past couple weeks. Goldman's Joe Ritchie, for instance, lowered his price target from $119 to $98 but upgraded his rating to Buy, saying Dover has "significant margin runway" and is much better positioned for the current economic downturn than in previous cycles.
Dover has a 64-year track record of dividend growth, and has improved its payout by an average of 8.7% annually over the past five years. This exceptional record of dividend growth is likely to continue due to Dover's modest 31% payout, proven ability to convert most of its earnings to free cash flow and solid balance sheet.
DOV shares typically aren't expensive to begin with, but a forward P/E below 14 and a price-to-cash flow of 13.3 are both a few points below their historical norms.
SEE ALSO: 11 Best Stocks to Ride Out the Coronavirus Outbreak
Medtronic
Market value: $123.4 billion
Dividend yield: 2.4%
Performance since 2/19/20: -19.1%
Medtronic (MDT, $92.05) develops medical devices and solutions for minimally invasive surgeries, cardiac and vascular treatment, restorative therapies and diabetes management. The company operates in more than 150 countries; its products have improved outcomes for more than 75 million patients.
And particularly noteworthy right now: MDT is a leading manufacturer of ventilators. In fact, it's in the process of more than doubling ventilator manufacturing capacity to meet unprecedented coronavirus-related demand.
Medtronic targets 8% annual EPS gains and a steadily rising dividend, which the company will achieve by expanding its development pipeline and new product launches and increasing its foothold in emerging markets, where growth is consistently in the double digits - an expectation that might need to be slimmed down somewhat, if only in the short term.
Nonetheless, this exceptional company has produced average annual dividend growth of 14% over the past five years, thus the payout has nearly doubled in that time. Medtronic has been among the ranks of the Dividend Aristocrats for nearly two decades, by virtue of 42 consecutive dividend increases.
MDT currently trades at a lower forward P/E and price-to-cash flow multiples than its five-year averages. But Medtronic isn't just about value - it's about the potential for future growth well after this pandemic has passed. SunTrust analyst Kaila Krum (Buy, $130 price target), for instance, is bullish about the company's renal denervation therapy, writing, "After a turbulent history of US pivotal trial failures and efforts by several companies in renal denervation, we're pleased to see steady progress towards FDA approval. We think Medtronic will be first to market and that the opportunity could be $1B market by 2026."
Emerson Electric
Market value: $28.5 billion
Dividend yield: 4.3%
Performance since 2/19/20: -35.1%
Emerson Electric (EMR, $46.63) is a global manufacturer of automated solutions for the chemicals, energy, power generation, pharmaceutical and food and beverage industries, which all make up two-thirds of its sales. EMR also provides commercial and residential solutions for heating and cooling applications, commercial and industrial refrigeration, and cold chain management.
The Automated Solutions business has an installed base of $115 billion worth of equipment, which drives recurring sales from equipment upgrades and service contracts. The Commercial and Residential Solutions business is resilient thanks to the recession-resistant nature of its end-markets, not to mention its proprietary technology.
EMR's problem right now is its connection to the energy sector, which is getting hammered thanks to plummeting oil prices. That said, there's a real growth opportunity developing in its Industrial Internet of Things, which manages things such as data collection and systems controls.
Emerson Electric has raised dividends 63 years in a row, testifying to the company's ability to reward investors even during economic downturns. Dividend payout targeted at 50% of free cash flow leaves a margin for safety even if coronavirus effects are worse than expected. The company had already been planning for a challenging 2020 and has initiated multiple programs designed to trim expenses and bolster margins. It's further supported by a balance sheet rated "A" by Standard & Poor's.
And EMR is genuinely cheap right now. Its forward P/E of 12.7 is roughly a third cheaper than its five-year average, and its price-to-cash flow of 13.3 is about a 40% discount to its historical average.
SEE ALSO: 30 Massive Dividend Increases From the Past Year
Automatic Data Processing
Market value: $59.5 billion
Dividend yield: 2.6%
Performance since 2/19/20: -24.0%
Automatic Data Processing (ADP, $137.82) is a world-leading provider of cloud-based human capital management solutions (HCM) for areas such as payroll processing, benefits administration, human resources, regulatory compliance and insurance services. The company serves over 810,000 clients in 140 countries.
ADP benefits from this large installed customer base as well as strong client retention, with most customers averaging 11 years with company. These characteristics of its business support high recurring revenues and good margins. Acquisitions and organic growth have enabled ADP to deliver 8% annual EPS growth over the past 10 years. Dividends have risen 45 years in a row, including a 3% uptick last year.
It's no wonder that ADP has taken a hit amid the bear market given what a potential recession could mean for many of its customers. That said, the company so far has tacked on expenses - in the form of a $1,000 check to every one of its employees, to be sent out in April - rather than reduced headcount so far, which is an encouraging sign. And in general, ADP's entrenchment should serve it well in an economic recovery.
In the meanwhile, ADP has an AA credit rating from agencies, low debt representing just 17% of capitalization and robust free cash flow that grew to $2.2 billion last year. That's enough to cover the dividend twice over. Meanwhile, ADP's forward P/E and price-to-cash flow are both several points lower than their historical averages.
Ecolab
Market value: $46.7 billion
Dividend yield: 1.2%
Performance since 2/19/20: -23.3%
Ecolab (ECL, $161.40) is the worldwide leader in water treatments, hygiene and energy technology and services. The company provides water treatment processes and technologies to the food and beverage, paper, life sciences and manufacturing industries and specialized cleaners and sanitizers to foodservice, healthcare, lodging and education industries. In its process chemicals and water treatment business, Ecolab serves the oil and gas, refining and petrochemical industries.
Ecolab's earnings growth has been solid and consistent, averaging close to 12% annually over the past 10 years. Like some Dividend Aristocrats, ECL's yield isn't much to talk about, at 1.2% despite the stock's 24% drawdown. And average annual payout growth of 7.3% over the past half-decade has been good, albeit not great.
But it's a safe dividend that only represents 35% of profits. It's also paid by a company whose free cash flow could pay off its debt within four years. And while Ecolab is hardly inexpensive compared to the broader market right now, it is cheaper than it has been on average by most metrics - P/E, forward P/E, price-to-cash flow and price-to-book.
SEE ALSO: Every Warren Buffett Stock Ranked: The Berkshire Hathaway Portfolio
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | SEE ALSO: 64 Dividend Stocks You Can Count On in 2020 AbbVie Market value: $111.1 billion Dividend yield: 6.3% Performance since 2/19/20: -20.1% (vs. -22.4% for the S&P 500) AbbVie (ABBV, $75.24) expects that its pending $63 billion merger with Allergan (AGN) will offset slowing growth of its blockbuster drug Humira. AbbVie initially said the merger, which is experiencing coronavirus-related delays in closing, would create a combined business that would generate more than $30 billion in sales this year, then high-single-digit growth into the foreseeable future. AbbVie develops drugs for autoimmune diseases, cancer, virology (including HIV and Hepatitis C) and neurological disorders. | ABBV shares look cheap at just 7.5 times forward-looking earnings estimates, which is modest compared to the company's historical average forward P/E of 12. Dividend growth investors will like AbbVie's 48 consecutive years of payout hikes; a conservative payout ratio of 48% that provides flexibility for dividend growth and debt reduction; and a five-year annual dividend growth rate of 18.3%. SEE ALSO: 64 Dividend Stocks You Can Count On in 2020 AbbVie Market value: $111.1 billion Dividend yield: 6.3% Performance since 2/19/20: -20.1% (vs. -22.4% for the S&P 500) AbbVie (ABBV, $75.24) expects that its pending $63 billion merger with Allergan (AGN) will offset slowing growth of its blockbuster drug Humira. AbbVie initially said the merger, which is experiencing coronavirus-related delays in closing, would create a combined business that would generate more than $30 billion in sales this year, then high-single-digit growth into the foreseeable future. | ABBV shares look cheap at just 7.5 times forward-looking earnings estimates, which is modest compared to the company's historical average forward P/E of 12. Dividend growth investors will like AbbVie's 48 consecutive years of payout hikes; a conservative payout ratio of 48% that provides flexibility for dividend growth and debt reduction; and a five-year annual dividend growth rate of 18.3%. SEE ALSO: 64 Dividend Stocks You Can Count On in 2020 AbbVie Market value: $111.1 billion Dividend yield: 6.3% Performance since 2/19/20: -20.1% (vs. -22.4% for the S&P 500) AbbVie (ABBV, $75.24) expects that its pending $63 billion merger with Allergan (AGN) will offset slowing growth of its blockbuster drug Humira. AbbVie initially said the merger, which is experiencing coronavirus-related delays in closing, would create a combined business that would generate more than $30 billion in sales this year, then high-single-digit growth into the foreseeable future. | ABBV shares look cheap at just 7.5 times forward-looking earnings estimates, which is modest compared to the company's historical average forward P/E of 12. Dividend growth investors will like AbbVie's 48 consecutive years of payout hikes; a conservative payout ratio of 48% that provides flexibility for dividend growth and debt reduction; and a five-year annual dividend growth rate of 18.3%. SEE ALSO: 64 Dividend Stocks You Can Count On in 2020 AbbVie Market value: $111.1 billion Dividend yield: 6.3% Performance since 2/19/20: -20.1% (vs. -22.4% for the S&P 500) AbbVie (ABBV, $75.24) expects that its pending $63 billion merger with Allergan (AGN) will offset slowing growth of its blockbuster drug Humira. AbbVie initially said the merger, which is experiencing coronavirus-related delays in closing, would create a combined business that would generate more than $30 billion in sales this year, then high-single-digit growth into the foreseeable future. |
24634.0 | 2020-03-30 00:00:00 UTC | Monday 3/30 Insider Buying Report: ABBV, NKE | ABBV | https://www.nasdaq.com/articles/monday-3-30-insider-buying-report%3A-abbv-nke-2020-03-30 | nan | nan | Bargain hunters are wise to pay careful attention to insider buying, because although there are many various reasons for an insider to sell a stock, presumably the only reason they would use their hard-earned dollars to make a purchase, is that they expect to make money. Today we look at two noteworthy recent insider buys.
At AbbVie, a filing with the SEC revealed that on Monday, VP, Controller Brian L. Durkin purchased 3,750 shares of ABBV, for a cost of $68.20 each, for a total investment of $255,755. So far Durkin is in the green, up about 11.8% on their purchase based on today's trading high of $76.24. AbbVie is trading up about 3.1% on the day Monday. Before this latest buy, Durkin made one other purchase in the past year, buying $255,755 shares at a cost of $68.20 a piece.
And at Nike, there was insider buying on Thursday, by Director John W. Rogers Jr. who purchased 2,500 shares for a cost of $84.22 each, for a total investment of $210,543. This buy marks the first one filed by Rogers Jr. in the past twelve months. Nike is trading up about 1.8% on the day Monday.
VIDEO: Monday 3/30 Insider Buying Report: ABBV, NKE
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | At AbbVie, a filing with the SEC revealed that on Monday, VP, Controller Brian L. Durkin purchased 3,750 shares of ABBV, for a cost of $68.20 each, for a total investment of $255,755. AbbVie is trading up about 3.1% on the day Monday. VIDEO: Monday 3/30 Insider Buying Report: ABBV, NKE The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | At AbbVie, a filing with the SEC revealed that on Monday, VP, Controller Brian L. Durkin purchased 3,750 shares of ABBV, for a cost of $68.20 each, for a total investment of $255,755. VIDEO: Monday 3/30 Insider Buying Report: ABBV, NKE The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. AbbVie is trading up about 3.1% on the day Monday. | At AbbVie, a filing with the SEC revealed that on Monday, VP, Controller Brian L. Durkin purchased 3,750 shares of ABBV, for a cost of $68.20 each, for a total investment of $255,755. AbbVie is trading up about 3.1% on the day Monday. VIDEO: Monday 3/30 Insider Buying Report: ABBV, NKE The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | At AbbVie, a filing with the SEC revealed that on Monday, VP, Controller Brian L. Durkin purchased 3,750 shares of ABBV, for a cost of $68.20 each, for a total investment of $255,755. AbbVie is trading up about 3.1% on the day Monday. VIDEO: Monday 3/30 Insider Buying Report: ABBV, NKE The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. |
24635.0 | 2020-03-30 00:00:00 UTC | 4 Reasons Drug Stocks Are a Buy Right Now | ABBV | https://www.nasdaq.com/articles/4-reasons-drug-stocks-are-a-buy-right-now-2020-03-30 | nan | nan | The emerging coronavirus pandemic highlights the world's dependence on pharmaceutical and biotech companies to produce drugs and vaccines to help overcome all types of illness. This outbreak may bring new appreciation for the industry. Here we explore four reasons that investors should consider drug stocks currently in the spotlight.
Image Source: Getty Images.
1. Diseases ignore the economy
In good times and bad, people fall ill or get injured and require medication. Individuals with chronic diseases like diabetes or rare genetic disorders such as Gaucher disease require ongoing therapy. Big pharmaceutical companies, smaller specialty pharma, and biotech companies will continue to deliver medicines to the extent that's possible.
In the current environment of social distancing and avoiding unnecessary exposure, we could witness a shift in the delivery of treatment. This includes virtual doctor visits or telemedicine. In disease areas with multiple treatment options, patients may transition to oral medicines (traditional pills and capsules) that can be taken at home rather than going to a clinic to receive an infusion or shot. These kinds of decisions will be made on a patient-by-patient basis. From an investment perspective, it could mark an uptick in self-administered treatment.
2. Beaten-down valuations
Healthcare did not evade the current market downturn. The stocks of big pharmaceutical companies like AbbVie (NYSE: ABBV), Bristol Myers Squibb (NYSE: BMY), Novartis (NYSE: NVS), and Pfizer (NYSE: PFE) are down 20% to 30% from peak prices in the past year. These global pharmas range in value from $100 billion to $200 billion even with the current haircut in price.
Biotech companies were not immune to the recent market sell-off. The iShares Nasdaq Biotechnology ETF (NASDAQ: IBB), the largest biotech ETF by assets, skews toward larger companies. In fact, its top ten holdings, including Gilead Sciences (NASDAQ: GILD), Vertex Pharmaceuticals (NASDAQ: VRTX), Amgen (NASDAQ: AMGN), and Biogen (NASDAQ: BIIB), make up 53% of the portfolio. The IBB was down over 20% but has since climbed back to post only a 12% loss so far this year.
The SPDR S&P Biotech ETF (NYSEMKT: XBI) comprises a larger cross-section of smaller drug developers than the IBB. The index fell more than 30% this year. Like the IBB, it has recaptured some of its losses in the second half of March. It is down approximately 20% year to date.
3. Financial stability
Big pharma companies sell boatloads of drugs and spend small fortunes on research and development (R&D). While sales may be impacted by COVID-19, the expense side is affected as well. Most big pharmas halted any new clinical trials and paused most that were ongoing. This will lower R&D expenses in the near term.
Six of the largest big pharma companies spent over $31 billion in 2019 to repurchase stock. Since buyback programs are discretionary and can be stopped or started at any time, the money can be diverted to fund operations through a business slowdown.
Along with paying dividends, buybacks of company stock represent a way to return value to stockholders. I would expect the companies to protect their dividend first. Then, as business begins to regain traction, the stock repurchases can restart again.
4. Binary bets drive performance
R&D-stage drug development companies enjoy what I'll call the luxury of unprofitability. By this, I mean that investors in these companies want to see advancements in the R&D pipeline. New scientific data, clinical trial results, and updates from regulators, like the Food and Drug Administration (FDA), can cause the stocks of these companies to spike or drop. Valuation is based on the potential of the drugs in development. This event-driven reality is in contrast to commercial entities that need to manage quarter-to-quarter and year-to-year revenue and profit expectations.
Drug developers burning through capital on the hopes of future success saw stock prices take a hit. Smaller companies often took a greater beating than their larger counterparts. Why? One big consideration is cash.
In contrast to big pharma and large biotechs with substantial cash war chests to ride out the downturn, smaller companies, with less cash on hand, become riskier in this environment. In some cases, stocks traded down to cash value or even below. This effectively wipes out any value for such companies' R&D pipeline.
While many drugs will fail, some will succeed. Drug developers can deliver huge home runs to investors if binary events are positive. Just look at the 2019 performance of Axsome Therapeutics, Kodiak Sciences, or ArQule as examples. Patient, bargain-hunting healthcare investors can find cheap stocks among smaller R&D-stage companies.
The world is looking to drug developers as the cavalry riding in to win the war against COVID-19. More people may seek to invest in these promising companies and realize the value they provide to both shareholders and society at large. In the meantime, focus on cash-rich companies that can fund operations until the world returns to "normal" and the economy starts chugging forward again.
10 stocks we like better than Pfizer
When investing geniuses David and Tom Gardner have a stock tip, it can pay to listen. After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor, has tripled the market.*
David and Tom just revealed what they believe are the ten best stocks for investors to buy right now... and Pfizer wasn't one of them! That's right -- they think these 10 stocks are even better buys.
See the 10 stocks
*Stock Advisor returns as of March 18, 2020
David Haen owns shares of Pfizer. The Motley Fool owns shares of and recommends Biogen, Bristol Myers Squibb, and Gilead Sciences. The Motley Fool recommends Amgen and Vertex Pharmaceuticals. The Motley Fool has a disclosure policy.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | The stocks of big pharmaceutical companies like AbbVie (NYSE: ABBV), Bristol Myers Squibb (NYSE: BMY), Novartis (NYSE: NVS), and Pfizer (NYSE: PFE) are down 20% to 30% from peak prices in the past year. The emerging coronavirus pandemic highlights the world's dependence on pharmaceutical and biotech companies to produce drugs and vaccines to help overcome all types of illness. In disease areas with multiple treatment options, patients may transition to oral medicines (traditional pills and capsules) that can be taken at home rather than going to a clinic to receive an infusion or shot. | The stocks of big pharmaceutical companies like AbbVie (NYSE: ABBV), Bristol Myers Squibb (NYSE: BMY), Novartis (NYSE: NVS), and Pfizer (NYSE: PFE) are down 20% to 30% from peak prices in the past year. In fact, its top ten holdings, including Gilead Sciences (NASDAQ: GILD), Vertex Pharmaceuticals (NASDAQ: VRTX), Amgen (NASDAQ: AMGN), and Biogen (NASDAQ: BIIB), make up 53% of the portfolio. The Motley Fool owns shares of and recommends Biogen, Bristol Myers Squibb, and Gilead Sciences. | The stocks of big pharmaceutical companies like AbbVie (NYSE: ABBV), Bristol Myers Squibb (NYSE: BMY), Novartis (NYSE: NVS), and Pfizer (NYSE: PFE) are down 20% to 30% from peak prices in the past year. Big pharmaceutical companies, smaller specialty pharma, and biotech companies will continue to deliver medicines to the extent that's possible. In contrast to big pharma and large biotechs with substantial cash war chests to ride out the downturn, smaller companies, with less cash on hand, become riskier in this environment. | The stocks of big pharmaceutical companies like AbbVie (NYSE: ABBV), Bristol Myers Squibb (NYSE: BMY), Novartis (NYSE: NVS), and Pfizer (NYSE: PFE) are down 20% to 30% from peak prices in the past year. Big pharmaceutical companies, smaller specialty pharma, and biotech companies will continue to deliver medicines to the extent that's possible. Six of the largest big pharma companies spent over $31 billion in 2019 to repurchase stock. |
24636.0 | 2020-03-29 00:00:00 UTC | Have $1,000 to Invest? 3 Great High-Yield Dividend Stocks to Buy Right Now | ABBV | https://www.nasdaq.com/articles/have-%241000-to-invest-3-great-high-yield-dividend-stocks-to-buy-right-now-2020-03-29 | nan | nan | It's raining gold. That's probably how Warren Buffett would summarize the stock market crash. Buffett wrote to Berkshire Hathaway shareholders in 2010: "Big opportunities come infrequently. When it's raining gold, reach for a bucket, not a thimble."
The problem for many investors, though, is that they don't exactly have a big bucket. Don't worry if you're in that group. Even if you don't have a ton of cash, it's still a very good time to buy stocks if you're prepared to hold them over the long run.
I think it's an especially opportune time to invest in strong dividend stocks with yields that soared as the market sank. If you have $1,000 to invest, here are three great high-yield dividend stocks to buy right now.
Image source: Getty Images.
1. AbbVie
AbbVie (NYSE: ABBV) belongs to an elite group of stocks known as Dividend Aristocrats. These stocks, all of which are members of the S&P 500, have increased their dividend payouts for at least 25 consecutive years. AbbVie easily surpasses that threshold, with a sterling track record of 47 years in a row of dividend hikes. Its dividend currently yields a little under 7%.
Many investors would be perfectly content to just receive a 7% return each year. The good news is that AbbVie has pretty good growth prospects to go along with its mouthwatering dividend.
The big pharma company launched two new immunology drugs last year, Rinvoq and Skyrizi, that should become megablockbusters within the next few years. Sales for its cancer drugs Imbruvica and Venclexta continue to soar.
There's one big knock against AbbVie: Its dependence on Humira, the company's top-selling immunology drug that's already losing market share in Europe and will face biosimilar competition in the U.S. in three years. However, AbbVie's other products and pipeline candidates along with its pending acquisition of Allergan should offset the sales losses for Humira and keep the drugmaker's great dividends flowing.
2. Brookfield Infrastructure Partners
Brookfield Infrastructure Partners (NYSE: BIP) doesn't have the long history of dividend increases that AbbVie does. But its dividend yield of close to 5.6% is very attractive. So is the fact that the company has boosted its dividend by 52% over the last five years.
Another big plus for Brookfield Infrastructure Partners is its diversification. The company owns lots of different kinds of infrastructure assets, including cell towers, data centers, electricity transmission systems, natural gas pipelines, ports, and railroads. Brookfield's biggest sector is utilities, but it contributes a little under one-third of the company's total cash flows -- a great sign of how diversified the company is.
You'll also probably like the financial stability that Brookfield Infrastructure offers. The company takes a conservative stance with how much debt it takes on. And roughly 95% of its total cash flows are regulated or contracted.
Brookfield Infrastructure likes to refer to itself as a "grow-tility" that provides investors both security and growth. This growth comes from a continual reevaluation of assets, with the company selling off lower performers to invest in assets that have a better chance of outperforming. Wall Street analysts agree that the company will deliver solid growth with consensus projections of average annual earnings growth of nearly 8% over the next five years.
3. Chevron
Chevron (NYSE: CVX) has been a favorite for income-seeking investors for a long time. And with a dividend that currently yields close to 7.5%, it should still be a favorite.
The entire oil and gas industry has been hit hard by the reduced travel caused by the coronavirus pandemic. To make matters even worse, an oil price war initiated by Russia wreaked havoc on oil stocks.
But if there's any company that's prepared to emerge a winner from a period of lower oil prices, it's Chevron. The energy giant has a strong balance sheet. It hasn't been spending aggressively like some in the industry have. In light of the current challenges, Chevron is reducing its capital spending by 20% and suspending its share buybacks to conserve cash.
If you think that oil prices will stay at current levels for a long time, it makes sense to avoid all oil and gas stocks. However, travel will pick up as the numbers of COVID-19 cases begin to decline. No one, including Russia and Saudi Arabia, wants the oil price wars to go on indefinitely. Sooner or later, oil prices will rebound, with Chevron benefiting. In the meantime, investors who buy the stock will enjoy a juicy dividend yield.
10 stocks we like better than Chevron
When investing geniuses David and Tom Gardner have a stock tip, it can pay to listen. After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor, has tripled the market.*
David and Tom just revealed what they believe are the ten best stocks for investors to buy right now... and Chevron wasn't one of them! That's right -- they think these 10 stocks are even better buys.
See the 10 stocks
*Stock Advisor returns as of March 18, 2020
Keith Speights owns shares of AbbVie, Brookfield Infrastructure Partners, and Chevron. The Motley Fool owns shares of and recommends Berkshire Hathaway (B shares). The Motley Fool recommends Brookfield Infrastructure Partners and recommends the following options: long January 2021 $200 calls on Berkshire Hathaway (B shares) and short January 2021 $200 puts on Berkshire Hathaway (B shares). The Motley Fool has a disclosure policy.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | There's one big knock against AbbVie: Its dependence on Humira, the company's top-selling immunology drug that's already losing market share in Europe and will face biosimilar competition in the U.S. in three years. However, AbbVie's other products and pipeline candidates along with its pending acquisition of Allergan should offset the sales losses for Humira and keep the drugmaker's great dividends flowing. AbbVie AbbVie (NYSE: ABBV) belongs to an elite group of stocks known as Dividend Aristocrats. | Brookfield Infrastructure Partners Brookfield Infrastructure Partners (NYSE: BIP) doesn't have the long history of dividend increases that AbbVie does. AbbVie AbbVie (NYSE: ABBV) belongs to an elite group of stocks known as Dividend Aristocrats. AbbVie easily surpasses that threshold, with a sterling track record of 47 years in a row of dividend hikes. | Brookfield Infrastructure Partners Brookfield Infrastructure Partners (NYSE: BIP) doesn't have the long history of dividend increases that AbbVie does. See the 10 stocks *Stock Advisor returns as of March 18, 2020 Keith Speights owns shares of AbbVie, Brookfield Infrastructure Partners, and Chevron. AbbVie AbbVie (NYSE: ABBV) belongs to an elite group of stocks known as Dividend Aristocrats. | See the 10 stocks *Stock Advisor returns as of March 18, 2020 Keith Speights owns shares of AbbVie, Brookfield Infrastructure Partners, and Chevron. AbbVie AbbVie (NYSE: ABBV) belongs to an elite group of stocks known as Dividend Aristocrats. AbbVie easily surpasses that threshold, with a sterling track record of 47 years in a row of dividend hikes. |
24637.0 | 2020-03-27 00:00:00 UTC | 2 Dividend Stocks Trading at Dirt-Cheap Prices | ABBV | https://www.nasdaq.com/articles/2-dividend-stocks-trading-at-dirt-cheap-prices-2020-03-27 | nan | nan | The COVID-19 pandemic is affecting our social lives, as governmental authorities in most U.S. states have implemented drastic measures -- including social distancing -- to mitigate the spread of the disease. The outbreak also continues to wreak havoc on equity markets. Year to date, the S&P 500 is down by 20% (at writing), and things could get worse before they get better.
The silver lining for investors -- if there is one -- is that many stocks are now trading at dirt-cheap prices. And while it's important to note that nothing, including dividends, is certain in today's market, some great dividend stocks are on sale. In particular, here are two that you can currently buy for a discount: AbbVie (NYSE: ABBV) and Pfizer (NYSE: PFE).
1. AbbVie
Pharma giant AbbVie hasn't performed particularly well of late. Last year, the company's shares slid by about 4%, while the S&P 500 climbed by almost 29%. The reason behind AbbVie's poor performance in 2019 isn't a secret: Sales of the company's blockbuster drug Humira -- which treats several autoimmune disorders including plaque psoriasis and rheumatoid arthritis -- have been declining in Europe because of competition from biosimilars. Humira still accounts for the bulk of AbbVie's revenue.
Image source: Getty Images.
During fiscal 2019, Humira's net revenue came in at $19.2 billion, which represented about 57.6% of the company's total. However, AbbVie has a plan to decrease its top-line exposure to Humira. First, several of its products are currently gaining solid momentum. For instance, Skyrizi, a treatment for moderate to severe plaque psoriasis that the U.S. Food and Drug Administration (FDA) approved in April of 2019, racked up $355 million in sales last year, including $216 million in the fourth quarter alone.
Cancer drug Venclexta also recorded revenue of $792 million in fiscal 2019, more than doubling its revenue from the year before. Imbruvica, another cancer drug, recorded revenue of $4.7 billion, a 35.8% year-over-year increase. AbbVie hopes that these products (and others) will gradually fill up some of the void left by Humira's international sales. AbbVie also announced in June that it would acquire Allergan (NYSE: AGN) in a cash-and-stock transaction valued at $63 billion; this transaction is set to close this May.
Thanks to this acquisition, AbbVie should be able to expand its lineup as well as its pipeline. In particular, the company will now have access to Botox, a product for which we are unlikely to see biosimilars anytime soon, at least according to AbbVie CEO Richard A. Gonzalez. Given all these factors, AbbVie could keep growing its revenue at a nice clip.
ABBV Dividend Yield data by YCharts
AbbVie's dividend yield is currently 6.18%, and the company has raised its dividends by 195% since it was created in 2013. AbbVie is also trading at just 7.2 times future earnings. Now might be as good a time as ever to purchase shares of this top dividend stock.
2. Pfizer
Pfizer went through some critical changes last year. For instance, the company formed a joint venture with GlaxoSmithKline (NYSE: GSK), called GSK Consumer Healthcare, which combined both companies' consumer healthcare segments; Pfizer owns a 32% stake in this venture. The transaction officially closed in August 2019.
In July 2019, Pfizer also announced it would merge Upjohn, its "off-patent branded and generic established medicines business," with Mylan (NASDAQ: MYL) to create a new company called Viatris. Given the terms of the merger, Pfizer's shareholders will hold a 57% stake in Viatris; this transaction is set to close in mid-2020. Pfizer decided to make these moves in part because its Upjohn unit and its consumer healthcare segment had been underperforming.
For instance, during the fourth quarter, the company recorded revenue of $12.7 billion, representing an 8% year-over-year decline. However, when the effects of its consumer healthcare business are excluded, the company's revenue increased by 1% year over year. Furthermore, Pfizer's Upjohn unit posted $2.2 billion in revenue during the fourth quarter, a 32% year-over-year decrease. The company's biopharma business, on the other hand, recorded a revenue of $10.5 billion during the quarter, a 9% increase compared to the prior-year quarter.
Pfizer will be able to focus on its biopharma business moving forward, and the pharma giant has several exciting products in its lineup that will likely drive decent sales growth in the future. For instance, its anticoagulant, Eliquis, reported sales of $4.2 billion in 2019, representing a 26% increase compared with fiscal 2018. And sales of cancer drug Ibrance were $4.96 million in 2019, 23% higher than the previous fiscal year.
Pfizer boasts other products with fast-growing sales, including rheumatoid arthritis drug Xeljanz, whose sales increased by 29% year over year to $2.2 billion in 2019. Eliquis and Ibrance deserve special mention, though: According to the research firm Evaluate Pharma, both of these products will be among the 10 best-selling drugs in the world by 2022.
Pfizer also boasts several interesting pipeline products. Notably, the company acquired Array BioPharma -- a company that focuses on the development of cancer treatments -- in an all-cash transaction valued at $11.4 billion that closed in July of 2019.
Thanks to this acquisition, Pfizer acquired the rights to Braftovi and Mektovi; the combined use of these two products is approved for the treatment of metastatic melanoma, a form of skin cancer. Braftovi and Mektovi are currently being investigated as a combination treatment for many other types of cancer in more than 30 clinical trials. As CEO of Pfizer Albert Bourla said when the company first announced the acquisition:
The proposed acquisition of Array strengthens our innovative biopharmaceutical business, is expected to enhance its long-term growth trajectory, and sets the stage to create a potentially industry-leading franchise for colorectal cancer alongside Pfizer's existing expertise in breast and prostate cancers.
Lastly, Pfizer is currently attractively valued.
PFE Dividend Yield data by YCharts
The company's dividend yield is 5.1%, well above the S&P's average yield of 2%, and Pfizer has raised its dividends by 35.7% over the past five years (not to mention that it's paid a dividend every year since 1980). Investors looking for attractive dividend-paying stocks would do well to buy shares of Pfizer.
10 stocks we like better than Pfizer
When investing geniuses David and Tom Gardner have a stock tip, it can pay to listen. After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor, has tripled the market.*
David and Tom just revealed what they believe are the ten best stocks for investors to buy right now... and Pfizer wasn't one of them! That's right -- they think these 10 stocks are even better buys.
See the 10 stocks
*Stock Advisor returns as of March 18, 2020
Prosper Junior Bakiny has no position in any of the stocks mentioned. The Motley Fool recommends Mylan. The Motley Fool has a disclosure policy.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | The reason behind AbbVie's poor performance in 2019 isn't a secret: Sales of the company's blockbuster drug Humira -- which treats several autoimmune disorders including plaque psoriasis and rheumatoid arthritis -- have been declining in Europe because of competition from biosimilars. In particular, here are two that you can currently buy for a discount: AbbVie (NYSE: ABBV) and Pfizer (NYSE: PFE). AbbVie Pharma giant AbbVie hasn't performed particularly well of late. | ABBV Dividend Yield data by YCharts AbbVie's dividend yield is currently 6.18%, and the company has raised its dividends by 195% since it was created in 2013. In particular, here are two that you can currently buy for a discount: AbbVie (NYSE: ABBV) and Pfizer (NYSE: PFE). AbbVie Pharma giant AbbVie hasn't performed particularly well of late. | In particular, here are two that you can currently buy for a discount: AbbVie (NYSE: ABBV) and Pfizer (NYSE: PFE). AbbVie Pharma giant AbbVie hasn't performed particularly well of late. The reason behind AbbVie's poor performance in 2019 isn't a secret: Sales of the company's blockbuster drug Humira -- which treats several autoimmune disorders including plaque psoriasis and rheumatoid arthritis -- have been declining in Europe because of competition from biosimilars. | In particular, here are two that you can currently buy for a discount: AbbVie (NYSE: ABBV) and Pfizer (NYSE: PFE). AbbVie Pharma giant AbbVie hasn't performed particularly well of late. The reason behind AbbVie's poor performance in 2019 isn't a secret: Sales of the company's blockbuster drug Humira -- which treats several autoimmune disorders including plaque psoriasis and rheumatoid arthritis -- have been declining in Europe because of competition from biosimilars. |
24638.0 | 2020-03-27 00:00:00 UTC | 3 Dirt-Cheap Healthcare Stocks to Buy Right Now | ABBV | https://www.nasdaq.com/articles/3-dirt-cheap-healthcare-stocks-to-buy-right-now-2020-03-27 | nan | nan | We're living out the memorable opening line of Charles Dickens' classic novel A Tale of Two Cities. It really is both the best of times and the worst of times.
Identifying what makes this the worst of times is easy. The coronavirus pandemic has arguably caused the greatest disruption to everyday life since World War II. But for investors, the resulting stock market crash has presented one of the greatest buying opportunities for stocks in our lifetimes.
There are bargains to be found in pretty much every sector. Healthcare is no exception. Here are three healthcare stocks that are dirt cheap and appear to be great buys right now.
Image source: Getty Images.
1. AbbVie
AbbVie (NYSE: ABBV) shares currently trade at less than 9 times expected earnings. That kind of low valuation might make sense for a company likely to experience an earnings decline, but that's not the case for AbbVie.
Granted, the big drugmaker faces some headwinds for its top-selling drug, Humira. Biosimilar rivals are already eating into the blockbuster drug's market share in Europe and will do the same in the U.S. beginning in 2023. However, AbbVie has been planning for this eventuality for years. I think the company's in good shape to survive and thrive in a post-Humira world.
AbbVie isn't as dependent on Humira as it used to be, thanks in large part to fast-rising sales for cancer drugs Imbruvica and Venclexta. Its pipeline has also been fruitful, with new immunology drugs Rinvoq and Skyrizi likely to rake in billions of dollars in sales annually over the next decade. And AbbVie's pending acquisition of Allergan will reduce its reliance on Humira even more.
Even with the challenges to Humira, Wall Street analysts expect AbbVie's earnings will increase by an average of close to 5% annually over the next five years. With the company's tremendous dividend yield of nearly 7% thrown into the mix, I think AbbVie will deliver attractive total returns for a long time to come.
2. Alexion Pharmaceuticals
If you like AbbVie's low valuation, you'll probably love Alexion Pharmaceuticals (NASDAQ: ALXN). This biotech stock trades at close to 7.5 times expected earnings. Factoring in Alexion's growth prospects makes its valuation look even more appealing.
Some might question just how much Alexion will be able to grow because of concerns about its flagship drug, Soliris. It's true that several key patents for Soliris will expire over the next few years. It's also true that a potential rival could soon be on the scene, with Apellis Pharmaceuticals reporting late-stage results earlier this year in which its drug pegcetacoplan produced greater improvement in hemoglobin levels of patients with rare blood disorder paroxysmal nocturnal hemoglobinuria (PNH) than Soliris did.
However, Alexion has its own successor to Soliris already on the market. That drug, Ultomiris, was even ranked as the top new drug launched last year by market researcher EvaluatePharma. So far, Ultomiris has been approved for treating PNH and atypical hemolytic uremic syndrome. Alexion is also evaluating the drug in treating other rare diseases, including generalized myasthenia gravis (gMG) and neuromyelitis optica spectrum disorder (NMOSD).
Alexion could even help in fighting coronavirus. The company is exploring the potential for Soliris in treating patients with severe cases of COVID-19 along with severe pneumonia or acute respiratory distress syndrome (ARDS). Alexion is already providing the drug as an experimental emergency treatment for some patients.
3. Bristol Myers Squibb
Bristol Myers Squibb (NYSE: BMY) is another cheap pharma stock, with shares trading at less than 9 times expected earnings. As was the case with Alexion, the company's tremendous longer-term growth prospects make BMS an even bigger bargain.
You only have to look at BMS' current product portfolio to see where a lot of that growth will come from. Two of the company's drugs, blood thinner Eliquis and cancer immunotherapy Opdivo, are on track to rank among the five best-selling drugs in the world, according to EvaluatePharma. Sales are also soaring for several of the company's other drugs, notably including multiple myeloma drugs Empliciti and Pomalyst.
What really makes Bristol Myers Squibb stand out, though, is its pipeline. The company has quite a few trials underway that could lead to additional approved indications for Opdivo, either as a monotherapy or in combination with Yervoy. It hopes to pick up additional approvals for other already-approved drugs as well, including Idhifa and Reblozyl. Most importantly, BMS anticipates launching several potential blockbusters by the end of 2021, with multiple sclerosis drug ozanimod heading up the list.
Then there's the dividend, which currently yields close to 3.7%. Anyone concerned that the acquisition of Celgene last year might impact BMS' dividend program can put those worries to rest. The drugmaker boosted its dividend by 9.8% in December. My take is that great growth prospects plus a great dividend make Bristol Myers Squibb a no-brainer stock to buy right now.
10 stocks we like better than Bristol-Myers Squibb
When investing geniuses David and Tom Gardner have a stock tip, it can pay to listen. After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor, has tripled the market.*
David and Tom just revealed what they believe are the ten best stocks for investors to buy right now... and Bristol-Myers Squibb wasn't one of them! That's right -- they think these 10 stocks are even better buys.
See the 10 stocks
*Stock Advisor returns as of March 18, 2020
Keith Speights owns shares of AbbVie and Bristol-Myers Squibb. The Motley Fool owns shares of and recommends Bristol-Myers Squibb. The Motley Fool has a disclosure policy.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | AbbVie AbbVie (NYSE: ABBV) shares currently trade at less than 9 times expected earnings. That kind of low valuation might make sense for a company likely to experience an earnings decline, but that's not the case for AbbVie. However, AbbVie has been planning for this eventuality for years. | AbbVie AbbVie (NYSE: ABBV) shares currently trade at less than 9 times expected earnings. That kind of low valuation might make sense for a company likely to experience an earnings decline, but that's not the case for AbbVie. However, AbbVie has been planning for this eventuality for years. | See the 10 stocks *Stock Advisor returns as of March 18, 2020 Keith Speights owns shares of AbbVie and Bristol-Myers Squibb. AbbVie AbbVie (NYSE: ABBV) shares currently trade at less than 9 times expected earnings. That kind of low valuation might make sense for a company likely to experience an earnings decline, but that's not the case for AbbVie. | AbbVie AbbVie (NYSE: ABBV) shares currently trade at less than 9 times expected earnings. That kind of low valuation might make sense for a company likely to experience an earnings decline, but that's not the case for AbbVie. However, AbbVie has been planning for this eventuality for years. |
24639.0 | 2020-03-26 00:00:00 UTC | ABBV May 8th Options Begin Trading | ABBV | https://www.nasdaq.com/articles/abbv-may-8th-options-begin-trading-2020-03-26 | nan | nan | Investors in AbbVie Inc (Symbol: ABBV) saw new options become available today, for the May 8th expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the ABBV options chain for the new May 8th contracts and identified one put and one call contract of particular interest.
The put contract at the $70.50 strike price has a current bid of $2.70. If an investor was to sell-to-open that put contract, they are committing to purchase the stock at $70.50, but will also collect the premium, putting the cost basis of the shares at $67.80 (before broker commissions). To an investor already interested in purchasing shares of ABBV, that could represent an attractive alternative to paying $73.09/share today.
Because the $70.50 strike represents an approximate 4% discount to the current trading price of the stock (in other words it is out-of-the-money by that percentage), there is also the possibility that the put contract would expire worthless. The current analytical data (including greeks and implied greeks) suggest the current odds of that happening are 62%. Stock Options Channel will track those odds over time to see how they change, publishing a chart of those numbers on our website under the contract detail page for this contract. Should the contract expire worthless, the premium would represent a 3.83% return on the cash commitment, or 32.51% annualized — at Stock Options Channel we call this the YieldBoost.
Below is a chart showing the trailing twelve month trading history for AbbVie Inc, and highlighting in green where the $70.50 strike is located relative to that history:
Turning to the calls side of the option chain, the call contract at the $73.50 strike price has a current bid of $2.50. If an investor was to purchase shares of ABBV stock at the current price level of $73.09/share, and then sell-to-open that call contract as a "covered call," they are committing to sell the stock at $73.50. Considering the call seller will also collect the premium, that would drive a total return (excluding dividends, if any) of 3.98% if the stock gets called away at the May 8th expiration (before broker commissions). Of course, a lot of upside could potentially be left on the table if ABBV shares really soar, which is why looking at the trailing twelve month trading history for AbbVie Inc, as well as studying the business fundamentals becomes important. Below is a chart showing ABBV's trailing twelve month trading history, with the $73.50 strike highlighted in red:
Considering the fact that the $73.50 strike represents an approximate 1% premium to the current trading price of the stock (in other words it is out-of-the-money by that percentage), there is also the possibility that the covered call contract would expire worthless, in which case the investor would keep both their shares of stock and the premium collected. The current analytical data (including greeks and implied greeks) suggest the current odds of that happening are 51%. On our website under the contract detail page for this contract, Stock Options Channel will track those odds over time to see how they change and publish a chart of those numbers (the trading history of the option contract will also be charted). Should the covered call contract expire worthless, the premium would represent a 3.42% boost of extra return to the investor, or 29.03% annualized, which we refer to as the YieldBoost.
The implied volatility in the put contract example is 85%, while the implied volatility in the call contract example is 70%.
Meanwhile, we calculate the actual trailing twelve month volatility (considering the last 252 trading day closing values as well as today's price of $73.09) to be 36%. For more put and call options contract ideas worth looking at, visit StockOptionsChannel.com.
Top YieldBoost Calls of the S&P 500 »
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Of course, a lot of upside could potentially be left on the table if ABBV shares really soar, which is why looking at the trailing twelve month trading history for AbbVie Inc, as well as studying the business fundamentals becomes important. Below is a chart showing ABBV's trailing twelve month trading history, with the $73.50 strike highlighted in red: Considering the fact that the $73.50 strike represents an approximate 1% premium to the current trading price of the stock (in other words it is out-of-the-money by that percentage), there is also the possibility that the covered call contract would expire worthless, in which case the investor would keep both their shares of stock and the premium collected. Investors in AbbVie Inc (Symbol: ABBV) saw new options become available today, for the May 8th expiration. | Below is a chart showing ABBV's trailing twelve month trading history, with the $73.50 strike highlighted in red: Considering the fact that the $73.50 strike represents an approximate 1% premium to the current trading price of the stock (in other words it is out-of-the-money by that percentage), there is also the possibility that the covered call contract would expire worthless, in which case the investor would keep both their shares of stock and the premium collected. Investors in AbbVie Inc (Symbol: ABBV) saw new options become available today, for the May 8th expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the ABBV options chain for the new May 8th contracts and identified one put and one call contract of particular interest. | Below is a chart showing the trailing twelve month trading history for AbbVie Inc, and highlighting in green where the $70.50 strike is located relative to that history: Turning to the calls side of the option chain, the call contract at the $73.50 strike price has a current bid of $2.50. Below is a chart showing ABBV's trailing twelve month trading history, with the $73.50 strike highlighted in red: Considering the fact that the $73.50 strike represents an approximate 1% premium to the current trading price of the stock (in other words it is out-of-the-money by that percentage), there is also the possibility that the covered call contract would expire worthless, in which case the investor would keep both their shares of stock and the premium collected. Investors in AbbVie Inc (Symbol: ABBV) saw new options become available today, for the May 8th expiration. | At Stock Options Channel, our YieldBoost formula has looked up and down the ABBV options chain for the new May 8th contracts and identified one put and one call contract of particular interest. Below is a chart showing ABBV's trailing twelve month trading history, with the $73.50 strike highlighted in red: Considering the fact that the $73.50 strike represents an approximate 1% premium to the current trading price of the stock (in other words it is out-of-the-money by that percentage), there is also the possibility that the covered call contract would expire worthless, in which case the investor would keep both their shares of stock and the premium collected. Investors in AbbVie Inc (Symbol: ABBV) saw new options become available today, for the May 8th expiration. |
24640.0 | 2020-03-25 00:00:00 UTC | 3 Reasons Pharma Stocks Are a Buy Right Now | ABBV | https://www.nasdaq.com/articles/3-reasons-pharma-stocks-are-a-buy-right-now-2020-03-25 | nan | nan | Few sectors have escaped the gravity of the investing black hole known as the coronavirus pandemic. Nearly every stock has plunged, with a 20% drop constituting a relatively mild decline. There have been bounces, including renewed buying on anticipation of a huge coronavirus rescue bill. However, it's impossible to know how long any bounce will last while the number of COVID-19 cases continues to rise.
There's one group of stocks, though, that I think merits investors' attention even in the midst of the chaos. Here are three reasons I believe pharma stocks are a buy right now.
Image source: Getty Images.
1. Resilient businesses
It's important to separate businesses from stock performances. Although share prices should roughly indicate the potential for a business, sometimes they don't. We're seeing such a time right now among pharma stocks.
Although pharma stocks have tanked, their businesses are trucking right along (at least, that's the case for most of them). Sure, some drugmakers have been negatively affected in some ways by the coronavirus pandemic, but there are plenty of other aspects of their businesses that are resilient in the current market environment.
Eli Lilly (NYSE: LLY), for example, paused enrollment in most of its clinical trials. Some, particularly generic drugmakers, have had their supply chains disrupted because of the COVID-19 outbreak in China. The situation in China is also likely to make a dent in sales for several large companies, including Pfizer (NYSE: PFE), which has its Upjohn segment headquartered in China. It's also possible there could be a dip in sales for prescription drugs because of patients' worries about their medications spreading the novel coronavirus.
Overall, though, pharma companies are in much better shape than many others. Most people won't stop taking their prescription drugs, especially those for serious conditions, because of the pandemic. And when the current crisis is over, drugmakers' revenue should quickly rebound to normal levels.
2. Attractive valuations -- and dividends
I'm combining these two pluses for pharma stocks because they're intertwined. As the share prices of most pharma companies have dropped, their stock valuations have become really attractive. These lower share prices have also pushed dividend yields significantly higher.
As a case in point, Pfizer's shares currently trade at only 12 times expected earnings. The big drugmaker's dividend yield stands above 5%. But there are even more attractive pharma stocks than Pfizer when it comes to valuation and dividend yield.
AbbVie (NYSE: ABBV), for example, boasts a super-low forward earnings multiple of 8.6. Its dividend yields over 7%. Investors who buy AbbVie right now will lock in fantastic dividend payments going forward. Considering that AbbVie has raised its dividend for an impressive 47 consecutive years, it's likely the dividend will keep moving higher.
3. Solid growth prospects
Many pharma stocks have solid growth prospects regardless of how long it takes to beat COVID-19. Of course, some companies have stronger opportunities than others.
Of the drugmakers that have already been mentioned, I think Lilly's growth prospects over the next five years might be the best. Sales for the company's diabetes franchise, which includes Trulicity and Jardiance, are soaring. Lilly's immunology drugs Taltz and Olumiant also continue to pick up momentum.
Pfizer's growth rate will pick up significantly after it merges Upjohn with Mylan. And while AbbVie faces sales erosion for Humira due to biosimilar competition, its new immunology drugs Rinvoq and Skyrizi and the pending acquisition of Allergan should help considerably.
My favorite growth story among pharma stocks, though, is Bristol Myers Squibb (NYSE: BMY). Thanks to the acquisition of Celgene last year, BMS has multiple pipeline candidates that could be huge winners soon. These include multiple sclerosis drug ozanimod and cancer cell therapies liso-cel and ide-cel.
Look to the future
I think pharma stocks will roar back in the not-too-distant future. Buying shares of well-run companies with solid current product lineups and strong pipelines should pay off for investors in the long run.
10 stocks we like better than Pfizer
When investing geniuses David and Tom Gardner have a stock tip, it can pay to listen. After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor, has tripled the market.*
David and Tom just revealed what they believe are the ten best stocks for investors to buy right now... and Pfizer wasn't one of them! That's right -- they think these 10 stocks are even better buys.
See the 10 stocks
*Stock Advisor returns as of March 18, 2020
Keith Speights owns shares of AbbVie, Bristol-Myers Squibb, and Pfizer. The Motley Fool owns shares of and recommends Bristol-Myers Squibb. The Motley Fool recommends Mylan. The Motley Fool has a disclosure policy.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | And while AbbVie faces sales erosion for Humira due to biosimilar competition, its new immunology drugs Rinvoq and Skyrizi and the pending acquisition of Allergan should help considerably. AbbVie (NYSE: ABBV), for example, boasts a super-low forward earnings multiple of 8.6. Investors who buy AbbVie right now will lock in fantastic dividend payments going forward. | See the 10 stocks *Stock Advisor returns as of March 18, 2020 Keith Speights owns shares of AbbVie, Bristol-Myers Squibb, and Pfizer. AbbVie (NYSE: ABBV), for example, boasts a super-low forward earnings multiple of 8.6. Investors who buy AbbVie right now will lock in fantastic dividend payments going forward. | See the 10 stocks *Stock Advisor returns as of March 18, 2020 Keith Speights owns shares of AbbVie, Bristol-Myers Squibb, and Pfizer. AbbVie (NYSE: ABBV), for example, boasts a super-low forward earnings multiple of 8.6. Investors who buy AbbVie right now will lock in fantastic dividend payments going forward. | AbbVie (NYSE: ABBV), for example, boasts a super-low forward earnings multiple of 8.6. Investors who buy AbbVie right now will lock in fantastic dividend payments going forward. Considering that AbbVie has raised its dividend for an impressive 47 consecutive years, it's likely the dividend will keep moving higher. |
24641.0 | 2020-03-25 00:00:00 UTC | Analysts Predict 34% Upside For TOK | ABBV | https://www.nasdaq.com/articles/analysts-predict-34-upside-for-tok-2020-03-25 | nan | nan | Looking at the underlying holdings of the ETFs in our coverage universe at ETF Channel, we have compared the trading price of each holding against the average analyst 12-month forward target price, and computed the weighted average implied analyst target price for the ETF itself. For the iShares MSCI Kokusai ETF (Symbol: TOK), we found that the implied analyst target price for the ETF based upon its underlying holdings is $72.22 per unit.
With TOK trading at a recent price near $53.81 per unit, that means that analysts see 34.22% upside for this ETF looking through to the average analyst targets of the underlying holdings. Three of TOK's underlying holdings with notable upside to their analyst target prices are Melco Resorts & Entertainment Ltd (Symbol: MLCO), Equifax Inc (Symbol: EFX), and AbbVie Inc (Symbol: ABBV). Although MLCO has traded at a recent price of $13.86/share, the average analyst target is 104.55% higher at $28.35/share. Similarly, EFX has 39.89% upside from the recent share price of $113.66 if the average analyst target price of $159.00/share is reached, and analysts on average are expecting ABBV to reach a target price of $94.40/share, which is 39.87% above the recent price of $67.49. Below is a twelve month price history chart comparing the stock performance of MLCO, EFX, and ABBV:
Below is a summary table of the current analyst target prices discussed above:
NAME SYMBOL RECENT PRICE AVG. ANALYST 12-MO. TARGET % UPSIDE TO TARGET
iShares MSCI Kokusai ETF TOK $53.81 $72.22 34.22%
Melco Resorts & Entertainment Ltd MLCO $13.86 $28.35 104.55%
Equifax Inc EFX $113.66 $159.00 39.89%
AbbVie Inc ABBV $67.49 $94.40 39.87%
Are analysts justified in these targets, or overly optimistic about where these stocks will be trading 12 months from now? Do the analysts have a valid justification for their targets, or are they behind the curve on recent company and industry developments? A high price target relative to a stock's trading price can reflect optimism about the future, but can also be a precursor to target price downgrades if the targets were a relic of the past. These are questions that require further investor research.
10 ETFs With Most Upside To Analyst Targets »
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | iShares MSCI Kokusai ETF TOK $53.81 $72.22 34.22% Melco Resorts & Entertainment Ltd MLCO $13.86 $28.35 104.55% Equifax Inc EFX $113.66 $159.00 39.89% AbbVie Inc ABBV $67.49 $94.40 39.87% Are analysts justified in these targets, or overly optimistic about where these stocks will be trading 12 months from now? Three of TOK's underlying holdings with notable upside to their analyst target prices are Melco Resorts & Entertainment Ltd (Symbol: MLCO), Equifax Inc (Symbol: EFX), and AbbVie Inc (Symbol: ABBV). Similarly, EFX has 39.89% upside from the recent share price of $113.66 if the average analyst target price of $159.00/share is reached, and analysts on average are expecting ABBV to reach a target price of $94.40/share, which is 39.87% above the recent price of $67.49. | Three of TOK's underlying holdings with notable upside to their analyst target prices are Melco Resorts & Entertainment Ltd (Symbol: MLCO), Equifax Inc (Symbol: EFX), and AbbVie Inc (Symbol: ABBV). Similarly, EFX has 39.89% upside from the recent share price of $113.66 if the average analyst target price of $159.00/share is reached, and analysts on average are expecting ABBV to reach a target price of $94.40/share, which is 39.87% above the recent price of $67.49. iShares MSCI Kokusai ETF TOK $53.81 $72.22 34.22% Melco Resorts & Entertainment Ltd MLCO $13.86 $28.35 104.55% Equifax Inc EFX $113.66 $159.00 39.89% AbbVie Inc ABBV $67.49 $94.40 39.87% Are analysts justified in these targets, or overly optimistic about where these stocks will be trading 12 months from now? | Similarly, EFX has 39.89% upside from the recent share price of $113.66 if the average analyst target price of $159.00/share is reached, and analysts on average are expecting ABBV to reach a target price of $94.40/share, which is 39.87% above the recent price of $67.49. Three of TOK's underlying holdings with notable upside to their analyst target prices are Melco Resorts & Entertainment Ltd (Symbol: MLCO), Equifax Inc (Symbol: EFX), and AbbVie Inc (Symbol: ABBV). Below is a twelve month price history chart comparing the stock performance of MLCO, EFX, and ABBV: Below is a summary table of the current analyst target prices discussed above: | iShares MSCI Kokusai ETF TOK $53.81 $72.22 34.22% Melco Resorts & Entertainment Ltd MLCO $13.86 $28.35 104.55% Equifax Inc EFX $113.66 $159.00 39.89% AbbVie Inc ABBV $67.49 $94.40 39.87% Are analysts justified in these targets, or overly optimistic about where these stocks will be trading 12 months from now? Three of TOK's underlying holdings with notable upside to their analyst target prices are Melco Resorts & Entertainment Ltd (Symbol: MLCO), Equifax Inc (Symbol: EFX), and AbbVie Inc (Symbol: ABBV). Similarly, EFX has 39.89% upside from the recent share price of $113.66 if the average analyst target price of $159.00/share is reached, and analysts on average are expecting ABBV to reach a target price of $94.40/share, which is 39.87% above the recent price of $67.49. |
24642.0 | 2020-03-25 00:00:00 UTC | Insiders Buy the Holdings of DEW ETF | ABBV | https://www.nasdaq.com/articles/insiders-buy-the-holdings-of-dew-etf-2020-03-25 | nan | nan | A look at the weighted underlying holdings of the WisdomTree Global High Dividend Fund (DEW) shows an impressive 12.5% of holdings on a weighted basis have experienced insider buying within the past six months.
AbbVie Inc (Symbol: ABBV), which makes up 2.14% of the WisdomTree Global High Dividend Fund (DEW), has seen 2 directors and officers purchase shares in the past six months, according to the recent Form 4 data. The ETF holds a total of $1,238,180 worth of ABBV, making it the #5 largest holding. The table below details the recent insider buying activity observed at ABBV:
ABBV — last trade: $67.49 — Recent Insider Buys:
PURCHASED INSIDER TITLE SHARES PRICE/SHARE VALUE
03/03/2020 Edward J. Rapp Director 2,875 $87.87 $252,617
03/20/2020 Brian L. Durkin VP, Controller 3,750 $68.20 $255,755
03/30/2020 Brian L. Durkin VP, Controller 3,750 $68.20 $255,755
And Simon Property Group, Inc. (Symbol: SPG), the #77 largest holding among components of the WisdomTree Global High Dividend Fund (DEW), shows 7 directors and officers as recently filing Form 4's indicating purchases. The ETF holds $147,954 worth of SPG, which represents approximately 0.26% of the ETF's total assets at last check. The recent insider buying activity observed at SPG is detailed in the table below:
SPG — last trade: $54.73 — Recent Insider Buys:
PURCHASED INSIDER TITLE SHARES PRICE/SHARE VALUE
03/17/2020 Reuben S. Leibowitz Director 1,500 $64.88 $97,325
03/19/2020 Larry C. Glasscock Director 10,000 $58.98 $589,788
03/18/2020 J. Albert Smith Jr. Director 1,750 $52.03 $91,052
03/18/2020 Daniel C. Smith Director 921 $53.14 $48,946
03/18/2020 Herbert Simon Director 188,572 $52.67 $9,933,030
03/18/2020 Allan B. Hubbard Director 3,615 $54.81 $198,138
03/18/2020 Reuben S. Leibowitz Director 1,000 $50.15 $50,145
03/18/2020 Stefan M. Selig Director 15,000 $46.17 $692,625
10 ETFs With Stocks That Insiders Are Buying »
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | AbbVie Inc (Symbol: ABBV), which makes up 2.14% of the WisdomTree Global High Dividend Fund (DEW), has seen 2 directors and officers purchase shares in the past six months, according to the recent Form 4 data. The ETF holds a total of $1,238,180 worth of ABBV, making it the #5 largest holding. The table below details the recent insider buying activity observed at ABBV: ABBV — last trade: $67.49 — Recent Insider Buys: | The table below details the recent insider buying activity observed at ABBV: ABBV — last trade: $67.49 — Recent Insider Buys: AbbVie Inc (Symbol: ABBV), which makes up 2.14% of the WisdomTree Global High Dividend Fund (DEW), has seen 2 directors and officers purchase shares in the past six months, according to the recent Form 4 data. The ETF holds a total of $1,238,180 worth of ABBV, making it the #5 largest holding. | The table below details the recent insider buying activity observed at ABBV: ABBV — last trade: $67.49 — Recent Insider Buys: AbbVie Inc (Symbol: ABBV), which makes up 2.14% of the WisdomTree Global High Dividend Fund (DEW), has seen 2 directors and officers purchase shares in the past six months, according to the recent Form 4 data. The ETF holds a total of $1,238,180 worth of ABBV, making it the #5 largest holding. | AbbVie Inc (Symbol: ABBV), which makes up 2.14% of the WisdomTree Global High Dividend Fund (DEW), has seen 2 directors and officers purchase shares in the past six months, according to the recent Form 4 data. The ETF holds a total of $1,238,180 worth of ABBV, making it the #5 largest holding. The table below details the recent insider buying activity observed at ABBV: ABBV — last trade: $67.49 — Recent Insider Buys: |
24643.0 | 2020-03-24 00:00:00 UTC | Top-Notch Vaccine Technology Makes iBio Stock a Smart Bet | ABBV | https://www.nasdaq.com/articles/top-notch-vaccine-technology-makes-ibio-stock-a-smart-bet-2020-03-24 | nan | nan | InvestorPlace - Stock Market News, Stock Advice & Trading Tips
iBio (NYSEMKT:IBIO) is one of the few stocks up for the year, with a 350% return so far. Keep in mind that the shares had climbed as high as $3.40, but are now at $1.10. IBIO stock is one of those small-cap names that — not too long ago — was mostly forgotten.
Source: Shutterstock
But of course, with the horrific impact of the coronavirus from China, things are much different now. IBIO may ultimately play a role in this war.
Founded in 2008, iBio is a plant-based expression biologics contract development and manufacturing organization (CDMO). Essentially, it helps with clinical development of treatments.
The company does this with its FastPharming expression system, which can produce a range of antibodies and antigens for vaccine design and virus-like particles.
The Latest Developments
It was in early February that IBIO stock started its surge. The company announced a collaboration with Beijing CC-Pharming to develop and test a coronavirus vaccine.
And if this effort proves successful, the treatment will be manufactured at scale with iBio’s FastPharming system.
7 Stocks Insiders Are Buying Big Amid the Market Panic
The vaccine candidate is based on the research of Dr. Kevin Wang, who is the chairman and chief scientific officer of CC-Pharming. He has spent decades on vaccine development.
So what can we expect from all this? Well, as is the case with any new vaccine, it is far from clear. It also does not help that there is not a lot of data available from CC-Pharming. And yes, there are numerous companies, such as AbbVie (NYSE:ABBV), Moderna (NASDAQ:MRNA), Regeneron (NASDAQ:REGN) and Gilead Sciences (NASDAQ:GILD), that are focused on finding a vaccine for Covid-19.
Yet the collaboration is a validation of iBio. Let’s face it, given the enormous spread of the coronavirus, there will need to be systems for efficient and quick manufacturing.
Keep in mind that iBio’s technology originally got backing from the Defense Advanced Research Projects Agency (DARPA), which is the agency that helped to create the internet and autonomous driving. The goal was to come up with effective approaches to combat pandemics. The result has been the creation of a highly automated factory that uses hydroponics and vertical farming.
This has since been used to create antibody candidates for Ebola and the Dengue fever virus.
iBio has also recently used its FastPharming System for the development of vaccine candidates for preventing infection from the virus that causes the Covid-19 infection. The company also filed four provisional patent applications for this.
The Bottom Line on IBIO Stock
U.S. Food and Drug Administration approval of a coronavirus vaccine could easily take a year or more. But the timeline could be much shorter in other countries that have lax regulatory requirements.
The widespread impact of the virus will also motivate research. In the coming months, it’s a good bet that we’ll see huge funding go toward drug development for Covid-19.
In other words, a company like iBio will probably get lots of attention. Not many companies specialize in drug development for vaccines.
Granted, IBIO stock will certainly see quite a bit of volatility — and investors need to be cautious. But again, given the extreme need to find solutions right now, I think there’s a good chance the shares will gain over time.
Tom Taulli (@ttaulli) is the author of various books on investing and technology, including Artificial Intelligence Basics, High-Profit IPO Strategies and All About Short Selling. He is also the founder of WebIPO, which was one of the first platforms for public offerings during the 1990s. As of this writing, he did not hold a position in any of the aforementioned securities.
The post Top-Notch Vaccine Technology Makes iBio Stock a Smart Bet appeared first on InvestorPlace.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | And yes, there are numerous companies, such as AbbVie (NYSE:ABBV), Moderna (NASDAQ:MRNA), Regeneron (NASDAQ:REGN) and Gilead Sciences (NASDAQ:GILD), that are focused on finding a vaccine for Covid-19. 7 Stocks Insiders Are Buying Big Amid the Market Panic The vaccine candidate is based on the research of Dr. Kevin Wang, who is the chairman and chief scientific officer of CC-Pharming. The Bottom Line on IBIO Stock U.S. Food and Drug Administration approval of a coronavirus vaccine could easily take a year or more. | And yes, there are numerous companies, such as AbbVie (NYSE:ABBV), Moderna (NASDAQ:MRNA), Regeneron (NASDAQ:REGN) and Gilead Sciences (NASDAQ:GILD), that are focused on finding a vaccine for Covid-19. InvestorPlace - Stock Market News, Stock Advice & Trading Tips iBio (NYSEMKT:IBIO) is one of the few stocks up for the year, with a 350% return so far. The company does this with its FastPharming expression system, which can produce a range of antibodies and antigens for vaccine design and virus-like particles. | And yes, there are numerous companies, such as AbbVie (NYSE:ABBV), Moderna (NASDAQ:MRNA), Regeneron (NASDAQ:REGN) and Gilead Sciences (NASDAQ:GILD), that are focused on finding a vaccine for Covid-19. InvestorPlace - Stock Market News, Stock Advice & Trading Tips iBio (NYSEMKT:IBIO) is one of the few stocks up for the year, with a 350% return so far. iBio has also recently used its FastPharming System for the development of vaccine candidates for preventing infection from the virus that causes the Covid-19 infection. | And yes, there are numerous companies, such as AbbVie (NYSE:ABBV), Moderna (NASDAQ:MRNA), Regeneron (NASDAQ:REGN) and Gilead Sciences (NASDAQ:GILD), that are focused on finding a vaccine for Covid-19. InvestorPlace - Stock Market News, Stock Advice & Trading Tips iBio (NYSEMKT:IBIO) is one of the few stocks up for the year, with a 350% return so far. And if this effort proves successful, the treatment will be manufactured at scale with iBio’s FastPharming system. |
24644.0 | 2020-03-24 00:00:00 UTC | Better Buy: AbbVie vs. Biogen | ABBV | https://www.nasdaq.com/articles/better-buy%3A-abbvie-vs.-biogen-2020-03-24 | nan | nan | For investors seeking stocks to put into their portfolios for the long term, healthcare's a great place to look. It's an industry where there's always going to be significant demand, especially as the population ages. Drug manufacturers AbbVie (NYSE: ABBV) and Biogen (NASDAQ: BIIB) are two of the bigger names in the industry, and their stocks offer investors two enticing approaches: one that's focused on growth, and another that's centered around stability and recurring income. Let's take a look at which is the better option today.
Is Biogen too volatile?
To say that Biogen's stock price has been unstable over the past year would be an understatement. Over the past 52 weeks, the drug manufacturer's stock has traded within a wide range of $215 to $375. Although it's technically down 18% since March 1, 2019, that number doesn't tell investors the full story. About a year ago, the company's stock went over a cliff, falling from $320 down to a low of about $215 after Biogen said it was going to scrap drug trials related to aducanumab, which treats Alzheimer's.
Then, in October, the company revived the drug, saying it was going to seek approval from U.S. regulators after collecting more data which showed the drug was making progress in fighting the disease after all. Shares popped, rising from about $220 to over $300 in the days following the news.
Image source: Getty Images.
Last month, Biogen's stock price got another boost when investors learned that Mylan (NASDAQ: MYL) had been unsuccessful in its patent challenge against Biogen's multiple sclerosis drug, Tecfidera. Biogen's stock is down 19% over the past month; the company has been unable to avoid the market's recent instability around rising concerns surrounding the spread of COVID-19. That said, it's ahead of the S&P 500, which is down 31% over the same time.
Biogen's stock isn't for the faint of heart. But the good news is that the company's consistently stayed in the black, with its profit margin remaining above 20% in each of the past 10 years.
It's an impressive feat, especially amid strong growth. From $4.7 billion in revenue in 2010, Biogen's sales reached $14.4 billion this past year. In 2019, its annual growth rate was a solid 6.9% from 2018's tally of $13.5 billion. Despite the strong numbers, Biogen still trades for less than 10 times its earnings.
Does the acquisition of Allergan make AbbVie a stronger buy?
On its own, AbbVie is a solid healthcare stock; its strong, consistent revenue has topped $30 billion for the past two years. It also pays a dividend that has increased for more than 40 consecutive years (counting the time it spent as part of Abbott Laboratories (NYSE: ABT)), making it a Dividend Aristocrat. Currently, it pays a quarterly dividend of $1.18 per share, which yields an impressive 6.8% today. Biogen doesn't pay its shareholders a dividend.
The problem for AbbVie is that in its most recent fiscal year, it generated sales growth of just 1.6%. That's where it needs something to jump-start its growth -- and its $63 billion acquisition of Allergan (NYSE: AGN) could play a big part in that. The deal, which the companies expect will close in May of this year, will give AbbVie access to Botox, which was Allergan's top-selling drug in 2019, generating $3.8 billion in revenue.
While it's a good addition, Allergan hasn't been blowing the doors off its revenue numbers, either. In 2019, revenue totaled $16.1 billion, which was just a 1.9% improvement from the previous year. Even with the acquisition, there may not be sufficient growth in AbbVie to make the investment attractive for investors who are looking for more than just value.
AbbVie is the safer buy, but growth investors may opt for Biogen
A quick look at how these two stocks have performed over the past year shows little difference, despite their very different paths along the way:
ABBV data by YCharts.
Deciding between these two stocks ultimately comes down to your investing approach. If you're a value-oriented investor who is risk-averse, then AbbVie, with its impressive dividend, is a solid pick. The stock trades at a very reasonable 12 times earnings, which is only slightly higher than Biogen's price. In addition, AbbVie can be a solid long-term pick for investors looking to benefit from a growing dividend. But investors who aren't so risk-averse may be willing to take a chance on Biogen, especially in light of the positive developments that have taken place over the past six months.
10 stocks we like better than Biogen
When investing geniuses David and Tom Gardner have a stock tip, it can pay to listen. After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor, has tripled the market.*
David and Tom just revealed what they believe are the ten best stocks for investors to buy right now... and Biogen wasn't one of them! That's right -- they think these 10 stocks are even better buys.
See the 10 stocks
*Stock Advisor returns as of March 18, 2020
David Jagielski has no position in any of the stocks mentioned. The Motley Fool owns shares of and recommends Biogen. The Motley Fool recommends Mylan. The Motley Fool has a disclosure policy.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Drug manufacturers AbbVie (NYSE: ABBV) and Biogen (NASDAQ: BIIB) are two of the bigger names in the industry, and their stocks offer investors two enticing approaches: one that's focused on growth, and another that's centered around stability and recurring income. The deal, which the companies expect will close in May of this year, will give AbbVie access to Botox, which was Allergan's top-selling drug in 2019, generating $3.8 billion in revenue. Does the acquisition of Allergan make AbbVie a stronger buy? | Drug manufacturers AbbVie (NYSE: ABBV) and Biogen (NASDAQ: BIIB) are two of the bigger names in the industry, and their stocks offer investors two enticing approaches: one that's focused on growth, and another that's centered around stability and recurring income. On its own, AbbVie is a solid healthcare stock; its strong, consistent revenue has topped $30 billion for the past two years. Does the acquisition of Allergan make AbbVie a stronger buy? | Drug manufacturers AbbVie (NYSE: ABBV) and Biogen (NASDAQ: BIIB) are two of the bigger names in the industry, and their stocks offer investors two enticing approaches: one that's focused on growth, and another that's centered around stability and recurring income. AbbVie is the safer buy, but growth investors may opt for Biogen A quick look at how these two stocks have performed over the past year shows little difference, despite their very different paths along the way: ABBV data by YCharts. Does the acquisition of Allergan make AbbVie a stronger buy? | On its own, AbbVie is a solid healthcare stock; its strong, consistent revenue has topped $30 billion for the past two years. AbbVie is the safer buy, but growth investors may opt for Biogen A quick look at how these two stocks have performed over the past year shows little difference, despite their very different paths along the way: ABBV data by YCharts. Drug manufacturers AbbVie (NYSE: ABBV) and Biogen (NASDAQ: BIIB) are two of the bigger names in the industry, and their stocks offer investors two enticing approaches: one that's focused on growth, and another that's centered around stability and recurring income. |
24645.0 | 2020-03-23 00:00:00 UTC | Monday's ETF with Unusual Volume: DDIV | ABBV | https://www.nasdaq.com/articles/mondays-etf-with-unusual-volume%3A-ddiv-2020-03-23 | nan | nan | The First Trust Dorsey Wright Momentum & Dividend ETF is seeing unusually high volume in afternoon trading Monday, with over 176,000 shares traded versus three month average volume of about 26,000. Shares of DDIV were off about 4.4% on the day.
Components of that ETF with the highest volume on Monday were JP Morgan Chase, trading off about 2.9% with over 16.2 million shares changing hands so far this session, and Abbvie, off about 4.8% on volume of over 8.6 million shares. Ryman Hospitality Properties is the component faring the best Monday, higher by about 10.9% on the day, while Blackstone Mortgage Trust is lagging other components of the First Trust Dorsey Wright Momentum & Dividend ETF, trading lower by about 18.3%.
VIDEO: Monday's ETF with Unusual Volume: DDIV
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Components of that ETF with the highest volume on Monday were JP Morgan Chase, trading off about 2.9% with over 16.2 million shares changing hands so far this session, and Abbvie, off about 4.8% on volume of over 8.6 million shares. The First Trust Dorsey Wright Momentum & Dividend ETF is seeing unusually high volume in afternoon trading Monday, with over 176,000 shares traded versus three month average volume of about 26,000. Ryman Hospitality Properties is the component faring the best Monday, higher by about 10.9% on the day, while Blackstone Mortgage Trust is lagging other components of the First Trust Dorsey Wright Momentum & Dividend ETF, trading lower by about 18.3%. | Components of that ETF with the highest volume on Monday were JP Morgan Chase, trading off about 2.9% with over 16.2 million shares changing hands so far this session, and Abbvie, off about 4.8% on volume of over 8.6 million shares. The First Trust Dorsey Wright Momentum & Dividend ETF is seeing unusually high volume in afternoon trading Monday, with over 176,000 shares traded versus three month average volume of about 26,000. Ryman Hospitality Properties is the component faring the best Monday, higher by about 10.9% on the day, while Blackstone Mortgage Trust is lagging other components of the First Trust Dorsey Wright Momentum & Dividend ETF, trading lower by about 18.3%. | Components of that ETF with the highest volume on Monday were JP Morgan Chase, trading off about 2.9% with over 16.2 million shares changing hands so far this session, and Abbvie, off about 4.8% on volume of over 8.6 million shares. The First Trust Dorsey Wright Momentum & Dividend ETF is seeing unusually high volume in afternoon trading Monday, with over 176,000 shares traded versus three month average volume of about 26,000. Ryman Hospitality Properties is the component faring the best Monday, higher by about 10.9% on the day, while Blackstone Mortgage Trust is lagging other components of the First Trust Dorsey Wright Momentum & Dividend ETF, trading lower by about 18.3%. | Components of that ETF with the highest volume on Monday were JP Morgan Chase, trading off about 2.9% with over 16.2 million shares changing hands so far this session, and Abbvie, off about 4.8% on volume of over 8.6 million shares. Ryman Hospitality Properties is the component faring the best Monday, higher by about 10.9% on the day, while Blackstone Mortgage Trust is lagging other components of the First Trust Dorsey Wright Momentum & Dividend ETF, trading lower by about 18.3%. VIDEO: Monday's ETF with Unusual Volume: DDIV The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. |
24646.0 | 2020-03-23 00:00:00 UTC | AbbVie Becomes Oversold (ABBV) | ABBV | https://www.nasdaq.com/articles/abbvie-becomes-oversold-abbv-2020-03-23 | nan | nan | Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a technical analysis indicator called the Relative Strength Index, or RSI, which measures momentum on a scale of zero to 100. A stock is considered to be oversold if the RSI reading falls below 30.
In trading on Monday, shares of AbbVie Inc (Symbol: ABBV) entered into oversold territory, hitting an RSI reading of 28.6, after changing hands as low as $64.33 per share. By comparison, the current RSI reading of the S&P 500 ETF (SPY) is 29.0. A bullish investor could look at ABBV's 28.6 RSI reading today as a sign that the recent heavy selling is in the process of exhausting itself, and begin to look for entry point opportunities on the buy side. The chart below shows the one year performance of ABBV shares:
Looking at the chart above, ABBV's low point in its 52 week range is $62.66 per share, with $97.86 as the 52 week high point — that compares with a last trade of $63.42.
Find out what 9 other oversold stocks you need to know about »
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | In trading on Monday, shares of AbbVie Inc (Symbol: ABBV) entered into oversold territory, hitting an RSI reading of 28.6, after changing hands as low as $64.33 per share. A bullish investor could look at ABBV's 28.6 RSI reading today as a sign that the recent heavy selling is in the process of exhausting itself, and begin to look for entry point opportunities on the buy side. The chart below shows the one year performance of ABBV shares: Looking at the chart above, ABBV's low point in its 52 week range is $62.66 per share, with $97.86 as the 52 week high point — that compares with a last trade of $63.42. | A bullish investor could look at ABBV's 28.6 RSI reading today as a sign that the recent heavy selling is in the process of exhausting itself, and begin to look for entry point opportunities on the buy side. The chart below shows the one year performance of ABBV shares: Looking at the chart above, ABBV's low point in its 52 week range is $62.66 per share, with $97.86 as the 52 week high point — that compares with a last trade of $63.42. In trading on Monday, shares of AbbVie Inc (Symbol: ABBV) entered into oversold territory, hitting an RSI reading of 28.6, after changing hands as low as $64.33 per share. | In trading on Monday, shares of AbbVie Inc (Symbol: ABBV) entered into oversold territory, hitting an RSI reading of 28.6, after changing hands as low as $64.33 per share. A bullish investor could look at ABBV's 28.6 RSI reading today as a sign that the recent heavy selling is in the process of exhausting itself, and begin to look for entry point opportunities on the buy side. The chart below shows the one year performance of ABBV shares: Looking at the chart above, ABBV's low point in its 52 week range is $62.66 per share, with $97.86 as the 52 week high point — that compares with a last trade of $63.42. | In trading on Monday, shares of AbbVie Inc (Symbol: ABBV) entered into oversold territory, hitting an RSI reading of 28.6, after changing hands as low as $64.33 per share. A bullish investor could look at ABBV's 28.6 RSI reading today as a sign that the recent heavy selling is in the process of exhausting itself, and begin to look for entry point opportunities on the buy side. The chart below shows the one year performance of ABBV shares: Looking at the chart above, ABBV's low point in its 52 week range is $62.66 per share, with $97.86 as the 52 week high point — that compares with a last trade of $63.42. |
24647.0 | 2020-03-23 00:00:00 UTC | These 3 Dividend Stocks Are Now Yielding Up to 20% | ABBV | https://www.nasdaq.com/articles/these-3-dividend-stocks-are-now-yielding-up-to-20-2020-03-23 | nan | nan | The coronavirus pandemic is having a significant impact on the markets. This month, the Dow Jones dropped below 20,000 -- the lowest it's been in three years. And when share prices fall, dividend yields rise.
For dividend investors, it could be an opportune time to buy. But investors still need to be careful as a high dividend may not be sustainable. Let's take a look at three high-yielding stocks to see whether they're good buys today, or if investors should steer clear of them:
1. AbbVie
AbbVie (NYSE: ABBV) is down about 20% since the start of 2020. That's stronger than the S&P 500, which entering trading on Friday was down 26%. The healthcare stock's quarterly dividend of $1.18 is now yielding 6.6% annually. The company has raised its payouts by 195% since the stock began trading in 2013. It's a Dividend Aristocrat, as its payouts have increased for more than 25 years including AbbVie's time as part of Abbott Laboratories (NYSE: ABT).
It's a high yield for the drug manufacturer, and investors may be wondering if it's sustainable.
One way that investors gauge the health of a dividend is by looking at its payout ratio, which involves looking at its earnings and annual dividend. In the company's year-end results, which AbbVie released on Feb. 7, it reported diluted earnings per share (EPS) of $5.28. That's up 44% from the prior year. With an EPS $5.28, the company has enough room to accommodate its dividend, which on an annual basis pays $4.72 per share. Although the payout ratio is a bit high at 89%, it looks to be sustainable.
Image source: Getty Images.
The statement of cash flow also corroborates the company's ability to continue paying its dividend. Operating cash flow was $13.3 billion in 2019, and after deducting acquisitions of $1.7 billion, there's still plenty left over to cover the company's dividend payments, which during the year totaled $6.4 billion.
AbbVie's future looks strong, and with healthcare in the spotlight as a result of the coronavirus and a possible shortage of drugs, the company's business shouldn't be a concern for long-term investors.
2. Carnival Corporation
Carnival Corporation (NYSE: CCL) stock has collapsed by 76% year to date as the coronavirus pandemic hit travel stocks particularly hard. With governments encouraging people to stay home, cruise ships are in low demand. And it certainly doesn't help that COVID-19's been spreading on cruise ships and stranding customers in the process.
The cruise ship operator pays a quarterly dividend of $0.50 per share, which at a price of around $12 yields more than 20% per year. The stock pays well above the S&P 500's average yield of 2%. It's a staggering yield, but whether it's sustainable is a separate issue.
The company released its fiscal 2019 results on Dec. 20. For the year, Carnival reported diluted EPS of $4.32, which makes the company's payout ratio a very manageable 46% of earnings. From a cash flow perspective, things were tighter as Carnival's operating activities generated $5.5 billion -- just enough to cover property and equipment purchases during the year totaling $5.4 billion. That wouldn't leave nearly enough to cover the $1.4 billion that Carnival paid out in dividends during the year.
However, even if cash flow wasn't a concern, the company's future is. The longer COVID-19 keeps customers from traveling, the longer the stock will stay down and the larger the impact will be on Carnival's future financials. The company has cut dividends in the past, and it wouldn't be surprising to see that happen again.
3. Enbridge
Enbridge (NYSE: ENB) is normally a safe long-term buy, but the recent uncertainty relating to not just COVID-19, but also a low price of oil, has sent the pipeline company into a tailspin.
The energy stock is down 30% this year as concerns in the Canadian oil and gas industry continue to rise, and both the coronavirus and low oil prices threaten the survival of many Alberta-based companies like Enbridge. The company transports oil through its pipelines, and it needs a strong oil and gas industry for there to be demand for its infrastructure.
Like AbbVie, Enbridge is a Dividend Aristocrat. When the company announced in December that it would raise its payouts by 9.8%, it was the 25th consecutive year Enbridge had done so. Shareholders now receive a quarterly dividend of 0.81 Canadian dollars per share, which yields 9% annually.
In its annual report released on Feb. 14, Enbridge had a strong showing, posting a diluted EPS of CA$2.63 for the full year of 2019. That was up 80% from the prior year.
However, its EPS is less than the annual dividend payment it pays of CA$3.24, and the payout appears to be unsustainable from a cash flow perspective as well. Cash from the company's operating activities of CA$9.4 billion during the year was insufficient to cover dividend payments of CA$6 billion after factoring in CA$5.5 billion in capital spending.
Despite its streak, Enbridge's dividend may be in danger if oil prices don't improve along with conditions in the Canadian oil and gas industry.
Which stock is the safest to buy today?
The safest of the three dividend stocks listed above is AbbVie. It offers the lowest payout, but at 6.6% it's still a very strong dividend yield, especially given that it'll likely grow over the years as well.
Image Source: YCharts
Enbridge offers a growing dividend as well, but the oil price war involving Saudi Arabia and Russia makes any oil and gas stock a risky buy today, even one like Enbridge that's normally pretty safe.
Carnival is the riskiest stock on the list. Not only has it cut its payouts in the past, but it has plenty of incentive to do so now. Investors would be taking a significant risk by assuming this dividend will remain intact.
AbbVie is the best buy of the three, and it's the most likely to continue paying its dividend in 2020 and beyond.
10 stocks we like better than Carnival
When investing geniuses David and Tom Gardner have a stock tip, it can pay to listen. After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor, has tripled the market.*
David and Tom just revealed what they believe are the ten best stocks for investors to buy right now... and Carnival wasn't one of them! That's right -- they think these 10 stocks are even better buys.
See the 10 stocks
*Stock Advisor returns as of March 18, 2020
David Jagielski has no position in any of the stocks mentioned. The Motley Fool owns shares of and recommends Enbridge. The Motley Fool recommends Carnival. The Motley Fool has a disclosure policy.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | It's a Dividend Aristocrat, as its payouts have increased for more than 25 years including AbbVie's time as part of Abbott Laboratories (NYSE: ABT). AbbVie's future looks strong, and with healthcare in the spotlight as a result of the coronavirus and a possible shortage of drugs, the company's business shouldn't be a concern for long-term investors. AbbVie AbbVie (NYSE: ABBV) is down about 20% since the start of 2020. | AbbVie AbbVie (NYSE: ABBV) is down about 20% since the start of 2020. It's a Dividend Aristocrat, as its payouts have increased for more than 25 years including AbbVie's time as part of Abbott Laboratories (NYSE: ABT). In the company's year-end results, which AbbVie released on Feb. 7, it reported diluted earnings per share (EPS) of $5.28. | AbbVie AbbVie (NYSE: ABBV) is down about 20% since the start of 2020. It's a Dividend Aristocrat, as its payouts have increased for more than 25 years including AbbVie's time as part of Abbott Laboratories (NYSE: ABT). In the company's year-end results, which AbbVie released on Feb. 7, it reported diluted earnings per share (EPS) of $5.28. | AbbVie is the best buy of the three, and it's the most likely to continue paying its dividend in 2020 and beyond. AbbVie AbbVie (NYSE: ABBV) is down about 20% since the start of 2020. It's a Dividend Aristocrat, as its payouts have increased for more than 25 years including AbbVie's time as part of Abbott Laboratories (NYSE: ABT). |
24648.0 | 2020-03-22 00:00:00 UTC | You Won't Regret Buying These 3 Bargain Stocks | ABBV | https://www.nasdaq.com/articles/you-wont-regret-buying-these-3-bargain-stocks-2020-03-22 | nan | nan | Two music legends, Frank Sinatra and Elvis Presley, each had a big hit with the song "My Way." The lyrics of the song include a line that says, "Regrets, I've had a few. But then again, too few to mention."
I don't know about you, but I've had more regrets with investing than I'd care to mention. And most of them aren't related to stocks that I bought. Instead, my biggest investing regrets are about the stocks that I didn't buy.
The coronavirus-caused bear market is presenting more great opportunities to buy high-quality stocks at attractive prices than we've seen in a very long time. Here are three bargain stocks that you won't regret buying.
Image source: Getty Images.
1. AbbVie
AbbVie (NYSE: ABBV) has been a bargain for a while in my view. But the stock is now even more attractively valued. The drugmaker's shares trade at a little over nine times expected earnings.
There have been some concerns about how AbbVie will fare after its top-selling drug Humira faces biosimilar competition in the U.S. starting in 2023. I think the company should be in good shape. For one thing, sales for Humira won't evaporate overnight. The immunology drug already faces biosimilar rivals in Europe and still raked in $4.3 billion in international sales last year.
More importantly, momentum for AbbVie's other drugs is reducing its dependence on Humira. Sales for cancer drugs Imbruvica and Venclexta continue to climb. New immunology drugs Rinvoq and Skyrizi should both become megablockbusters. AbbVie should soon close its acquisition of Allergan, which will bring even more successful drugs into its product lineup and candidates into its pipeline.
We can't leave out AbbVie's dividend yield, which stands at 6.6% right now. The company has increased its dividend for 47 consecutive years, including the time it was part of Abbott Labs. Since being spun off from Abbott in 2013, AbbVie has nearly tripled its dividend payout. I think AbbVie will deliver solid share price appreciation over the long run, but it won't have to do too much to provide a market-beating total return with its awesome dividend program.
2. Bristol Myers Squibb
Bristol Myers Squibb (NYSE: BMY) is another stock that looked relatively inexpensive to me even before the coronavirus pandemic hit. With its shares trading below 10 times expected earnings, BMS is even cheaper now.
The drugmaker's acquisition of Celgene last year puts it in the same boat as AbbVie to some extent. Celgene's blockbuster blood disease drug Remicade will face generic competition beginning in 2022. The good news, though, that generic rivals will only be able to sell limited volumes of their products for a few years under their agreements with Celgene.
In the meantime, BMS' current lineup, including enormously successful drugs Eliquis, Empliciti, Opdivo, Orencia, and Pomalyst, should gain even more traction. Thanks to the Celgene deal, BMS' pipeline is as strong as it's ever been. The company expects to launch multiple drugs with blockbuster potential over the next couple of years, including ozanimod in treating multiple sclerosis and cancer cell therapies ide-cel and liso-cel.
BMS' dividend yield currently stands at 3.7%. That's the icing on the cake for a company that Wall Street expects will grow earnings by an average of more than 18% annually over the next five years.
3. Pfizer
Pfizer (NYSE: PFE) is more expensive than AbbVie or Bristol Myers Squibb. But I would still categorize shares of a profitable company that are trading at only 13 times expected earnings as a bargain.
Loss of exclusivity for Lyrica weighed on Pfizer's top and bottom lines in 2019. However, the drug shouldn't be an anchor for Pfizer very much longer. That's because Pfizer plans to merge its Upjohn unit, which is home to Lyrica and other older drugs, with Mylan.
I like this deal because it will make Pfizer a smaller yet faster-growing company. The "new" Pfizer will keep blockbuster drugs including Ibrance and Eliquis (which it co-markets with BMS). Pfizer will also still have newer rising stars such as rare-disease drug Vyndaquel and a pipeline with potential winners including its 20-valent pneumococcal vaccine.
Granted, the Upjohn-Mylan combination will cause Pfizer's dividend to be lower. However, Pfizer shareholders will own part of the new company, to be named Viatris, which will pay a dividend of its own. The combination of Pfizer's and Viatris' dividends should be roughly at the same level as Pfizer's current dividend, which yields 5% right now.
Notice something in common?
You might have noticed that all three of the bargain buys that I like are major pharmaceutical stocks. That's no accident. My view is that these big drugmakers have a greater ability than most companies to keep trucking through the coronavirus crisis and its aftermath.
AbbVie, Bristol Myers Squibb, and Pfizer each have strong cash flows. They've weathered previous economic storms in the past. They all sell products that people will need regardless of pandemics and quarantines. And they're priced attractively, of course. Those are the kinds of bargains I don't think anyone will regret buying.
10 stocks we like better than Pfizer
When investing geniuses David and Tom Gardner have a stock tip, it can pay to listen. After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor, has tripled the market.*
David and Tom just revealed what they believe are the ten best stocks for investors to buy right now... and Pfizer wasn't one of them! That's right -- they think these 10 stocks are even better buys.
See the 10 stocks
*Stock Advisor returns as of March 18, 2020
Keith Speights owns shares of AbbVie, Bristol-Myers Squibb, and Pfizer. The Motley Fool owns shares of and recommends Bristol-Myers Squibb. The Motley Fool recommends Mylan. The Motley Fool has a disclosure policy.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | I think AbbVie will deliver solid share price appreciation over the long run, but it won't have to do too much to provide a market-beating total return with its awesome dividend program. AbbVie AbbVie (NYSE: ABBV) has been a bargain for a while in my view. There have been some concerns about how AbbVie will fare after its top-selling drug Humira faces biosimilar competition in the U.S. starting in 2023. | AbbVie AbbVie (NYSE: ABBV) has been a bargain for a while in my view. There have been some concerns about how AbbVie will fare after its top-selling drug Humira faces biosimilar competition in the U.S. starting in 2023. More importantly, momentum for AbbVie's other drugs is reducing its dependence on Humira. | Pfizer Pfizer (NYSE: PFE) is more expensive than AbbVie or Bristol Myers Squibb. See the 10 stocks *Stock Advisor returns as of March 18, 2020 Keith Speights owns shares of AbbVie, Bristol-Myers Squibb, and Pfizer. AbbVie AbbVie (NYSE: ABBV) has been a bargain for a while in my view. | AbbVie AbbVie (NYSE: ABBV) has been a bargain for a while in my view. There have been some concerns about how AbbVie will fare after its top-selling drug Humira faces biosimilar competition in the U.S. starting in 2023. More importantly, momentum for AbbVie's other drugs is reducing its dependence on Humira. |
24649.0 | 2020-03-22 00:00:00 UTC | Should You Really Buy Stocks Now or Wait a While Longer? | ABBV | https://www.nasdaq.com/articles/should-you-really-buy-stocks-now-or-wait-a-while-longer-2020-03-22 | nan | nan | Anyone who lived through the financial crisis of 2008 and 2009 knows that the turmoil during that period presented a fantastic opportunity to buy stocks. Not everyone realized it at the time, though. There was a lot of fear and trepidation about what could happen next.
It's a similar story today. Most investors probably realize that the stock market crash caused by the coronavirus pandemic will in retrospect be one of the best opportunities to buy stocks in a generation. But that still doesn't make it easy. As was the case during the financial crisis more than a decade ago, no one knows for sure what might happen next.
Should you really buy stocks now? Would it be smarter to wait a while longer? Here are the answers to those pressing questions.
Image source: Getty Images.
Known knowns and unknowns
Whatever you think about former Secretary of Defense Donald Rumsfeld, he said something in 2002 that I think is applicable to what's going on now. Rumsfeld stated, "There are known knowns; there are things we know we know. We also know there are known unknowns; that is to say, we know there are some things we do not know."
What are the known knowns for investors? One is that we know the U.S. hasn't seen the worst yet in terms of COVID-19 cases. Based on the experiences of other countries that were hit by the coronavirus outbreak earlier, the next month or two could bring more bad news than good news.
But, more importantly, we also know that the challenges are temporary. The numbers of new COVID-19 cases in China have dwindled. That will happen in the U.S. also. The economy will bounce back once the fears about the pandemic subside.
However, there are known unknowns. We don't know, for example, exactly how long it will take for the wave of COVID-19 diagnoses to diminish. We don't know how much a government stimulus package will help. And no one knows for sure if the stock market will continue fall and, if so, by how much.
Now or later?
All of that might seem confusing, but I think it's helpful in answering the question of whether or not you should buy stocks now or wait a while. Actually, my view is that considering the known knowns and unknowns should give investors confidence in making the right decision.
Based on the known knowns, buying stocks right now is a good idea for investors with a long-term perspective. Knowing that the U.S. and global economies will rebound should allow you to buy stocks and feel good that you'll make solid returns over the next decade.
On the other hand, those known unknowns make it apparent that keeping some cash on the sidelines to invest later is also a prudent move. We don't know how long the coronavirus crisis will last or how much more the stock market might decline. Having money to buy stocks at potentially even cheaper prices makes sense.
The right answer to the question, therefore, of should you really buy stocks now or wait a while longer is "do both." Stagger your investments over the next several weeks and months. This approach should improve your chances of winning over the long run.
An even more important question
But there's an even more important question that investors should be asking: Which stocks should I buy? I think there's a nuanced answer to this question.
If you're retired, probably the best course of action is to buy dividend stocks that now have much juicier yields thanks to the stock market crash. AbbVie (NYSE: ABBV) is one of my favorite dividend stocks to buy right now. Its dividend yield stands at a mouth-watering 6.6%. The company has lost close to one-fourth of its market cap during the stock market sell-off, but patients will need its drugs regardless of what happens with the COVID-19 pandemic.
A lot of investors are looking for dirt cheap bargain stocks to buy. You can get both a bargain and a sky-high dividend yield with Enterprise Products Partners (NYSE: EPD). Shares of the midstream energy company have plunged more than 50%, driving its dividend yield to a sky-high 12.3%. It could take a while for the stock to recover, though. Oil and gas stocks have fallen because of an oil price war in addition to the coronavirus outbreak. However, for long-term investors, Enterprise Products Partners looks like a steal right now.
My favorite approach is to incrementally buy shares of stocks with tremendous growth prospects that are now cheaper than they've been in a while. I really like Guardant Health (NASDAQ: GH). The stock has fallen more than 25%. But the company's liquid biopsy products have a massive opportunity in diagnosing cancer at early stages and monitoring for cancer recurrence.
Those are just a few examples of stocks that should be smart long-term picks. Invest some of your money now, more of it in a couple of weeks, and then continue to buy over the next few months. As was the case in 2008 and 2009, fortunes will be made as a result of the opportunity investors will have during the current crisis.
10 stocks we like better than Guardant Health
When investing geniuses David and Tom Gardner have a stock tip, it can pay to listen. After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor, has tripled the market.*
David and Tom just revealed what they believe are the ten best stocks for investors to buy right now... and Guardant Health wasn't one of them! That's right -- they think these 10 stocks are even better buys.
See the 10 stocks
*Stock Advisor returns as of March 18, 2020
Keith Speights owns shares of AbbVie and Guardant Health. The Motley Fool owns shares of and recommends Guardant Health. The Motley Fool recommends Enterprise Products Partners. The Motley Fool has a disclosure policy.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | AbbVie (NYSE: ABBV) is one of my favorite dividend stocks to buy right now. See the 10 stocks *Stock Advisor returns as of March 18, 2020 Keith Speights owns shares of AbbVie and Guardant Health. Anyone who lived through the financial crisis of 2008 and 2009 knows that the turmoil during that period presented a fantastic opportunity to buy stocks. | AbbVie (NYSE: ABBV) is one of my favorite dividend stocks to buy right now. See the 10 stocks *Stock Advisor returns as of March 18, 2020 Keith Speights owns shares of AbbVie and Guardant Health. You can get both a bargain and a sky-high dividend yield with Enterprise Products Partners (NYSE: EPD). | AbbVie (NYSE: ABBV) is one of my favorite dividend stocks to buy right now. See the 10 stocks *Stock Advisor returns as of March 18, 2020 Keith Speights owns shares of AbbVie and Guardant Health. Most investors probably realize that the stock market crash caused by the coronavirus pandemic will in retrospect be one of the best opportunities to buy stocks in a generation. | AbbVie (NYSE: ABBV) is one of my favorite dividend stocks to buy right now. See the 10 stocks *Stock Advisor returns as of March 18, 2020 Keith Speights owns shares of AbbVie and Guardant Health. Should you really buy stocks now? |
24650.0 | 2020-03-20 00:00:00 UTC | 3 Dividend Stocks Ideal for Retirees With Money To Invest In The Bear Market | ABBV | https://www.nasdaq.com/articles/3-dividend-stocks-ideal-for-retirees-with-money-to-invest-in-the-bear-market-2020-03-20 | nan | nan | Dividend stocks provide many people with a viable option for retirement income. The S&P 500 average dividend stands at approximately 2.4%, exceeding what most bank-related instruments yield in a savings account. Moreover, the return on many dividend stocks dramatically exceeds the S&P 500's average price appreciation. Several dividend-paying companies have increased their payout annually for years, or in some cases, decades.
Furthermore, the sell-off driven by the COVID-19 pandemic has significantly raised dividend yields. The S&P 500 has fallen by nearly 30% from its recent high. Consequently, the average return on dividends, which stood at an estimated 1.78% in February, has risen by almost 35% in less than one month. Those with the courage to buy into a volatile market could earn significant, long-term returns on the payout alone.
Some of these stocks are in a position to benefit from the growing number of baby boomers entering retirement. This is a large population that could drive revenue growth for certain dividend stocks. To earn some of this dividend income, retirees should consider buying these three stocks.
1. AbbVie
AbbVie (NYSE: ABBV) finds itself in a transition phase. Since it split from Abbott Laboratories in 2013, Its injectable biologic drug Humira has driven much of its revenue. Investors sold off the stock as Humira patents began to expire across the world. AbbVie traded as high as $125.86 per share in 2018. Thanks in large part to Humira-related selling, it has fallen below the $75 per share range.
However, AbbVie did not rest on its laurels with Humira. Even though Humira's sales have begun to fall, the company has seen a massive surge in growth from its hematologic oncology, or blood cancer, drugs. For 2019, sales of Imbruvica rose by 30.2%. Venclexta saw an increase in revenue for the same period exceeding 100%.
Image Source: Getty Images
The sales increases should not end there. Evaluate Pharma ranked Upadacitinib, a rheumatoid arthritis treatment, the second most valuable research and development project. Upadacitinib already received Food and Drug Administration approval for rheumatoid arthritis in the U.S. Evaluate Pharma estimates that drug can generate more than $2.5 billion in annual sales by 2024. The rising number of enrollees in the Medicare Part D Drug coverage should help to boost these sales.
Thanks to the recent market decline, AbbVie's stock trades for just over 8.6 times forward earnings. However, analysts forecast earnings to increase by 8.2% this year and 8.7% in fiscal 2021.
The new bear market has left the company with a dividend yield of more than 6.6%. Moreover, thanks to its previous history as part of Abbott, its $4.72 annual payout has been raised for 47 consecutive years. Profit increases appear set to continue, and the payout ratio indicates that AbbVie pays out around 48.8% of profits in the form of dividends meaning the annual payout hikes should continue for the foreseeable future.
The dividend income could also help to fund the retirement of baby boomers. Since it offers a higher-than-average return that rises annually, it could serve as a viable income stream in retirement.
2. Innovative Industrial Properties
The massive decline in marijuana stocks may make Innovative Industrial Properties (NYSE: IIPR) seem like a strange choice. The fact that the Horizons Life Sciences Index has fallen by about 80% from its 52-week high describes the extent to which marijuana stocks have dropped. As a real estate investment trust (REIT) known as a "marijuana REIT," it may look like a stock to avoid considering the performance of cannabis stocks recently.
However, Grandview Research forecasted a compound annual growth rate (CAGR) for the cannabis industry of 18.7% until 2027. Moreover, with hemp, a form of marijuana, becoming legal in the U.S. in 2018, farmers in all 50 states can grow at least some type of cannabis legally. Further, since the company merely owns and leases property, it does not face the federal schedule 1 drug restrictions hampering most marijuana stocks.
The freedom from schedule 1 restrictions provides a competitive advantage for Innovative Industrial, which owns 35 properties in 15 U.S. states. Its recent growth has been fueled by buying the property of financially troubled marijuana companies and leasing it back to them. This provides the company with assets while giving Innovative Industrial Properties a source of cash flow. Early this year, the company bought and leased back a property in Yellow Springs, Ohio, to Cresco Labs.
This strategy has helped to boost the top and bottom lines as analysts predict profits for Innovative Industrial Properties will increase by 108.4% this year and 24.1% the next. The recent stock sell-off means investors can buy the stock for less than half of what it sold for in July, a move that brought its forward P/E ratio to about 11. This has taken its $4 per share payout to a yield of around 8.6%.
Moreover, considering the 90% minimum payout required of REITs, the payout ratio of about 93.6% is nothing unusual. Much like AbbVie's payout, this dividend offers a possible income stream for retirees. Innovative Industrial may benefit indirectly if more seniors choose to use medical cannabis products. As the marijuana industry continues its expansion, Innovative Industrial Properties and its dividend should grow along with it.
3. Omega Healthcare Investors
With an estimated 10,000 Americans turning 65 every day, this means a similar number of people are aging into the Medicare system daily. Such a statistic plays into the hands of another REIT stock: Omega Healthcare Investors (NYSE: OHI). An aging population increases the demand for healthcare services, and, by extension, demand for healthcare-related properties. Omega owns 964 skilled nursing and assisted living facilities across 40 U.S. states and the U.K.
Thanks to the current market sell-off, the company has lost more than two-thirds of its value since February. This swoon took its current P/E ratio to about 9.4. Though analysts only forecast 5.8% profit growth for this fiscal year, they expect earnings increases to average 15.8% per year for the next five years.
Not only does Omega Healthcare offer a dividend yield of about 18%, but it has also increased the payout for 10 consecutive years. Understandably, the payout ratio of over 159% might concern some investors. However, this does not mean that 159% of the company's net income is going to dividends. REITs derive the cash to pay their dividends through funds from operations (FFO). Investors have to remember that net income includes deductions. Hence, these companies may bring in significantly more cash than their net income might indicate.
In the case of Omega Healthcare, it earned $0.78 per share of FFO income in the previous quarter. This left the company easily able to cover the $0.67 per share it paid in quarterly dividends. Hence, even with only $0.268 per share of quarterly net income, the REIT can pay a dividend far exceeding that amount. Admittedly, a dividend yield at current levels makes it unclear whether the company will maintain the annual streak of payout hikes. Still, with an increasing customer base and the cash to maintain the payout, Omega Healthcare will likely remain a lucrative dividend investment.
10 stocks we like better than AbbVie
When investing geniuses David and Tom Gardner have a stock tip, it can pay to listen. After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor, has tripled the market.*
David and Tom just revealed what they believe are the ten best stocks for investors to buy right now... and AbbVie wasn't one of them! That's right -- they think these 10 stocks are even better buys.
See the 10 stocks
*Stock Advisor returns as of December 1, 2019
Will Healy owns shares of AbbVie. The Motley Fool owns shares of and recommends Cresco Labs Inc. and Innovative Industrial Properties. The Motley Fool has a disclosure policy.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | AbbVie AbbVie (NYSE: ABBV) finds itself in a transition phase. AbbVie traded as high as $125.86 per share in 2018. However, AbbVie did not rest on its laurels with Humira. | Profit increases appear set to continue, and the payout ratio indicates that AbbVie pays out around 48.8% of profits in the form of dividends meaning the annual payout hikes should continue for the foreseeable future. AbbVie AbbVie (NYSE: ABBV) finds itself in a transition phase. AbbVie traded as high as $125.86 per share in 2018. | Profit increases appear set to continue, and the payout ratio indicates that AbbVie pays out around 48.8% of profits in the form of dividends meaning the annual payout hikes should continue for the foreseeable future. See the 10 stocks *Stock Advisor returns as of December 1, 2019 Will Healy owns shares of AbbVie. AbbVie AbbVie (NYSE: ABBV) finds itself in a transition phase. | AbbVie AbbVie (NYSE: ABBV) finds itself in a transition phase. AbbVie traded as high as $125.86 per share in 2018. However, AbbVie did not rest on its laurels with Humira. |
24651.0 | 2020-03-19 00:00:00 UTC | Coronavirus-Fighting Tech Makes iBio Stock an Interesting Play | ABBV | https://www.nasdaq.com/articles/coronavirus-fighting-tech-makes-ibio-stock-an-interesting-play-2020-03-19 | nan | nan | InvestorPlace - Stock Market News, Stock Advice & Trading Tips
iBio (NYSEMKT:IBIO) stock spent much of the last year trading as a penny stock. That changed at the end of February 2020 when IBIO stock surged to as high as $3.40.
Source: Shutterstock
Though the stock lasted only briefly there, investors rushed into the stock for one reason. iBio partnered with Beijing CC-Pharming to develop a plant-based vaccine. As simple as the news sounds, the partnership still allowed the company to file a $100 million shelf registration.
When other big firms like AbbVie (NYSE:ABBV), Regeneron (NASDAQ:REGN) and Gilead Sciences (NASDAQ:GILD) are developing therapies for the coronavirus from China, IBIO stock looks more like a gamble.
After IBIO stock surged, the company announced that it will not seek to reverse split its shares. This is good news for investors. Instead of holding fewer shares at a higher price, the outstanding share count will stay the same. The stock still trades at a decent stock price and has a healthy level of liquidity.
On March 12, 2020, iBio announced a new CEO. Thomas Isett has a strong knowledge of proprietary product development. He has experience working in firms dedicated to biologics contract development and manufacturing organizations.
Covid-19 Vaccine
On Feb. 3, 2020, iBio announced a collaboration with Beijing CC-Pharming to initiate the joint development of a coronavirus vaccine. Beijing CC-Pharming’s chief scientific officer has 25 years of vaccine research and development experience. iBio’s Sylvain Marcel has experience in the rapid design of manufacturing processes.
10 of the Best Long-Term Stocks to Buy in a Bear Market
iBio and Beijing CC-Pharming are in the early innings of bringing a vaccine to market. Yet investors that bought IBIO stock in the $3 range are betting otherwise. Its plant-based expression systems power iBio’s FastPharming manufacturing facility.
The technology previously produced antibody candidates for Dengue fever and the Ebola virus. The firm has also completed studies for a few vaccine candidates. These include the avian influenza, seasonal influenza and human papillomavirus.
iBio uses modified “relatives of the tobacco plant to grow viral proteins for vaccines.” Beijing CC-Pharming will then work on developing the vaccine.
Balance Sheet
iBio ended 2019 with $3.6 million in cash. It generated $314,000 in revenue while operating expenses totaled $3.2 million. The net loss for the three-month period was $25.4 million.
The regular stock issuance gives the company the cash it needs to continue with its research and development activities. With the market keenly interested in a coronavirus vaccine and antiviral suppliers, IBIO may sell the stock when it needs to.
Speculators are not concerned about the losses. So if it gets closer to developing a successful vaccine, the stock will reward shareholders.
Risks With IBIO Stock
Stock Rover lists many warnings on iBio stock. The company reported negative cash flow for much of the last decade. Bearish bets against the company suggest more downside ahead. Over 16% of the float is being sold short.
On the charts, the moving average convergence/divergence turned negative. What does that mean? The bearish signal implies the stock will fall after sharp selling in the last week.
iBio is a risky investment and is, in effect, only a good trade for speculators. If the stock shoots higher again, consider locking in your profits.
Chris Lau is a contributing author for InvestorPlace.com and numerous other financial sites. Chris has over 20 years of investing experience in the stock market and runs the Do-It-Yourself Value Investing Marketplace on Seeking Alpha. He shares his stock picks so readers get original insight that helps improve investment returns. As of this writing, Chris did not hold a position in any of the aforementioned securities.
The post Coronavirus-Fighting Tech Makes iBio Stock an Interesting Play appeared first on InvestorPlace.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | When other big firms like AbbVie (NYSE:ABBV), Regeneron (NASDAQ:REGN) and Gilead Sciences (NASDAQ:GILD) are developing therapies for the coronavirus from China, IBIO stock looks more like a gamble. iBio uses modified “relatives of the tobacco plant to grow viral proteins for vaccines.” Beijing CC-Pharming will then work on developing the vaccine. He shares his stock picks so readers get original insight that helps improve investment returns. | When other big firms like AbbVie (NYSE:ABBV), Regeneron (NASDAQ:REGN) and Gilead Sciences (NASDAQ:GILD) are developing therapies for the coronavirus from China, IBIO stock looks more like a gamble. InvestorPlace - Stock Market News, Stock Advice & Trading Tips iBio (NYSEMKT:IBIO) stock spent much of the last year trading as a penny stock. iBio partnered with Beijing CC-Pharming to develop a plant-based vaccine. | When other big firms like AbbVie (NYSE:ABBV), Regeneron (NASDAQ:REGN) and Gilead Sciences (NASDAQ:GILD) are developing therapies for the coronavirus from China, IBIO stock looks more like a gamble. InvestorPlace - Stock Market News, Stock Advice & Trading Tips iBio (NYSEMKT:IBIO) stock spent much of the last year trading as a penny stock. 10 of the Best Long-Term Stocks to Buy in a Bear Market iBio and Beijing CC-Pharming are in the early innings of bringing a vaccine to market. | When other big firms like AbbVie (NYSE:ABBV), Regeneron (NASDAQ:REGN) and Gilead Sciences (NASDAQ:GILD) are developing therapies for the coronavirus from China, IBIO stock looks more like a gamble. InvestorPlace - Stock Market News, Stock Advice & Trading Tips iBio (NYSEMKT:IBIO) stock spent much of the last year trading as a penny stock. Instead of holding fewer shares at a higher price, the outstanding share count will stay the same. |
24652.0 | 2020-03-19 00:00:00 UTC | Abbvie's HIV Drug Kaletra Fails to Help COVID-19 Patients | ABBV | https://www.nasdaq.com/articles/abbvies-hiv-drug-kaletra-fails-to-help-covid-19-patients-2020-03-19 | nan | nan | The coronavirus that causes COVID-19 and HIV are both RNA-based viruses, so there was hope that current HIV medications might be able to speed recovery of patients with COVID-19. Unfortunately, early evidence suggests that just isn't the case.
On Monday, Johnson & Johnson (NYSE: JNJ) said there was no evidence that its HIV drug Prezista, by itself or in combination with other HIV drugs, has any effect against SARS-CoV-2, the virus that causes COVID-19.
And on Wednesday, doctors in China published an article in The New England Journal of Medicine reporting that AbbVie's (NYSE: ABBV) HIV drug Kaletra plus standard of care wasn't any better than the standard of care.
In the clinical trial, which enrolled 199 patients, treatment with Kaletra for two weeks didn't improve survival, the amount of virus in the patients, or even the length of time that patients stayed in the hospital.
Image source: Getty Images.
The patients in the trial were severely ill; the mortality rate of 22.1% was higher than the mortality rate found in other studies, which could have skewed the results. When excluding three patients who died early in the study, the median time to clinical improvement was better for patients treated with Kaletra (15 days vs. 16 days).
Kaletra also appeared to improve recovery and mortality in patients who were treated within 12 days of onset of COVID-19 symptoms, although the analysis was after the fact and not built into the study. "These observations are hypothesis-generating and require additional studies to determine whether [Kaletra] treatment given at a certain stage of illness can reduce some complications in COVID-19," the authors of the study noted.
10 stocks we like better than AbbVie
When investing geniuses David and Tom Gardner have a stock tip, it can pay to listen. After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor, has tripled the market.*
David and Tom just revealed what they believe are the ten best stocks for investors to buy right now... and AbbVie wasn't one of them! That's right -- they think these 10 stocks are even better buys.
See the 10 stocks
*Stock Advisor returns as of March 18, 2020
Brian Orelli has no position in any of the stocks mentioned. The Motley Fool recommends Johnson & Johnson. The Motley Fool has a disclosure policy.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | * David and Tom just revealed what they believe are the ten best stocks for investors to buy right now... and AbbVie wasn't one of them! And on Wednesday, doctors in China published an article in The New England Journal of Medicine reporting that AbbVie's (NYSE: ABBV) HIV drug Kaletra plus standard of care wasn't any better than the standard of care. 10 stocks we like better than AbbVie When investing geniuses David and Tom Gardner have a stock tip, it can pay to listen. | And on Wednesday, doctors in China published an article in The New England Journal of Medicine reporting that AbbVie's (NYSE: ABBV) HIV drug Kaletra plus standard of care wasn't any better than the standard of care. 10 stocks we like better than AbbVie When investing geniuses David and Tom Gardner have a stock tip, it can pay to listen. * David and Tom just revealed what they believe are the ten best stocks for investors to buy right now... and AbbVie wasn't one of them! | And on Wednesday, doctors in China published an article in The New England Journal of Medicine reporting that AbbVie's (NYSE: ABBV) HIV drug Kaletra plus standard of care wasn't any better than the standard of care. 10 stocks we like better than AbbVie When investing geniuses David and Tom Gardner have a stock tip, it can pay to listen. * David and Tom just revealed what they believe are the ten best stocks for investors to buy right now... and AbbVie wasn't one of them! | And on Wednesday, doctors in China published an article in The New England Journal of Medicine reporting that AbbVie's (NYSE: ABBV) HIV drug Kaletra plus standard of care wasn't any better than the standard of care. 10 stocks we like better than AbbVie When investing geniuses David and Tom Gardner have a stock tip, it can pay to listen. * David and Tom just revealed what they believe are the ten best stocks for investors to buy right now... and AbbVie wasn't one of them! |
24653.0 | 2020-03-18 00:00:00 UTC | Is This 1 Healthcare Stock Coronavirus-Proof? | ABBV | https://www.nasdaq.com/articles/is-this-1-healthcare-stock-coronavirus-proof-2020-03-18 | nan | nan | On March 11, the Dow Jones slid by over 1,400 points -- or about 5.8% of its value at the time -- and fell 20% from its most recent high, thus officially entering bear market territory. The culprit? The COVID-19 pandemic that continues to spread worldwide. According to Johns Hopkins University, as of March 17, there are more than 189,000 confirmed cases of the rapidly spreading disease and over 7,500 deaths, across more than 155 countries.
In the U.S., several states are taking drastic measures -- such as closing public schools and banning large gatherings -- to mitigate the spread of COVID-19 and 'flatten the curve'. While this pandemic will likely keep affecting the stock market, some stocks seem to be handling the market crash much better than others. One such resilient stock is the pharma giant Johnson & Johnson (NYSE: JNJ).
Image source: Getty Images.
Why Johnson & Johnson is performing better than others
While shares of Johnson & Johnson are down by 6.9% (at writing) year to date, that actually compares favorably to the performance of the S&P 500, which is down by 22.6% over the same period. Why is Johnson & Johnson not falling as hard as many other companies?
Image Source: YCharts
There are at least two major reasons. First, Johnson & Johnson's largest segment by revenue is its pharmaceutical segment. During its fiscal year 2019, sales of its pharmaceutical products accounted for 51.4% of Johnson & Johnson's total sales. Since people don't choose when they get sick -- or for that matter, when they will need to take drugs -- the demand for Johnson & Johnson's pharmaceutical products will remain largely unaffected by the chaos surrounding the COVID-19 pandemic.
As a result, investors are likely more reluctant to sell off shares of the pharmaceutical giant. It's also worth noting that Johnson & Johnson's consumer segment -- which sells over-the-counter (OTC) medical products -- seems to be benefiting from the situation surrounding COVID-19. The company recently said the demand for some of its consumer products increased as a result of the rapidly spreading disease. Johnson & Johnson also vowed to take the necessary measures to ensure the availability of these products. It's increasing its production of Tylenol to keep up with demand, for instance.
Second, Johnson & Johnson's stream of revenue is diversified. While the company makes the bulk of its revenue from its pharmaceutical segment, it offers products across many different fields in the pharmaceutical industry, including oncology, neuroscience, and immunology.
Johnson & Johnson boasts more than a dozen products in its late-stage pipeline. Its rich lineup and pipeline allow the company to offset declining sales of some of its key products. For instance, during the fourth quarter, Johnson & Johnson's Remicade, which is a treatment for rheumatoid arthritis, recorded about $1 billion in sales, down from $1.2 billion compared to the prior-year quarter.
Cancer drug Zytiga -- which has been facing competition from biosimilars -- also recorded $677 million in sales, down from $786 million compared to the year-ago period. However, Johnson & Johnson had several products with growing sales, including sales of cancer drugs Darzalex and Imbruvica. For the fourth quarter, Darzalex reported $830 million in sales, up 42.1% year over year, while Imbruvica recorded sales of $875 million, up 24.5% year over year.
Johnson & Johnson's other segments, consumer and medical devices, further diversify its revenue base, thus ensuring that even if one of its segments is struggling, the other two can pick up the slack. In other words, the company's top and bottom lines will probably remain more or less unaffected by the current situation.
Risk factors
While Johnson & Johnson looks like it's handling the market correction better than most, before buying shares of the company, it is important to consider potential headwinds that could hinder its prospects.
First, there's competition, which Johnson & Johnson faces across the range of its products and services. In particular, many of the company's key pharmaceutical products face stiff competition. For instance, Darzalex was recently approved for the treatment of multiple myeloma (a type of bone marrow cancer) in patients who aren't eligible for a transplant. Other drugs -- such as Bristol Myers Squibb's (NYSE: BMY) Revlimid -- also treat multiple myeloma. During the fourth quarter, Revlimid racked up $1.3 billion in sales.
Furthermore, Johnson & Johnson's blockbuster drug Stelara -- which treats several immune system conditions such as plaque psoriasis and Crohn's disease -- has to contend with products such as AbbVie's (NYSE: ABBV) Humira. And although Humira faces competition from biosimilars in Europe, the blockbuster drug still generated $5.2 billion in sales during the fourth quarter.
Second, Johnson & Johnson currently faces thousands of lawsuits. For instance, in October 2019, the company reached a $20 million settlement with two Ohio counties -- Cuyahoga and Summit -- that allowed Johnson & Johnson to avoid a federal trial for its alleged role in the opioid crisis. The settlement was not an admission of guilt on the company's part.
There are many more product liability lawsuits Johnson & Johnson has to deal with, but the behemoth pharma company does not expect these lawsuits to make a "material adverse effect on the Company's financial position."
Should you buy?
Investors cannot ignore Johnson & Johnson's risk factors. However, due to the nature of the company's operations, its revenue and earnings are unlikely to be significantly affected by market downturns.
What's more, Johnson & Johnson's strong pipeline will likely allow the company to remain competitive within the pharmaceutical industry, which is its largest segment by revenue. This makes Johnson & Johnson an interesting stock to consider buying, especially given the current market conditions.
10 stocks we like better than Johnson & Johnson
When investing geniuses David and Tom Gardner have a stock tip, it can pay to listen. After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor, has tripled the market.*
David and Tom just revealed what they believe are the ten best stocks for investors to buy right now... and Johnson & Johnson wasn't one of them! That's right -- they think these 10 stocks are even better buys.
See the 10 stocks
*Stock Advisor returns as of December 1, 2019
Prosper Junior Bakiny has no position in any of the stocks mentioned. The Motley Fool owns shares of and recommends Bristol-Myers Squibb. The Motley Fool recommends Johnson & Johnson. The Motley Fool has a disclosure policy.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Furthermore, Johnson & Johnson's blockbuster drug Stelara -- which treats several immune system conditions such as plaque psoriasis and Crohn's disease -- has to contend with products such as AbbVie's (NYSE: ABBV) Humira. On March 11, the Dow Jones slid by over 1,400 points -- or about 5.8% of its value at the time -- and fell 20% from its most recent high, thus officially entering bear market territory. In the U.S., several states are taking drastic measures -- such as closing public schools and banning large gatherings -- to mitigate the spread of COVID-19 and 'flatten the curve'. | Furthermore, Johnson & Johnson's blockbuster drug Stelara -- which treats several immune system conditions such as plaque psoriasis and Crohn's disease -- has to contend with products such as AbbVie's (NYSE: ABBV) Humira. Since people don't choose when they get sick -- or for that matter, when they will need to take drugs -- the demand for Johnson & Johnson's pharmaceutical products will remain largely unaffected by the chaos surrounding the COVID-19 pandemic. However, Johnson & Johnson had several products with growing sales, including sales of cancer drugs Darzalex and Imbruvica. | Furthermore, Johnson & Johnson's blockbuster drug Stelara -- which treats several immune system conditions such as plaque psoriasis and Crohn's disease -- has to contend with products such as AbbVie's (NYSE: ABBV) Humira. Why Johnson & Johnson is performing better than others While shares of Johnson & Johnson are down by 6.9% (at writing) year to date, that actually compares favorably to the performance of the S&P 500, which is down by 22.6% over the same period. During its fiscal year 2019, sales of its pharmaceutical products accounted for 51.4% of Johnson & Johnson's total sales. | Furthermore, Johnson & Johnson's blockbuster drug Stelara -- which treats several immune system conditions such as plaque psoriasis and Crohn's disease -- has to contend with products such as AbbVie's (NYSE: ABBV) Humira. While this pandemic will likely keep affecting the stock market, some stocks seem to be handling the market crash much better than others. What's more, Johnson & Johnson's strong pipeline will likely allow the company to remain competitive within the pharmaceutical industry, which is its largest segment by revenue. |
24654.0 | 2020-03-18 00:00:00 UTC | AbbVie Strikes Deal With the FTC to Move Its Allergan Acquisition Forward | ABBV | https://www.nasdaq.com/articles/abbvie-strikes-deal-with-the-ftc-to-move-its-allergan-acquisition-forward-2020-03-18 | nan | nan | In June, AbbVie (NYSE: ABBV) made a bid to purchase Allergan (NYSE: AGN) in a cash and stock transaction valued at $63 billion. AbbVie likely decided to pursue the massive acquisition in part to decrease its reliance on its best-selling drug Humira, sales of which have been declining in Europe due to competition from biosimilars. However, the deal has faced some resistance. In a letter sent to the U.S. Federal Trade Commission (FTC) in September, a coalition of consumer groups and unions expressed their concerns that AbbVie's acquisition of Allergan "will likely harm consumers." The coalition asked the FTC to investigate further, and potentially block the acquisition.
Image Source: Getty Images.
Selling assets to reduce the anticompetitive risks
AbbVie and Allergan have agreed to divest some of their assets to move the acquisition forward, and the pharma giants recently reached an agreement with the FTC on the deal. Allergan agreed to sell Brazikumab -- a drug in its pipeline that is being developed as a treatment for Crohn's disease and ulcerative colitis -- to AstraZeneca (NYSE: AZN). Allergan will also be selling Zenpep -- an enzyme-replacement therapy used by patients with conditions such as cystic fibrosis -- to Nestle (OTC: NSRGY). The acquisition of Allergan was initially supposed to close during the first quarter of 2020. However, AbbVie now says it expects the deal to close in May. Still, the good news is that AbbVie should not encounter any more obstacles now that is has reached a deal with the FTC.
10 stocks we like better than Allergan
When investing geniuses David and Tom Gardner have a stock tip, it can pay to listen. After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor, has tripled the market.*
David and Tom just revealed what they believe are the ten best stocks for investors to buy right now... and Allergan wasn't one of them! That's right -- they think these 10 stocks are even better buys.
See the 10 stocks
*Stock Advisor returns as of December 1, 2019
Prosper Junior Bakiny has no position in any of the stocks mentioned. The Motley Fool recommends Nestle. The Motley Fool has a disclosure policy.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | AbbVie likely decided to pursue the massive acquisition in part to decrease its reliance on its best-selling drug Humira, sales of which have been declining in Europe due to competition from biosimilars. In June, AbbVie (NYSE: ABBV) made a bid to purchase Allergan (NYSE: AGN) in a cash and stock transaction valued at $63 billion. In a letter sent to the U.S. Federal Trade Commission (FTC) in September, a coalition of consumer groups and unions expressed their concerns that AbbVie's acquisition of Allergan "will likely harm consumers." | In a letter sent to the U.S. Federal Trade Commission (FTC) in September, a coalition of consumer groups and unions expressed their concerns that AbbVie's acquisition of Allergan "will likely harm consumers." In June, AbbVie (NYSE: ABBV) made a bid to purchase Allergan (NYSE: AGN) in a cash and stock transaction valued at $63 billion. AbbVie likely decided to pursue the massive acquisition in part to decrease its reliance on its best-selling drug Humira, sales of which have been declining in Europe due to competition from biosimilars. | In a letter sent to the U.S. Federal Trade Commission (FTC) in September, a coalition of consumer groups and unions expressed their concerns that AbbVie's acquisition of Allergan "will likely harm consumers." Selling assets to reduce the anticompetitive risks AbbVie and Allergan have agreed to divest some of their assets to move the acquisition forward, and the pharma giants recently reached an agreement with the FTC on the deal. In June, AbbVie (NYSE: ABBV) made a bid to purchase Allergan (NYSE: AGN) in a cash and stock transaction valued at $63 billion. | However, AbbVie now says it expects the deal to close in May. Still, the good news is that AbbVie should not encounter any more obstacles now that is has reached a deal with the FTC. In June, AbbVie (NYSE: ABBV) made a bid to purchase Allergan (NYSE: AGN) in a cash and stock transaction valued at $63 billion. |
24655.0 | 2020-03-18 00:00:00 UTC | Health Care Sector Update for 03/18/2020: VKTX,BMRA,ABBV,AGN | ABBV | https://www.nasdaq.com/articles/health-care-sector-update-for-03-18-2020%3A-vktxbmraabbvagn-2020-03-18-0 | nan | nan | Top Health Care Stocks
JNJ -4.58%
PFE -2.57%
ABT -3.65%
MRK -6.47%
AMGN -4.01%
Health care stocks stabilized somewhat Wednesday afternoon, with the NYSE Health Care Index declining 6.5% in late trade while the SPDR Health Care Select Sector ETF was down 6.7%. The Nasdaq Biotechnology index also was falling 4.8% shortly before the closing bell.
Among health care stocks moving on news:
(-) Pacific Biosciences of California (PACB) slid 24% to a worst-ever $2.20 a share after saying the verdict in its patent fight with Oxford Nanopore Technologies was "not overall favorable" when a Delaware district court jury declined to find the three of its patents to be valid and also decided against the company on a fourth patent. Pacific Bio said it expects to post-trial motions seeking to overturn aspects of the jury verdict and also will ask for a new trial.
In other sector news:
(+) Biomerica (BMRA) more than quadrupled in value on Wednesday, climbing over 340% in recent trading, after the company said it has started shipping samples of its COVID-19 IgG/IgM rapid test kits to multiple health authorities around the world.
(+) Viking Therapeutics (VKTX) climbed over 7% on Wednesday after the specialty drugmaker disclosed in a regulatory filing that its board of directors has approved the repurchase of up to $50 million of its common stock over the next two years.
(-) AbbVie (ABBV) slid 3% after agreeing to divest a monoclonal antibody used to treat autoimmune diseases along with two pancreatic enzyme treatments all owned by Allergen (AGN) to win regulatory approval for its proposed acquisition of the Irish drugmaker. Under terms of a consent decree with the US Federal Trade Commission, the companies will sell Allergan's brazikumab autoimmune medication to AstraZeneca (AZN) and also will spin off its Zenpep and Viokace enzyme preparations to Nestle. The companies expect to close their deal in May.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | (-) AbbVie (ABBV) slid 3% after agreeing to divest a monoclonal antibody used to treat autoimmune diseases along with two pancreatic enzyme treatments all owned by Allergen (AGN) to win regulatory approval for its proposed acquisition of the Irish drugmaker. In other sector news: (+) Biomerica (BMRA) more than quadrupled in value on Wednesday, climbing over 340% in recent trading, after the company said it has started shipping samples of its COVID-19 IgG/IgM rapid test kits to multiple health authorities around the world. Under terms of a consent decree with the US Federal Trade Commission, the companies will sell Allergan's brazikumab autoimmune medication to AstraZeneca (AZN) and also will spin off its Zenpep and Viokace enzyme preparations to Nestle. | (-) AbbVie (ABBV) slid 3% after agreeing to divest a monoclonal antibody used to treat autoimmune diseases along with two pancreatic enzyme treatments all owned by Allergen (AGN) to win regulatory approval for its proposed acquisition of the Irish drugmaker. Top Health Care Stocks Health care stocks stabilized somewhat Wednesday afternoon, with the NYSE Health Care Index declining 6.5% in late trade while the SPDR Health Care Select Sector ETF was down 6.7%. | (-) AbbVie (ABBV) slid 3% after agreeing to divest a monoclonal antibody used to treat autoimmune diseases along with two pancreatic enzyme treatments all owned by Allergen (AGN) to win regulatory approval for its proposed acquisition of the Irish drugmaker. Health care stocks stabilized somewhat Wednesday afternoon, with the NYSE Health Care Index declining 6.5% in late trade while the SPDR Health Care Select Sector ETF was down 6.7%. Among health care stocks moving on news: (-) Pacific Biosciences of California (PACB) slid 24% to a worst-ever $2.20 a share after saying the verdict in its patent fight with Oxford Nanopore Technologies was "not overall favorable" when a Delaware district court jury declined to find the three of its patents to be valid and also decided against the company on a fourth patent. | (-) AbbVie (ABBV) slid 3% after agreeing to divest a monoclonal antibody used to treat autoimmune diseases along with two pancreatic enzyme treatments all owned by Allergen (AGN) to win regulatory approval for its proposed acquisition of the Irish drugmaker. Health care stocks stabilized somewhat Wednesday afternoon, with the NYSE Health Care Index declining 6.5% in late trade while the SPDR Health Care Select Sector ETF was down 6.7%. Among health care stocks moving on news: (-) Pacific Biosciences of California (PACB) slid 24% to a worst-ever $2.20 a share after saying the verdict in its patent fight with Oxford Nanopore Technologies was "not overall favorable" when a Delaware district court jury declined to find the three of its patents to be valid and also decided against the company on a fourth patent. |
24656.0 | 2020-03-17 00:00:00 UTC | Noteworthy ETF Outflows: VT, HON, ABBV, LLY | ABBV | https://www.nasdaq.com/articles/noteworthy-etf-outflows%3A-vt-hon-abbv-lly-2020-03-17 | nan | nan | Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel, one standout is the Vanguard Total World Stock ETF (Symbol: VT) where we have detected an approximate $150.1 million dollar outflow -- that's a 1.5% decrease week over week (from 172,217,177 to 169,638,922). Among the largest underlying components of VT, in trading today Honeywell International Inc (Symbol: HON) is up about 4.5%, AbbVie Inc (Symbol: ABBV) is down about 3.7%, and Lilly (Eli) & Co (Symbol: LLY) is up by about 4.4%. For a complete list of holdings, visit the VT Holdings page » The chart below shows the one year price performance of VT, versus its 200 day moving average:
Looking at the chart above, VT's low point in its 52 week range is $57.14 per share, with $83.23 as the 52 week high point — that compares with a last trade of $58.60. Comparing the most recent share price to the 200 day moving average can also be a useful technical analysis technique -- learn more about the 200 day moving average ».
Exchange traded funds (ETFs) trade just like stocks, but instead of ''shares'' investors are actually buying and selling ''units''. These ''units'' can be traded back and forth just like stocks, but can also be created or destroyed to accommodate investor demand. Each week we monitor the week-over-week change in shares outstanding data, to keep a lookout for those ETFs experiencing notable inflows (many new units created) or outflows (many old units destroyed). Creation of new units will mean the underlying holdings of the ETF need to be purchased, while destruction of units involves selling underlying holdings, so large flows can also impact the individual components held within ETFs.
Click here to find out which 9 other ETFs experienced notable outflows »
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Among the largest underlying components of VT, in trading today Honeywell International Inc (Symbol: HON) is up about 4.5%, AbbVie Inc (Symbol: ABBV) is down about 3.7%, and Lilly (Eli) & Co (Symbol: LLY) is up by about 4.4%. For a complete list of holdings, visit the VT Holdings page » The chart below shows the one year price performance of VT, versus its 200 day moving average: Looking at the chart above, VT's low point in its 52 week range is $57.14 per share, with $83.23 as the 52 week high point — that compares with a last trade of $58.60. These ''units'' can be traded back and forth just like stocks, but can also be created or destroyed to accommodate investor demand. | Among the largest underlying components of VT, in trading today Honeywell International Inc (Symbol: HON) is up about 4.5%, AbbVie Inc (Symbol: ABBV) is down about 3.7%, and Lilly (Eli) & Co (Symbol: LLY) is up by about 4.4%. For a complete list of holdings, visit the VT Holdings page » The chart below shows the one year price performance of VT, versus its 200 day moving average: Looking at the chart above, VT's low point in its 52 week range is $57.14 per share, with $83.23 as the 52 week high point — that compares with a last trade of $58.60. Each week we monitor the week-over-week change in shares outstanding data, to keep a lookout for those ETFs experiencing notable inflows (many new units created) or outflows (many old units destroyed). | Among the largest underlying components of VT, in trading today Honeywell International Inc (Symbol: HON) is up about 4.5%, AbbVie Inc (Symbol: ABBV) is down about 3.7%, and Lilly (Eli) & Co (Symbol: LLY) is up by about 4.4%. Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel, one standout is the Vanguard Total World Stock ETF (Symbol: VT) where we have detected an approximate $150.1 million dollar outflow -- that's a 1.5% decrease week over week (from 172,217,177 to 169,638,922). For a complete list of holdings, visit the VT Holdings page » The chart below shows the one year price performance of VT, versus its 200 day moving average: Looking at the chart above, VT's low point in its 52 week range is $57.14 per share, with $83.23 as the 52 week high point — that compares with a last trade of $58.60. | Among the largest underlying components of VT, in trading today Honeywell International Inc (Symbol: HON) is up about 4.5%, AbbVie Inc (Symbol: ABBV) is down about 3.7%, and Lilly (Eli) & Co (Symbol: LLY) is up by about 4.4%. For a complete list of holdings, visit the VT Holdings page » The chart below shows the one year price performance of VT, versus its 200 day moving average: Looking at the chart above, VT's low point in its 52 week range is $57.14 per share, with $83.23 as the 52 week high point — that compares with a last trade of $58.60. Each week we monitor the week-over-week change in shares outstanding data, to keep a lookout for those ETFs experiencing notable inflows (many new units created) or outflows (many old units destroyed). |
24657.0 | 2020-03-17 00:00:00 UTC | Coronavirus Correction: 3 Must-Own Dividend Stocks | ABBV | https://www.nasdaq.com/articles/coronavirus-correction%3A-3-must-own-dividend-stocks-2020-03-17 | nan | nan | The coronavirus is smashing stock markets across the globe. In nearly every sector and asset class, valuations are tumbling as investors wrestle with the economic impact of this deadly virus. The offshoot of this "sell first, ask questions later" mentality is that a handful of stocks are getting unfairly punished right now.
Dividend-paying pharmaceutical stocks are a prime example. Pharmaceuticals are one of the few areas of the economy that will likely prove resistant to the painful economic effects of social distancing, making their dividends a fairly safe bet going forward. The same can't be said for airlines, big-box retailers, cruise ships, restaurants, or even a fair number of tech stocks. As such, pharmaceutical companies that pay an above average dividend should prove to be a safe harbor from the coronavirus fallout, once everything is said and done.
Image source: Getty Images.
Which dividend-paying pharma stocks are a must-own right now? AbbVie (NYSE: ABBV), Gilead Sciences (NASDAQ: GILD), and Pfizer (NYSE: PFE) are three top biopharmas investors may want to look to for safe haven in this chaotic environment. Here's why.
AbbVie: An ultra-high yield biopharmaceutical play
AbbVie's shares are down by 16% so far this year. There are three clear-cut reasons why investors might want to go ahead and catch this falling knife right now. First off, AbbVie's shares are now trading at less than three times forward-looking sales. That's a historically dirt cheap valuation.
Second, the drugmaker's sharp pullback has caused its dividend yield to skyrocket to an eye-catching 6.3% at current levels. AbbVie's shares are thus offering a junk-bond type yield right now.
Third, the company's product portfolio sports several medicines patients simply can't go without for very long, such as the arthritis drug Humira and the cancer drugs Imbruvica and Venclexta.
So, once the market gets back to normal a few months from now, AbbVie's stock should quickly regain its footing. Meanwhile, investors can bank the biopharma's monstrous dividend yield and wait for better days.
Gilead: A leader in the realm of infectious diseases
Gilead has been one of the few winners in this market. Because of its experimental coronavirus treatment remdesivir, investors have bid up this large-cap biotech stock by a respectable 6% in 2020. Nonetheless, Gilead's stock still offers an above-average dividend yield of 3.9% and its shares are only trading at about 3.9 times next year's sales right now. That's a bargain any way you cut it.
What's more, the biotech's stock might be even cheaper. If remdesivir hits the mark in its late-stage program for COVID-19 (the respiratory illness caused by this coronavirus), Gilead could be in line for a massive revenue windfall. The long and short of it is that remdesivir is the only drug capable of bending the curve on this global pandemic in the near-term. That fact alone should attract bargain hunters.
The real reason to buy Gilead's stock during this marketwide sell-off, though, is the company's strong outlook. By signing a sizable collaborative deal with the Belgian biotech Galapagos NV, Gilead may have secured its next flagship product: the anti-inflammatory medication filgotinib. Moreover, the biotech's cancer franchise is starting to round into shape. As proof, the biotech is close to gaining some key regulatory approvals in the area of anti-cancer cellular therapies, and it recently acquired the CD47 drugmaker Forty Seven.
All told, Gilead's stellar dividend yield, improving top-line prospects, and tie-in to the global COVID-19 pandemic make this biotech a must-own stock right now.
Pfizer: Dog of the Dow no more
Pfizer was one of the worst components of the Dow Jones in 2019. However, Pfizer's stock has actually outperformed this broader index by a wide margin in 2020, even though its shares have actually performed rather poorly. There are several reasons behind Pfizer's relative strength in this volatile market.
First off, Pfizer's dividend yield now stands at a jaw-dropping 5%. That kind of yield is nearly unheard of for a blue chip big pharma stock or a large-cap healthcare stock.
The company also manufactures and distributes a wide range of essential medicines, such as the breast cancer drug Ibrance, blood thinner Eliquis, and the nerve pain drug Lyrica. Demand for these drugs may wane somewhat as the global economy sputters, but the sales of these critical medicines won't come to a screeching halt.
Pfizer's shares have been trading at an absurdly low sales multiple for months now due to concerns over its forthcoming breakup. Last year, Pfizer announced plans to combine its generic drug business with Mylan.
Wall Street wasn't too fond of the idea because of its potential impacts on the company's free cash flows and deal-making capacity. But these fears are likely overblown. The bottom line is that Pfizer's branded drug business has been growing by leaps and bounds of late. Therefore, a breakup should allow this outstanding top-line growth to shine through, attracting a stronger base of growth-oriented investors.
All things considered, Pfizer's stock has all the tools to mount a rapid comeback in the back half of 2020. In a worst-case scenario, though, this top drugmaker should at least fall at a slower pace than the broader markets during this coronavirus-induced sell-off. As an added bonus, Pfizer is in no danger of slashing its dividend. Patient investors can sit back and collect this generous dividend while the market figures out what to do next.
10 stocks we like better than Pfizer
When investing geniuses David and Tom Gardner have a stock tip, it can pay to listen. After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor, has tripled the market.*
David and Tom just revealed what they believe are the ten best stocks for investors to buy right now... and Pfizer wasn't one of them! That's right -- they think these 10 stocks are even better buys.
See the 10 stocks
*Stock Advisor returns as of December 1, 2019
George Budwell owns shares of AbbVie and Pfizer. The Motley Fool owns shares of and recommends Gilead Sciences. The Motley Fool recommends Mylan. The Motley Fool has a disclosure policy.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | AbbVie (NYSE: ABBV), Gilead Sciences (NASDAQ: GILD), and Pfizer (NYSE: PFE) are three top biopharmas investors may want to look to for safe haven in this chaotic environment. AbbVie: An ultra-high yield biopharmaceutical play AbbVie's shares are down by 16% so far this year. First off, AbbVie's shares are now trading at less than three times forward-looking sales. | AbbVie (NYSE: ABBV), Gilead Sciences (NASDAQ: GILD), and Pfizer (NYSE: PFE) are three top biopharmas investors may want to look to for safe haven in this chaotic environment. AbbVie: An ultra-high yield biopharmaceutical play AbbVie's shares are down by 16% so far this year. First off, AbbVie's shares are now trading at less than three times forward-looking sales. | See the 10 stocks *Stock Advisor returns as of December 1, 2019 George Budwell owns shares of AbbVie and Pfizer. AbbVie (NYSE: ABBV), Gilead Sciences (NASDAQ: GILD), and Pfizer (NYSE: PFE) are three top biopharmas investors may want to look to for safe haven in this chaotic environment. AbbVie: An ultra-high yield biopharmaceutical play AbbVie's shares are down by 16% so far this year. | So, once the market gets back to normal a few months from now, AbbVie's stock should quickly regain its footing. AbbVie (NYSE: ABBV), Gilead Sciences (NASDAQ: GILD), and Pfizer (NYSE: PFE) are three top biopharmas investors may want to look to for safe haven in this chaotic environment. AbbVie: An ultra-high yield biopharmaceutical play AbbVie's shares are down by 16% so far this year. |
24658.0 | 2020-03-16 00:00:00 UTC | 7 Biotech Stocks to Buy and Hold in 2020 | ABBV | https://www.nasdaq.com/articles/7-biotech-stocks-to-buy-and-hold-in-2020-2020-03-16 | nan | nan | InvestorPlace - Stock Market News, Stock Advice & Trading Tips
[Editor’s note: “7 Biotech Stocks to Buy and Hold in 2020” was previously published in December 2019. It has since been updated to include the most relevant information available.]
If it were not for the surge in stock prices in the fourth quarter, biotechnology stocks would have ended the year in double-digit losses. Instead, they had a banner end of the year and now are suffering or succeeding based on the coronavirus and broad market pressures.
At a macroeconomic level, markets now believe the government regulators will not scrutinize drug pricing. The government is starting to realize that high healthcare costs are not due solely to rising drug prices. So, biotech companies that raise prices to offset higher research and development costs may do so in 2020.
Mega mergers in 2019, like AbbVie (NYSE:ABBV) buying Allergan (NYSE:AGN), signaled the undervaluation in the sector. In 2020, price-to-earnings valuations may expand to correct the market discount.
There are seven biotechnology stocks in 2020 that investors should hone in on. Get ready to pop these in your portfolio.
Biotech Stocks to Buy: Biogen (BIIB)
Source: Pavel Kapysh / Shutterstock.com
Biogen (NASDAQ:BIIB) rose from $220 to $300 in October when the company said it would resume filing for approval to bring its Alzheimer’s therapy drug to market. Then on Dec. 6, the company presented Phase 3 results for Aducanumab.
Over an 18-month period, it enrolled 3,285 patients over the two studies. The results showed that with a high dose over a long period of time, there was a meaningful slowing of decline in Alzheimer’s patients. And so, if the drug passes regulatory review, BIIB stock will live up to its hype.
The Aducanumab data showed mixed results. Although a higher dosage benefited patients, the side effects on the higher dosage are not clear.
Biogen reported steady revenue growth in the third quarter. Revenue grew 5% to $3.6 billion as earnings per share grew 17% to $8.39 (on a GAAP basis). Its multiple sclerosis drug portfolio is resilient. But Biogen is focused on addressing the intellectual property challenge with Tecfidera, a drug that treats relapsing forms of MS. This is offset by the launch of Vumerity, a drug also used to treat people with relapsing forms of MS.
7 Drowning Energy Stocks to Avoid for Now
Biogen reported revenue for Spinraza growing in the double-digits year-over-year and quarter-over-quarter. This drug treats patients with spinal muscular atrophy (SMA). Since Spinraza has a well-characterized safety profile, Biogen will run further studies to evaluate the benefits of higher doses to achieve greater efficacy.
Analysts who offer a price target on BIIB stock have an average of a $306.75 price target.
Amgen (AMGN)
Source: Michael Vi / Shutterstock.com
Amgen (NASDAQ:AMGN) trades with analyst price targets that average $248. But at a trailing P/E of 18.6 times, the company’s Otezla acquisition from Celgene (NASDAQ:CELG) is accretive to full-year results.
Last year Amgen announced a collaboration with BeiGene (NASDAQ:BGNE). Forming collaborations are in Amgen’s growth strategy. Since 2011, it grew by expanding to 100 countries, including China and other emerging markets. BeiGene, which represents a strategic investment in China, offers strong oncology expertise. It also has good commercial and clinical capabilities.
In 2020 and beyond, the Amgen-BeiGene collaboration may accelerate the commercialization of Amgen’s approved oncology products in the region. It paid $2.7 billion for a 20.5% equity stake, which was a 36% premium to BeiGene’s 30-day average share price.
In Q3, Amgen reported EPS of $3.66. Revenue declined 2.9% to $5.7 billion. Despite a global sales decline, Amgen reported double-digit sales for a multitude of drugs. If generic competition lessens in 2020 and drug pricing improves, Amgen stock could continue trending higher.
Gilead Sciences (GILD)
Source: Casimiro PT / Shutterstock.com
Gilead Sciences (NASDAQ:GILD) surged early as a coronavirus darling before getting sucked back down into range by the prevailing market forces. And as investors wait for the stock to build an uptrend, they may collect a dividend that yields around 4%.
The U.S. approved Gilead’s Descovy for PrEP (pre-exposure prophylaxis). This drug is indicated to reduce the risk of sexually acquired HIV-1. Filgotinib was validated in the European Union and the company submitted a new drug application in Japan. Filgotinib is a JAK1 inhibitor that treats rheumatoid arthritis. If approved, it will compete with AbbVie’s (NYSE:ABBV) Humira.
Setting aside Gilead’s viability as a coronavirus vaccine leader, investors should consider Gilead for 2020 because of its strong cash flow generation. It produced $2.6 billion in cash from operations in the third quarter and now has $25.1 billion in cash and investments.
That healthy cash flow allowed the company to easily spend on R&D. It paid $5.5 billion for global research collaboration activities and it also invested in Galapagos (NASDAQ:GLPG). Galapagos gives Gilead access to many compounds, including six molecules that are in clinical trials. For example, Gilead gains rights to a Phase 3 candidate that treats idiopathic pulmonary fibrosis. GLPG1972 is a Phase 2b candidate that treats osteoarthritis.
7 Stocks to Sell as We Enter a Bear Market
Gilead could grow its revenue beyond the 12.7% rate. If its purchase of Kite Pharmaceuticals yields new products brought to market, the stock is set to blast off in late 2020 and beyond.
Regeneron Pharmaceuticals (REGN)
Source: Shutterstock
Regeneron (NASDAQ:REGN), which is getting better known for its blockbuster drug Dupixent, broke out of a downtrend late last year and hasn’t stopped growing.
The company reported an EPS of $6.67 as revenue soared 23.1% year-over-year to $2.1 billion. Markets incorrectly worried over generic pressure on Eylea, which treats advanced wet age-related macular degeneration. Eylea sales grew 14% to $1.9 billion.
Dupixent has a growing addressable market. As it gains approvals worldwide, sales might even accelerate. In 2020, Regeneron will continue investing in researching activities for the drug to have additional indications.
For example, late this year it will have data in combination with Aimmune’s (NASDAQ:AIMT) AR101 for treating peanut allergies. It will also have a data readout for its interleukin-33 (IL-33) antibody called Regeneron 3500 for treating atopic dermatitis and COPD (chronic obstructive pulmonary disease).
Regeneron continues to develop drugs in the oncology market. It launched Libtayo, an anti-PD-1 therapy that treats cutaneous squamous cell carcinoma. It also has new data from Libtayo in treating lung cancer.
At a P/E near 20 times, Regeneron still has plenty of upside potential. Even if the company’s revenue were to slow to the 4% range in the next five years, the stock is still worth around $526.
Crispr Therapeutics (CRSP)
Source: Shutterstock
Crispr Therapeutics (NASDAQ:CRSP), which is based in Switzerland, almost doubled in 2019. So after that performance, why should investors expect any more upside in 2020?
CRSP reported encouraging results for a potential immune-evasive cell replacement therapy for diabetes. From its press release, it said: “The data demonstrate that the CyT49 pluripotent stem cell line, which has been shown to be amenable to efficient scaling and differentiation, can be successfully edited with CRISPR.”
The results are further proof that regenerative medicine and gene editing may lead to cures in various diseases. Crispr is currently focusing on chronic diseases like diabetes.
Optimism for CRSP stock is so strong that a 4.3 million stock offering at $64.50 barely hurt the stock. The stock sale will add $274.1 million of cash, which Crispr may use to fund its ongoing clinical studies in sickle cell disease and beta-thalassemia.
The 10 Best Stocks to Buy After The Market's Historic Sell-Off
Digging into the details, Crispr said that it successfully treated its first patient in the CLIMB SCD-121 study. The neutrophil engraftment had 46.6% hemoglobin F four months later. That suggests a curative response. Since the study is ongoing, the company will continue to inform investors of the safety profile of the treatment and its efficacy.
Crispr is ushering in an innovative form of therapy through gene editing. And markets like what the future holds.
Editas Medicine (EDIT)
Source: Shutterstock
Editas Medicine (NASDAQ:EDIT) has negligible revenue and is losing money, but its collaboration with Celgene gives it the resources in advancing its pipeline.
Editas reported a $70 million payment from its Celgene collaboration. This payment is in recognition of the work it did so far. It also includes contributions it will make to the collaboration. Its first patient will receive a doss of EDIT-101 by early 2020. This medicine treats subjects suffering from LCA10 or Leber congenital amaurosis. In Q3, Editas presented data for its USH2A study. It produced up to 60% corrected gene expression.
Looking ahead, additional collaborations with Celgene could give EDIT stock a lift. On its conference call, the company said:
“All of that work is rolled into the new collaboration with Celgene. As you can imagine, as a leader — and we believe the leader in T cell medicines for oncology including arguably the best CD19 and the best BCMA CAR-T programs that have a strong interest in maintaining their leadership position and gene editing is certainly an important part of what are likely to be the next generation of T cell medicines for oncology.”
Editas’ collaboration with Celgene continues to progress nicely. Wall Street, which has a $42.50 price target, is also optimistic that the company will reward investors in 2020.
Innoviva (INVA)
Source: Shutterstock
Innoviva (NASDAQ:INVA) has been trading sidewas all year until the recent mass-sell-off.
Last year, Innoviva booked $69.2 million in gross royalty revenues from GlaxoSmithKline (NYSE:GSK). This included royalties of $46.4 million connected to sales of Relvar/Breo Ellipta. This drug is a combination inhaled corticosteroid that treats patients with COPD (chronic obstructive pulmonary disease). Anoro Ellipta, which treats COPD and is taken once daily, brought in royalties of $11.6 million.
The company had $2.8 million in legal and related fees. Theravance Biopharma (NASDAQ:TBPH) initiated an arbitration. In the final decision, the Theravance Respiratory Company would reimburse those legal costs.
Global Relvar/Breo Ellipta sales fell 10% globally and by 32% in the U.S. Pricing discounts hurt revenue, and that revenue was partially offset by volume growth. Market share gains in various European markets and in Japan offset the overall revenue declines. Anoro Ellipta net sales grew 18% globally and were up 17% in the U.S. The negative impact of higher rebates was offset by higher sales volumes.
For 2020, Innoviva has a lower operating cost basis, helped by ending its Brisbane office lease. So, if the company reduces rebate offers and continues to grow its sales volume, revenue and profits may rebound.
As of this writing, Chris Lau held shares of INVA.
The post 7 Biotech Stocks to Buy and Hold in 2020 appeared first on InvestorPlace.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Mega mergers in 2019, like AbbVie (NYSE:ABBV) buying Allergan (NYSE:AGN), signaled the undervaluation in the sector. If approved, it will compete with AbbVie’s (NYSE:ABBV) Humira. This is offset by the launch of Vumerity, a drug also used to treat people with relapsing forms of MS. 7 Drowning Energy Stocks to Avoid for Now Biogen reported revenue for Spinraza growing in the double-digits year-over-year and quarter-over-quarter. | Mega mergers in 2019, like AbbVie (NYSE:ABBV) buying Allergan (NYSE:AGN), signaled the undervaluation in the sector. If approved, it will compete with AbbVie’s (NYSE:ABBV) Humira. Amgen (AMGN) Source: Michael Vi / Shutterstock.com Amgen (NASDAQ:AMGN) trades with analyst price targets that average $248. | Mega mergers in 2019, like AbbVie (NYSE:ABBV) buying Allergan (NYSE:AGN), signaled the undervaluation in the sector. If approved, it will compete with AbbVie’s (NYSE:ABBV) Humira. InvestorPlace - Stock Market News, Stock Advice & Trading Tips [Editor’s note: “7 Biotech Stocks to Buy and Hold in 2020” was previously published in December 2019. | Mega mergers in 2019, like AbbVie (NYSE:ABBV) buying Allergan (NYSE:AGN), signaled the undervaluation in the sector. If approved, it will compete with AbbVie’s (NYSE:ABBV) Humira. So, biotech companies that raise prices to offset higher research and development costs may do so in 2020. |
24659.0 | 2020-03-16 00:00:00 UTC | Better Buy: AbbVie vs. Johnson & Johnson | ABBV | https://www.nasdaq.com/articles/better-buy%3A-abbvie-vs.-johnson-johnson-2020-03-16 | nan | nan | One company produces the top-selling pharmaceuticals in the world. The other is a household name that offers various consumer health products as well as pharmaceutical products. Both are dealing with some hurdles and challenges.
We're talking about AbbVie (NYSE: ABBV) and Johnson & Johnson (NYSE: JNJ). Are either of these stocks worth buying right now? If so, which is the better buy? Let's take a closer look at each of these healthcare companies.
Image source: Getty Images.
AbbVie
AbbVie underperformed the broader market last year, down 3.9% in a year when the S&P 500 returned 28.9%. This year, the stock has outperformed, down 10% compared to the S&P 500, which has lost 24.7% year to date.
The company is coming off a solid fourth quarter with $2.8 billion in net income, a drastic difference from its loss of $1.8 billion in the fourth quarter of 2018. For the full year, net income was $7.9 billion, up from $5.7 billion. Earnings per share were $5.28 in 2019, up from $3.66 in 2018. Quarterly earnings were boosted by solid U.S. sales of AbbVie's top-selling drug, Humira, which treats rheumatoid arthritis.
Humira, the world's top-selling drug, had net revenue of $3.9 billion in the U.S. in the fourth quarter, an increase of 9.8% over the fourth quarter of 2018. Internationally, net revenues were down 27% to $948 million due to biosimilar competition. Overall, Humira had $4.9 billion in quarterly net revenues globally, which is flat compared to the fourth quarter of 2018.
AbbVie also had strong sales from Imbruvica, a cancer drug, which saw global net revenues climb 28.9% to $1.3 billion in the quarter, an increase of 28.9%. Imbruvica is the market leader in treating CLL (chronic lymphocytic leukemia) and the company expects continued growth from it. Net revenues from its hematologic oncology portfolio, which includes Imbruvica and Venclexta, were $1.5 billion, up 37% in the quarter.
New immunology drugs Skyrizi and Rinvoq had net revenues of $216 million and $33 million, respectively. The company expects Skyrizi and Rinvoq to deliver $1.7 billion in revenue this year, up from past projections of $1 billion.
The company has some good momentum but is still waiting to close on its $63 billion acquisition of Allergan. Allergan produces the blockbuster cosmetic drug Botox, which will further diversify AbbVie's revenue stream. The deal was supposed to close in the first quarter but has been postponed due to a delay in the Federal Trade Commission's verdict. The company expects a decision in the second quarter. The good news is that the European Commission signed off on the deal in early March.
Johnson & Johnson
Johnson & Johnson is coming off a better year than AbbVie, at least as far as shareholders are concerned. The stock was up 13% in 2019, which trailed the S&P 500, but was ahead of AbbVie. This year, the stock has suffered more than AbbVie, down about 13% year to date.
They are two very different companies, as AbbVie is solely focused on pharmaceuticals while Johnson & Johnson has a more diversified revenue stream. Its consumer products division manufactures and sells branded skincare products including Neutrogena and Aveeno, pain relievers Tylenol and Motrin, and popular health products including Band-Aid, Listerine, and Johnson's soap and baby powder. Johnson & Johnson also has a medical device division that sells orthopedics, surgery, and vision devices. Its subsidiary Janssen is its pharmaceutical business, producing immunology drugs including Stelara, which treats Crohn's disease, and Remicade which treats an array of autoimmune conditions.
In the fourth quarter, sales were up 1.7% over the previous year's quarter to $20.7 billion, while net income climbed 31.8% to $4 billion. For the full year, sales were up nearly 1% to $82.1 billion while net income was down 1.2% to $15.1 billion. Earnings per share were $5.63 for 2019, up 0.4%. For the full year, the pharmaceutical division saw 5.8% sales growth, while medical device sales were up 3.9% and consumer products sales were up 1.4%. The company's 2020 guidance calls for a 5% to 6% increase in sales and 3.1% to 4.8% increase in adjusted EPS.
Johnson & Johnson has been able to grow despite some major legal issues. In 2018, the company paid out $4.7 billion to plaintiffs in a lawsuit who alleged its baby powder caused them to develop cancer. J&J appealed the decision, saying the product does not cause cancer. Last year, an Oklahoma judge ordered the company to pay $572 million for its role in the state's opioid crisis. The company has appealed.
Last year, the company was ordered to pay out $8 billion in a lawsuit brought by a plaintiff over alleged side effects of its drug Risperdal, an antipsychotic medicine, that caused the patient to develop gynecomastia (swelling of breast tissue in males). J&J appealed the decision and the payout was ultimately reduced to $6.8 million.
In February, the company was ordered to pay $750 million to four plaintiffs over claims related to its baby powder. These legal troubles are not over yet as some 16,800 plaintiffs have filed lawsuits against the company related to its talcum powder products.
Which is the better buy?
AbbVie is the better buy right now. Johnson & Johnson has been able to grow through these lawsuits, but they are not going away and will continue to be a drag on earnings.
AbbVie is undervalued with a forward P/E ratio of around 9, and it has great growth potential from its pending Allergan acquisition, which looks like a go, and its promising new products. Plus, AbbVie pays out an excellent quarterly dividend of $1.18 per share – which has gone up every year for the past seven years. Johnson & Johnson also pays investors a dividend, but it's not enough to entice investors to take on all that risk.
10 stocks we like better than Johnson & Johnson
When investing geniuses David and Tom Gardner have a stock tip, it can pay to listen. After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor, has tripled the market.*
David and Tom just revealed what they believe are the ten best stocks for investors to buy right now... and Johnson & Johnson wasn't one of them! That's right -- they think these 10 stocks are even better buys.
See the 10 stocks
*Stock Advisor returns as of December 1, 2019
Dave Kovaleski has no position in any of the stocks mentioned. The Motley Fool recommends Johnson & Johnson. The Motley Fool has a disclosure policy.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | AbbVie also had strong sales from Imbruvica, a cancer drug, which saw global net revenues climb 28.9% to $1.3 billion in the quarter, an increase of 28.9%. We're talking about AbbVie (NYSE: ABBV) and Johnson & Johnson (NYSE: JNJ). AbbVie AbbVie underperformed the broader market last year, down 3.9% in a year when the S&P 500 returned 28.9%. | Quarterly earnings were boosted by solid U.S. sales of AbbVie's top-selling drug, Humira, which treats rheumatoid arthritis. AbbVie also had strong sales from Imbruvica, a cancer drug, which saw global net revenues climb 28.9% to $1.3 billion in the quarter, an increase of 28.9%. We're talking about AbbVie (NYSE: ABBV) and Johnson & Johnson (NYSE: JNJ). | Johnson & Johnson Johnson & Johnson is coming off a better year than AbbVie, at least as far as shareholders are concerned. We're talking about AbbVie (NYSE: ABBV) and Johnson & Johnson (NYSE: JNJ). AbbVie AbbVie underperformed the broader market last year, down 3.9% in a year when the S&P 500 returned 28.9%. | AbbVie also had strong sales from Imbruvica, a cancer drug, which saw global net revenues climb 28.9% to $1.3 billion in the quarter, an increase of 28.9%. We're talking about AbbVie (NYSE: ABBV) and Johnson & Johnson (NYSE: JNJ). AbbVie AbbVie underperformed the broader market last year, down 3.9% in a year when the S&P 500 returned 28.9%. |
24660.0 | 2020-03-15 00:00:00 UTC | 3 Great Dividend Stocks to Buy If You're Sick and Tired of Hearing About the Coronavirus | ABBV | https://www.nasdaq.com/articles/3-great-dividend-stocks-to-buy-if-youre-sick-and-tired-of-hearing-about-the-coronavirus | nan | nan | It's pretty much nothing but coronavirus and COVID-19 coverage non-stop everywhere you turn. Quite frankly, that's the way it should be. The pandemic is serious and requires sober-minded efforts to minimize its effects. But I suspect that many Americans are feeling COVID-19 information overload right now.
There's a great way to take your mind off the viral outbreak and set yourself up for long-term profits at the same time. How, you ask? Invest in dividend stocks that now have much higher yields thanks to the stock market crash. If you're sick and tired of hearing about the coronavirus, here are three great dividend stocks to buy right now.
Image source: Getty Images.
1. AbbVie
AbbVie's (NYSE: ABBV) shares have fallen during the overall market sell-off, although not as much as the S&P 500 index has. But this drop has made the drugmaker's fantastic dividend yield even more fantastic. AbbVie's dividend now yields a mouthwatering 6%.
And as for that infectious disease that shall not be named, it shouldn't have any effect on AbbVie's business. The company makes its money from prescription drugs for treating blood cancer, endometriosis, hepatitis C, rheumatoid arthritis, and multiple other diseases. Doctors are going to keep on prescribing those drugs, and patients are going to keep on taking them, whether there's a pandemic spreading or not.
That's not to say that AbbVie doesn't have a challenge or two. Sales for its blockbuster drug Humira are falling in Europe due to competition from biosimilars. The company will face biosimilar rivals in the U.S. in 2023.
However, AbbVie seems to have a good strategy to address the issues. It has launched a couple of new immunology drugs to take the baton from Humira -- Rinvoq and Skyrizi. The company also awaits final regulatory approvals to acquire Allergan, a deal that will significantly reduce reliance on Humira.
2. AT&T
Like AbbVie, AT&T (NYSE: T) stock is down, but not as bad as the major market indexes. The telecommunications giant's dividend yield has also become even more attractive and now stands north of 6.6%. That juicy yield combined with a track record of 36 consecutive years of dividend increases makes AT&T a top-tier dividend stock.
But what about that viral you-know-who? AT&T shouldn't have anything to worry about. If anything, there could be greater demand for the company's wireless services if lots of people stay home to avoid the potential of becoming infected.
It's true that AT&T's TV business continues to lose subscribers. There's no guarantee that the company's efforts to offset these losses with its new streaming services will be as successful as the company hopes.
My view, though, is that AT&T's overall prospects remain pretty good and are strong enough to keep the nice dividends flowing and growing. In particular, I like the opportunities for the company as high-speed 5G wireless networks become more widely adopted.
3. Medical Properties Trust
Not every great dividend stock is as large and well-known as AbbVie and AT&T. Medical Properties Trust (NYSE: MPW) shares have tanked close to 25% with the stock market crash, but its dividend yield is now nearly 6.5%.
I think that the sell-off of Medical Properties Trust is way overdone. The company is a real estate investment trust (REIT) that focuses primarily on acute care hospitals. Do you think these hospitals are going to see admissions go down if the virus that rhymes with Sharona hits the U.S. hard? I don't either.
Also, with concerns that the U.S. could slip into a recession, it's a pretty safe bet that the Federal Reserve won't give a second's thought to increasing interest rates. Rates are more likely to go down, which would be good news for Medical Properties Trust because it could borrow money for investing in new properties more cheaply.
My colleague Matt Dilallo wrote recently that Medical Properties Trust is a REIT that's immune to the coronavirus. Sorry for using the word you're sick and tired of hearing, but Matt's exactly right. I view the stock as an excellent choice to buy right now and lock in an attractive dividend yield that's likely to rise in the future.
10 stocks we like better than AT&T
When investing geniuses David and Tom Gardner have a stock tip, it can pay to listen. After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor, has tripled the market.*
David and Tom just revealed what they believe are the ten best stocks for investors to buy right now... and AT&T wasn't one of them! That's right -- they think these 10 stocks are even better buys.
See the 10 stocks
*Stock Advisor returns as of December 1, 2019
Keith Speights owns shares of AbbVie. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | AbbVie AbbVie's (NYSE: ABBV) shares have fallen during the overall market sell-off, although not as much as the S&P 500 index has. AbbVie's dividend now yields a mouthwatering 6%. And as for that infectious disease that shall not be named, it shouldn't have any effect on AbbVie's business. | Medical Properties Trust Not every great dividend stock is as large and well-known as AbbVie and AT&T. AbbVie AbbVie's (NYSE: ABBV) shares have fallen during the overall market sell-off, although not as much as the S&P 500 index has. AbbVie's dividend now yields a mouthwatering 6%. | Medical Properties Trust Not every great dividend stock is as large and well-known as AbbVie and AT&T. AbbVie AbbVie's (NYSE: ABBV) shares have fallen during the overall market sell-off, although not as much as the S&P 500 index has. AbbVie's dividend now yields a mouthwatering 6%. | AbbVie's dividend now yields a mouthwatering 6%. AbbVie AbbVie's (NYSE: ABBV) shares have fallen during the overall market sell-off, although not as much as the S&P 500 index has. And as for that infectious disease that shall not be named, it shouldn't have any effect on AbbVie's business. |
24661.0 | 2020-03-12 00:00:00 UTC | Roche : EC Oks Venclyxto-Gazyvaro For Adults With Chronic Lymphocytic Leukaemia | ABBV | https://www.nasdaq.com/articles/roche-%3A-ec-oks-venclyxto-gazyvaro-for-adults-with-chronic-lymphocytic-leukaemia-2020-03-12 | nan | nan | (RTTNews) - Roche (RHHBY) said that the European Commission has approved Venclyxto or venetoclax in combination with Gazyvaro or obinutuzumab for the treatment of adult patients with previously untreated chronic lymphocytic leukaemia or CLL.
Venclexta/Venclyxto is being developed by AbbVie and Roche. It is jointly commercialised by AbbVie and Genentech, a member of the Roche Group, in the US, under the brand name Venclexta, and commercialised by AbbVie outside of the US.
The approval was based on results from the primary analysis of the pivotal phase III CLL14 study, which evaluated the combination of 12-month, fixed-duration Venclyxto plus Gazyvaro compared to Gazyvaro plus chlorambucil in adults with previously untreated CLL who had co-existing medical conditions.
Results from the primary analysis showed that the combination of Venclyxto plus Gazyvaro led to a 65% reduction in the risk of disease worsening or death compared to Gazyvaro plus chlorambucil, a current standard-of-care for CLL.
chronic lymphocytic leukaemia is a slow-growing form of leukemia, or blood cancer, in which too many immature lymphocytes (a type of white blood cell) are found predominantly in the blood and bone marrow.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Venclexta/Venclyxto is being developed by AbbVie and Roche. It is jointly commercialised by AbbVie and Genentech, a member of the Roche Group, in the US, under the brand name Venclexta, and commercialised by AbbVie outside of the US. (RTTNews) - Roche (RHHBY) said that the European Commission has approved Venclyxto or venetoclax in combination with Gazyvaro or obinutuzumab for the treatment of adult patients with previously untreated chronic lymphocytic leukaemia or CLL. | Venclexta/Venclyxto is being developed by AbbVie and Roche. It is jointly commercialised by AbbVie and Genentech, a member of the Roche Group, in the US, under the brand name Venclexta, and commercialised by AbbVie outside of the US. (RTTNews) - Roche (RHHBY) said that the European Commission has approved Venclyxto or venetoclax in combination with Gazyvaro or obinutuzumab for the treatment of adult patients with previously untreated chronic lymphocytic leukaemia or CLL. | It is jointly commercialised by AbbVie and Genentech, a member of the Roche Group, in the US, under the brand name Venclexta, and commercialised by AbbVie outside of the US. Venclexta/Venclyxto is being developed by AbbVie and Roche. (RTTNews) - Roche (RHHBY) said that the European Commission has approved Venclyxto or venetoclax in combination with Gazyvaro or obinutuzumab for the treatment of adult patients with previously untreated chronic lymphocytic leukaemia or CLL. | Venclexta/Venclyxto is being developed by AbbVie and Roche. It is jointly commercialised by AbbVie and Genentech, a member of the Roche Group, in the US, under the brand name Venclexta, and commercialised by AbbVie outside of the US. (RTTNews) - Roche (RHHBY) said that the European Commission has approved Venclyxto or venetoclax in combination with Gazyvaro or obinutuzumab for the treatment of adult patients with previously untreated chronic lymphocytic leukaemia or CLL. |
24662.0 | 2020-03-12 00:00:00 UTC | May 1st Options Now Available For AbbVie | ABBV | https://www.nasdaq.com/articles/may-1st-options-now-available-for-abbvie-2020-03-12 | nan | nan | Investors in AbbVie Inc (Symbol: ABBV) saw new options begin trading today, for the May 1st expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the ABBV options chain for the new May 1st contracts and identified one put and one call contract of particular interest.
The put contract at the $78.00 strike price has a current bid of $3.50. If an investor was to sell-to-open that put contract, they are committing to purchase the stock at $78.00, but will also collect the premium, putting the cost basis of the shares at $74.50 (before broker commissions). To an investor already interested in purchasing shares of ABBV, that could represent an attractive alternative to paying $79.39/share today.
Because the $78.00 strike represents an approximate 2% discount to the current trading price of the stock (in other words it is out-of-the-money by that percentage), there is also the possibility that the put contract would expire worthless. The current analytical data (including greeks and implied greeks) suggest the current odds of that happening are 56%. Stock Options Channel will track those odds over time to see how they change, publishing a chart of those numbers on our website under the contract detail page for this contract. Should the contract expire worthless, the premium would represent a 4.49% return on the cash commitment, or 32.76% annualized — at Stock Options Channel we call this the YieldBoost.
Below is a chart showing the trailing twelve month trading history for AbbVie Inc, and highlighting in green where the $78.00 strike is located relative to that history:
Turning to the calls side of the option chain, the call contract at the $81.00 strike price has a current bid of $2.90. If an investor was to purchase shares of ABBV stock at the current price level of $79.39/share, and then sell-to-open that call contract as a "covered call," they are committing to sell the stock at $81.00. Considering the call seller will also collect the premium, that would drive a total return (excluding dividends, if any) of 5.68% if the stock gets called away at the May 1st expiration (before broker commissions). Of course, a lot of upside could potentially be left on the table if ABBV shares really soar, which is why looking at the trailing twelve month trading history for AbbVie Inc, as well as studying the business fundamentals becomes important. Below is a chart showing ABBV's trailing twelve month trading history, with the $81.00 strike highlighted in red:
Considering the fact that the $81.00 strike represents an approximate 2% premium to the current trading price of the stock (in other words it is out-of-the-money by that percentage), there is also the possibility that the covered call contract would expire worthless, in which case the investor would keep both their shares of stock and the premium collected. The current analytical data (including greeks and implied greeks) suggest the current odds of that happening are 58%. On our website under the contract detail page for this contract, Stock Options Channel will track those odds over time to see how they change and publish a chart of those numbers (the trading history of the option contract will also be charted). Should the covered call contract expire worthless, the premium would represent a 3.65% boost of extra return to the investor, or 26.67% annualized, which we refer to as the YieldBoost.
The implied volatility in the put contract example is 60%, while the implied volatility in the call contract example is 50%.
Meanwhile, we calculate the actual trailing twelve month volatility (considering the last 252 trading day closing values as well as today's price of $79.39) to be 30%. For more put and call options contract ideas worth looking at, visit StockOptionsChannel.com.
Top YieldBoost Calls of the S&P 500 »
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Of course, a lot of upside could potentially be left on the table if ABBV shares really soar, which is why looking at the trailing twelve month trading history for AbbVie Inc, as well as studying the business fundamentals becomes important. Below is a chart showing ABBV's trailing twelve month trading history, with the $81.00 strike highlighted in red: Considering the fact that the $81.00 strike represents an approximate 2% premium to the current trading price of the stock (in other words it is out-of-the-money by that percentage), there is also the possibility that the covered call contract would expire worthless, in which case the investor would keep both their shares of stock and the premium collected. Investors in AbbVie Inc (Symbol: ABBV) saw new options begin trading today, for the May 1st expiration. | Below is a chart showing ABBV's trailing twelve month trading history, with the $81.00 strike highlighted in red: Considering the fact that the $81.00 strike represents an approximate 2% premium to the current trading price of the stock (in other words it is out-of-the-money by that percentage), there is also the possibility that the covered call contract would expire worthless, in which case the investor would keep both their shares of stock and the premium collected. Investors in AbbVie Inc (Symbol: ABBV) saw new options begin trading today, for the May 1st expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the ABBV options chain for the new May 1st contracts and identified one put and one call contract of particular interest. | Below is a chart showing the trailing twelve month trading history for AbbVie Inc, and highlighting in green where the $78.00 strike is located relative to that history: Turning to the calls side of the option chain, the call contract at the $81.00 strike price has a current bid of $2.90. Below is a chart showing ABBV's trailing twelve month trading history, with the $81.00 strike highlighted in red: Considering the fact that the $81.00 strike represents an approximate 2% premium to the current trading price of the stock (in other words it is out-of-the-money by that percentage), there is also the possibility that the covered call contract would expire worthless, in which case the investor would keep both their shares of stock and the premium collected. Investors in AbbVie Inc (Symbol: ABBV) saw new options begin trading today, for the May 1st expiration. | At Stock Options Channel, our YieldBoost formula has looked up and down the ABBV options chain for the new May 1st contracts and identified one put and one call contract of particular interest. Below is a chart showing ABBV's trailing twelve month trading history, with the $81.00 strike highlighted in red: Considering the fact that the $81.00 strike represents an approximate 2% premium to the current trading price of the stock (in other words it is out-of-the-money by that percentage), there is also the possibility that the covered call contract would expire worthless, in which case the investor would keep both their shares of stock and the premium collected. Investors in AbbVie Inc (Symbol: ABBV) saw new options begin trading today, for the May 1st expiration. |
24663.0 | 2020-03-11 00:00:00 UTC | Health Care Sector Update for 03/11/2020: AYTU,ONCT,JNJ,ABBV,DXC,SEEL | ABBV | https://www.nasdaq.com/articles/health-care-sector-update-for-03-11-2020%3A-aytuonctjnjabbvdxcseel-2020-03-11 | nan | nan | Top Health Care Stocks
JNJ -6.06%
PFE -7.31%
ABT -3.47%
MRK -3.37%
AMGN -3.74%
Health care stocks fell Wednesday, with the NYSE Health Care Index declining about 4.9% while the SPDR Health Care Select Sector ETF was down 3.7%. The Nasdaq Biotechnology index was dropping 4.9% this afternoon.
Among health care stocks moving on news:
(-) Aytu BioScience (AYTU) slumped Wednesday, dropping over 34% and reversing a nearly 20% advance for the specialty drugmaker that followed the company earlier announcing a $9 million at-the-market direct offering of more than 7.8 million shares priced at $1.15 apiece with an unnamed healthcare-focused institutional investor. Net proceeds will be used for working capital and general corporate purposes, including continued commercialization of its prescription and consumer health products.
In other sector news:
(+) Oncternal Therapeutics (ONCT) rose 17% after the company reported encouraging interim data from phase I/II testing of a combination of its cirmtuzumab monoclonal antibody with Johnson & Johnson's (JNJ) and AbbVie's (ABBV) ibrutinib cancer medication in patients with relapsed/refactory mantle cell lympoma.
(+) DXC Technology (DXC) was fractionally higher this afternoon after the company said it will sell its state and local Health and human services business for $5 billion in cash to private-equity investors Veritas Capital while retaining its health care practice. Net proceeds from the transaction will be used to pay down debt.
(-) Seelos Therapeutics (SEEL) turned more than 8% lower this afternoon, giving back a nearly 14% gain earlier Wednesday after the company said European regulators have recommended a non-placebo controlled and open-label phase IIb/III trial of its SLS-005 drug candidate to treat pediatric Sanfilippo syndrome. The European Medicines Agency also said Seelos should use appropriate natural history data of patients with the rare genetic condition that damages the brain.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | In other sector news: (+) Oncternal Therapeutics (ONCT) rose 17% after the company reported encouraging interim data from phase I/II testing of a combination of its cirmtuzumab monoclonal antibody with Johnson & Johnson's (JNJ) and AbbVie's (ABBV) ibrutinib cancer medication in patients with relapsed/refactory mantle cell lympoma. Net proceeds will be used for working capital and general corporate purposes, including continued commercialization of its prescription and consumer health products. (-) Seelos Therapeutics (SEEL) turned more than 8% lower this afternoon, giving back a nearly 14% gain earlier Wednesday after the company said European regulators have recommended a non-placebo controlled and open-label phase IIb/III trial of its SLS-005 drug candidate to treat pediatric Sanfilippo syndrome. | In other sector news: (+) Oncternal Therapeutics (ONCT) rose 17% after the company reported encouraging interim data from phase I/II testing of a combination of its cirmtuzumab monoclonal antibody with Johnson & Johnson's (JNJ) and AbbVie's (ABBV) ibrutinib cancer medication in patients with relapsed/refactory mantle cell lympoma. Top Health Care Stocks Health care stocks fell Wednesday, with the NYSE Health Care Index declining about 4.9% while the SPDR Health Care Select Sector ETF was down 3.7%. | In other sector news: (+) Oncternal Therapeutics (ONCT) rose 17% after the company reported encouraging interim data from phase I/II testing of a combination of its cirmtuzumab monoclonal antibody with Johnson & Johnson's (JNJ) and AbbVie's (ABBV) ibrutinib cancer medication in patients with relapsed/refactory mantle cell lympoma. Health care stocks fell Wednesday, with the NYSE Health Care Index declining about 4.9% while the SPDR Health Care Select Sector ETF was down 3.7%. Among health care stocks moving on news: (-) Aytu BioScience (AYTU) slumped Wednesday, dropping over 34% and reversing a nearly 20% advance for the specialty drugmaker that followed the company earlier announcing a $9 million at-the-market direct offering of more than 7.8 million shares priced at $1.15 apiece with an unnamed healthcare-focused institutional investor. | In other sector news: (+) Oncternal Therapeutics (ONCT) rose 17% after the company reported encouraging interim data from phase I/II testing of a combination of its cirmtuzumab monoclonal antibody with Johnson & Johnson's (JNJ) and AbbVie's (ABBV) ibrutinib cancer medication in patients with relapsed/refactory mantle cell lympoma. Top Health Care Stocks Health care stocks fell Wednesday, with the NYSE Health Care Index declining about 4.9% while the SPDR Health Care Select Sector ETF was down 3.7%. |
24664.0 | 2020-03-11 00:00:00 UTC | Health Care Sector Update for 03/11/2020: SEEL,DXC,ONCT,JNJ,ABBV | ABBV | https://www.nasdaq.com/articles/health-care-sector-update-for-03-11-2020%3A-seeldxconctjnjabbv-2020-03-11 | nan | nan | Top Health Care Stocks
JNJ -5.77%
PFE -5.80%
ABT -4.03%
MRK -3.17%
AMGN -3.05%
Health care stocks were falling, with the NYSE Health Care Index declining about 4.0% while the SPDR Health Care Select Sector ETF was down 3.2%. The Nasdaq Biotechnology index was dropping 3.9% this afternoon.
Among health care stocks moving on news:
(+) Seelos Therapeutics (SEEL) turned 2.2% lower this afternoon, giving back a nearly 14% gain earlier Wednesday after the company said European regulators have recommended a non-placebo controlled and open-label phase IIb/III trial of its SLS-005 drug candidate to treat pediatric Sanfilippo syndrome. The European Medicines Agency also said Seelos should use appropriate natural history data of patients with the rare genetic condition that damages the brain.
In other sector news:
(+) Oncternal Therapeutics (ONCT) rose 3.1% after the company reported encouraging interim data from phase I/II testing of a combination of its cirmtuzumab monoclonal antibody with Johnson & Johnson's (JNJ) and AbbVie's (ABBV) ibrutinib cancer medication in patients with relapsed/refactory mantle cell lympoma.
(-) DXC Technology (DXC) was 1.2% lower this afternoon, reversing its prior gain after the company said it will sell its state and local Health and human services business for $5 billion in cash to private-equity investors Veritas Capital while retaining its health care practice. Net proceeds from the transcaction will be used to pay down debt.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | In other sector news: (+) Oncternal Therapeutics (ONCT) rose 3.1% after the company reported encouraging interim data from phase I/II testing of a combination of its cirmtuzumab monoclonal antibody with Johnson & Johnson's (JNJ) and AbbVie's (ABBV) ibrutinib cancer medication in patients with relapsed/refactory mantle cell lympoma. Among health care stocks moving on news: (+) Seelos Therapeutics (SEEL) turned 2.2% lower this afternoon, giving back a nearly 14% gain earlier Wednesday after the company said European regulators have recommended a non-placebo controlled and open-label phase IIb/III trial of its SLS-005 drug candidate to treat pediatric Sanfilippo syndrome. The European Medicines Agency also said Seelos should use appropriate natural history data of patients with the rare genetic condition that damages the brain. | In other sector news: (+) Oncternal Therapeutics (ONCT) rose 3.1% after the company reported encouraging interim data from phase I/II testing of a combination of its cirmtuzumab monoclonal antibody with Johnson & Johnson's (JNJ) and AbbVie's (ABBV) ibrutinib cancer medication in patients with relapsed/refactory mantle cell lympoma. Top Health Care Stocks Health care stocks were falling, with the NYSE Health Care Index declining about 4.0% while the SPDR Health Care Select Sector ETF was down 3.2%. | In other sector news: (+) Oncternal Therapeutics (ONCT) rose 3.1% after the company reported encouraging interim data from phase I/II testing of a combination of its cirmtuzumab monoclonal antibody with Johnson & Johnson's (JNJ) and AbbVie's (ABBV) ibrutinib cancer medication in patients with relapsed/refactory mantle cell lympoma. Health care stocks were falling, with the NYSE Health Care Index declining about 4.0% while the SPDR Health Care Select Sector ETF was down 3.2%. Among health care stocks moving on news: (+) Seelos Therapeutics (SEEL) turned 2.2% lower this afternoon, giving back a nearly 14% gain earlier Wednesday after the company said European regulators have recommended a non-placebo controlled and open-label phase IIb/III trial of its SLS-005 drug candidate to treat pediatric Sanfilippo syndrome. | In other sector news: (+) Oncternal Therapeutics (ONCT) rose 3.1% after the company reported encouraging interim data from phase I/II testing of a combination of its cirmtuzumab monoclonal antibody with Johnson & Johnson's (JNJ) and AbbVie's (ABBV) ibrutinib cancer medication in patients with relapsed/refactory mantle cell lympoma. Top Health Care Stocks Health care stocks were falling, with the NYSE Health Care Index declining about 4.0% while the SPDR Health Care Select Sector ETF was down 3.2%. |
24665.0 | 2020-03-10 00:00:00 UTC | AbbVie to Test HIV Drug as a Potential Coronavirus Treatment | ABBV | https://www.nasdaq.com/articles/abbvie-to-test-hiv-drug-as-a-potential-coronavirus-treatment-2020-03-10 | nan | nan | As the COVID-19 epidemic continues to spread worldwide, the race to find treatments and vaccines for the disease is heating up. Among those searching for solutions is AbbVie (NYSE: ABBV), which is investigating whether its HIV drug Kaletra could be a treatment for COVID-19.
Kaletra is a combination of lopinavir and ritonavir, both of which are antiviral drugs that prevent HIV from multiplying inside a patient's body. There have been reports coming from China that Kaletra (also sold as Aluvia) has shown effectiveness as a treatment for COVID-19, but AbbVie has no access to the clinical data involved, and therefore could not assess the accuracy of those reports.
However, the company recently announced that it was partnering with health agencies worldwide to study the efficacy of Kaletra as a treatment for COVID-19, among them the U.S. Food and Drug Administration (FDA), U.S. Centers for Disease Control and Prevention (CDC), and European health authorities.
Image Source: Getty Images.
The number of confirmed cases of COVID-19 in the U.S. now exceeds 750, the worldwide total has topped 109,000, and the CDC recently warned that this disease outbreak could continue until 2021. If one of the biotech companies working to find a treatment or a vaccine for the disease were to succeed, it could profit handsomely. With that in mind, investors in the healthcare sector should continue to monitor AbbVie, Gilead Sciences (NASDAQ: GILD), Inovio Pharmaceuticals (NASDAQ: INO), and Novavax (NASDAQ: NVAX), all of which are racing to find an effective response to the novel coronavirus.
10 stocks we like better than AbbVie
When investing geniuses David and Tom Gardner have a stock tip, it can pay to listen. After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor, has tripled the market.*
David and Tom just revealed what they believe are the ten best stocks for investors to buy right now... and AbbVie wasn't one of them! That's right -- they think these 10 stocks are even better buys.
See the 10 stocks
*Stock Advisor returns as of December 1, 2019
Prosper Junior Bakiny has no position in any of the stocks mentioned. The Motley Fool owns shares of and recommends Gilead Sciences. The Motley Fool has a disclosure policy.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Among those searching for solutions is AbbVie (NYSE: ABBV), which is investigating whether its HIV drug Kaletra could be a treatment for COVID-19. There have been reports coming from China that Kaletra (also sold as Aluvia) has shown effectiveness as a treatment for COVID-19, but AbbVie has no access to the clinical data involved, and therefore could not assess the accuracy of those reports. With that in mind, investors in the healthcare sector should continue to monitor AbbVie, Gilead Sciences (NASDAQ: GILD), Inovio Pharmaceuticals (NASDAQ: INO), and Novavax (NASDAQ: NVAX), all of which are racing to find an effective response to the novel coronavirus. | With that in mind, investors in the healthcare sector should continue to monitor AbbVie, Gilead Sciences (NASDAQ: GILD), Inovio Pharmaceuticals (NASDAQ: INO), and Novavax (NASDAQ: NVAX), all of which are racing to find an effective response to the novel coronavirus. Among those searching for solutions is AbbVie (NYSE: ABBV), which is investigating whether its HIV drug Kaletra could be a treatment for COVID-19. There have been reports coming from China that Kaletra (also sold as Aluvia) has shown effectiveness as a treatment for COVID-19, but AbbVie has no access to the clinical data involved, and therefore could not assess the accuracy of those reports. | With that in mind, investors in the healthcare sector should continue to monitor AbbVie, Gilead Sciences (NASDAQ: GILD), Inovio Pharmaceuticals (NASDAQ: INO), and Novavax (NASDAQ: NVAX), all of which are racing to find an effective response to the novel coronavirus. Among those searching for solutions is AbbVie (NYSE: ABBV), which is investigating whether its HIV drug Kaletra could be a treatment for COVID-19. There have been reports coming from China that Kaletra (also sold as Aluvia) has shown effectiveness as a treatment for COVID-19, but AbbVie has no access to the clinical data involved, and therefore could not assess the accuracy of those reports. | With that in mind, investors in the healthcare sector should continue to monitor AbbVie, Gilead Sciences (NASDAQ: GILD), Inovio Pharmaceuticals (NASDAQ: INO), and Novavax (NASDAQ: NVAX), all of which are racing to find an effective response to the novel coronavirus. Among those searching for solutions is AbbVie (NYSE: ABBV), which is investigating whether its HIV drug Kaletra could be a treatment for COVID-19. There have been reports coming from China that Kaletra (also sold as Aluvia) has shown effectiveness as a treatment for COVID-19, but AbbVie has no access to the clinical data involved, and therefore could not assess the accuracy of those reports. |
24666.0 | 2020-03-10 00:00:00 UTC | Validea Peter Lynch Strategy Daily Upgrade Report - 3/10/2020 | ABBV | https://www.nasdaq.com/articles/validea-peter-lynch-strategy-daily-upgrade-report-3-10-2020-2020-03-10 | nan | nan | The following are today's upgrades for Validea's P/E/Growth Investor model based on the published strategy of Peter Lynch. This strategy looks for stocks trading at a reasonable price relative to earnings growth that also possess strong balance sheets.
CIVISTA BANCSHARES INC (CIVB) is a small-cap value stock in the Regional Banks industry. The rating according to our strategy based on Peter Lynch changed from 72% to 74% based on the firm’s underlying fundamentals and the stock’s valuation. A score of 80% or above typically indicates that the strategy has some interest in the stock and a score above 90% typically indicates strong interest.
Company Description: Civista Bancshares, Inc. is a financial holding company. The Company, through the subsidiary bank, Civista Bank, is primarily engaged in the business of community banking. Civista Bank, located in Erie, Crawford, Champaign, Cuyahoga, Franklin, Logan, Madison, Montgomery, Summit, Huron, Ottawa and Richland Counties, Ohio, conducts a general banking business that involves collecting customer deposits, making loans, purchasing securities, and offering Trust services. The Company's loan portfolio consists of commercial and agriculture, commercial real estate-owner occupied, commercial real estate non-owner occupied, residential real estate, real estate construction, consumer and other. Its securities are classified as available-for-sale (AFS) securities. Its deposits include non-interest-bearing demand deposits; interest-bearing demand deposits; savings account, including money market deposit accounts, and certificates of deposit, including individual retirement accounts (IRAs).
The following table summarizes whether the stock meets each of this strategy's tests. Not all criteria in the below table receive equal weighting or are independent, but the table provides a brief overview of the strong and weak points of the security in the context of the strategy's criteria.
YIELD ADJUSTED P/E TO GROWTH (PEG) RATIO: PASS
EARNINGS PER SHARE: PASS
TOTAL DEBT/EQUITY RATIO: NEUTRAL
EQUITY/ASSETS RATIO: PASS
RETURN ON ASSETS: PASS
For a full detailed analysis using NASDAQ's Guru Analysis tool, click here
PERFORMANCE FOOD GROUP CO (PFGC) is a mid-cap growth stock in the Food Processing industry. The rating according to our strategy based on Peter Lynch changed from 72% to 74% based on the firm’s underlying fundamentals and the stock’s valuation. A score of 80% or above typically indicates that the strategy has some interest in the stock and a score above 90% typically indicates strong interest.
Company Description: Performance Food Group Company, through its subsidiaries, markets and distributes food and food-related products. The Company operates through three segments: Performance Foodservice, PFG Customized and Vistar. The Performance Foodservice segment distributes a range of national brands, customer brands, and branded food and food-related products. It sells to independent or street, and multi-unit or chain, restaurants and other institutions. Its PFG Customized segment provides service to family and casual dining restaurant chains, and fast casual and quick service restaurant chains. Its Vistar segment specializes in distributing candy, snacks, beverages and other items nationally to the vending, office coffee service, theater, hospitality and other channels. Its products include a range of frozen foods, such as meats, fully prepared appetizers and entrees, and desserts; a range of canned and dry foods; fresh meats; dairy products; beverage products, and snack and other products.
The following table summarizes whether the stock meets each of this strategy's tests. Not all criteria in the below table receive equal weighting or are independent, but the table provides a brief overview of the strong and weak points of the security in the context of the strategy's criteria.
P/E/GROWTH RATIO: PASS
SALES AND P/E RATIO: PASS
INVENTORY TO SALES: PASS
EPS GROWTH RATE: PASS
TOTAL DEBT/EQUITY RATIO: FAIL
FREE CASH FLOW: NEUTRAL
NET CASH POSITION: NEUTRAL
For a full detailed analysis using NASDAQ's Guru Analysis tool, click here
ASSOCIATED CAPITAL GROUP INC (AC) is a small-cap growth stock in the Investment Services industry. The rating according to our strategy based on Peter Lynch changed from 0% to 74% based on the firm’s underlying fundamentals and the stock’s valuation. A score of 80% or above typically indicates that the strategy has some interest in the stock and a score above 90% typically indicates strong interest.
Company Description: Associated Capital Group, Inc. is a parent operating company for the spin-off of GAMCO Investors, Inc.'s (GAMCO's) alternative investment management business, institutional research services operations and certain cash and other assets. The Company, through its subsidiaries, provides alternative investment management services and institutional research services, as well as management of its investment portfolio. It operates through the investment advisory and asset management business segment. Gabelli & Company Investment Advisers, Inc. (GCIA) is a subsidiary of the Company. GCIA and its subsidiary, Gabelli & Partners, LLC (Gabelli & Partners), collectively serve as general partners, co-general partners or investment managers to investment funds, including limited partnerships and offshore companies (collectively, Investment Partnerships), and separate accounts. It primarily manages assets in equity event-driven value strategies, across a range of risk and event arbitrage portfolios.
The following table summarizes whether the stock meets each of this strategy's tests. Not all criteria in the below table receive equal weighting or are independent, but the table provides a brief overview of the strong and weak points of the security in the context of the strategy's criteria.
P/E/GROWTH RATIO: PASS
SALES AND P/E RATIO: NEUTRAL
EPS GROWTH RATE: FAIL
TOTAL DEBT/EQUITY RATIO: NEUTRAL
EQUITY/ASSETS RATIO: PASS
RETURN ON ASSETS: PASS
For a full detailed analysis using NASDAQ's Guru Analysis tool, click here
ASML HOLDING NV (ADR) (ASML) is a large-cap growth stock in the Misc. Capital Goods industry. The rating according to our strategy based on Peter Lynch changed from 0% to 74% based on the firm’s underlying fundamentals and the stock’s valuation. A score of 80% or above typically indicates that the strategy has some interest in the stock and a score above 90% typically indicates strong interest.
Company Description: ASML Holding N.V. is a holding company. The Company is a manufacturer of chip-making equipment. The Company is engaged in the development, production, marketing, selling and servicing of semiconductor equipment systems, consisting of lithography systems. The Company's products include systems, and installed base products and services. The Company's principal operations are in the Netherlands, the United States and Asia. The Company offers TWINSCAN systems, equipped with lithography system with a mercury lamp as light source (i-line), Krypton Fluoride (KrF) and Argon Fluoride (ArF) light sources for 300 millimeter processing wafers for manufacturing environments for which imaging at a small resolution is required. TWINSCAN systems also include immersion lithography systems (TWINSCAN immersion systems). The Company also offers NXE systems, which are equipped with extreme ultraviolet (EUV) light source technology. The Company offers YieldStar, a wafer metrology system.
The following table summarizes whether the stock meets each of this strategy's tests. Not all criteria in the below table receive equal weighting or are independent, but the table provides a brief overview of the strong and weak points of the security in the context of the strategy's criteria.
P/E/GROWTH RATIO: FAIL
SALES AND P/E RATIO: PASS
INVENTORY TO SALES: PASS
EPS GROWTH RATE: PASS
TOTAL DEBT/EQUITY RATIO: PASS
FREE CASH FLOW: NEUTRAL
NET CASH POSITION: NEUTRAL
For a full detailed analysis using NASDAQ's Guru Analysis tool, click here
ITT INC (ITT) is a mid-cap value stock in the Misc. Capital Goods industry. The rating according to our strategy based on Peter Lynch changed from 0% to 91% based on the firm’s underlying fundamentals and the stock’s valuation. A score of 80% or above typically indicates that the strategy has some interest in the stock and a score above 90% typically indicates strong interest.
Company Description: ITT Inc. is a manufacturer of engineered critical components and customized technology solutions for the energy, transportation and industrial markets. The Company operates through four segments. The Industrial Process (IP) segment is an original equipment manufacturer and service provider offering a range of industrial pumps, valves and plant optimization systems and services. The Motion Technologies (MT) segment is a manufacturer of braking pads, shims, shock absorbers, damping, and sealing technologies for the transportation industry, including passenger cars, buses, and rail transportation. The Interconnect Solutions (ICS) segment designs and manufactures engineered connectors and cable assemblies for a range of applications in a range of environments. The Control Technologies (CT) segment manufactures equipment, including actuation, fuel management, noise and energy absorption, and environmental control system components, for the aerospace and defense, and industrial markets.
The following table summarizes whether the stock meets each of this strategy's tests. Not all criteria in the below table receive equal weighting or are independent, but the table provides a brief overview of the strong and weak points of the security in the context of the strategy's criteria.
INVENTORY TO SALES: PASS
YIELD ADJUSTED P/E TO GROWTH (PEG) RATIO: PASS
EARNINGS PER SHARE: PASS
TOTAL DEBT/EQUITY RATIO: PASS
FREE CASH FLOW: NEUTRAL
NET CASH POSITION: NEUTRAL
For a full detailed analysis using NASDAQ's Guru Analysis tool, click here
ITURAN LOCATION AND CONTROL LTD. (US) (ITRN) is a small-cap value stock in the Security Systems & Services industry. The rating according to our strategy based on Peter Lynch changed from 72% to 74% based on the firm’s underlying fundamentals and the stock’s valuation. A score of 80% or above typically indicates that the strategy has some interest in the stock and a score above 90% typically indicates strong interest.
Company Description: Ituran Location and Control Ltd. is a provider of location-based services, consisting of stolen vehicle recovery (SVR), fleet management services and other tracking services. The Company also provides wireless communication products used in connection with its location-based services and various other applications. Its operations consist of two segments: location-based services and wireless communications products. Its location-based services segment consists of its SVR and tracking services, fleet management and value-added services consisted of personal locater services and concierge services. Its wireless communications products segment consists of short and medium range two-way machine-to-machine wireless communications products that are used for various applications, including automatic vehicle location (AVL) and automatic vehicle identification. It primarily provides its services, as well as sells and leases its products in Israel, Brazil, Argentina and the United States.
The following table summarizes whether the stock meets each of this strategy's tests. Not all criteria in the below table receive equal weighting or are independent, but the table provides a brief overview of the strong and weak points of the security in the context of the strategy's criteria.
YIELD ADJUSTED P/E TO GROWTH (PEG) RATIO: PASS
EARNINGS PER SHARE: PASS
TOTAL DEBT/EQUITY RATIO: PASS
FREE CASH FLOW: NEUTRAL
NET CASH POSITION: NEUTRAL
For a full detailed analysis using NASDAQ's Guru Analysis tool, click here
GLADSTONE INVESTMENT CORPORATION (GAIN) is a small-cap value stock in the Misc. Financial Services industry. The rating according to our strategy based on Peter Lynch changed from 72% to 74% based on the firm’s underlying fundamentals and the stock’s valuation. A score of 80% or above typically indicates that the strategy has some interest in the stock and a score above 90% typically indicates strong interest.
Company Description: Gladstone Investment Corporation is an externally managed, closed-end, non-diversified management investment company. The Company's investment objectives are to achieve and grow current income by investing in debt securities of established businesses that it believes will provide stable earnings and cash flow to pay expenses, make principal and interest payments on its outstanding indebtedness and make distributions to stockholders that grow over time, and provide its stockholders with long-term capital appreciation in the value of its assets by investing in equity securities, generally in combination with the aforementioned debt securities, of businesses that it believes can grow over time to permit it to sell its equity investments for capital gains. It has investments in sectors, such as chemicals, plastics, and rubber, and home and office furnishings, house wares, and durable consumer products, among others. Its investment advisor is Gladstone Management Corporation.
The following table summarizes whether the stock meets each of this strategy's tests. Not all criteria in the below table receive equal weighting or are independent, but the table provides a brief overview of the strong and weak points of the security in the context of the strategy's criteria.
YIELD ADJUSTED P/E TO GROWTH (PEG) RATIO: PASS
EARNINGS PER SHARE: PASS
TOTAL DEBT/EQUITY RATIO: NEUTRAL
EQUITY/ASSETS RATIO: PASS
RETURN ON ASSETS: PASS
FREE CASH FLOW: NEUTRAL
NET CASH POSITION: NEUTRAL
For a full detailed analysis using NASDAQ's Guru Analysis tool, click here
BLACKROCK, INC. (BLK) is a large-cap value stock in the Investment Services industry. The rating according to our strategy based on Peter Lynch changed from 0% to 91% based on the firm’s underlying fundamentals and the stock’s valuation. A score of 80% or above typically indicates that the strategy has some interest in the stock and a score above 90% typically indicates strong interest.
Company Description: BlackRock, Inc. (BlackRock) is an investment management company. BlackRock provides a range of investment and risk management services to institutional and retail clients worldwide. Its diverse platform of active (alpha) and index (beta) investment strategies across asset classes enables the Company to tailor investment outcomes and asset allocation solutions for clients. Its product offerings include single- and multi-asset portfolios investing in equities, fixed income, alternatives and money market instruments. Its products are offered directly and through intermediaries in a range of vehicles, including open-end and closed-end mutual funds, iShares exchange-traded funds (ETFs), separate accounts, collective investment funds and other pooled investment vehicles. It offers its Aladdin investment system, as well as risk management, outsourcing, advisory and technology services, to institutional investors and wealth management intermediaries under the BlackRock Solutions name.
The following table summarizes whether the stock meets each of this strategy's tests. Not all criteria in the below table receive equal weighting or are independent, but the table provides a brief overview of the strong and weak points of the security in the context of the strategy's criteria.
YIELD ADJUSTED P/E TO GROWTH (PEG) RATIO: PASS
EARNINGS PER SHARE: PASS
TOTAL DEBT/EQUITY RATIO: NEUTRAL
EQUITY/ASSETS RATIO: PASS
RETURN ON ASSETS: PASS
FREE CASH FLOW: NEUTRAL
NET CASH POSITION: NEUTRAL
For a full detailed analysis using NASDAQ's Guru Analysis tool, click here
ABERCROMBIE & FITCH CO. (ANF) is a small-cap growth stock in the Retail (Apparel) industry. The rating according to our strategy based on Peter Lynch changed from 0% to 93% based on the firm’s underlying fundamentals and the stock’s valuation. A score of 80% or above typically indicates that the strategy has some interest in the stock and a score above 90% typically indicates strong interest.
Company Description: Abercrombie & Fitch Co. is a specialty retailer who primarily sells its products through store and direct-to-consumer operations, as well as through various wholesale, franchise and licensing arrangements. The Company operates through two segments: Abercrombie, which includes the Company's Abercrombie & Fitch and abercrombie kids brands, and Hollister, which includes the Company's Hollister and Gilly Hicks brands. The Company offers an array of apparel products, including knit tops, woven shirts, graphic t-shirts, fleece, sweaters, jeans, woven pants, shorts, outerwear, dresses, intimates and swimwear, and personal care products and accessories for men, women and kids under the Abercrombie & Fitch, abercrombie kids, Hollister and Gilly Hicks brands. The Company has operations in North America, Europe, Asia and the Middle East. As of January 28, 2017, the Company operated 709 stores in the United States and 189 stores outside of the United States.
The following table summarizes whether the stock meets each of this strategy's tests. Not all criteria in the below table receive equal weighting or are independent, but the table provides a brief overview of the strong and weak points of the security in the context of the strategy's criteria.
P/E/GROWTH RATIO: PASS
SALES AND P/E RATIO: PASS
EPS GROWTH RATE: PASS
TOTAL DEBT/EQUITY RATIO: PASS
For a full detailed analysis using NASDAQ's Guru Analysis tool, click here
EATON VANCE CORP (EV) is a mid-cap value stock in the Investment Services industry. The rating according to our strategy based on Peter Lynch changed from 72% to 74% based on the firm’s underlying fundamentals and the stock’s valuation. A score of 80% or above typically indicates that the strategy has some interest in the stock and a score above 90% typically indicates strong interest.
Company Description: Eaton Vance Corp. is engaged in the business of managing investment funds and providing investment management and advisory services to high-net-worth individuals and institutions. The Company operates as an investment advisor to funds and separate accounts. The Company, through its subsidiaries and other affiliates, manages active equity, income and alternative strategies across a range of investment styles and asset classes, including the United States and global equities, floating-rate bank loans, municipal bonds, global income, high-yield and investment grade bonds. Through its subsidiary, the Company also manages a range of engineered alpha strategies, including systematic equity, systematic alternatives and managed options strategies. The Company's open-end fund lineup includes tax-managed equity funds, and non-tax-managed equity and multi-asset funds. The Company's family of closed-end funds includes municipal bond, domestic and global equity, and bank loan.
The following table summarizes whether the stock meets each of this strategy's tests. Not all criteria in the below table receive equal weighting or are independent, but the table provides a brief overview of the strong and weak points of the security in the context of the strategy's criteria.
YIELD ADJUSTED P/E TO GROWTH (PEG) RATIO: PASS
EARNINGS PER SHARE: PASS
TOTAL DEBT/EQUITY RATIO: NEUTRAL
EQUITY/ASSETS RATIO: PASS
RETURN ON ASSETS: PASS
FREE CASH FLOW: NEUTRAL
NET CASH POSITION: NEUTRAL
For a full detailed analysis using NASDAQ's Guru Analysis tool, click here
FMC CORP (FMC) is a large-cap growth stock in the Chemical Manufacturing industry. The rating according to our strategy based on Peter Lynch changed from 0% to 74% based on the firm’s underlying fundamentals and the stock’s valuation. A score of 80% or above typically indicates that the strategy has some interest in the stock and a score above 90% typically indicates strong interest.
Company Description: FMC Corporation is a diversified chemical company serving agricultural, consumer and industrial markets. The Company operates in three business segments: FMC Agricultural Solutions, FMC Health and Nutrition, and FMC Lithium. As of December 31, 2016, the FMC Agricultural Solutions segment developed, marketed and sold three classes of crop protection chemicals: insecticides, herbicides and fungicides. The Company's FMC Agricultural Solutions segment operates in the agrochemicals industry. This segment develops, manufactures and sells a portfolio of professional pest control, and lawn and garden products. The FMC Health and Nutrition segment focuses on nutritional ingredients, health excipients and functional health ingredients. The Company's FMC Health and Nutrition segment focuses on food ingredients, pharmaceutical excipients and omega-3 oils. The Company's FMC Lithium segment manufactures lithium for use in a range of lithium products.
The following table summarizes whether the stock meets each of this strategy's tests. Not all criteria in the below table receive equal weighting or are independent, but the table provides a brief overview of the strong and weak points of the security in the context of the strategy's criteria.
P/E/GROWTH RATIO: PASS
SALES AND P/E RATIO: PASS
INVENTORY TO SALES: PASS
EPS GROWTH RATE: PASS
TOTAL DEBT/EQUITY RATIO: FAIL
FREE CASH FLOW: NEUTRAL
NET CASH POSITION: NEUTRAL
For a full detailed analysis using NASDAQ's Guru Analysis tool, click here
CATERPILLAR INC. (CAT) is a large-cap value stock in the Constr. & Agric. Machinery industry. The rating according to our strategy based on Peter Lynch changed from 72% to 74% based on the firm’s underlying fundamentals and the stock’s valuation. A score of 80% or above typically indicates that the strategy has some interest in the stock and a score above 90% typically indicates strong interest.
Company Description: Caterpillar Inc. is a manufacturer of construction and mining equipment, diesel and natural gas engines, industrial gas turbines and diesel-electric locomotives. The Company operates through segments, including Construction Industries, which is engaged in supporting customers using machinery in infrastructure, forestry and building construction; Resource Industries, which is engaged in supporting customers using machinery in mining, quarry, waste and material handling applications; Energy & Transportation, which supports customers in oil and gas, power generation, marine, rail and industrial applications, including Cat machines; Financial Products segment, which provides financing and related services, and All Other operating segments, which includes activities, such as product management and development, and manufacturing of filters and fluids, undercarriage, tires and rims, ground engaging tools, fluid transfer products, and sealing and connecting components for Cat products.
The following table summarizes whether the stock meets each of this strategy's tests. Not all criteria in the below table receive equal weighting or are independent, but the table provides a brief overview of the strong and weak points of the security in the context of the strategy's criteria.
P/E/GROWTH RATIO: PASS
SALES AND P/E RATIO: PASS
INVENTORY TO SALES: PASS
EPS GROWTH RATE: PASS
TOTAL DEBT/EQUITY RATIO: FAIL
FREE CASH FLOW: NEUTRAL
NET CASH POSITION: NEUTRAL
For a full detailed analysis using NASDAQ's Guru Analysis tool, click here
FIRST FINANCIAL BANCORP (FFBC) is a small-cap value stock in the Regional Banks industry. The rating according to our strategy based on Peter Lynch changed from 72% to 74% based on the firm’s underlying fundamentals and the stock’s valuation. A score of 80% or above typically indicates that the strategy has some interest in the stock and a score above 90% typically indicates strong interest.
Company Description: First Financial Bancorp. (First Financial) is a regional bank holding company. First Financial is engaged in the business of commercial banking and other banking and banking-related activities through its subsidiary, First Financial Bank, National Association (the Bank). The range of banking services provided by First Financial to individuals and businesses includes commercial lending, real estate lending and consumer financing. First Financial offers deposit products that include interest-bearing and non-interest-bearing accounts, and cash management services for commercial customers. First Financial's Wealth Management division provides a range of trust and asset management services. It operates 159 banking centers in Ohio, Indiana and Kentucky. It operates its Commercial Finance division, responsible for its insurance lending business and franchise lending business, from a non-banking center location in Indiana.
The following table summarizes whether the stock meets each of this strategy's tests. Not all criteria in the below table receive equal weighting or are independent, but the table provides a brief overview of the strong and weak points of the security in the context of the strategy's criteria.
YIELD ADJUSTED P/E TO GROWTH (PEG) RATIO: PASS
EARNINGS PER SHARE: PASS
TOTAL DEBT/EQUITY RATIO: NEUTRAL
EQUITY/ASSETS RATIO: PASS
RETURN ON ASSETS: PASS
FREE CASH FLOW: NEUTRAL
NET CASH POSITION: NEUTRAL
For a full detailed analysis using NASDAQ's Guru Analysis tool, click here
FIRST MERCHANTS CORPORATION (FRME) is a small-cap value stock in the Regional Banks industry. The rating according to our strategy based on Peter Lynch changed from 72% to 74% based on the firm’s underlying fundamentals and the stock’s valuation. A score of 80% or above typically indicates that the strategy has some interest in the stock and a score above 90% typically indicates strong interest.
Company Description: First Merchants Corporation is a financial holding company. The Company has a bank charter, First Merchants Bank (the Bank), which is opened for business in Muncie, Indiana. It operates through community banking business segment. The Bank also operates Lafayette Bank and Trust, and First Merchants Private Wealth Advisors (each as a division of First Merchants Bank). As of July 17, 2017, the Bank included 122 banking centers in Indiana, Illinois and Ohio counties. In addition to its branch network, the Company's delivery channels include automated teller machines, check cards and Internet technology. Through the Bank, it offers a range of financial services, including accepting time deposits, savings and demand deposits; making consumer, commercial and real estate mortgage loans; renting safe deposit facilities; providing personal and corporate trust services, and providing other corporate services, letters of credit and repurchase agreements.
The following table summarizes whether the stock meets each of this strategy's tests. Not all criteria in the below table receive equal weighting or are independent, but the table provides a brief overview of the strong and weak points of the security in the context of the strategy's criteria.
YIELD ADJUSTED P/E TO GROWTH (PEG) RATIO: PASS
EARNINGS PER SHARE: PASS
TOTAL DEBT/EQUITY RATIO: NEUTRAL
EQUITY/ASSETS RATIO: PASS
RETURN ON ASSETS: PASS
FREE CASH FLOW: NEUTRAL
NET CASH POSITION: NEUTRAL
For a full detailed analysis using NASDAQ's Guru Analysis tool, click here
COLUMBUS MCKINNON CORP. (CMCO) is a small-cap value stock in the Misc. Capital Goods industry. The rating according to our strategy based on Peter Lynch changed from 72% to 74% based on the firm’s underlying fundamentals and the stock’s valuation. A score of 80% or above typically indicates that the strategy has some interest in the stock and a score above 90% typically indicates strong interest.
Company Description: Columbus McKinnon Corporation is a global designer, manufacturer and marketer of hoists, actuators, cranes, rigging tools, digital power control systems, and other material handling products serving various commercial and industrial end user markets. The Company's products include various electric, air-powered, lever, and hand hoists, hoist trolleys, winches, industrial crane systems, such as steel bridge, gantry and jib cranes and aluminum work station cranes; alloy and carbon steel chain; forged attachments, such as hooks, shackles, textile slings, clamps, logging tools and load binders; mechanical and electromechanical actuators and rotary unions; below-the-hook special purpose lifters and tire shredders; power and motion control systems, such as alternate current (AC) and direct current (DC) drive systems, radio remote controls, push button pendant stations, brakes, and collision avoidance and power delivery subsystems.
The following table summarizes whether the stock meets each of this strategy's tests. Not all criteria in the below table receive equal weighting or are independent, but the table provides a brief overview of the strong and weak points of the security in the context of the strategy's criteria.
INVENTORY TO SALES: PASS
YIELD ADJUSTED P/E TO GROWTH (PEG) RATIO: PASS
EARNINGS PER SHARE: PASS
TOTAL DEBT/EQUITY RATIO: PASS
FREE CASH FLOW: NEUTRAL
NET CASH POSITION: NEUTRAL
For a full detailed analysis using NASDAQ's Guru Analysis tool, click here
ALBEMARLE CORPORATION (ALB) is a mid-cap value stock in the Chemicals - Plastics & Rubber industry. The rating according to our strategy based on Peter Lynch changed from 0% to 91% based on the firm’s underlying fundamentals and the stock’s valuation. A score of 80% or above typically indicates that the strategy has some interest in the stock and a score above 90% typically indicates strong interest.
Company Description: Albemarle Corporation is a global developer, manufacturer and marketer of highly-engineered specialty chemicals. The Company operates through three segments: Lithium and Advanced Materials, Bromine Specialties and Refining Solutions. Lithium and Advanced Materials segment consist of two product categories: Lithium and Performance Catalyst Solutions. The bromine and bromine-based business includes products used in fire safety solutions and other specialty chemicals applications. The Company serves various end markets, including petroleum refining, consumer electronics, energy storage, construction, automotive, lubricants, pharmaceuticals, crop protection, food safety and custom chemistry services. As of December 31, 2016, the Company and its joint ventures operated 31 production and research and development (R&D) facilities, as well as a number of administrative and sales offices, around the world.
The following table summarizes whether the stock meets each of this strategy's tests. Not all criteria in the below table receive equal weighting or are independent, but the table provides a brief overview of the strong and weak points of the security in the context of the strategy's criteria.
INVENTORY TO SALES: PASS
YIELD ADJUSTED P/E TO GROWTH (PEG) RATIO: PASS
EARNINGS PER SHARE: PASS
TOTAL DEBT/EQUITY RATIO: PASS
FREE CASH FLOW: NEUTRAL
NET CASH POSITION: NEUTRAL
For a full detailed analysis using NASDAQ's Guru Analysis tool, click here
AMERICAN NATIONAL INSURANCE COMPANY (ANAT) is a mid-cap value stock in the Insurance (Prop. & Casualty) industry. The rating according to our strategy based on Peter Lynch changed from 0% to 93% based on the firm’s underlying fundamentals and the stock’s valuation. A score of 80% or above typically indicates that the strategy has some interest in the stock and a score above 90% typically indicates strong interest.
Company Description: American National Insurance Company is engaged in life insurance, annuities, and property and casualty insurance. The Company also offers limited health insurance. Its family of companies includes six life insurance companies, eight property and casualty insurance companies, and various non-insurance subsidiaries. Its business segments include Life, which offers products, such as Whole Life, Term Life, Universal Life, Variable Universal Life and Credit Life Insurance; Annuity, including products, such as Deferred Annuity, Single Premium Immediate Annuity and Variable Annuity; Health, including, such as Medicare Supplement, Supplemental Insurance, Stop-Loss, Credit Disability and Medical Expense; Property and Casualty, which offers products, such as Personal Lines, Commercial Lines and Credit-Related Property Insurance products, and Corporate and Other, which consists of its invested assets that are not used to support insurance activities, and non-insurance subsidiaries.
The following table summarizes whether the stock meets each of this strategy's tests. Not all criteria in the below table receive equal weighting or are independent, but the table provides a brief overview of the strong and weak points of the security in the context of the strategy's criteria.
P/E/GROWTH RATIO: PASS
SALES AND P/E RATIO: PASS
EPS GROWTH RATE: PASS
TOTAL DEBT/EQUITY RATIO: NEUTRAL
EQUITY/ASSETS RATIO: PASS
RETURN ON ASSETS: PASS
FREE CASH FLOW: NEUTRAL
NET CASH POSITION: NEUTRAL
For a full detailed analysis using NASDAQ's Guru Analysis tool, click here
BANCFIRST CORPORATION (BANF) is a small-cap value stock in the Regional Banks industry. The rating according to our strategy based on Peter Lynch changed from 72% to 74% based on the firm’s underlying fundamentals and the stock’s valuation. A score of 80% or above typically indicates that the strategy has some interest in the stock and a score above 90% typically indicates strong interest.
Company Description: BancFirst Corporation is a financial holding company. The Company conducts its operating activities through its principal subsidiary, BancFirst (the Bank), a state-chartered bank. It has four business units, which include metropolitan banks, community banks, other financial services, and executive, operations and support. The metropolitan and community banks offer traditional banking products, such as commercial and retail lending, and a line of deposit accounts. The metropolitan banks consist of banking locations in the metropolitan Oklahoma City and Tulsa areas. The community banks consist of banking locations in communities throughout Oklahoma. Its other financial services are specialty product business units, including guaranteed small business lending, residential mortgage lending, trust services, securities brokerage, electronic banking and insurance. The executive, operations and support groups represent executive management, operational support and corporate functions.
The following table summarizes whether the stock meets each of this strategy's tests. Not all criteria in the below table receive equal weighting or are independent, but the table provides a brief overview of the strong and weak points of the security in the context of the strategy's criteria.
YIELD ADJUSTED P/E TO GROWTH (PEG) RATIO: PASS
EARNINGS PER SHARE: PASS
TOTAL DEBT/EQUITY RATIO: NEUTRAL
EQUITY/ASSETS RATIO: PASS
RETURN ON ASSETS: PASS
FREE CASH FLOW: NEUTRAL
NET CASH POSITION: NEUTRAL
For a full detailed analysis using NASDAQ's Guru Analysis tool, click here
BRINKER INTERNATIONAL, INC. (EAT) is a small-cap value stock in the Restaurants industry. The rating according to our strategy based on Peter Lynch changed from 72% to 74% based on the firm’s underlying fundamentals and the stock’s valuation. A score of 80% or above typically indicates that the strategy has some interest in the stock and a score above 90% typically indicates strong interest.
Company Description: Brinker International, Inc. is engaged in the ownership, operation, development, and franchising of the Chili's Grill & Bar (Chili's) and Maggiano's Little Italy (Maggiano's) restaurant brands. The Company's Chili's operates Bar & Grill category of casual dining. Chili's menu features authentic Fresh Mex and Fresh Tex cuisine, including signature items, such as Baby Back Ribs smoked in-house, Hand-Crafted Burgers served with house-made garlic dill pickles, Mix and Match Fajitas, Tableside Guacamole and house-made Chips and Salsa. Maggiano's is a full-service, casual dining Italian restaurant brand. Its Maggiano's restaurants feature individual and family-style menus, and its restaurants also has banquet facilities designed to host party business or social events. The Company owns, operates or franchises restaurants, which include approximately 1,650 restaurants in the United States, over 30 countries and approximately two territories outside of the United States.
The following table summarizes whether the stock meets each of this strategy's tests. Not all criteria in the below table receive equal weighting or are independent, but the table provides a brief overview of the strong and weak points of the security in the context of the strategy's criteria.
SALES: PASS
YIELD COMPARED TO THE S&P 500: PASS
YIELD ADJUSTED P/E/GROWTH (PEG) RATIO: PASS
TOTAL DEBT/EQUITY RATIO: FAIL
FREE CASH FLOW: NEUTRAL
NET CASH POSITION: NEUTRAL
For a full detailed analysis using NASDAQ's Guru Analysis tool, click here
BRYN MAWR BANK CORP. (BMTC) is a small-cap value stock in the Regional Banks industry. The rating according to our strategy based on Peter Lynch changed from 72% to 74% based on the firm’s underlying fundamentals and the stock’s valuation. A score of 80% or above typically indicates that the strategy has some interest in the stock and a score above 90% typically indicates strong interest.
Company Description: Bryn Mawr Bank Corporation is the bank holding company of the Bryn Mawr Trust Company (the Bank). The Company and its subsidiaries offer a range of personal and business banking services, consumer and commercial loans, equipment leasing, mortgages, insurance and wealth management services, including investment management, trust and estate administration, retirement planning, custody services, and tax planning and preparation from various location across Montgomery, Delaware, Chester, Philadelphia and Dauphin counties of Pennsylvania, and New Castle county in Delaware. The Company's segments include Banking and Wealth Management. The Banking segment consists of commercial and retail banking. The Wealth Management segment's activities include trust administration, other related fiduciary services, custody, investment management and advisory services, employee benefits and individual retirement accounts (IRA) administration, estate settlement, tax services and brokerage.
The following table summarizes whether the stock meets each of this strategy's tests. Not all criteria in the below table receive equal weighting or are independent, but the table provides a brief overview of the strong and weak points of the security in the context of the strategy's criteria.
YIELD ADJUSTED P/E TO GROWTH (PEG) RATIO: PASS
EARNINGS PER SHARE: PASS
TOTAL DEBT/EQUITY RATIO: NEUTRAL
EQUITY/ASSETS RATIO: PASS
RETURN ON ASSETS: PASS
FREE CASH FLOW: NEUTRAL
NET CASH POSITION: NEUTRAL
For a full detailed analysis using NASDAQ's Guru Analysis tool, click here
ICU MEDICAL, INCORPORATED (ICUI) is a mid-cap growth stock in the Medical Equipment & Supplies industry. The rating according to our strategy based on Peter Lynch changed from 56% to 74% based on the firm’s underlying fundamentals and the stock’s valuation. A score of 80% or above typically indicates that the strategy has some interest in the stock and a score above 90% typically indicates strong interest.
Company Description: ICU Medical, Inc. is engaged in the development, manufacture and sales of medical devices used in infusion therapy, oncology and critical care applications. The Company's product line includes needlefree connection devices, custom infusion sets, closed system transfer devices (CSTD) for the handling of hazardous drugs, advanced sensor catheters, needlefree closed blood sampling systems, disposable pressure transducer systems and hemodynamic monitoring systems. The primary critical care products it manufactures are Hemodynamic Monitoring Systems, SafeSet Closed Blood Sampling and Conservation System, Transpac Consumable Blood Pressure Transducers and Other Critical Care Products. The primary oncology products it manufactures are ChemoLock Needlefree CSTD, ChemoClave Needlefree CSTD and Diana Hazardous Drug Compounding System. As of December 31, 2016, its products were used in acute care hospitals and ambulatory clinics in more than 65 countries throughout the world.
The following table summarizes whether the stock meets each of this strategy's tests. Not all criteria in the below table receive equal weighting or are independent, but the table provides a brief overview of the strong and weak points of the security in the context of the strategy's criteria.
P/E/GROWTH RATIO: FAIL
SALES AND P/E RATIO: PASS
INVENTORY TO SALES: PASS
EPS GROWTH RATE: PASS
TOTAL DEBT/EQUITY RATIO: PASS
FREE CASH FLOW: NEUTRAL
NET CASH POSITION: NEUTRAL
For a full detailed analysis using NASDAQ's Guru Analysis tool, click here
IMPERIAL OIL LTD (USA) (IMO) is a large-cap value stock in the Oil & Gas Operations industry. The rating according to our strategy based on Peter Lynch changed from 0% to 91% based on the firm’s underlying fundamentals and the stock’s valuation. A score of 80% or above typically indicates that the strategy has some interest in the stock and a score above 90% typically indicates strong interest.
Company Description: Imperial Oil Limited is an integrated oil company. The Company is engaged in all the phases of the petroleum industry in Canada, including exploration for, and production and sale of, crude oil and natural gas. Its operations are conducted in three segments: Upstream, Downstream and Chemical. Upstream operations include the exploration for, and production of, crude oil, natural gas, synthetic oil and bitumen. Downstream operations consist of the transportation and refining of crude oil, blending of refined products and the distribution and marketing of those products. Chemical operations consist of the manufacturing and marketing of various petrochemicals. The Company owns and operates approximately three refineries, which process predominantly Canadian crude oil. The Company markets petroleum products throughout Canada under its brand names, including Esso and Mobil, to all types of customers.
The following table summarizes whether the stock meets each of this strategy's tests. Not all criteria in the below table receive equal weighting or are independent, but the table provides a brief overview of the strong and weak points of the security in the context of the strategy's criteria.
SALES: PASS
INVENTORY TO SALES: PASS
YIELD COMPARED TO THE S&P 500: PASS
YIELD ADJUSTED P/E/GROWTH (PEG) RATIO: PASS
TOTAL DEBT/EQUITY RATIO: PASS
FREE CASH FLOW: NEUTRAL
NET CASH POSITION: NEUTRAL
For a full detailed analysis using NASDAQ's Guru Analysis tool, click here
FINANCIAL INSTITUTIONS, INC. (FISI) is a small-cap value stock in the Regional Banks industry. The rating according to our strategy based on Peter Lynch changed from 72% to 74% based on the firm’s underlying fundamentals and the stock’s valuation. A score of 80% or above typically indicates that the strategy has some interest in the stock and a score above 90% typically indicates strong interest.
Company Description: Financial Institutions, Inc. is a financial holding company. The Company conducts its business through its subsidiaries: Five Star Bank (the Bank), a New York chartered bank; Scott Danahy Naylon, LLC (SDN), a full service insurance agency, and Courier Capital, LLC (Courier Capital), an investment advisory and wealth management company. The Company operates through two segments: Banking and Non-Banking. The Banking segment includes all of the Company's retail and commercial banking operations. The Non-Banking segment includes the activities of SDN and Courier Capital. The Company offers a range of banking and related financial services to consumer, commercial and municipal customers through its bank and nonbank subsidiaries. The Company's indirect lending network includes relationships with franchised automobile dealers in Western and Central New York, the Capital District of New York and Northern and Central Pennsylvania.
The following table summarizes whether the stock meets each of this strategy's tests. Not all criteria in the below table receive equal weighting or are independent, but the table provides a brief overview of the strong and weak points of the security in the context of the strategy's criteria.
SALES: FAIL
YIELD COMPARED TO THE S&P 500: PASS
YIELD ADJUSTED P/E/GROWTH (PEG) RATIO: PASS
TOTAL DEBT/EQUITY RATIO: NEUTRAL
EQUITY/ASSETS RATIO: PASS
RETURN ON ASSETS: PASS
FREE CASH FLOW: NEUTRAL
NET CASH POSITION: NEUTRAL
For a full detailed analysis using NASDAQ's Guru Analysis tool, click here
EAGLE BANCORP, INC. (EGBN) is a small-cap value stock in the Regional Banks industry. The rating according to our strategy based on Peter Lynch changed from 72% to 74% based on the firm’s underlying fundamentals and the stock’s valuation. A score of 80% or above typically indicates that the strategy has some interest in the stock and a score above 90% typically indicates strong interest.
Company Description: Eagle Bancorp, Inc. is a bank holding company for EagleBank (the Bank). The Bank is the Company's principal operating subsidiary. The Bank is a chartered commercial bank. As of December 31, 2016, the Bank operated 21 banking offices: seven in Montgomery County, Maryland; five located in the District of Columbia, and nine in Northern Virginia. The Bank offers a range of commercial banking services to its business and professional clients, as well as consumer banking services to individuals living or working in the service area. The Bank also provides commercial banking services to proprietorships, businesses, partnerships, corporations, non-profit organizations and associations, and investors living and working in and near the Bank's primary service area. The Bank offers a range of retail banking services to accommodate the individual needs of both corporate customers, as well as the community the Bank serves. It also offers online banking, mobile banking and remote deposit services.
The following table summarizes whether the stock meets each of this strategy's tests. Not all criteria in the below table receive equal weighting or are independent, but the table provides a brief overview of the strong and weak points of the security in the context of the strategy's criteria.
YIELD ADJUSTED P/E TO GROWTH (PEG) RATIO: PASS
EARNINGS PER SHARE: PASS
TOTAL DEBT/EQUITY RATIO: NEUTRAL
EQUITY/ASSETS RATIO: PASS
RETURN ON ASSETS: PASS
FREE CASH FLOW: NEUTRAL
NET CASH POSITION: NEUTRAL
For a full detailed analysis using NASDAQ's Guru Analysis tool, click here
MARVELL TECHNOLOGY GROUP LTD. (MRVL) is a large-cap value stock in the Semiconductors industry. The rating according to our strategy based on Peter Lynch changed from 0% to 74% based on the firm’s underlying fundamentals and the stock’s valuation. A score of 80% or above typically indicates that the strategy has some interest in the stock and a score above 90% typically indicates strong interest.
Company Description: Marvell Technology Group Ltd. is a semiconductor provider of application-specific standard products. The Company is engaged in the design, development and sale of integrated circuits. The Company develops System-on-a-Chip (SoC) devices. It also develops integrated hardware platforms along with software that incorporates digital computing technologies designed and configured to provide an optimized computing solution. Its product portfolio includes devices for storage, networking and connectivity. In storage, it is engaged in data storage controller solutions spanning consumer, mobile, desktop and enterprise markets. Its storage solutions enable customers to engineer products for hard disk drives and solid state drives. Its networking products address end markets in cloud, enterprise, small and medium business and service provider networks. It offers a complete spectrum of semiconductor solutions spanning fifth generation (5G), data center, enterprise and automotive applications
The following table summarizes whether the stock meets each of this strategy's tests. Not all criteria in the below table receive equal weighting or are independent, but the table provides a brief overview of the strong and weak points of the security in the context of the strategy's criteria.
P/E/GROWTH RATIO: PASS
SALES AND P/E RATIO: PASS
INVENTORY TO SALES: PASS
EPS GROWTH RATE: FAIL
TOTAL DEBT/EQUITY RATIO: PASS
FREE CASH FLOW: NEUTRAL
NET CASH POSITION: NEUTRAL
For a full detailed analysis using NASDAQ's Guru Analysis tool, click here
FIRST COMMUNITY BANKSHARES INC (FCBC) is a small-cap value stock in the Regional Banks industry. The rating according to our strategy based on Peter Lynch changed from 72% to 74% based on the firm’s underlying fundamentals and the stock’s valuation. A score of 80% or above typically indicates that the strategy has some interest in the stock and a score above 90% typically indicates strong interest.
Company Description: First Community Bankshares, Inc. is a financial holding company. The Company provides commercial banking products and services through its subsidiary First Community Bank (the Bank). The Bank operates as First Community Bank in Virginia, West Virginia, and North Carolina and People's Community Bank, a Division of First Community Bank, in Tennessee. It provides insurance services through its subsidiary First Community Insurance Services, and offers wealth management andinvestment advicethrough its Trust Division and subsidiary First Community Wealth Management. Its products include demand deposit accounts, savings and money market accounts, certificates of deposit, and individual retirement arrangements; commercial, consumer, and real estate mortgage loans and lines of credit; various credit card, debit card, and automated teller machine card services; corporate and personal trust services; investment management services, and life, health, and property and casualty insurance products.
The following table summarizes whether the stock meets each of this strategy's tests. Not all criteria in the below table receive equal weighting or are independent, but the table provides a brief overview of the strong and weak points of the security in the context of the strategy's criteria.
YIELD ADJUSTED P/E TO GROWTH (PEG) RATIO: PASS
EARNINGS PER SHARE: PASS
TOTAL DEBT/EQUITY RATIO: NEUTRAL
EQUITY/ASSETS RATIO: PASS
RETURN ON ASSETS: PASS
For a full detailed analysis using NASDAQ's Guru Analysis tool, click here
SONIC AUTOMOTIVE INC (SAH) is a small-cap value stock in the Retail (Specialty) industry. The rating according to our strategy based on Peter Lynch changed from 72% to 74% based on the firm’s underlying fundamentals and the stock’s valuation. A score of 80% or above typically indicates that the strategy has some interest in the stock and a score above 90% typically indicates strong interest.
Company Description: Sonic Automotive, Inc. is an automotive retailer in the United States. The Company's operating segments include Franchised Dealerships and EchoPark. Its Franchised Dealerships segment consists of retail automotive franchises that sell new vehicles and buy and sell used vehicles, sell replacement parts, perform vehicle repair and maintenance services, and arrange finance and insurance products. The EchoPark segment consists of standalone specialty retail locations that provide customers an opportunity to search, buy, service, finance and sell pre-owned vehicles. Its franchised dealerships provide services, including sales of both new and used cars, and light trucks; sales of replacement parts and performance of vehicle maintenance, manufacturer warranty repairs, and paint and collision repair services (collectively, Fixed Operations), and arrangement of extended warranties, service contracts, financing, insurance and other aftermarket products (collectively, F&I) for its customers.
The following table summarizes whether the stock meets each of this strategy's tests. Not all criteria in the below table receive equal weighting or are independent, but the table provides a brief overview of the strong and weak points of the security in the context of the strategy's criteria.
YIELD ADJUSTED P/E TO GROWTH (PEG) RATIO: PASS
EARNINGS PER SHARE: PASS
TOTAL DEBT/EQUITY RATIO: FAIL
FREE CASH FLOW: NEUTRAL
NET CASH POSITION: NEUTRAL
For a full detailed analysis using NASDAQ's Guru Analysis tool, click here
FEDERATED HERMES INC (FHI) is a mid-cap value stock in the Investment Services industry. The rating according to our strategy based on Peter Lynch changed from 72% to 74% based on the firm’s underlying fundamentals and the stock’s valuation. A score of 80% or above typically indicates that the strategy has some interest in the stock and a score above 90% typically indicates strong interest.
Company Description: Federated Hermes, Inc. (Federated), formerly Federated Investors, Inc., is a provider of investment management products and related financial services. Federated operates through investment management business segment. It is engaged in sponsoring, marketing and providing investment-related services to various investment products, including mutual funds and Separate Accounts, which include separately managed accounts, institutional accounts, sub-advised funds and other managed products. It operates in one segment, the investment management business. Federated provides investment advisory services to sponsored investment companies and other funds (Federated Funds). It markets these funds to banks, brokers and dealers and other financial intermediaries using them to meet the needs of their customers and clients, including retail investors, corporations and retirement plans. The Company offers a range of products and strategies, including money market, equity and fixed-income investments.
The following table summarizes whether the stock meets each of this strategy's tests. Not all criteria in the below table receive equal weighting or are independent, but the table provides a brief overview of the strong and weak points of the security in the context of the strategy's criteria.
YIELD ADJUSTED P/E TO GROWTH (PEG) RATIO: PASS
EARNINGS PER SHARE: PASS
TOTAL DEBT/EQUITY RATIO: NEUTRAL
EQUITY/ASSETS RATIO: PASS
RETURN ON ASSETS: PASS
FREE CASH FLOW: NEUTRAL
NET CASH POSITION: NEUTRAL
For a full detailed analysis using NASDAQ's Guru Analysis tool, click here
HERITAGE COMMERCE CORP. (HTBK) is a small-cap value stock in the Regional Banks industry. The rating according to our strategy based on Peter Lynch changed from 72% to 74% based on the firm’s underlying fundamentals and the stock’s valuation. A score of 80% or above typically indicates that the strategy has some interest in the stock and a score above 90% typically indicates strong interest.
Company Description: Heritage Commerce Corp is a bank holding company. The Company, through its subsidiary Heritage Bank of Commerce (the Bank), provides a range of banking services. The Bank is a California state-chartered multi-community independent bank that offers a range of commercial banking services to small and medium-sized businesses and their owners, managers and employees. The Company operates through approximately 19 service branch offices located in the southern and eastern regions of the general San Francisco Bay Area of California in the counties of Santa Clara, Alameda, Contra Costa and San Benito. The Company's subsidiary, CSNK Working Capital Finance Corp., doing business as Bay View Funding, provides business-essential working capital factoring financing to various industries across the United States. The Bank operates automated teller machines (ATMs) at approximately five different locations.
The following table summarizes whether the stock meets each of this strategy's tests. Not all criteria in the below table receive equal weighting or are independent, but the table provides a brief overview of the strong and weak points of the security in the context of the strategy's criteria.
YIELD ADJUSTED P/E TO GROWTH (PEG) RATIO: PASS
EARNINGS PER SHARE: PASS
TOTAL DEBT/EQUITY RATIO: NEUTRAL
EQUITY/ASSETS RATIO: PASS
RETURN ON ASSETS: PASS
For a full detailed analysis using NASDAQ's Guru Analysis tool, click here
SAPPI LIMITED (ADR) (SPPJY) is a small-cap value stock in the Paper & Paper Products industry. The rating according to our strategy based on Peter Lynch changed from 72% to 74% based on the firm’s underlying fundamentals and the stock’s valuation. A score of 80% or above typically indicates that the strategy has some interest in the stock and a score above 90% typically indicates strong interest.
Company Description: Sappi Limited is a woodfiber company focused on providing graphic/printing papers, packaging and specialty papers, dissolving wood pulp (DWP), as well as products in adjacent fields, including nanocellulose and lignosulfonate. The Company's segments include North America, Europe and Southern Africa. Its range of graphic paper products is used by printers in the production of books, brochures, magazines, catalogues, direct mail and various other print applications; packaging and specialty papers are used in the manufacture of such products as soup sachets, carry bags, cosmetic and confectionery packaging, boxes for agricultural products for export, tissue wadding for household tissue products and casting release papers used by suppliers to the fashion, textiles, automobile and household industries, and DWP products are used around the world by converters to create viscose fiber for clothing and textiles, pharmaceutical products, as well as a range of consumer and household products.
The following table summarizes whether the stock meets each of this strategy's tests. Not all criteria in the below table receive equal weighting or are independent, but the table provides a brief overview of the strong and weak points of the security in the context of the strategy's criteria.
SALES: PASS
INVENTORY TO SALES: PASS
YIELD COMPARED TO THE S&P 500: PASS
YIELD ADJUSTED P/E/GROWTH (PEG) RATIO: PASS
TOTAL DEBT/EQUITY RATIO: FAIL
FREE CASH FLOW: NEUTRAL
NET CASH POSITION: NEUTRAL
For a full detailed analysis using NASDAQ's Guru Analysis tool, click here
BANCOLOMBIA SA (ADR) (CIB) is a mid-cap value stock in the Regional Banks industry. The rating according to our strategy based on Peter Lynch changed from 72% to 91% based on the firm’s underlying fundamentals and the stock’s valuation. A score of 80% or above typically indicates that the strategy has some interest in the stock and a score above 90% typically indicates strong interest.
Company Description: Bancolombia S.A. (Bancolombia) is a financial institution engaged in providing a range of financial products and services to a diversified individual, corporate, and government customer base throughout Colombia, Latin America and the Caribbean region. The Bank operates through 10 segments: Banking Colombia, Banking Panama, Banking El Salvador, Leasing, Trust, Investment Banking, Brokerage, Off Shore and All other. It delivers its products and services through its regional network comprising Colombia's non-Government owned banking network, El Salvador's financial conglomerate by gross loans, Guatemala's bank, Panama's bank and off-shore banking subsidiaries in Panama, Cayman and Puerto Rico, as well as subsidiaries in Peru. The Bank and its subsidiaries offer Savings And Investment, Ahorro A La Mano, Financing, Mortgage Banking, Factoring, Financial and Operating Leases, Capital Markets, eTrading, Cash Management, Foreign Currency, Bancassurance, Investment Banking and Trust Services.
The following table summarizes whether the stock meets each of this strategy's tests. Not all criteria in the below table receive equal weighting or are independent, but the table provides a brief overview of the strong and weak points of the security in the context of the strategy's criteria.
SALES: PASS
YIELD COMPARED TO THE S&P 500: PASS
YIELD ADJUSTED P/E/GROWTH (PEG) RATIO: PASS
TOTAL DEBT/EQUITY RATIO: NEUTRAL
EQUITY/ASSETS RATIO: PASS
RETURN ON ASSETS: PASS
FREE CASH FLOW: NEUTRAL
NET CASH POSITION: NEUTRAL
For a full detailed analysis using NASDAQ's Guru Analysis tool, click here
MOOG INC (MOG.A) is a mid-cap value stock in the Aerospace & Defense industry. The rating according to our strategy based on Peter Lynch changed from 0% to 91% based on the firm’s underlying fundamentals and the stock’s valuation. A score of 80% or above typically indicates that the strategy has some interest in the stock and a score above 90% typically indicates strong interest.
Company Description: Moog Inc. is a designer, manufacturer and integrator of precision motion and fluid controls and systems for a range of applications in aerospace and defense and industrial markets. The Company has five segments: Aircraft Controls, Space and Defense Controls, Industrial Systems, Components and Medical Devices. Its Aircraft Controls segment designs, manufactures and integrates primary and secondary flight controls for military and commercial aircraft, and provides aftermarket support. Its Space and Defense Controls segment provides controls for satellites, space vehicles, launch vehicles, armored combat vehicles, tactical and strategic missiles, security and surveillance and other defense applications. Its Industrial Systems segment serves a global customer base across various markets. Its Components segment offers slip rings, fiber optic rotary joints, motors, sensors and handpieces product line. Its Medical Devices segment focuses on infusion therapy and enteral clinical nutrition.
The following table summarizes whether the stock meets each of this strategy's tests. Not all criteria in the below table receive equal weighting or are independent, but the table provides a brief overview of the strong and weak points of the security in the context of the strategy's criteria.
INVENTORY TO SALES: PASS
YIELD ADJUSTED P/E TO GROWTH (PEG) RATIO: PASS
EARNINGS PER SHARE: PASS
TOTAL DEBT/EQUITY RATIO: PASS
FREE CASH FLOW: NEUTRAL
NET CASH POSITION: NEUTRAL
For a full detailed analysis using NASDAQ's Guru Analysis tool, click here
PREMIER FINANCIAL BANCORP, INC. (PFBI) is a small-cap value stock in the Regional Banks industry. The rating according to our strategy based on Peter Lynch changed from 72% to 74% based on the firm’s underlying fundamentals and the stock’s valuation. A score of 80% or above typically indicates that the strategy has some interest in the stock and a score above 90% typically indicates strong interest.
Company Description: Premier Financial Bancorp, Inc. (Premier) is a multi-bank holding company. The Company's banking subsidiaries (the Banks or Affiliate Banks) consist of Citizens Deposit Bank and Trust, Inc., Vanceburg, Kentucky and Premier Bank, Inc., Huntington, West Virginia. Through the Banks, the Company focuses on providing community banking services to individuals and small-to-medium sized businesses. The Banks provide a range of retail and commercial banking services, including commercial, real estate, agricultural and consumer lending; depository and funds transfer services; collections; safe deposit boxes; cash management services; and other services tailored for both individuals and businesses. The Company operates over nine banking offices in Kentucky, approximately five banking offices in Ohio, over 30 banking offices in West Virginia, approximately four banking offices in Washington, DC, over one banking offices in Maryland and approximately four banking offices in Virginia.
The following table summarizes whether the stock meets each of this strategy's tests. Not all criteria in the below table receive equal weighting or are independent, but the table provides a brief overview of the strong and weak points of the security in the context of the strategy's criteria.
YIELD ADJUSTED P/E TO GROWTH (PEG) RATIO: PASS
EARNINGS PER SHARE: PASS
TOTAL DEBT/EQUITY RATIO: NEUTRAL
EQUITY/ASSETS RATIO: PASS
RETURN ON ASSETS: PASS
For a full detailed analysis using NASDAQ's Guru Analysis tool, click here
TRI-CONTINENTAL CORPORATION (TY) is a small-cap value stock in the Misc. Financial Services industry. The rating according to our strategy based on Peter Lynch changed from 0% to 93% based on the firm’s underlying fundamentals and the stock’s valuation. A score of 80% or above typically indicates that the strategy has some interest in the stock and a score above 90% typically indicates strong interest.
Company Description: Tri-Continental Corporation (the Fund) is a diversified, closed-end management investment company. The Fund's objective is to produce future growth of both capital and income while providing reasonable current incomes. The Fund's permissible investments include preferred and common stocks, convertible securities, including convertible preferred stocks and convertible bonds, debt securities, repurchase agreements, derivatives, including options, futures contracts and equity-linked notes, illiquid securities and securities of foreign issuers, including emerging markets issuers. The Fund invests in a range of sectors, which include consumer discretionary, consumer staples, energy, financials, healthcare, industrials, information technology, materials, real estate, telecommunication services and utilities. Columbia Management Investment Advisers, LLC is the Fund's investment manager.
The following table summarizes whether the stock meets each of this strategy's tests. Not all criteria in the below table receive equal weighting or are independent, but the table provides a brief overview of the strong and weak points of the security in the context of the strategy's criteria.
P/E/GROWTH RATIO: PASS
SALES AND P/E RATIO: NEUTRAL
EPS GROWTH RATE: PASS
TOTAL DEBT/EQUITY RATIO: NEUTRAL
EQUITY/ASSETS RATIO: PASS
RETURN ON ASSETS: PASS
FREE CASH FLOW: NEUTRAL
NET CASH POSITION: NEUTRAL
For a full detailed analysis using NASDAQ's Guru Analysis tool, click here
NU SKIN ENTERPRISES, INC. (NUS) is a small-cap value stock in the Personal & Household Prods. industry. The rating according to our strategy based on Peter Lynch changed from 0% to 91% based on the firm’s underlying fundamentals and the stock’s valuation. A score of 80% or above typically indicates that the strategy has some interest in the stock and a score above 90% typically indicates strong interest.
Company Description: Nu Skin Enterprises, Inc. is a direct selling company that develops and distributes personal care products and nutritional supplements, and a range of other products and services. The Company offers anti-aging personal care products and nutritional supplements under its Nu Skin and Pharmanex brands. The Nu Skin brand offers a range of products, including ageLOC Me customized skin care system, ageLOC Spa systems and ageLOC Transformation anti-aging skin care system. The Pharmanex product line includes ageLOC Youth nutritional supplement, ageLOC TR90 weight management and body shaping system, and LifePak nutritional supplements. The Company has operations in various geographic regions, including Greater China, North Asia, Americas, South Asia/Pacific, and Europe, the Middle East and Africa (EMEA). It is focused on offering ageLOC Youth nutritional supplement and ageLOC Me personalized skin care system. The Company also offers household products and technology services.
The following table summarizes whether the stock meets each of this strategy's tests. Not all criteria in the below table receive equal weighting or are independent, but the table provides a brief overview of the strong and weak points of the security in the context of the strategy's criteria.
SALES: PASS
INVENTORY TO SALES: PASS
YIELD COMPARED TO THE S&P 500: PASS
YIELD ADJUSTED P/E/GROWTH (PEG) RATIO: PASS
TOTAL DEBT/EQUITY RATIO: PASS
FREE CASH FLOW: NEUTRAL
NET CASH POSITION: NEUTRAL
For a full detailed analysis using NASDAQ's Guru Analysis tool, click here
MARTIN MARIETTA MATERIALS, INC. (MLM) is a large-cap growth stock in the Construction - Raw Materials industry. The rating according to our strategy based on Peter Lynch changed from 87% to 91% based on the firm’s underlying fundamentals and the stock’s valuation. A score of 80% or above typically indicates that the strategy has some interest in the stock and a score above 90% typically indicates strong interest.
Company Description: Martin Marietta Materials, Inc. is a supplier of aggregates products (crushed stone, sand, and gravel) used for the construction of infrastructure, nonresidential, and residential projects. Aggregates products are also used for railroad ballast and in agricultural, utility and environmental applications. The Company's Aggregates business operates through three segments: the Mid-America Group, Southeast Group and West Group. The Company's business is categorized into Aggregates Business, Cement Business and Magnesia Specialties Business. Its Cement business is reported through the Cement segment. Its Magnesia Specialties business manufactures and markets magnesia-based chemical products used in industrial, agricultural, and environmental applications, and dolomitic lime sold to customers in the steel industry. Its Cement business produces Portland and specialty cements. It manufactures and markets, through its Magnesia Specialties business, magnesia-based chemical products.
The following table summarizes whether the stock meets each of this strategy's tests. Not all criteria in the below table receive equal weighting or are independent, but the table provides a brief overview of the strong and weak points of the security in the context of the strategy's criteria.
P/E/GROWTH RATIO: PASS
SALES AND P/E RATIO: PASS
INVENTORY TO SALES: PASS
EPS GROWTH RATE: PASS
TOTAL DEBT/EQUITY RATIO: PASS
FREE CASH FLOW: NEUTRAL
NET CASH POSITION: NEUTRAL
For a full detailed analysis using NASDAQ's Guru Analysis tool, click here
MOVADO GROUP, INC (MOV) is a small-cap value stock in the Jewelry & Silverware industry. The rating according to our strategy based on Peter Lynch changed from 0% to 80% based on the firm’s underlying fundamentals and the stock’s valuation. A score of 80% or above typically indicates that the strategy has some interest in the stock and a score above 90% typically indicates strong interest.
Company Description: Movado Group, Inc. designs, sources, markets and distributes watches. The Company operates through two segments: Wholesale and Retail. The Wholesale segment includes the design, development, sourcing, marketing and distribution of watches, and after-sales service activities and shipping. It sells all of its brands to jewelry store chains and department stores, as well as independent jewelers. The Retail segment includes its outlet stores. As of January 31, 2017, its subsidiary, Movado Retail Group, Inc., operated 40 outlet stores located in outlet centers across the United States. It divides its business into two geographic locations: the United States operations and International operations. It has international operations in Europe, the Americas, the Middle East and Asia. Its portfolio of brands includes Coach Watches, Concord, Ebel, ESQ Movado, Scuderia Ferrari Watches, HUGO BOSS Watches, Juicy Couture Watches, Lacoste Watches, Movado and Tommy Hilfiger Watches.
The following table summarizes whether the stock meets each of this strategy's tests. Not all criteria in the below table receive equal weighting or are independent, but the table provides a brief overview of the strong and weak points of the security in the context of the strategy's criteria.
SALES: FAIL
INVENTORY TO SALES: PASS
YIELD COMPARED TO THE S&P 500: PASS
YIELD ADJUSTED P/E/GROWTH (PEG) RATIO: PASS
TOTAL DEBT/EQUITY RATIO: PASS
FREE CASH FLOW: NEUTRAL
NET CASH POSITION: BONUS PASS
For a full detailed analysis using NASDAQ's Guru Analysis tool, click here
PATRICK INDUSTRIES, INC. (PATK) is a small-cap value stock in the Constr. - Supplies & Fixtures industry. The rating according to our strategy based on Peter Lynch changed from 72% to 74% based on the firm’s underlying fundamentals and the stock’s valuation. A score of 80% or above typically indicates that the strategy has some interest in the stock and a score above 90% typically indicates strong interest.
Company Description: Patrick Industries, Inc. is a manufacturer of component products and distributor of building products and materials for the recreational vehicle (RV) and manufactured housing (MH) industrial markets for customers throughout the United States and Canada. In addition, it is a supplier to certain other industrial markets, such as kitchen cabinet, office and household furniture, fixtures and commercial furnishings, marine, and other industrial markets. The Company's segments include Manufacturing and Distribution. It manufactures a range of products, which include decorative vinyl and paper laminated panels, solid surface, granite and quartz countertops, fabricated aluminum products, wrapped vinyl, paper and hardwood profile mouldings, slide-out trim and fascia, cabinet doors and components, hardwood furniture, fiberglass and plastic component products including front and rear caps and marine helms, interior passage doors, RV painting, and slotwall panels and components, among others.
The following table summarizes whether the stock meets each of this strategy's tests. Not all criteria in the below table receive equal weighting or are independent, but the table provides a brief overview of the strong and weak points of the security in the context of the strategy's criteria.
P/E/GROWTH RATIO: PASS
SALES AND P/E RATIO: PASS
INVENTORY TO SALES: PASS
EPS GROWTH RATE: PASS
TOTAL DEBT/EQUITY RATIO: FAIL
FREE CASH FLOW: NEUTRAL
NET CASH POSITION: NEUTRAL
For a full detailed analysis using NASDAQ's Guru Analysis tool, click here
STATE STREET CORP (STT) is a large-cap value stock in the Investment Services industry. The rating according to our strategy based on Peter Lynch changed from 0% to 81% based on the firm’s underlying fundamentals and the stock’s valuation. A score of 80% or above typically indicates that the strategy has some interest in the stock and a score above 90% typically indicates strong interest.
Company Description: State Street Corporation is a financial holding company. The Company operates through two lines of business: Investment Servicing and Investment Management. The Company, through its subsidiary, State Street Bank and Trust Company (State Street Bank), provides a range of financial products and services to institutional investors across the world. Investment servicing line of business performs functions, such as providing institutional investors with clearing, settlement and payment services. The Company operates investment management line of business through State Street Global Advisors (SSGA). SSGA provides a range of investment management,investment researchand investment advisory services to corporations, public funds and other investors. Its clients include mutual funds, collective investment funds and other investment pools, corporate and public retirement plans, insurance companies, foundations, endowments and investment managers.
The following table summarizes whether the stock meets each of this strategy's tests. Not all criteria in the below table receive equal weighting or are independent, but the table provides a brief overview of the strong and weak points of the security in the context of the strategy's criteria.
SALES: PASS
YIELD COMPARED TO THE S&P 500: PASS
YIELD ADJUSTED P/E/GROWTH (PEG) RATIO: PASS
TOTAL DEBT/EQUITY RATIO: NEUTRAL
EQUITY/ASSETS RATIO: PASS
RETURN ON ASSETS: FAIL
FREE CASH FLOW: NEUTRAL
NET CASH POSITION: NEUTRAL
For a full detailed analysis using NASDAQ's Guru Analysis tool, click here
TOLL BROTHERS INC (TOL) is a mid-cap value stock in the Construction Services industry. The rating according to our strategy based on Peter Lynch changed from 72% to 74% based on the firm’s underlying fundamentals and the stock’s valuation. A score of 80% or above typically indicates that the strategy has some interest in the stock and a score above 90% typically indicates strong interest.
Company Description: Toll Brothers, Inc. is engaged in designing, building, marketing, selling and arranging financing for detached and attached homes in luxury residential communities. It operates through two segments: Traditional Home Building and Toll Brothers City Living (City Living). Within the Traditional Home Building segment, it operates in five geographic segments in the United States: the North, consisting of Connecticut, Illinois, Massachusetts, Michigan, Minnesota, New Jersey and New York; the Mid-Atlantic, consisting of Delaware, Maryland, Pennsylvania and Virginia; the South, consisting of Florida, North and South Carolina and Texas; the West, consisting of Arizona, Colorado, Nevada and Washington, and California. City Living is the Company's urban development division. Its products include Traditional Home Building Product and City Living Product. Its Traditional Home Building Product includes detached homes, move-up, executive, estate, and active-adult and age-qualified lines of home.
The following table summarizes whether the stock meets each of this strategy's tests. Not all criteria in the below table receive equal weighting or are independent, but the table provides a brief overview of the strong and weak points of the security in the context of the strategy's criteria.
INVENTORY TO SALES: PASS
YIELD ADJUSTED P/E TO GROWTH (PEG) RATIO: PASS
EARNINGS PER SHARE: PASS
TOTAL DEBT/EQUITY RATIO: FAIL
FREE CASH FLOW: NEUTRAL
NET CASH POSITION: NEUTRAL
For a full detailed analysis using NASDAQ's Guru Analysis tool, click here
UFP TECHNOLOGIES, INC. (UFPT) is a small-cap growth stock in the Containers & Packaging industry. The rating according to our strategy based on Peter Lynch changed from 0% to 91% based on the firm’s underlying fundamentals and the stock’s valuation. A score of 80% or above typically indicates that the strategy has some interest in the stock and a score above 90% typically indicates strong interest.
Company Description: UFP Technologies, Inc. is a designer and custom converter of foams, plastics, composites and natural fiber materials. The Company is engaged in providing solutions to customers primarily within the medical, automotive, consumer, electronics, industrial, and aerospace and defense markets. It converts these materials using laminating, molding, and fabricating manufacturing technologies. The Company's raw materials consist of polyethylene and polyurethane foams, sheet plastics, pulp fiber, cross-linked polyethylene and reticulated polyurethane foams, fabric and foam laminates, and natural fiber materials. The Company converts these materials to provide customers various solutions, including automotive interior trim, medical device components, disposable wound care components, military uniform and gear components, athletic padding, air filtration, high-temperature insulation, abrasive nail files and other beauty aids, and cushion packaging for their products.
The following table summarizes whether the stock meets each of this strategy's tests. Not all criteria in the below table receive equal weighting or are independent, but the table provides a brief overview of the strong and weak points of the security in the context of the strategy's criteria.
P/E/GROWTH RATIO: PASS
SALES AND P/E RATIO: NEUTRAL
INVENTORY TO SALES: PASS
EPS GROWTH RATE: PASS
TOTAL DEBT/EQUITY RATIO: PASS
For a full detailed analysis using NASDAQ's Guru Analysis tool, click here
UNIVEST FINANCIAL CORP (UVSP) is a small-cap value stock in the Regional Banks industry. The rating according to our strategy based on Peter Lynch changed from 72% to 74% based on the firm’s underlying fundamentals and the stock’s valuation. A score of 80% or above typically indicates that the strategy has some interest in the stock and a score above 90% typically indicates strong interest.
Company Description: Univest Financial Corporation, formerly Univest Corporation of Pennsylvania is the bank holding company of Univest Bank and Trust Co. (the Bank). The Bank is a Pennsylvania state-chartered bank and trust company. Its business segments include Banking, Wealth Management and Insurance. The Banking segment provides financial services, such as deposit taking, loan origination and servicing, mortgage banking, other general banking services and equipment lease financing. The Wealth Management segment offers trust and investment advisory services, guardian and custodian of employee benefits and other trust and brokerage services, as well as a registered investment advisory managing private investment accounts for both individuals and institutions. The Insurance segment includes a full-service insurance brokerage agency offering commercial property and casualty insurance, group life and health coverage, employee benefit solutions, personal insurance lines and human resources consulting.
The following table summarizes whether the stock meets each of this strategy's tests. Not all criteria in the below table receive equal weighting or are independent, but the table provides a brief overview of the strong and weak points of the security in the context of the strategy's criteria.
YIELD ADJUSTED P/E TO GROWTH (PEG) RATIO: PASS
EARNINGS PER SHARE: PASS
TOTAL DEBT/EQUITY RATIO: NEUTRAL
EQUITY/ASSETS RATIO: PASS
RETURN ON ASSETS: PASS
FREE CASH FLOW: NEUTRAL
NET CASH POSITION: NEUTRAL
For a full detailed analysis using NASDAQ's Guru Analysis tool, click here
VALMONT INDUSTRIES, INC. (VMI) is a mid-cap growth stock in the Constr. - Supplies & Fixtures industry. The rating according to our strategy based on Peter Lynch changed from 0% to 91% based on the firm’s underlying fundamentals and the stock’s valuation. A score of 80% or above typically indicates that the strategy has some interest in the stock and a score above 90% typically indicates strong interest.
Company Description: Valmont Industries, Inc. is a producer of fabricated metal products, and steel, aluminum and composite pole, tower and other structures, and mechanized irrigation systems. The Company's segments are Engineered Support Structures (ESS); Utility Support Structures; Energy and Mining; Coatings; Irrigation, and Other. The ESS segment manufactures steel, aluminum, and composite poles and structures. The Utility Support Structures Segment manufactures steel and concrete pole structures for electrical transmission, substation and distribution applications. The Energy and Mining Segment produces access systems, which are engineered structures and components that allow people to move safely in an industrial, infrastructure or commercial facility. The Coatings Segment consists of galvanizing, anodizing and powder coating services on a global basis. The Irrigation Segment manufactures and distributes mechanical irrigation equipment and related service parts under the Valley brand name.
The following table summarizes whether the stock meets each of this strategy's tests. Not all criteria in the below table receive equal weighting or are independent, but the table provides a brief overview of the strong and weak points of the security in the context of the strategy's criteria.
INVENTORY TO SALES: PASS
YIELD ADJUSTED P/E TO GROWTH (PEG) RATIO: PASS
EARNINGS PER SHARE: PASS
TOTAL DEBT/EQUITY RATIO: PASS
FREE CASH FLOW: NEUTRAL
NET CASH POSITION: NEUTRAL
For a full detailed analysis using NASDAQ's Guru Analysis tool, click here
BRIDGE BANCORP, INC. (BDGE) is a small-cap value stock in the Regional Banks industry. The rating according to our strategy based on Peter Lynch changed from 72% to 74% based on the firm’s underlying fundamentals and the stock’s valuation. A score of 80% or above typically indicates that the strategy has some interest in the stock and a score above 90% typically indicates strong interest.
Company Description: Bridge Bancorp, Inc. is a bank holding company for BNB Bank, formerly known as The Bridgehampton National Bank (the Bank). The Bank's operations include its real estate investment trust subsidiary, Bridgehampton Community, Inc. (BCI), a financial title insurance subsidiary, Bridge Abstract LLC (Bridge Abstract), and an investment services subsidiary, Bridge Financial Services LLC (Bridge Financial Services). As of December 31, 2017, the Bank operated 38 branches, in its primary market areas of Suffolk and Nassau Counties on Long Island and the New York City boroughs, including 35 in Suffolk and Nassau Counties, two in Queens and one in Manhattan. The Bank engages in full service commercial and consumer banking business, including accepting time, savings and demand deposits from the consumers, businesses and local municipalities in its market area. The Bank also offers the Certificate of Deposit Account Registry Service (CDARS) and Insured Cash Sweep (ICS) programs.
The following table summarizes whether the stock meets each of this strategy's tests. Not all criteria in the below table receive equal weighting or are independent, but the table provides a brief overview of the strong and weak points of the security in the context of the strategy's criteria.
YIELD ADJUSTED P/E TO GROWTH (PEG) RATIO: PASS
EARNINGS PER SHARE: PASS
TOTAL DEBT/EQUITY RATIO: NEUTRAL
EQUITY/ASSETS RATIO: PASS
RETURN ON ASSETS: PASS
For a full detailed analysis using NASDAQ's Guru Analysis tool, click here
MOBIL'NYE TELESISTEMY PAO (ADR) (MBT) is a mid-cap value stock in the Communications Services industry. The rating according to our strategy based on Peter Lynch changed from 72% to 74% based on the firm’s underlying fundamentals and the stock’s valuation. A score of 80% or above typically indicates that the strategy has some interest in the stock and a score above 90% typically indicates strong interest.
Company Description: Mobil'nye Telesistemy PAO is a Russia-based provider of telecommunications services. The Company provides mobile and fixed-line voice and data telecommunications services, including data transfer, broadband, pay-television (pay-TV) and various value-added services, as well as selling equipment and accessories. The Company operates through segments, which include Russia convergent, Moscow fixed line and Ukraine. Its Russia Convergent segment includes mobile and fixed-line operations, which encompasses services rendered to customers across regions of Russia, including voice and data services, transmission, broadband, pay-TV and other value-added services. Its Moscow fixed-line segment includes fixed-line operations carried out in Moscow by the Company's subsidiary MGTS. Its Ukraine segment includes mobile and fixed-line operations carried out across multiple regions of Ukraine. The Company also offers software solutions, such as LiteBox, a cloud-based tool for online cash operations.
The following table summarizes whether the stock meets each of this strategy's tests. Not all criteria in the below table receive equal weighting or are independent, but the table provides a brief overview of the strong and weak points of the security in the context of the strategy's criteria.
SALES: PASS
YIELD COMPARED TO THE S&P 500: PASS
YIELD ADJUSTED P/E/GROWTH (PEG) RATIO: PASS
TOTAL DEBT/EQUITY RATIO: FAIL
FREE CASH FLOW: NEUTRAL
NET CASH POSITION: NEUTRAL
For a full detailed analysis using NASDAQ's Guru Analysis tool, click here
EATON VANCE RISK-MNGD DVRSFD EQTY INC FD (ETJ) is a small-cap value stock in the Misc. Financial Services industry. The rating according to our strategy based on Peter Lynch changed from 0% to 93% based on the firm’s underlying fundamentals and the stock’s valuation. A score of 80% or above typically indicates that the strategy has some interest in the stock and a score above 90% typically indicates strong interest.
Company Description: Eaton Vance Risk-Managed Diversified Equity Income Fund is a United States-based diversified, closed-end management investment company. The Fund's investment objective is to provide income and gains, with a secondary objective of capital appreciation. The Fund invests in a diversified portfolio of common stocks and purchases out-of-the money, short-dated Standard and Poor's 500 (S&P's) Index put options and sells out-of-the-money S&P 500 Index call options of the same term as the put options with roll dates that are staggered across the options portfolio. It evaluates returns on an after tax basis and seeks to minimize and defer federal income taxes incurred by shareholders in connection with their investment in the Fund. Its portfolio of investments includes information technology, financials, healthcare, consumer discretionary, consumer staples, industrials, energy, utilities, telecommunication services and materials. Its investment advisor is Eaton Vance Management.
The following table summarizes whether the stock meets each of this strategy's tests. Not all criteria in the below table receive equal weighting or are independent, but the table provides a brief overview of the strong and weak points of the security in the context of the strategy's criteria.
P/E/GROWTH RATIO: PASS
SALES AND P/E RATIO: NEUTRAL
EPS GROWTH RATE: PASS
TOTAL DEBT/EQUITY RATIO: NEUTRAL
EQUITY/ASSETS RATIO: PASS
RETURN ON ASSETS: PASS
FREE CASH FLOW: NEUTRAL
NET CASH POSITION: NEUTRAL
For a full detailed analysis using NASDAQ's Guru Analysis tool, click here
TRIPLE-S MANAGEMENT CORP. (GTS) is a small-cap value stock in the Healthcare Facilities industry. The rating according to our strategy based on Peter Lynch changed from 0% to 74% based on the firm’s underlying fundamentals and the stock’s valuation. A score of 80% or above typically indicates that the strategy has some interest in the stock and a score above 90% typically indicates strong interest.
Company Description: Triple-S Management Corporation operates as a managed care company. The Company offers a range of managed care and related products in the commercial, Medicaid and Medicare markets. The Company's segments include Managed Care, Life Insurance, and Property and Casualty Insurance. The Managed Care segment is engaged in the sale of managed care products to the Commercial, Medicare and Medicaid market sectors. The Life Insurance segment offers life and accident and health insurance coverage, and annuity products. The premiums for this segment are mainly subscribed through an internal sales force and a network of independent brokers and agents. The insurance products of Property and Casualty Insurance segment includes commercial package, commercial auto, and personal package. The premiums for this segment are originated through a network of independent insurance agents and brokers.
The following table summarizes whether the stock meets each of this strategy's tests. Not all criteria in the below table receive equal weighting or are independent, but the table provides a brief overview of the strong and weak points of the security in the context of the strategy's criteria.
P/E/GROWTH RATIO: PASS
SALES AND P/E RATIO: PASS
INVENTORY TO SALES: FAIL
EPS GROWTH RATE: PASS
TOTAL DEBT/EQUITY RATIO: PASS
FREE CASH FLOW: NEUTRAL
NET CASH POSITION: NEUTRAL
For a full detailed analysis using NASDAQ's Guru Analysis tool, click here
DOUGLAS EMMETT, INC. (DEI) is a mid-cap growth stock in the Real Estate Operations industry. The rating according to our strategy based on Peter Lynch changed from 72% to 74% based on the firm’s underlying fundamentals and the stock’s valuation. A score of 80% or above typically indicates that the strategy has some interest in the stock and a score above 90% typically indicates strong interest.
Company Description: Douglas Emmett, Inc. is a self-administered and self-managed real estate investment trust (REIT). The Company is owner and operator of office and multifamily properties located in submarkets in Los Angeles and Honolulu. The Company operates through two segments: the acquisition, development, ownership and management of office real estate (Office Segment), and the acquisition, development, ownership and management of multifamily real estate (Multifamily Segment). The services for its Office segment include primarily rental of office space and other tenant services, including parking and storage space rental. The services for its Multifamily segment include primarily rental of apartments and other tenant services, including parking and storage space rental. It focuses on owning, acquiring developing and managing a substantial share of office properties and multifamily communities in neighborhoods.
The following table summarizes whether the stock meets each of this strategy's tests. Not all criteria in the below table receive equal weighting or are independent, but the table provides a brief overview of the strong and weak points of the security in the context of the strategy's criteria.
P/E/GROWTH RATIO: PASS
SALES AND P/E RATIO: NEUTRAL
EPS GROWTH RATE: PASS
TOTAL DEBT/EQUITY RATIO: FAIL
FREE CASH FLOW: NEUTRAL
NET CASH POSITION: NEUTRAL
For a full detailed analysis using NASDAQ's Guru Analysis tool, click here
ARMSTRONG WORLD INDUSTRIES INC (AWI) is a mid-cap growth stock in the Constr. - Supplies & Fixtures industry. The rating according to our strategy based on Peter Lynch changed from 72% to 74% based on the firm’s underlying fundamentals and the stock’s valuation. A score of 80% or above typically indicates that the strategy has some interest in the stock and a score above 90% typically indicates strong interest.
Company Description: Armstrong World Industries, Inc. (AWI) is a global producer of ceiling systems. The Company owns and operates the Building Products (Ceilings) segment. The Company designs, manufactures and sells ceiling systems (primarily mineral fiber, fiberglass wool and metal) around the world. Its products are used in commercial and institutional buildings. Its geographical segment is Americas, including Canada. It operates approximately 15 manufacturing plants in eight countries, including six plants located throughout the United States. Its Americas segment sells products for use in single and multi-family housing. It sells commercial products to building materials distributors re-selling its products to contractors, subcontractors' alliances, architect and design firms, and facility owners. Residential ceiling products are sold in the Americas primarily to wholesalers and retailers.
The following table summarizes whether the stock meets each of this strategy's tests. Not all criteria in the below table receive equal weighting or are independent, but the table provides a brief overview of the strong and weak points of the security in the context of the strategy's criteria.
P/E/GROWTH RATIO: PASS
SALES AND P/E RATIO: PASS
INVENTORY TO SALES: PASS
EPS GROWTH RATE: PASS
TOTAL DEBT/EQUITY RATIO: FAIL
FREE CASH FLOW: NEUTRAL
NET CASH POSITION: NEUTRAL
For a full detailed analysis using NASDAQ's Guru Analysis tool, click here
SOUTHERN NATIONAL BANC. OF VIRGINIA, INC (SONA) is a small-cap value stock in the Regional Banks industry. The rating according to our strategy based on Peter Lynch changed from 72% to 74% based on the firm’s underlying fundamentals and the stock’s valuation. A score of 80% or above typically indicates that the strategy has some interest in the stock and a score above 90% typically indicates strong interest.
Company Description: Southern National Bancorp of Virginia, Inc. (Southern National) is the bank holding company for Sonabank (Sonabank). The Company's principal business is the acquisition of deposits from the general public through its branch offices and deposit intermediaries, as well as the use of these deposits to fund its loan and investment portfolios. Sonabank is a Virginia state chartered bank. Sonabank provides a range of financial services to individuals, and small and medium sized businesses. The Company focuses on making loans secured primarily by commercial real estate and other types of secured and unsecured commercial loans to small and medium-sized businesses in various industries, as well as loans to individuals for a variety of purposes. It focuses on serving small to medium-sized businesses in its market with a range of services, including an array of commercial mortgage and non-mortgage loans.
The following table summarizes whether the stock meets each of this strategy's tests. Not all criteria in the below table receive equal weighting or are independent, but the table provides a brief overview of the strong and weak points of the security in the context of the strategy's criteria.
YIELD ADJUSTED P/E TO GROWTH (PEG) RATIO: PASS
EARNINGS PER SHARE: PASS
TOTAL DEBT/EQUITY RATIO: NEUTRAL
EQUITY/ASSETS RATIO: PASS
RETURN ON ASSETS: PASS
For a full detailed analysis using NASDAQ's Guru Analysis tool, click here
CANADIAN SOLAR INC. (CSIQ) is a small-cap value stock in the Semiconductors industry. The rating according to our strategy based on Peter Lynch changed from 72% to 74% based on the firm’s underlying fundamentals and the stock’s valuation. A score of 80% or above typically indicates that the strategy has some interest in the stock and a score above 90% typically indicates strong interest.
Company Description: Canadian Solar Inc. is a solar power company. The Company is a provider of solar power products, services and system solutions with operations in North America, South America, Europe, Africa, the Middle East, Australia and Asia. The Company's segments include Module and system solutions (MSS) segment and Energy segment. The Company designs, develops and manufactures solar wafers, solar cells and solar power products. The module segment primarily involves the design, development, manufacturing and sale of a range of solar power products, including standard solar modules and specialty solar products, and solar system kits. Its energy segment consists of solar power project development, engineering, procurement and construction (EPC) services, and operation and maintenance (O&M) services. Its products include a range of solar modules for use in residential, commercial and industrial solar power generation systems.
The following table summarizes whether the stock meets each of this strategy's tests. Not all criteria in the below table receive equal weighting or are independent, but the table provides a brief overview of the strong and weak points of the security in the context of the strategy's criteria.
INVENTORY TO SALES: PASS
YIELD ADJUSTED P/E TO GROWTH (PEG) RATIO: PASS
EARNINGS PER SHARE: PASS
TOTAL DEBT/EQUITY RATIO: FAIL
FREE CASH FLOW: NEUTRAL
NET CASH POSITION: NEUTRAL
For a full detailed analysis using NASDAQ's Guru Analysis tool, click here
SALLY BEAUTY HOLDINGS, INC. (SBH) is a small-cap value stock in the Retail (Specialty) industry. The rating according to our strategy based on Peter Lynch changed from 72% to 74% based on the firm’s underlying fundamentals and the stock’s valuation. A score of 80% or above typically indicates that the strategy has some interest in the stock and a score above 90% typically indicates strong interest.
Company Description: Sally Beauty Holdings, Inc. is an international specialty retailer and distributor of professional beauty supplies with operations primarily in North America, South America and Europe. The Company operates through two business segments: Sally Beauty Supply and Beauty Systems Group (BSG). Sally Beauty Supply is a domestic and international chain of cash and carry retail stores, which offers professional beauty supplies to both salon professionals and retail customers primarily in North America, Puerto Rico, and parts of Europe and South America. BSG, including its franchise-based business Armstrong McCall, is a full service beauty supply distributor, which offers professional brands of beauty products directly to salons and salon professionals through its own sales force and professional-only stores (including franchise stores) in partially exclusive geographical territories in North America and parts of Europe.
The following table summarizes whether the stock meets each of this strategy's tests. Not all criteria in the below table receive equal weighting or are independent, but the table provides a brief overview of the strong and weak points of the security in the context of the strategy's criteria.
YIELD ADJUSTED P/E TO GROWTH (PEG) RATIO: PASS
EARNINGS PER SHARE: PASS
TOTAL DEBT/EQUITY RATIO: FAIL
FREE CASH FLOW: NEUTRAL
NET CASH POSITION: NEUTRAL
For a full detailed analysis using NASDAQ's Guru Analysis tool, click here
WESTERN ASSET EMERGING MRKTS DBT FND INC (EMD) is a small-cap value stock in the Misc. Financial Services industry. The rating according to our strategy based on Peter Lynch changed from 0% to 93% based on the firm’s underlying fundamentals and the stock’s valuation. A score of 80% or above typically indicates that the strategy has some interest in the stock and a score above 90% typically indicates strong interest.
Company Description: Western Asset Emerging Markets Debt Fund Inc. (the Fund) is a non-diversified, closed-end management investment company. The Fund's primary investment objective is to seek high current income. The Fund's secondary objective is to seek capital appreciation. The Fund invests in the United States dollar and non-United States dollar-denominated debt securities of issuers in emerging market countries. The Fund's sector holdings include sovereign bonds, energy, materials, consumer staples, financials, industrials, telecommunication services and utilities. Legg Mason Partners Fund Advisor, LLC (LMPFA) is the investment manager. LMPFA provides administrative and certain oversight services to the Fund. Western Asset Management Company (Western Asset), Western Asset Management Company Limited (Western Asset Limited) and Western Asset Management Company Pte. Ltd. (Western Singapore) are the sub advisors of the Fund.
The following table summarizes whether the stock meets each of this strategy's tests. Not all criteria in the below table receive equal weighting or are independent, but the table provides a brief overview of the strong and weak points of the security in the context of the strategy's criteria.
P/E/GROWTH RATIO: PASS
SALES AND P/E RATIO: NEUTRAL
EPS GROWTH RATE: PASS
TOTAL DEBT/EQUITY RATIO: NEUTRAL
EQUITY/ASSETS RATIO: PASS
RETURN ON ASSETS: PASS
FREE CASH FLOW: NEUTRAL
NET CASH POSITION: NEUTRAL
For a full detailed analysis using NASDAQ's Guru Analysis tool, click here
QCR HOLDINGS, INC. (QCRH) is a small-cap value stock in the Regional Banks industry. The rating according to our strategy based on Peter Lynch changed from 72% to 74% based on the firm’s underlying fundamentals and the stock’s valuation. A score of 80% or above typically indicates that the strategy has some interest in the stock and a score above 90% typically indicates strong interest.
Company Description: QCR Holdings, Inc. is a multi-bank holding company. The Company serves the Quad Cities, Cedar Rapids, Waterloo/Cedar Falls, Des Moines/Ankeny and Rockford communities through its banking subsidiaries, Quad City Bank and Trust Company (QCBT), Cedar Rapids Bank and Trust Company (CRBT), Community State Bank (CSB), and Guaranty Bank and Trust Company, which provide full-service commercial and consumer banking and trust and asset management services. It is also engaged in direct financing lease contracts through m2 Lease Funds, LLC (m2), a subsidiary of QCBT. Its principal business consists of attracting deposits and investing those deposits in loans/leases and securities. The Company and its subsidiaries provide a range of commercial and retail lending/leasing, and investment services to corporations, partnerships, individuals and government agencies. It offers a range of loans, including one-to four-family residential loans and multi-family loans.
The following table summarizes whether the stock meets each of this strategy's tests. Not all criteria in the below table receive equal weighting or are independent, but the table provides a brief overview of the strong and weak points of the security in the context of the strategy's criteria.
YIELD ADJUSTED P/E TO GROWTH (PEG) RATIO: PASS
EARNINGS PER SHARE: PASS
TOTAL DEBT/EQUITY RATIO: NEUTRAL
EQUITY/ASSETS RATIO: PASS
RETURN ON ASSETS: PASS
For a full detailed analysis using NASDAQ's Guru Analysis tool, click here
BRUKER CORPORATION (BRKR) is a mid-cap growth stock in the Scientific & Technical Instr. industry. The rating according to our strategy based on Peter Lynch changed from 87% to 91% based on the firm’s underlying fundamentals and the stock’s valuation. A score of 80% or above typically indicates that the strategy has some interest in the stock and a score above 90% typically indicates strong interest.
Company Description: Bruker Corporation designs and manufactures scientific instruments, and analytical and diagnostic solutions. Its segments include the Bruker BioSpin Group; the Bruker Chemicals, Applied Markets, Life Science, In-Vitro Diagnostics, Detection (CALID) Group; the Bruker Nano Group, and the Bruker Energy & Supercon Technologies (BEST) Segment. The Bruker BioSpin Group segment designs, manufactures and distributes enabling life science tools. The Bruker CALID segment designs, manufactures and distributes life science mass spectrometry instruments that can be integrated and used along with other sample preparation or chromatography instruments, as well as chemical, biological, radiological, nuclear and explosive detection products. The Bruker Nano segment designs, manufactures and distributes spectroscopy and microscopy instruments. The BEST segment develops and manufactures superconducting and non-superconducting materials and devices. It also focuses on nanomechanical testing instruments.
The following table summarizes whether the stock meets each of this strategy's tests. Not all criteria in the below table receive equal weighting or are independent, but the table provides a brief overview of the strong and weak points of the security in the context of the strategy's criteria.
P/E/GROWTH RATIO: PASS
SALES AND P/E RATIO: PASS
INVENTORY TO SALES: PASS
EPS GROWTH RATE: PASS
TOTAL DEBT/EQUITY RATIO: PASS
FREE CASH FLOW: NEUTRAL
NET CASH POSITION: NEUTRAL
For a full detailed analysis using NASDAQ's Guru Analysis tool, click here
TEXAS ROADHOUSE INC (TXRH) is a mid-cap growth stock in the Restaurants industry. The rating according to our strategy based on Peter Lynch changed from 0% to 91% based on the firm’s underlying fundamentals and the stock’s valuation. A score of 80% or above typically indicates that the strategy has some interest in the stock and a score above 90% typically indicates strong interest.
Company Description: Texas Roadhouse, Inc. is a restaurant company, which operates in the casual dining segment. The Company offers an assortment of seasoned and aged steaks, all cooked over open grills and all but one hand cut daily on the premises. Its restaurants offer a range of menu items at prices that are designed to appeal to a range of consumer tastes. The Company also offers its guests a selection of ribs, fish, seafood, chicken, pork chops, pulled pork and vegetable plates, and an assortment of hamburgers, salads and sandwiches. The Company offers an assortment of wings, sandwiches, pizzas and burgers, including its bacon grind patty. In addition, the Company also offers its guests a selection of chicken, beef, fish and seafood. Other menu items include specialty appetizers, such as the Cactus Blossom and Rattlesnake Bites. As of December 27, 2016, the Company had 23 franchisees that operated 86 Texas Roadhouse restaurants in 23 states and six foreign countries.
The following table summarizes whether the stock meets each of this strategy's tests. Not all criteria in the below table receive equal weighting or are independent, but the table provides a brief overview of the strong and weak points of the security in the context of the strategy's criteria.
YIELD ADJUSTED P/E TO GROWTH (PEG) RATIO: PASS
EARNINGS PER SHARE: PASS
TOTAL DEBT/EQUITY RATIO: PASS
FREE CASH FLOW: NEUTRAL
NET CASH POSITION: NEUTRAL
For a full detailed analysis using NASDAQ's Guru Analysis tool, click here
GIBRALTAR INDUSTRIES INC (ROCK) is a small-cap growth stock in the Constr. - Supplies & Fixtures industry. The rating according to our strategy based on Peter Lynch changed from 0% to 91% based on the firm’s underlying fundamentals and the stock’s valuation. A score of 80% or above typically indicates that the strategy has some interest in the stock and a score above 90% typically indicates strong interest.
Company Description: Gibraltar Industries, Inc. is a manufacturer and distributor of building products for industrial, transportation infrastructure, residential housing, renewable energy and resource conservation markets. The Company's segments include Residential Products; Industrial and Infrastructure Products, and Renewable Energy and Conservation. The Residential Products segment services residential housing construction and residential repair and remodeling activity with products including roof and foundation ventilation products, rain dispersion products and roof ventilation accessories. The Industrial and Infrastructure Products segment focuses on a range of markets, including industrial and commercial construction, automotive, airports and energy and power generation markets with products. The Renewable Energy and Conservation segment focuses on the design, engineering, manufacturing and installation of solar racking systems and commercial, institutional and retail greenhouse structures.
The following table summarizes whether the stock meets each of this strategy's tests. Not all criteria in the below table receive equal weighting or are independent, but the table provides a brief overview of the strong and weak points of the security in the context of the strategy's criteria.
P/E/GROWTH RATIO: PASS
SALES AND P/E RATIO: PASS
INVENTORY TO SALES: PASS
EPS GROWTH RATE: PASS
TOTAL DEBT/EQUITY RATIO: PASS
FREE CASH FLOW: NEUTRAL
NET CASH POSITION: NEUTRAL
For a full detailed analysis using NASDAQ's Guru Analysis tool, click here
CELANESE CORPORATION (CE) is a mid-cap value stock in the Chemical Manufacturing industry. The rating according to our strategy based on Peter Lynch changed from 72% to 74% based on the firm’s underlying fundamentals and the stock’s valuation. A score of 80% or above typically indicates that the strategy has some interest in the stock and a score above 90% typically indicates strong interest.
Company Description: Celanese Corporation (Celanese) is a technology and specialty materials company. The Company's segments include Advanced Engineered Materials, Consumer Specialties, Industrial Specialties, Acetyl Intermediates and Other Activities. The Advanced Engineered Materials segment includes the Company's engineered materials business and certain affiliates. The Consumer Specialties segment includes the Company's cellulose derivatives and food ingredients businesses, which serve consumer-driven applications. The Industrial Specialties segment includes the Company's emulsion polymers and ethylene vinyl acetate (EVA) polymers businesses. The Acetyl Intermediates segment includes the Company's intermediate chemistry business, which produces and supplies acetyl products, including acetic acid, vinyl acetate monomer (VAM), acetic anhydride and acetate esters. The Company has operations in North America, Europe and Asia. As of December 31, 2016, the Company had 30 global production facilities.
The following table summarizes whether the stock meets each of this strategy's tests. Not all criteria in the below table receive equal weighting or are independent, but the table provides a brief overview of the strong and weak points of the security in the context of the strategy's criteria.
P/E/GROWTH RATIO: PASS
SALES AND P/E RATIO: PASS
INVENTORY TO SALES: PASS
EPS GROWTH RATE: PASS
TOTAL DEBT/EQUITY RATIO: FAIL
FREE CASH FLOW: NEUTRAL
NET CASH POSITION: NEUTRAL
For a full detailed analysis using NASDAQ's Guru Analysis tool, click here
HOME BANCSHARES INC (HOMB) is a mid-cap value stock in the Regional Banks industry. The rating according to our strategy based on Peter Lynch changed from 72% to 74% based on the firm’s underlying fundamentals and the stock’s valuation. A score of 80% or above typically indicates that the strategy has some interest in the stock and a score above 90% typically indicates strong interest.
Company Description: Home BancShares, Inc. is a bank holding company. The Company is engaged in providing a range of commercial and retail banking, and related financial services to businesses, real estate developers and investors, individuals and municipalities through its community bank subsidiary, Centennial Bank (the Bank). It operates through community banking segment. It offers a range of products and services, including Internet banking, mobile banking and voice response information, cash management, overdraft protection, direct deposit, safe deposit boxes, the United States savings bonds and automatic account transfers. The Bank has locations in Arkansas, Florida, South Alabama and New York City. As of September 26, 2017, the Company conducted business principally through 76 branches in Arkansas, 89 branches in Florida, six branches in Alabama and one branch in New York City. It originates loans secured by single and multi-family real estate, residential construction and commercial buildings.
The following table summarizes whether the stock meets each of this strategy's tests. Not all criteria in the below table receive equal weighting or are independent, but the table provides a brief overview of the strong and weak points of the security in the context of the strategy's criteria.
YIELD ADJUSTED P/E TO GROWTH (PEG) RATIO: PASS
EARNINGS PER SHARE: PASS
TOTAL DEBT/EQUITY RATIO: NEUTRAL
EQUITY/ASSETS RATIO: PASS
RETURN ON ASSETS: PASS
FREE CASH FLOW: NEUTRAL
NET CASH POSITION: NEUTRAL
For a full detailed analysis using NASDAQ's Guru Analysis tool, click here
EATON VANCE ENHANCED EQUITY INCM. FD. II (EOS) is a small-cap value stock in the Misc. Financial Services industry. The rating according to our strategy based on Peter Lynch changed from 0% to 74% based on the firm’s underlying fundamentals and the stock’s valuation. A score of 80% or above typically indicates that the strategy has some interest in the stock and a score above 90% typically indicates strong interest.
Company Description: Eaton Vance Enhanced Equity Income Fund II (the Fund) is a diversified, closed-end management investment company. The Fund's primary investment objective is to provide current income, with a secondary objective of capital appreciation. The Fund invests in a portfolio of primarily large- and mid-cap securities. The Fund invests in various sectors, including aerospace and defense; banks; beverages; biotechnology; building products; chemicals; communications equipment; energy equipment and services; food and staples retailing; food products; healthcare equipment and supplies; hotels, restaurants and leisure; household durables; Internet software and services; machinery; media; multiline retail; oil, gas and consumable fuels; personal products; pharmaceuticals; semiconductors and semiconductor equipment; technology hardware, storage and peripherals, and textiles, apparel and luxury goods. Eaton Vance Management is the investment advisor of the Fund.
The following table summarizes whether the stock meets each of this strategy's tests. Not all criteria in the below table receive equal weighting or are independent, but the table provides a brief overview of the strong and weak points of the security in the context of the strategy's criteria.
P/E/GROWTH RATIO: PASS
SALES AND P/E RATIO: NEUTRAL
EPS GROWTH RATE: FAIL
TOTAL DEBT/EQUITY RATIO: NEUTRAL
EQUITY/ASSETS RATIO: PASS
RETURN ON ASSETS: PASS
FREE CASH FLOW: NEUTRAL
NET CASH POSITION: NEUTRAL
For a full detailed analysis using NASDAQ's Guru Analysis tool, click here
WNS (HOLDINGS) LIMITED (ADR) (WNS) is a mid-cap growth stock in the Computer Services industry. The rating according to our strategy based on Peter Lynch changed from 87% to 91% based on the firm’s underlying fundamentals and the stock’s valuation. A score of 80% or above typically indicates that the strategy has some interest in the stock and a score above 90% typically indicates strong interest.
Company Description: WNS (Holdings) Limited is a global provider of business process management (BPM) services. The Company offers data, voice, analytical and business transformation services. The Company's segments include WNS Global BPM and WNS Auto Claims BPM. Its operating segments include travel, insurance, banking and financial services, healthcare, utilities, retail and consumer products groups, auto claims and others. The WNS Global BPM includes the Company's business activities with the exception of WNS Auto Claims BPM. WNS Auto Claims BPM is the Company's automobile claims management business. The Company focuses on various industry verticals, such as insurance; travel and leisure; diversified businesses, including manufacturing, retail, consumer packaged goods (CPG), media and entertainment, and telecommunication (telecom); utilities; consulting and professional services; banking and financial services; healthcare, and shipping and logistics.
The following table summarizes whether the stock meets each of this strategy's tests. Not all criteria in the below table receive equal weighting or are independent, but the table provides a brief overview of the strong and weak points of the security in the context of the strategy's criteria.
P/E/GROWTH RATIO: PASS
SALES AND P/E RATIO: NEUTRAL
INVENTORY TO SALES: PASS
EPS GROWTH RATE: PASS
TOTAL DEBT/EQUITY RATIO: PASS
FREE CASH FLOW: NEUTRAL
NET CASH POSITION: NEUTRAL
For a full detailed analysis using NASDAQ's Guru Analysis tool, click here
HOME BANCORP, INC. (HBCP) is a small-cap value stock in the Regional Banks industry. The rating according to our strategy based on Peter Lynch changed from 72% to 74% based on the firm’s underlying fundamentals and the stock’s valuation. A score of 80% or above typically indicates that the strategy has some interest in the stock and a score above 90% typically indicates strong interest.
Company Description: Home Bancorp, Inc. is a bank holding company for Home Bank, N.A. (the Bank). The Bank conducts business through banking offices in the Greater Lafayette, Baton Rouge, Greater New Orleans and Northshore (of Lake Pontchartrain) regions of south Louisiana and the Natchez and Vicksburg regions of west Mississippi. The Bank is engaged in attracting deposits from the general public and using those funds to invest in loans and securities. The Bank originates loans, including one- to four-family first mortgage loans, home equity loans and lines, construction and land loans, multi-family residential loans and consumer loans. The Bank's lending activities include loans secured by commercial real estate loans, and commercial and industrial loans. In addition to commercial real estate and commercial and industrial loans, the Bank holds a portfolio of construction and land loans.
The following table summarizes whether the stock meets each of this strategy's tests. Not all criteria in the below table receive equal weighting or are independent, but the table provides a brief overview of the strong and weak points of the security in the context of the strategy's criteria.
YIELD ADJUSTED P/E TO GROWTH (PEG) RATIO: PASS
EARNINGS PER SHARE: PASS
TOTAL DEBT/EQUITY RATIO: NEUTRAL
EQUITY/ASSETS RATIO: PASS
RETURN ON ASSETS: PASS
For a full detailed analysis using NASDAQ's Guru Analysis tool, click here
GENERAL MOTORS COMPANY (GM) is a large-cap value stock in the Auto & Truck Manufacturers industry. The rating according to our strategy based on Peter Lynch changed from 72% to 74% based on the firm’s underlying fundamentals and the stock’s valuation. A score of 80% or above typically indicates that the strategy has some interest in the stock and a score above 90% typically indicates strong interest.
Company Description: General Motors Co designs, builds and sells trucks, crossovers, cars and automobile parts worldwide. The Company also provides automotive financing services through General Motors Financial Company, Inc. (GM Financial). GM North America (GMNA) and GM International (GMI) are its automotive segments. GMNA and GMI are meeting the demands of customers with vehicles developed, manufactured and/or marketed under the Buick, Cadillac, Chevrolet and GMC and Holden brands. Its brands offer luxury cars, crossovers, sport utility vehicles (SUVs) and sedans. The Company's Car-and Ride-Sharing Maven is a shared vehicle marketplace. Through its subsidiary, OnStar, LLC (OnStar), it provides connected safety, security and mobility solutions for retail and fleet customers. GM Cruise is its global segment engaged in the development and commercialization of autonomous vehicle technology.
The following table summarizes whether the stock meets each of this strategy's tests. Not all criteria in the below table receive equal weighting or are independent, but the table provides a brief overview of the strong and weak points of the security in the context of the strategy's criteria.
SALES: PASS
INVENTORY TO SALES: PASS
YIELD COMPARED TO THE S&P 500: PASS
YIELD ADJUSTED P/E/GROWTH (PEG) RATIO: PASS
TOTAL DEBT/EQUITY RATIO: FAIL
FREE CASH FLOW: NEUTRAL
NET CASH POSITION: NEUTRAL
For a full detailed analysis using NASDAQ's Guru Analysis tool, click here
POINTS INTERNATIONAL LTD (USA) (PCOM) is a small-cap growth stock in the Software & Programming industry. The rating according to our strategy based on Peter Lynch changed from 0% to 80% based on the firm’s underlying fundamentals and the stock’s valuation. A score of 80% or above typically indicates that the strategy has some interest in the stock and a score above 90% typically indicates strong interest.
Company Description: Points International Ltd. (Points) provides a range of e-commerce and technology services to loyalty program operators using a common infrastructure. These services include a range of white label or private branded e-commerce services (Loyalty Currency Services) that enable the sale of loyalty currencies (such as frequent flyer miles, hotel points and credit card points), both retail and wholesale, and support the loyalty program consumer offerings and their back end operations. The Company offers the consumer-focused Points Loyalty Wallet that allows users to track, manage and access multiple loyalty rewards programs through the Points.com Website. It also offers Points Travel, which is private label travel e-commerce platform designed specifically for the loyalty industry. The Company operates the PointsHound.com Website, a hotel booking engine and loyalty currency aggregator built specifically for frequent travelers.
The following table summarizes whether the stock meets each of this strategy's tests. Not all criteria in the below table receive equal weighting or are independent, but the table provides a brief overview of the strong and weak points of the security in the context of the strategy's criteria.
P/E/GROWTH RATIO: PASS
SALES AND P/E RATIO: NEUTRAL
INVENTORY TO SALES: FAIL
EPS GROWTH RATE: PASS
TOTAL DEBT/EQUITY RATIO: PASS
FREE CASH FLOW: NEUTRAL
NET CASH POSITION: BONUS PASS
For a full detailed analysis using NASDAQ's Guru Analysis tool, click here
RENEWABLE ENERGY GROUP INC (REGI) is a small-cap value stock in the Chemical Manufacturing industry. The rating according to our strategy based on Peter Lynch changed from 0% to 93% based on the firm’s underlying fundamentals and the stock’s valuation. A score of 80% or above typically indicates that the strategy has some interest in the stock and a score above 90% typically indicates strong interest.
Company Description: Renewable Energy Group, Inc. is focused on providing cleaner, lower carbon intensity products and services. The Company is a producer of biomass-based diesel in North America. Its segments include Biomass-based diesel, Services, Renewable Chemicals and Corporate and other activities. It is involved in various activities related to biomass-based diesel production, from acquiring feedstock, managing construction and operating biomass-based diesel production facilities to marketing, selling and distributing biomass-based diesel and its co-products. As of December 31, 2016, it owned and operated a network of 14 biorefineries. As of December 31, 2016, 12 biorefineries were located in the United States and two in Germany, and 13 of which produce biodiesel or renewable hydrocarbon diesel and had an aggregate nameplate production capacity of 502 million gallons per year (mmgy). As of December 31, 2016, it also operated one microbial fermentation facility and one feedstock processing facility.
The following table summarizes whether the stock meets each of this strategy's tests. Not all criteria in the below table receive equal weighting or are independent, but the table provides a brief overview of the strong and weak points of the security in the context of the strategy's criteria.
INVENTORY TO SALES: PASS
YIELD ADJUSTED P/E TO GROWTH (PEG) RATIO: PASS
EARNINGS PER SHARE: PASS
TOTAL DEBT/EQUITY RATIO: PASS
FREE CASH FLOW: NEUTRAL
NET CASH POSITION: NEUTRAL
For a full detailed analysis using NASDAQ's Guru Analysis tool, click here
BANNER CORPORATION (BANR) is a small-cap value stock in the Regional Banks industry. The rating according to our strategy based on Peter Lynch changed from 72% to 74% based on the firm’s underlying fundamentals and the stock’s valuation. A score of 80% or above typically indicates that the strategy has some interest in the stock and a score above 90% typically indicates strong interest.
Company Description: Banner Corporation is a bank holding company. The Company is engaged in the business of planning, directing and coordinating the business activities of its subsidiaries, Banner Bank and Islanders Bank. Banner Bank is a Washington-chartered commercial bank. Banner Bank is a regional bank, which offers a range of commercial banking services and financial products to individuals, businesses and public sector entities in its primary market areas. Banner Bank is also an active participant in the secondary market, engaging in mortgage banking operations through the origination and sale of one- to four-family and multi-family residential loans. Islanders Bank is also a Washington-chartered commercial bank. Islanders Bank is a community bank, which offers similar banking services to individuals, businesses and public entities located primarily in the San Juan Islands. The Banks' primary business is that of traditional banking institutions, accepting deposits and originating loans.
The following table summarizes whether the stock meets each of this strategy's tests. Not all criteria in the below table receive equal weighting or are independent, but the table provides a brief overview of the strong and weak points of the security in the context of the strategy's criteria.
YIELD ADJUSTED P/E TO GROWTH (PEG) RATIO: PASS
EARNINGS PER SHARE: PASS
TOTAL DEBT/EQUITY RATIO: NEUTRAL
EQUITY/ASSETS RATIO: PASS
RETURN ON ASSETS: PASS
FREE CASH FLOW: NEUTRAL
NET CASH POSITION: NEUTRAL
For a full detailed analysis using NASDAQ's Guru Analysis tool, click here
FRP HOLDINGS INC (FRPH) is a small-cap growth stock in the Rental & Leasing industry. The rating according to our strategy based on Peter Lynch changed from 0% to 74% based on the firm’s underlying fundamentals and the stock’s valuation. A score of 80% or above typically indicates that the strategy has some interest in the stock and a score above 90% typically indicates strong interest.
Company Description: FRP Holdings, Inc. is a holding company engaged in various real estate businesses. The Company conducts its business through its subsidiaries, FRP Maryland, Inc., FRP Development Corp. and Florida Rock Properties, Inc. The segments of the Company include leasing and management of warehouse and office building owned by the Company (the Asset Management Segment), leasing and management of mining royalty land owned by the Company (the Mining Royalty Lands Segment) and real property acquisition, entitlement, development and construction primarily for warehouse and office buildings (the Land Development and Construction Segment). The Company's Asset Management Segment owns leases and manages warehouse and office buildings. Its Mining Royalty Lands Segment owns several properties comprising approximately 15,000 acres under lease for mining rents or royalties. Its Land Development and Construction Segment owns and monitors the parcels of land that are in various stages of development.
The following table summarizes whether the stock meets each of this strategy's tests. Not all criteria in the below table receive equal weighting or are independent, but the table provides a brief overview of the strong and weak points of the security in the context of the strategy's criteria.
P/E/GROWTH RATIO: FAIL
SALES AND P/E RATIO: NEUTRAL
EPS GROWTH RATE: PASS
TOTAL DEBT/EQUITY RATIO: PASS
For a full detailed analysis using NASDAQ's Guru Analysis tool, click here
GREEN BRICK PARTNERS INC (GRBK) is a small-cap value stock in the Construction Services industry. The rating according to our strategy based on Peter Lynch changed from 0% to 74% based on the firm’s underlying fundamentals and the stock’s valuation. A score of 80% or above typically indicates that the strategy has some interest in the stock and a score above 90% typically indicates strong interest.
Company Description: Green Brick Partners, Inc. operates in the real estate industry. The Company operates through two segments. The builder operations segment includes its controlled builders results, which include building and selling single-family detached homes and townhomes that are designed and built to meet local customer preferences, and the sale of lots. Builder operations consist of three operating segments: Texas, Georgia, and corporate and other. Corporate operations segment develops and implements strategic initiatives and supports its builder operations and land development by centralizing certain administrative functions, such as finance, treasury, information technology and human resources. The land development segment includes operations related to the acquisition and development of land, which is sold to its controlled builders and third-party homebuilders. As of December 31, 2016, it had owned or controlled over 5,200 home sites in various locations in the Dallas and Atlanta markets.
The following table summarizes whether the stock meets each of this strategy's tests. Not all criteria in the below table receive equal weighting or are independent, but the table provides a brief overview of the strong and weak points of the security in the context of the strategy's criteria.
INVENTORY TO SALES: PASS
YIELD ADJUSTED P/E TO GROWTH (PEG) RATIO: PASS
EARNINGS PER SHARE: PASS
TOTAL DEBT/EQUITY RATIO: PASS
FREE CASH FLOW: NEUTRAL
NET CASH POSITION: NEUTRAL
For a full detailed analysis using NASDAQ's Guru Analysis tool, click here
B. RILEY FINANCIAL INC (RILY) is a small-cap value stock in the Investment Services industry. The rating according to our strategy based on Peter Lynch changed from 0% to 93% based on the firm’s underlying fundamentals and the stock’s valuation. A score of 80% or above typically indicates that the strategy has some interest in the stock and a score above 90% typically indicates strong interest.
Company Description: B. Riley Financial, Inc. is an independent investment bank. The Company's segments include capital markets, auction and liquidation, valuation and appraisal, and Principal Investments-United Online. The capital markets segment provides an array of investment banking, corporate finance, research, wealth management, sales and trading services to corporate, institutional and high net worth clients. The auction and liquidation segment utilizes a scalable network of independent contractors and industry-specific advisors to tailor its services to the needs of a multitude of clients, logistical challenges and distressed circumstances. The valuation and appraisal segment provides valuation and appraisal services to financial institutions, lenders, private equity firms and other providers of capital. The principal investments-United Online segment consists of businesses, which has been acquired primarily for attractive investment return characteristics.
The following table summarizes whether the stock meets each of this strategy's tests. Not all criteria in the below table receive equal weighting or are independent, but the table provides a brief overview of the strong and weak points of the security in the context of the strategy's criteria.
P/E/GROWTH RATIO: PASS
SALES AND P/E RATIO: NEUTRAL
EPS GROWTH RATE: PASS
TOTAL DEBT/EQUITY RATIO: NEUTRAL
EQUITY/ASSETS RATIO: PASS
RETURN ON ASSETS: PASS
FREE CASH FLOW: NEUTRAL
NET CASH POSITION: NEUTRAL
For a full detailed analysis using NASDAQ's Guru Analysis tool, click here
GREAT WESTERN BANCORP INC (GWB) is a small-cap value stock in the Regional Banks industry. The rating according to our strategy based on Peter Lynch changed from 72% to 74% based on the firm’s underlying fundamentals and the stock’s valuation. A score of 80% or above typically indicates that the strategy has some interest in the stock and a score above 90% typically indicates strong interest.
Company Description: Great Western Bancorp, Inc. is a full-service regional bank holding company. The Company is the holding company of the Great Western Bank (the Bank). As of September 30, 2016, the Company served customers through 173 branches in various markets in Arizona, Colorado, Iowa, Kansas, Minnesota, Missouri, Nebraska, North Dakota and South Dakota. The Company focuses on business and agribusiness banking, complemented by retail banking and wealth management services. The Company's loan portfolio consists primarily of business loans, consisting of commercial and industrial loans (C&I), commercial real estate loans and agribusiness loans. The Company offers its business banking customers a focused range of financial products designed to meet the specific needs of their businesses, including loans, lines of credit, cash management services, online business deposit and wire transfer services, in addition to non-interest-bearing demand deposit and savings accounts, and corporate credit cards.
The following table summarizes whether the stock meets each of this strategy's tests. Not all criteria in the below table receive equal weighting or are independent, but the table provides a brief overview of the strong and weak points of the security in the context of the strategy's criteria.
YIELD ADJUSTED P/E TO GROWTH (PEG) RATIO: PASS
EARNINGS PER SHARE: PASS
TOTAL DEBT/EQUITY RATIO: NEUTRAL
EQUITY/ASSETS RATIO: PASS
RETURN ON ASSETS: PASS
FREE CASH FLOW: NEUTRAL
NET CASH POSITION: NEUTRAL
For a full detailed analysis using NASDAQ's Guru Analysis tool, click here
ABBVIE INC (ABBV) is a large-cap growth stock in the Biotechnology & Drugs industry. The rating according to our strategy based on Peter Lynch changed from 72% to 74% based on the firm’s underlying fundamentals and the stock’s valuation. A score of 80% or above typically indicates that the strategy has some interest in the stock and a score above 90% typically indicates strong interest.
Company Description: AbbVie Inc. (AbbVie) is a research-based biopharmaceutical company. The Company is engaged in the discovery, development, manufacture and sale of a range of pharmaceutical products. Its products are focused on treating conditions, such as chronic autoimmune diseases in rheumatology, gastroenterology and dermatology; oncology, including blood cancers; virology, including hepatitis C virus (HCV) and human immunodeficiency virus (HIV); neurological disorders, such as Parkinson's disease and multiple sclerosis; metabolic diseases, including thyroid disease and complications associated with cystic fibrosis, and other serious health conditions. It offers products in various categories, including HUMIRA (adalimumab), Oncology products, Virology Products, Additional Virology products, Metabolics/Hormones products, Endocrinology products and other products, which include Duopa and Duodopa (carbidopa and levodopa), Anesthesia products and ZINBRYTA (daclizumab).
The following table summarizes whether the stock meets each of this strategy's tests. Not all criteria in the below table receive equal weighting or are independent, but the table provides a brief overview of the strong and weak points of the security in the context of the strategy's criteria.
P/E/GROWTH RATIO: PASS
SALES AND P/E RATIO: PASS
INVENTORY TO SALES: PASS
EPS GROWTH RATE: PASS
TOTAL DEBT/EQUITY RATIO: FAIL
FREE CASH FLOW: NEUTRAL
NET CASH POSITION: NEUTRAL
For a full detailed analysis using NASDAQ's Guru Analysis tool, click here
EAGLE PHARMACEUTICALS INC (EGRX) is a small-cap growth stock in the Biotechnology & Drugs industry. The rating according to our strategy based on Peter Lynch changed from 0% to 87% based on the firm’s underlying fundamentals and the stock’s valuation. A score of 80% or above typically indicates that the strategy has some interest in the stock and a score above 90% typically indicates strong interest.
Company Description: Eagle Pharmaceuticals, Inc. is a specialty pharmaceutical company. The Company focuses on developing and commercializing injectable products in the critical care and oncology areas. The Company's product portfolio includes products, including Argatroban; Ryanodex; docetaxel injection, non-alcohol formulation; and Bendeka. Its advanced candidates include EP-3101 (bendamustine Resistance Temperature Detectors (RTD)) (EP-3101), EP-4104 (dantrolene sodium for exertional heat stroke (EHS)) (EP-4104), EGL-4104-C-1702 (dantrolene sodium for drug induced hyperthermia), EP-5101 (pemetrexed) (EP-5101) and EGL-5385-C-1701 (fulvestrant). Its product portfolio focuses on oncology, critical care and orphan diseases. Bendamustine is an alkylating agent approved for use in chronic lymphocytic leukemia (CLL), and indolent B-cell non-Hodgkin's lymphoma (NHL), that has progressed during or within six months of treatment with rituximab or a rituximab-containing regimen.
The following table summarizes whether the stock meets each of this strategy's tests. Not all criteria in the below table receive equal weighting or are independent, but the table provides a brief overview of the strong and weak points of the security in the context of the strategy's criteria.
P/E/GROWTH RATIO: PASS
SALES AND P/E RATIO: NEUTRAL
INVENTORY TO SALES: PASS
EPS GROWTH RATE: PASS
TOTAL DEBT/EQUITY RATIO: PASS
FREE CASH FLOW: NEUTRAL
NET CASH POSITION: NEUTRAL
For a full detailed analysis using NASDAQ's Guru Analysis tool, click here
SILVERCREST ASSET MANAGEMENT GROUP INC (SAMG) is a small-cap value stock in the Investment Services industry. The rating according to our strategy based on Peter Lynch changed from 80% to 98% based on the firm’s underlying fundamentals and the stock’s valuation. A score of 80% or above typically indicates that the strategy has some interest in the stock and a score above 90% typically indicates strong interest.
Company Description: Silvercrest Asset Management Group Inc. (Silvercrest) is a full-service wealth management firm focused on providing financial advisory and related family office services to ultra-high net worth individuals and institutional investors. The Company offers a suite of family office services for families seeking oversight of financial affairs. It advises clients on traditional investment strategies focused on equities, fixed income and cash, as well as non-traditional investment strategies, including hedge funds, private equity funds, real estate and commodities. It offers clients an array of investment solutions together with an array of non-proprietary solutions offered by unaffiliated firms selected. Silvercrest's family office services include financial planning; tax planning and preparation; partnership accounting and fund administration; consolidated wealth reporting; estate or trust agency, and art consultancy and management.
The following table summarizes whether the stock meets each of this strategy's tests. Not all criteria in the below table receive equal weighting or are independent, but the table provides a brief overview of the strong and weak points of the security in the context of the strategy's criteria.
P/E/GROWTH RATIO: PASS
SALES AND P/E RATIO: NEUTRAL
EPS GROWTH RATE: PASS
TOTAL DEBT/EQUITY RATIO: NEUTRAL
EQUITY/ASSETS RATIO: PASS
RETURN ON ASSETS: PASS
FREE CASH FLOW: NEUTRAL
NET CASH POSITION: BONUS PASS
For a full detailed analysis using NASDAQ's Guru Analysis tool, click here
THIRD POINT REINSURANCE LTD (TPRE) is a small-cap value stock in the Insurance (Prop. & Casualty) industry. The rating according to our strategy based on Peter Lynch changed from 0% to 89% based on the firm’s underlying fundamentals and the stock’s valuation. A score of 80% or above typically indicates that the strategy has some interest in the stock and a score above 90% typically indicates strong interest.
Company Description: Third Point Reinsurance Ltd. is a holding company. Through the Company's reinsurance subsidiaries, it provides property and casualty reinsurance coverage to insurance and reinsurance companies. The Company's segments include Property and Casualty Reinsurance, and Corporate. The Company's investable assets are managed by its investment manager, Third Point LLC. The Company also writes reinsurance contracts that provide protection against adverse development on loss reserves. Through Third Point LLC, the Company makes investments globally in all sectors, and in equity, credit, commodity, currency, options and other instruments. The Company also acts as the underwriter for the majority of the premium that it underwrites. The Company writes reinsurance contracts covering product lines, such as property, workers' compensation, auto, general liability, professional liability, credit and financial lines, and multi-line.
The following table summarizes whether the stock meets each of this strategy's tests. Not all criteria in the below table receive equal weighting or are independent, but the table provides a brief overview of the strong and weak points of the security in the context of the strategy's criteria.
P/E/GROWTH RATIO: PASS
SALES AND P/E RATIO: NEUTRAL
EPS GROWTH RATE: FAIL
TOTAL DEBT/EQUITY RATIO: NEUTRAL
EQUITY/ASSETS RATIO: PASS
RETURN ON ASSETS: PASS
FREE CASH FLOW: NEUTRAL
NET CASH POSITION: BONUS PASS
For a full detailed analysis using NASDAQ's Guru Analysis tool, click here
XPEL INC (XPEL) is a small-cap growth stock in the Business Services industry. The rating according to our strategy based on Peter Lynch changed from 72% to 74% based on the firm’s underlying fundamentals and the stock’s valuation. A score of 80% or above typically indicates that the strategy has some interest in the stock and a score above 90% typically indicates strong interest.
Company Description: Xpel Inc., formerly XPEL Technologies Corp., manufactures, sells and installs after-market automotive products, including automotive paint protection film, headlight protection film, automotive window films and other related products. The Company offers bulk paint protection film (PPF), pre-cut PPF and headlight protection kits. In the United States, Canada and parts of Europe, it operates primarily by selling a turnkey solution directly to independent installers and new car dealerships, which includes XPEL Protection Films, installation training, access to the Company's Design Access Program (DAP) Software, marketing support and lead generation. It operates approximately five Company-owned installation centers that serve wholesale and/or retail customers in their respective markets. In other parts of the world, it operates primarily through third-party distributors operating under agreement with the Company to develop a market or a region under the Company's supervision and direction.
The following table summarizes whether the stock meets each of this strategy's tests. Not all criteria in the below table receive equal weighting or are independent, but the table provides a brief overview of the strong and weak points of the security in the context of the strategy's criteria.
P/E/GROWTH RATIO: PASS
SALES AND P/E RATIO: NEUTRAL
EPS GROWTH RATE: FAIL
TOTAL DEBT/EQUITY RATIO: PASS
FREE CASH FLOW: NEUTRAL
NET CASH POSITION: NEUTRAL
For a full detailed analysis using NASDAQ's Guru Analysis tool, click here
SILVERGATE CAPITAL CORP (SI) is a small-cap value stock in the Regional Banks industry. The rating according to our strategy based on Peter Lynch changed from 72% to 93% based on the firm’s underlying fundamentals and the stock’s valuation. A score of 80% or above typically indicates that the strategy has some interest in the stock and a score above 90% typically indicates strong interest.
Company Description: Silvergate Capital Corp. is a bank holding company for Silvergate Bank, which is a provider of financial infrastructure solutions and services to participants in the digital currency industry. It has designed Silvergate Exchange Network (SEN), a network of digital currency exchanges and digital currency investors that enables the movement of the currency between participating digital currency exchanges and investors. Its services include commercial banking, business lending, commercial and residential real estate lending and mortgage warehouse lending. The commercial real estate lending activities focuses on deposit and cash management services for digital currency-related businesses, as well as mortgage warehouse and correspondent residential lending. It provides a range of deposit products and services, including a variety of checking and savings accounts, certificates of deposit, online banking, mobile banking, e-Statements, bank-by-mail and direct deposit services.
The following table summarizes whether the stock meets each of this strategy's tests. Not all criteria in the below table receive equal weighting or are independent, but the table provides a brief overview of the strong and weak points of the security in the context of the strategy's criteria.
P/E/GROWTH RATIO: PASS
SALES AND P/E RATIO: NEUTRAL
EPS GROWTH RATE: PASS
TOTAL DEBT/EQUITY RATIO: NEUTRAL
EQUITY/ASSETS RATIO: PASS
RETURN ON ASSETS: PASS
For a full detailed analysis using NASDAQ's Guru Analysis tool, click here
ATLANTIC UNION BANKSHARES CORP (AUB) is a small-cap value stock in the Regional Banks industry. The rating according to our strategy based on Peter Lynch changed from 72% to 74% based on the firm’s underlying fundamentals and the stock’s valuation. A score of 80% or above typically indicates that the strategy has some interest in the stock and a score above 90% typically indicates strong interest.
Company Description: Atlantic Union Bankshares Corporation, formerly Union Bankshares Corporation, is a financial holding company and bank holding company. The Company operates through a community bank segment. The Company offers financial services through its community bank subsidiary, Union Bank & Trust (the Bank) and three non-bank financial services affiliates. The Company's non-bank financial services affiliates include Union Insurance Group, LLC, which provides various lines of insurance products; Old Dominion Capital Management, Inc., Outfitter Advisors, Ltd., and Dixon, Hubard, Feinour & Brown, Inc., which provide investment advisory services. The community bank segment included one subsidiary bank, which provided loan, investment, and trust services to retail and commercial customers.
The following table summarizes whether the stock meets each of this strategy's tests. Not all criteria in the below table receive equal weighting or are independent, but the table provides a brief overview of the strong and weak points of the security in the context of the strategy's criteria.
YIELD ADJUSTED P/E TO GROWTH (PEG) RATIO: PASS
EARNINGS PER SHARE: PASS
TOTAL DEBT/EQUITY RATIO: NEUTRAL
EQUITY/ASSETS RATIO: PASS
RETURN ON ASSETS: PASS
FREE CASH FLOW: NEUTRAL
NET CASH POSITION: NEUTRAL
For a full detailed analysis using NASDAQ's Guru Analysis tool, click here
BJS WHOLESALE CLUB HOLDINGS INC (BJ) is a mid-cap growth stock in the Retail (Specialty) industry. The rating according to our strategy based on Peter Lynch changed from 72% to 74% based on the firm’s underlying fundamentals and the stock’s valuation. A score of 80% or above typically indicates that the strategy has some interest in the stock and a score above 90% typically indicates strong interest.
Company Description: BJ's Wholesale Club Holdings, Inc. is an operator of membership warehouse clubs in the Eastern United States. The Company provides a one-stop shopping destination filled with brands, including its exclusive Wellsley Farms and Berkley Jensen brands, along with USDA Choice meats, and delicious organics, many in supermarket sizes. The Company operates 215 clubs and 134 BJ's Gas locations in 16 states. The Company offers two base types of memberships Inner Circle memberships and business memberships. The Company also offers its co-branded My BJ's Perks, and Mastercard program. The Company's products are sold under Wellsley Farms and Berkley Jensen brands.
The following table summarizes whether the stock meets each of this strategy's tests. Not all criteria in the below table receive equal weighting or are independent, but the table provides a brief overview of the strong and weak points of the security in the context of the strategy's criteria.
P/E/GROWTH RATIO: PASS
SALES AND P/E RATIO: PASS
EPS GROWTH RATE: PASS
TOTAL DEBT/EQUITY RATIO: FAIL
FREE CASH FLOW: NEUTRAL
NET CASH POSITION: NEUTRAL
For a full detailed analysis using NASDAQ's Guru Analysis tool, click here
AGNC INVESTMENT CORP (AGNC) is a mid-cap value stock in the Real Estate Operations industry. The rating according to our strategy based on Peter Lynch changed from 72% to 74% based on the firm’s underlying fundamentals and the stock’s valuation. A score of 80% or above typically indicates that the strategy has some interest in the stock and a score above 90% typically indicates strong interest.
Company Description: AGNC Investment Corp., formerly American Capital Agency Corp., is a real estate investment trust. The Company invests in agency residential mortgage-backed securities on a leveraged basis. Its investments consist of residential mortgage pass-through securities and collateralized mortgage obligations (CMOs) for which the principal and interest payments are guaranteed by a government-sponsored enterprise, such as the Federal National Mortgage Association (Fannie Mae) and the Federal Home Loan Mortgage Corporation (Freddie Mac), or by the United States Government agency, such as the Government National Mortgage Association (Ginnie Mae) (collectively, GSEs). Its agency securities include agency residential mortgage-backed securities (Agency RMBS) and to-be-announced forward contracts (TBAs). Its Non-Agency Securities include credit risk transfer securities (CRT), non-agency residential mortgage-backed securities (Non-Agency RMBS) and commercial mortgage-backed securities (CMBS).
The following table summarizes whether the stock meets each of this strategy's tests. Not all criteria in the below table receive equal weighting or are independent, but the table provides a brief overview of the strong and weak points of the security in the context of the strategy's criteria.
YIELD ADJUSTED P/E TO GROWTH (PEG) RATIO: PASS
EARNINGS PER SHARE: PASS
TOTAL DEBT/EQUITY RATIO: FAIL
FREE CASH FLOW: NEUTRAL
NET CASH POSITION: NEUTRAL
For a full detailed analysis using NASDAQ's Guru Analysis tool, click here
TCG BDC INC (CGBD) is a small-cap value stock in the Misc. Financial Services industry. The rating according to our strategy based on Peter Lynch changed from 72% to 74% based on the firm’s underlying fundamentals and the stock’s valuation. A score of 80% or above typically indicates that the strategy has some interest in the stock and a score above 90% typically indicates strong interest.
Company Description: TCG BDC, Inc., formerly Carlyle GMS Finance, Inc., is a managed and non-diversified closed-end investment company. The Company is focused on lending to middle market companies. The Company's investment objective is to generate current income and capital appreciation primarily through debt investments in the United States and middle market companies. The Company seeks to achieve its investment objective primarily through direct originations of secured debt, including first lien senior secured loans and second lien senior secured loans. The Company's first lien senior secured loans include stand-alone first lien loans, first lien/last out loans, and unitranche loans. Second lien senior secured loans (Middle Market Senior Loans), with the balance of its assets invested yielding in higher investments include unsecured debt, mezzanine debt and investments in equities. The Company's investment adviser is Carlyle GMS Investment Management L.L.C.
The following table summarizes whether the stock meets each of this strategy's tests. Not all criteria in the below table receive equal weighting or are independent, but the table provides a brief overview of the strong and weak points of the security in the context of the strategy's criteria.
YIELD ADJUSTED P/E TO GROWTH (PEG) RATIO: PASS
EARNINGS PER SHARE: PASS
TOTAL DEBT/EQUITY RATIO: NEUTRAL
EQUITY/ASSETS RATIO: PASS
RETURN ON ASSETS: PASS
FREE CASH FLOW: NEUTRAL
NET CASH POSITION: NEUTRAL
For a full detailed analysis using NASDAQ's Guru Analysis tool, click here
BANCORPSOUTH BANK (BXS) is a mid-cap value stock in the Regional Banks industry. The rating according to our strategy based on Peter Lynch changed from 72% to 74% based on the firm’s underlying fundamentals and the stock’s valuation. A score of 80% or above typically indicates that the strategy has some interest in the stock and a score above 90% typically indicates strong interest.
Company Description: BancorpSouth Bank is a financial holding company. The Company, through its principal bank subsidiary, conducts commercial banking and financial services operations in Alabama, Arkansas, Florida, Louisiana, Mississippi, Missouri, Tennessee, Texas and Illinois. The Company's segments include Community Banking, Insurance Agencies, and General Corporate and Other. Its Community Banking segment provides a range of deposit products, commercial loans and consumer loans. Its Insurance Agencies segment serves as agents in the sale of commercial lines of insurance and full lines of property and casualty, life, health and employee benefits products and services. Its General Corporate and Other segment includes mortgage banking, trust services, credit card activities, investment services and other activities not allocated to the Community Banking or Insurance Agencies segments.
The following table summarizes whether the stock meets each of this strategy's tests. Not all criteria in the below table receive equal weighting or are independent, but the table provides a brief overview of the strong and weak points of the security in the context of the strategy's criteria.
YIELD ADJUSTED P/E TO GROWTH (PEG) RATIO: PASS
EARNINGS PER SHARE: PASS
TOTAL DEBT/EQUITY RATIO: NEUTRAL
EQUITY/ASSETS RATIO: PASS
RETURN ON ASSETS: PASS
For a full detailed analysis using NASDAQ's Guru Analysis tool, click here
SLEEP NUMBER CORP (SNBR) is a small-cap value stock in the Furniture & Fixtures industry. The rating according to our strategy based on Peter Lynch changed from 72% to 74% based on the firm’s underlying fundamentals and the stock’s valuation. A score of 80% or above typically indicates that the strategy has some interest in the stock and a score above 90% typically indicates strong interest.
Company Description: Sleep Number Corporation, formerly Select Comfort Corporation, is a designer, manufacturer, marketer, retailer and servicer of a line of Sleep Number beds. The Company offers consumers individualized sleep solutions and services, which include a complete line of Sleep Number beds, bases and bedding accessories. Its Sleep Number bed offers SleepIQ technology sensors that work directly with the bed's DualAir technology to track each individual's sleep. The Sleep Number bedding collection comprises a line of sleep products that are designed to solve sleep issues. It offers FlextFit adjustable bases, and Sleep Number pillows, sheets and other bedding products. It offers Sleep Number beds in ranges within the mattress category, and in a range of sizes, including twin, full, queen, eastern king and California king. It also offers an assortment of temperature-balancing products.
The following table summarizes whether the stock meets each of this strategy's tests. Not all criteria in the below table receive equal weighting or are independent, but the table provides a brief overview of the strong and weak points of the security in the context of the strategy's criteria.
P/E/GROWTH RATIO: PASS
SALES AND P/E RATIO: PASS
INVENTORY TO SALES: PASS
EPS GROWTH RATE: PASS
TOTAL DEBT/EQUITY RATIO: FAIL
FREE CASH FLOW: NEUTRAL
NET CASH POSITION: NEUTRAL
For a full detailed analysis using NASDAQ's Guru Analysis tool, click here
TAPESTRY INC (TPR) is a mid-cap value stock in the Apparel/Accessories industry. The rating according to our strategy based on Peter Lynch changed from 0% to 91% based on the firm’s underlying fundamentals and the stock’s valuation. A score of 80% or above typically indicates that the strategy has some interest in the stock and a score above 90% typically indicates strong interest.
Company Description: Tapestry, Inc., formerly Coach, Inc., is a design house of luxury accessories and lifestyle collections. The Company's product offering uses a range of leathers, fabrics and materials. The Company's brands include Coach, Kate Spade, and Stuart Weitzman. Its segments include North America, International and Stuart Weitzman. The North America segment includes sales of Tapestry brand products to North American customers through Tapestry-operated stores (including the Internet) and sales to North American wholesale customers. The International segment operates department store concession shop-in-shop locations and retail and outlet stores, as well as e-commerce Websites. The Stuart Weitzman segment includes sales across the world generated by the Stuart Weitzman brand, primarily through department stores in North America and international locations, and within Stuart Weitzman operated stores (including the Internet) in the United States, Canada and Europe.
The following table summarizes whether the stock meets each of this strategy's tests. Not all criteria in the below table receive equal weighting or are independent, but the table provides a brief overview of the strong and weak points of the security in the context of the strategy's criteria.
SALES: PASS
INVENTORY TO SALES: PASS
YIELD COMPARED TO THE S&P 500: PASS
YIELD ADJUSTED P/E/GROWTH (PEG) RATIO: PASS
TOTAL DEBT/EQUITY RATIO: PASS
FREE CASH FLOW: NEUTRAL
NET CASH POSITION: NEUTRAL
For a full detailed analysis using NASDAQ's Guru Analysis tool, click here
Since its inception, Validea's strategy based on Peter Lynch has returned 306.00% vs. 176.29% for the S&P 500. For more details on this strategy, click here
About Peter Lynch: Perhaps the greatest mutual fund manager of all-time, Lynch guided Fidelity Investment's Magellan Fund to a 29.2 percent average annual return from 1977 until his retirement in 1990, almost doubling the S&P 500's 15.8 percent yearly return over that time. Lynch's common sense approach and quick wit made him one of the most quoted investors on Wall Street. ("Go for a business that any idiot can run -- because sooner or later, any idiot probably is going to run it," is one of his many pearls of wisdom.) Lynch's bestseller One Up on Wall Street is something of a "stocks for the everyman/everywoman", breaking his approach down into easy-to-understand concepts.
About Validea: Validea is aninvestment researchservice that follows the published strategies of investment legends. Validea offers both stock analysis and model portfolios based on gurus who have outperformed the market over the long-term, including Warren Buffett, Benjamin Graham, Peter Lynch and Martin Zweig. For more information about Validea, click here
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | For a full detailed analysis using NASDAQ's Guru Analysis tool, click here ABBVIE INC (ABBV) is a large-cap growth stock in the Biotechnology & Drugs industry. Company Description: AbbVie Inc. (AbbVie) is a research-based biopharmaceutical company. The Company serves various end markets, including petroleum refining, consumer electronics, energy storage, construction, automotive, lubricants, pharmaceuticals, crop protection, food safety and custom chemistry services. | For a full detailed analysis using NASDAQ's Guru Analysis tool, click here ABBVIE INC (ABBV) is a large-cap growth stock in the Biotechnology & Drugs industry. Company Description: AbbVie Inc. (AbbVie) is a research-based biopharmaceutical company. The Company operates through segments, including Construction Industries, which is engaged in supporting customers using machinery in infrastructure, forestry and building construction; Resource Industries, which is engaged in supporting customers using machinery in mining, quarry, waste and material handling applications; Energy & Transportation, which supports customers in oil and gas, power generation, marine, rail and industrial applications, including Cat machines; Financial Products segment, which provides financing and related services, and All Other operating segments, which includes activities, such as product management and development, and manufacturing of filters and fluids, undercarriage, tires and rims, ground engaging tools, fluid transfer products, and sealing and connecting components for Cat products. | For a full detailed analysis using NASDAQ's Guru Analysis tool, click here ABBVIE INC (ABBV) is a large-cap growth stock in the Biotechnology & Drugs industry. Company Description: AbbVie Inc. (AbbVie) is a research-based biopharmaceutical company. The Company operates through segments, including Construction Industries, which is engaged in supporting customers using machinery in infrastructure, forestry and building construction; Resource Industries, which is engaged in supporting customers using machinery in mining, quarry, waste and material handling applications; Energy & Transportation, which supports customers in oil and gas, power generation, marine, rail and industrial applications, including Cat machines; Financial Products segment, which provides financing and related services, and All Other operating segments, which includes activities, such as product management and development, and manufacturing of filters and fluids, undercarriage, tires and rims, ground engaging tools, fluid transfer products, and sealing and connecting components for Cat products. | For a full detailed analysis using NASDAQ's Guru Analysis tool, click here ABBVIE INC (ABBV) is a large-cap growth stock in the Biotechnology & Drugs industry. Company Description: AbbVie Inc. (AbbVie) is a research-based biopharmaceutical company. The Company's products include systems, and installed base products and services. |
24667.0 | 2020-03-09 00:00:00 UTC | AbbVie: Chinese Media Reports Claim HIV Medicine Effective In COVID-19 Treatment | ABBV | https://www.nasdaq.com/articles/abbvie%3A-chinese-media-reports-claim-hiv-medicine-effective-in-covid-19-treatment-2020-03 | nan | nan | (RTTNews) - AbbVie said Monday that unconfirmed media reports from China claimed that the HIV medicine, Kaletra/Aluvia or lopinavir/ritonavir is effective in COVID-19 treatment.
But, the company said it does not have access to Chinese clinical information and therefore cannot confirm its accuracy.
The company said it donated Aluvia to the Chinese government for experimental use against COVID-19.
The company also noted that it is working with global health authorities to determine the efficacy and safety of the HIV medicine, Kaletra/Aluvia or lopinavir/ritonavir against COVID-19.
Meanwhile, the company stated that it does not anticipate disruption to the medicine supply for HIV patients as a result of the investigation of the effectiveness against COVID-19.
AbbVie was down $5.32 or 5.99 percent to $83.50 in the pre-Market trade.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | (RTTNews) - AbbVie said Monday that unconfirmed media reports from China claimed that the HIV medicine, Kaletra/Aluvia or lopinavir/ritonavir is effective in COVID-19 treatment. AbbVie was down $5.32 or 5.99 percent to $83.50 in the pre-Market trade. The company also noted that it is working with global health authorities to determine the efficacy and safety of the HIV medicine, Kaletra/Aluvia or lopinavir/ritonavir against COVID-19. | (RTTNews) - AbbVie said Monday that unconfirmed media reports from China claimed that the HIV medicine, Kaletra/Aluvia or lopinavir/ritonavir is effective in COVID-19 treatment. AbbVie was down $5.32 or 5.99 percent to $83.50 in the pre-Market trade. The company also noted that it is working with global health authorities to determine the efficacy and safety of the HIV medicine, Kaletra/Aluvia or lopinavir/ritonavir against COVID-19. | (RTTNews) - AbbVie said Monday that unconfirmed media reports from China claimed that the HIV medicine, Kaletra/Aluvia or lopinavir/ritonavir is effective in COVID-19 treatment. AbbVie was down $5.32 or 5.99 percent to $83.50 in the pre-Market trade. The company also noted that it is working with global health authorities to determine the efficacy and safety of the HIV medicine, Kaletra/Aluvia or lopinavir/ritonavir against COVID-19. | (RTTNews) - AbbVie said Monday that unconfirmed media reports from China claimed that the HIV medicine, Kaletra/Aluvia or lopinavir/ritonavir is effective in COVID-19 treatment. AbbVie was down $5.32 or 5.99 percent to $83.50 in the pre-Market trade. But, the company said it does not have access to Chinese clinical information and therefore cannot confirm its accuracy. |
24668.0 | 2020-03-08 00:00:00 UTC | 5 High-Yield Dividend Stocks to Watch in the Coronavirus Sell-Off | ABBV | https://www.nasdaq.com/articles/5-high-yield-dividend-stocks-to-watch-in-the-coronavirus-sell-off-2020-03-08 | nan | nan | In a world where investors struggle to earn decent returns from fixed-income instruments, dividend stocks have emerged as a strategy for earning higher returns. The average dividend yield for the S&P 500 is just over 1.9%, dramatically higher than the 0.09% in interest people earn in a savings account on average.
Moreover, the stock market offers investments that not only produce dividend yields that significantly exceed that average, but they also provide the income or cash flow that will allow them to maintain or increase dividends over time. Here are five stocks in five different industries that fit that description. Investors with cash on the sidelines to deploy at current discounted prices should consider these high-paying stocks.
1. AbbVie
AbbVie (NYSE: ABBV) stock sold off in recent years due to the impending patent expiration of its primary revenue driver, Humira. As it began to recover amid new drug developments, the announcement of its purchase of Allergan initially weighed further on the stock.
However, AbbVie looks positioned to move on from Humira. Two hematologic oncology drugs, Imbruvica and Venclexta, together registered 37% in reported revenue growth year over year. Humira saw no net increase over the same period.
Image source: Getty Images.
Moreover, AbbVie has shown signs of recovery in recent months. Despite this increase, AbbVie stock trades at a forward P/E ratio of around 8.7. This occurred despite the fact that analysts forecast earnings increases of 8.3% this year and 8.7% in fiscal 2021.
Furthermore, due to its history as a subsidiary of Abbott Laboratories, it has now benefited from 47 consecutive years of payout hikes. This year's annual payout of $4.72 per share yields around 5.3%.
The company should be able to easily maintain this dividend. The dividend payout ratio stands at about 48.8%, and cash flow has consistently come in well above the cost of paying the dividend. Moreover, Dividend Aristocrats such as AbbVie tend to continue dividend hikes unless the company's financial condition makes payout raises untenable. As sales of its hematologic oncology drugs continue to grow, investors could find it hard to pass up on this growth and income play.
2. AT&T
AT&T (NYSE: T) struggled for much of the decade as wireless competition and cord-cutting ate into the telecom giant's profits. On top of that, the cost of building out a 5G network weighed on the company. Then, acquisitions of DirecTV and the division now known as WarnerMedia placed further pressure on AT&T's balance sheet.
The company's dividend is another significant cost. In 2019, dividend payments set the company back $14.89 billion. The yearly payout has since risen from $2.04 to $2.08 per share.
However, AT&T is also a Dividend Aristocrat, and the company probably wants to avoid the pain of ending the 35-year streak of payout hikes. Hence, even at a yield of around 5.8%, the dividend will likely keep rising. Furthermore, at a payout ratio of about 57.6%, AT&T can probably continue to fund the dividend.
To be sure, the profit growth rate of 1.1% forecasted for the year will likely not inspire investors. However, profit growth should improve, and once 5G takes off, AT&T will be one of only three companies providing this next-generation service in the U.S. Furthermore, with a forward P/E ratio of around 9.9, investors can pick this stock up at a relative bargain.
3. Altria
Altria (NYSE: MO) continues to defy odds. The Surgeon General's report that warned of the dangers of smoking came out more than 56 years ago. At that time, around 42% of Americans smoked cigarettes.
That number fell to 15.5% by 2016. Nonetheless, both Altria stock and its dividend continued to rise amid the smoking decline. In January 1964, Altria traded at a split-adjusted level of about $0.13 per share. The stock has since seen seven stock splits and numerous dividend increases. The current $3.36 per share annual dividend yields around 8.3% and has risen for 11 consecutive years.
Further, even with the massive increases, Altria sells for only about 9.2 times forward earnings. While the payout ratio of around 75.8% may appear elevated, earnings growth of 5% for the current year should be enough to keep the high payout and the subsequent increases coming.
Altria continues to face challenges. Declines in smoking could still hurt the company's growth. Also, the SEC probe of the JUUL Labs investment could weigh on Altria stock for now. However, Altria also invested $1.8 billion in Canadian marijuana giant Cronos Group. As more jurisdictions legalize cannabis for both medical and recreational purposes, this investment could eventually drive earnings growth for Altria stock.
4. ExxonMobil
ExxonMobil's (NYSE: XOM) yearly dividend of $3.48 per share, or a yield of 6.75%, seems impressive. However, a slowdown in China related to the coronavirus has reduced overall energy consumption. This caused ExxonMobil stock to drop by nearly 27% in the first two months of 2020.
Still, some seem to forget that ExxonMobil is a diversified energy play. Yes, its upstream segment deals with volatility as fluctuating oil prices often make or break the profitability of drilling projects. However, the company also refines and sells petroleum products and chemicals, a relatively steady business regardless of oil prices.
Moreover, for all of the focus on renewables, electric vehicles only made up 1.8% of all vehicle sales in March 2019. Hence, investors can safely assume that fossil fuels are not going anywhere.
Nonetheless, ExxonMobil now trades at a forward P/E ratio of around 14. With five-year profit growth projections averaging 5.65% per year, the dividend is arguably the primary motivation to buy Exxon stock now.
More importantly, ExxonMobil has maintained a 37-year streak of consecutive annual payout hikes. This means the dividend rose in both high and low-oil-price environments. It also means that dividends increased when the payout ratio reached 108.9%, as it has now. Free cash flow fell well below the dividend expense in 2019. Still, even if prices remain depressed, both divestitures and new ventures could fund annual payout hikes for the foreseeable future.
5. PennyMac Mortgage Investment Trust
PennyMac Mortgage Investment Trust (NYSE: PMT) specializes in mortgage-related assets, particularly on the residential side. As a real estate investment trust, it must pay out at least 90% of its net income in the form of dividends to avoid most income taxes.
PennyMac is not a household name among stocks. However, the payout could compensate for a lack of name recognition. Current shareholders receive an annual payout of $1.88 per share, a yield of around 8.75%.
Moreover, given the previously mentioned 90% payout requirement, the dividend payout ratio of about 84.5% appears slightly low. Also, in 2019, it generated almost $201.42 million in net income attributable to common shareholders, more than enough to cover the required dividend payments.
Furthermore, in addition to the dividend, PennyMac stock trades at a reasonable valuation. It sells for just over 10.1 times forward earnings. The average annual earnings growth rate of 4.15% may not excite investors. Still, given its dividend, investors will more than likely buy PennyMac primarily for its payout, which has remained steady since 2015. Moreover, as income rises, payouts will have to rise for the company to maintain its REIT status.
10 stocks we like better than AT&T
When investing geniuses David and Tom Gardner have a stock tip, it can pay to listen. After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor, has tripled the market.*
David and Tom just revealed what they believe are the ten best stocks for investors to buy right now... and AT&T wasn't one of them! That's right -- they think these 10 stocks are even better buys.
See the 10 stocks
*Stock Advisor returns as of December 1, 2019
Will Healy owns shares of AbbVie. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | AbbVie AbbVie (NYSE: ABBV) stock sold off in recent years due to the impending patent expiration of its primary revenue driver, Humira. However, AbbVie looks positioned to move on from Humira. Moreover, AbbVie has shown signs of recovery in recent months. | AbbVie AbbVie (NYSE: ABBV) stock sold off in recent years due to the impending patent expiration of its primary revenue driver, Humira. However, AbbVie looks positioned to move on from Humira. Moreover, AbbVie has shown signs of recovery in recent months. | Moreover, Dividend Aristocrats such as AbbVie tend to continue dividend hikes unless the company's financial condition makes payout raises untenable. AbbVie AbbVie (NYSE: ABBV) stock sold off in recent years due to the impending patent expiration of its primary revenue driver, Humira. However, AbbVie looks positioned to move on from Humira. | AbbVie AbbVie (NYSE: ABBV) stock sold off in recent years due to the impending patent expiration of its primary revenue driver, Humira. However, AbbVie looks positioned to move on from Humira. Moreover, AbbVie has shown signs of recovery in recent months. |
24669.0 | 2020-03-06 00:00:00 UTC | Is There a Cure for the SARS-CoV-2 Coronavirus? | ABBV | https://www.nasdaq.com/articles/is-there-a-cure-for-the-sars-cov-2-coronavirus-2020-03-06 | nan | nan | There have been over 100,000 confirmed cases of COVID-19, the disease caused by the novel coronavirus SARS-CoV-2, and more than 3,400 people have died from the disease, according to data tracked by Johns Hopkins University's Center for Systems Science and Engineering. Unfortunately, there is no cure for the disease yet, but multiple drugmakers are working on treatments that might help fight off the coronavirus or prevent infections altogether.
Because it takes awhile to discover and develop new drugs, most treatments being tested against COVID-19 right now were designed to treat other viral infections. Pharmaceuticals hope they can be effectively repurposed to combat this one.
Gilead Sciences (NASDAQ: GILD) has started two clinical trials testing remdesivir, which had only limited success as an Ebola treatment, in patients with COVID-19. Both double-blind trials will test 5- and 10-day treatment regimens, but one will enroll patients with moderate cases, while the other will enroll those with severe manifestations.
Johnson & Johnson (NYSE: JNJ) has donated its drugs for HIV as potential treatments for the coronavirus. Since both viruses are RNA-based, the theory is that the protease inhibitors that block HIV viral replication might also block the replication of SARS-CoV-2. AbbVie's (NYSE: ABBV) HIV drug Kaletra has also been tested on patients with some reports of patients recovering. The treatments weren't part of a clinical trial, so there's no way of knowing if the drug helped the patients or if they would have recovered on their own.
Image source: Getty Images.
Takeda (NYSE: TAK) recently announced plans for what it dubs TAK-888, a plasma-derived therapy. Takeda will take blood from people who have recovered from COVID-19 -- and therefore have antibodies to the coronavirus -- and extract those antibodies to create a treatment for new patients.
Other companies are attempting to develop effective vaccines to protect against the coronavirus. Both Moderna (NASDAQ: MRNA) and Inovio Pharmaceuticals (NASDAQ: INO) plan to start clinical trials of their vaccine candidates next month.
10 stocks we like better than Johnson & Johnson
When investing geniuses David and Tom Gardner have a stock tip, it can pay to listen. After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor, has tripled the market.*
David and Tom just revealed what they believe are the ten best stocks for investors to buy right now... and Johnson & Johnson wasn't one of them! That's right -- they think these 10 stocks are even better buys.
See the 10 stocks
*Stock Advisor returns as of December 1, 2019
Brian Orelli has no position in any of the stocks mentioned. The Motley Fool owns shares of and recommends Gilead Sciences. The Motley Fool recommends Johnson & Johnson. The Motley Fool has a disclosure policy.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | AbbVie's (NYSE: ABBV) HIV drug Kaletra has also been tested on patients with some reports of patients recovering. Unfortunately, there is no cure for the disease yet, but multiple drugmakers are working on treatments that might help fight off the coronavirus or prevent infections altogether. Because it takes awhile to discover and develop new drugs, most treatments being tested against COVID-19 right now were designed to treat other viral infections. | AbbVie's (NYSE: ABBV) HIV drug Kaletra has also been tested on patients with some reports of patients recovering. Gilead Sciences (NASDAQ: GILD) has started two clinical trials testing remdesivir, which had only limited success as an Ebola treatment, in patients with COVID-19. Both Moderna (NASDAQ: MRNA) and Inovio Pharmaceuticals (NASDAQ: INO) plan to start clinical trials of their vaccine candidates next month. | AbbVie's (NYSE: ABBV) HIV drug Kaletra has also been tested on patients with some reports of patients recovering. Gilead Sciences (NASDAQ: GILD) has started two clinical trials testing remdesivir, which had only limited success as an Ebola treatment, in patients with COVID-19. Johnson & Johnson (NYSE: JNJ) has donated its drugs for HIV as potential treatments for the coronavirus. | AbbVie's (NYSE: ABBV) HIV drug Kaletra has also been tested on patients with some reports of patients recovering. The treatments weren't part of a clinical trial, so there's no way of knowing if the drug helped the patients or if they would have recovered on their own. The Motley Fool recommends Johnson & Johnson. |
24670.0 | 2020-03-06 00:00:00 UTC | AbbVie : EU Approves Change To Marketing Authorization For Maviret | ABBV | https://www.nasdaq.com/articles/abbvie-%3A-eu-approves-change-to-marketing-authorization-for-maviret-2020-03-06 | nan | nan | (RTTNews) - AbbVie (ABBV) said Friday that the European Commission has approved a change to the marketing authorization for Maviret to shorten once-daily treatment duration from 12 to 8 weeks in treatment-naïve, compensated cirrhotic, chronic hepatitis C (HCV) patients with genotype (GT) 3 infection.
Maviret was already indicated as an 8-week, pan-genotypic (GT1-6), once-daily regimen for treatment-naïve HCV patients without cirrhosis, and as an 8-week, once-daily regimen for treatment-naïve GT 1, 2, 4, 5 and 6 HCV patients with compensated cirrhosis.
"A shorter treatment duration means that more patients with HCV can be treated with an 8-week course of MAVIRET in the absence of initial tests to determine their genotype or degree of fibrosis or cirrhosis," said Janet Hammond, vice president, general medicine and virology therapeutic area, AbbVie.
Maviret is approved in the European Union for the treatment of chronic hepatitis C virus (HCV) infection in adults and adolescents aged 12 to
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | (RTTNews) - AbbVie (ABBV) said Friday that the European Commission has approved a change to the marketing authorization for Maviret to shorten once-daily treatment duration from 12 to 8 weeks in treatment-naïve, compensated cirrhotic, chronic hepatitis C (HCV) patients with genotype (GT) 3 infection. "A shorter treatment duration means that more patients with HCV can be treated with an 8-week course of MAVIRET in the absence of initial tests to determine their genotype or degree of fibrosis or cirrhosis," said Janet Hammond, vice president, general medicine and virology therapeutic area, AbbVie. Maviret is approved in the European Union for the treatment of chronic hepatitis C virus (HCV) infection in adults and adolescents aged 12 to The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | (RTTNews) - AbbVie (ABBV) said Friday that the European Commission has approved a change to the marketing authorization for Maviret to shorten once-daily treatment duration from 12 to 8 weeks in treatment-naïve, compensated cirrhotic, chronic hepatitis C (HCV) patients with genotype (GT) 3 infection. "A shorter treatment duration means that more patients with HCV can be treated with an 8-week course of MAVIRET in the absence of initial tests to determine their genotype or degree of fibrosis or cirrhosis," said Janet Hammond, vice president, general medicine and virology therapeutic area, AbbVie. Maviret was already indicated as an 8-week, pan-genotypic (GT1-6), once-daily regimen for treatment-naïve HCV patients without cirrhosis, and as an 8-week, once-daily regimen for treatment-naïve GT 1, 2, 4, 5 and 6 HCV patients with compensated cirrhosis. | (RTTNews) - AbbVie (ABBV) said Friday that the European Commission has approved a change to the marketing authorization for Maviret to shorten once-daily treatment duration from 12 to 8 weeks in treatment-naïve, compensated cirrhotic, chronic hepatitis C (HCV) patients with genotype (GT) 3 infection. "A shorter treatment duration means that more patients with HCV can be treated with an 8-week course of MAVIRET in the absence of initial tests to determine their genotype or degree of fibrosis or cirrhosis," said Janet Hammond, vice president, general medicine and virology therapeutic area, AbbVie. Maviret was already indicated as an 8-week, pan-genotypic (GT1-6), once-daily regimen for treatment-naïve HCV patients without cirrhosis, and as an 8-week, once-daily regimen for treatment-naïve GT 1, 2, 4, 5 and 6 HCV patients with compensated cirrhosis. | (RTTNews) - AbbVie (ABBV) said Friday that the European Commission has approved a change to the marketing authorization for Maviret to shorten once-daily treatment duration from 12 to 8 weeks in treatment-naïve, compensated cirrhotic, chronic hepatitis C (HCV) patients with genotype (GT) 3 infection. "A shorter treatment duration means that more patients with HCV can be treated with an 8-week course of MAVIRET in the absence of initial tests to determine their genotype or degree of fibrosis or cirrhosis," said Janet Hammond, vice president, general medicine and virology therapeutic area, AbbVie. Maviret was already indicated as an 8-week, pan-genotypic (GT1-6), once-daily regimen for treatment-naïve HCV patients without cirrhosis, and as an 8-week, once-daily regimen for treatment-naïve GT 1, 2, 4, 5 and 6 HCV patients with compensated cirrhosis. |
24671.0 | 2020-03-05 00:00:00 UTC | 3 Top Large-Cap Stocks to Buy in March | ABBV | https://www.nasdaq.com/articles/3-top-large-cap-stocks-to-buy-in-march-2020-03-05 | nan | nan | February is finally in the rearview mirror, and none too soon. While it started out on the right foot, it ended in disaster. The last week of the month dished out an 11.5% loss for the S&P 500, translating into an 8.4% setback for the full month. It was the worst single week for stocks since 2008 when we were in the throes of the subprime mortgage meltdown.
As is so often the case though, the sell-off was self-exaggerating, meaning investors flinched at the first sign of trouble, prompting more selling, prompting even more fear, prompting even more selling, and so on. It was not until late last week that the market realized a much-needed correction may have been completed, in full. That's not to say stocks can only move higher from here. It is to suggest, however, there may be more upside than downside ahead.
With that as the backdrop, here's a look at three of the top large-cap stocks (generally, companies with a market capitalization of more than $10 billion) that went "on sale" as a result of the recent drubbing and may be worth adding to your portfolio.
Image source: Getty Images.
1. AbbVie (ABBV): $134 billion market cap
Through 2017, AbbVie (NYSE: ABBV) was practically bulletproof. The stock was riding high on the double-barreled growth of anti-inflammatory drug Humira and cancer therapy Imbruvica, and the world didn't seem to think the good news would ever end.
It did end, of course, or perhaps it would be more accurate to say it's in the process of ending. Humira's primary patent in Europe has expired, and it's set to expire in the United States by 2023 -- only a matter of minutes in the drug development world. Imbruvica is still going strong, but its sales growth is slowing down, and it still only makes up about 15% of the company's total revenue. It can't carry all of AbbVie's weight on its own.
Concerns about these realities are a key reason shares fell by 50% from peak to trough between early 2018 and August of last year. Its market cap now hovers around $134 billion with a P/E ratio of 17.1, indicating it's trading at a bargain.
Patent expirations and maturing drugs are nothing new to the big names in the business, however, including AbbVie. While it continues to cultivate its pipeline, it also adds to its portfolio via acquisitions, announcing a deal to acquire Allergan (NYSE: AGN) last year for $63 billion. It's a hefty price tag, but Allergan is also a prized asset. More importantly, nothing about the strategy is out of the ordinary. Most important of all, analysts expect AbbVie to grow the top line to the tune of 8% this year, and beef it up by 6.5% next year. Earnings are modeled to grow similarly, and the dividend yield of 3.6% isn't too shabby either.
2. Home Depot (HD): $259 billion market cap
Home improvement retailer Home Depot (NYSE: HD) aced its fiscal 2019 fourth-quarter report, earning $2.28 per share on sales of $25.78 billion, versus expectations of only $2.10 per share and a top line of $25.76 billion. Total revenue was down to the tune of 2.7%, but earnings were up from $2.09 per share, and perhaps most importantly, same-store sales grew 5.2% versus expectations of only a 4.8% increase.
Credit has to be given to the environment. Even with sluggish economic growth stemming from a tariff war with China, home buying has continued to grow. The National Association of Realtors' Pending Home Sales Index hit a two-year high in February, while building permits soared to a 13-year high in January. Actual sales of new homes in the United States also reached their best levels since 2007 in January, hitting an annualized pace of 764,000. All of it drives consumers and homebuilders to hardware stores.
More of the same is apt to be on the way too. The Federal Reserve just announced an emergency cut in the Fed Funds Rate, lowering its target range by 50 basis points in response to the potential adverse effects of the novel coronavirus outbreak. That, in turn, has pushed mortgage rates to near the all-time lows seen in 2012, which keeps home-investing an attractive proposition for most consumers. Home Depot benefits from that home-investment enthusiasm. The company's market cap currently hovers around $259 billion and its P/E ratio stands at 23.2. That's not exactly a bargain for a value investor, but it is if you consider Home Depot to be a growth stock.
3. Adobe (ADBE)
Finally, add Adobe (NASDAQ: ADBE) to your list of large-cap stocks to buy in March following what was a rare, market-driven stumble from the stock in February. From high to low, shares gave up about 11% of their value, but given the 48% advance they logged between October's low and February's high -- and how vulnerable that move made the stock -- the stumble is nothing. The stock's recovery effort thus far is also going well.
The sustained interest reflects a shift in Adobe's strategy. It still sells the Acrobat/PDF and Photoshop software that made it a powerhouse, but it doesn't just sell it like it used to. Like so many other software developers, Adobe is shifting toward cloud-based access to its tech that's sold on a subscription basis. The model drives recurring revenue that makes the company's results relatively predictable for shareholders.
And its customers love the approach. Analysts project this year's revenue to grow by nearly 18%, followed by almost a 16% improvement next year. Earnings are expected to improve at an even stronger clip of 24.6% and 18.6%, respectively, as more scale means better margins. Adobe only has to create or update its software once, but can sell it as often as it wants, creating additional production expenses. The stock has a market cap of $174 billion and its P/E ratio of 59.8 suggests the growth stock is trading at a premium, even after its recent sell-off.
10 stocks we like better than AbbVie
When investing geniuses David and Tom Gardner have a stock tip, it can pay to listen. After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor, has tripled the market.*
David and Tom just revealed what they believe are the ten best stocks for investors to buy right now... and AbbVie wasn't one of them! That's right -- they think these 10 stocks are even better buys.
See the 10 stocks
*Stock Advisor returns as of December 1, 2019
James Brumley has no position in any of the stocks mentioned. The Motley Fool owns shares of and recommends Home Depot. The Motley Fool recommends Adobe Systems and recommends the following options: long January 2021 $120 calls on Home Depot and short January 2021 $210 calls on Home Depot. The Motley Fool has a disclosure policy.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | AbbVie (ABBV): $134 billion market cap Through 2017, AbbVie (NYSE: ABBV) was practically bulletproof. It can't carry all of AbbVie's weight on its own. Patent expirations and maturing drugs are nothing new to the big names in the business, however, including AbbVie. | AbbVie (ABBV): $134 billion market cap Through 2017, AbbVie (NYSE: ABBV) was practically bulletproof. It can't carry all of AbbVie's weight on its own. Patent expirations and maturing drugs are nothing new to the big names in the business, however, including AbbVie. | AbbVie (ABBV): $134 billion market cap Through 2017, AbbVie (NYSE: ABBV) was practically bulletproof. It can't carry all of AbbVie's weight on its own. Patent expirations and maturing drugs are nothing new to the big names in the business, however, including AbbVie. | AbbVie (ABBV): $134 billion market cap Through 2017, AbbVie (NYSE: ABBV) was practically bulletproof. It can't carry all of AbbVie's weight on its own. Patent expirations and maturing drugs are nothing new to the big names in the business, however, including AbbVie. |
24672.0 | 2020-03-05 00:00:00 UTC | 3 Dividend Stocks to Ride out the Market Volatility | ABBV | https://www.nasdaq.com/articles/3-dividend-stocks-to-ride-out-the-market-volatility-2020-03-05 | nan | nan | Should dividend stocks have a place in your portfolio as the market continues to churn? The from China is delivering a level of uncertainty that investors despise. Aside from the understandable â if perhaps overstated â health concerns, investors are trying to evaluate the impact on global supply chains. Investment banks JPMorgan Chase (NYSE:), Morgan Stanley (NYSE:) and Goldman Sachs (NYSE:) are all concerned about global economic growth due to the coronavirus. Moreover, Goldman Sachs projected that the coronavirus may for 2020.
However, for most investors, this is not a time to panic. Rather than take a flight to safety, now is a time to take a flight to quality. And when investors look for quality stocks in volatile markets, dividend stocks take center stage.
One benefit of dividend stocks is that they are generally in defensive sectors of the market. This means that their products will be in demand regardless of how the broader economy looks.
However, the reason why dividend stocks look attractive now is that some of them are giving investors some capital growth, as well.
That said, letâÂÂs dive into three dividend stocks that investors should look to in order to ride out this market volatility.
Dividend Stocks for Volatility: Procter & Gamble (PG)
Source: Jonathan Weiss / Shutterstock.com
Dividend Yield: 2.5%
Procter & Gamble (NYSE:) is one stock that should clean up as the market digests the impact of the coronavirus. P&G recently launched a new brand, Microban 24, which includes a line of surface antibacterial cleaning products. Microban comes in both sanitizing spray and cleanser forms, and its unique selling proposition is that it offers 24-hour protection. After consumers apply Microban and allow it to air dry, the solution releases small amounts of anti-bacterial ingredients over the span of 24 hours.
Since Microban was in development long before the outbreak of the coronavirus, itâÂÂs unrealistic to view the launch as anything but a happy accident for Procter & Gamble. Nonetheless, the product will undoubtedly get a boost which should the companyâÂÂs quarterly revenue.
Furthermore, PG stock currently pays an annual dividend of $2.98 per share with a dividend yield of around 2.5%. By themselves, yields are an imperfect measuring stick. However, this than the Soap & Cleaning Materials sector (2.26%) and the S&P 500 (2.07%).
The company has delivered an average 2.9% dividend growth over the last three years. Plus Procter & Gamble is with 63 consecutive years of annual dividend growth.
AbbVie (ABBV)
Source: Piotr Swat / Shutterstock.com
Dividend Yield: 5.1%
The key word for AbbVie (NYSE:) will be synergy. AbbVie is losing the patent protection on its flagship drug, Humira. The rheumatoid arthritis drug is responsible for nearly 50% of AbbVieâÂÂs revenue. However, AbbVie is close to finalizing its purchase of Allergen and this will provide the company with $2 billion of synergies that will lead to combined in the first year.
And the reality for AbbVie is that the company is moving beyond Humira. Sales of the drug are already softening in Europe (23% decline in the first quarter). And while U.S. sales remain strong (Humira sales grew 7%), the company is looking for whatâÂÂs next.
To that end, AbbVie currently has a drug in its pipeline that is being used to treat the coronavirus. The company also has a solid pipeline of oncology and anti-viral drugs. And for dividend investors, the important thing to know is AbbVie has massive cash flow.
AbbVie stock currently pays an annual dividend of $4.72 per share with a dividend yield of about 5.1%. Additionally, the company has posted annual dividend growth of 22.62% over the last three years. Moreover, AbbVie is a dividend aristocrat that has delivered 47 years of consecutive dividend growth.
AT&T (T)
Source: Lester Balajadia / Shutterstock.com
Dividend Yield: 5.7%
Shares of AT&T (NYSE:) stock gave a valiant effort at holding its 2020 gains through the correction. However, T stock is currently slightly negative for the year. But, it has remained in positive territory over the last 12 months.
One reason for the stockâÂÂs growth is the from Apple (NASDAQ:) and Samsung later this year. But investors looking at the here and now can count on AT&T as a good defensive stock.
Plus, in 2018, to acquire content from Time-Warner. This new business unit, Warner Media â which includes HBO â puts AT&T into the streaming wars. And as more customers may be choosing to spend more time under voluntary quarantine, there is an opportunity for its offering to get legs.
Also, donâÂÂt forget they already have a relationship with DirecTV. Some analysts express concern about the long-term partnership between the companies. However, DirecTV has the contract for the NFL Sunday Ticket through the 2020 season â and that is a significant profit driver for the company.
AT&T stock currently pays an annual dividend of $2.08 per share with a dividend yield of nearly 5.7%. The company has posted annual dividend growth of 2% over the last three years and is a dividend aristocrat with 35 years of consecutive dividend growth.
As of this writing, Chris Markoch did not hold a position in any of the aforementioned securities.
The post appeared first on InvestorPlace.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | AbbVie (ABBV) Source: Piotr Swat / Shutterstock.com Dividend Yield: 5.1% The key word for AbbVie (NYSE:) will be synergy. AbbVie is losing the patent protection on its flagship drug, Humira. The rheumatoid arthritis drug is responsible for nearly 50% of AbbVieâÂÂs revenue. | Moreover, AbbVie is a dividend aristocrat that has delivered 47 years of consecutive dividend growth. AbbVie (ABBV) Source: Piotr Swat / Shutterstock.com Dividend Yield: 5.1% The key word for AbbVie (NYSE:) will be synergy. AbbVie is losing the patent protection on its flagship drug, Humira. | AbbVie stock currently pays an annual dividend of $4.72 per share with a dividend yield of about 5.1%. AbbVie (ABBV) Source: Piotr Swat / Shutterstock.com Dividend Yield: 5.1% The key word for AbbVie (NYSE:) will be synergy. AbbVie is losing the patent protection on its flagship drug, Humira. | AbbVie stock currently pays an annual dividend of $4.72 per share with a dividend yield of about 5.1%. Moreover, AbbVie is a dividend aristocrat that has delivered 47 years of consecutive dividend growth. AbbVie (ABBV) Source: Piotr Swat / Shutterstock.com Dividend Yield: 5.1% The key word for AbbVie (NYSE:) will be synergy. |
24673.0 | 2020-03-04 00:00:00 UTC | Is Gilead Sciences the Best Buy in the Coronavirus Sell-Off? | ABBV | https://www.nasdaq.com/articles/is-gilead-sciences-the-best-buy-in-the-coronavirus-sell-off-2020-03-04 | nan | nan | Fears over the SARS-CoV-2 virus, and a potential COVID-19 pandemic, are hurting the stock market. On Feb. 27, the S&P 500 fell by about 138 points, representing a 4.4% decline.
The health-related risks posed by COVID-19 are a more significant concern. Fortunately, several pharmaceutical and biotech companies are racing to develop vaccines and treatments for the disease. One of the companies that has emerged as a leader of this endeavor is none other than Gilead Sciences (NASDAQ: GILD). It is worth wondering whether the company's shares are worth buying right now.
Gilead Sciences' remdesivir shows promise in treating COVID-19
Gilead Sciences is currently looking to develop a treatment for COVID-19, namely a drug called remdesivir, which was previously investigated as a treatment for Ebola but with little success. Gilead Sciences hopes that remdesivir will be successful as a treatment for COVID-19, and this isn't merely wishful thinking. According to World Health Organization (WHO) officials, remdesivir may not only be able to treat COVID-19 successfully, but it shows the most promise out of all the potential treatments.
Gilead Sciences has been moving rapidly to get remdesivir on the market. In late February, the company announced that it had initiated two phase 3 studies to investigate the efficacy of remdesivir as a treatment for COVID-19.
Image source: Getty Images.
Gilead Sciences faces competition
If COVID-19 keeps spreading worldwide, Gilead Sciences will do the world a great service if it releases a treatment for the disease. And of course, the company would benefit financially as well. With that said, however, other companies are looking to develop treatments or vaccines for COVID-19. For instance, Johnson & Jonhson (NYSE: JNJ) partnered up with the U.S. Department of Health and Human Services (HHS) to develop a vaccine for the disease. In a press release, Johnson & Jonhson said it was looking to "screen its library of existing antiviral compounds with the goal of identifying those with antiviral activity against COVID-19."
Another company trying to develop a vaccine for COVID-19 is Moderna (NASDAQ: MRNA). This biotech company created a potential vaccine for the disease in record time and recently shipped a batch of this vaccine to the National Institute of Allergy and Infectious Diseases (NIAID) to begin a phase 1 study. Moderna's shares are up by 59% year to date, a terrific performance considering the S&P 500 is down by 4.4% since the beginning of the year. Clearly, investors have lofty expectations for Moderna's potential vaccine for COVID-19.
There are still other companies looking to develop vaccines for COVID-19, but Gilead Sciences is further along than most of its competitors.
Other reasons to consider Gilead Sciences
There are several reasons to consider buying shares of Gilead Sciences, that is, outside of its recent attempt to prevent a global pandemic. First, there's the company's HIV lineup. Gilead Sciences boasts several HIV drugs whose sales could grow at a nice clip in the coming quarters. In particular, there's HIV treatment drug Biktarvy, with sales for the fiscal year 2019 of $4.7 billion, compared to $1.2 billion in 2018.
There's also HIV treatment drug Descovy. Although this product has not been performing particularly well -- with its sales remaining practically flat in 2019 compared to 2018 -- the U.S. Food and Drug Administration (FDA) approved Descovy for the prevention of HIV in October 2019. Thanks to this approval, sales of Descovy could pick up once again.
Second, Gilead Sciences has several interesting pipeline candidates, including filgotinib, a potential treatment for rheumatoid arthritis (RA) that the company submitted to the FDA for review in December 2019. Of course, there are other treatments for RA, including AbbVie's (NYSE: ABBV) Humira. However, Gilead Sciences has high hopes for filgotinib.
The company's Chief Commercial Officer Johanna Mercier said:
Despite currently available treatment options many patients are still living with symptoms of inadequately controlled RA around the world. In fact, only one out of five patients living with RA achieve complete remission at year one, which means four to five do not. Filgotinib has a compelling and differentiated clinical profile that we believe may uniquely address the significant unmet need for patients with RA.
Gilead Sciences also believes filgotinib has the potential to add five indications over the next four years. The drug is currently being evaluated for the treatment of Crohn's disease, ulcerative colitis, and psoriatic arthritis.
Furthermore, Gilead Sciences could benefit from its partnership with Galapagos (NASDAQ: GLPG). Last year, Galapagos received an equity investment of $1.1 billion as well as an upfront payment of $3.95 billion from Gilead Sciences. For its part, Gilead Sciences acquired "an exclusive product license and option rights to develop and commercialize all current and future programs in all countries outside Europe." Gilead Sciences could find more exciting products to market thanks to this agreement.
Should you buy?
It is difficult to assess what effect (if any) Gilead Sciences' potential treatment for COVID-19 will have on its financial results. At this point, no one knows whether the company's remdesivir will prove effective at treating COVID-19. Even if it is, other companies could develop vaccines or treatments for the disease -- thus stealing Gilead Sciences' thunder -- or the epidemic could slow down (or both) by the time remdesivir hits the market.
We don't know which of these scenarios will come true, and for that reason, I would recommend assessing Gilead Sciences' prospects outside of its potential treatment for COVID-19. And based on these prospects, Gilead Sciences looks like a stock worth serious consideration.
Finally, despite its recent rally (Gilead Sciences' shares are up by 15.4% year to date), the company is trading at just 11 times future earnings, and its price-to-earnings growth (PEG) ratio is 0.52. These attractive valuation metrics constitute yet another reason to seriously consider buying shares of this biotech stock.
10 stocks we like better than Gilead Sciences
When investing geniuses David and Tom Gardner have a stock tip, it can pay to listen. After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor, has tripled the market.*
David and Tom just revealed what they believe are the ten best stocks for investors to buy right now... and Gilead Sciences wasn't one of them! That's right -- they think these 10 stocks are even better buys.
See the 10 stocks
*Stock Advisor returns as of December 1, 2019
Prosper Junior Bakiny has no position in any of the stocks mentioned. The Motley Fool owns shares of and recommends Gilead Sciences. The Motley Fool recommends Johnson & Johnson. The Motley Fool has a disclosure policy.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Of course, there are other treatments for RA, including AbbVie's (NYSE: ABBV) Humira. Although this product has not been performing particularly well -- with its sales remaining practically flat in 2019 compared to 2018 -- the U.S. Food and Drug Administration (FDA) approved Descovy for the prevention of HIV in October 2019. Second, Gilead Sciences has several interesting pipeline candidates, including filgotinib, a potential treatment for rheumatoid arthritis (RA) that the company submitted to the FDA for review in December 2019. | Of course, there are other treatments for RA, including AbbVie's (NYSE: ABBV) Humira. Gilead Sciences' remdesivir shows promise in treating COVID-19 Gilead Sciences is currently looking to develop a treatment for COVID-19, namely a drug called remdesivir, which was previously investigated as a treatment for Ebola but with little success. We don't know which of these scenarios will come true, and for that reason, I would recommend assessing Gilead Sciences' prospects outside of its potential treatment for COVID-19. | Of course, there are other treatments for RA, including AbbVie's (NYSE: ABBV) Humira. Gilead Sciences' remdesivir shows promise in treating COVID-19 Gilead Sciences is currently looking to develop a treatment for COVID-19, namely a drug called remdesivir, which was previously investigated as a treatment for Ebola but with little success. Gilead Sciences faces competition If COVID-19 keeps spreading worldwide, Gilead Sciences will do the world a great service if it releases a treatment for the disease. | Of course, there are other treatments for RA, including AbbVie's (NYSE: ABBV) Humira. With that said, however, other companies are looking to develop treatments or vaccines for COVID-19. For instance, Johnson & Jonhson (NYSE: JNJ) partnered up with the U.S. Department of Health and Human Services (HHS) to develop a vaccine for the disease. |
24674.0 | 2020-03-04 00:00:00 UTC | AbbVie To Present At Cowen Health Care Conference; Webcast At 11:20 AM ET | ABBV | https://www.nasdaq.com/articles/abbvie-to-present-at-cowen-health-care-conference-webcast-at-11%3A20-am-et-2020-03-04 | nan | nan | (RTTNews) - AbbVie (ABBV) will participate in the Cowen 40th Annual Health Care Conference.
The event is scheduled to begin at 11:20 AM ET on March 4, 2020.
To access the live webcast, log on to investors.abbvie.com
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | (RTTNews) - AbbVie (ABBV) will participate in the Cowen 40th Annual Health Care Conference. To access the live webcast, log on to investors.abbvie.com The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. The event is scheduled to begin at 11:20 AM ET on March 4, 2020. | (RTTNews) - AbbVie (ABBV) will participate in the Cowen 40th Annual Health Care Conference. To access the live webcast, log on to investors.abbvie.com The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. The event is scheduled to begin at 11:20 AM ET on March 4, 2020. | (RTTNews) - AbbVie (ABBV) will participate in the Cowen 40th Annual Health Care Conference. To access the live webcast, log on to investors.abbvie.com The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. The event is scheduled to begin at 11:20 AM ET on March 4, 2020. | (RTTNews) - AbbVie (ABBV) will participate in the Cowen 40th Annual Health Care Conference. To access the live webcast, log on to investors.abbvie.com The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. The event is scheduled to begin at 11:20 AM ET on March 4, 2020. |
24675.0 | 2020-03-01 00:00:00 UTC | The Best Dividend Aristocrat You Can Buy Right Now | ABBV | https://www.nasdaq.com/articles/the-best-dividend-aristocrat-you-can-buy-right-now-2020-03-01 | nan | nan | Dividends are really good. Dividends that keep coming every year are great. But dividends that keep growing year after year are absolutely fantastic.
There's a category of stocks that delivers such fantastic dividends. Dividend Aristocrats are companies in the S&P 500 that have increased their dividends annually for at least 25 consecutive years. Only 57 companies are currently on the list.
Some of these dividend-hiking stocks are better than others. But I think that the best Dividend Aristocrat you can buy right now is Abbot Laboratories (NYSE: ABT).
Image source: Getty Images.
A rock-solid business
What I like the most about Abbott Labs is that it's simply a great company with a rock-solid business. Abbott ranks as one of the biggest healthcare stocks on the market. It generated $31.9 billion in revenue last year, with a profit of nearly $3.7 billion.
Abbott's medical devices segment rakes in the most money, with sales of more than $12.2 billion in 2019. This unit develops and markets a wide range of products, including cardiac monitors, diabetes-care devices, heart ablation catheters, heart valve clips, neuromodulation devices, and stents.
The company's diagnostics products segment made $7.7 billion in revenue last year. This segment's products include core laboratory testing, molecular diagnostics, point of care diagnostics systems, and rapid diagnostics products for infectious-disease and cardio-metabolic testing.
Trailing close behind is Abbott's nutritional products segment, which generated $7.4 billion in 2019. This business sells nutritional products for children and adults such as Similac and PediaSure.
Although Abbott spun off big drugmaker AbbVie as a stand-alone business in 2013, it still has an established pharmaceuticals segment that pulled in $4.5 billion in sales last year. This unit focuses on marketing drugs to emerging countries including India, Russia, China, and Brazil.
I'm not the only one who thinks Abbott is a great company. Fortune magazine has ranked Abbott among its most admired companies in the world every year since 1984. Abbott has taken the No. 1 spot among medical products companies in Fortune's list in each of the last seven years. Working Mother magazine has listed Abbott in its 100 best companies ranking for 19 consecutive years. And Science magazine has picked Abbott as one of the top employers for 16 years.
Exceptional growth prospects
To be fair, most of the other Dividend Aristocrats also have solid business models. But what I think especially sets Abbott Labs apart from the pack is its exceptionally strong growth prospects. Wall Street analysts project that Abbott will increase its earnings by more than 11% annually over the next five years.
Granted, analysts have higher earnings growth projections for four other Dividend Aristocrats -- Lowe's (NYSE: LOW), ADP (NASDAQ: ADP), Air Products & Chemicals (NYSE: APD), and Linde (NYSE: LIN). However, I think Abbott's growth is more assured than any of these companies.
All of these other companies depend on a strong economy to achieve their growth. A housing downturn would probably hurt sales for both ADP and Lowe's. A global recession would weaken the financial performance for both of these companies as well as Air Products & Chemicals and Linde. Abbott, on the other hand, should be able to deliver strong earnings growth regardless of what happens at the macroeconomic level.
Just look at some of the key products that should drive Abbott's growth. Freestyle Libre is a continuous glucose monitoring (CGM) system for individuals with diabetes. The Alimta line of diagnostics systems is used for blood and plasma screening and more. MitraClip is a device used to treat mitral regurgitation caused by a leaky heart valve. These devices are going to enjoy strong demand whether the economy is surging or sagging.
A pretty good dividend, too
What about Abbott's dividend? Admittedly, its dividend yield of close to 1.8% isn't as high as the yield of many other Dividend Aristocrats. However, Abbott ranks in the top tier in terms of dividend growth over the last three years and recently boosted its dividend by 12.5%. Abbott also claims one of the more impressive streaks of dividend increases, with 48 consecutive years of dividend hikes.
Most of the Dividend Aristocrats are relatively good options for income-seeking investors. Abbott is a good pick for growth investors as well. Putting these two positives together along with Abbott's strong position in multiple relatively safe healthcare markets makes this stock the best Dividend Aristocrat around, in my view.
10 stocks we like better than Abbott Laboratories
When investing geniuses David and Tom Gardner have a stock tip, it can pay to listen. After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor, has tripled the market.*
David and Tom just revealed what they believe are the ten best stocks for investors to buy right now... and Abbott Laboratories wasn't one of them! That's right -- they think these 10 stocks are even better buys.
See the 10 stocks
*Stock Advisor returns as of December 1, 2019
Keith Speights owns shares of AbbVie and Air Products & Chemicals. The Motley Fool recommends Lowe's. The Motley Fool has a disclosure policy.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Although Abbott spun off big drugmaker AbbVie as a stand-alone business in 2013, it still has an established pharmaceuticals segment that pulled in $4.5 billion in sales last year. See the 10 stocks *Stock Advisor returns as of December 1, 2019 Keith Speights owns shares of AbbVie and Air Products & Chemicals. This unit focuses on marketing drugs to emerging countries including India, Russia, China, and Brazil. | Although Abbott spun off big drugmaker AbbVie as a stand-alone business in 2013, it still has an established pharmaceuticals segment that pulled in $4.5 billion in sales last year. See the 10 stocks *Stock Advisor returns as of December 1, 2019 Keith Speights owns shares of AbbVie and Air Products & Chemicals. The company's diagnostics products segment made $7.7 billion in revenue last year. | Although Abbott spun off big drugmaker AbbVie as a stand-alone business in 2013, it still has an established pharmaceuticals segment that pulled in $4.5 billion in sales last year. See the 10 stocks *Stock Advisor returns as of December 1, 2019 Keith Speights owns shares of AbbVie and Air Products & Chemicals. Granted, analysts have higher earnings growth projections for four other Dividend Aristocrats -- Lowe's (NYSE: LOW), ADP (NASDAQ: ADP), Air Products & Chemicals (NYSE: APD), and Linde (NYSE: LIN). | Although Abbott spun off big drugmaker AbbVie as a stand-alone business in 2013, it still has an established pharmaceuticals segment that pulled in $4.5 billion in sales last year. See the 10 stocks *Stock Advisor returns as of December 1, 2019 Keith Speights owns shares of AbbVie and Air Products & Chemicals. Dividend Aristocrats are companies in the S&P 500 that have increased their dividends annually for at least 25 consecutive years. |
24676.0 | 2020-02-28 00:00:00 UTC | 3 Top Healthcare Stocks to Buy Right Now | ABBV | https://www.nasdaq.com/articles/3-top-healthcare-stocks-to-buy-right-now-2020-02-28 | nan | nan | Worry over the growing spread of the novel coronavirus has sent shares of some of my favorite long-term healthcare stocks -- like leading telehealth provider Teladoc Health (NYSE: TDOC) -- skyrocketing in recent weeks against the cascade of red descending on stock markets. For investors, the hope is that a search for a vaccine and heightened demand for health services could help offset pain in other sectors.
Picking stocks based on what is sure to be a transient disruptor of the economy is not the point of this article, though. Instead, these three healthcare stocks have my attention, two for their cheap valuation and one for its long-term potential: Amgen (NASDAQ: AMGN), AbbVie (NYSE: ABBV), and Veeva Systems (NYSE: VEEV).
A pioneer of biotech still going strong
Amgen has been around for decades now, but one of the largest pharmaceutical and biotech companies in the world still has a lot going for it. Its extensive portfolio of treatments covers everything from asthma and arthritis to cancer. Over 20 products are also undergoing phase 3 testing -- including psoriasis treatment Otezla for use in treating other inflammatory diseases, which it acquired in 2019. That drug is expected to drive renewed revenue growth in 2020.
However, Amgen isn't without some imperfections. Biosimilar treatments have eroded the strength of its core portfolio of products, and a full-year 2019 revenue decline of 1.6% to $23.4 billion is proof of that. During that time, expenses were higher, offset by the company's share repurchase program (which reduces share count and thus increases earnings per share). As a result, earnings per share were still able to notch a 2.1% increase. A promised return to revenue growth in 2020 (at least 7% according to guidance) is nevertheless good news.
But why buy this massive biotech stock now? Post-Q4 2019 earnings and coronavirus-fueled declines, Amgen is down nearly 15% from all-time highs on fear that pharmaceutical makers' access to ingredients may get disrupted due to manufacturing closures in China. As a result, Amgen stock trades for just 12.3 times one-year forward expected earnings. The drug developer also generated $8.5 billion in free cash flow (revenue less cash operating and capital expenses), giving it plenty of room to continue investing in new treatments, making acquisitions, and returning cash to shareholders.
As to that last point, that is another reason to give the stock a look. Amgen is serious about increasing its cash payout (in addition to share repurchases) and has raised its dividend 84% since 2015. As of this writing, the biotech outfit yields 3% a year. With shares down double-digits on short-term worry and trading for a value, this looks like a good buy point for investors looking longer-term.
Image source: Getty Images.
An even steeper discount on big pharma
Here's another timely buy for value-oriented investors: AbbVie, which expects its takeover of peer Allergan to be complete sometime during the first quarter of 2020. While that pending deal and AbbVie's patents on autoimmune disease treatment Humira expiring in the next few years (they already have expired in Europe) clouds the picture a bit, not to mention coronavirus-fueled selling like Amgen has been experiencing, quite a bit of uncertainty looks priced in.
It's true that Humira still made up 58% of sales in 2019, in spite of losing a third of its sales internationally due to biosimilar competition. There will be further disruption in a few more years when the same happens to the treatment stateside. However, combining with Allergan will significantly diversify the product portfolio. Besides inorganic growth, though, AbbVie is also seeing great success with its oncology products, most notably with lymphatic cancer and leukemia treatment Imbruvica, which grew global sales by 30% last year.
In total, AbbVie's full-year revenue grew just 1.6%, but it forecast an 8% increase in 2020 (excluding Allergan) over the $33.3 billion posted in 2019. Even better was expected adjusted earnings growth of 8% at the midpoint of guidance (again excluding Allergan). Shares are thus trading for only 9.6 times that new-year earnings guide.
Much like peer Amgen, AbbVie is a cash cow. Free cash generation of $12.8 billion in 2019 means this biotech giant has plenty of wiggle room to keep investing and reward shareholders. Stock repurchases are ongoing, as is a current annual dividend yield of 5.1%. With patent expirations, merger worry, and global pandemic supply chain disruption keeping stock valuation low, AbbVie looks too cheap to ignore for investors looking for value and yield.
A new digital toolkit for life sciences
Let's go from value stock to growth stock. Veeva Systems is actually a software company, but with the purpose of helping modernize the life science industries -- biotech, pharmaceutical, and healthcare companies -- and more recently it announced it's making a push with its software into cosmetic and personal care products. Veeva is still getting north of 20% a year growth from its core competencies, but the new adjacent industry could provide an opportunity just as large as the first one.
Through the first three quarters of 2019, Veeva's revenue is up 25%, and management has said to expect a full-year growth rate of 26% -- which would make it the first year Veeva crosses the $1 billion in revenue milestone. Even better than the top line, though, are high profit margins that are leading to even faster earnings growth. Adjusted earnings are up 41% through the first three quarters of 2019 and expected to finish the year up 33%.
Veeva isn't a cheap stock; on the contrary, it's downright expensive when viewed purely in the context of profit generation. Shares trade for 56 times trailing one-year free cash flow and 49 times one-year forward earnings. It's all about the long-term future for this software outfit, though, and the company's steady addition of new revenue is leading to an increasingly efficient profit-generating machine. If the bottom line can continue to outpace the already-high rate of revenue growth, the premium on share prices isn't totally unreasonable.
Of course, as I often suggest with growth stocks, it's advisable to start with a very small position (less than 1% of investable net worth) and buy more shares on the dips. And dip it has. Veeva is still off all-time highs set over the summer of 2019 by 15%, including a nearly 10% tumble since coronavirus fears have flared up. I'm a buyer ahead of the company's final 2019 report card due out on March 3.
10 stocks we like better than AbbVie
When investing geniuses David and Tom Gardner have a stock tip, it can pay to listen. After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor, has tripled the market.*
David and Tom just revealed what they believe are the ten best stocks for investors to buy right now... and AbbVie wasn't one of them! That's right -- they think these 10 stocks are even better buys.
See the 10 stocks
*Stock Advisor returns as of December 1, 2019
Nicholas Rossolillo and his clients own shares of AbbVie and Teladoc Health. The Motley Fool owns shares of and recommends Teladoc Health and Veeva Systems. The Motley Fool has a disclosure policy.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Besides inorganic growth, though, AbbVie is also seeing great success with its oncology products, most notably with lymphatic cancer and leukemia treatment Imbruvica, which grew global sales by 30% last year. With patent expirations, merger worry, and global pandemic supply chain disruption keeping stock valuation low, AbbVie looks too cheap to ignore for investors looking for value and yield. Instead, these three healthcare stocks have my attention, two for their cheap valuation and one for its long-term potential: Amgen (NASDAQ: AMGN), AbbVie (NYSE: ABBV), and Veeva Systems (NYSE: VEEV). | Instead, these three healthcare stocks have my attention, two for their cheap valuation and one for its long-term potential: Amgen (NASDAQ: AMGN), AbbVie (NYSE: ABBV), and Veeva Systems (NYSE: VEEV). An even steeper discount on big pharma Here's another timely buy for value-oriented investors: AbbVie, which expects its takeover of peer Allergan to be complete sometime during the first quarter of 2020. While that pending deal and AbbVie's patents on autoimmune disease treatment Humira expiring in the next few years (they already have expired in Europe) clouds the picture a bit, not to mention coronavirus-fueled selling like Amgen has been experiencing, quite a bit of uncertainty looks priced in. | See the 10 stocks *Stock Advisor returns as of December 1, 2019 Nicholas Rossolillo and his clients own shares of AbbVie and Teladoc Health. Instead, these three healthcare stocks have my attention, two for their cheap valuation and one for its long-term potential: Amgen (NASDAQ: AMGN), AbbVie (NYSE: ABBV), and Veeva Systems (NYSE: VEEV). An even steeper discount on big pharma Here's another timely buy for value-oriented investors: AbbVie, which expects its takeover of peer Allergan to be complete sometime during the first quarter of 2020. | Instead, these three healthcare stocks have my attention, two for their cheap valuation and one for its long-term potential: Amgen (NASDAQ: AMGN), AbbVie (NYSE: ABBV), and Veeva Systems (NYSE: VEEV). An even steeper discount on big pharma Here's another timely buy for value-oriented investors: AbbVie, which expects its takeover of peer Allergan to be complete sometime during the first quarter of 2020. While that pending deal and AbbVie's patents on autoimmune disease treatment Humira expiring in the next few years (they already have expired in Europe) clouds the picture a bit, not to mention coronavirus-fueled selling like Amgen has been experiencing, quite a bit of uncertainty looks priced in. |
24677.0 | 2020-02-27 00:00:00 UTC | April 9th Options Now Available For AbbVie (ABBV) | ABBV | https://www.nasdaq.com/articles/april-9th-options-now-available-for-abbvie-abbv-2020-02-27 | nan | nan | Investors in AbbVie Inc (Symbol: ABBV) saw new options become available today, for the April 9th expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the ABBV options chain for the new April 9th contracts and identified one put and one call contract of particular interest.
The put contract at the $84.00 strike price has a current bid of $2.11. If an investor was to sell-to-open that put contract, they are committing to purchase the stock at $84.00, but will also collect the premium, putting the cost basis of the shares at $81.89 (before broker commissions). To an investor already interested in purchasing shares of ABBV, that could represent an attractive alternative to paying $87.75/share today.
Because the $84.00 strike represents an approximate 4% discount to the current trading price of the stock (in other words it is out-of-the-money by that percentage), there is also the possibility that the put contract would expire worthless. The current analytical data (including greeks and implied greeks) suggest the current odds of that happening are 68%. Stock Options Channel will track those odds over time to see how they change, publishing a chart of those numbers on our website under the contract detail page for this contract. Should the contract expire worthless, the premium would represent a 2.51% return on the cash commitment, or 21.85% annualized — at Stock Options Channel we call this the YieldBoost.
Below is a chart showing the trailing twelve month trading history for AbbVie Inc, and highlighting in green where the $84.00 strike is located relative to that history:
Turning to the calls side of the option chain, the call contract at the $93.50 strike price has a current bid of $1.45. If an investor was to purchase shares of ABBV stock at the current price level of $87.75/share, and then sell-to-open that call contract as a "covered call," they are committing to sell the stock at $93.50. Considering the call seller will also collect the premium, that would drive a total return (excluding dividends, if any) of 8.21% if the stock gets called away at the April 9th expiration (before broker commissions). Of course, a lot of upside could potentially be left on the table if ABBV shares really soar, which is why looking at the trailing twelve month trading history for AbbVie Inc, as well as studying the business fundamentals becomes important. Below is a chart showing ABBV's trailing twelve month trading history, with the $93.50 strike highlighted in red:
Considering the fact that the $93.50 strike represents an approximate 7% premium to the current trading price of the stock (in other words it is out-of-the-money by that percentage), there is also the possibility that the covered call contract would expire worthless, in which case the investor would keep both their shares of stock and the premium collected. The current analytical data (including greeks and implied greeks) suggest the current odds of that happening are 75%. On our website under the contract detail page for this contract, Stock Options Channel will track those odds over time to see how they change and publish a chart of those numbers (the trading history of the option contract will also be charted). Should the covered call contract expire worthless, the premium would represent a 1.65% boost of extra return to the investor, or 14.37% annualized, which we refer to as the YieldBoost.
The implied volatility in the put contract example is 46%, while the implied volatility in the call contract example is 42%.
Meanwhile, we calculate the actual trailing twelve month volatility (considering the last 252 trading day closing values as well as today's price of $87.75) to be 28%. For more put and call options contract ideas worth looking at, visit StockOptionsChannel.com.
Top YieldBoost Calls of the S&P 500 »
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Of course, a lot of upside could potentially be left on the table if ABBV shares really soar, which is why looking at the trailing twelve month trading history for AbbVie Inc, as well as studying the business fundamentals becomes important. Below is a chart showing ABBV's trailing twelve month trading history, with the $93.50 strike highlighted in red: Considering the fact that the $93.50 strike represents an approximate 7% premium to the current trading price of the stock (in other words it is out-of-the-money by that percentage), there is also the possibility that the covered call contract would expire worthless, in which case the investor would keep both their shares of stock and the premium collected. Investors in AbbVie Inc (Symbol: ABBV) saw new options become available today, for the April 9th expiration. | Below is a chart showing ABBV's trailing twelve month trading history, with the $93.50 strike highlighted in red: Considering the fact that the $93.50 strike represents an approximate 7% premium to the current trading price of the stock (in other words it is out-of-the-money by that percentage), there is also the possibility that the covered call contract would expire worthless, in which case the investor would keep both their shares of stock and the premium collected. Investors in AbbVie Inc (Symbol: ABBV) saw new options become available today, for the April 9th expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the ABBV options chain for the new April 9th contracts and identified one put and one call contract of particular interest. | Below is a chart showing the trailing twelve month trading history for AbbVie Inc, and highlighting in green where the $84.00 strike is located relative to that history: Turning to the calls side of the option chain, the call contract at the $93.50 strike price has a current bid of $1.45. Below is a chart showing ABBV's trailing twelve month trading history, with the $93.50 strike highlighted in red: Considering the fact that the $93.50 strike represents an approximate 7% premium to the current trading price of the stock (in other words it is out-of-the-money by that percentage), there is also the possibility that the covered call contract would expire worthless, in which case the investor would keep both their shares of stock and the premium collected. Investors in AbbVie Inc (Symbol: ABBV) saw new options become available today, for the April 9th expiration. | At Stock Options Channel, our YieldBoost formula has looked up and down the ABBV options chain for the new April 9th contracts and identified one put and one call contract of particular interest. Below is a chart showing ABBV's trailing twelve month trading history, with the $93.50 strike highlighted in red: Considering the fact that the $93.50 strike represents an approximate 7% premium to the current trading price of the stock (in other words it is out-of-the-money by that percentage), there is also the possibility that the covered call contract would expire worthless, in which case the investor would keep both their shares of stock and the premium collected. Investors in AbbVie Inc (Symbol: ABBV) saw new options become available today, for the April 9th expiration. |
24678.0 | 2020-02-27 00:00:00 UTC | Fighting The Deadly Coronavirus | ABBV | https://www.nasdaq.com/articles/fighting-the-deadly-coronavirus-2020-02-27 | nan | nan | (RTTNews) - The new coronavirus, COVID-19, which originated in China, has now spread to least 47 countries, infecting over 81,000 people and killing 3,000 people, with the majority of them in China.
A report released by the World Health Organisation on February 25, 2020, says "for the first time, since the onset of symptoms of the first identified case of COVID-19 on December 8, 2019, there have been more new cases reported from countries outside of China than from China."
A number of companies have joined the hunt for a treatment to tackle the new coronavirus. Nearly 124 studies have either commenced or are expected to do so shortly, with all but three taking place in China, STAT News reported sourcing the information to Informa Pharma Intelligence.
Let's take a look at some of the companies that are involved in finding a cure for the killer disease COVID-19.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | A report released by the World Health Organisation on February 25, 2020, says "for the first time, since the onset of symptoms of the first identified case of COVID-19 on December 8, 2019, there have been more new cases reported from countries outside of China than from China." Nearly 124 studies have either commenced or are expected to do so shortly, with all but three taking place in China, STAT News reported sourcing the information to Informa Pharma Intelligence. Let's take a look at some of the companies that are involved in finding a cure for the killer disease COVID-19. | (RTTNews) - The new coronavirus, COVID-19, which originated in China, has now spread to least 47 countries, infecting over 81,000 people and killing 3,000 people, with the majority of them in China. A report released by the World Health Organisation on February 25, 2020, says "for the first time, since the onset of symptoms of the first identified case of COVID-19 on December 8, 2019, there have been more new cases reported from countries outside of China than from China." The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | (RTTNews) - The new coronavirus, COVID-19, which originated in China, has now spread to least 47 countries, infecting over 81,000 people and killing 3,000 people, with the majority of them in China. A report released by the World Health Organisation on February 25, 2020, says "for the first time, since the onset of symptoms of the first identified case of COVID-19 on December 8, 2019, there have been more new cases reported from countries outside of China than from China." The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | (RTTNews) - The new coronavirus, COVID-19, which originated in China, has now spread to least 47 countries, infecting over 81,000 people and killing 3,000 people, with the majority of them in China. A report released by the World Health Organisation on February 25, 2020, says "for the first time, since the onset of symptoms of the first identified case of COVID-19 on December 8, 2019, there have been more new cases reported from countries outside of China than from China." A number of companies have joined the hunt for a treatment to tackle the new coronavirus. |
24679.0 | 2020-02-26 00:00:00 UTC | Where Will Johnson & Johnson Be in 1 Year? | ABBV | https://www.nasdaq.com/articles/where-will-johnson-johnson-be-in-1-year-2020-02-26 | nan | nan | Last year, shares of the big pharma company Johnson & Johnson (NYSE: JNJ) rose by 13%, a performance that trailed that of the pharmaceuticals industry, which was up by 24.7% as measured by the SPDR S&P Pharmaceuticals Index. The S&P 500 -- which was up by about 29% in 2019 -- also outpaced Johnson & Johnson last year.
There are several reasons why Johnson & Johnson did not perform as well as the broader market in 2019. First, some of its key products within its pharmaceuticals segment -- by far its largest segment by revenue -- have been recording declining sales. For instance, the company's rheumatoid arthritis drug Remicade reported $4.4 billion in sales for the full fiscal year 2019, down 17.8% year over year. Second, Johnson & Johnson is currently drowning in a sea of lawsuits. A California court recently ordered Johnson & Johnson to pay $344 million for "deceptively marketing" its pelvic mesh products, which are surgical implants aimed at treating pelvic organ prolapse. Johnson & Jonhson plans to appeal this decision, but there are more lawsuits the company has to worry about.
Amid all these troubles, investors might be inclined to avoid shares of the pharma giant altogether. However, a lot can happen in just one year, and despite its issues, Johnson & Johnson's trajectory within the next 12 months may not be that catastrophic. Here's why.
Image source: Getty Images.
Johnson & Johnson's lineup and pipeline
While some of Johnson & Johnson's pharmaceutical products are losing steam, others are on the rise. The company's drug Stelara, which treats plaque psoriasis and psoriatic arthritis, recorded $6.4 billion in sales during fiscal year 2019, a 23.4% year-over-year increase. Tremfya, which is a treatment for severe plaque psoriasis, reported $1 billion in sales, up 85.9% compared with the previous fiscal year. Further, Johnson & Johnson's cancer drug Imbruvica recorded $3.4 billion in sales, up 30.4% year over year, and Darzalex -- which treats multiple myeloma -- recorded about $3 billion in sales, 48% higher than in fiscal year 2018.
In other words, Johnson & Johnson has enough products with sales on the rise -- and will likely continue delivering growing sales -- to keep revenue from its pharmaceuticals segment afloat. Some of the company's current products are also seeking additional indications. For instance, Imbruvica is currently in phase 3 testing for the treatment of mantle cell lymphoma, and Tremfya is in phase 3 testing for the treatment of pediatric psoriasis.
Also, Johnson & Johnson recently submitted a supplemental Biologics License Application to the U.S. Food and Drug Administration for Darzalex as a treatment for relapsed/refractory multiple myeloma (that is, multiple myeloma that does not respond to treatment or resurfaces after a period of remission). According to estimates, about 32,270 people will be diagnosed with relapsed/refractory multiple myeloma in 2020, and approximately 12,830 will die from it. Lastly, with the novel coronavirus outbreak worsening by the day, Johnson & Johnson is partnering with the U.S. Department of Health and Human Services to develop a vaccine for COVID-19, the deadly disease caused by the virus.
While Johnson & Johson boast a strong product lineup, the company has to contend with some competitors in these markets. For instance, AbbVie's (NYSE: ABBV) Humira is a treatment for plaque psoriasis. And although Humira is experiencing declining sales due to generic competition in Europe, it remains a blockbuster drug. Humira recorded $19.2 billion in sales in 2019. AbbVie's Skyrizi -- which also treats plaque psoriasis -- has been recording growing sales. Skyrizi was approved by the FDA for moderate to severe plaque psoriasis in April 2019, and the drug generated $355 million in sales last year.
Novartis (NYSE: NVS) is another pharma company with footprints in this market. The company's top-selling product Cosentyx, which treats moderate to severe plaque psoriasis -- generated $3.6 billion in sales last year.
In the market for multiple myeloma, Johnson & Johnson competes with Bristol-Myers Squibb (NYSE: BMY). Thanks to its acquisition of Celgene in a cash and stock transaction valued at $74 billion, Bristol-Myers acquired such products as Revlimid. Sales of Revlimid -- from the time of the closing of the acquisition on Nov. 20, to the end Bristol-Myers' third quarter, on Dec. 31 -- were $1.3 billion. Bristol-Myers should also submit ide-cel -- a potential treatment for relapsed/refractory multiple myeloma -- to the FDA sometime this year for approval.
Also, it isn't clear whether the company will benefit from its current efforts to develop a vaccine for COVID-19. While the epidemic continues to get worse -- with cases outside of China and in countries such as Italy and Iran growing -- several companies are currently working on that project, and some of Johnson & Jonhson's peers could beat the company to the punch.
Even given these competitors, Johnson & Johnson's pipeline, as well as its current lineup should allow the company's sales to remain afloat.
A stable dividend stock
One of Johnson & Johnson's biggest attractions is its dividend history. The company -- which ranks as one of the prestigious dividend aristocrats -- has more than 50 years of consecutive dividend increases under its belt, and Johnson & Johnson still affirms the importance of rewarding shareholders by way of dividend increases.
Chief Financial Officer Joseph J. Wolk said:
As investors in Johnson & Johnson know, delivering a competitive and increasing dividend is a capital allocation priority for us. In 2019, we returned almost $10 billion to investors, which is approximately 50% of our free cash flow, increasing the quarterly dividend by 5.6%.
The company's current dividend yield is 2.56%, and its payout ratio is 66.6%. Investors can count on Johnson & Johnson to keep increasing its quarterly dividend payout within the next year.
What about the lawsuits?
What should investors make of Johnson & Johnson's current legal troubles? On the one hand, the company has faced scores of lawsuits before. The pharma giant has always managed to come out of these relatively unscathed. The recent verdict mentioned above cost Johnson & Johnson $344 million. For context, this merely represents about 1.7% of the company's net sales during the fourth quarter.
On the other hand, these ongoing (and numerous lawsuits) represents a risk for Johnson & Jonhson. The company itself mentions risks, including "declining sales and reputational damage," that could ensue as a result of these lawsuits. Johnson & Jonhson continually monitors these legal troubles and the company records provisions for losses for those lawsuits for "which a loss is probable or reasonably possible." Investors should keep a close eye on the lawsuits that are currently plaguing Johnson & Johnson.
Should you buy?
Johnson & Johnson didn't outperform the S&P 500 last year, and it is unlikely to do so this year. Also, there are other pharma giants that are likely to outperform the company over the next year. For instance, Bristol-Myers is still riding the wave from its Celgene acquisition and the company performed well during the fourth quarter. Further, Bristol-Myers currently provides better value. The company is trading at 8.44 times future earnings and its price to earnings growth (PEG) is 0.76. By contrast, Johnson & Johnson forward P/E is 14.9 while its PEG is 2.93. While I think both of these companies deserve consideration, I believe Bristol-Myers is a better pick given the 12 months time horizon.
10 stocks we like better than Johnson & Johnson
When investing geniuses David and Tom Gardner have a stock tip, it can pay to listen. After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor, has tripled the market.*
David and Tom just revealed what they believe are the ten best stocks for investors to buy right now... and Johnson & Johnson wasn't one of them! That's right -- they think these 10 stocks are even better buys.
See the 10 stocks
*Stock Advisor returns as of December 1, 2019
Prosper Junior Bakiny has no position in any of the stocks mentioned. The Motley Fool owns shares of and recommends Bristol-Myers Squibb. The Motley Fool recommends Johnson & Johnson. The Motley Fool has a disclosure policy.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | For instance, AbbVie's (NYSE: ABBV) Humira is a treatment for plaque psoriasis. AbbVie's Skyrizi -- which also treats plaque psoriasis -- has been recording growing sales. The company's drug Stelara, which treats plaque psoriasis and psoriatic arthritis, recorded $6.4 billion in sales during fiscal year 2019, a 23.4% year-over-year increase. | For instance, AbbVie's (NYSE: ABBV) Humira is a treatment for plaque psoriasis. AbbVie's Skyrizi -- which also treats plaque psoriasis -- has been recording growing sales. The company's drug Stelara, which treats plaque psoriasis and psoriatic arthritis, recorded $6.4 billion in sales during fiscal year 2019, a 23.4% year-over-year increase. | For instance, AbbVie's (NYSE: ABBV) Humira is a treatment for plaque psoriasis. AbbVie's Skyrizi -- which also treats plaque psoriasis -- has been recording growing sales. Johnson & Johnson's lineup and pipeline While some of Johnson & Johnson's pharmaceutical products are losing steam, others are on the rise. | For instance, AbbVie's (NYSE: ABBV) Humira is a treatment for plaque psoriasis. AbbVie's Skyrizi -- which also treats plaque psoriasis -- has been recording growing sales. The S&P 500 -- which was up by about 29% in 2019 -- also outpaced Johnson & Johnson last year. |
24680.0 | 2020-02-26 00:00:00 UTC | If You Invested $5,000 in AbbVie IPO, This Is How Much Money You'd Have Now | ABBV | https://www.nasdaq.com/articles/if-you-invested-%245000-in-abbvie-ipo-this-is-how-much-money-youd-have-now-2020-02-26 | nan | nan | AbbVie (NYSE: ABBV) was officially launched on Jan. 2, 2013 as a spinoff from Abbott Laboratories (NYSE: ABT). That was the first day the company traded on the New York Stock Exchange. The move was made so that Abbott could focus on its business of manufacturing medical devices and equipment, while AbbVie would prioritize pharmaceuticals.
AbbVie took with it the rheumatoid arthritis drug Humira, which has been the worldʻs top-selling pharmaceutical since 2012. In 2018, it did about $20 billion in global sales, and it was on pace for a similar number in 2019. Sales of Humira were basically flat in the fourth quarter of 2019 compared to the previous yearʻs quarter at $4.92 billion. However, the drug is expected to remain in the top two in worldwide sales until 2024.
Given the sustained success of Humira, how much money would you have made if you had invested $5,000 in AbbVie when the firm spun off on Jan. 2, 2013? Before we do the math, letʻs look at the company in a little more depth.
AbbVie produces Humira, the worldʻs top-selling drug. Image source: Getty Images.
Beyond Humira
But AbbVie has more than just Humira going for it. Cancer drug Imbruvica, which was the 14th best-seller in 2018, saw sales increase 28.9% in the fourth quarter, year over year, to $1.3 billion. Venclexta, another cancer drug, did $251 million in sales in the quarter (up 100%), while new immunology drug Skyrizi did $216 million in the quarter. A drug to treat Hepatitis C, Mavyret, the firmʻs third-largest seller, saw revenue decline 23% to $628 million in the quarter.
AbbVie is also closing on a deal to acquire Allergan (NYSE: AGN), the pharmaceutical company that produces cosmetic Botox, which generated $991 million in sales in 2019 -- an increase of about 9% over 2018. Bipolar depression drug Vraylar also generated net revenue of $857 million last year, up 76% from the previous year. The deal should close in the first quarter of this year.
An annual return that beats the S&P 500
AbbVieʻs performance has fluctuated over the years. This year, through Feb. 24, the stock is up about 5%. However, the share price has declined each of the past two years, down 3.9% in 2019 and 4.7% in 2018. But the company outperformed in 2017 as the stock rose 54.4%.
When it debuted on the NYSE on Jan. 2, 2013, AbbVie was trading at $26.33 per share. At the end of trading on Feb. 24, 2020, it closed at $93.29.
If you had invested $5,000 when it launched, your investment would have purchased about 142 shares. Over the ensuing seven-plus years, the stock has returned about 20.1% per year with a total return of about 168%. That beats the S&P 500, which returned about 14% over that same period. It also beats Abbott Labs, which posted an average annual return of about 17% over that same time frame.
Letʻs not forget dividends. AbbVie has a great track record of paying dividends, having increased them every year since inception. The company started with a $0.40 annual dividend in 2013 and has increased it almost every year since -- without reducing it once. In February, the company bumped up the dividend from $1.07 to $1.18.
So, including reinvesting quarterly dividends, that $5,000 invested on Jan. 2, 2013 would now be worth $18,377. Not a bad chunk of change.
While it's got a good track record and delivers an excellent dividend, AbbVie is in a period of transition now with Humira sales slowing down and the Allergan sale pending, so investors may want to watch and wait before picking up new shares.
10 stocks we like better than AbbVie
When investing geniuses David and Tom Gardner have a stock tip, it can pay to listen. After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor, has tripled the market.*
David and Tom just revealed what they believe are the ten best stocks for investors to buy right now... and AbbVie wasn't one of them! That's right -- they think these 10 stocks are even better buys.
See the 10 stocks
*Stock Advisor returns as of December 1, 2019
Dave Kovaleski has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | The move was made so that Abbott could focus on its business of manufacturing medical devices and equipment, while AbbVie would prioritize pharmaceuticals. AbbVie is also closing on a deal to acquire Allergan (NYSE: AGN), the pharmaceutical company that produces cosmetic Botox, which generated $991 million in sales in 2019 -- an increase of about 9% over 2018. AbbVie (NYSE: ABBV) was officially launched on Jan. 2, 2013 as a spinoff from Abbott Laboratories (NYSE: ABT). | AbbVie produces Humira, the worldʻs top-selling drug. AbbVie is also closing on a deal to acquire Allergan (NYSE: AGN), the pharmaceutical company that produces cosmetic Botox, which generated $991 million in sales in 2019 -- an increase of about 9% over 2018. AbbVie (NYSE: ABBV) was officially launched on Jan. 2, 2013 as a spinoff from Abbott Laboratories (NYSE: ABT). | AbbVie (NYSE: ABBV) was officially launched on Jan. 2, 2013 as a spinoff from Abbott Laboratories (NYSE: ABT). The move was made so that Abbott could focus on its business of manufacturing medical devices and equipment, while AbbVie would prioritize pharmaceuticals. AbbVie took with it the rheumatoid arthritis drug Humira, which has been the worldʻs top-selling pharmaceutical since 2012. | AbbVie is also closing on a deal to acquire Allergan (NYSE: AGN), the pharmaceutical company that produces cosmetic Botox, which generated $991 million in sales in 2019 -- an increase of about 9% over 2018. AbbVie (NYSE: ABBV) was officially launched on Jan. 2, 2013 as a spinoff from Abbott Laboratories (NYSE: ABT). The move was made so that Abbott could focus on its business of manufacturing medical devices and equipment, while AbbVie would prioritize pharmaceuticals. |
24681.0 | 2020-02-26 00:00:00 UTC | What Happens With AbbVie If Its Allergan Buyout Is Blocked? | ABBV | https://www.nasdaq.com/articles/what-happens-with-abbvie-if-its-allergan-buyout-is-blocked-2020-02-26 | nan | nan | A deal isn't done until the ink dries on the paper. And for AbbVie's (NYSE: ABBV) pending acquisition of Allergan (NYSE: AGN), the ink hasn't dried yet.
AbbVie first announced plans to buy Allergan in June 2019. CEO Rick Gonzalez stated in the company's Q4 conference call earlier this month that the deal was on track to close in the first quarter of 2020.
But now there's a threat that could prevent the transaction from receiving regulatory clearance from the U.S. Federal Trade Commission (FTC). What happens for AbbVie if its Allergan buyout is blocked?
Image source: Getty Images.
Mounting opposition
A coalition of consumer groups and trade unions representing over 10 millions subscribers and members oppose AbbVie's takeover of Allergan. These organizations sent a letter to the director of the FTC's Bureau of Competition on Feb. 18, stating that Allergan's sale of brazikumab to AstraZeneca isn't enough to address the anti-competitive impact of the acquisition.
AstraZeneca initially developed brazikumab. The drug is currently in mid-stage clinical studies for treating Crohn's disease and ulcerative colitis. Allergan's divestiture of the immunology drug enabled AstraZeneca to recover its full commercialization rights.
But the allied consumer groups and trade unions are concerned that AstraZeneca won't be able to compete against AbbVie's immunology juggernaut. These groups pointed out in the letter to the FTC that AstraZeneca wasn't able to bring brazikumab to the market in the past and doesn't have the immunology infrastructure in place to be successful against AbbVie.
The consumer groups and unions are also worried that AbbVie will gain increased bargaining leverage with payers by picking up Allergan's lineup of drugs. Allergan claims current blockbuster products including Botox and a fast-rising star in antipsychotic drug Vraylar.
AbbVie's plan B
What would AbbVie's backup plan be if the FTC blocks its acquisition of Allergan? For one thing, the company wouldn't probably walk away from the deal without putting up a fight. It's spent too much time and money trying to make the acquisition happen to immediately throw in the towel.
If, however, the transaction does fall apart, it seems likely that AbbVie would go back to the drawing board to identify other potential transformative acquisitions. The problem is that if the FTC scuttles the Allergan buyout, it would probably be opposed to nearly any major deal that AbbVie might want to make.
One possible candidate that would be an intriguing pick for AbbVie is Vertex Pharmaceuticals (NASDAQ: VRTX). The only significant overlap between the two companies' pipelines and product lineups is in cystic fibrosis (CF). But AbbVie's CF drugs are only in early-stage development, while Vertex claims four FDA-approved CF drugs.
Vertex and Allergan have similar market caps. However, the price tag for AbbVie to acquire Vertex would probably have to be well above what it plans to pay for Allergan because of Vertex's strong growth prospects. It's also doubtful that Vertex would be interested in an acquisition at this point.
Another potential plan B strategy for AbbVie would be to go with the "string-of-pearls" approach and scoop up multiple smaller biotech stocks. The problem with this, though, is that AbbVie is looking for reliable revenue to reduce its dependence on Humira. A string-of-pearls shopping spree wouldn't likely achieve the big drugmaker's objective.
AbbVie could also go back to its roots and acquire a medical device maker instead of a biopharmaceutical company. Before it was a stand-alone company, AbbVie was part of Abbott Labs, which ranks as one of the biggest medical device makers in the world. The chances that AbbVie would take this course of action, though, are probably really low.
Most likely scenario
The most likely scenario of all for AbbVie is that it doesn't have to find a plan B at all. AbbVie has already obtained a green light from the European Union for its buyout of Allergan. Allergan sold Zenpep in addition to brazikumab to grease the wheels for the EU's blessing. It also sold pancreatic enzyme Viokace as a sweetener to gain FTC approval.
It's still possible that the FTC could block AbbVie's acquisition of Allergan. However, any arguments that the deal will significantly boost the company's competitive position in immunology or oncology don't appear to be compelling ones. Look for the ink to dry on the $63 billion transaction sooner rather than later.
10 stocks we like better than AbbVie
When investing geniuses David and Tom Gardner have a stock tip, it can pay to listen. After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor, has tripled the market.*
David and Tom just revealed what they believe are the 10 best stocks for investors to buy right now... and AbbVie wasn't one of them! That's right -- they think these 10 stocks are even better buys.
See the 10 stocks
*Stock Advisor returns as of December 1, 2019
Keith Speights owns shares of AbbVie and Vertex Pharmaceuticals. The Motley Fool recommends Vertex Pharmaceuticals. The Motley Fool has a disclosure policy.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Mounting opposition A coalition of consumer groups and trade unions representing over 10 millions subscribers and members oppose AbbVie's takeover of Allergan. The consumer groups and unions are also worried that AbbVie will gain increased bargaining leverage with payers by picking up Allergan's lineup of drugs. And for AbbVie's (NYSE: ABBV) pending acquisition of Allergan (NYSE: AGN), the ink hasn't dried yet. | And for AbbVie's (NYSE: ABBV) pending acquisition of Allergan (NYSE: AGN), the ink hasn't dried yet. AbbVie's plan B What would AbbVie's backup plan be if the FTC blocks its acquisition of Allergan? One possible candidate that would be an intriguing pick for AbbVie is Vertex Pharmaceuticals (NASDAQ: VRTX). | And for AbbVie's (NYSE: ABBV) pending acquisition of Allergan (NYSE: AGN), the ink hasn't dried yet. These groups pointed out in the letter to the FTC that AstraZeneca wasn't able to bring brazikumab to the market in the past and doesn't have the immunology infrastructure in place to be successful against AbbVie. AbbVie's plan B What would AbbVie's backup plan be if the FTC blocks its acquisition of Allergan? | The problem is that if the FTC scuttles the Allergan buyout, it would probably be opposed to nearly any major deal that AbbVie might want to make. But AbbVie's CF drugs are only in early-stage development, while Vertex claims four FDA-approved CF drugs. It's still possible that the FTC could block AbbVie's acquisition of Allergan. |
24682.0 | 2020-02-25 00:00:00 UTC | 3 Value Stocks to Buy if the Stock Market Implodes | ABBV | https://www.nasdaq.com/articles/3-value-stocks-to-buy-if-the-stock-market-implodes-2020-02-25 | nan | nan | The U.S. stock markets took a sizable step backwards yesterday, presumably on the emerging COVID-19 threat. A more careful look, however, suggests that the market was basically due for a correction. After all, most major indices were bumping up against their all-time highs, and valuations across the large-cap space were close to twice the historical average prior to this viral outbreak. So while the COVID-19 illness may have sparked this sell-off, it was arguably long overdue from a fundamental standpoint. In fact, Warren Buffett warned the retail crowd about this very issue via Berkshire Hathaway's 2019 annual letter to shareholders.
Despite these unfavorable market dynamics, there are a few rare gems still worth buying. Who are these unicorns? The pharmaceutical companies AbbVie (NYSE: ABBV), Bausch Health Companies Inc. (NYSE: BHC), and Bristol-Myers Squibb (NYSE: BMY) are all trading at less than 10 times next year's projected earnings right now. Here's why risk-averse investors might want to pounce on these three value stocks in the days and weeks ahead.
Image source: Getty Images.
An incredibly cheap dividend growth play
AbbVie, an Illinois-based drugmaker, is currently trading at 8.85 times next year's projected earnings. That's one of the lowest valuations within its peer group, as well as one of the lowest for a Dividend Aristocrat, a status it gained through its former parent company Abbott Laboratories. AbbVie, though, arguably doesn't deserve such a ridiculously low valuation.
The bugaboo with this large-cap biopharma stock is the upcoming patent cliff for its flagship arthritis medication Humira. However, this overhang has now been dealt with through the commercial launch of the immunology meds Rinvoq and Skyrizi, as well as the forthcoming merger with Allergan (NYSE: AGN) that's expected to close before the end of the first quarter.
What makes AbbVie an outstanding defensive stock? Apart from its rock-bottom valuation, AbbVie should ultimately post near industry-leading levels of top-line growth with Allergan in the fold. What's more, the drugmaker offers a dividend yield of almost 5% at current levels. That's essentially a junk-bond-type yield attached to a Dividend Aristocrat. In all, AbbVie's shares may pull back with the broader market, but it should hold its own better than most because of its attractive valuation and sky-high dividend yield.
A well-diversified Canadian pharma on the mend
After Bausch Health's blistering rebound in 2019, its comeback has largely stalled in 2020. The company's less-than-stellar fourth-quarter 2019 results, combined with its ongoing debt overhang, has apparently been reason enough for some investors to take profits this year. The direct consequence of Bausch's latest downturn is that its stock is now trading at a paltry 5.76 times next year's estimated earnings. That's ridiculously cheap any way you slice it.
Why should bargain hunters consider this name during this turbulent period in the market? The simple answer is management. Bausch's new management team has guided the company from the brink of bankruptcy just a few years ago to where it is today -- a solid mid-cap biopharma set to post low-single-digit sales growth for the next few years.
Of course, the debt issue will continue to loom large for perhaps the next five years. But Bausch's creative management team should be able to navigate these troubled waters. As proof, they successfully reinvigorated the flagging commercialization of the constipation med Trulance since taking it over from Synergy Pharmaceuticals. That's an impressive feat, to be sure.
Now, Bausch will arguably need to unearth a few more hidden gems like Trulance to complete its comeback. But the company's brain trust has given investors a surfeit of reasons to be optimistic about the future. In turn, this Canadian pharma stock probably shouldn't be trading like a distressed asset gearing up for a bankruptcy filing.
A rock-solid competitive moat
Bristol's shares have failed to capture Wall Street's imagination of late, thanks to the dwindling market share for its immuno-oncology med Opdivo. Underscoring this point, this big pharma stock is being presently valued at less than 9 times 2021 estimated earnings, which is among the cheapest valuations within its entire peer group. Wall Street, however, is arguably dead wrong about this name.
Following the company's tie-up with cancer behemoth Celgene, Bristol now sports eight blockbuster-level products and one of the most robust oncology pipelines in the pharmaceutical industry. The company's highly diverse product portfolio and top-shelf pipeline should thus translate into a a rock-solid competitive moat in the years ahead. Put simply, Wall Street is making far too much of a fuss over Opdivo's competitive positioning. Bristol is no longer a one-trick pony, after all.
What's more, Bristol also offers investors a respectable annualized yield of 2.74% at current levels. The drugmaker's fairly average yield for a big pharma stock may not be overly exciting, but it does give investors another avenue for capital appreciation. Dividends of any kind, after all, have proven to be a powerful way to generate substantial returns on capital over the long term.
All told, defensive-minded investors may want to consider this big pharma stock for its attractive near-term growth prospects, robust clinical pipeline, dirt-cheap valuation, and prospects as a steady income play in an increasingly uncertain environment.
10 stocks we like better than Bristol-Myers Squibb
When investing geniuses David and Tom Gardner have a stock tip, it can pay to listen. After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor, has tripled the market.*
David and Tom just revealed what they believe are the ten best stocks for investors to buy right now... and Bristol-Myers Squibb wasn't one of them! That's right -- they think these 10 stocks are even better buys.
See the 10 stocks
*Stock Advisor returns as of December 1, 2019
George Budwell has no position in any of the stocks mentioned. The Motley Fool owns shares of and recommends Bausch Health Companies, Berkshire Hathaway (B shares), and Bristol-Myers Squibb and recommends the following options: long January 2021 $200 calls on Berkshire Hathaway (B shares), short January 2021 $200 puts on Berkshire Hathaway (B shares), and short March 2020 $225 calls on Berkshire Hathaway (B shares). The Motley Fool has a disclosure policy.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | An incredibly cheap dividend growth play AbbVie, an Illinois-based drugmaker, is currently trading at 8.85 times next year's projected earnings. The pharmaceutical companies AbbVie (NYSE: ABBV), Bausch Health Companies Inc. (NYSE: BHC), and Bristol-Myers Squibb (NYSE: BMY) are all trading at less than 10 times next year's projected earnings right now. AbbVie, though, arguably doesn't deserve such a ridiculously low valuation. | The pharmaceutical companies AbbVie (NYSE: ABBV), Bausch Health Companies Inc. (NYSE: BHC), and Bristol-Myers Squibb (NYSE: BMY) are all trading at less than 10 times next year's projected earnings right now. An incredibly cheap dividend growth play AbbVie, an Illinois-based drugmaker, is currently trading at 8.85 times next year's projected earnings. AbbVie, though, arguably doesn't deserve such a ridiculously low valuation. | The pharmaceutical companies AbbVie (NYSE: ABBV), Bausch Health Companies Inc. (NYSE: BHC), and Bristol-Myers Squibb (NYSE: BMY) are all trading at less than 10 times next year's projected earnings right now. An incredibly cheap dividend growth play AbbVie, an Illinois-based drugmaker, is currently trading at 8.85 times next year's projected earnings. AbbVie, though, arguably doesn't deserve such a ridiculously low valuation. | An incredibly cheap dividend growth play AbbVie, an Illinois-based drugmaker, is currently trading at 8.85 times next year's projected earnings. The pharmaceutical companies AbbVie (NYSE: ABBV), Bausch Health Companies Inc. (NYSE: BHC), and Bristol-Myers Squibb (NYSE: BMY) are all trading at less than 10 times next year's projected earnings right now. AbbVie, though, arguably doesn't deserve such a ridiculously low valuation. |
24683.0 | 2020-02-25 00:00:00 UTC | Is It Too Late to Buy High-Flying Galapagos? | ABBV | https://www.nasdaq.com/articles/is-it-too-late-to-buy-high-flying-galapagos-2020-02-25 | nan | nan | Galapagos (NASDAQ: GLPG) galloped to all-time highs heading into this week. Although a pullback in the overall market has caused the biotech to give up some of its gains, Galapagos is still up close to 20% year to date and up around 150% over the past 12 months.
Some investors could view Galapagos as valued at a steep premium after its big run-up. But is it really too late to buy the high-flying biotech stock?
Image source: Getty Images.
Behind Galapagos' great gains
The primary catalyst behind Galapagos' meteoric rise over the last year was its major collaboration deal signed with Gilead Sciences (NASDAQ: GILD) in July last year. Gilead forked over $5.1 billion for the 10-year agreement, with a $3.95 billion upfront payment and a $1.1 billion equity investment in Galapagos.
Gilead and Galapagos were already partnering on immunology drug filgotinib. The new deal gave Gilead the rights to Galapagos' other late-stage pipeline candidate, idiopathic pulmonary fibrosis (IPF) drug GLPG1690. In addition, Gilead can exercise an option to license any of Galapagos' other candidates.
You can attribute Gilead's interest in Galapagos to the tremendous promise for filgotinib. The experimental drug sailed through late-stage clinical studies targeting rheumatoid arthritis with flying colors. Gilead and Galapagos filed for U.S. and European regulatory approvals for filgotinib in treating rheumatoid arthritis in 2019. Approvals are anticipated later this year in the indication.
And that could be just the start. Gilead and Galapagos are also evaluating filgotinib in other late-stage clinical studies in treating Crohn's disease, psoriatic arthritis, and ulcerative colitis. It's also in phase 2 clinical studies targeting ankylosing spondylitis and other inflammatory diseases.
Crunching the numbers
Just how successful filgotinib could be if it wins approval remains to be seen. But peak annual sales of close to $3 billion in treating rheumatoid arthritis and another $3 billion in treating other immunology indications could be possible. Filgotinib's safety profile and convenience (it's an oral medication instead of an injection) could boost its commercial success.
That kind of market potential might make Galapagos' current market cap of under $16 billion seem like a steal. However, it's important to remember that the biotech won't rake in all of the money that filgotinib could make.
Galapagos will market filgotinib on its own in Belgium, the Netherlands and Luxembourg. It will split profits generated by filgotinib equally with Gilead in France, Germany, Italy, Spain, and the United Kingdom. In other countries, Galapagos stands to receive tiered royalties between 20% and 30%.
Based on AbbVie's experience with blockbuster drug Humira prior to it losing exclusivity in Europe, I expect somewhere around two-thirds of filgotinib's sales will be made in the U.S. If we use a peak annual sales estimate of $6 billion, that would give Galapagos a maximum of $1.2 billion from U.S. sales of the drug. Outside of the U.S., my back-of-the-napkin estimate is that Galapagos would make a little under $1 billion annually.
It's more difficult to predict the financial impact for Galapagos' other drugs. Galapagos thinks that theglobal marketfor IPF could be $5 billion by 2025. If we assumed GLPG1690 could capture half of that market, Galapagos would probably make around $750 million annually at peak sales due to its licensing deal with Gilead.
To buy or not to buy?
My numbers are admittedly very rough. However, I think that peak revenue from filgotinib and GLPG1690 could bring in somewhere in the ballpark of $3 billion for Galapagos in the future. The company's other earlier-stage programs could boost its sales. In addition, Galapagos is eligible to receive some hefty milestone payments from Gilead if all goes well.
Still, though, we're looking at a stock that currently trades at more than five times sales that it might achieve sometime in the future. I like the potential for Galapagos' products. However, I think that there are other biotech stocks with more room to run. My view is that it is a little too late to jump on the Galapagos bandwagon.
10 stocks we like better than Galapagos
When investing geniuses David and Tom Gardner have a stock tip, it can pay to listen. After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor, has tripled the market.*
David and Tom just revealed what they believe are the ten best stocks for investors to buy right now... and Galapagos wasn't one of them! That's right -- they think these 10 stocks are even better buys.
See the 10 stocks
*Stock Advisor returns as of December 1, 2019
Keith Speights owns shares of AbbVie and Gilead Sciences. The Motley Fool owns shares of and recommends Gilead Sciences. The Motley Fool has a disclosure policy.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Based on AbbVie's experience with blockbuster drug Humira prior to it losing exclusivity in Europe, I expect somewhere around two-thirds of filgotinib's sales will be made in the U.S. See the 10 stocks *Stock Advisor returns as of December 1, 2019 Keith Speights owns shares of AbbVie and Gilead Sciences. Gilead and Galapagos are also evaluating filgotinib in other late-stage clinical studies in treating Crohn's disease, psoriatic arthritis, and ulcerative colitis. | Based on AbbVie's experience with blockbuster drug Humira prior to it losing exclusivity in Europe, I expect somewhere around two-thirds of filgotinib's sales will be made in the U.S. See the 10 stocks *Stock Advisor returns as of December 1, 2019 Keith Speights owns shares of AbbVie and Gilead Sciences. The experimental drug sailed through late-stage clinical studies targeting rheumatoid arthritis with flying colors. | Based on AbbVie's experience with blockbuster drug Humira prior to it losing exclusivity in Europe, I expect somewhere around two-thirds of filgotinib's sales will be made in the U.S. See the 10 stocks *Stock Advisor returns as of December 1, 2019 Keith Speights owns shares of AbbVie and Gilead Sciences. Behind Galapagos' great gains The primary catalyst behind Galapagos' meteoric rise over the last year was its major collaboration deal signed with Gilead Sciences (NASDAQ: GILD) in July last year. | Based on AbbVie's experience with blockbuster drug Humira prior to it losing exclusivity in Europe, I expect somewhere around two-thirds of filgotinib's sales will be made in the U.S. See the 10 stocks *Stock Advisor returns as of December 1, 2019 Keith Speights owns shares of AbbVie and Gilead Sciences. But peak annual sales of close to $3 billion in treating rheumatoid arthritis and another $3 billion in treating other immunology indications could be possible. |
24684.0 | 2020-02-25 00:00:00 UTC | Validea Peter Lynch Strategy Daily Upgrade Report - 2/25/2020 | ABBV | https://www.nasdaq.com/articles/validea-peter-lynch-strategy-daily-upgrade-report-2-25-2020-2020-02-25 | nan | nan | The following are today's upgrades for Validea's P/E/Growth Investor model based on the published strategy of Peter Lynch. This strategy looks for stocks trading at a reasonable price relative to earnings growth that also possess strong balance sheets.
ROBERT HALF INTERNATIONAL INC. (RHI) is a mid-cap value stock in the Business Services industry. The rating according to our strategy based on Peter Lynch changed from 0% to 91% based on the firm’s underlying fundamentals and the stock’s valuation. A score of 80% or above typically indicates that the strategy has some interest in the stock and a score above 90% typically indicates strong interest.
Company Description: Robert Half International Inc. provides specialized staffing and risk consulting services. The Company provides these services through its divisions, including Accountemps, Robert Half Finance & Accounting, OfficeTeam, Robert Half Technology, Robert Half Management Resources, Robert Half Legal, The Creative Group and Protiviti. The Company operates through three segments: temporary and consultant staffing, permanent placement staffing, and risk consulting and internal audit services. The temporary and consultant staffing segment provides specialized staffing in the accounting and finance, administrative and office, information technology (IT), legal, advertising, marketing and Web design fields. The permanent placement staffing segment provides full-time personnel in the accounting, finance, administrative and office, and IT fields. The risk consulting and internal audit services segment provides business and technology risk consulting, and internal audit services.
The following table summarizes whether the stock meets each of this strategy's tests. Not all criteria in the below table receive equal weighting or are independent, but the table provides a brief overview of the strong and weak points of the security in the context of the strategy's criteria.
YIELD ADJUSTED P/E TO GROWTH (PEG) RATIO: PASS
EARNINGS PER SHARE: PASS
TOTAL DEBT/EQUITY RATIO: PASS
FREE CASH FLOW: NEUTRAL
NET CASH POSITION: NEUTRAL
For a full detailed analysis using NASDAQ's Guru Analysis tool, click here
SOUTHERN CO (SO) is a large-cap growth stock in the Electric Utilities industry. The rating according to our strategy based on Peter Lynch changed from 0% to 91% based on the firm’s underlying fundamentals and the stock’s valuation. A score of 80% or above typically indicates that the strategy has some interest in the stock and a score above 90% typically indicates strong interest.
Company Description: The Southern Company (Southern Company) is a holding company. The Company owns all of the stock of the traditional electric operating companies and the parent entities of Southern Power Company (Southern Power) and Southern Company Gas, and owns other direct and indirect subsidiaries. The Company's segments include Gas distribution operations, Gas marketing services, Wholesale gas services, Gas midstream operations and All other. The Gas distribution operations segment includes natural gas local distribution utilities that construct, manage, and maintain intrastate natural gas pipelines and gas distribution facilities in seven states. The Gas marketing services segment provides natural gas commodity and related services to customers markets that provide for customer choice. The Wholesale gas services segment engages in natural gas storage and gas pipeline arbitrage. The Gas midstream operations consist primarily of gas pipeline investments, with storage and fuels.
The following table summarizes whether the stock meets each of this strategy's tests. Not all criteria in the below table receive equal weighting or are independent, but the table provides a brief overview of the strong and weak points of the security in the context of the strategy's criteria.
INVENTORY TO SALES: PASS
YIELD ADJUSTED P/E TO GROWTH (PEG) RATIO: PASS
EARNINGS PER SHARE: PASS
TOTAL DEBT/EQUITY RATIO: PASS
FREE CASH FLOW: NEUTRAL
NET CASH POSITION: NEUTRAL
For a full detailed analysis using NASDAQ's Guru Analysis tool, click here
AEGON N.V. (ADR) (AEG) is a mid-cap value stock in the Insurance (Life) industry. The rating according to our strategy based on Peter Lynch changed from 0% to 83% based on the firm’s underlying fundamentals and the stock’s valuation. A score of 80% or above typically indicates that the strategy has some interest in the stock and a score above 90% typically indicates strong interest.
Company Description: Aegon N.V. (Aegon) is an international life insurance, pensions and asset management company. The Company's segments include the Americas, which includes the United States, Mexico and Brazil; the Netherlands; the United Kingdom; Central & Eastern Europe; Spain & Portugal; Asia, and Aegon Asset Management. It offers protection against mortality, morbidity and longevity risks, including traditional and universal life. It offers products with mortality, morbidity, and longevity risks, including traditional and universal life; mortgages; annuity products, and banking products. It offers individual protection products, such as annuities, term insurance, income protection and international/offshore bonds. It has activities in Hungary, Poland, Romania and Turkey. It offers life insurance marketed to high-net-worth individuals in Hong Kong and Singapore. It also offers investment products covering third-party customers, insurance-linked solutions.
The following table summarizes whether the stock meets each of this strategy's tests. Not all criteria in the below table receive equal weighting or are independent, but the table provides a brief overview of the strong and weak points of the security in the context of the strategy's criteria.
P/E/GROWTH RATIO: PASS
SALES AND P/E RATIO: PASS
EPS GROWTH RATE: PASS
TOTAL DEBT/EQUITY RATIO: NEUTRAL
EQUITY/ASSETS RATIO: PASS
RETURN ON ASSETS: FAIL
For a full detailed analysis using NASDAQ's Guru Analysis tool, click here
KELLY SERVICES, INC. (KELYA) is a small-cap value stock in the Business Services industry. The rating according to our strategy based on Peter Lynch changed from 0% to 93% based on the firm’s underlying fundamentals and the stock’s valuation. A score of 80% or above typically indicates that the strategy has some interest in the stock and a score above 90% typically indicates strong interest.
Company Description: Kelly Services, Inc. is a workforce solutions provider, which is engaged in offering a range of specialty services. The Company provides workforce solutions in three regions: the Americas; Europe, the Middle East and Africa (EMEA), and Asia Pacific (APAC). The Company's segments are Americas Commercial, Americas Professional and Technical (Americas PT), EMEA Commercial, EMEA Professional and Technical (EMEA PT), and Outsourcing and Consulting Group (OCG). The Americas Commercial segment includes Office, Contact Center, Education, Marketing and Electronic Assembly. The Americas PT segment includes a range of specialty staffing services. The EMEA Commercial segment provides a range of staffing services, including Office, Contact Center and its temporary-to-hire service. The EMEA PT segment provides Engineering, Finance and Accounting services. The OCG segment delivers talent management solutions across multiple regions, skill sets and a spectrum of talent categories.
The following table summarizes whether the stock meets each of this strategy's tests. Not all criteria in the below table receive equal weighting or are independent, but the table provides a brief overview of the strong and weak points of the security in the context of the strategy's criteria.
YIELD ADJUSTED P/E TO GROWTH (PEG) RATIO: PASS
EARNINGS PER SHARE: PASS
TOTAL DEBT/EQUITY RATIO: PASS
FREE CASH FLOW: NEUTRAL
NET CASH POSITION: NEUTRAL
For a full detailed analysis using NASDAQ's Guru Analysis tool, click here
MARKEL CORPORATION (MKL) is a large-cap value stock in the Insurance (Prop. & Casualty) industry. The rating according to our strategy based on Peter Lynch changed from 83% to 93% based on the firm’s underlying fundamentals and the stock’s valuation. A score of 80% or above typically indicates that the strategy has some interest in the stock and a score above 90% typically indicates strong interest.
Company Description: Markel Corporation is a financial holding company serving a range of markets. The Company's principal business markets and underwrites specialty insurance products. It monitors and reports its ongoing underwriting operations in three segments: U.S. Insurance, International Insurance and Reinsurance. The Company, through its subsidiary Markel Ventures, Inc. (Markel Ventures), owns interests in various industrial and service businesses that operate outside of the specialty insurance marketplace. The U.S. Insurance segment includes all direct business and facultative placements written by its insurance subsidiaries domiciled in the United States. The International Insurance segment includes all direct business and facultative placements written by its insurance subsidiaries domiciled outside of the United States, including its syndicate at Lloyd's of London (Lloyd's). The Reinsurance segment includes all treaty reinsurance written across the Company.
The following table summarizes whether the stock meets each of this strategy's tests. Not all criteria in the below table receive equal weighting or are independent, but the table provides a brief overview of the strong and weak points of the security in the context of the strategy's criteria.
P/E/GROWTH RATIO: PASS
SALES AND P/E RATIO: PASS
EPS GROWTH RATE: PASS
TOTAL DEBT/EQUITY RATIO: NEUTRAL
EQUITY/ASSETS RATIO: PASS
RETURN ON ASSETS: PASS
FREE CASH FLOW: NEUTRAL
NET CASH POSITION: NEUTRAL
For a full detailed analysis using NASDAQ's Guru Analysis tool, click here
MARTIN MARIETTA MATERIALS, INC. (MLM) is a large-cap growth stock in the Construction - Raw Materials industry. The rating according to our strategy based on Peter Lynch changed from 0% to 87% based on the firm’s underlying fundamentals and the stock’s valuation. A score of 80% or above typically indicates that the strategy has some interest in the stock and a score above 90% typically indicates strong interest.
Company Description: Martin Marietta Materials, Inc. is a supplier of aggregates products (crushed stone, sand, and gravel) used for the construction of infrastructure, nonresidential, and residential projects. Aggregates products are also used for railroad ballast and in agricultural, utility and environmental applications. The Company's Aggregates business operates through three segments: the Mid-America Group, Southeast Group and West Group. The Company's business is categorized into Aggregates Business, Cement Business and Magnesia Specialties Business. Its Cement business is reported through the Cement segment. Its Magnesia Specialties business manufactures and markets magnesia-based chemical products used in industrial, agricultural, and environmental applications, and dolomitic lime sold to customers in the steel industry. Its Cement business produces Portland and specialty cements. It manufactures and markets, through its Magnesia Specialties business, magnesia-based chemical products.
The following table summarizes whether the stock meets each of this strategy's tests. Not all criteria in the below table receive equal weighting or are independent, but the table provides a brief overview of the strong and weak points of the security in the context of the strategy's criteria.
P/E/GROWTH RATIO: PASS
SALES AND P/E RATIO: PASS
INVENTORY TO SALES: PASS
EPS GROWTH RATE: PASS
TOTAL DEBT/EQUITY RATIO: PASS
FREE CASH FLOW: NEUTRAL
NET CASH POSITION: NEUTRAL
For a full detailed analysis using NASDAQ's Guru Analysis tool, click here
TELEFLEX INCORPORATED (TFX) is a large-cap growth stock in the Medical Equipment & Supplies industry. The rating according to our strategy based on Peter Lynch changed from 0% to 74% based on the firm’s underlying fundamentals and the stock’s valuation. A score of 80% or above typically indicates that the strategy has some interest in the stock and a score above 90% typically indicates strong interest.
Company Description: Teleflex Incorporated is a provider of medical technology products. The Company designs, develops, manufactures and supplies single-use medical devices used by hospitals and healthcare providers for diagnostic and therapeutic procedures in critical care and surgical applications. The Company operates through six segments: Vascular North America; Anesthesia North America; Surgical North America; Europe, the Middle East and Africa (EMEA); Asia, and Original Equipment Manufacturer (OEM). The Company's products include oxygen therapy products, aerosol therapy products, spirometry products, and ventilation management products, which are offered under Hudson RCI brand. As of December 31, 2016, it manufactured its products at approximately 30 manufacturing sites, with manufacturing operations located in the Czech Republic, Germany, Malaysia, Mexico and the United States. Its all others businesses include single-use respiratory, urology and cardiac care products, as well as capital equipment.
The following table summarizes whether the stock meets each of this strategy's tests. Not all criteria in the below table receive equal weighting or are independent, but the table provides a brief overview of the strong and weak points of the security in the context of the strategy's criteria.
P/E/GROWTH RATIO: FAIL
SALES AND P/E RATIO: PASS
INVENTORY TO SALES: PASS
EPS GROWTH RATE: PASS
TOTAL DEBT/EQUITY RATIO: PASS
FREE CASH FLOW: NEUTRAL
NET CASH POSITION: NEUTRAL
For a full detailed analysis using NASDAQ's Guru Analysis tool, click here
UNIVERSAL DISPLAY CORPORATION (OLED) is a mid-cap growth stock in the Semiconductors industry. The rating according to our strategy based on Peter Lynch changed from 56% to 87% based on the firm’s underlying fundamentals and the stock’s valuation. A score of 80% or above typically indicates that the strategy has some interest in the stock and a score above 90% typically indicates strong interest.
Company Description: Universal Display Corporation is engaged in the research, development and commercialization of organic light emitting diode (OLED), technologies and materials for use in display and solid-state lighting applications. The Company also supplies its OLED materials to manufacturers of OLED displays and lighting products for evaluation and for use in product development and for pre-commercial activities, and it also provides technical assistance and support to these manufacturers. The Company has produced and sold phosphorescent emitter materials that produce red, yellow, green and light-blue light, which are combined in various ways for the display and lighting markets. It has also developed host materials for the emissive layer. The Company is a supplier of phosphorescent emitter materials to OLED product manufacturers. Phosphorescent OLEDs utilize specialized materials and device structures that allow OLEDs to emit light through a process known as phosphorescence.
The following table summarizes whether the stock meets each of this strategy's tests. Not all criteria in the below table receive equal weighting or are independent, but the table provides a brief overview of the strong and weak points of the security in the context of the strategy's criteria.
P/E/GROWTH RATIO: PASS
SALES AND P/E RATIO: NEUTRAL
INVENTORY TO SALES: PASS
EPS GROWTH RATE: PASS
TOTAL DEBT/EQUITY RATIO: PASS
FREE CASH FLOW: NEUTRAL
NET CASH POSITION: NEUTRAL
For a full detailed analysis using NASDAQ's Guru Analysis tool, click here
GROUP 1 AUTOMOTIVE, INC. (GPI) is a small-cap value stock in the Retail (Specialty) industry. The rating according to our strategy based on Peter Lynch changed from 72% to 74% based on the firm’s underlying fundamentals and the stock’s valuation. A score of 80% or above typically indicates that the strategy has some interest in the stock and a score above 90% typically indicates strong interest.
Company Description: Group 1 Automotive, Inc. is an operator in the automotive retail industry. The Company, through its dealerships, sells new and used cars and light trucks; arranges related vehicle financing; sells service and insurance contracts; provides automotive maintenance and repair services, and sells vehicle parts. The Company operates through three segments: the U.S., which includes the activities of its corporate office, the United Kingdom and Brazil.The Company owned and operated 233 franchises, representing 30 brands of automobiles, at 180 dealership locations and 47 collision centers. The Company's operations are primarily located in metropolitan areas including in Alabama, California, Florida, Georgia, Kansas, Louisiana, Maryland, Massachusetts, Mississippi, New Hampshire, New Jersey, Oklahoma, South Carolina, Texas in the United States, United Kingdom, and in metropolitan markets in the states of Sao Paulo, Parana, Mato Grosso do Sul and Santa Catarina in Brazil.
The following table summarizes whether the stock meets each of this strategy's tests. Not all criteria in the below table receive equal weighting or are independent, but the table provides a brief overview of the strong and weak points of the security in the context of the strategy's criteria.
P/E/GROWTH RATIO: PASS
SALES AND P/E RATIO: PASS
EPS GROWTH RATE: PASS
TOTAL DEBT/EQUITY RATIO: FAIL
FREE CASH FLOW: NEUTRAL
NET CASH POSITION: NEUTRAL
For a full detailed analysis using NASDAQ's Guru Analysis tool, click here
OWL ROCK CAPITAL CORP (ORCC) is a mid-cap value stock in the Investment Services industry. The rating according to our strategy based on Peter Lynch changed from 0% to 74% based on the firm’s underlying fundamentals and the stock’s valuation. A score of 80% or above typically indicates that the strategy has some interest in the stock and a score above 90% typically indicates strong interest.
Company Description: Owl Rock Capital Corporation is a specialty finance company. The Company is focused on lending to the United States and middle-market companies. The Company invests in senior secured or unsecured loans, subordinated loans or mezzanine loans and, to a lesser extent, equity-related securities including warrants, preferred stock and similar forms of senior equity, which may or may not be convertible into a portfolio Company's common equity. Its investment objective is to generate current income and, to a lesser extent, capital appreciation by targeting investment opportunities with favorable risk-adjusted returns.
The following table summarizes whether the stock meets each of this strategy's tests. Not all criteria in the below table receive equal weighting or are independent, but the table provides a brief overview of the strong and weak points of the security in the context of the strategy's criteria.
P/E/GROWTH RATIO: PASS
SALES AND P/E RATIO: NEUTRAL
EPS GROWTH RATE: FAIL
TOTAL DEBT/EQUITY RATIO: NEUTRAL
EQUITY/ASSETS RATIO: PASS
RETURN ON ASSETS: PASS
FREE CASH FLOW: NEUTRAL
NET CASH POSITION: NEUTRAL
For a full detailed analysis using NASDAQ's Guru Analysis tool, click here
PHILLIPS 66 (PSX) is a large-cap value stock in the Oil & Gas Operations industry. The rating according to our strategy based on Peter Lynch changed from 0% to 91% based on the firm’s underlying fundamentals and the stock’s valuation. A score of 80% or above typically indicates that the strategy has some interest in the stock and a score above 90% typically indicates strong interest.
Company Description: Phillips 66 is an energy manufacturing and logistics company with midstream, chemicals, refining, and marketing and specialties businesses. The Company operates through four segments: Midstream, Chemicals, Refining, and Marketing and Specialties (M&S). The Midstream segment gathers, processes, transports and markets natural gas, and transports, stores, fractionates and markets natural gas liquids (NGLs) in the United States. The Chemicals segment consists of its equity investment in Chevron Phillips Chemical Company LLC (CPChem), which manufactures and markets petrochemicals and plastics. The Refining segment buys, sells and refines crude oil and other feedstocks at refineries in the United States and Europe. The M&S segment purchases for resale and markets refined petroleum products, such as gasolines, distillates and aviation fuels, primarily in the United States and Europe, as well as includes the manufacturing and marketing of specialty products, and power generation operations.
The following table summarizes whether the stock meets each of this strategy's tests. Not all criteria in the below table receive equal weighting or are independent, but the table provides a brief overview of the strong and weak points of the security in the context of the strategy's criteria.
INVENTORY TO SALES: PASS
YIELD ADJUSTED P/E TO GROWTH (PEG) RATIO: PASS
EARNINGS PER SHARE: PASS
TOTAL DEBT/EQUITY RATIO: PASS
FREE CASH FLOW: NEUTRAL
NET CASH POSITION: NEUTRAL
For a full detailed analysis using NASDAQ's Guru Analysis tool, click here
ABBVIE INC (ABBV) is a large-cap growth stock in the Biotechnology & Drugs industry. The rating according to our strategy based on Peter Lynch changed from 50% to 74% based on the firm’s underlying fundamentals and the stock’s valuation. A score of 80% or above typically indicates that the strategy has some interest in the stock and a score above 90% typically indicates strong interest.
Company Description: AbbVie Inc. (AbbVie) is a research-based biopharmaceutical company. The Company is engaged in the discovery, development, manufacture and sale of a range of pharmaceutical products. Its products are focused on treating conditions, such as chronic autoimmune diseases in rheumatology, gastroenterology and dermatology; oncology, including blood cancers; virology, including hepatitis C virus (HCV) and human immunodeficiency virus (HIV); neurological disorders, such as Parkinson's disease and multiple sclerosis; metabolic diseases, including thyroid disease and complications associated with cystic fibrosis, and other serious health conditions. It offers products in various categories, including HUMIRA (adalimumab), Oncology products, Virology Products, Additional Virology products, Metabolics/Hormones products, Endocrinology products and other products, which include Duopa and Duodopa (carbidopa and levodopa), Anesthesia products and ZINBRYTA (daclizumab).
The following table summarizes whether the stock meets each of this strategy's tests. Not all criteria in the below table receive equal weighting or are independent, but the table provides a brief overview of the strong and weak points of the security in the context of the strategy's criteria.
P/E/GROWTH RATIO: PASS
SALES AND P/E RATIO: PASS
INVENTORY TO SALES: PASS
EPS GROWTH RATE: PASS
TOTAL DEBT/EQUITY RATIO: FAIL
FREE CASH FLOW: NEUTRAL
NET CASH POSITION: NEUTRAL
For a full detailed analysis using NASDAQ's Guru Analysis tool, click here
ARTISAN PARTNERS ASSET MANAGEMENT INC (APAM) is a mid-cap value stock in the Investment Services industry. The rating according to our strategy based on Peter Lynch changed from 0% to 74% based on the firm’s underlying fundamentals and the stock’s valuation. A score of 80% or above typically indicates that the strategy has some interest in the stock and a score above 90% typically indicates strong interest.
Company Description: Artisan Partners Asset Management Inc. is an investment management company. The Company provides a range of the United States, non-United States and global investment strategies, each of which is managed by one of its investment teams. The Company provides investment management services to separate accounts, mutual funds and other pooled investment vehicles. The Company offers its investment management services primarily to institutions and through intermediaries that operate with institutional-like decision-making processes and have long-term investment horizons. The Company provides clients with multiple equity investment strategies spanning market capitalization segments and investing styles in both the United States and non-United States markets. The Company also offers one fixed income strategy, the Artisan High Income strategy. Each strategy is managed by one of the investment teams.
The following table summarizes whether the stock meets each of this strategy's tests. Not all criteria in the below table receive equal weighting or are independent, but the table provides a brief overview of the strong and weak points of the security in the context of the strategy's criteria.
YIELD ADJUSTED P/E TO GROWTH (PEG) RATIO: PASS
EARNINGS PER SHARE: PASS
TOTAL DEBT/EQUITY RATIO: NEUTRAL
EQUITY/ASSETS RATIO: PASS
RETURN ON ASSETS: PASS
FREE CASH FLOW: NEUTRAL
NET CASH POSITION: NEUTRAL
For a full detailed analysis using NASDAQ's Guru Analysis tool, click here
ENABLE MIDSTREAM PARTNERS LP (ENBL) is a mid-cap value stock in the Natural Gas Utilities industry. The rating according to our strategy based on Peter Lynch changed from 0% to 93% based on the firm’s underlying fundamentals and the stock’s valuation. A score of 80% or above typically indicates that the strategy has some interest in the stock and a score above 90% typically indicates strong interest.
Company Description: Enable Midstream Partners LP owns, operates and develops midstream energy infrastructure assets strategically located to serve its customers. The Company operates in two business segments: Gathering and Processing, and Transportation and Storage. Its gathering and processing segment primarily provides natural gas and crude oil gathering and natural gas processing services to its producer customers. Its transportation and storage segment provides interstate and intrastate natural gas pipeline transportation and storage services primarily to its producer, power plant, Local distribution company (LDC) and industrial end user customers. As of December 31, 2016, the Company owned and operated natural gas and crude oil gathering and natural gas processing assets in five states. As of December 31, 2016, the Company owned and operated interstate and intrastate transportation and storage systems across nine states.
The following table summarizes whether the stock meets each of this strategy's tests. Not all criteria in the below table receive equal weighting or are independent, but the table provides a brief overview of the strong and weak points of the security in the context of the strategy's criteria.
SALES: PASS
INVENTORY TO SALES: PASS
YIELD COMPARED TO THE S&P 500: PASS
YIELD ADJUSTED P/E/GROWTH (PEG) RATIO: PASS
TOTAL DEBT/EQUITY RATIO: PASS
FREE CASH FLOW: NEUTRAL
NET CASH POSITION: NEUTRAL
For a full detailed analysis using NASDAQ's Guru Analysis tool, click here
INTEGER HOLDINGS CORP (ITGR) is a mid-cap growth stock in the Medical Equipment & Supplies industry. The rating according to our strategy based on Peter Lynch changed from 0% to 91% based on the firm’s underlying fundamentals and the stock’s valuation. A score of 80% or above typically indicates that the strategy has some interest in the stock and a score above 90% typically indicates strong interest.
Company Description: Integer Holdings Corporation, formerly Greatbatch, Inc., is a medical device outsource manufacturing company. The Company's segments include Medical and Non-Medical. Medical segment includes Portable Medical, Cardio & Vascular, and Cardiac & Neuromodulation product lines. Non-Medical segment includes Electrochem product line. It serves the cardiac, neuromodulation and vascular markets. It also serves the non-medical power solutions market. In addition, the Company develops batteries for niche applications in energy, military, and environmental markets. Its brands include Greatbatch Medical, Lake Region Medical and Electrochem. Its primary customers include multi-national original equipment manufacturers (OEMs) and their affiliated subsidiaries.
The following table summarizes whether the stock meets each of this strategy's tests. Not all criteria in the below table receive equal weighting or are independent, but the table provides a brief overview of the strong and weak points of the security in the context of the strategy's criteria.
P/E/GROWTH RATIO: PASS
SALES AND P/E RATIO: PASS
INVENTORY TO SALES: PASS
EPS GROWTH RATE: PASS
TOTAL DEBT/EQUITY RATIO: PASS
FREE CASH FLOW: NEUTRAL
NET CASH POSITION: NEUTRAL
For a full detailed analysis using NASDAQ's Guru Analysis tool, click here
GLOBAL INDEMNITY LTD (GBLI) is a small-cap value stock in the Insurance (Prop. & Casualty) industry. The rating according to our strategy based on Peter Lynch changed from 0% to 74% based on the firm’s underlying fundamentals and the stock’s valuation. A score of 80% or above typically indicates that the strategy has some interest in the stock and a score above 90% typically indicates strong interest.
Company Description: Global Indemnity Limited is a holding company. The Company, through its subsidiary insurance and reinsurance companies, provides both admitted and non-admitted specialty property and casualty insurance coverage and individual policyholder coverage in the United States, as well as reinsurance services worldwide. Its segments include Commercial Lines Operations, Personal Lines Operations and Reinsurance Operations. The Company's personal lines and commercial lines segments comprises of the Company's insurance operations and offers its insurance products through division, including Penn-America Group (Binding Authority), Diamond State Group (Brokerage), United National Group (Programs), American Reliable Insurance Company (Binding Authority), J.H. Ferguson & Associates, LLC, VacantExpress.com (Agency), and Collectibles Insurance Services, LLC (Agency). Reinsurance Operations includes the operations of Global Indemnity Reinsurance Company, Ltd.
The following table summarizes whether the stock meets each of this strategy's tests. Not all criteria in the below table receive equal weighting or are independent, but the table provides a brief overview of the strong and weak points of the security in the context of the strategy's criteria.
YIELD ADJUSTED P/E TO GROWTH (PEG) RATIO: PASS
EARNINGS PER SHARE: PASS
TOTAL DEBT/EQUITY RATIO: NEUTRAL
EQUITY/ASSETS RATIO: PASS
RETURN ON ASSETS: PASS
For a full detailed analysis using NASDAQ's Guru Analysis tool, click here
SKECHERS USA INC (SKX) is a mid-cap growth stock in the Footwear industry. The rating according to our strategy based on Peter Lynch changed from 0% to 91% based on the firm’s underlying fundamentals and the stock’s valuation. A score of 80% or above typically indicates that the strategy has some interest in the stock and a score above 90% typically indicates strong interest.
Company Description: Skechers U.S.A., Inc. is a designer and marketer of Skechers-branded lifestyle footwear for men, women and children, and performance footwear for men and women under the Skechers Performance brand name. It also offers apparel, accessories, eyewear, scrubs and other merchandise. It sells its footwear in department, specialty and independent stores, as well as through its Skechers retail stores and online at skechers.com. The Company operates through three segments: domestic wholesale sales, international wholesale sales, and retail sales, which includes e-commerce sales. Its lifestyle brands include Skechers USA, Skechers Sport, and Skechers Active and Skechers Sport Active. Its Performance Brands include Skechers Performance, Skechers Kids and Skechers Work. As of December 31, 2017, the Company's products are available in over 170 countries and territories through its network of subsidiaries in Asia, Europe, Canada, Central America and South America.
The following table summarizes whether the stock meets each of this strategy's tests. Not all criteria in the below table receive equal weighting or are independent, but the table provides a brief overview of the strong and weak points of the security in the context of the strategy's criteria.
INVENTORY TO SALES: PASS
YIELD ADJUSTED P/E TO GROWTH (PEG) RATIO: PASS
EARNINGS PER SHARE: PASS
TOTAL DEBT/EQUITY RATIO: PASS
For a full detailed analysis using NASDAQ's Guru Analysis tool, click here
HERCULES CAPITAL INC (HTGC) is a small-cap value stock in the Misc. Financial Services industry. The rating according to our strategy based on Peter Lynch changed from 72% to 74% based on the firm’s underlying fundamentals and the stock’s valuation. A score of 80% or above typically indicates that the strategy has some interest in the stock and a score above 90% typically indicates strong interest.
Company Description: Hercules Capital, Inc. is a specialty finance company. The Company is an internally managed, non-diversified, closed-end investment company. The Company focuses on providing senior secured venture growth loans to venture capital-backed companies in a range of technology, life sciences, and sustainable and renewable technology industries. The Company's investment objective is to maximize its portfolio total return by generating current income from its debt investments and capital appreciation from its warrant and equity-related investments. The Company's primary business objectives are to increase its net income, net operating income and net asset value (NAV) by investing in structured debt with warrants and equity of venture capital-backed companies in technology-related industries with attractive current yields and the potential for equity appreciation and realized gains. The Company focuses its investments in companies active in the technology industry sub-sectors.
The following table summarizes whether the stock meets each of this strategy's tests. Not all criteria in the below table receive equal weighting or are independent, but the table provides a brief overview of the strong and weak points of the security in the context of the strategy's criteria.
YIELD ADJUSTED P/E TO GROWTH (PEG) RATIO: PASS
EARNINGS PER SHARE: PASS
TOTAL DEBT/EQUITY RATIO: NEUTRAL
EQUITY/ASSETS RATIO: PASS
RETURN ON ASSETS: PASS
FREE CASH FLOW: NEUTRAL
NET CASH POSITION: NEUTRAL
For a full detailed analysis using NASDAQ's Guru Analysis tool, click here
TENARIS SA (ADR) (TS) is a large-cap growth stock in the Constr. - Supplies & Fixtures industry. The rating according to our strategy based on Peter Lynch changed from 0% to 74% based on the firm’s underlying fundamentals and the stock’s valuation. A score of 80% or above typically indicates that the strategy has some interest in the stock and a score above 90% typically indicates strong interest.
Company Description: Tenaris S.A. is a holding company, which is a steel producer with production facilities in Mexico, Argentina, Colombia, United States and Guatemala. The Company supplies round steel bars and flat steel products for its pipes business. It operates through Tubes business segment. The Tubes segment includes the production and sale of both seamless and welded steel tubular products, and related services primarily for the oil and gas industry, principally oil country tubular goods (OCTG) used in drilling operations, and for other industrial applications with production processes that include in the transformation of steel into tubular products. It operates in geographical areas, such as North America, South America, Europe, Middle East and Africa, and Asia Pacific. Its products and services include OCTG, Premium Connections, Rig Direct, Offshore Line Pipe, Onshore Line Pipe, Hydrocarbon Processing, Power Generation, Sucker Rods, Coiled Tubing, Industrial and Mechanical, and Automotive.
The following table summarizes whether the stock meets each of this strategy's tests. Not all criteria in the below table receive equal weighting or are independent, but the table provides a brief overview of the strong and weak points of the security in the context of the strategy's criteria.
P/E/GROWTH RATIO: PASS
SALES AND P/E RATIO: PASS
INVENTORY TO SALES: PASS
EPS GROWTH RATE: FAIL
TOTAL DEBT/EQUITY RATIO: PASS
FREE CASH FLOW: NEUTRAL
NET CASH POSITION: NEUTRAL
For a full detailed analysis using NASDAQ's Guru Analysis tool, click here
CIT GROUP INC. (CIT) is a mid-cap value stock in the Consumer Financial Services industry. The rating according to our strategy based on Peter Lynch changed from 72% to 91% based on the firm’s underlying fundamentals and the stock’s valuation. A score of 80% or above typically indicates that the strategy has some interest in the stock and a score above 90% typically indicates strong interest.
Company Description: CIT Group Inc. (CIT) is a bank holding company (BHC) and a financial holding company (FHC). The Company, together with its subsidiaries, provides financing, leasing and advisory services to middle market companies in a range of industries in North America. The Company's segments include Commercial Banking, Consumer Banking, Non-Strategic Portfolios, and Corporate and Other. The Commercial Banking segment consists of four divisions: Commercial Finance, Rail, Real Estate Finance, and Business Capital. The Consumer Banking segment includes Retail Banking, Mortgage Lending, and SBA Lending (together referred to as Other Consumer Banking), and Legacy Consumer Mortgages (LCM). The Company's products and services include account receivables collection, acquisition and expansion financing, asset management and servicing, asset-based loans, debt underwriting and syndication, deposits, enterprise value and cash flow loans, equipment leases, factoring services and financial risk management.
The following table summarizes whether the stock meets each of this strategy's tests. Not all criteria in the below table receive equal weighting or are independent, but the table provides a brief overview of the strong and weak points of the security in the context of the strategy's criteria.
SALES: PASS
YIELD COMPARED TO THE S&P 500: PASS
YIELD ADJUSTED P/E/GROWTH (PEG) RATIO: PASS
TOTAL DEBT/EQUITY RATIO: NEUTRAL
EQUITY/ASSETS RATIO: PASS
RETURN ON ASSETS: PASS
FREE CASH FLOW: NEUTRAL
NET CASH POSITION: NEUTRAL
For a full detailed analysis using NASDAQ's Guru Analysis tool, click here
GARMIN LTD. (GRMN) is a large-cap growth stock in the Communications Equipment industry. The rating according to our strategy based on Peter Lynch changed from 0% to 91% based on the firm’s underlying fundamentals and the stock’s valuation. A score of 80% or above typically indicates that the strategy has some interest in the stock and a score above 90% typically indicates strong interest.
Company Description: Garmin Ltd. (Garmin) and subsidiaries offer global positioning system (GPS) navigation and wireless devices and applications. The Company operates through five segments. It offers a range of auto navigation products, as well as a range of products and applications designed for the mobile GPS market. It offers products to consumers around the world, including Outdoor Handhelds, Wearable Devices, Golf Devices, and Dog Tracking and Training/Pet Obedience Devices. It offers a range of products designed for use in fitness and activity tracking. Garmin offers a range of products designed for use in fitness and activity tracking. Its aviation business segment is a provider of solutions to aircraft manufacturers, existing aircraft owners and operators, as well as military and government customers and serves a range of aircraft, including transport aircraft, business aviation, general aviation, experimental/light sport, helicopters, optionally piloted vehicles and unmanned aerial vehicles.
The following table summarizes whether the stock meets each of this strategy's tests. Not all criteria in the below table receive equal weighting or are independent, but the table provides a brief overview of the strong and weak points of the security in the context of the strategy's criteria.
INVENTORY TO SALES: PASS
YIELD ADJUSTED P/E TO GROWTH (PEG) RATIO: PASS
EARNINGS PER SHARE: PASS
TOTAL DEBT/EQUITY RATIO: PASS
FREE CASH FLOW: NEUTRAL
NET CASH POSITION: NEUTRAL
For a full detailed analysis using NASDAQ's Guru Analysis tool, click here
INVESCO MORTGAGE CAPITAL INC (IVR) is a mid-cap value stock in the Consumer Financial Services industry. The rating according to our strategy based on Peter Lynch changed from 0% to 74% based on the firm’s underlying fundamentals and the stock’s valuation. A score of 80% or above typically indicates that the strategy has some interest in the stock and a score above 90% typically indicates strong interest.
Company Description: Invesco Mortgage Capital Inc. is a holding company, which conducts its businesses through IAS Operating Partnership LP (the Operating Partnership) and subsidiaries. The Company's objective is to provide risk-adjusted returns to its investors through dividends and through capital appreciation. It invests in residential mortgage-backed securities that are guaranteed by the United States Government agency, such as the Government National Mortgage Association or a federally chartered corporation, such as the Federal National Mortgage Association or the Federal Home Loan Mortgage Corporation (collectively Agency RMBS); RMBS that are not guaranteed by the United States Government agency; Credit risk transfer securities that are unsecured obligations issued by government-sponsored enterprises; commercial mortgage-backed securities; residential and commercial mortgage loans, and other real estate-related financing arrangements. It is externally managed and advised by Invesco Advisers, Inc.
The following table summarizes whether the stock meets each of this strategy's tests. Not all criteria in the below table receive equal weighting or are independent, but the table provides a brief overview of the strong and weak points of the security in the context of the strategy's criteria.
YIELD ADJUSTED P/E TO GROWTH (PEG) RATIO: PASS
EARNINGS PER SHARE: PASS
TOTAL DEBT/EQUITY RATIO: NEUTRAL
EQUITY/ASSETS RATIO: PASS
RETURN ON ASSETS: PASS
FREE CASH FLOW: NEUTRAL
NET CASH POSITION: NEUTRAL
For a full detailed analysis using NASDAQ's Guru Analysis tool, click here
Since its inception, Validea's strategy based on Peter Lynch has returned 406.13% vs. 224.51% for the S&P 500. For more details on this strategy, click here
About Peter Lynch: Perhaps the greatest mutual fund manager of all-time, Lynch guided Fidelity Investment's Magellan Fund to a 29.2 percent average annual return from 1977 until his retirement in 1990, almost doubling the S&P 500's 15.8 percent yearly return over that time. Lynch's common sense approach and quick wit made him one of the most quoted investors on Wall Street. ("Go for a business that any idiot can run -- because sooner or later, any idiot probably is going to run it," is one of his many pearls of wisdom.) Lynch's bestseller One Up on Wall Street is something of a "stocks for the everyman/everywoman", breaking his approach down into easy-to-understand concepts.
About Validea: Validea is aninvestment researchservice that follows the published strategies of investment legends. Validea offers both stock analysis and model portfolios based on gurus who have outperformed the market over the long-term, including Warren Buffett, Benjamin Graham, Peter Lynch and Martin Zweig. For more information about Validea, click here
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | For a full detailed analysis using NASDAQ's Guru Analysis tool, click here ABBVIE INC (ABBV) is a large-cap growth stock in the Biotechnology & Drugs industry. Company Description: AbbVie Inc. (AbbVie) is a research-based biopharmaceutical company. Company Description: Martin Marietta Materials, Inc. is a supplier of aggregates products (crushed stone, sand, and gravel) used for the construction of infrastructure, nonresidential, and residential projects. | For a full detailed analysis using NASDAQ's Guru Analysis tool, click here ABBVIE INC (ABBV) is a large-cap growth stock in the Biotechnology & Drugs industry. Company Description: AbbVie Inc. (AbbVie) is a research-based biopharmaceutical company. The Company operates through six segments: Vascular North America; Anesthesia North America; Surgical North America; Europe, the Middle East and Africa (EMEA); Asia, and Original Equipment Manufacturer (OEM). | For a full detailed analysis using NASDAQ's Guru Analysis tool, click here ABBVIE INC (ABBV) is a large-cap growth stock in the Biotechnology & Drugs industry. Company Description: AbbVie Inc. (AbbVie) is a research-based biopharmaceutical company. Company Description: The Southern Company (Southern Company) is a holding company. | For a full detailed analysis using NASDAQ's Guru Analysis tool, click here ABBVIE INC (ABBV) is a large-cap growth stock in the Biotechnology & Drugs industry. Company Description: AbbVie Inc. (AbbVie) is a research-based biopharmaceutical company. The Company's business is categorized into Aggregates Business, Cement Business and Magnesia Specialties Business. |
24685.0 | 2020-02-22 00:00:00 UTC | 5 Ways to Make Your Money Work for You | ABBV | https://www.nasdaq.com/articles/5-ways-to-make-your-money-work-for-you-2020-02-22 | nan | nan | If you work 40 hours per week for 50 weeks a year, you're toiling for 2,000 hours per year. That's 120,000 minutes of labor, and you're probably not even earning as much as you'd like to earn or think you should earn. One way to enjoy more income -- now and/or later -- is to put some of your money to work for you.
Just imagine it -- while you're toiling for, say, eight hours a day on weekdays, your dollars can be working for you 24/7 -- all the time, nonstop. Here are five ways to make your money work for you.
Image source: Getty Images.
1. Pay off debts
It might not seem like spending money paying off your debts is a way to make money, but it is. Because each dollar of debt that you pay off today will prevent you from having to pay interest on it going forward. Here's an extreme, large-scale example: If you borrow $200,000 to buy a home with a 30-year, 4% fixed-rate mortgage, you'll pay about $955 per month in interest and principal, paying a total of $343,800 over the 30 years. A whopping $143,739 of that, fully 42%, will be interest payments. If you could pay off the whole loan in the first months, you'd avoid having to pay more than $140,000. You'd keep much more of your money.
Of course, few of us can pay off our home loans all at once when we owe vast sums, and when your interest rate is low, as mortgage rates currently are, home loans are not very problematic. But still -- the principle is true for smaller debts. If you owe, say, $10,000 on credit cards, and you're paying 20% interest on that, you're forking over around $2,000 in interest annually. Pay that debt off this year, and you can save thousands in interest. Getting out of debt isn't always easy, but it can be done. And it should be done, at least in the case of high-interest rate debt, before you tackle investing.
2. Stocks
Next is a more obvious way to make your money work for you: Invest in stocks. If you choose solid long-term growers, their stock prices should appreciate over time, gaining value for you. According to the research of University of Pennsylvania professor Jeremy Siegel, the U.S. stock market posted an average annual return of 9.6% between 1926 and 2012, topping the performance of bonds and gold. His research also found stocks outperforming bonds in 96% of all 20-year holding periods between 1871 and 2012, and in 99% of all 30-year holding periods.
Of course, you're not guaranteed a 9.6% average growth rate during your investment period; you'll probably average less -- or more. The table below shows how annual investments of $10,000 could grow at several different rates:
GROWING FOR
GROWING AT 6%
GROWING AT 8%
GROWING AT 10%
10 years
$139,716
$156,455
$175,312
15 years
$246,725
$293,243
$349,497
20 years
$389,927
$494,229
$630,025
25 years
$581,564
$789,544
$1.1 million
30 years
$838,017
$1.2 million
$1.8 million
35 years
$1.2 million
$1.9 million
$3.0 million
40 years
$1.6 million
$2.8 million
$4.9 million
Calculations by author.
You don't have to spend many hours or years studying up to become a great selector of the best stocks in order to profit from the stock market. You can just invest money regularly in one or more low-fee, broad-market index funds such as one that tracks the S&P 500 index. The SPDR S&P 500 ETF (NYSEMKT: SPY) is a fine example.
Image source: Getty Images.
3. Dividend-paying stocks
Dividend-paying stocks can be even more appealing than nonpayers, as they offer a one-two punch: both stock price appreciation and dividend income -- and keep in mind that healthy and growing companies tend to increase their dividend payouts over time, too.
Spread $100,000 across a bunch of dividend payers with an average overall yield of 4%, and you'll be looking at annual income of around $4,000. Each of those invested dollars will be sending you $0.04 every year, and over time that's likely to become $0.05, $0.07, $0.10, and more. Years down the road, you may well be collecting $10,000 annually from your initial $100,000 investment -- and those shares will likely have grown in value, too, if they were in solid businesses.
Here are some examples of familiar companies and their recent yields:
STOCK
RECENT DIVIDEND YIELD
AT&T
5.4%
AbbVie
5%
Chevron
4.7%
Verizon Communications
4.2%
3M
3.7%
Walgreens Boots Alliance
3.5%
MetLife
3.4%
PepsiCo
2.6%
Johnson & Johnson
2.5%
McDonald's
2.3%
Source: Yahoo! Financial.
4. Look into annuities
Here's a powerful way to have your dollars work for you: You can use them to buy an immediate fixed annuity (or a deferred one) that will pay you a set sum every month -- for a fixed period or even for the rest of your life. That can go a long way to providing peace of mind and financial security late in life.
Read up on why you might want annuities before taking any action, but get an idea of what's possible in the table below, which shows what some people might receive in immediate fixed annuity income in the current interest rate environment:
PERSON/PEOPLE
COST
MONTHLY INCOME
ANNUAL INCOME EQUIVALENT
65-year-old man
$100,000
$524
$6,288
65-year-old woman
$100,000
$496
$5,952
70-year-old man
$100,000
$599
$7,188
70-year-old woman
$100,000
$566
$6,792
65-year-old couple
$200,000
$886
$10,632
70-year-old couple
$200,000
$987
$11,844
75-year-old couple
$200,000
$1,133
$13,596
Source: immediateannuities.com.
5. Make the most of credit cards
Finally, your money can work for you when you simply make ordinary purchases -- if you're using credit cards that offer rewards or cash back. There are lots of great cash-back credit cards that offer up to 5% or 6% back on certain purchases at certain retailers, and some cash-back cards will pay you as much as 2% back on just about all purchases.
Spend $300 per month at a certain retailer or at supermarkets? You may be able to get between $180 and $216 back in cash -- without your exerting yourself at all, other than extending your credit card to a cashier.
There are lots of ways to make your money work for you. Look into these and others, and you may enjoy greater income now or in the future, with some help from your money.
The $16,728 Social Security bonus most retirees completely overlook
If you're like most Americans, you're a few years (or more) behind on your retirement savings. But a handful of little-known "Social Security secrets" could help ensure a boost in your retirement income. For example: one easy trick could pay you as much as $16,728 more... each year! Once you learn how to maximize your Social Security benefits, we think you could retire confidently with the peace of mind we're all after. Simply click here to discover how to learn more about these strategies.
Selena Maranjian owns shares of AbbVie, AT&T, Johnson & Johnson, and Verizon Communications. The Motley Fool recommends 3M, Johnson & Johnson, and Verizon Communications. The Motley Fool has a disclosure policy.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | 5.4% AbbVie 5% Chevron 4.7% Verizon Communications 4.2% Selena Maranjian owns shares of AbbVie, AT&T, Johnson & Johnson, and Verizon Communications. According to the research of University of Pennsylvania professor Jeremy Siegel, the U.S. stock market posted an average annual return of 9.6% between 1926 and 2012, topping the performance of bonds and gold. | 5.4% AbbVie 5% Chevron 4.7% Verizon Communications 4.2% Selena Maranjian owns shares of AbbVie, AT&T, Johnson & Johnson, and Verizon Communications. 10 years $139,716 $156,455 $175,312 15 years $246,725 $293,243 $349,497 20 years $389,927 $494,229 $630,025 25 years $581,564 $789,544 $1.1 million 30 years $838,017 $1.2 million $1.8 million 35 years $1.2 million $1.9 million $3.0 million 40 years $1.6 million $2.8 million $4.9 million Calculations by author. | 5.4% AbbVie 5% Chevron 4.7% Verizon Communications 4.2% Selena Maranjian owns shares of AbbVie, AT&T, Johnson & Johnson, and Verizon Communications. Pay off debts It might not seem like spending money paying off your debts is a way to make money, but it is. | 5.4% AbbVie 5% Chevron 4.7% Verizon Communications 4.2% Selena Maranjian owns shares of AbbVie, AT&T, Johnson & Johnson, and Verizon Communications. Pay off debts It might not seem like spending money paying off your debts is a way to make money, but it is. |
24686.0 | 2020-02-22 00:00:00 UTC | Is Gilead Sciences Stock a Buy? | ABBV | https://www.nasdaq.com/articles/is-gilead-sciences-stock-a-buy-2020-02-22 | nan | nan | Gilead Sciences (NASDAQ: GILD) has been getting a lot of attention these days for remdesivir, its possible treatment for the coronavirus, which so far has resulted in more than 2,000 deaths. Even though remdesivir could be a plus for the company if approved, there are still too many unknowns to make it a reason for buying shares of Gilead Sciences.
Instead, eyes should be on the fate of filgotinib, the rheumatoid arthritis treatment now under review at the U.S. Food and Drug Administration. Addressing a much broader market, this treatment could compensate for declines in sales of the company's older drugs.
Image source: Getty Images.
In December, Gilead Sciences submitted filgotinib to the FDA along with a priority review voucher, which reduces the review time. Standard review takes about 10 months, while priority review is completed in about six months. Filgotinib is an oral JAK1 inhibitor for adults suffering from moderate to severe rheumatoid arthritis. JAK inhibitors block the action of enzymes that support the inflammation process.
Global sales of $1.3 billion
For Gilead Sciences, the opportunity is significant. The global rheumatoid arthritis market is forecast to reach $34 billion by 2025, according to Fortune Business Insights, which said the North American market alone was worth $9.9 billion in 2017. Arthritis Foundation data show that 1.5 million Americans have rheumatoid arthritis. EvaluatePharma predicts filgotinib could bring in global sales of $1.3 billion in 2024. Gilead Sciences has also applied for approval in Europe and Japan. While Gilead is solely responsible for the commercialization of the drug in the U.S., partner Galapagos (NASDAQ: GLPG) will co-commercialize the drug in certain European countries.
More good news is that filgotinib has the potential for launches in five new indications over the next four years, the company said in its recent earnings call. Indications now in late-stage trials include ulcerative colitis, Crohn's disease, and psoriatic arthritis.
The big question, if filgotinib is approved, is about labeling. Safety issues have come up with some JAK inhibitors, and last year, the FDA ordered a "boxed warning" about increased risk of blood clots and death with higher doses of Pfizer's tofacitinib. The FDA also approved a boxed warning for another rival, AbbVie's upadacitinib, mentioning thrombosis and other risks. For Gilead's filgotinib, the concern is that the FDA might decide to apply boxed warnings to the whole drug class even if some have better safety profiles than others.
Durable safety and efficacy
While the application of such a warning across an entire drug class isn't great news for filgotinib, its impact might be limited. Sure, some doctors may turn away from the entire drug class, but others may look further into the data and choose the safest options. Here, Gilead Sciences' drug may stand out. Filgotinib's FDA submission is backed up by safety and efficacy data in a trial involving 3,452 patients over a period of 52 weeks. The company said filgotinib showed durable safety and efficacy in a variety of patient populations.
Overall, filgotinib is a reason to be optimistic about Gilead Sciences. Though a 15% drop in chronic hepatitis C product sales in the fourth quarter disappointed investors, and earnings of $1.3 per share fell short of analysts' expectations, HIV product sales and the company's pipeline provide additional bright spots. HIV product sales rose 12% in the quarter and for the whole year, and the HIV drug market is growing, with Allied Market Research predicting the market will reach $26 billion by 2022 from $20 billion in 2015. In the earnings report, Gilead Sciences said that at year end, it had $25.8 billion in cash, cash equivalents, and marketable debt securities, meaning it has the resources to support pipeline development. Of the more than 35 drug candidates, seven are in phase 3 trials. That number doesn't include filgotinib for the rheumatoid arthritis indication.
Is Gilead Sciences a buy?
And finally, let's talk about its stock price and valuation. The shares posted a lackluster performance last year, rising 3.9%, and so far this year, they're up 3.3%. Analysts expect 11% upside from here. While the valuation of nearly 16 is higher than that of Pfizer, which trades at a bit more than 12 times earnings, it's lower than peer AbbVie, which trades at almost 18 times earnings. The valuation could be considered reasonable, especially in light of the pipeline and the number of late-stage candidates.
So, is Gilead Sciences a stock to buy? Yes. Any weakness is a good opportunity to get in on a company with products for vast markets and many others waiting to grow revenue in the years to come.
10 stocks we like better than Gilead Sciences
When investing geniuses David and Tom Gardner have a stock tip, it can pay to listen. After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor, has tripled the market.*
David and Tom just revealed what they believe are the ten best stocks for investors to buy right now... and Gilead Sciences wasn't one of them! That's right -- they think these 10 stocks are even better buys.
See the 10 stocks
*Stock Advisor returns as of December 1, 2019
Adria Cimino has no position in any of the stocks mentioned. The Motley Fool owns shares of and recommends Gilead Sciences. The Motley Fool has a disclosure policy.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | The FDA also approved a boxed warning for another rival, AbbVie's upadacitinib, mentioning thrombosis and other risks. While the valuation of nearly 16 is higher than that of Pfizer, which trades at a bit more than 12 times earnings, it's lower than peer AbbVie, which trades at almost 18 times earnings. Gilead Sciences (NASDAQ: GILD) has been getting a lot of attention these days for remdesivir, its possible treatment for the coronavirus, which so far has resulted in more than 2,000 deaths. | The FDA also approved a boxed warning for another rival, AbbVie's upadacitinib, mentioning thrombosis and other risks. While the valuation of nearly 16 is higher than that of Pfizer, which trades at a bit more than 12 times earnings, it's lower than peer AbbVie, which trades at almost 18 times earnings. Though a 15% drop in chronic hepatitis C product sales in the fourth quarter disappointed investors, and earnings of $1.3 per share fell short of analysts' expectations, HIV product sales and the company's pipeline provide additional bright spots. | The FDA also approved a boxed warning for another rival, AbbVie's upadacitinib, mentioning thrombosis and other risks. While the valuation of nearly 16 is higher than that of Pfizer, which trades at a bit more than 12 times earnings, it's lower than peer AbbVie, which trades at almost 18 times earnings. In December, Gilead Sciences submitted filgotinib to the FDA along with a priority review voucher, which reduces the review time. | The FDA also approved a boxed warning for another rival, AbbVie's upadacitinib, mentioning thrombosis and other risks. While the valuation of nearly 16 is higher than that of Pfizer, which trades at a bit more than 12 times earnings, it's lower than peer AbbVie, which trades at almost 18 times earnings. Even though remdesivir could be a plus for the company if approved, there are still too many unknowns to make it a reason for buying shares of Gilead Sciences. |
24687.0 | 2020-02-21 00:00:00 UTC | Daily Dividend Report: RY,KO,PLD,WRB,ABBV | ABBV | https://www.nasdaq.com/articles/daily-dividend-report%3A-rykopldwrbabbv-2020-02-21 | nan | nan | Royal Bank of Canada announced today that its board of directors has declared an increase to its quarterly common share dividend of three cents, or three per cent, to $1.08 per share, payable on and after May 22, 2020, to common shareholders of record at the close of business on April 23, 2020.
The Board of Directors of Coca-Cola today approved the company's 58th consecutive annual dividend increase, raising the quarterly dividend 2.5 percent from 40 cents to 41 cents per common share. The quarterly dividend is equivalent to an annual dividend of $1.64 per share, up from $1.60 per share in 2019. The first quarter dividend is payable April 1, 2020, to shareowners of record as of March 16, 2020. The company returned $6.8 billion in dividends to shareowners in 2019, bringing the total amount given back to shareowners through dividends since Jan. 1, 2010, to $54.9 billion.
The Board of Directors of Prologis today approved a plan to raise the company's annualized dividend level by 9.4 percent to $2.32 per share of common stock. The board declared a regular cash dividend for the quarter ending March 31, 2020. A dividend of $0.58 per share of the company's common stock, which will be payable on March 31, 2020, to common stockholders of record at the close of business on March 16, 2020.
W. R. Berkley announced today that its Board of Directors has declared a regular quarterly cash dividend on its common stock of 11 cents per share to be paid on March 25, 2020 to stockholders of record at the close of business on March 11, 2020.
The board of directors of AbbVie today declared a quarterly cash dividend of $1.18 per share. The cash dividend is payable May 15, 2020 to stockholders of record at the close of business on April 15, 2020. Since the company's inception in 2013, AbbVie has increased its dividend by 195 percent. AbbVie is a member of the S&P Dividend Aristocrats Index, which tracks companies that have annually increased their dividend for at least 25 consecutive years.
VIDEO: Daily Dividend Report: RY,KO,PLD,WRB,ABBV
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | The board of directors of AbbVie today declared a quarterly cash dividend of $1.18 per share. Since the company's inception in 2013, AbbVie has increased its dividend by 195 percent. AbbVie is a member of the S&P Dividend Aristocrats Index, which tracks companies that have annually increased their dividend for at least 25 consecutive years. | The board of directors of AbbVie today declared a quarterly cash dividend of $1.18 per share. Since the company's inception in 2013, AbbVie has increased its dividend by 195 percent. AbbVie is a member of the S&P Dividend Aristocrats Index, which tracks companies that have annually increased their dividend for at least 25 consecutive years. | The board of directors of AbbVie today declared a quarterly cash dividend of $1.18 per share. Since the company's inception in 2013, AbbVie has increased its dividend by 195 percent. AbbVie is a member of the S&P Dividend Aristocrats Index, which tracks companies that have annually increased their dividend for at least 25 consecutive years. | The board of directors of AbbVie today declared a quarterly cash dividend of $1.18 per share. Since the company's inception in 2013, AbbVie has increased its dividend by 195 percent. AbbVie is a member of the S&P Dividend Aristocrats Index, which tracks companies that have annually increased their dividend for at least 25 consecutive years. |
24688.0 | 2020-02-19 00:00:00 UTC | Where Will Gilead Sciences Be in 10 Years? | ABBV | https://www.nasdaq.com/articles/where-will-gilead-sciences-be-in-10-years-2020-02-19 | nan | nan | Biotech investing is generally cyclic in nature. The interplay between innovation and patent expirations makes many of these companies prone to enormous swings in revenue every couple of years. To smooth out the edges, biotechs must continually restock the cupboard through a mix of organic pipeline development and business development activities, such as external licensing deals or acquisitions.
Unfortunately, the vast majority of clinical-stage assets fail to evolve into commercial-stage products. So, despite management's best efforts to offset the eventual decline of top-selling medicines through aggressive clinical or business development activities, prolonged lean periods are still commonplace throughout the biotech industry.
American biotech giant Gilead Sciences (NASDAQ: GILD) encapsulates this narrative almost to a T. During the company's formative years, it built a market-leading HIV franchise, which provided the capital necessary to take on larger acquisitions. In 2011, for instance, the biotech purchased Pharmasset for approximately $11 billion. This seminal transaction would form the backbone of Gilead's game-changing hepatitis C franchise. At its peak, Gilead's hep-C drug sales hit a whopping $19.1 billion in 2015.
Image source: Getty Images.
A boom followed by a bust and a managerial shake-up
However, the hepatitis C drug market quickly fell apart because these new therapies effectively cured patients. The bad news is that Gilead has never been able to replace the bulk of the lost hep-C revenue because of a string of clinical failures across its pipeline, poor execution on the business development front, and the underwhelming commercial performance of its fledgling cancer franchise. So with Gilead losing a staggering $100 billion in market capitalization from 2015 to 2018 (see the following chart), the biotech decided that a shake-up in the C-suite was necessary. Former Roche executive Daniel O'Day replaced John Milligan as chief executive officer of the biotech in March 2019.
GILD Market Cap data by YCharts
Five months later, O'Day's vision for the company would start to become clear. Eschewing pricey acquisitions, Gilead instead decided to deepen its relationship with Belgian biotech Galapagos (NASDAQ: GLPG) through a $5 billion collaboration agreement. This deal gave Gilead access to more than 20 preclinical programs, and six compounds already in clinical development. Chief among them, Gilead gained more control over the megablockbuster-in-waiting filgotinib, an experimental medication that's widely expected to become a big seller as a treatment for rheumatoid arthritis and other inflammatory diseases. Filgotinib is the undisputed centerpiece of Gilead's long-term value proposition.
Where will Gilead be 10 years from now?
Gilead is at a critical juncture in its life cycle. The biotech's core plan seems to be to return to growth on the back of filgotinib's stellar commercial potential and then use its $25.8 billion in cash to flesh out other areas of need in its pipeline. Most likely, Gilead will buy a few oncology companies to bulk up this less-than-stellar franchise and perhaps dive deeper in the non-alcoholic steatohepatitis (NASH) space with an acquisition or two as well. So if things go according to plan, we're looking at a large-cap biotech that could be generating high-single-digit top-line growth during the period covering 2024 to 2030.
The big problem is that Gilead really hasn't had much luck outside infectious diseases. Its $12 billion Kite Pharma acquisition has turned into a boondoggle, its NASH assets have repeatedly flamed out in clinical studies, and its rather questionable strategy of sitting on a mountain of cash -- while key competitiors rapidly gobbled up the most promising bolt-on biopharmas -- hasn't played out well in the least.
Driving this point home, Gilead has missed out on acquisition targets such as Array BioPharma, Celgene, Medivation, Pharmacyclics, Otezla, and Tesaro, among many others, since 2015. Most of these former acquisition targets would have made a positive impact on the biotech's near- and long-term outlook.
Therefore, the idea that Gilead is suddenly going to turn the corner by attempting to go after AbbVie's (NYSE: ABBV) bread-and-butter franchise of anti-inflammatory drugs with filgotinib is a questionable investing thesis, to put it mildly. AbbVie, after all, returned filgotinib's commercial rights to Galapagos back in 2015 to focus on the development of Rinvoq, a drug that has already hit the market and is off to a blazing start.
So if past is indeed prologue, Gilead seems more likely to continue to flounder and slowly lose even more value over the next 10 years, the inevitable outcome of which seems to be that Johnson & Johnson, Pfizer, or maybe even AbbVie will acquire Gilead in the latter half of the decade.
On the flip side, Gilead does have an enormous amount of financial flexibility to throw at M&A, which could radically alter its trajectory in the blink of an eye. But that's been the case for the better part of the past five years, and nothing has really changed in that time. The bottom line is that more of the same from Gilead is unlikely to move the needle from a value creation standpoint over the course of the 2020s.
10 stocks we like better than Gilead Sciences
When investing geniuses David and Tom Gardner have a stock tip, it can pay to listen. After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor, has tripled the market.*
David and Tom just revealed what they believe are the 10 best stocks for investors to buy right now... and Gilead Sciences wasn't one of them! That's right -- they think these 10 stocks are even better buys.
See the 10 stocks
*Stock Advisor returns as of December 1, 2019
George Budwell has no position in any of the stocks mentioned. The Motley Fool owns shares of and recommends Gilead Sciences. The Motley Fool recommends Johnson & Johnson. The Motley Fool has a disclosure policy.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Therefore, the idea that Gilead is suddenly going to turn the corner by attempting to go after AbbVie's (NYSE: ABBV) bread-and-butter franchise of anti-inflammatory drugs with filgotinib is a questionable investing thesis, to put it mildly. AbbVie, after all, returned filgotinib's commercial rights to Galapagos back in 2015 to focus on the development of Rinvoq, a drug that has already hit the market and is off to a blazing start. So if past is indeed prologue, Gilead seems more likely to continue to flounder and slowly lose even more value over the next 10 years, the inevitable outcome of which seems to be that Johnson & Johnson, Pfizer, or maybe even AbbVie will acquire Gilead in the latter half of the decade. | Therefore, the idea that Gilead is suddenly going to turn the corner by attempting to go after AbbVie's (NYSE: ABBV) bread-and-butter franchise of anti-inflammatory drugs with filgotinib is a questionable investing thesis, to put it mildly. AbbVie, after all, returned filgotinib's commercial rights to Galapagos back in 2015 to focus on the development of Rinvoq, a drug that has already hit the market and is off to a blazing start. So if past is indeed prologue, Gilead seems more likely to continue to flounder and slowly lose even more value over the next 10 years, the inevitable outcome of which seems to be that Johnson & Johnson, Pfizer, or maybe even AbbVie will acquire Gilead in the latter half of the decade. | So if past is indeed prologue, Gilead seems more likely to continue to flounder and slowly lose even more value over the next 10 years, the inevitable outcome of which seems to be that Johnson & Johnson, Pfizer, or maybe even AbbVie will acquire Gilead in the latter half of the decade. Therefore, the idea that Gilead is suddenly going to turn the corner by attempting to go after AbbVie's (NYSE: ABBV) bread-and-butter franchise of anti-inflammatory drugs with filgotinib is a questionable investing thesis, to put it mildly. AbbVie, after all, returned filgotinib's commercial rights to Galapagos back in 2015 to focus on the development of Rinvoq, a drug that has already hit the market and is off to a blazing start. | AbbVie, after all, returned filgotinib's commercial rights to Galapagos back in 2015 to focus on the development of Rinvoq, a drug that has already hit the market and is off to a blazing start. Therefore, the idea that Gilead is suddenly going to turn the corner by attempting to go after AbbVie's (NYSE: ABBV) bread-and-butter franchise of anti-inflammatory drugs with filgotinib is a questionable investing thesis, to put it mildly. So if past is indeed prologue, Gilead seems more likely to continue to flounder and slowly lose even more value over the next 10 years, the inevitable outcome of which seems to be that Johnson & Johnson, Pfizer, or maybe even AbbVie will acquire Gilead in the latter half of the decade. |
24689.0 | 2020-02-18 00:00:00 UTC | 17 Consumer Groups and Unions Ask FTC to Block AbbVie's Acquisition of Allergan | ABBV | https://www.nasdaq.com/articles/17-consumer-groups-and-unions-ask-ftc-to-block-abbvies-acquisition-of-allergan-2020-02-18 | nan | nan | Seventeen consumer groups and unions have again voiced their opposition to AbbVie's (NYSE: ABBV) acquisition of Allergan (NYSE: AGN) in a letter to the Federal Trade Commission. The organizations, which represent over 10 million subscribers and members, originally raised concerns in September that the merger would harm competition.
Since then, the FTC has requested the drugmakers divest themselves of a few products to reduce the anticompetitive nature of the deal. In the Crohn's disease and ulcerative colitis space, Allergan agreed to hand the rights to brazikumab back to AstraZeneca (NYSE: AZN) from which it had licensed the drug. Brazikumab is in mid-to-late stage clinical trials for the two diseases.
Allergan also agreed to sell its gastrointestinal medication Zenpep to Nestle. The drug, which is used by patients who don't produce enough enzymes to break down fat, protein, and carbohydrates, competes with AbbVie's Creon.
Image source: Getty Images.
Given AbbVie's strong position in the autoimmune diseases space with Humira and Skyrizi, the groups are concerned that divesting rights to brazikumab may not do enough to support a competitive marketplace. "Based on the limited public information, we believe there are signs that AstraZeneca may lack the incentive and ability to fully restore competition," the letter states.
The groups don't seem to have much of an issue with the divestiture of Zenpep because it's already approved, but they do argue that companies shouldn't be allowed to divest themselves of drug candidates to appease antitrust regulators because "pipeline assets in the pharmaceutical industry are often unsuccessful in terms of actual product launches."
AbbVie and Allergan have said they expect their deal to close this quarter.
10 stocks we like better than AbbVie
When investing geniuses David and Tom Gardner have a stock tip, it can pay to listen. After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor, has tripled the market.*
David and Tom just revealed what they believe are the ten best stocks for investors to buy right now... and AbbVie wasn't one of them! That's right -- they think these 10 stocks are even better buys.
See the 10 stocks
*Stock Advisor returns as of December 1, 2019
Brian Orelli has no position in any of the stocks mentioned. The Motley Fool recommends Nestle. The Motley Fool has a disclosure policy.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Given AbbVie's strong position in the autoimmune diseases space with Humira and Skyrizi, the groups are concerned that divesting rights to brazikumab may not do enough to support a competitive marketplace. Seventeen consumer groups and unions have again voiced their opposition to AbbVie's (NYSE: ABBV) acquisition of Allergan (NYSE: AGN) in a letter to the Federal Trade Commission. The drug, which is used by patients who don't produce enough enzymes to break down fat, protein, and carbohydrates, competes with AbbVie's Creon. | Given AbbVie's strong position in the autoimmune diseases space with Humira and Skyrizi, the groups are concerned that divesting rights to brazikumab may not do enough to support a competitive marketplace. Seventeen consumer groups and unions have again voiced their opposition to AbbVie's (NYSE: ABBV) acquisition of Allergan (NYSE: AGN) in a letter to the Federal Trade Commission. The drug, which is used by patients who don't produce enough enzymes to break down fat, protein, and carbohydrates, competes with AbbVie's Creon. | Given AbbVie's strong position in the autoimmune diseases space with Humira and Skyrizi, the groups are concerned that divesting rights to brazikumab may not do enough to support a competitive marketplace. 10 stocks we like better than AbbVie When investing geniuses David and Tom Gardner have a stock tip, it can pay to listen. Seventeen consumer groups and unions have again voiced their opposition to AbbVie's (NYSE: ABBV) acquisition of Allergan (NYSE: AGN) in a letter to the Federal Trade Commission. | Given AbbVie's strong position in the autoimmune diseases space with Humira and Skyrizi, the groups are concerned that divesting rights to brazikumab may not do enough to support a competitive marketplace. Seventeen consumer groups and unions have again voiced their opposition to AbbVie's (NYSE: ABBV) acquisition of Allergan (NYSE: AGN) in a letter to the Federal Trade Commission. The drug, which is used by patients who don't produce enough enzymes to break down fat, protein, and carbohydrates, competes with AbbVie's Creon. |
24690.0 | 2020-02-18 00:00:00 UTC | IVV, MDT, ABBV, PYPL: ETF Outflow Alert | ABBV | https://www.nasdaq.com/articles/ivv-mdt-abbv-pypl%3A-etf-outflow-alert-2020-02-18 | nan | nan | Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel, one standout is the iShares Core S&P 500 ETF (Symbol: IVV) where we have detected an approximate $356.0 million dollar outflow -- that's a 0.2% decrease week over week (from 651,100,000 to 650,050,000). Among the largest underlying components of IVV, in trading today Medtronic PLC (Symbol: MDT) is down about 4.4%, AbbVie Inc (Symbol: ABBV) is down about 0.2%, and PayPal Holdings Inc (Symbol: PYPL) is lower by about 0.6%. For a complete list of holdings, visit the IVV Holdings page » The chart below shows the one year price performance of IVV, versus its 200 day moving average:
Looking at the chart above, IVV's low point in its 52 week range is $274.10 per share, with $339.68 as the 52 week high point — that compares with a last trade of $337.95. Comparing the most recent share price to the 200 day moving average can also be a useful technical analysis technique -- learn more about the 200 day moving average ».
Exchange traded funds (ETFs) trade just like stocks, but instead of ''shares'' investors are actually buying and selling ''units''. These ''units'' can be traded back and forth just like stocks, but can also be created or destroyed to accommodate investor demand. Each week we monitor the week-over-week change in shares outstanding data, to keep a lookout for those ETFs experiencing notable inflows (many new units created) or outflows (many old units destroyed). Creation of new units will mean the underlying holdings of the ETF need to be purchased, while destruction of units involves selling underlying holdings, so large flows can also impact the individual components held within ETFs.
Click here to find out which 9 other ETFs experienced notable outflows »
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Among the largest underlying components of IVV, in trading today Medtronic PLC (Symbol: MDT) is down about 4.4%, AbbVie Inc (Symbol: ABBV) is down about 0.2%, and PayPal Holdings Inc (Symbol: PYPL) is lower by about 0.6%. For a complete list of holdings, visit the IVV Holdings page » The chart below shows the one year price performance of IVV, versus its 200 day moving average: Looking at the chart above, IVV's low point in its 52 week range is $274.10 per share, with $339.68 as the 52 week high point — that compares with a last trade of $337.95. These ''units'' can be traded back and forth just like stocks, but can also be created or destroyed to accommodate investor demand. | Among the largest underlying components of IVV, in trading today Medtronic PLC (Symbol: MDT) is down about 4.4%, AbbVie Inc (Symbol: ABBV) is down about 0.2%, and PayPal Holdings Inc (Symbol: PYPL) is lower by about 0.6%. For a complete list of holdings, visit the IVV Holdings page » The chart below shows the one year price performance of IVV, versus its 200 day moving average: Looking at the chart above, IVV's low point in its 52 week range is $274.10 per share, with $339.68 as the 52 week high point — that compares with a last trade of $337.95. Each week we monitor the week-over-week change in shares outstanding data, to keep a lookout for those ETFs experiencing notable inflows (many new units created) or outflows (many old units destroyed). | Among the largest underlying components of IVV, in trading today Medtronic PLC (Symbol: MDT) is down about 4.4%, AbbVie Inc (Symbol: ABBV) is down about 0.2%, and PayPal Holdings Inc (Symbol: PYPL) is lower by about 0.6%. Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel, one standout is the iShares Core S&P 500 ETF (Symbol: IVV) where we have detected an approximate $356.0 million dollar outflow -- that's a 0.2% decrease week over week (from 651,100,000 to 650,050,000). For a complete list of holdings, visit the IVV Holdings page » The chart below shows the one year price performance of IVV, versus its 200 day moving average: Looking at the chart above, IVV's low point in its 52 week range is $274.10 per share, with $339.68 as the 52 week high point — that compares with a last trade of $337.95. | Among the largest underlying components of IVV, in trading today Medtronic PLC (Symbol: MDT) is down about 4.4%, AbbVie Inc (Symbol: ABBV) is down about 0.2%, and PayPal Holdings Inc (Symbol: PYPL) is lower by about 0.6%. Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel, one standout is the iShares Core S&P 500 ETF (Symbol: IVV) where we have detected an approximate $356.0 million dollar outflow -- that's a 0.2% decrease week over week (from 651,100,000 to 650,050,000). For a complete list of holdings, visit the IVV Holdings page » The chart below shows the one year price performance of IVV, versus its 200 day moving average: Looking at the chart above, IVV's low point in its 52 week range is $274.10 per share, with $339.68 as the 52 week high point — that compares with a last trade of $337.95. |
24691.0 | 2020-02-18 00:00:00 UTC | Better Buy: AbbVie vs. Eli Lilly | ABBV | https://www.nasdaq.com/articles/better-buy%3A-abbvie-vs.-eli-lilly-2020-02-18 | nan | nan | Biopharmaceutical giants AbbVie (NYSE: ABBV) and Eli Lilly (NYSE: LLY) have both provided shareholders with market-crushing returns over the past five years. The secret to their success has been their laserlike focus on creating value for shareholders through various business development activities, an aggressive approach to clinical trials, and regular hikes to their respective dividend programs.
AbbVie and Lilly, in fact, have been two of the most generous pharma companies over this period in terms of raising their dividends. Keeping with this theme, AbbVie has boosted its dividend by a staggering 141% since the start of 2015, whereas Lilly has hiked its annual payout by 48% over the same period.
Image source: Getty Images.
Which of these two top dividend growth stocks is the better buy right now? Lets take a look at the strengths and weaknesses of each company to find out.
The case for AbbVie
AbbVie is currently putting the finishing touches on its highly anticipated megamerger with Botox maker Allergan (NYSE: AGN). This transaction is supposed to close before the end of the first quarter of 2020. And with Allergan in the mix, AbbVie should easily generate high single-digit top-line growth in the years ahead. The drugmaker's combined portfolio will sport a healthy mix of established legacy products like Botox and Humira, along with a bevy of newer growth medicines such as Imbruvica, Linzess, Orilissa, Ozurdex, Rinvoq, Skyrizi, Venclexta, and Vraylar. That's an impressive lineup of top-notch growth products.
That said, it won't be all rainbows and unicorns once this megamerger is consummated. Right out of the gate, the new-look AbbVie will be straddled with a shocking amount of debt. AbbVie's management has tried to assuage shareholders by stating that Humira's sizable revenue stream should provide a viable pathway to quickly de-lever post-transaction.
At a minimum, though, AbbVie won't have much in the way of financial flexibility to pursue additional bolt-on transactions for perhaps the next two to three years. That's not a showstopper, but the big biotech won't have much room for error, either. It must fold in Allergan quickly to begin generating value-creating synergies as soon as possible. Too much debt, after all, is never a good thing.
The case for Lilly
Lilly is apparently feeling rather acquisitive these days. Despite its recent acquisitions of both Loxo Oncology and Dermira, the drugmaker said that it plans to make several additional midsized transactions throughout the course of 2020. Presumably, these future bolt-on deals are part of a broader strategy designed to head off any forthcoming headwinds over the prescription drug pricing debate inside the United States.
After all, the enormous cost of diabetes drugs -- one of Lilly's core areas of expertise -- has been a key area of concern for lawmakers. A Bernie Sanders presidency, while far from a sure thing, would accentuate the need for companies like Lilly to drive top-line growth through rising sales volumes, instead of regular price hikes for already-pricey medicines. So Lilly's decision to take a hyper-aggressive approach to business development well ahead of the upcoming U.S. presidential election is arguably a wise move.
The bad news is that Lilly's shares are on the pricey side right now. With a forward price-to-earnings ratio of 18.4, the drugmaker's stock is the second most expensive within its big pharma peer group. Investors have steadily piled into this name in response to the rapidly rising sales of the company's battery of growth products, such as Trulicity, Taltz, Jardiance, Verzenio, Olumiant, Emgality, Basaglar, and Cyramza. Future share price appreciation, in turn, is likely to be dependent on Lilly's planned mergers and acquisitions bonanza.
Which stock is the better buy?
AbbVie and Lilly are both proven winners. So it's arguably worthwhile to own both of these top dividend growth stocks for the long term. But if you can only buy one of these big biopharmas, AbbVie comes across as the more attractive play right now. AbbVie's Allergan deal should significantly acccelerate its top-line growth going forward and allow it to table its biggest headwind -- the eventual decline of Humira. Lilly, on the other hand, doesn't seem to have much more room to run in the near term, thanks to its market-crushing performance over the past 36 straight months.
10 stocks we like better than Eli Lilly and Company
When investing geniuses David and Tom Gardner have a stock tip, it can pay to listen. After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor, has tripled the market.*
David and Tom just revealed what they believe are the ten best stocks for investors to buy right now... and Eli Lilly and Company wasn't one of them! That's right -- they think these 10 stocks are even better buys.
See the 10 stocks
*Stock Advisor returns as of December 1, 2019
George Budwell has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Biopharmaceutical giants AbbVie (NYSE: ABBV) and Eli Lilly (NYSE: LLY) have both provided shareholders with market-crushing returns over the past five years. AbbVie and Lilly, in fact, have been two of the most generous pharma companies over this period in terms of raising their dividends. Keeping with this theme, AbbVie has boosted its dividend by a staggering 141% since the start of 2015, whereas Lilly has hiked its annual payout by 48% over the same period. | Biopharmaceutical giants AbbVie (NYSE: ABBV) and Eli Lilly (NYSE: LLY) have both provided shareholders with market-crushing returns over the past five years. And with Allergan in the mix, AbbVie should easily generate high single-digit top-line growth in the years ahead. AbbVie and Lilly, in fact, have been two of the most generous pharma companies over this period in terms of raising their dividends. | Biopharmaceutical giants AbbVie (NYSE: ABBV) and Eli Lilly (NYSE: LLY) have both provided shareholders with market-crushing returns over the past five years. AbbVie and Lilly, in fact, have been two of the most generous pharma companies over this period in terms of raising their dividends. Keeping with this theme, AbbVie has boosted its dividend by a staggering 141% since the start of 2015, whereas Lilly has hiked its annual payout by 48% over the same period. | AbbVie and Lilly, in fact, have been two of the most generous pharma companies over this period in terms of raising their dividends. And with Allergan in the mix, AbbVie should easily generate high single-digit top-line growth in the years ahead. Biopharmaceutical giants AbbVie (NYSE: ABBV) and Eli Lilly (NYSE: LLY) have both provided shareholders with market-crushing returns over the past five years. |
24692.0 | 2020-02-18 00:00:00 UTC | Moderna Will Rebound, But Wait for a Dip Lower to Buy Shares | ABBV | https://www.nasdaq.com/articles/moderna-will-rebound-but-wait-for-a-dip-lower-to-buy-shares-2020-02-18 | nan | nan | The six-month uptrend in Moderna (NASDAQ:) ended on Feb. 12 when the company priced a secondary offering of its stock at $19. That 15% discount in the stock fills the balance sheet with plenty of additional cash, ensuring the company will have the resources it needs to develop therapeutics and vaccines. Plus, now that it is in the limelight for its work on the new coronavirus from China, the timing of the sale benefits Moderna stock in the long haul.
Source: Shutterstock
Moderna shares at $19. The nearly $500 million in gross proceeds is a double-edged sword for Moderna stock. Existing shareholders face a 9%-10% dilution (based on the 285 million shares outstanding).
But when the stock traded in the $20-$24 range in the last few weeks, investors must wonder if Goldman Sachs and Morgan Stanley are short-changing the company. The sum left on the table is a trade-off compared to making sure that demand is strong enough to sell all the shares.
Moderna Developing Coronavirus Vaccine
On Jan. 23, Moderna gained the marketâÂÂs attention when the Coalition for Epidemic Preparedness Innovations (CEPI) said that it would finance Moderna. CEPI will fund the manufacturing of an mRNA vaccine candidate against the . China has reported over 73,000 confirmed cases and at least 1,800 deaths. It also reported more than 10,000 cases where patients have recovered.
The country needs vaccine development to contain its spread. Even as infections eventually peak and fall, China needs to immunize its citizens to prevent further deaths. ModernaâÂÂs mRNA approach is one of many potential cures under development. Regeneron (NASDAQ:), Gilead Sciences (NASDAQ:), AbbVie (NYSE:), and Inovioà(NASDAQ:) are also working on vaccines and treatments.
Moderna it advanced its cytomegalovirus (CMV) study. It now expects CMV vaccine Phase 2 to start in 2020âÂÂs third quarter. Moderna also expanded investment in this space with three new vaccine candidates for infectious diseases. It said that the three new infectious disease vaccine candidates complement âÂÂtwo autoimmune development candidates, PD-L1 (mRNA-6231) and IL-2 (mRNA-6981), in the CompanyâÂÂs other core modality, systemic secreted & cell surface therapeutics.âÂÂ
Deep Pipeline
The mRNA-1647 CMV vaccine is the to enter a Phase 2 study and is ahead of schedule. The next part of the study will involve 252 healthy adults who will take three different doses. If the company reports good safety and immunogenicity results, the stock may rebound.
To highlight, mRNA-1189 is a vaccine study against the Epstein-Barr virus, mRNA-1345 studies the respiratory syncytial virus in children and mRNA-1273 is for the new coronavirus. Moderna has 24 mRNA development candidates underway, while 12 are in clinical studies. The studies involve over 1,500 participants.
Six analysts who on Moderna stock have an average target of $31.20, 64% above its recent $19 closing price. Individual investors who prefer to crunch their own numbers may use a 10-year discounted cash flow revenue exit model. This uses a revenue exit multiple to calculate terminal value.
Assuming a step discount rate and the following below, the downside fair value on Moderna stock is $18.28.
Metrics Range Conclusion Discount Rate 13%-14% 13.5% Terminal Revenue Multiple 10.6x-11.6x 11.1x Fair Value $17.08-$19.54 $18.28 Upside -10.1%-2.9% -3.8%
Source: finbox.io (click on to change your assumptions)
Sentiment on Moderna stock is negative, compared to the industry and the S&P 500.
Source: Chart courtesy of
Investors who missed the last run-up may want to let the selling pressure end before starting a new position. The share dilution is a near-term headwind for now. But in a few months, positive clinical results will help lift the stock.
As such, buying the stock if it dips toward the $15-$18 range may offer the biggest margin of safety.
As of this writing, Chris Lau did not hold a position in any of the aforementioned securities.
The post appeared first on InvestorPlace.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Regeneron (NASDAQ:), Gilead Sciences (NASDAQ:), AbbVie (NYSE:), and Inovioà(NASDAQ:) are also working on vaccines and treatments. That 15% discount in the stock fills the balance sheet with plenty of additional cash, ensuring the company will have the resources it needs to develop therapeutics and vaccines. Plus, now that it is in the limelight for its work on the new coronavirus from China, the timing of the sale benefits Moderna stock in the long haul. | Regeneron (NASDAQ:), Gilead Sciences (NASDAQ:), AbbVie (NYSE:), and Inovioà(NASDAQ:) are also working on vaccines and treatments. Moderna Developing Coronavirus Vaccine On Jan. 23, Moderna gained the marketâÂÂs attention when the Coalition for Epidemic Preparedness Innovations (CEPI) said that it would finance Moderna. It said that the three new infectious disease vaccine candidates complement âÂÂtwo autoimmune development candidates, PD-L1 (mRNA-6231) and IL-2 (mRNA-6981), in the CompanyâÂÂs other core modality, systemic secreted & cell surface therapeutics.â Deep Pipeline The mRNA-1647 CMV vaccine is the to enter a Phase 2 study and is ahead of schedule. | Regeneron (NASDAQ:), Gilead Sciences (NASDAQ:), AbbVie (NYSE:), and Inovioà(NASDAQ:) are also working on vaccines and treatments. Moderna Developing Coronavirus Vaccine On Jan. 23, Moderna gained the marketâÂÂs attention when the Coalition for Epidemic Preparedness Innovations (CEPI) said that it would finance Moderna. It said that the three new infectious disease vaccine candidates complement âÂÂtwo autoimmune development candidates, PD-L1 (mRNA-6231) and IL-2 (mRNA-6981), in the CompanyâÂÂs other core modality, systemic secreted & cell surface therapeutics.â Deep Pipeline The mRNA-1647 CMV vaccine is the to enter a Phase 2 study and is ahead of schedule. | Regeneron (NASDAQ:), Gilead Sciences (NASDAQ:), AbbVie (NYSE:), and Inovioà(NASDAQ:) are also working on vaccines and treatments. The six-month uptrend in Moderna (NASDAQ:) ended on Feb. 12 when the company priced a secondary offering of its stock at $19. Source: Shutterstock Moderna shares at $19. |
24693.0 | 2020-02-16 00:00:00 UTC | Better Buy: AbbVie vs. Gilead Sciences | ABBV | https://www.nasdaq.com/articles/better-buy%3A-abbvie-vs.-gilead-sciences-2020-02-16 | nan | nan | AbbVie (NYSE: ABBV) and Gilead Sciences (NASDAQ: GILD) must have missed the invitation to the party the stock market threw last year. Both stocks trailed the S&P 500 index's performance in 2019 by a wide margin.
However, both AbbVie and Gilead have been big winners in the past. And they both could deliver strong returns in the future. Which of these two stocks is the better pick right now? Here's how AbbVie and Gilead compare.
Image source: Getty Images.
Growth
Some investors have focused primarily on AbbVie's challenges with its top-selling drug Humira facing biosimilar competition in Europe already and on the way in the U.S. in 2023. To be sure, those challenges are real and daunting. But AbbVie's strong fourth-quarter results showed that there's more to its story than just Humira.
The reality is that AbbVie has multiple growth drivers. Put Imbruvica at the top of the list. Market researcher EvaluatePharma projects that the blood cancer drug will rank among the world's top five best-selling blockbusters by 2024. Another blood cancer drug, Venclexta, is also a fast-rising star.
Probably the best thing going for AbbVie, though, is its two drugs that could take the immunology baton from Humira -- Rinvoq and Skyrizi. Both drugs should become megablockbusters within the next few years.
In addition, AbbVie is betting that its pending acquisition of Allergan will help offset the inevitable sales declines on the way for Humira. Allergan's Botox franchise and up-and-coming new drugs such as antipsychotic Vraylar should give AbbVie a boost once the deal is done.
Gilead Sciences' biggest trouble spot in recent years has been its hepatitis C virus (HCV) franchise. Part of the problem has been competition from AbbVie, but the main issue is that there are simply fewer patients now that so many patients have been cured of hep-C. The good news for Gilead, though, is that its HCV sales are stabilizing somewhat.
This stabilization should allow Gilead to generate growth with its other drugs. The company has long dominated the HIV market. It should continue to do so with powerhouse drug Biktarvy and a promising long-acting HIV capsid in the pipeline.
Gilead also expects to soon expand into the immunology market with filgotinib, a drug licensed from Galapagos. The big biotech hopes to win FDA approval for filgotinib in treating rheumatoid arthritis later this year and is evaluating the drug in late-stage clinical studies targeting several other immunology indications.
Although Yescarta hasn't delivered the sales growth so far that some predicted, the cell therapy should continue to pick up momentum. Gilead also has several other cell therapies in development that could be winners in the future.
Valuation
Both AbbVie and Gilead appear to be cheap based on their forward earnings multiples. AbbVie's shares trade at only nine times expected earnings, while Gilead's shares trade at 10.5 times expected earnings.
However, Gilead appears to be more attractively valued using another metric. Its enterprise value-to-sales multiple currently stands at 3.9 compared to AbbVie's EV-to-sales ratio of 5.2.
Dividends
You won't find many if any biotech stocks with more attractive dividends than AbbVie and Gilead Sciences. AbbVie's dividend yield currently stands north of 4.8%. Gilead's dividend yields a little over 4%.
Gilead has boosted its dividend by an impressive 58% since initiating its dividend program in 2015. However, AbbVie's dividend track record is hard to top. The company has increased its dividend for 47 consecutive years, including the time it was part of Abbott Labs. And since being spun off from Abbott in 2013, AbbVie has raised its dividend by a total of 195%.
Better buy
I like both AbbVie and Gilead Sciences. I've owned both stocks for years. But if I had to pick just one of these two stocks, it would be AbbVie.
My view is that AbbVie's strategy to reduce its dependence on Humira is working. I think that the combination of solid growth despite the headwinds for Humira with an exceptionally strong dividend should enable AbbVie to deliver market-beating total returns over the long run.
10 stocks we like better than AbbVie
When investing geniuses David and Tom Gardner have a stock tip, it can pay to listen. After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor, has tripled the market.*
David and Tom just revealed what they believe are the 10 best stocks for investors to buy right now... and AbbVie wasn't one of them! That's right -- they think these 10 stocks are even better buys.
See the 10 stocks
*Stock Advisor returns as of December 1, 2019
Keith Speights owns shares of AbbVie and Gilead Sciences. The Motley Fool owns shares of and recommends Gilead Sciences. The Motley Fool has a disclosure policy.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | AbbVie (NYSE: ABBV) and Gilead Sciences (NASDAQ: GILD) must have missed the invitation to the party the stock market threw last year. I think that the combination of solid growth despite the headwinds for Humira with an exceptionally strong dividend should enable AbbVie to deliver market-beating total returns over the long run. However, both AbbVie and Gilead have been big winners in the past. | AbbVie's shares trade at only nine times expected earnings, while Gilead's shares trade at 10.5 times expected earnings. Dividends You won't find many if any biotech stocks with more attractive dividends than AbbVie and Gilead Sciences. I think that the combination of solid growth despite the headwinds for Humira with an exceptionally strong dividend should enable AbbVie to deliver market-beating total returns over the long run. | AbbVie (NYSE: ABBV) and Gilead Sciences (NASDAQ: GILD) must have missed the invitation to the party the stock market threw last year. Dividends You won't find many if any biotech stocks with more attractive dividends than AbbVie and Gilead Sciences. See the 10 stocks *Stock Advisor returns as of December 1, 2019 Keith Speights owns shares of AbbVie and Gilead Sciences. | Dividends You won't find many if any biotech stocks with more attractive dividends than AbbVie and Gilead Sciences. See the 10 stocks *Stock Advisor returns as of December 1, 2019 Keith Speights owns shares of AbbVie and Gilead Sciences. AbbVie (NYSE: ABBV) and Gilead Sciences (NASDAQ: GILD) must have missed the invitation to the party the stock market threw last year. |
24694.0 | 2020-02-16 00:00:00 UTC | Validea's Top Five Healthcare Stocks Based On Joel Greenblatt - 2/16/2020 | ABBV | https://www.nasdaq.com/articles/valideas-top-five-healthcare-stocks-based-on-joel-greenblatt-2-16-2020-2020-02-16 | nan | nan | The following are the top rated Healthcare stocks according to Validea's Earnings Yield Investor model based on the published strategy of Joel Greenblatt. This value model looks for companies with high return on capital and earnings yields.
AMERISOURCEBERGEN CORP. (ABC) is a large-cap growth stock in the Biotechnology & Drugs industry. The rating according to our strategy based on Joel Greenblatt is 100% based on the firm’s underlying fundamentals and the stock’s valuation. A score of 80% or above typically indicates that the strategy has some interest in the stock and a score above 90% typically indicates strong interest.
Company Description: AmerisourceBergen Corporation is a pharmaceutical sourcing and distribution services company. The Company's segments include Pharmaceutical Distribution and Other. The Company provides services to healthcare providers, and pharmaceutical and biotech manufacturers. As of June 30, 2016, the Pharmaceutical Distribution segment consists of two operating segments, including the operations of AmerisourceBergen Drug Corporation (ABDC) and AmerisourceBergen Specialty Group (ABSG), which distributes specialty drugs to their customers. Servicing healthcare providers in the pharmaceutical supply channel, the Pharmaceutical Distribution segment's operations provide drug distribution and related services. The Other segment consists of the operations of various segments, including the AmerisourceBergen Consulting Services (ABCS), the World Courier Group, Inc. and the MWI Veterinary Supply, Inc. ABSG operates distribution facilities that focus primarily on complex disease treatment regimens.
The following table summarizes whether the stock meets each of this strategy's tests. Not all criteria in the below table receive equal weighting or are independent, but the table provides a brief overview of the strong and weak points of the security in the context of the strategy's criteria.
EARNINGS YIELD: NEUTRAL
RETURN ON TANGIBLE CAPITAL: NEUTRAL
FINAL RANKING: PASS
For a full detailed analysis using NASDAQ's Guru Analysis tool, click here
BIOGEN INC (BIIB) is a large-cap value stock in the Biotechnology & Drugs industry. The rating according to our strategy based on Joel Greenblatt is 100% based on the firm’s underlying fundamentals and the stock’s valuation. A score of 80% or above typically indicates that the strategy has some interest in the stock and a score above 90% typically indicates strong interest.
Company Description: Biogen Inc. is a biopharmaceutical company. The Company focuses on discovering, developing, manufacturing and delivering therapies to people living with serious neurological, rare and autoimmune diseases. The Company markets products, including TECFIDERA, AVONEX, PLEGRIDY, TYSABRI, ZINBRYTA and FAMPYRA for multiple sclerosis (MS), FUMADERM for the treatment of severe plaque psoriasis and SPINRAZA for the treatment of spinal muscular atrophy (SMA). It also has a collaboration agreement with Genentech, Inc. (Genentech), a member of the Roche Group, with respect to RITUXAN for the treatment of non-Hodgkin's lymphoma, chronic lymphocytic leukemia (CLL) and other conditions, GAZYVA indicated for the treatment of CLL and follicular lymphoma, and other anti-CD20 therapies. The Company's product candidate includes OCREVUS; Biosimilar adalimumab; Aducanumab; E2609; BIIB074; BAN2401; Opicinumab; CIRARA; BIIB061; BIIB054; BIIB067, and BIIB068.
The following table summarizes whether the stock meets each of this strategy's tests. Not all criteria in the below table receive equal weighting or are independent, but the table provides a brief overview of the strong and weak points of the security in the context of the strategy's criteria.
EARNINGS YIELD: NEUTRAL
RETURN ON TANGIBLE CAPITAL: NEUTRAL
FINAL RANKING: PASS
For a full detailed analysis using NASDAQ's Guru Analysis tool, click here
BELLRING BRANDS INC (BRBR) is a small-cap value stock in the Biotechnology & Drugs industry. The rating according to our strategy based on Joel Greenblatt is 100% based on the firm’s underlying fundamentals and the stock’s valuation. A score of 80% or above typically indicates that the strategy has some interest in the stock and a score above 90% typically indicates strong interest.
Company Description: BellRing Brands, Inc. provides nutrition products. The Company offers its products under various brands, such as Premier Protein, Dymatize and PowerBar. It offers products in various forms, including ready to drink (RTD) protein shakes, powders and nutrition bars. Its secondary brands include Joint Juice and Supreme Protein. Its Premier Protein's product portfolio consists of RTD protein shakes, protein beverages, nutrition bars and protein powders. Dymatize brand's portfolio includes an assortment of sports nutrition products, including primarily protein powders as well as protein bars and nutritional supplements. Its PowerBar's product portfolio ranges from protein and energy snacks for fitness enthusiasts to functional and technical energy products for competitive athletes' in-game usage. Joint Juice is a line of joint health liquid supplements. Supreme Protein is a line of multi-layered protein bars.
The following table summarizes whether the stock meets each of this strategy's tests. Not all criteria in the below table receive equal weighting or are independent, but the table provides a brief overview of the strong and weak points of the security in the context of the strategy's criteria.
EARNINGS YIELD: NEUTRAL
RETURN ON TANGIBLE CAPITAL: NEUTRAL
FINAL RANKING: PASS
For a full detailed analysis using NASDAQ's Guru Analysis tool, click here
INNOVIVA INC (INVA) is a small-cap value stock in the Biotechnology & Drugs industry. The rating according to our strategy based on Joel Greenblatt is 100% based on the firm’s underlying fundamentals and the stock’s valuation. A score of 80% or above typically indicates that the strategy has some interest in the stock and a score above 90% typically indicates strong interest.
Company Description: Innoviva, Inc., formerly Theravance, Inc., is engaged in the development, commercialization and financial management of bio-pharmaceuticals. It focuses on the respiratory assets partnered with Glaxo Group Limited (GSK), including RELVAR/BREO ELLIPTA (fluticasone furoate (FF)/vilanterol (VI)) and ANORO ELLIPTA (umeclidinium bromide/vilanterol (UMEC/VI)). Under the Long-Acting Beta2 Agonist (LABA) Collaboration Agreement and the Strategic Alliance Agreement with GSK, the Company is eligible to receive the annual royalties from GSK on sales of RELVAR/BREO ELLIPTA. For other products combined with a LABA from the LABA collaboration, such as ANORO ELLIPTA, royalties are upward tiering and range from 6.5% to 10%. RELVAR/BREO is a once-a-day combination inhaled respiratory medicine consisting of a LABA (VI) and an inhaled corticosteroid (ICS), FF. ANORO ELLIPTA a once-daily medicine combining a long-acting muscarinic antagonist (LAMA), umeclidinium bromide (UMEC), with a LABA.
The following table summarizes whether the stock meets each of this strategy's tests. Not all criteria in the below table receive equal weighting or are independent, but the table provides a brief overview of the strong and weak points of the security in the context of the strategy's criteria.
EARNINGS YIELD: NEUTRAL
RETURN ON TANGIBLE CAPITAL: NEUTRAL
FINAL RANKING: PASS
For a full detailed analysis using NASDAQ's Guru Analysis tool, click here
ABBVIE INC (ABBV) is a large-cap growth stock in the Biotechnology & Drugs industry. The rating according to our strategy based on Joel Greenblatt is 90% based on the firm’s underlying fundamentals and the stock’s valuation. A score of 80% or above typically indicates that the strategy has some interest in the stock and a score above 90% typically indicates strong interest.
Company Description: AbbVie Inc. (AbbVie) is a research-based biopharmaceutical company. The Company is engaged in the discovery, development, manufacture and sale of a range of pharmaceutical products. Its products are focused on treating conditions, such as chronic autoimmune diseases in rheumatology, gastroenterology and dermatology; oncology, including blood cancers; virology, including hepatitis C virus (HCV) and human immunodeficiency virus (HIV); neurological disorders, such as Parkinson's disease and multiple sclerosis; metabolic diseases, including thyroid disease and complications associated with cystic fibrosis, and other serious health conditions. It offers products in various categories, including HUMIRA (adalimumab), Oncology products, Virology Products, Additional Virology products, Metabolics/Hormones products, Endocrinology products and other products, which include Duopa and Duodopa (carbidopa and levodopa), Anesthesia products and ZINBRYTA (daclizumab).
The following table summarizes whether the stock meets each of this strategy's tests. Not all criteria in the below table receive equal weighting or are independent, but the table provides a brief overview of the strong and weak points of the security in the context of the strategy's criteria.
EARNINGS YIELD: NEUTRAL
RETURN ON TANGIBLE CAPITAL: NEUTRAL
FINAL RANKING: PASS
For a full detailed analysis using NASDAQ's Guru Analysis tool, click here
Since its inception, Validea's strategy based on Joel Greenblatt has returned 104.79% vs. 167.19% for the S&P 500. For more details on this strategy, click here
About Joel Greenblatt: In his 2005 bestseller The Little Book That Beats The Market, hedge fund manager Joel Greenblatt laid out a stunningly simple way to beat the market using two -- and only two -- fundamental variables. The "Magic Formula," as he called it, produced back-tested returns of 30.8 percent per year from 1988 through 2004, more than doubling the S&P 500's 12.4 percent return during that time. Greenblatt also produced exceptional returns as managing partner at Gotham Capital, a New York City-based hedge fund he founded. The firm averaged a remarkable 40 percent annualized return over more than two decades.
About Validea: Validea is aninvestment researchservice that follows the published strategies of investment legends. Validea offers both stock analysis and model portfolios based on gurus who have outperformed the market over the long-term, including Warren Buffett, Benjamin Graham, Peter Lynch and Martin Zweig. For more information about Validea, click here
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | For a full detailed analysis using NASDAQ's Guru Analysis tool, click here ABBVIE INC (ABBV) is a large-cap growth stock in the Biotechnology & Drugs industry. Company Description: AbbVie Inc. (AbbVie) is a research-based biopharmaceutical company. The following are the top rated Healthcare stocks according to Validea's Earnings Yield Investor model based on the published strategy of Joel Greenblatt. | For a full detailed analysis using NASDAQ's Guru Analysis tool, click here ABBVIE INC (ABBV) is a large-cap growth stock in the Biotechnology & Drugs industry. Company Description: AbbVie Inc. (AbbVie) is a research-based biopharmaceutical company. As of June 30, 2016, the Pharmaceutical Distribution segment consists of two operating segments, including the operations of AmerisourceBergen Drug Corporation (ABDC) and AmerisourceBergen Specialty Group (ABSG), which distributes specialty drugs to their customers. | For a full detailed analysis using NASDAQ's Guru Analysis tool, click here ABBVIE INC (ABBV) is a large-cap growth stock in the Biotechnology & Drugs industry. Company Description: AbbVie Inc. (AbbVie) is a research-based biopharmaceutical company. Dymatize brand's portfolio includes an assortment of sports nutrition products, including primarily protein powders as well as protein bars and nutritional supplements. | For a full detailed analysis using NASDAQ's Guru Analysis tool, click here ABBVIE INC (ABBV) is a large-cap growth stock in the Biotechnology & Drugs industry. Company Description: AbbVie Inc. (AbbVie) is a research-based biopharmaceutical company. The following are the top rated Healthcare stocks according to Validea's Earnings Yield Investor model based on the published strategy of Joel Greenblatt. |
24695.0 | 2020-02-15 00:00:00 UTC | 3 High-Yielding U.S. Pharmaceutical Companies to Consider | ABBV | https://www.nasdaq.com/articles/3-high-yielding-u.s.-pharmaceutical-companies-to-consider-2020-02-15 | nan | nan | The stock market has been bullish for years now, and most companies are richly valued as a result. Meanwhile, dividend yields remain low -- right now, the SPDR S&P 500 ETF (NYSEMKT: SPY) offers just 1.7%.
What's an investor seeking returns to do?
One attractive option is the pharmaceutical sector, where some large-cap companies are maintaining the winning trifecta of a stable dividend yield, ongoing earnings growth, and attractive valuation. For these three businesses in particular, company-specific events including acquisitions and new drugs make for particularly enticing prospects. Let's take a look at AbbVie (NYSE: ABBV), Bristol-Myers Squibb (NYSE: BMY), and Gilead Sciences (NASDAQ: GILD).
Image Source: Getty Images.
What to like about all of them
Each of these companies looks set to maintain or increase its dividend in 2020, and each is attractively priced relative to the S&P 500. As a whole, the S&P 500 is currently selling for 19 times anticipated 2020 earnings per share. Bristol-Myers Squibb trades for slightly less than 9 times projected 2020 earnings estimates, and AbbVie trades for less than 10 times 2020 earnings estimates. Gilead, meanwhile, trades at 10.5 times anticipated EPS.
Earnings at pharmaceutical companies tend to be stable because these businesses are not particularly sensitive to weak economic growth. People need drugs in good times and bad, and consumers are unlikely to cancel or even delay filling their prescriptions in response to lower personal income. These companies are also market leaders in treating several large and growing chronic conditions, which translates into a recurring and growing revenue base as existing customers are retained and new ones are brought in. And there's a lot of growth possible in the form of new drugs, additional indications for approved drugs, and the acquisition and/or licensing of other drugs from other pharmaceutical and biotechnology companies.
What to like about AbbVie
AbbVie offers a 5.4% dividend yield, and its pending merger with Allergan (NYSE: AGN) should expand its drug portfolio, cut costs by reducing headcount and other expenses, and increase its pipeline of promising drug candidates.
While the company's total revenue for 2019 grew by only 1.6%, U.S. sales of its blockbuster drug, Humira, were up 8.6%, and worldwide sales of another big name, Imbruvica, were up more than 30%. Humira, which is injected under the skin, is a medication used to treat rheumatoid arthritis, psoriatic arthritis, and several other conditions. Imbruvica, taken orally once a day, treats certain cancers such as mantle cell lymphoma, chronic lymphocytic leukemia, and small lymphocytic lymphoma.
AbbVie expects to deliver standalone adjusted diluted earnings of between $9.61 and $9.71 a share in 2020, up 7.5% to 8.7%; this guidance excludes intangible asset amortization expenses and other non-cash charges. Management expects that standalone revenue could grow by about 8% on an operational basis, which excludes the impact of a potential change in foreign exchange rates.
What to like about Bristol-Myers Squibb
With the recently completed acquisition of Celgene, Bristol-Myers Squibb (which offers a 2.8% yield) has significantly expanded its product portfolio and increased its pipeline of new drugs, as well as securing a significant opportunity to expand the labels of existing drugs.
Excluding the Celgene acquisition, total revenue grew by 7.9% to almost $23.4 billion in 2019, thanks to a 23% increase in sales of Elquis and a 7% rise in sales of Opdivo. Elquis, an alternative to warfarin that does not require monitoring by blood tests, treats and prevents blood clots in patients following hip or knee replacement and in those patients with a history of prior blood clots. Opdivio, which is administered via intravenous infusion over 30 minutes, treats advanced non-small-cell lung cancer that has spread or grown in patients who have already tried chemotherapy that contained platinum.
In 2020, thanks to the full-year impact of Celgene and continued improvement in the core business, Bristol-Myers Squibb expects to report revenue between $40.5 billion and $42.5 billion (up from $26.1 billion in 2019) and non-GAAP earnings per share of between $6 and $6.20 a share (up from $4.69).
What to like about Gilead Sciences
In 2020, Gilead is likely to use part of its short-term cash balance of almost $26 billion (as of Dec. 31) to repurchase additional shares of its common stock and/or increase its annual dividend payment per share, which currently stands at 4%.
Importantly, total revenue was up for the first time in four years with a rise of 2% in 2019. The 12% increase in revenue for core HIV treatments and the 73% growth in Yescarta revenue more than offset the 20% drop in revenue from HCV (hepatitis) treatments. Yescarta modifies a patient's own white blood cells to recognize and destroy cancer cells, and has been prescribed to treat certain types of non-Hodgkin lymphoma in adults.
For 2020, Gilead expects to report product sales of between $21.8 billion and $22.2 billion, compared with $22.1 billion for 2019. These estimates reflect continued growth in the core HIV drug franchise, an expansion of cell therapy revenue, the full-year impact of the loss of two drug patents, and the potential entry of a generic counterpart to its HIV treatment, Truvada, in late 2020.
Management also anticipates non-GAAP diluted earnings per share of between $6.05 and $6.45 per share, up from $6.13 per share in 2019, as the company benefits from stable to slightly higher gross product margins, lower outstanding shares of its common stock, and a more modest, single-digit percentage growth in operating expenses.
A prescription for income
In a highly valued market with low interest rates, it can be hard to find promising investments. The pharmaceutical space offers stability in its earnings forecasts and dividend payments, and the above three companies in particular stand out as high-paying stalwarts with room to grow. Investors looking for yield as well as growth should find plenty to interest them here.
10 stocks we like better than Gilead Sciences
When investing geniuses David and Tom Gardner have a stock tip, it can pay to listen. After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor, has tripled the market.*
David and Tom just revealed what they believe are the ten best stocks for investors to buy right now… and Gilead Sciences wasn't one of them! That's right -- they think these 10 stocks are even better buys.
See the 10 stocks
*Stock Advisor returns as of December 1, 2019
Paul Bienstock has no position in any of the stocks mentioned. The Motley Fool owns shares of and recommends Bristol-Myers Squibb and Gilead Sciences. The Motley Fool has a disclosure policy.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | AbbVie expects to deliver standalone adjusted diluted earnings of between $9.61 and $9.71 a share in 2020, up 7.5% to 8.7%; this guidance excludes intangible asset amortization expenses and other non-cash charges. Let's take a look at AbbVie (NYSE: ABBV), Bristol-Myers Squibb (NYSE: BMY), and Gilead Sciences (NASDAQ: GILD). Bristol-Myers Squibb trades for slightly less than 9 times projected 2020 earnings estimates, and AbbVie trades for less than 10 times 2020 earnings estimates. | Bristol-Myers Squibb trades for slightly less than 9 times projected 2020 earnings estimates, and AbbVie trades for less than 10 times 2020 earnings estimates. Let's take a look at AbbVie (NYSE: ABBV), Bristol-Myers Squibb (NYSE: BMY), and Gilead Sciences (NASDAQ: GILD). What to like about AbbVie AbbVie offers a 5.4% dividend yield, and its pending merger with Allergan (NYSE: AGN) should expand its drug portfolio, cut costs by reducing headcount and other expenses, and increase its pipeline of promising drug candidates. | Let's take a look at AbbVie (NYSE: ABBV), Bristol-Myers Squibb (NYSE: BMY), and Gilead Sciences (NASDAQ: GILD). Bristol-Myers Squibb trades for slightly less than 9 times projected 2020 earnings estimates, and AbbVie trades for less than 10 times 2020 earnings estimates. What to like about AbbVie AbbVie offers a 5.4% dividend yield, and its pending merger with Allergan (NYSE: AGN) should expand its drug portfolio, cut costs by reducing headcount and other expenses, and increase its pipeline of promising drug candidates. | Let's take a look at AbbVie (NYSE: ABBV), Bristol-Myers Squibb (NYSE: BMY), and Gilead Sciences (NASDAQ: GILD). Bristol-Myers Squibb trades for slightly less than 9 times projected 2020 earnings estimates, and AbbVie trades for less than 10 times 2020 earnings estimates. What to like about AbbVie AbbVie offers a 5.4% dividend yield, and its pending merger with Allergan (NYSE: AGN) should expand its drug portfolio, cut costs by reducing headcount and other expenses, and increase its pipeline of promising drug candidates. |
24696.0 | 2020-02-14 00:00:00 UTC | 3 Reasons AbbVie Is a Better Bargain Than You Might Think | ABBV | https://www.nasdaq.com/articles/3-reasons-abbvie-is-a-better-bargain-than-you-might-think-2020-02-14 | nan | nan | At first glance, the picture for AbbVie (NYSE: ABBV) looks bad. The company's top-selling drug that generated over half of the company's total revenue in the past has lost patent exclusivity in Europe and will do so in the U.S. within the next three years. Last year, while the overall market skyrocketed AbbVie's shares fell 4%.
But I think that AbbVie is a much better bargain right now than you might think. Here are three reasons why that's the case.
Image source: Getty Images.
1. Humira protection plan is working
AbbVie has known for years that the day would come when Humira would face biosimilar competition. The company has been planning for that day, which has now arrived (at least in part).
To be sure, AbbVie didn't foresee everything that has happened with Humira. The company didn't expect its competitors to price their biosimilars so aggressively. As a result, the initial hit to Humira's international sales was bigger than AbbVie initially anticipated.
However, AbbVie CEO Rick Gonzalez noted in the drugmaker's Q4 conference call last week that the company has held on to around two-thirds of the volume for Humira. In Europe, where the biosimilars are challenging the immunology drug, Humira's sales have eroded by around 45%. This means that AbbVie has been able to retain roughly 55% of the previous sales level for Humira. That's actually pretty good.
The company has also learned some lessons from its experience in Europe that could help it better handle the entrance of biosimilars in the U.S. market in 2023. For investors who have fretted about the impact that loss of exclusivity for Humira would have on AbbVie, the fact that the company's protection plan for the drug appears to be working well overall is very good news.
2. Post-Humira strategy is paying off
AbbVie didn't just bank on playing defense with Humira, though. The company has invested heavily in its pipeline and made strategic acquisitions along the way with the goal of reducing its dependence on Humira. Several signs seem to point to this strategy paying off.
The company's blood cancer drugs continue to perform really well. In the fourth quarter, sales for Imbruvica jumped nearly 29% year over year to $1.3 billion. It's on track to become one of the top five best-selling drugs in the world by 2024. Venclexta appears destined to become another blockbuster for AbbVie, with the drug racking up sales of $251 million in Q4.
Two successors to Humira are also delivering tremendous sales growth. Skyrizi, which won FDA approval in April 2019 for treating plaque psoriasis, more than doubled its sales in Q4 compared to Q3, pulling in $216 million. Sales for Rinvoq, which received FDA approval for treating rheumatoid arthritis in August 2019, totaled $33 million in Q4. That might seem a little low, but the drug didn't gain fuller market access until January. Even better, Rinvoq doesn't appear to be cannibalizing sales of Humira too much so far.
AbbVie awaits the closing of its acquisition of Allergan (NYSE: AGN), which should be on track to wrap up later in the first quarter of 2020. Even though some were initially skeptical of the deal, Allergan brings several drugs to AbbVie's lineup that will lower its reliance on Humira. Botox stands at the top of the list, but several other Allergan products -- notably including antipsychotic drug Vraylar and gastrointestinal drug Linzess/Constella -- should also boost AbbVie's growth prospects.
3. AbbVie has an ace in the hole
While AbbVie's shares trade at only nine times expected earnings, some investors won't consider the stock a bargain because of its longer-term prospects are clouded by the future for Humira. However, we've already seen evidence that AbbVie's strategy for defending Humira as much as possible while reducing its dependence on the drug appears to be working.
Perhaps just as important, though, AbbVie's earnings growth doesn't have to be all that high to make the stock an attractive investment because of the company's ace in the hole: its strong dividend. AbbVie ranks as one of the most appealing dividend stocks on the market with a juicy yield of nearly 5%.
The company's track record of dividend hikes is nothing short of spectacular. AbbVie has increased its dividend for 47 consecutive years including the time that it was a part of Abbott Labs. Since being spun off from Abbott in 2013, AbbVie has boosted its dividend by a whopping 195%.
Can AbbVie keep the dividends flowing and growing in the future? I think so, especially with the solid cash flow that the acquisition of Allergan will bring to the table.
A pretty good picture after all
I'm not dismissing the challenges that AbbVie faces with the inevitable decline of sales for Humira that's on the way. However, my view is that the company is effectively tackling those challenges head on. The combination of a strong lineup of other drugs with fast-growing sales, the likely addition of more drugs on the way with the close of the Allergan deal, and its mouth-watering dividend should provide solid total returns for AbbVie over the long run.
10 stocks we like better than AbbVie
When investing geniuses David and Tom Gardner have a stock tip, it can pay to listen. After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor, has tripled the market.*
David and Tom just revealed what they believe are the ten best stocks for investors to buy right now... and AbbVie wasn't one of them! That's right -- they think these 10 stocks are even better buys.
See the 10 stocks
*Stock Advisor returns as of December 1, 2019
Keith Speights owns shares of AbbVie. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | However, AbbVie CEO Rick Gonzalez noted in the drugmaker's Q4 conference call last week that the company has held on to around two-thirds of the volume for Humira. For investors who have fretted about the impact that loss of exclusivity for Humira would have on AbbVie, the fact that the company's protection plan for the drug appears to be working well overall is very good news. Perhaps just as important, though, AbbVie's earnings growth doesn't have to be all that high to make the stock an attractive investment because of the company's ace in the hole: its strong dividend. | Humira protection plan is working AbbVie has known for years that the day would come when Humira would face biosimilar competition. Even though some were initially skeptical of the deal, Allergan brings several drugs to AbbVie's lineup that will lower its reliance on Humira. AbbVie has an ace in the hole While AbbVie's shares trade at only nine times expected earnings, some investors won't consider the stock a bargain because of its longer-term prospects are clouded by the future for Humira. | For investors who have fretted about the impact that loss of exclusivity for Humira would have on AbbVie, the fact that the company's protection plan for the drug appears to be working well overall is very good news. AbbVie has an ace in the hole While AbbVie's shares trade at only nine times expected earnings, some investors won't consider the stock a bargain because of its longer-term prospects are clouded by the future for Humira. The combination of a strong lineup of other drugs with fast-growing sales, the likely addition of more drugs on the way with the close of the Allergan deal, and its mouth-watering dividend should provide solid total returns for AbbVie over the long run. | AbbVie awaits the closing of its acquisition of Allergan (NYSE: AGN), which should be on track to wrap up later in the first quarter of 2020. AbbVie has an ace in the hole While AbbVie's shares trade at only nine times expected earnings, some investors won't consider the stock a bargain because of its longer-term prospects are clouded by the future for Humira. However, we've already seen evidence that AbbVie's strategy for defending Humira as much as possible while reducing its dependence on the drug appears to be working. |
24697.0 | 2020-02-14 00:00:00 UTC | Could This Cancer Drug Developer’s Stock Make You Rich? | ABBV | https://www.nasdaq.com/articles/could-this-cancer-drug-developers-stock-make-you-rich-2020-02-14-0 | nan | nan | Bolstered by new data presented at a key medical conference, Aptose Biosciences's (NASDAQ: APTO) stock bolted skyward in December, more than doubling in price. Savvy investors looking for exposure to the high-risk, high-reward biotech sector need to look no further.
Image source: Getty Images
The company's lead drug, CG-806, inhibits a cancer target called Bruton's tyrosine kinase (BTK). BTK emerged as a promising target and inhibitors rapidly advanced through the clinic as treatments for chronic lymphocytic leukemia (CLL), one of the most common forms of leukemia, and other blood malignancies. FLT3 mutations occur in roughly 30% of acute myelogenous leukemia (AML) patients, according to a 2019 publication in the scientific journal Leukemia.
These two blood cancers present a lucrative opportunity if CG-806 works. The National Cancer Institute (NCI) states that more than 20,000 people in the U.S. were diagnosed with CLL in 2019 and more than 178,000 in the U.S. lived with the cancer in 2016. More than 61,000 people in the U.S. live with AML and nearly 11,000 died of the cancer last year, according to the NCI.
Aptose claims CG-806's ability to inhibit all forms of BTK and FLT3, including those that have mutations, makes it unique. Furthermore, it binds to a different location on the BTK enzyme than other inhibitors, including those that have already been approved. For these reasons, Aptose believes patients who stopped responding to other BTK inhibitors could respond to CG-806 treatment.
BTK inhibitors attract big paydays
Imbruvica leads the BTK inhibitor pack. Pharmacyclics initially developed the drug until Johnson & Johnson (NYSE: JNJ) entered into a 50/50 co-development partnership in December 2011. Pharmacyclics stock jumped from the mid-teens to around $30 per share on the news. Fast forward to spring 2015, when AbbVie (NYSE: ABBV) bought Pharmacyclics for $21 billion, or $261.25 per share. Keep in mind, that's for Pharmacyclics' half of Imbruvica. In 2019, Imbruvica generated $4.67 billion in sales for AbbVie and $3.41 billion in sales for Johnson & Johnson.
Seeking to get a piece of the action, AstraZeneca (NYSE: AZN) bought privately held Acerta Pharma in December 2015 for up to $7 billion for its BTK inhibitor. In November 2019, the FDA approved the drug called Calquence for the treatment of CLL, following a 2017 approval as a treatment for mantle cell lymphoma, an aggressive form of non-Hodgkin's lymphoma with a poor prognosis.
Brukinsa, a BTK inhibitor approved for patients with mantle cell lymphoma who had at least one prior treatment, gained FDA approval in November 2019, marking the first FDA approval for the China-based drug developer BeiGene (NASDAQ: BGNE).
What's the takeaway? First, BTK inhibitors are a proven class of drug. Second, big pharma has a history of paying considerable sums of money for successful BTK inhibitors. If Aptose proves CG-806 benefits CLL patients that failed prior BTK therapy, then a big suitor could write a large check for the company rewarding shareholders.
But wait, there's more
As with BTK, precedent exists for Aptose pursuing FLT3. Novartis (NYSE: NVS) markets the drug Rydapt, and Japanese company Astellas Pharma sells Xospata as treatments for AML patients with FLT3 mutations. Aptose touts CG-806's superior potency over other FLT3 inhibitors based on testing in more than 200 AML samples. Aptose announced in January that the phase 1 trial is now enrolling the fourth cohort of patients.
For a bit of historical perspective, AML had few new treatments for decades until the relatively recent approvals for Novartis, Astellas, and Jazz Pharmaceuticals (NASDAQ: JAZZ). Jazz gained approval in 2017 for Vyxeos, a fixed combination of two older chemotherapy agents that provided the backbone for treatment of AML.
Vyxeos was originally developed by Celator Pharmaceuticals, a small biotech that struggled to gain attention for its combo product. However, when its phase 3 trial demonstrated a benefit in overall survival, the stock shot through the roof, from under $2 to the mid-teens. Shortly thereafter, Jazz bought the company for $30.25 per share, or $1.5 billion. Some fortunate investors experienced a 15-fold return within months.
Why do I highlight these deals from the past? In many cases, small companies like Aptose never commercialize a drug. Much like the farm system in baseball, small biotechs develop drugs that big pharma and biotech companies ultimately sell. Either the drug is licensed to a bigger company with commercial capabilities or the smaller company is outright acquired. In my opinion, Aptose will not commercialize this drug but rather do one of these types of deals. The big unknown for investors is when will a deal occur, if at all.
Let's look at the numbers
Let's just do a back of the envelope analysis on CG-806's potential. Using the NCI's prevalence numbers, there are approximately 239,000 eligible patients (178,000 CLL and 61,000 AML). Let's assume half are diagnosed and receiving treatment. That gives us 119,500 treatable patients. If we assume 15% market penetration and a price of $120,000 annually ($10,000 per month), the annual revenue exceeds $2.15 billion. Divide that by the 76.1 million shares outstanding results in revenue over $28 per share, and that's only for a single year. Simply put, the $7.85 stock price may look cheap in hindsight if the drug performs.
Biotech stocks like Aptose, are high-risk, high-reward investments. Speculative investors may wish to add some to their portfolios for potentially huge upside. As demonstrated by both the Pharmacyclics and Celator acquisitions, 10- to 20-time returns can happen in certain situations. Aptose, if successful, will likely be an acquisition target for a hungry pharma looking to replenish its pipeline.
10 stocks we like better than Aptose Biosciences
When investing geniuses David and Tom Gardner have a stock tip, it can pay to listen. After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor, has tripled the market.*
David and Tom just revealed what they believe are the ten best stocks for investors to buy right now... and Aptose Biosciences wasn't one of them! That's right -- they think these 10 stocks are even better buys.
See the 10 stocks
*Stock Advisor returns as of December 1, 2019
David Haen has no position in any of the stocks mentioned. The Motley Fool owns shares of and recommends Bristol-Myers Squibb. The Motley Fool recommends Johnson & Johnson. The Motley Fool has a disclosure policy.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Fast forward to spring 2015, when AbbVie (NYSE: ABBV) bought Pharmacyclics for $21 billion, or $261.25 per share. In 2019, Imbruvica generated $4.67 billion in sales for AbbVie and $3.41 billion in sales for Johnson & Johnson. Bolstered by new data presented at a key medical conference, Aptose Biosciences's (NASDAQ: APTO) stock bolted skyward in December, more than doubling in price. | Fast forward to spring 2015, when AbbVie (NYSE: ABBV) bought Pharmacyclics for $21 billion, or $261.25 per share. In 2019, Imbruvica generated $4.67 billion in sales for AbbVie and $3.41 billion in sales for Johnson & Johnson. In November 2019, the FDA approved the drug called Calquence for the treatment of CLL, following a 2017 approval as a treatment for mantle cell lymphoma, an aggressive form of non-Hodgkin's lymphoma with a poor prognosis. | Fast forward to spring 2015, when AbbVie (NYSE: ABBV) bought Pharmacyclics for $21 billion, or $261.25 per share. In 2019, Imbruvica generated $4.67 billion in sales for AbbVie and $3.41 billion in sales for Johnson & Johnson. Brukinsa, a BTK inhibitor approved for patients with mantle cell lymphoma who had at least one prior treatment, gained FDA approval in November 2019, marking the first FDA approval for the China-based drug developer BeiGene (NASDAQ: BGNE). | Fast forward to spring 2015, when AbbVie (NYSE: ABBV) bought Pharmacyclics for $21 billion, or $261.25 per share. In 2019, Imbruvica generated $4.67 billion in sales for AbbVie and $3.41 billion in sales for Johnson & Johnson. Shortly thereafter, Jazz bought the company for $30.25 per share, or $1.5 billion. |
24698.0 | 2020-02-13 00:00:00 UTC | Inovio’s Surge on a Coronavirus Vaccine Was Just Speculation | ABBV | https://www.nasdaq.com/articles/inovios-surge-on-a-coronavirus-vaccine-was-just-speculation-2020-02-13 | nan | nan | The monster rally in shares of Inovio Pharmaceuticals (NASDAQ:) did not last at all. INO stock traded as high as $5.95 at the end of January, but closed Feb. 12 at $3.34. Investors sought any drug company that would promise a vaccine or treatment for the coronavirus from China. But when the reality that getting a drug to market would take months at the very least, speculators sold off INO stock.
Source: Shutterstock
What should investors do next, especially if they bought the stock at the peak?
On Jan. 30, Inovio with Beijing Advaccine to advance the INO-4800 vaccine against the coronavirus. INO-4800âÂÂs development would go through Phase 1 human testing in the U.S. The purpose of the study is to evaluate the drugâÂÂs safety and immunogenicity â its ability to provoke a specific immune response. With a vaccine, one would want a strong immune response, which typically means that it would trigger the body to get rid of the virus. The Coalition for Epidemic Preparedness Innovations (CEPI) will provide up to $9 million in support. In effect, Inovio stock rose by more than $300 million in market capitalization on news of just $9 million of funding.
Still, the safety testing will let the company determine the drugâÂÂs toxicity and risks to the patient relative to the dangers of the virus itself.
InovioâÂÂs Competition
InovioâÂÂs INO-4800 may come too late if GileadâÂÂs (NASDAQ:) Remdesivir proves to be an effective treatment for those infected in Wuhan. The study will involve 761 patients in two trials. Just under half of the patients have mild or moderate infection levels. Another 453 of the severely infected patients will be studied.
AbbVieâÂÂs (NYSE:) HIV drug Aluvia â a combination of lopinavir and ritonavir â will also be used to treat those infected with the new virus.
On Jan. 31, Inovio of the surge in its stock price in an offering of 8,014,201 shares. This will raise up to $34 million. The money raised is a double-edged sword for investors. The cash gives the company the financial flexibility to fund its next stage of clinical studies. If management did not increase its cash levels now, that opportunity may not come again. But the flip side is that it may run low on cash and would not have enough funds to support its studies.
The bad news for existing shareholders is that the stock sale dilutes the current holding value.
Valuation and My Takeaway on INO Stock
As a drug discovery firm, Inovio does not make money. In fact, it lost money in the last seven years.
Q1 Q2 Q3 Q4 Year 2020 E ($0.23) 2019 ($0.30) ($0.30) ($0.25) E ($0.24) ($1.20) 2018 ($0.36) ($0.07) ($0.27) ($0.34) ($1.05) 2017 ($0.31) ($0.13) ($0.39) ($0.24) ($1.08) 2016 ($0.11) ($0.26) ($0.28) ($0.35) ($1.01) 2015 ($0.17) ($0.09) $0.08 ($0.25) ($0.43) 2014 ($0.20) ($0.18) ($0.12) ($0.12) ($0.61) 2013 ($0.23) ($0.24) ($0.64) ($0.30) ($1.43)
Chart courtesy of , âÂÂEâ denotes estimate, all numbers from InovioâÂÂs annual 10-K filings
Although the company is not profitable, investors may use an enterprise value-to-sales ratio to extrapolate a $4.16 fair value on Inovio stock.
Inovio was last weekâÂÂs hot stock. Prior to its surge, shares traded in the $2.00 to $2.50 range for much of the last half-year. Investors who want to hold a company that develops DNA-based immunotherapies and vaccines should watch Inovio. Have a small weighting in this stock at best, since this is a speculative play.
As of this writing, Chris Lau did not hold a position in any of the aforementioned securities.
The post appeared first on InvestorPlace.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | AbbVieâÂÂs (NYSE:) HIV drug Aluvia â a combination of lopinavir and ritonavir â will also be used to treat those infected with the new virus. Valuation and My Takeaway on INO Stock As a drug discovery firm, Inovio does not make money. Q1 Q2 Q3 Q4 Year 2020 E ($0.23) 2019 ($0.30) ($0.30) ($0.25) E ($0.24) ($1.20) 2018 ($0.36) ($0.07) ($0.27) ($0.34) ($1.05) 2017 ($0.31) ($0.13) ($0.39) ($0.24) ($1.08) 2016 ($0.11) ($0.26) ($0.28) ($0.35) ($1.01) 2015 ($0.17) ($0.09) $0.08 ($0.25) ($0.43) 2014 ($0.20) ($0.18) ($0.12) ($0.12) ($0.61) 2013 ($0.23) ($0.24) ($0.64) ($0.30) ($1.43) Chart courtesy of , âÂÂEâ denotes estimate, all numbers from InovioâÂÂs annual 10-K filings Although the company is not profitable, investors may use an enterprise value-to-sales ratio to extrapolate a $4.16 fair value on Inovio stock. | AbbVieâÂÂs (NYSE:) HIV drug Aluvia â a combination of lopinavir and ritonavir â will also be used to treat those infected with the new virus. INO stock traded as high as $5.95 at the end of January, but closed Feb. 12 at $3.34. In effect, Inovio stock rose by more than $300 million in market capitalization on news of just $9 million of funding. | AbbVieâÂÂs (NYSE:) HIV drug Aluvia â a combination of lopinavir and ritonavir â will also be used to treat those infected with the new virus. In effect, Inovio stock rose by more than $300 million in market capitalization on news of just $9 million of funding. Valuation and My Takeaway on INO Stock As a drug discovery firm, Inovio does not make money. | AbbVieâÂÂs (NYSE:) HIV drug Aluvia â a combination of lopinavir and ritonavir â will also be used to treat those infected with the new virus. In effect, Inovio stock rose by more than $300 million in market capitalization on news of just $9 million of funding. Another 453 of the severely infected patients will be studied. |
24699.0 | 2020-02-12 00:00:00 UTC | Allergan Pins Hopes on Millennials With Juvederm Marketing | ABBV | https://www.nasdaq.com/articles/allergan-pins-hopes-on-millennials-with-juvederm-marketing-2020-02-12 | nan | nan | Allergan (NYSE: AGN) is continuing its strategy of targeting millennials with its new advertising campaign. In what could be seen as a counterintuitive strategy, the campaign is the latest one for the company's popular Juvederm dermal filler, a product that older customers traditionally use for cosmetic alterations.
Allergan's new video ads for its "Juvederm It" campaign specifically address the millennial preference of using cosmetic filler either without, or before, injecting Botox. It's more typical for people to get Botox treatments to freeze targeted areas and slow the development of wrinkles, and then deploy filler to smooth out those areas.
Instead, some millennials are applying filler exclusively, in an effort to plump out or shape certain body parts. This latest Juvederm It ad in particular zeroes in on the lips, a target of choice for that demographic.
Image source: Allergan.
The Juvederm It lip spot features millennial reality-TV star Audrina Partridge and makeup artist to the stars Kelsey Deenihan. It will air on TV in addition to social media sites and other digital properties, and it centers on the Juvederm Ultra XC and Juvederm Volbella XC fillers.
Although Allergan is in the process of merging with pharmaceutical major AbbVie (NYSE: ABBV), it seems that change won't affect the future of its aesthetic products. Revenue from these products is still growing at healthy rates -- Juvederm's sales rose almost 5% year over year in the company's Q4 -- and contributing heavily to overall revenue. Allergan and AbbVie are planning to house these goods in a new Allergan Aesthetics business unit.
Both Allergan and AbbVie closed slightly higher in trading on Wednesday.
10 stocks we like better than Allergan
When investing geniuses David and Tom Gardner have a stock tip, it can pay to listen. After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor, has tripled the market.*
David and Tom just revealed what they believe are the 10 best stocks for investors to buy right now... and Allergan wasn't one of them! That's right -- they think these 10 stocks are even better buys.
See the 10 stocks
*Stock Advisor returns as of December 1, 2019
Eric Volkman has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Although Allergan is in the process of merging with pharmaceutical major AbbVie (NYSE: ABBV), it seems that change won't affect the future of its aesthetic products. Allergan and AbbVie are planning to house these goods in a new Allergan Aesthetics business unit. Both Allergan and AbbVie closed slightly higher in trading on Wednesday. | Although Allergan is in the process of merging with pharmaceutical major AbbVie (NYSE: ABBV), it seems that change won't affect the future of its aesthetic products. Allergan and AbbVie are planning to house these goods in a new Allergan Aesthetics business unit. Both Allergan and AbbVie closed slightly higher in trading on Wednesday. | Although Allergan is in the process of merging with pharmaceutical major AbbVie (NYSE: ABBV), it seems that change won't affect the future of its aesthetic products. Allergan and AbbVie are planning to house these goods in a new Allergan Aesthetics business unit. Both Allergan and AbbVie closed slightly higher in trading on Wednesday. | Allergan and AbbVie are planning to house these goods in a new Allergan Aesthetics business unit. Although Allergan is in the process of merging with pharmaceutical major AbbVie (NYSE: ABBV), it seems that change won't affect the future of its aesthetic products. Both Allergan and AbbVie closed slightly higher in trading on Wednesday. |
Subsets and Splits
No community queries yet
The top public SQL queries from the community will appear here once available.